<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006626.pub2" GROUP_ID="SCHIZ" ID="844206090713185103" MERGED_FROM="" MODIFIED="2012-12-12 21:45:03 +0000" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;/p&gt;" NOTES_MODIFIED="2010-12-08 15:20:57 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-12-12 21:45:03 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Risperidone versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-12-12 21:45:03 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-12-12 21:45:03 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON><PERSON ID="90591E5482E26AA201AA8B42BEBB7D04" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sandra</FIRST_NAME><LAST_NAME>Schwarz</LAST_NAME><EMAIL_1>sandra.schwarz@khsweb.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="D99E43AC82E26AA201BA4B549DE5F4E8" ROLE="AUTHOR"><FIRST_NAME>Franziska</FIRST_NAME><LAST_NAME>Schmid</LAST_NAME><EMAIL_1>supra.renin@web.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="2E84257C82E26AA201BA4B54250245B7" ROLE="AUTHOR"><FIRST_NAME>Heike</FIRST_NAME><LAST_NAME>Hunger</LAST_NAME><EMAIL_1>mailtoHeike@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+498 941 404247</PHONE_1></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-12-12 21:45:03 +0000" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Minor update: 07/03/07&lt;/p&gt;" NOTES_MODIFIED="2010-12-08 15:20:57 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="5" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="4" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="5" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2012-12-12 21:45:03 +0000" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-12-12 21:45:03 +0000" MODIFIED_BY="Claire Irving"><DATE DAY="12" MONTH="12" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW>
<HISTORY MODIFIED="2010-12-07 13:44:19 +0000" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Psychiatrische Klinik , Klinikum rechts der Isar, TU München, Friestaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Bundesministerium für Bildung und Forschung, Nr FKZ: 01 KG 0606, GZ:GF-GFKG01100506</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-12-07 14:19:51 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-11-08 10:35:44 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-12-12 12:41:52 +0000" MODIFIED_BY="[Empty name]">Risperidone versus other atypical antipsychotics for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2010-11-08 10:35:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>This review examines the effects of risperidone compared to other second-generation antipsychotic (SGA) drugs for schizophrenia. We identified 45 relevant studies with 7760 participants comparing risperidone with amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole and ziprasidone. Comparisons of risperidone with zotepine are currently not available. Risperidone was somewhat more successful than quetiapine and ziprasidone, but somewhat less successful than clozapine and olanzapine. The main disadvantage of risperidone were more frequent movement disorders and more prolactin increase compared to most other SGA drugs.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-12-07 13:21:14 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-11-08 10:33:49 +0000" MODIFIED_BY="[Empty name]">
<P>In many countries of the industrialised world second-generation ("atypical") antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether and if so how much the effects of the various SGAs differ is a matter of debate. In this review we examined how the efficacy and tolerability of risperidone differs from that of other SGAs.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-10-06 14:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Electronic searching<BR/>We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO.</P>
<P>2. Reference searching<BR/>We inspected the references of all identified studies for more trials.</P>
<P>3. Personal contact<BR/>We contacted the first author of each included study for missing information.</P>
<P>4. Drug companies<BR/>We contacted the manufacturers of all atypical antipsychotics included for additional data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-10-06 14:58:33 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomised, blinded trials comparing oral risperidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-11-23 21:25:57 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For dichotomous data we calculated risk ratio (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated mean differences (MD), again based on a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-12-07 13:21:14 +0000" MODIFIED_BY="[Empty name]">
<P>The review currently includes 45 blinded RCTs with 7760 participants. The number of RCTs available for each comparison varied: four studies compared risperidone with amisulpride, two with aripiprazole, 11 with clozapine, 23 with olanzapine, eleven with quetiapine, two with sertindole, three with ziprasidone and none with zotepine. Attrition from these studies was high (46.9%), leaving the interpretation of results problematic. Furthermore, 60% were industry sponsored, which can be a source of bias.</P>
<P>There were few significant differences in overall acceptability of treatment as measured by leaving the studies early. Risperidone was slightly less acceptable than olanzapine, and slightly more acceptable than ziprasidone in this regard.</P>
<P>Risperidone improved the general mental state (PANSS total score) slightly less than olanzapine (15 RCTs, n = 2390, MD 1.94 CI 0.58 to 3.31), but slightly more than quetiapine (9 RCTs, n = 1953, MD -3.09 CI -5.16 to -1.01) and ziprasidone (3 RCTs, n = 1016, MD -3.91 CI -7.55 to -0.27). The comparisons with the other SGA drugs were equivocal. Risperidone was also less efficacious than olanzapine and clozapine in terms of leaving the studies early due to inefficacy, but more efficacious than ziprasidone in the same outcome.</P>
<P>Risperidone produced somewhat more extrapyramidal side effects than a number of other SGAs (use of antiparkinson medication versus clozapine 6 RCTs, n = 304, RR 2.57 CI 1.47 to 4.48, NNH 6 CI 33 to 3; versus olanzapine 13 RCTs, n = 2599, RR 1.28 CI 1.06 to 1.55, NNH 17 CI 9 to 100; versus quetiapine 6 RCTs, n = 1715, RR 1.98 CI 1.16 to 3.39, NNH 20 CI 10 to 100; versus ziprasidone 2 RCTs, n = 822, RR 1.42 CI 1.03 to 1.96, NNH not estimable; parkinsonism versus sertindole 1 RCT, n = 321, RR 4.11 CI 1.44 to 11.73, NNH 14 CI 100 to 8). Risperidone also increased prolactin levels clearly more than all comparators, except for amisulpride and sertindole for which no data were available.</P>
<P>Other adverse events were less consistently reported, but risperidone may well produce more weight gain and/or associated metabolic problems than amisulpride (weight gain: 3 RCTs, n = 585, MD 0.99 CI 0.37 to 1.61), aripiprazole (cholesterol increase: 1 RCT, n = 83, MD 22.30 CI 4.91 to 39.69) and ziprasidone (cholesterol increase 2 RCTs, n = 767, MD 8.58 CI 1.11 to 16.04) but less than clozapine (weight gain 3 RCTs n = 373, MD -3.30 CI -5.65 to -0.95), olanzapine (weight gain 13 RCTs, n = 2116, MD -2.61 CI -3.74 to -1.48), quetiapine (cholesterol increase: 5 RCTs, n = 1433, MD -8.49 CI -12. 23 to -4.75) and sertindole (weight gain: 2 RCTs, n = 328, MD -0.99 CI -1.86 to -0.12). It may be less sedating than clozapine and quetiapine, lengthen the QTc interval less than sertindole (QTc change: 2 RCTs, n = 495, MD -18.60 CI -22.37 to 14.83), produce fewer seizures than clozapine (2 RCTs, n = 354, RR 0.22 CI 0.07 to 0.70, NNT 14 CI 8 to 33) and less sexual dysfunction in men than sertindole (2 RCTs, n = 437, RR 0.34 CI 0.16 to 0.76, NNT 13 CI 8 to 33).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-23 21:11:09 +0000" MODIFIED_BY="[Empty name]">
<P>Risperidone seems to produce somewhat more extrapyramidal side effects and clearly more prolactin increase than most other SGAs. It may also differ from other compounds in efficacy and in the occurrence of other adverse effects such as weight gain, metabolic problems, cardiac effects, sedation and seizures. Nevertheless, the large proportion of participants leaving studies early and incomplete reporting of outcomes makes it difficult to draw firm conclusions. Further large trials, especially comparing risperidone with those other new drugs for which only a few RCTs are available, are needed.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-12-07 13:41:36 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-11-10 12:39:47 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-11-08 10:30:44 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is usually a chronic and disabling psychiatric disorder which afflicts approximately one per cent of the population world-wide with little gender differences. The annual incidence of schizophrenia averages 15 per 100,000, the point prevalence averages approximately 4.5 per population of 1000, and the risk of developing the illness over one's lifetime averages 0.7%. (<LINK REF="REF-Tandon-2008" TYPE="REFERENCE">Tandon 2008</LINK>). Its typical manifestations are positive symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), negative symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable, with 80%-90% not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>). In the age group of 15-44 years, schizophrenia is among the top 10 leading causes of disease-related disability in the world (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). </P>
</CONDITION>
<INTERVENTION MODIFIED="2010-11-08 10:36:25 +0000" MODIFIED_BY="[Empty name]">
<P>Conventional antipsychotic drugs such as chlorpromazine and haloperidol have traditionally been used as first-line antipsychotics for people with schizophrenia (<LINK REF="REF-Kane-1993" TYPE="REFERENCE">Kane 1993</LINK>). The reintroduction of clozapine in the United States of America and a finding that clozapine was more efficacious and associated with fewer movement disorders than chlorpromazine (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>) has boosted the development of so-called "atypical" or new (second) generation antipsychotics (SGA). There is no good definition of what an "atypical" or SGA is, but they were initially said to differ from typical antipsychotics in that they do not cause movement disorders (catalepsy) in rats at clinically effective doses (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). The terms "new" or "second generation" antipsychotics are not much better, because clozapine is a very old drug. According to treatment guidelines (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>; <LINK REF="REF-Gaebel-2006" TYPE="REFERENCE">Gaebel 2006</LINK>) SGAs include drugs such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone sertindole, ziprasidone and zotepine, although it is unclear whether some old and cheap compounds such as sulpiride or perazine have similar properties (<LINK REF="REF-M_x00f6_ller-2000" TYPE="REFERENCE">Möller 2000</LINK>). The SGAs raised major hopes of superior effects in a number of areas such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and the treatment of refractory people with schizophrenia.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-11-08 10:32:15 +0000" MODIFIED_BY="[Empty name]">
<P>Risperidone has high affinity to 5-HT2 and D2 receptors; it also binds to a1 receptors and with lower affinity to H1 and a2 receptors. It was developed following the observation that a selective serotonin receptor blocker (ritanserin) produced a beneficial effect when combined with conventional neuroleptics (<LINK REF="REF-Gupta-1994" TYPE="REFERENCE">Gupta 1994</LINK>; <LINK REF="REF-Curtis-1995" TYPE="REFERENCE">Curtis 1995</LINK>). Risperidone is described to have no affinity to cholinergic receptors. Although being a potential D2 antagonist it causes less motor retardation and cataleptic symptoms than typical antipsychotics (<LINK REF="REF-Janssen_x002d_Cilag-2005" TYPE="REFERENCE">Janssen-Cilag 2005</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-11-10 12:39:47 +0000" MODIFIED_BY="[Empty name]">
<P>The debate as to how far the SGA improve these outcomes compared to conventional antipsychotics continues (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>; <LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>) and the results from recent studies are sobering (<LINK REF="STD-Jones-2006" TYPE="STUDY">Jones 2006</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>). Nevertheless, in some parts of the world, especially in the highly industrialised countries, SGA have become the mainstay of treatment. The SGAs also differ in terms of their costs: while amisulpride and risperidone are already generic in many countries in 2009, aripiprazole, olanzapine, quetiapine, sertindole and ziprasidone are still not. Therefore the question as to whether they differ from each other in their clinical effects becomes increasingly important. In this review we aim to summarise evidence from randomised controlled trials that compared risperidone with other SGAs.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To review the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-23 21:26:05 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-11-08 10:37:04 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-11-08 10:37:04 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) which were at least single-blind (blind raters). Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week. In crossover studies, we only included the first treatment phase prior to crossover.</P>
<P>We included randomised crossover studies, but only data up to the point of first crossover because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia and other types of schizophrenia-like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Risperidone: any oral form of application, any dose<BR/>2. Other "atypical" antipsychotic drugs: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole, ziprasidone, zotepine: any oral form of application, any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-09-30 15:53:55 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into the short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks). </P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-28 10:36:43 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: no clinically important response as defined by the individual studies (e.g. global impression less than much improved or less than 50% reduction on a rating scale).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-09-30 14:16:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Leaving the studies early (any reason, adverse events, inefficacy of treatment)</P>
<P>2. Global state<BR/>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Relapse (as defined by the individual studies)</P>
<P>3. Mental state (with particular reference to the 'positive' and 'negative' symptoms of schizophrenia)<BR/>3.1 No clinically important change in general mental state score<BR/>3.2 Average endpoint general mental state score<BR/>3.3 Average change in general mental state score<BR/>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<BR/>3.5 Average endpoint specific symptom score<BR/>3.6 Average change in specific symptom score</P>
<P>4. General functioning<BR/>4.1 No clinically important change in general functioning<BR/>4.2 Average endpoint general functioning score<BR/>4.3 Average change in general functioning score</P>
<P>5. Quality of life/satisfaction with treatment<BR/>5.1 No clinically important change in general quality of life<BR/>5.2 Average endpoint general quality of life score<BR/>5.3 Average change in general quality of life score</P>
<P>6. Cognitive functioning<BR/>6.1 No clinically important change in overall cognitive functioning<BR/>6.2 Average endpoint of overall cognitive functioning score<BR/>6.3 Average change of overall cognitive functioning score</P>
<P>7. Service use<BR/>7.1 Number of people hospitalised</P>
<P>8. Adverse effects<BR/>8.1 Number of participants with at least one adverse effect<BR/>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, sedation, seizures, weight gain, effects on white blood cell count)<BR/>8.3 Average endpoint in specific adverse effects<BR/>8.4 Average change in specific adverse effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-08 10:40:05 +0000" MODIFIED_BY="[Empty name]">
<P>We applied no language restriction within the limitations of the search tools.</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-07-28 10:40:12 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group's Specialised Register (April 2007) using the phrase:</P>
<P>[((ziprasidon* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon* OR zotepin*)) in title, abstract or index terms of REFERENCE) or ((ziprasidon* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon * OR zotepin*)) in interventions of STUDY)]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references which have been identified as the same study are also selected.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-11-08 10:40:05 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected the reference lists of all studies identified in the search for more trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first author of each included study for missing information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Drug companies</HEADING>
<P>We contacted the manufacturers of all atypical antipsychotics included for additional data.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-23 21:26:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2010-11-08 10:40:36 +0000" MODIFIED_BY="[Empty name]">
<P>KK, CRK and SL independently inspected all reports. We resolved any disagreement by discussion, and where there was still doubt, we acquired the full article for further inspection. Once we obtained the full articles, we independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and added these trials to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-11-08 10:41:50 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Data extraction</HEADING>
<P>KK, CRK and SL independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<P>KK, CRK, SS, HH, FS and SL extracted the data onto standard simple forms. Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for risperidone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Rating scales</HEADING>
<P>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore we included continuous data from rating scales only if the measuring instrument had been described in a peer-reviewed journal.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-11-09 12:07:01 +0000" MODIFIED_BY="[Empty name]">
<P>Again working independently, KK and SL assessed risk of bias using the tool described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases.</P>
<P>We assessed the risk of bias in each domain and overall and categorised them into:</P>
<P>A. Low risk of bias: plausible bias unlikely to seriously alter the results (categorised as 'Yes' in Risk of Bias table)<BR/>B. High risk of bias: plausible bias that seriously weakens confidence in the results (categorised as 'No' in Risk of Bias table)<BR/>C. Unclear risk of bias: plausible bias that raises some doubt about the results (categorised as 'Unclear' in Risk of Bias table)</P>
<P>We categorised trials with high risk of bias (defined as at least four out of seven domains) as 'No'. Where allocation was clearly not concealed, we did not include these trials in the review. If the initial raters disagreed, we made the final rating by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. We reported non-concurrence in quality assessment.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-23 21:26:05 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Data types</HEADING>
<P>We assessed outcomes using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as "little change", "moderate change" or "much change") or dichotomous (for example, either "no important changes or "important change" in a person's behaviour) measures. Currently The Cochrane Collaboration's Review Manager (RevMan) software (RevMan 2008) does not support categorical data so we were unable to analyse this.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Dichotomous- yes/no- data</HEADING>
<P>We carried out an intention-to-treat analysis. We counted everyone allocated to the intervention, whether they completed the follow-up or not. We assumed that those who dropped out had no change of their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning side effects, because it assumes that those discontinuing the studies would not have developed the side effect if they had remained in the study, but we felt that assuming that all drop-outs would have developed side effects would overestimate the risk. Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into "clinically improved" or "not clinically improved". It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>); this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>; <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>We calculated the risk ratio (RR) and its 95% confidence interval (CI) based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios (OR) and that OR tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number- needed- to- harm (NNH) as the inverse of the risk difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Continuous data</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.2.1 Normal distribution of the data</HEADING>
<P>The meta-analytic formulae applied by RevMan Analyses (the statistical programme included in RevMan) require a normal distribution of data (RevMan 2008). The software is robust towards some skew, but to which degree of skewness meta-analytic calculations can still be reliably carried out is unclear. Conversely, excluding all studies on the basis of estimates of the normal distribution of the data also leads to a bias, because a considerable amount of data may be lost leading to a selection bias. Therefore, we included all studies in the primary analysis. In a sensitivity analysis we excluded potentially skewed data applying the following rules.<BR/>
<BR/>a) When a scale started from the finite number zero the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>).<BR/>b) If a scale started from a positive value (such as PANSS which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.<BR/>c) In large studies (as a cut-off we used 200 participants) skewed data pose less of a problem. In these cases we entered the data in a synthesis.<BR/>d) The rules explained in a) and b) do not apply to change data. The reason is that when continuous data are presented on a scale which includes a possibility of negative values, it is difficult to tell whether data are non-normally distributed (skewed) or not. This is also the case for change data (endpoint minus baseline). In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan Analyses in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew. Without individual patient data it is impossible to test this assumption. We therefore included change data and did not apply a sensitivity analysis.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Data synthesis</HEADING>
<P>For continuous outcomes we estimated a mean difference (MD) between groups. MDs were again based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We combined both endpoint data and change data in the analysis, because there is no principal statistical reason why endpoint and change data should measure different effects (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). When standard errors instead of standard deviations (SD) were presented, we converted the former to standard deviations. If both were missing we estimated SDs from P values or used the average SD of the other studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-11-10 12:33:42 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported we assumed it to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account ICC and relevant data documented in the report, we synthesised these with other studies using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Crossover trials</HEADING>
<P>A major concern of crossover trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason crossover trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will only use data of the first phase of crossover studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment groups, if relevant, we presented the additional treatment groups in additional relevant comparisons. We have not double counted data. Where the additional treatment groups were not relevant, we have not reproduced these data.<BR/>
</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-07-28 11:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>At some degree of loss of follow-up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). Although high rates of premature discontinuation are a major problem in this field, we feel that it is unclear which degree of attrition leads to a high degree of bias. We, therefore, did not exclude trials on the basis of the percentage of participants completing them. However we addressed the drop-out problem in all parts of the review, including the abstract. For this purpose we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled and their ranges).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-11-10 12:34:53 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all the included studies within any comparison to judge for clinical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Statistical</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>We supplemented visual inspection using, primarily, the I<SUP>2</SUP>statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I<SUP>2</SUP> estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-11-10 12:36:02 +0000" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in section 10.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We are aware that funnel plots may be useful in investigating small-study effects but are of limited power to detect such effects when there are few studies. We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. We did not undertake a formal test for funnel-plot asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-11-10 12:36:18 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible for both dichotomous and continuous data, we used the random-effects model for data synthesis as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-07-28 11:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>If data are clearly heterogeneous we checked that data are correctly extracted and entered and that we had made no unit of analysis errors. If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-12-12 15:23:25 +0000" MODIFIED_BY="[Empty name]">
<P>In sensitivity analyses we excluded studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotics may have been biased by using inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). We, therefore, also analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-23 21:12:59 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-11-10 12:59:50 +0000" MODIFIED_BY="[Empty name]">
<P>For substantive description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2010-11-10 12:38:46 +0000" MODIFIED_BY="[Empty name]">
<P>The search strategy yielded 3620 reports. We closely inspected 330 reports. We excluded 241 studies, included 45 and designated seven as ongoing (<LINK REF="STD-Eli-Lilly-2003" TYPE="STUDY">Eli Lilly 2003</LINK>; <LINK REF="STD-Eli-Lilly-2006" TYPE="STUDY">Eli Lilly 2006</LINK>; <LINK REF="STD-Gafoor-2005" TYPE="STUDY">Gafoor 2005</LINK>; <LINK REF="STD-Lieberman-2001" TYPE="STUDY">Lieberman 2001</LINK>; <LINK REF="STD-Ratna-2003" TYPE="STUDY">Ratna 2003</LINK>; <LINK REF="STD-Reveley-2000" TYPE="STUDY">Reveley 2000</LINK>; <LINK REF="STD-Sireling-2003" TYPE="STUDY">Sireling 2003</LINK>). No study is awaiting assessment . For further descriptions please see below and the included, excluded and ongoing studies tables.</P>
<P>The 45 included studies provided data on seven comparisons: four studies compared risperidone with amisulpride, two with aripiprazole, 11 with clozapine, 23 with olanzapine, 11 with quetiapine, two with sertindole and three with ziprasidone. We identified no RCTs comparing risperidone with zotepine.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-11-10 12:57:26 +0000" MODIFIED_BY="[Empty name]">
<P>The 45 studies randomised approximately 7700 people with schizophrenia and schizophrenia-like disorders. All but six included studies were double blind; the remaining six were single blind (blind raters). Eight studies were sponsored by pharmaceutical companies producing risperidone; 19 studies were sponsored by pharmaceutical companies producing the comparator substances and 14 studies had a neutral sponsor. The sponsoring of four studies remained unclear despite written requests.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of studies</HEADING>
<P>Thirty-one studies presented short-term (up to 12 weeks) data. Six studies fell into the medium-term category (13-26 weeks) and eight trials fell in the long-term category (more than 26 weeks).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Setting</HEADING>
<P>Eighteen trials took place in both inpatient and outpatient settings; 12 used an inpatient design and three studies an outpatient setting. The setting of 10 studies was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>All studies used operationalised diagnostic criteria, most frequently the Diagnostic and Statistical Manual (DSM, <LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>), usually version IV, only <LINK REF="STD-Addington-2004" TYPE="STUDY">Addington 2004</LINK>, <LINK REF="STD-Daniel-1996" TYPE="STUDY">Daniel 1996</LINK> and <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK> used DSM-III). <LINK REF="STD-Svestka-2003" TYPE="STUDY">Svestka 2003</LINK> applied the International Classification of Diseases and Related Health Problems (ICD-10). <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK> diagnosed according to DSM-IV and ICD-10. <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK> applied DSM-IV as well as the Schedule for Affective Disorders and Schizophrenia (K-SADS-P). <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>, a study from China, used the Chinese Classification of Mental Disorders Version 3 (CCDM-3) and <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK> used Version 2 (CCDM-2) of the same classification.</P>
<P>All studies included people with schizophrenia; 21 studies additionally included those with schizoaffective disorder (<LINK REF="STD-Addington-2004" TYPE="STUDY">Addington 2004</LINK>; <LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>; <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>; <LINK REF="STD-Daniel-1996" TYPE="STUDY">Daniel 1996</LINK>; <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>; <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>; <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>; <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>; <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>; <LINK REF="STD-Potkin-2003" TYPE="STUDY">Potkin 2003</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>; <LINK REF="STD-Robinson-2005" TYPE="STUDY">Robinson 2005</LINK>; <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>; <LINK REF="STD-Svestka-2003" TYPE="STUDY">Svestka 2003</LINK>; <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>; <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>; <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>; <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>) and seven studies also included people with schizophreniform disorder (<LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>; <LINK REF="STD-Robinson-2005" TYPE="STUDY">Robinson 2005</LINK>; <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>; <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>; <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>). Nevertheless, people with schizophrenia clearly dominated the trials.<BR/>
</P>
<P>Five studies randomised people with acute exacerbations (<LINK REF="STD-Addington-2004" TYPE="STUDY">Addington 2004</LINK>; <LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>; <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>; <LINK REF="STD-Potkin-2003" TYPE="STUDY">Potkin 2003</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>). <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Robinson-2005" TYPE="STUDY">Robinson 2005</LINK> and <LINK REF="STD-Svestka-2003" TYPE="STUDY">Svestka 2003</LINK> examined those with a first episode of schizophrenia, and <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK> included only participants in the early phase of the illness. Five studies restricted randomisation to chronic schizophrenia (<LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK>; <LINK REF="STD-Daniel-1996" TYPE="STUDY">Daniel 1996</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>). Insufficient response or resistance to previous treatment was an inclusion criterion in nine studies (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>; <LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>; <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>; <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>; <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>; <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>; <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>), but the criteria varied widely. One study examined people with postpsychotic depression (<LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>) and another one participants with predominant negative symptoms (<LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK>).</P>
<P>In most studies participants were 18 years old or older. Two studies randomised only patients aged 60 or older (<LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>; <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>). Another study examined childhood schizophrenia and included only children and adolescents with ages between 8 and 19 years (<LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>).</P>
<P>In <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK> all participants had a recent history of cannabis use in addition to schizophrenia.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.Study size</HEADING>
<P>
<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> was the largest study (1460 participants) whereas <LINK REF="STD-Daniel-1996" TYPE="STUDY">Daniel 1996</LINK> and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> included the smallest samples with 20 participants each. Twelve studies had fewer than 50 participants, 13 had 50 to 100 participants, 16 had 100 to 400 participants and two randomised more than 400 people. Two studies did not indicate the total number of randomised participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5 Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Risperidone</HEADING>
<P>The trialists gave risperidone in a wide range of doses from 0.5 mg/day to 12 mg/day (<LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK> up to 16 mg/ per day). Three studies used a fixed dose design. Seven studies did not report the dose range.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Comparators</HEADING>
<P>Seven other SGA drugs were used as comparators with the following dose ranges: amisulpride (100 mg/day to 1000 mg/day), aripiprazole (15 mg/day to 30 mg/day), clozapine (25 mg/day to 900 mg/day), quetiapine (50 mg/day to 800 mg/day), olanzapine (2.5 mg/day to 40 mg/day), sertindole (12 mg/day to 24 mg/day), and zisprasidone (40 mg/day to 160 mg/day). Eight studies included more than one comparator arms of interest therefore number of comparisons (56) is higher than number of included studies (45). Some studies also included additional arms with the typical antipsychotic drugs haloperidol, perospirone or perphenazine as comparators. These results were not considered in the current review.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Leaving the study early</HEADING>
<P>We evaluated the number of participants leaving the studies early due to any reason, due to adverse events and due to lack of efficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Response to treatment</HEADING>
<P>The studies rarely reported the response cut off at least 50% reduction (<LINK REF="STD-Addington-2004" TYPE="STUDY">Addington 2004</LINK>; <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>; <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>; <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>; <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>) of a scale's baseline value that we considered clinically meaningful. In contrast, <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> used at least 20% BPRS total score reduction from baseline, <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK> and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> at least 20% PANSS total score reduction, and <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK> and <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK> at least 30% PANSS total score reduction from baseline.</P>
<P>
<LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK> based its assessment of response on the Clinical Global Impression Scale (CGI) and defined 'at least much improved compared to baseline' as a cutoff.</P>
<P>Other studies applied combined criteria: <LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK> and <LINK REF="STD-Potkin-2003" TYPE="STUDY">Potkin 2003</LINK> used at least much improved on the CGI or at least 30% PANSS total score reduction from baseline; <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK> and <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK> at least minimally improved on the CGI and at least 20% BPRS total reduction from baseline; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> all PANSS items mild or better and a CGI-severity scale of mildly ill or better; <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK> at least 20% improvement on the BPRS psychosis cluster and no psychotic symptom rated worse than mild and <LINK REF="STD-Robinson-2005" TYPE="STUDY">Robinson 2005</LINK> certain SADS-C+PD items mild or better and at least much improved on the CGI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Relapse</HEADING>
<P>Only three studies (<LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>) provided data for relapse and used different definitions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Service use</HEADING>
<P>A few studies reported the number of participants who had to be readmitted to the hospital.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.5 Outcome scales</HEADING>
<P>We have provided details below of scales that provided usable data. We have provided reasons for exclusion of data from other instruments under 'Outcomes' in the 'Included studies' section.</P>
<SUBSECTION>
<HEADING LEVEL="6">6.5.1 Global state scales</HEADING>
<P>6.5.1.1 Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used, with low scores showing decreased severity and/or overall improvement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.5.2 Mental state scales</HEADING>
<P>6.5.2.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms.</P>
<P>6.5.2.2 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. It can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates less severity.</P>
<P>6.5.2.3 Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1983" TYPE="REFERENCE">Andreasen 1983</LINK>)<BR/>This six-point scale gives a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more symptoms.</P>
<P>6.5.2.4 Scale for the Assessment of Positive Symptoms - SAPS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>)<BR/>This four-point scale gives a global rating of the following positive symptoms: hallucinations, paranoia, disorganised behaviour and disorganised thinking. Higher scores indicate more symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.5.3 General functioning scales</HEADING>
<P>6.5.3.1 Social and Occupational Functioning Assessment Scale - SOFAS (<LINK REF="REF-Goldman-1992" TYPE="REFERENCE">Goldman 1992</LINK>)<BR/>The SOFAS focuses on the different levels of social and occupational functioning. Higher scores indicate a higher level of functioning.</P>
<P>6.5.3.2 Global Assessment of Functioning - GAF (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>)<BR/>This is a rating scale for a patients overall capacity of psychosocial functioning scoring from 1-100. Higher scores indicate a higher level of functioning.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.5.4 Quality of life scales</HEADING>
<P>6.5.4.1 Quality of Life Scale - QLS (<LINK REF="REF-Carpenter-1984" TYPE="REFERENCE">Carpenter 1984</LINK>)<BR/>This semi-structured interview is administered and rated by trained clinicians. It contains 21 items rated on a seven-point scale based on the interviewers judgement of patient functioning. A total QLS and four subscale scores are calculated, with higher scores indicating less impairment.</P>
<P>6.5.4.2 Subjective Well-being under Neuroleptics Scale - SWN (<LINK REF="STD-De-Haan-2002" TYPE="STUDY">De Haan 2002</LINK>)<BR/>The SWN is an instrument to measure the subtle subjective changes, such as restrictions in emotionality, the clarity of thinking and spontaneity, that are often referred as 'pharmacogenic depression' or the 'neuroleptic induced deficit syndrome'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.5.5 Cognitive functioning scales</HEADING>
<P>6.5.5.1 Global Neurocognitive Score (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>)<BR/>This score consists of 15 tests that assess the domains' general ability, learning and memory, attention, executive functions, and motor skills. Sixteen variables were selected from 12 tests. For each test variable, z-scores were computed. This global score was then computed by averaging the z-scores of contributing variables. All z-scores were computed in a way that positive scores indicate better performance.</P>
<P>6.5.5.2 Neurocognitive Composite Score (<LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>)<BR/>The Neurocognitive Composite Score comprises individual cognitive domains (executive function, learning and memory, processing speed, attention/vigilance, verbal working memory, verbal fluency, motor function, and visuospatial ability) measured by various tests that were transformed into a composite score.</P>
<P>6.5.5.3 PANSS cognitive subscore<BR/>This score has been derived from the Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.5.6 Adverse effects scales</HEADING>
<P>6.5.6.1 Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder and short-term movement disorders such as tremor.</P>
<P>6.5.6.2 Barnes Akathisia Scale - BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from 0 - normal to 3 - severe. In addition, there is an item for rating global severity (from 0 - absent to 5 - severe). A low score indicates low levels of akathisia.</P>
<P>6.5.6.3 Extrapyramidal Symptom Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder.</P>
<P>6.5.6.4 Hillside Akathisia Scale - HAS (<LINK REF="REF-Fleischhacker-1989" TYPE="REFERENCE">Fleischhacker 1989</LINK>)<BR/>The Hillside Akathisia Scale (HAS) is another rating scale to examine akathisia, a subjective awareness of restlessness, and any distress associated with the condition. It has two subjective and three objective items for which anchored rating points are provided.</P>
<P>6.5.6.5 Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This 10-item scale, with a scoring system of 0-4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-11-10 12:59:50 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded 241 studies for the following reasons: 22 studies because they were not randomised; 186 because they were open-label trials without any effort to blind medication; 17 because they were pooled-analyses of several trials; 11 because they did not use appropriate interventions; and five because they did not present any usable data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Awaiting assessment</HEADING>
<P>No studies are awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>We identified six RCTs comparing risperidone with other atypical antipsychotics which appear to be ongoing (Astra Zeneca 2002; <LINK REF="STD-Eli-Lilly-2006" TYPE="STUDY">Eli Lilly 2006</LINK>; <LINK REF="STD-Eli-Lilly-2003" TYPE="STUDY">Eli Lilly 2003</LINK>; <LINK REF="STD-Lieberman-2001" TYPE="STUDY">Lieberman 2001</LINK>; Lundbeck 2002; <LINK REF="STD-Reveley-2000" TYPE="STUDY">Reveley 2000</LINK>). We have presented further details in the ongoing studies table.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-10 17:01:11 +0000" MODIFIED_BY="[Empty name]">
<P>For details of risk of bias, please refer to risk of bias table (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>)</P>
<ALLOCATION MODIFIED="2010-11-10 13:01:08 +0000" MODIFIED_BY="[Empty name]">
<P>All included studies were randomised, but only eight trials provided some details about the randomisation process (<LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>; <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>; <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>; <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>; <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>; <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>). Four studies (<LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>; <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>; <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>) used a computer-generated randomisation procedure, and <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK> described a process to make participants draw a ball out of a box. For all the other studies the information was so little that it remained unclear whether there was a risk of bias. Details on allocation concealment were not provided for any of the studies.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-11-10 13:02:39 +0000" MODIFIED_BY="[Empty name]">
<P>Of the included studies, 38 were double-blind. The remaining seven trials were single-blind (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>; <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>; <LINK REF="STD-Daniel-1996" TYPE="STUDY">Daniel 1996</LINK>; <LINK REF="STD-Robinson-2005" TYPE="STUDY">Robinson 2005</LINK>; <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>; <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK>). Another 16 studies described using identical capsules for blinding. No study examined whether blinding was effective. We found that the side-effect profiles of the examined compounds are quite different, which may have made blinding difficult. We therefore conclude that the risk of bias for objective outcomes (e.g. death or laboratory values) was low, but there was a risk of bias for subjective outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-11-10 13:03:39 +0000" MODIFIED_BY="[Empty name]">
<P>The overall number of participants leaving the studies early was high (46.9%), although the percentages in the different comparisons varied. Eight studies did not report on leaving the study early (<LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK>; <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>; <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>; <LINK REF="STD-Svestka-2003" TYPE="STUDY">Svestka 2003</LINK>; <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>; <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>). Nearly all the studies analysed their data on an intention-to-treat basis using the last observation carried forward. This method of accounting for missing data is imperfect, because it assumes that participants would not have experienced a change of their condition if they had stayed in the trial. This assumption can obviously be wrong. Conversely it is a positive aspect of the evidence base that most studies indicated the specific reasons for leaving early.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-11-10 17:00:20 +0000" MODIFIED_BY="[Empty name]">
<P>In most studies the reporting of secondary or even primary outcome data was incomplete (<LINK REF="STD-Addington-2004" TYPE="STUDY">Addington 2004</LINK>; <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>; <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>; <LINK REF="STD-Daniel-1996" TYPE="STUDY">Daniel 1996</LINK>; <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>; <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>; <LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>; <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>; <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>; <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>; <LINK REF="STD-Potkin-2003" TYPE="STUDY">Potkin 2003</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>; <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>; <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>; <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK>; <LINK REF="STD-Robinson-2005" TYPE="STUDY">Robinson 2005</LINK>; <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>; <LINK REF="STD-Svestka-2003" TYPE="STUDY">Svestka 2003</LINK>; <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>; <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>; <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>; <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK>). Often only those adverse events that occurred in at least 5% or 10% of the participants, or that were of moderate or worse severity, or that were significantly different between groups were reported (<LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>; <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>; <LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>; <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>; <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>; <LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>; <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>; <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>; <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>; <LINK REF="STD-Potkin-2003" TYPE="STUDY">Potkin 2003</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>; <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>; <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>; <LINK REF="STD-Zhong-2006" TYPE="STUDY">Zhong 2006</LINK>). This procedure is problematic, because rare, but potentially serious side effects may be missed. Only five studies appeared to have a low risk of bias (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>; <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-11-10 17:01:11 +0000" MODIFIED_BY="[Empty name]">
<P>One study was free of other bias (<LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>), but for all others we felt that there was at least a possibility of risk of bias. The main reason was sponsoring of the pharmaceutical industry. Of the included studies, 60% were sponsored by pharmaceutical companies, 18% by the manufacturers of risperidone and 42% by the manufacturers of the comparator compounds. Pharmaceutical companies have an inevitable conflict of interest which may well lead to bias (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>; <LINK REF="REF-Leucht-2008" TYPE="REFERENCE">Leucht 2008</LINK>). Other potential sources of bias were missing wash-out phases (<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>; <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>), low numbers of participants (<LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>; <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>), baseline imbalance in duration of illness (<LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>) and missing data on allowed dose ranges (<LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-23 21:12:59 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison 1. Risperidone versus amisulpride</HEADING>
<P>Four included studies fell in this category.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 No clinically significant response - as defined by the original studies</HEADING>
<P>The results of three studies were slightly heterogeneous (I<SUP>2 </SUP>54%). The combined analysis did not indicate a difference (3 RCTs, n = 586, RR 1.12 CI 0.83 to 1.50), but when the outlier study (<LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>) was excluded there was a significant superiority of amisulpride (2 RCTs, n = 538, RR 1.25 CI1.05 to 1.50, NNH 9 CI 5 to 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2 Global state: no clinically important change</HEADING>
<P>Overall there was no significant difference (3 RCTs, n = 586, RR 1.12 CI 0.82 to 1.53), but some heterogeneity (I<SUP>2 </SUP>54%). Again, when the outlier study (<LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK>) was excluded there was a significant superiority of amisulpride (2 RCTs, n = 586, RR 1.28 CI 1.04 to 1.56, NNH 10 CI 6 to 50) in the short (<LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK>) (1 RCT, n=228, RR 0.96 CI 0.50 to 1.85) and medium term (<LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>) (1 RCT, n = 310, RR 1.27 CI 0.99 to 1.64).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.3 Global state: relapse - medium term</HEADING>
<P>Only one study provided data for this outcome and did not reveal a significant difference between amisulpride and risperidone (1 RCT, n = 173, RR 1.50 CI 0.94 to 2.39).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Leaving the study early</HEADING>
<P>There was no significant difference between groups. Of the participants, 34% in the amisulpride group and 32% in the risperidone group left the studies early due to any reason (3 RCTs, n = 586, RR 1.02 CI 0.68 to 1.53); 11% in the amisulpride group and 12% in the risperidone group left the studies early due to adverse events (4 RCTs, n = 622, RR 0.93 CI 0.61 to 1.42); and 10 % in the amisulpride group compared to 7% in the risperidone group left the studies early due to lack of efficacy of treatment (3 RCTs, n = 586, RR 1.45 CI 0.83 to 2.53).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 General - no clinically important change - medium term (less than 50% PANSS total score reduction)</HEADING>
<P>
<LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK> showed a tendency in favour of amisulpride which did not reach a conventional level of statistical significance (1 RCT, n = 310, RR 1.24 CI 1.00 to 1.53).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2 General - no clinically important change - short term (less than 20% PANSS total score reduction)</HEADING>
<P>In <LINK REF="STD-Hwang-2003" TYPE="STUDY">Hwang 2003</LINK> there was no significant difference between groups (1 RCT, n = 48, RR 0.69 CI 0.28 to 1.69).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.3 General - no clinically important change - medium term (less than 50% BPRS total score reduction)</HEADING>
<P>A single study (<LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>) found a significant superiority of amisulpride (1 RCT, n = 310, RR 1.29 CI 1.02 to 1.62, NNH 8 CI 4 to 100).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.4 General - no clinically important change - short term (less than 40% BPRS total score reduction)</HEADING>
<P>
<LINK REF="STD-Peuskens-1999" TYPE="STUDY">Peuskens 1999</LINK> found no significant difference (1 RCT, n = 228, RR 1.29 CI 0.92 to 1.80).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.5 General - average score at endpoint - PANSS total</HEADING>
<P>There was no significant difference (2 RCTs, n = 291, MD -0.38 CI -5.33 to 4.57) in either the short (1 RCT, n = 47, MD -4.30 (-14.59 to 5.99) or the medium term (1 RCT, n = 244, MD 0.80 CI -4.5 to 6.45).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.6 General - average score at endpoint - BPRS total</HEADING>
<P>There was no significant difference (3 RCTs, n = 519, MD 0.68 CI -1.79 to 3.14) in either the short (2 RCTs, n = 275, MD 0.50 CI -4.54 to 5.53) or medium term (1 RCT, n = 244, MD 0.20 CI -3.28 to 3.68).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.7 Positive symptoms - average score at endpoint - PANSS positive</HEADING>
<P>There was no significant difference (3 RCTs, n = 519, MD 0.03 CI -1.24 to 1.29) in either the short (2 RCTs, n = 275, MD 0.15 CI -2.17 to 2.47) or medium term (1 RCT, n = 244, MD -0.30 CI -2.11 to 1.51).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.8 Positive symptoms - average score at endpoint - BPRS positive</HEADING>
<P>There was no significant difference (1 RCT, n = 228, MD 0.50 CI -0.89 to 1.89).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.9 Negative symptoms - average score at endpoint - PANSS negative</HEADING>
<P>There was no significant difference (3 RCTs, n = 519, MD 1.00 CI -0.11 to 2.11) in either the short (2 RCTs, n = 275, MD 0.60 CI -1.72 to 2.92) or the medium term (1 RCT, n = 244, MD 1.20 CI -0.21 to 2.61).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.10 Negative symptoms - average score at endpoint - SANS total</HEADING>
<P>There was no significant difference (1 RCT, n = 224, MD 2.70 CI -2.33 to 7.73).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 General functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.4.1 General functioning - no clinically important change - medium term (less than 50 % SOFAS total score reduction)</HEADING>
<P>There was no significant difference (1 RCT, n = 310, MD 1.11 CI 0.98 to 1.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.2 General functioning - average score at endpoint - SOFAS total score</HEADING>
<P>There was no significant difference (2 RCTs, n = 291, MD 2.31 CI -1.28 to 5.90) in either the short (1 RCT, n = 47, MD 1.10 CI -7.03 to 9.23) or medium term (1 RCT, n = 244, MD 2.60 CI -1.40 to 6.60).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.5.1 General - at least one adverse effect</HEADING>
<P>There was no significant difference (4 RCTs, n = 622, RR 1.00 CI 0.90 to 1.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.2 Death</HEADING>
<P>Only <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK> reported on death and did not find a significant difference in terms of natural causes (1 RCT, n = 310, RR 0.32 CI 0.01 to 7.81) or suicide (1 RCT, n = 310, RR 0.48 CI 0.04 to 5.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.3 Cardiac effects - number of participants with QTc prolongation</HEADING>
<P>No participant had a prolongation of the QTc interval (2 RCTs, n = 276, RR not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.4 Central nervous system - sedation</HEADING>
<P>There was no significant difference (1 RCT, n = 310, RR 1.44 CI 0.61 to 3.43).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.5 Central nervous system - seizures</HEADING>
<P>Only <LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK> reported on this outcome. No participant had a seizure (1 RCT, n = 310, RR not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.6 Extrapyramidal effects</HEADING>
<P>There was no significant difference between risperidone and amisulpride in the frequency of akathisia (3 RCTs, n = 586, RR 1.25 CI 0.90 to 1.74), extrapyramidal symptoms (1 RCT, n = 228, RR 0.88 CI 0.60 to 1.30), hyperkinesia (2 RCTs, n = 538, RR 0.75 CI 0.49 to 1.14), parkinsonism (2 RCTs, n = 538, RR 1.13 CI 0.66 to 1.95), rigor (2 RCTs, n = 276, RR 1.08 CI 0.27 to 4.36), tremor (3 RCTs, n = 586, RR 1.46 CI 0.66 to 3.21) or use of antiparkinson medication (3 RCTs, n = 586, RR 1.07 CI 0.72 to 1.57).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.7 Extrapyramidal effects - scale measured</HEADING>
<P>There was no significant difference in dyskinesia (AIMS: 2 RCTs, n = 538, MD -0.08 CI -0.72 to 0.55) or extrapyramidal side effects in general (SAS: 2 RCTs, n = 538, MD 0.03 CI -0.06 to 0.13).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.8 Prolactin associated side effects</HEADING>
<P>There was no significant difference in the frequency of amenorrhea (1 RCT, n = 310, RR 0.96 CI 0.06 to 15.24) and galactorrhea (2 RCTs, n = 538, RR 0.74 CI 0.17 to 3.27). In men sexual dysfunction occurred more frequently in the risperidone group than in the amisulpride group (2 RCTs, n = 538, RR 9.52 CI 1.22 to 74.44, NNH 33 CI 100 to 17).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.9 Metabolic - weight gain</HEADING>
<P>More participants in the risperidone group than in the amisulpride group had a clinically important weight gain (2 RCTs, n = 538, RR 1.75 CI 1.07 to 2.87, NNH not estimable).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.10 Metabolic - weight gain - mean change from baseline in kg</HEADING>
<P>Risperidone was associated with more weight gain than amisulpride (3 RCTs, n = 585, MD 0.99 CI 0.37 to 1.61).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Publication bias</HEADING>
<P>Due to small number of included studies (&lt; 10 studies), we did not perform a funnel plot analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Sensitivity analyses</HEADING>
<P>The reasons for the preplanned sensitivity analyses did not apply and therefore we have not performed these.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparison 2. Risperidone versus aripiprazole - all data short term</HEADING>
<P>Two included studies fell in this category.</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1.1 Global state - no clinically significant response - as defined by the original studies</HEADING>
<P>There was no significant difference (2 RCTs, n = 384, RR 0.88 CI 0.62 to 1.24).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.2 Global state - no clinically important change</HEADING>
<P>There was no significant difference (2 RCTs, n = 384, RR 0.88 CI 0.62 to 1.24).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Leaving the study early</HEADING>
<P>There was no significant difference between groups. 35% of the participants in the risperidone group and 34% of the participants in the aripiprazole group left the studies early due to any reason (2 RCTs, n = 384, RR 1.06 CI 0.79 to 1.41). There was also no significant difference in leaving the studies early due to adverse events (8% versus 10%; 2 RCTs, n = 384, RR 0.79 CI 0.39 to 1.61), or in leaving the studies early due to inefficacy of treatment (6% versus 8%; 2 RCTs, n = 384, RR 0.89 CI 0.41 to 1.93).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 General - average endpoint score - PANSS total</HEADING>
<P>There was no significant difference (2 RCTs, n = 372, MD -1.50 CI -5.96 to 2.96).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 Positive symptoms - average endpoint score - PANSS positive</HEADING>
<P>There was no significant difference (2 RCTs, n = 372, MD -1.24 CI -2.74 to 0.26).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.3 Negative symptoms - average endpoint score - PANSS negative</HEADING>
<P>There was no significant difference (2 RCTs, n = 372, MD 0.45 CI -0.87 to 1.78).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.4.1 General - at least one adverse effect</HEADING>
<P>There was no significant difference (2 RCTs, n = 384, RR 1.02 CI 0.95 to 1.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.2 Cardiac effects - number of participants with QTc prolongation</HEADING>
<P>There was no significant difference (1 RCT, n = 301, RR 14.21 CI 0.74 to 272.45).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.3 Cardiac effects - mean change of QTc interval from baseline in ms</HEADING>
<P>There was no significant difference (2 RCTs, n = 383, MD 7.19 CI 2.19 to 12.19).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.4 Extrapyramidal effects</HEADING>
<P>There was no significant difference in akathisia (2 RCTs, n = 384, RR 1.56 CI 0.21 to 11.45). The results of the two included studies were heterogeneous, but neither one found a significant difference between groups (<LINK REF="STD-Potkin-2003" TYPE="STUDY">Potkin 2003</LINK>: n = 301, RR 0.71 CI 0.41 to 1.25 and <LINK REF="STD-Chan-2007" TYPE="STUDY">Chan 2007</LINK>: n = 83, RR 5.76 CI 0.67 to 49.35). There was also no significant difference in extrapyramidal symptoms (2 RCTs, n = 384, RR 1.18 CI 0.68 to 2.06), parkinsonism (1 RCT, n = 301, RR 0.14 CI 0.01 to 2.35) and use of antiparkinson medication (1 RCT, n = 83, RR 1.68 CI 0.89 to 3.17). More participants in the risperidone group than in the amisulpride group had a dystonia (1 RCT, n = 301, RR 7.14 CI 2.41 to 21.13, NNH 8 CI 20 to 5), while in the same study more participants in the aripiprazole group suffered from tremor (1 RCT, n = 301, RR 0.21 CI 0.05 to 0.90, NNH 14 CI 8 to 50).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.5 Extrapyramidal symptoms - scale measured</HEADING>
<P>There was no significant difference in dyskinesia (AIMS: 2 RCTs, n = 383, MD 0.25 CI -0.75 to 1.24), akathisia (BAS: 2 RCTs, n = 388, MD 0.11 CI -0.11 to 0.49) or extrapyramidal side effects in general (SAS: 2 RCTs, n = 388, MD 0.70 CI -0.82 to 2.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.6 Prolactin associated side effects</HEADING>
<P>In one study many more participants in the risperidone group than in the aripiprazole group had elevated prolactin levels (1 RCT, n = 301, RR 26.23 CI 12.64 to 54.46, NNH not estimable).<BR/>There was no significant difference in the frequency of dysmenorrhoea (1 RCT, n = 91, RR 0.32 CI 0.02 to 5.91).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.7 Prolactin - mean change from baseline in ng/ml</HEADING>
<P>Risperidone was associated with clearly more prolactin increase than aripiprazole (2 RCTs, n = 383, MD 54.71 CI 49.36 to 60.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.8 Metabolic - cholesterol - mean change from baseline in mg/dl</HEADING>
<P>Risperidone was associated with significantly more cholesterol increase than aripiprazole (1 RCT, n = 83, MD 22.30 CI 4.91 to 39.69).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.9 Metabolic - glucose - mean change from baseline in mg/dl</HEADING>
<P>There was no significant difference (1 RCT, n = 83, MD -6.80 CI -19.70 to 6.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.10 Metabolic - weight gain of 7% or more of total body weight</HEADING>
<P>There was no significant difference (2 RCTs, n = 284, RR 1.30 CI 0.55 to 3.07).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.11 Metabolic - weight gain - mean change from baseline in kg</HEADING>
<P>There was no significant difference (2 RCTs, n = 383, MD 0.54 CI -0.15 to 1.24).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Publication bias</HEADING>
<P>Due to the small number of included studies, we have not performed a funnel plot analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Sensitivity analysis</HEADING>
<P>The reason for the preplanned sensitivity analyses did not apply and we have therefore not performed these.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Comparison 3. Risperidone versus clozapine</HEADING>
<P>Eleven included studies fell in this category.</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1.1 Global state - no clinically significant response - as defined by the original studies</HEADING>
<P>There was no significant difference (6 RCTs, n = 575, RR 1.07 CI 0.98 to 1.16).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.2 Global state - no clinically important change - short term - as defined by the original studies</HEADING>
<P>There was no significant difference (2 RCTs, n = 333, RR 1.07 CI 0.88 to 1.30).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Leaving the study early</HEADING>
<P>A similar number of participants in the risperidone group (35%) and the clozapine group (31%) left the studies early due to any reason (8 RCTs, n = 675, RR 1.10 CI 0.86 to 1.41). Nevertheless, fewer participants in the risperidone group (7%) than in the clozapine group (12%) left the studies early due to adverse events (7 RCTs, n = 647, RR 0.55 CI 0.31 to 0.98, NNH not estimable). In contrast, more participants in the risperidone group (14%) than in the clozapine group (5%) left the studies early due to inefficacy of treatment (7 RCTs, n = 647, RR 2.51 CI 1.43 to 4.40, NNH not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1 General - no clinically important change - short term - less than 20% PANSS total score reduction</HEADING>
<P>There was no significant difference (2 RCTs, n = 106, RR 0.84 CI 0.50 to 1.42).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2 General - no clinically important change - short term</HEADING>
<P>(<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK> criteria)<BR/>There was no significant difference (1 RCT, n = 273, RR 1.05 CI 0.85 to 1.29).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.3 General - no clinically important change - long term - less than 20% BPRS total score reduction</HEADING>
<P>There was no significant difference (1 RCT, n = 29, RR 1.24 CI 0.78 to 1.98).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.4 General - no clinically important change - short term - less than 40% BPRS total score reduction</HEADING>
<P>There was no significant difference (1 RCT, n = 107, RR 1.05 CI 0.76 to 1.45).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.5 General - average score at endpoint - PANSS total</HEADING>
<P>There was no significant difference, in the short term (4 RCTs, n = 387, MD 0.75 CI -5.35 to 6.85) in the medium term (1 RCT, n = 81, MD 3.60 CI -6.12 to 13.32), or overall (5 RCTs, n = 468, RR 1.49 CI -3.44 to 6.42). The results were heterogeneous due to the study by <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> which showed a pronounced superiority of clozapine. Excluding this study did not change the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.6 General - average score at endpoint - BPRS total</HEADING>
<P>There was a trend in favour of clozapine which did not reach the conventional 5% level of statistical significance (4 RCTs, n = 364, MD 3.07 CI -0.01 to 6.16). This was in contrast to long-term (1 RCT, n = 52, MD -0.20 CI -4.12 to 3.72) and short-term data (3 RCTs, n = 345, MD 4.90 CI 2.17 to 7.64).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.7 Positive symptoms - average score at endpoint - PANSS positive</HEADING>
<P>Data on this outcome showed a superiority of clozapine (6 RCTs, n = 591, 1.26 CI 0.18 to 2.35), but when two studies with potentially skewed data were excluded (<LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK>; <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>) the difference was no longer statistically significant (4 RCTs, n = 442, MD 0.60, CI -1.34 to 2.53).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.8 Positive symptoms - average score at endpoint - short term - BPRS positive</HEADING>
<P>There was no significant difference (1 RCT, n = 29, RR 2.10 CI -0.56 to 4.76).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.9 Negative symptoms - average score at endpoint - PANSS negative</HEADING>
<P>There was no significant difference, in the short (4 RCTs, n = 481, MD -0.55 CI -2.80 to 1.71) or medium term (1 RCT, n = 81, MD 1.40 CI -1.42 to 4.22), or overall (5 RCTs, n = 562, MD -0.13 CI -1.96 to 1.71).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.10 Negative symptoms - average score at endpoint - short term - SANS total</HEADING>
<P>There was no significant difference (2 RCTs, n = 69, MD -0.62 CI -3.74 to 2.51).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 General functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.4.1 General functioning - average score at endpoint - GAF</HEADING>
<P>There was no significant difference (1 RCT, n = 19, MD 9.00 CI -0.44 to 18.44).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.2 General functioning - average endpoint - short term - social functioning scale</HEADING>
<P>There was no significant difference (1 RCT, n = 19, MD 47.00 CI 0.45 to 93.55, P = 0.05).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Cognitive functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.5.1 Cognitive functioning - medium term - no clinically important change in global neurocognitive score (less than 1/2 SD)</HEADING>
<P>There was no significant difference (1 RCT, n = 81, RR 0.79 CI 0.60 to 1.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.2 Cognitive functioning - average endpoint - medium term - global neurocognitive score</HEADING>
<P>There was no significant difference (1 RCT, n = 50, RR 0.33 CI -0.06 to 0.72).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.6.1 General - at least one adverse effect</HEADING>
<P>There was no significant difference (2 RCTs, n = 333, RR 0.85 CI 0.51 to 1.42), but the results of two studies were heterogeneous (<LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>: n = 60, RR 0.63 CI 0.42 to 0.96; <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>: n = 273, RR 1.06 CI 0.94 to 1.19). We did not identify obvious reasons for the heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.2 Death</HEADING>
<P>One study reported on death due to any reason and showed no significant difference between groups (1 RCT, n = 273, RR 1.02 CI 0.06 to 16.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.3 Cardiac effects</HEADING>
<P>Cardiac effects were reported as 'preterminally negative t-wave' (1 RCT, n = 60, RR 1.54 CI 0.07 to 36.11) and 'any significant cardiac effect' (1 RCT, n = 86, RR not estimable), but there was not significant difference.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.4 Central nervous system - sedation</HEADING>
<P>There was a significant difference in favour of risperidone (5 RCTs, n = 479, RR 0.53 CI 0.32 to 0.86, NNT 5 CI not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.5 Central nervous system - seizures</HEADING>
<P>There was a significant difference in favour of risperidone (2 RCTs, n = 354, RR 0.22 CI 0.07 to 0.70, NNT 14 CI 8 to 33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.6 Extrapyramidal effects</HEADING>
<P>There was no significant difference in akathisia (1 RCT, n = 40, RR 0.11 CI 0.01 to 1.94), akinesia (1 RCT, n = 86, RR 1.00 CI 0.38 to 2.61), dystonia (1 RCT, n = 86, RR 2.00 CI 0.19 to 21.24), extrapyramidal symptoms (2 RCTs, n = 333, RR 1.30 CI 0.44 to 3.85) and tremor (1 RCT, n = 40, RR 0.50 CI 0.18 to 1.40).</P>
<P>However, a single small study found more parkinsonism (1 RCT, n = 86, RR 0.63 CI 0.41 to 0.97, NNH 4 CI 2 to 33) in the clozapine group. In contrast, the combination of six RCTs revealed a consistently more frequent use of antiparkinson medication in the risperidone group (6 RCTs, n = 304, RR 2.57 CI 1.47 to 4.48, NNH 6 CI 33 to 3).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.7 Extrapyramidal effects - scale measured</HEADING>
<P>There was no difference in extrapyramidal side effects according to the Simpson-Angus Scale (2 RCTs, n = 69, MD 0.81 CI -0.10 to 1.73) nor the ESRS total score (1 RCT, n = 81, MD -0.30 CI -1.91 to 1.31).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.8 Haematological - white blood cells - low white blood cell count</HEADING>
<P>There was no significant difference (5 RCTs, n = 567, RR 1.69 CI 0.51 to 5.58).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.9 Prolactin associated side effects</HEADING>
<P>There was no significant difference in the frequency of sexual dysfunction (1 RCT, n = 86, RR 2.00 CI 0.39 to 10.35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.10 Prolactin - change from baseline in ng/ml</HEADING>
<P>Risperidone was associated with a clearly higher increase of prolactin levels than clozapine (men and women: 1 RCT, n = 27, MD 38.50 CI 23.30 to 53.70; men only: 1 RCT, n = 28, MD 20.00 CI 8.19 to 31.81).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.11 Metabolic - cholesterol - change from baseline in mg/dl</HEADING>
<P>There was no significant difference .(1 RCT, n = 31, MD -7.10 CI -34.01 to 19.81).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.12 Metabolic - glucose - change from baseline in mg/dl</HEADING>
<P>There was no significant difference (1 RCT, n = 31, MD -1.70 CI -12.04 to 8.64).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.13 Metabolic - weight gain</HEADING>
<P>There was no significant difference in 'weight gain of 10% or more of total body weight' (1 RCT, n = 81, RR 0.56 CI 0.18 to 1.76) or in 'weight gain reported as an adverse event' (1 RCT, n = 86, RR 0.63 CI 0.32 to 1.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.14 Metabolic - weight gain - mean change from baseline in kg</HEADING>
<P>Clozapine was associated with significantly more weight gain than risperidone (3 RCTs, n = 373, MD -3.30 CI -5.65 to -0.95). Although all three studies showed a consistent trend in favour of risperidone, the results were heterogeneous, with <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> revealing a particularly high difference (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>: n = 270, MD -2.20 CI -3.50 to -0.90; <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>: n = 77, MD -1.90 CI -3.63 to -0.17; <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>: n = 26, MD -5.98 CI -7.87 to -4.09).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Publication bias:</HEADING>
<P>Due to the small number of included studies, we did not perform a funnel plot analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.8 Investigation for heterogeneity and sensitivity analysis:</HEADING>
<P>Excluding <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> (skewed data) from the outcome BPRS total score did not change the overall result. Excluding <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK> (skewed data) and <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> (skewed data) from the outcome PANSS positive subscore, the advantage for clozapine was no longer significant (4 RCTs, n = 441, MD 0.60 CI -1.34 to 2.53). The exclusion of <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK> (skewed data) from the outcome PANSS negative subscore did not influence the result to any important extent.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Comparison 4. Risperidone versus olanzapine</HEADING>
<P>Twenty-three studies fell into this category.</P>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1.1 Global state - no clinically significant response - as defined by the original studies</HEADING>
<P>There was no significant difference (7 RCTs, n = 1376, RR 1.06 CI 0.99 to 1.13).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.2 Global state: no clinically important change (as defined by the original studies)</HEADING>
<P>There was no significant difference (5 RCTs, n = 975, RR 0.98 CI 0.88 to 1.09) in short-term (3 RCTs, n = 589, RR 1.00 CI 0.87 to 1.16), medium-term (1 RCT, n = 120, RR 0.83 CI 0.60 to 1.16) or long-term data (1 RCT, n = 266, 0.98 CI 0.71 to 1.35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.3 Global state: relapse (as defined by the original studies)</HEADING>
<P>There was no significant difference (2 RCTs, n = 211, RR 1.25 CI 0.57 to 2.71) in either short-term (1 RCT, n = 76, RR 0.75 CI 0.25 to 2.25) or long-term data (1 RCT, n = 135, RR 1.70 CI 0.79 to 3.67).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Leaving the study early</HEADING>
<P>Significantly more participants in the risperidone group (56%) than in the olanzapine group (48%) left the studies early due to any reason (15 RCTs, n = 2662, RR 1.14 CI 1.07 to 1.21, NNH 13 CI 9 to 25).<BR/>Leaving the studies early due to adverse events did not differ between groups (11% versus 12%, 13 RCTs, n = 2519, RR 0.96 CI 0.71 to 1.30). There was a trend that more participants in the risperidone group (15%) than in the olanzapine group (11%) left the studies early due to inefficacy of treatment, but the difference did not reach a conventional level of significance (14 RCTs, n = 2668, RR 1.28 CI 1.02 to 1.60).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3.1 General - no clinically important change - (less than 50% PANSS total score reduction)</HEADING>
<P>There was a significant difference in favour of olanzapine (3 RCTs, n = 472, RR 1.09 CI 1.00 to 1.18, NNH not estimable) in short-term (1 RCT, n = 71, RR 0.43 CI 0.04 to 4.57) and long-term outcomes (2 RCTs, n = 401, RR 1.09 CI 1.00 to1.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.2 General - no clinically important change - short term (less than 20% PANSS total score reduction)</HEADING>
<P>There was no significant difference (2 RCTs, n = 553, RR 1.02 CI 0.88 to 1.19).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.3 General - average endpoint score - PANSS total</HEADING>
<P>There was a significant difference in favour of olanzapine (15 RCTs, n = 2390, MD 1.94 CI 0.58 to 3.31), which was most prominent in long-term (5 RCTs, n = 1431, MD 2.59 CI 0.20 to 4.98), short-term (7 RCTs, n = 728, MD 0.97 CI -1.10 to 3.05) and medium-term outcomes (4 RCTs, n = 231, MD 4.11 CI -0.71 to 8.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.4 General - average endpoint score - BPRS total</HEADING>
<P>There was no significant difference (3 RCTs, n = 428, MD 4.16 CI 0.03 to 8.29) in either short-term (1 RCT, n = 35, MD 5.00 CI -5.74 to 15.74) or long-term outcomes (2 RCTs, n = 493, MD 4.28 CI -1.34 to 9.91).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.5 Positive symptoms - no clinically important change - short term - less than 50% PANSS positive subscore reduction</HEADING>
<P>There was no significant difference (1 RCT, n = 377, RR 0.98 CI 0.93 to 1.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.6 Positive symptoms - average endpoint score - PANSS positive</HEADING>
<P>There was no significant difference (13 RCTs, n = 1702, MD 0.46 CI -0.09 to 1.02), but medium- (3 RCTs, n = 231, MD 1.58 CI -0.03 to 3.20) and long-term data (5 RCTs, n = 810, MD 0.68 CI -0.04 to 1.40) almost indicated a benefit for the control group, compared to short-term (5 RCTs, n = 661, MD -0.48 CI -1.53 to 0.57).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.7 Negative symptoms - average endpoint score - PANSS negative</HEADING>
<P>There was no significant difference (13 RCTs, n = 1702, MD 0.46 CI -0.09 to 1.02). Long-term data (5 RCTs, n = 810, MD 0.81 CI 0.07 to 1.54) indicated a benefit for the control group, whereas short-term (5 RCTs, n = 661, MD 0.19 CI -0.85 to 1.22) and medium-term data did not show a significant difference (3 RCTs, n = 231, MD 0.00 CI -1.58 to 1.59).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.8 Negative symptoms - average endpoint score - long term - SANS total</HEADING>
<P>There was a significant superiority in favour of olanzapine (1 RCT, n = 308, MD 1.40 CI 0.37 to 2.43).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 Quality of life - average endpoint score - long term - QLS total</HEADING>
<P>In two trials the quality of life of the participants in the olanzapine group was significantly better than that of those in the risperidone group (2 RCTs, n = 296, MD 5.10 CI 1.09 to 9.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Cognitive functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.5.1 Cognitive functioning - no clinically important change - medium term (less than half a standard deviation improvement in a global neurocognitive score)</HEADING>
<P>There was no significant difference (1 RCT, n = 80, RR 1.30 CI 0.88 to 1.94).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5.2 Cognitive functioning - average score at endpoint - medium term - mean global neurocognitive score</HEADING>
<P>There was no significant difference (1 RCT, n = 52, MD 0.04 CI -0.31 to 0.39).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5.3 Cognitive functioning - average score at endpoint - long term - neurocognitive composite score</HEADING>
<P>There was no significant difference (1 RCT, n = 263, MD 0.01 CI -0.11 to 0.13).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.6 Service use - number of patients rehospitalised</HEADING>
<P>There was no significant difference overall (3 RCTs, n = 965, RR 1.34 CI 0.96 to 1.86) or in the short (1 RCT, n = 76, RR 1.35 CI 0.41 to 4.40), medium (1 RCT, n = 212, RR 1.38 CI 0.69 to 2.78) or long term (1 RCT, n = 677, RR 1.32 CI 0.89 to 1.96).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.7 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.7.1 At least one adverse effect</HEADING>
<P>There was no significant difference (11 RCTs, n = 2576, RR 0.96 CI 0.88 to 1.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.2 Death</HEADING>
<P>
<LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK> reported on death due to any reason and found no difference between groups (1 RCT, n = 339, RR 3.09 CI 0.13 to 75.30).<BR/>Two studies examined death due to natural causes. Overall there was no significant difference, but there was only one death which occurred in the olanzapine group (2 RCTs, n = 252, RR 0.34 CI 0.01 to 8.26).<BR/>Completed suicides and suicide attempts were reported by four and five studies, respectively. There was no significant difference in either outcome (suicide: 4 RCTs, n = 730, RR 3.11 CI 0.13 to 75.59; suicide attempts: 5 RCTs, n = 1724, RR 1.15 CI 0.37 to 3.54).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.3 Cardiac effects</HEADING>
<P>Cardiac effects were reported as 'ECG abnormalities' (2 RCTs, n = 415, RR 0.42 CI 0.08 to 2.30) and 'QTc prolongation' (2 RCTs, n = 853, RR 2.69 CI 0.12 to 60.00), without significant difference between groups.<BR/>The data on QTc prolongation were heterogeneous, possibly due to a difference in age groups, because <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK> included only elderly participants with schizophrenia. Nevertheless, neither one of the two individual studies found a significant difference between groups (<LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>: n = 176, RR 0.77 CI 0.18 to 3.33; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: 1 RCT, n = 677, RR 14.78 CI 0.85 to 257.77).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.4 Cardiac effects - mean change of QTc interval from baseline in ms</HEADING>
<P>There was no significant difference (6 RCTs, n = 1518, MD 0.96 CI -2.74 to 4.67).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.5 Central nervous system - sedation</HEADING>
<P>There was no significant difference (11 RCTs, n = 2576, RR 0.93 CI 0.84 to 1.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.6 Central nervous system - seizures</HEADING>
<P>There was no significant difference (4 RCTs, n = 671, RR 0.26 CI 0.03 to 2.35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.7 Extrapyramidal effects</HEADING>
<P>There was no significant difference in the number of participants with akinesia (3 RCTs, n = 681, RR 1.21 CI 0.82 to 1.79), dyskinesia (3 RCTs, n = 580, RR 1.02 CI 0.36 to 2.90), dystonia (3 RCTs, n = 591, RR 1.79 CI 0.37 to 8.77), rigor (2 RCTs, n = 141, RR 0.41 CI 0.06 to 2.70), tremor (5 RCTs, n = 973, RR 0.87 CI 0.48 to 1.57) or extrapyramidal symptoms (4 RCTs, n = 1104, RR 1.33 CI 0.83 to 2.13). The results of the latter outcome were heterogeneous, possibly due to a single study in elderly participants which showed an opposite trend compared to the other studies (<LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>). Excluding <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK> there was a significant superiority of olanzapine (RR 1.54, CI 1.05 to 2.28, NNH 13 CI 8 to 33).</P>
<P>Risperidone produced more akathisia (8 RCTs, n = 1988, RR 1.30 CI 1.02 to 1.66, NNH not estimable) and parkinsonism (1 RCT, n = 776, RR 1.65 CI 1.08 to 2.51, NNH not estimable), and it was associated with more frequent use of antiparkinson medication (13 RCTs, n = 2599, RR 1.28 CI 1.06 to 1.55, NNH 17 CI 9 to 100).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.8 Extrapyramidal symptoms - scale measured</HEADING>
<P>There was no significant difference in akathisia (BAS: 2 RCTs, n = 353, MD 0.72 CI -0.36 to 1.81; ESRS akathisia subscore: 1 RCT, n = 359, MD 0.00 CI -0.27 to 0.27), dyskinesia (AIMS: 11 RCTs, n = 302, MD 0.03 CI -0.72 to 0.78; ESRS dyskinesia subscore: 3 RCTs, n = 572, MD -0.08 CI -0.76 to 0.60), dystonia (ESRS dystonia subscore: 1 RCT, n = 42, MD -0.09 CI -0.91 to 0.73), overall general extrapyramidal symptoms (ESRS total score: 4 RCTs, n = 682, MD 0.30 CI -0.35 to 0.94; SAS: 5 RCTs, n = 522, MD 0.62 CI -0.08 to 1.33) or parkinsonism (ESRS parkinsonism subscore: 3 RCTs, n = 572, MD 0.24 CI -1.09 to 1.57. It should be noted that some of these results were heterogeneous, but no clear reason for the heterogeneity could be identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.9 Haematological - white blood cells - number of participants with low white blood cell count</HEADING>
<P>Overall there was no significant difference (3 RCTs, n = 484, RR 1.00 CI 0.09 to 10.59). The results of the three studies were heterogeneous, but the single trials did not show significant differences between risperidone and olanzapine either (<LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>: n = 339, RR 0.15 CI 0.02 to 1.18; <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>: n = 80, RR 4.76 CI 0.24 to 96.16; and <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>: n = 65, RR 2.91 CI 0.12 to 68.95).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.10 Prolactin associated side effects</HEADING>
<P>Significantly more participants in the risperidone group suffered from amenorrhea (7 RCTs, n = 565, RR 1.50 CI 1.02 to 2.22, NNH not estimable) and 'abnormal ejaculation' (3 RCTs, n = 531, RR 4.34 CI 1.49 to 12.69, NNH not estimable). More participants in the risperidone group had abnormally high prolactin levels, but this result did not reach conventional levels of statistical significance (3 RCTs, n = 477, RR 3.02 CI 0.99 to 9.23).</P>
<P>There were no significant differences in decreased libido (3 RCTs, n = 781, RR 2.48 CI 0.77 to 8.00), galactorrhea (7 RCTs, n = 547, RR 1.64 CI 0.79 to 3.39), gynaecomastia (5 RCTs, n = 1083, RR 1.39 CI 0.70 to 2.77), impotence (3 RCTs, n = 531, RR 2.00 CI 0.68 to 5.89), orgasmic dysfunction (1 RCT, n = 377, RR 5.03 CI 0.24 to 104.00) and sexual dysfunction (7 RCTs, n = 1715, RR 1.07 CI 0.90 to 1.28).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.11 Prolactin - mean change from baseline in ng/ml</HEADING>
<P>Risperidone was associated with significantly more prolactin increase than olanzapine (men and women combined: 6 RCTs, n = 1291, MD 22.84 CI 17.69 to 27.98; men only: 2 RCTs, n = 70, MD 19.91 CI 13.64 to 26.18; women only: 1 RCT, n = 71, MD 41.40 CI 29.64 to 53.16). There was some heterogeneity in the degree of the difference, but all studies consistently favoured olanzapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.12 Metabolic - cholesterol - number of participants with a cholesterol increase</HEADING>
<P>There was no significant difference (1 RCT, n = 266, RR 0.78 CI 0.44 to 1.38).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.13 Metabolic - cholesterol - mean change from baseline in mg/dl</HEADING>
<P>There was a significant difference favouring risperidone (7 RCTs, n = 1391, MD -10.36 CI -14.43 to -6.28).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.14 Metabolic - glucose - abnormally high fasting glucose value</HEADING>
<P>There was no significant difference (3 RCTs, n = 670, RR 0.50 CI 0.22 to 1.16).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.15 Metabolic - glucose - change from baseline in mg/dl</HEADING>
<P>There was a significant difference in favour of risperidone (7 RCTs, n = 1201, MD -7.58 CI -11.23 to -3.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.16 Metabolic - weight gain - number of participants with weight gain</HEADING>
<P>Significantly fewer participants in the risperidone group than in the olanzapine group suffered from weight gain (11 RCTs, n = 2594, RR 0.55 CI 0.43 to 0.72, NNT 9 CI 7 to 14). There was some heterogeneity due to a first episode study (<LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>) which showed only a small difference between groups, but the overall trend was very consistent in favour of risperidone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7.17 Metabolic - weight gain - mean change from baseline in kg</HEADING>
<P>Risperidone was associated with significantly less weight gain than olanzapine (3 RCTs, n = 2116, MD -2.61 CI -3.74 to -1.48). The results were heterogeneous, because <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> showed an extreme superiority of risperidone. Excluding this study resolved the heterogeneity and risperidone's superiority prevailed (12 RCTs, n = 2090, MD -2.06 CI -2.74 to -1.37).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.8 Publication bias</HEADING>
<P>A funnel plot of the outcome PANSS total score (&gt; 10 included studies) did not suggest a significant publication bias.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.9 Investigation for heterogeneity and sensitivity analysis</HEADING>
<P>Excluding <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK> (skewed data) from the outcome 'PANSS positive score' did not change the result. The exclusion of <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK> (skewed data) from the analysis of the BPRS total score did not have an important impact on this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Comparison 5. Risperidone versus quetiapine</HEADING>
<P>Eleven included studies fell in this category.</P>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1.1 Global state - no clinically significant response - as defined by the original studies</HEADING>
<P>Overall there was no significant difference. As the results were heterogeneous we present the single studies separately. <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK> reported a significant difference in favour of risperidone (1 RCT, n = 177, RR 0.79 CI 0.65 to 0.96), while <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK> (1 RCT, n = 495, RR 1.00 CI 0.92 to 1.10), <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> (1 RCT, n = 103, RR 0.85 CI 0.62 to 1.15) and <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK> found no significant difference between groups (1 RCT, n = 25, RR not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.1.2 Global state - no clinically important change (as defined by the original studies)</HEADING>
<P>Short-term studies (3 RCTs, n = 1007, RR 0.86 CI 0.70 to 1.07) and long-term studies (1 RCT, n = 267, RR 0.85 CI 0.62 to 1.15) tended to favour risperidone, but the difference was not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2 Leaving the study early</HEADING>
<P>There was no significant difference in the number of participants leaving the studies early due to any reason (risperidone 54%, quetiapine 57%, 10 RCTs, n = 2278, RR 0.94 CI 0.87 to 1.02) or due to adverse events (9% versus 11%, 7 RCTs, n = 1851, RR 0.84 CI 0.56 to 1.27). Leaving early due to inefficacy showed an almost significant superiority of risperidone (24% versus 19%, 7 RCTs, n = 1851, RR 0.79 CI 0.62 to 1.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.3.1 General - no clinically important change - short term - less than 30% PANSS total score reduction from baseline</HEADING>
<P>There was no significant difference (2 RCTs, n = 982, RR 0.90 CI 0.71 to 1.15), but the results were heterogeneous. <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK> found a superiority of risperidone (n = 177, RR 0.79 CI 0.65 to 0.96), whereas <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK> found no difference between groups (n = 495, RR 1.00 CI 0.92 to 1.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.2 General - no clinically important change - short term - less than 20% BPRS total score reduction from baseline</HEADING>
<P>There was no significant difference (1 RCT, n = 25, RR 1.03 CI 0.66 to 1.60).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.3 General - average score at endpoint - PANSS total</HEADING>
<P>There was a significant difference in favour of risperidone (9 RCTs, n = 1953, MD -3.09 CI -5.16 to -1.01), which was seen in long-term data (2 RCTs, n = 743, MD -3.11 CI -5.82 to -0.40), but not in medium-term (2 RCTs, n = 146, MD -6.27 CI -16.48 to 3.94) or short-term (5 RCTs, n = 1064, MD -2.44 CI -5.69 to 0.81) data.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.4 General - average score at endpoint - short term - BPRS total</HEADING>
<P>There was no significant difference (1 RCT, n = 25, MD -1.68 CI -11.69 to 8.33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.5 Positive symptoms - short term - less than 40% PANSS positive subscore reduction from baseline</HEADING>
<P>There was no significant difference (1 RCT, n = 673, RR 1.00 CI 0.9 to 1.12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.6 Positive symptoms - average endpoint score - PANSS positive</HEADING>
<P>There was a significant difference in favour of risperidone (7 RCTs, n = 1264, MD -1.82 CI -2.48 to -1.16),<BR/>which was most prominent in short-term data (4 RCTs, n = 1037, MD -2.10 CI -3.19 to -1.00) as well as medium-term (2 RCTs, n = 146, MD -2.15 CI -4.31 to 0.01) and long-term (1 RCT, n = 81, MD -1.30 CI -2.73 to 0.13) data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.7 Positive symptoms - average endpoint score - short term - BPRS positive</HEADING>
<P>There was a significant difference in favour of risperidone (1 RCT, n = 25, MD -1.10 CI -2.02 to -0.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.8 Negative symptoms - average endpoint score - short term - less than 40% PANSS negative subscore reduction from baseline</HEADING>
<P>There was no significant difference (1 RCT, n = 673, RR 1.02 CI 0.96 to 1.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.9 Negative symptoms - average endpoint score - PANSS negative</HEADING>
<P>There was no significant difference in the short (4 RCTs, n = 956, MD -1.46 CI -4.11 to 1.19), medium (2 RCTs, n = 146, MD 1.3 CI -3.35 to 0.75) or long term (1 RCT, n = 81, MD 0.8 CI -2.27 to 0.61).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.10 Negative symptoms - average endpoint score - short term - BPRS negative</HEADING>
<P>There was a significant difference favouring risperidone (1 RCT, n = 25, MD -0.57 CI -0.97 to -0.17).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.4 Quality of life: average endpoint score - short term - QLS total</HEADING>
<P>There was no significant difference (1 RCT, n = 22, MD 0.5 CI -12.87 to 13.87).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.5 Service use: number of participants rehospitalised</HEADING>
<P>There was a benefit in favour of risperidone in the overall analysis (2 RCTs, n = 877, RR 0.75 CI 0.56 to 1.00), as well as in the medium (1 RCT, n = 199, RR 0.77 CI 0.42 1.41) and long term (1 RCT, n = 681, RR 0.7 CI 0.53 1.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.6 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.6.1 General - at least one adverse effect</HEADING>
<P>There was no significant difference (8 RCTs, n = 2226, RR 0.96 CI 0.85 to 1.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.2 Death</HEADING>
<P>There was no significant difference in the number of completed suicides (3 RCTs, n = 1139, RR 0.71 CI 0.05 to 9.16) or in the number of suicide attempts (2 RCTs, n = 945, RR 2.30 CI 0.34 to 15.65).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.3 Cardiac effects - number of participants with QTc prolongation</HEADING>
<P>There was no significant difference between groups (2 RCTs, n = 1351, RR 1.15 CI 0.39 to 3.40).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.4 Cardiac effects - mean change of QTc interval from baseline in ms</HEADING>
<P>There was no significant difference (3 RCTs, n = 940, MD -2.21 CI -9.48 to 5.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.5 Central nervous system - sedation</HEADING>
<P>There was a significant difference in favour of risperidone (8 RCTs, n = 2226, RR 0.82 CI 0.69 to 0.97, NNT 20 CI 11 to 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.6 Central nervous system - somnolence</HEADING>
<P>There was a significant difference in favour of risperidone (1 RCT, n = 309, RR 0.25 CI 0.09 to 0.75, NNT 13 CI 8 to 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.7 Extrapyramidal effects - number of participants with extrapyramidal side effects</HEADING>
<P>There was no significant difference in akinesia (1 RCT, n = 267, RR 1.10 CI 0.73 to 1.65) and rigor (1 RCT, n = 309, RR 2.24 CI 0.80 to 6.30). Nevertheless, risperidone produced more dystonias (1 RCT, n = 673, RR 18.16 CI 2.44 to 135.27, NNH 20 CI 33 to 13) and more extrapyramidal symptoms (2 RCTs, n = 872, RR 1.69 CI 1.23 to 2.34, NNH 14 CI 33 to 8). More participants in the risperidone group used antiparkinson medication at least once (6 RCTs, n = 1715, RR 1.98 CI 1.16 to 3.39, NNH 20 CI 10 to 100).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.8. Extrapyramidal symptoms - scale measured</HEADING>
<P>Risperidone induced more extrapyramidal side effects than quetiapine according to the Simpson-Angus Scale (5 RCTs, n = 1077, MD 0.59 CI 0.02 to 1.16). There was no significant difference in dyskinesia (AIMS, 2 RCTs, n = 958, MD 0.34 CI -0.08 to 0.75) and akathisia (BAS, 2 RCTs, n = 700, MD 0.73 CI -0.54 to 2.0).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.9 Haematological - white blood cell count - number of participants with low white blood cell count</HEADING>
<P>There was no significant difference (1 RCT, n = 673, RR 0.34 CI 0.01 to 8.23)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.10 Prolactin associated side effects</HEADING>
<P>Amenorrhea (4 RCTs, n = 359, RR 2.14 CI 1.26 to 3.64, NNH not estimable) and galactorrhea (5 RCTs, n = 478, RR 2.65 CI 1.19 to 5.91, NNH 25 CI 100 to 13) were more frequent in the risperidone group, while gynaecomastia (1 RCT, n = 78, RR 4.33 CI 1.34 to 14.02, NNH 4 CI 11 to 2) occurred more frequently in the quetiapine group. There was no significant difference in the frequency of sexual dysfunction (6 RCTs, n = 2157, RR 1.24 CI 0.99 to 1.54) or dysmenorrhoea (1 RCT, n = 163, RR 2.23 CI 0.42 to 11.86).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.11 Prolactin - change from baseline in ng/ml</HEADING>
<P>There was a significant and consistent difference in favour of quetiapine (6 RCTs, n = 1731, MD 35.28 CI 26.19 to 44.36). Only the amount of the difference varied, leading to significant heterogeneity (<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: n = 678, MD 24.70 CI -20.68 to 28.72; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>: n = 24, MD 28.6 CI 14.18 to 43.02; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>: n = 309, MD 50.4 CI -40.56 to 60.24; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>: n = 199, MD 30.3 CI 23.50 to 37.10; <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK>: n = 440, MD 47.0 CI 41.03 to 52.97; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>: n = 81, MD 30.8 CI 23.50 to 38.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.12 Metabolic - cholesterol - number of participants with increased cholesterol</HEADING>
<P>There was no significant difference (2 RCTs, n = 940, RR 0.79 CI 0.45 to 1.39).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.13 Metabolic - cholesterol - mean change from baseline in mg/dl</HEADING>
<P>Risperidone was associated with less cholesterol increase than quetiapine (5 RCTs, n = 1433, MD -8.49 CI -12.23 to 4.75).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.14 Metabolic - glucose - abnormally high fasting glucose value</HEADING>
<P>There was no significant difference (2 RCTs, n = 940, RR 0.72 CI 0.29 to 1.79).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.6.15 Metabolic - glucose - mean change from baseline in mg/dl</HEADING>
<P>There was no significant difference (5 RCTs, n = 1436, MD 0.04 CI -2.83 to 2.92).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.7.16 Metabolic - weight gain - number of participants with 7% or more gain of total body weight</HEADING>
<P>There was no significant difference (7 RCTs, n = 1942, RR 1.03 CI 0.88 to 1.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.7.17 Metabolic - weight gain - mean change from baseline in kg</HEADING>
<P>Overall there was no significant difference (7 RCTs, n = 1446, MD -0.71 CI -2.47 to 1.04), but the data were highly heterogeneous presumably due to one small outlier study (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>) that showed a dramatic advantage of risperidone. Nevertheless, excluding this study did not change the overall result.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.8 Publication bias</HEADING>
<P>The funnel plot of the outcome PANSS total score (&gt; 10 included studies) did not suggest a significant publication bias.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="5">5.9 Investigation for heterogeneity and sensitivity analysis</HEADING>
<P>Excluding <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK> (skewed data) from the analysis of the PANSS positive subscore did not change the overall result. When <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK> was excluded from the analysis of the SAS score, quetiapine was no longer significantly superior in terms of general extrapyramidal side effects.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Comparison 6. Risperidone versus sertindole - all data short term</HEADING>
<P>Two included studies fell in this category.</P>
<SUBSECTION>
<HEADING LEVEL="4">6.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1.1 Global state - no clinically significant response - as defined by the original studies</HEADING>
<P>There was no significant difference (1 RCT, n = 187, RR 1.14 CI 0.92 to 1.40).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.1.2 Global state - no clinically important change</HEADING>
<P>There was no significant difference (1 RCT, n = 187, RR 1.24 CI 0.91 to 1.68).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2 Leaving the study early</HEADING>
<P>There were no significant differences between groups. 30% of the participants in the risperidone group and 36% of those in the sertindole group left the study early due to any reason (2 RCTs, n = 508, RR 0.81 CI 0.63 to 1.06). 7% of the participants in the treatment group and 9% of those in the sertindole group left the studies due to adverse events (2 RCTs, n = 508, RR 0.73 CI 0.39 to 1.35). 10% and 14% of the participants in the risperidone and sertindole groups, respectively, left the studies early due to lack of efficacy (2 RCTs, n = 508, RR 0.76 CI 0.46 to 1.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.3.1 General - no clinically important change (less than 50% PANSS total score reduction)</HEADING>
<P>There was no significant difference (1 RCT, n = 187, RR 1.14 CI 0.92 to 1.40).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3.2 General - average endpoint score - PANSS total</HEADING>
<P>There was no significant difference (2 RCTs, n = 493, MD -1.98 CI -12.20 to 8.24), but the results were heterogeneous. One study in treatment refractory participants showed a significant superiority of risperidone (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>: n = 321, MD -6.94 CI -12.14 to -1.74), whereas another study without this criterion revealed no significant difference (<LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>: n = 172, MD 3.50 CI -3.42 to 10.42).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3.3 Positive symptoms - average endpoint score - PANSS positive</HEADING>
<P>There was no significant difference (1 RCT, n = 172, MD 0.80 CI -1.35 to 2.95).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3.4 Negative symptoms - average endpoint score - PANSS negative</HEADING>
<P>There was no significant difference (1 RCT, n = 172, MD 1.30 CI -0.53 to 3.13).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3.5 General functioning - average endpoint score - GAF total</HEADING>
<P>There was no significant difference (1 RCT, n = 114, RR 2.90 CI -2.61 to 8.41).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.4 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.4.1 General - at least one adverse effect</HEADING>
<P>There was no significant difference (2 RCTs, n = 508, RR 0.97 CI 0.90 to 1.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.2 Death</HEADING>
<P>There was no significant difference (1 RCT, n = 187, RR 3.30 CI 0.14 to 79.98).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.3 Cardiac effects - number of participants with QTc prolongation</HEADING>
<P>Fewer participants in the risperidone group had a prolongation of the QTc interval (2 RCTs, n = 508, RR 0.21 CI 0.08 to 0.51, NNH not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.4 Cardiac effects - mean change of QTc interval from baseline in ms</HEADING>
<P>Risperidone was associated with less QTc change than sertindole (2 RCTs, n = 495, MD -18.60 CI -22.37 to -14.83).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.5 Central nervous system - sedation</HEADING>
<P>There was no significant difference (2 RCTs, n = 508, RR 1.15 CI 0.69 to 1.92).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.6 Extrapyramidal effects</HEADING>
<P>Risperidone produced more akathisia (1 RCT, n = 321, RR 2.24 CI 1.02 to 4.92, NNH not estimable) and more parkinsonism (1 RCT, n = 321, RR 4.11 CI 1.44 to 11.73, NNH 14 CI 100 to 8) than sertindole. There was no significant difference in the frequency extrapyramidal symptoms (1 RCT, n = 187, RR 1.53 CI 0.90 to 2.61) or tremor (1 RCT, n = 187, RR 0.66 CI 0.16 to 2.69).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.7 Extrapyramidal effects - scale measured</HEADING>
<P>There was no significant difference in dyskinesia (AIMS: 2 RCTs, n = 477, MD 0.31 CI -0.25 to 0.86) and general EPS (SAS: 2 RCTs, n = 500, MD 0.37 CI -0.61 to 1.35), but there was a significant superiority of sertindole in akathisia (BAS: 2 RCTs, n = 500, MD 0.22 CI 0.03 to 0.41).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.8 Prolactin associated effects - sexual dysfunction</HEADING>
<P>Overall, risperidone produced less sexual dysfunction than sertindole (2 RCT, n = 437, RR 0.34 CI 0.16 to 0.76, NNT 13 CI 8 to 33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.9 Metabolic - cholesterol - change from baseline in mg/dl</HEADING>
<P>There was no significant difference (1 RCT, n = 176, MD 4.90 CI -3.73 to 13.53).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.10 Metabolic - glucose - mean change from baseline in mg/dl</HEADING>
<P>There was no significant difference (1 RCT, n = 176, MD 2.00 CI -5.85 to 9.85).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.11 Metabolic - weight gain - number of participants with weight gain</HEADING>
<P>There was no significant difference (1 RCT, n = 187, RR 0.77 CI 0.41 to 1.43).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.12 Metabolic - weight gain - mean change from baseline in kg</HEADING>
<P>Risperidone was associated with less weight gain than sertindole (2 RCTs, n = 328, MD -0.99 CI -1.86 to -0.12).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.5 Publication bias</HEADING>
<P>Due to the small number of included studies, a funnel plot analysis was not meaningful.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.6 Investigation for heterogeneity and sensitivity analysis</HEADING>
<P>The reason for the preplanned sensitivity analysis did not apply and we therefore have not performed this.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Comparison 7. Risperidone versus ziprasidone</HEADING>
<P>Three included studies fell in this category.</P>
<SUBSECTION>
<HEADING LEVEL="4">7.1 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.1.1 Global state - no clinically significant response - as defined by the original studies</HEADING>
<P>There was no significant difference (1 RCT, n = 296, RR 1.02 CI 0.93 to 1.12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.1.2 Global state - no clinically important change - short term - as defined by the original studies</HEADING>
<P>There was no significant difference (1 RCT, n=296, RR 0.81 CI 0.63 to 1.04).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.2 Leaving the study early</HEADING>
<P>There were no significant differences. 58% of the participants in the risperidone group and 65% of those in the ziprasidone group left the studies early due to any reason (3 RCTs, n = 1036, RR 0.90 CI 0.83 to 0.98). 9% of the risperidone group and 11% of the ziprasidone group left the studies early due to adverse events (3 RCTs, n = 1036, RR 0.82 CI 0.50 to 1.32). 20% of the risperidone group and 23% of the ziprasidone group left the studies early due to lack of efficacy of treatment (3 RCTs, n = 1036, RR 0.88 CI 0.60 to 1.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.3.1 General - no clinically important change - short term - less than 50% PANSS total reduction</HEADING>
<P>There was no significant difference (1 RCT, n = 296, RR 1.02 CI 0.93 to 1.12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.3.2 General - average endpoint score - PANSS total</HEADING>
<P>There was a significant difference in favour of risperidone (3 RCTs, n = 1016, MD -3.91 CI -7.55 to -0.27), but the results were heterogeneous. The long-term study by <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> revealed a significant difference (1 RCT, n = 516, MD -6.01 CI -10.03 to -1.99), whereas a short-term study (<LINK REF="STD-Addington-2004" TYPE="STUDY">Addington 2004</LINK>: 1 RCT, n = 296, MD -1.50 CI -3.16 to 0.16), and a medium-term study (<LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>: 1 RCT, n = 204, MD -6.30 CI -12.77 to 0.17) revealed only a trend in favour of risperidone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.3.3 General - average endpoint score - short term - BPRS total</HEADING>
<P>There was no significant difference (1 RCT, n = 296, MD -0.70 CI -4.33 to 2.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.3.4 Positive symptoms - average endpoint score - medium term - PANSS positive</HEADING>
<P>There was a significant difference in favour of risperidone (1 RCT, n = 204, MD -2.50 CI -4.62 to -0.38).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.4.5 Positive symptoms - average endpoint score - medium term - BPRS positive</HEADING>
<P>There was no significant difference (1 RCT, n = 296, MD-0.50 CI -1.15 to 0.15).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.4.6 Negative symptoms - average endpoint score - PANSS negative</HEADING>
<P>There was no significant difference overall (2 RCTs, n = 500, MD -0.04 CI -1.20 to 1.12), or in the short (1 RCT, n = 296, MD 0.00 CI -1.48 to 1.48) or medium term (1 RCT, n = 204, MD -0.10 CI -1.98 to 1.78).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.5 Service use - number of participants rehospitalised</HEADING>
<P>There was no significant difference (2 RCTs, n = 777, RR 0.87 CI 0.63 to 1.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.6 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.6.1 At least one adverse effect</HEADING>
<P>There was no significant difference (3 RCTs, n = 1063, RR 1.07 CI 0.98 to 1.17).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.2 Death</HEADING>
<P>There was no significant difference in the number of suicide attempts (1 RCT, n = 526, RR 1.09 CI 0.10 to 11.89) or in the number of completed suicides (1 RCT, n = 241, RR 0.66 CI 0.06 to 7.17)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.3 Cardiac effects - number of participants with QTc prolongation</HEADING>
<P>There was no significant difference (2 RCTs, n = 822, RR 1.90 CI 0.40 to 9.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.4 Cardiac effects - mean change of QTc interval from baseline in ms</HEADING>
<P>There was no significant difference (3 RCTs, n = 793, RR -2.24 CI -6.39 to 1.92).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.5 Central nervous system - sedation</HEADING>
<P>There was no significant difference (3 RCTs, n = 1063, RR 1.15 CI 0.83 to 1.59).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.6 Extrapyramidal effects</HEADING>
<P>There was no significant difference in the frequency of akathisia (2 RCTs, n = 1063, RR 1.02 CI 0.55 to 1.89) and tremor (1 RCT, n = 296, RR 0.95 CI 0.47 to 1.89), but risperidone produced more extrapyramidal symptoms (1 RCT, n = 241, RR 3.16 CI 1.15 to 8.69, NNH 13 CI 100 to 7) and more participants in the risperidone group used antiparkinson medication at least once (2 RCTs, n = 822, RR 1.42 CI 1.03 to 1.96, NNH not estimable).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.7 Extrapyramidal effects - scale measured</HEADING>
<P>There were no significant differences in dykinesia (AIMS: 1 RCT, n = 296, MD 0.21 CI 0.17 to 0.25) and akathisia (BAS: 1 RCT, n = 296, MD 0.56 CI 0.51 to 0.61), but risperidone produced more overall EPS than ziprasidone (SAS: 1 RCT, n = 296, MD 0.34 CI 0.26 to 0.42).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.8 Prolactin-associated side effects</HEADING>
<P>There was no significant difference in the frequency of abnormal ejaculation (1 RCT, n = 215, RR 2.10 CI 0.65 to 6.75), amenorrhea (1 RCT, n = 81, RR 0.93 CI 0.20 to 4.33), decreased libido (1 RCT, n = 296, RR 1.65 CI 0.70 to 3.86), erectile dysfunction (1 RCT, n = 215, RR 1.05 CI 0.38 to 2.88) and galactorrhea (2 RCTs, n = 159, RR 5.07 CI 0.61 to 42.45). Only orgastic dysfunction occurred more frequently in the risperidone group than in the ziprasidone group (2 RCTs, n = 516, RR 1.44 CI 1.03 to 2.02).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.9 Prolactin - mean change from baseline in ng/ml</HEADING>
<P>Risperidone was associated with more prolactin increase than ziprasidone (2 RCTs, n = 767, MD 21.97 CI 16.60 to 27.34).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.10 Metabolic - cholesterol - change from baseline in mg/dl</HEADING>
<P>There was a significant difference in favour of ziprasidone (2 RCTs, n = 767, MD 8.58 CI 1.11 to 16.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.11 Metabolic - glucose - mean change from baseline in mg/dl</HEADING>
<P>There was no significant difference (2 RCTs, n = 767, RR 4.94 CI -1.91 to 11.80).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.12 Metabolic - weight gain of 7% or more of total body weight</HEADING>
<P>Three studies showed a significant difference in favour of ziprasidone (3 RCTs, n = 1063, RR 2.03 CI 1.35 to 3.06, NNH 14 CI 33 to 10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.6.13 Metabolic - weight gain - change from baseline in kg</HEADING>
<P>Only one study reported on this outcome. It found no significant difference (1 RCT, n = 461, MD 1.10 CI -0.15 to 2.35).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.7 Publication bias</HEADING>
<P>Due to the small number of included studies, a funnel plot analysis was not meaningful.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.8 Sensitivity analyses</HEADING>
<P>The reasons for the preplanned sensitivity analysis did not apply and we have therefore not performed this.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-12-07 13:41:36 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-12-07 13:41:36 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. General</HEADING>
<P>In the last years the number of randomised risperidone trials has dramatically increased. A previous Cochrane review comparing risperidone with other SGA drugs included only nine RCTs (<LINK REF="REF-Gilbody-2000" TYPE="REFERENCE">Gilbody 2000</LINK>). The current review includes 45 RCTs, although we had more stringent inclusion criteria and excluded open RCTs. Nevertheless, many problems that were identified by the previous review have not been solved:</P>
<P>The number of participants leaving schizophrenia trials prematurely remain high (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>). The overall attrition of 47% in the included studies is a threat to the validity of the findings.</P>
<P>Adverse events were often only reported if they had a frequency of 5%/10% or greater. This procedure results in underreporting of rare but important adverse effects. We suggest to abandon the &gt; 5%/10% frequency rule for reporting of adverse effects and suggest that all adverse events should be reported instead, for example as online supplements that are nowadays made available by most journals.</P>
<P>Most trials provided data on leaving the studies early and overall efficacy. Outcomes that are possibly more important for daily life such as general functioning or satisfaction with treatment are rarely presented. Authors keep using different criteria for 'response to treatment' making comparisons difficult, although validated suggestions for the presentation of response to treatment are available (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>; <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>; <LINK REF="REF-Van-Os-2006" TYPE="REFERENCE">Van Os 2006</LINK>).</P>
<P>More than half of the 45 included trials were categorised as 'short-term' studies and only eight were 'long-term' studies with a length of more than 26 weeks. Schizophrenia is a chronic, often life-long disorder, making more long-term studies necessary.</P>
<P>60% of the studies were sponsored by pharmaceutical companies producing either risperidone or its comparator drugs, whereas only 31% of the studies had a neutral sponsor (the sponsor of the remaining RCTs remained unclear). Due to the inevitable conflict of interest, industry sponsorship is a concern (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>).</P>
<P>Finally, most studies compared risperidone with clozapine, olanzapine and quetiapine. Fewer RCTs comparing risperidone with amisulpride, aripiprazole, sertindole and ziprasidone are available, and comparisons with zotepine are completely missing.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparison 1. Risperidone versus amisulpride</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Leaving the studies early</HEADING>
<P>There were no significant differences in the number of participants leaving the studies early due to any reason, due to adverse events or due to inefficacy of treatment. These results suggest a similar overall acceptability, tolerability and efficacy of risperidone and amisulpride. Nevertheless, four studies with 622 participants do not provide a firm basis for such a conclusion. Furthermore, although the overall rate of participants leaving the studies early of 33.2% was lower than that of some other comparisons, it was still considerable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>There was no clear efficacy difference between risperidone and amisulpride. There was a significant superiority of amisulpride in terms of 50% BPRS reduction. However, this result was based on only one trial and may have well occurred by chance alone, given the high number of statistical tests applied (<LINK REF="STD-Sechter-2002" TYPE="STUDY">Sechter 2002</LINK>). Furthermore, the same trial did not find any difference in the mean values at endpoint of the BPRS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 General functioning</HEADING>
<P>A single study using the SOFAS scale reported on social functioning and found no difference between risperidone and amisulpride. Pragmatic studies that are conducted in situations that are more similar to routine care are needed to address this important outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Adverse effects</HEADING>
<P>There were some data on extrapyramidal side effects, cardiac effects, prolactin associated side effects, sedation, seizures and death.</P>
<P>Besides the reporting on sexual dysfunction which indicated a benefit for amisulpride, the only adverse event showing a significant difference was weight gain which was 1kg more in the risperidone group. This difference was found in short- to medium-term studies. It may well be that the difference would be more pronounced in the long term, but longer studies are needed to verify this assumption. Nevertheless, if metabolic issues are a concern, amisulpride may be a better choice than risperidone.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Comparison 2. Risperidone versus aripiprazole</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Leaving the studies early</HEADING>
<P>Again, the number of participants leaving the two studies early was considerable (34.4%). There was no significant difference between both compounds, suggesting that their acceptability is similar, but two included studies - both sponsored by the manufacturers of aripiprazole - are no firm basis for any conclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>There were no statistically significant differences in global state, general mental state, positive and negative symptoms. The currently available small evidence base does thus not suggest a difference in efficacy between both compounds. Nevertheless, "no evidence of effect does not mean evidence of no effect" (<LINK REF="REF-Tarnow_x002d_Mordi-1999" TYPE="REFERENCE">Tarnow-Mordi 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Adverse effects</HEADING>
<P>Limited data were available on extrapyramidal side effects, cardiac effects, cholesterol, glucose, prolactin increase, prolactin associated side effects and weight gain.</P>
<P>There was a significant benefit for aripiprazole in terms of dystonia, QTc abnormalities, prolactin increase and cholesterol levels, whereas tremor was less frequent in the risperidone group. Overall risperidone´s tolerability profile may be somewhat worse than that of aripiprazole, but these results are based on very limited data. Any conclusion would be premature.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Comparison 3. Risperidone versus clozapine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Leaving the studies early</HEADING>
<P>The 11 included studies showed a considerable overall attrition of 33.4%. Although this attrition was not as high as in some other comparisons of this review, it nevertheless limits the interpretation of all results beyond the outcome of leaving the studies early.</P>
<P>A similar number of participants in the risperidone and the clozapine groups left the studies early due to any reason, suggesting a comparable overall acceptability of both compounds. Nevertheless, there were significant differences in the reasons why participants left the studies.</P>
<P>Adverse events were a greater problem in the clozapine group. Clozapine is associated with a number of serious and partly dangerous adverse effects such agranulocytosis, seizures, sedation or weight gain (see 4.4 below), which may explain risperidone's superiority in this regard.</P>
<P>Inefficacy of treatment led more frequently to leaving the studies early in the risperidone group. This suggests a certain efficacy superiority of clozapine. Indeed, clozapine was associated with a somewhat more pronounced reduction of positive symptoms than risperidone, although the difference was not robust (see 4.2 below).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>The only significant difference between risperidone and clozapine was a superiority of the latter in terms of positive symptoms. Even this difference was not robust, because when two studies with possibly skewed data were excluded it was no longer statistically significant.</P>
<P>This failure to find clozapine superior was surprising, because clozapine is generally considered to be the most efficacious antipsychotic drug available. This superiority has recently been confirmed by the industry independent studies CATIE II (<LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>) and CUtLASS (<LINK REF="REF-Lewis-2006" TYPE="REFERENCE">Lewis 2006</LINK>) which could not be included here. The clozapine group of CATIE II was a non-blinded study arm and CUtLASS compared clozapine with a number of second generation antipsychotics as a group.</P>
<P>One reason for the failure to find a consistent superiority of clozapine may be that efficacy was addressed in different ways (e.g. different scales or different definitions of response to treatment), making a summation difficult. Indeed at most six out of 11 studies could be combined in a meta-analysis, and frequently the results were even based on only one RCT.</P>
<P>Another possible explanation may be relatively low clozapine doses. The mean doses in two pivotal studies demonstrating clozapine&#8217;s superiority to first-generation antipsychotic drugs were 600mg/day (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>) and 523mg/day (<LINK REF="REF-Rosenheck-1997" TYPE="REFERENCE">Rosenheck 1997</LINK>). A randomised, blinded dose finding study found that a clozapine dose of 600mg/day was more efficacious than lower doses (<LINK REF="REF-Simpson-1999" TYPE="REFERENCE">Simpson 1999</LINK>). In contrast, of the 11 trials included in this review only two studies had mean clozapine doses higher than 500mg/day (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>: 526mg/day; <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>: 642 mg/day), and indeed the latter study found a superiority of clozapine. Several trials limited the upper clozapine dose range to 400mg/day.</P>
<P>Nevertheless, a definitive, industry independent trial with sufficient clozapine doses is necessary to establish the relative efficacy of clozapine and risperidone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 General functioning</HEADING>
<P>Only a very small study reported on general and social functioning, but found no significant difference between groups. From a more global public health perspective, but also for people with schizophrenia, it may be more important to know whether a drug improves functioning in the community than whether it reduces symptoms. It is therefore disappointing that so few data on these important outcomes were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 Adverse effects</HEADING>
<P>Very few data on extrapyramidal side effects, cardiac effects, change in cholesterol level, death, prolactin increase and associated side effects, sedation, seizures, and low white blood cell count were available. At most five (sedation, white blood cell count) to six (use of antiparkinson medication) out of 11 included studies could be combined in a meta-analysis. This may well reflect selective reporting and limits the conclusions.</P>
<P>Nevertheless, risperidone was associated with clearly more use of antiparkinson medication than clozapine. Use of antiparkinson medication is a useful proxy measure of movement disorders. One out of six people treated with risperidone instead of clozapine suffered from these very unpleasant adverse events which are well visible and can therefore contribute to the stigma associated with schizophrenia.</P>
<P>Risperidone also produced more prolactin increase than clozapine. This result was based on only two RCTs, but prolactin increase is a well-known adverse event of risperidone. The long-term consequences can be osteoporosis and sexual side effects, although the latter could not be demonstrated in this review, at least partly because the individual studies presented so few data.</P>
<P>Conversely clozapine was associated with more seizures, sedation and weight gain. One out of 14 participants treated with clozapine instead of risperidone had a seizure. This is a considerable and clinically important difference, because seizures are dangerous adverse events. Clozapine is well known for its sedating effects. Many people taking antipsychotic drugs do not like the sedation associated in varying degrees with these compounds, but sometimes sedation is only transient. The weight gain produced by clozapine is a major concern, because in the long term it can lead to diabetes and cardiovascular diseases such as myocardial infarction or stroke.</P>
<P>It is reassuring that - despite the limited data available - the review was able to document some of the expected differences in tolerability between risperidone and clozapine. Clinicians and people with schizophrenia may use the results in their choice of drug.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Comparison 4. Risperidone versus olanzapine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Leaving the studies early</HEADING>
<P>Risperidone and olanzapine have been compared in a relatively large number of 23 blinded RCTs and 3207 participants. Nevertheless, the high overall rate of participants leaving the studies early (52%) is a source of concern. The field must urgently find ways to decrease the amount of attrition in schizophrenia trials, because the typically high discontinuation rates make the validity of the results questionable.</P>
<P>Risperidone may be a somewhat less acceptable treatment than olanzapine for people with schizophrenia, because more participants in the risperidone group left the studies early due to any reason. In addition, more risperidone treated participants left the studies early due to inefficacy of treatment. This may reflect a somewhat better efficacy of olanzapine which is also supported by a stronger improvement of the participants' general mental state (see below). Leaving the studies early due to adverse events showed no difference between groups suggesting a similar overall tolerability of risperidone and olanzapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>Most data were available for the general mental state (PANSS total score, 15 RCTs) and positive and negative symptoms of schizophrenia (PANSS positive and negative subscore, 13 RCTs). Olanzapine was slightly superior in the improvement of the general mental state, but not superior for specific symptoms of schizophrenia. The difference was numerically very small (two points difference on the PANSS total score) and of questionable clinical importance. Only three studies reported on responder rates defined as 'at least 50% reduction of the PANSS total score' and found a marginal but statistically significant difference in favour of olanzapine (RR 1.09). A number needed to harm could not be calculated, because the risk difference was not significant. Most other efficacy-related outcomes were based on very small numbers and showed equivocal results.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.3 Quality of life</HEADING>
<P>The results suggested a better quality of life of participants treated with olanzapine compared to risperidone. Since only two studies provided data on this outcome, any recommendation for practice would be premature.</P>
<SUBSECTION>
<HEADING LEVEL="5">5.4 Cognitive functioning</HEADING>
<P>Only two studies compared the cognitive effects of risperidone and olanzapine and found no significant difference between groups.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.5 Service use</HEADING>
<P>In three trials a similar number of participants in the risperidone and olanzapine groups had to be rehospitalised. This lack of a difference suggests a similar efficacy of both compounds. Or possible efficacy differences are so small that they do not translate in more global outcomes such as rehospitalisation.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.6 Adverse effects</HEADING>
<P>The adverse effects that occurred in a statistically significantly different frequency can be grouped in three categories.</P>
<P>Olanzapine was associated with more weight gain and associated metabolic problems such as cholesterol and glucose increase. Therefore, risperidone might be a more appropriate treatment for people at risk to develop a metabolic syndrome, overweight people, individuals suffering from diabetes or those with high cholesterol levels.</P>
<P>Risperidone produced some extrapyramidal side effects more frequently than olanzapine. Namely, the participants in the risperidone group used more antiparkinson medication and suffered more frequently from akathisia and parkinsonism. Although the number needed to treat for use of antiparkinson medication was relatively high (NNT 17), movement disorders are very unpleasant side effects and should be avoided.</P>
<P>Risperidone was also associated with clearly more prolactin increase and related sexual dysfunctions such as abnormal ejaculation in men and amenorrhea in women. Clinicians and people with schizophrenia may consider these different tolerability profiles of both compounds in their drug choice.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Comparison 5. Risperidone versus quetiapine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">6.1 Leaving the studies early</HEADING>
<P>We included 11 studies with 3770 participants in this comparison. This could be a reasonable basis for the examination of the relative effects of risperidone and quetiapine, but the overall discontinuation rate was high (56.7%). Such high attrition limits the interpretation of any other results beyond the outcome leaving the studies early. If more than 50% of the data must be estimated by statistical modelling, the validity of the findings is called into question. Nevertheless, there was no clear difference in the number of participants leaving the studies early due to any reason or due to adverse events, suggesting a similar overall acceptability and tolerability of risperidone and quetiapine. Only the outcome leaving the studies early due to inefficacy tended to favour risperidone, which is consistent with a certain efficacy superiority of risperidone (see 6.2 below).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>The only statistically significant differences in efficacy were found for the general mental state and positive symptoms. Risperidone was more efficacious than quetiapine in these aspects of psychopathology. Nevertheless, the differences were small (e.g. only 3 points on the PANSS total score). The clinical relevance of this difference is difficult to interpret. Unfortunately, dichotomous data on response to treatment, which can be interpreted more intuitively, were rarely indicated. Only four studies (less than half of those available for the PANSS total score) showed a trend in favour of risperidone in terms of 'no important improvement of the participants' global state' (P = 0.06) which did not reach the conventional 5% level of statistical significance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3 Adverse effects</HEADING>
<P>Adverse effects were available for at least one adverse effect, cardiac effects, cholesterol increase, changes in serum glucose, increase of prolactin level and associated side effects, death, extrapyramidal side-effects, sedation, weight gain and white blood cell count.</P>
<P>Among these, risperidone was worse than quetiapine in various measures of extrapyramidal side effects and prolactin associated effects. Although the differences were not very large (e.g. among 20 participants treated with risperidone instead of quetiapine one needed antiparkinson medication) extrapyramidal side effects are very unpleasant adverse events which should be avoided. Prolactin increase can lead to sexual side effects and indeed the frequency of amenorrhea and galactorrhea was approximately two times higher in the risperidone group.</P>
<P>Conversely quetiapine was associated with more sedation and cholesterol increase than risperidone. The long-term consequences of the latter adverse event can be cardiovascular problems such as myocardial infarction or stroke.</P>
<P>These differences in the side effect profile and the slightly better efficacy of risperidone may be weighed in drug choice.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Comparison 6. Risperidone versus sertindole</HEADING>
<P>Again only two studies could be included in this comparison and one of the studies (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>) has to date only been published as a conference poster presenting limited information. This evidence base is too limited to draw firm conclusions.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">7.1 Leaving the studies early</HEADING>
<P>Although the number of participants leaving the studies early due to any reason was considerable (33.7%), there was no significant difference between sertindole and risperidone, suggesting a similar overall acceptability of treatment. Specific reasons for leaving the studies early (adverse events, inefficacy of treatment) did not show a difference between both compounds either.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>There was no clear difference in efficacy based on CGI, PANSS totals score, PANSS positive and negative subscore. Nevertheless, the results on the general mental state as measured by the PANSS total score were heterogeneous. One study suggested that in people with treatment-resistant schizophrenia, risperidone may be somewhat more efficacious (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>), while in the other study without this criterion, no difference was found (<LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>). Any interpretation is certainly limited by the small number of included trials and participants. Replications are needed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.3 General functioning</HEADING>
<P>Only one short-term study provided data on general functioning and showed no difference between groups. We believe that long-term, real world, pragmatic studies are needed to examine this important outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.4 Adverse effects</HEADING>
<P>There were some data on extrapyramidal symptoms, cardiac effects, cholesterol, glucose, sedation, sexual dysfunction, suicide and weight gain.</P>
<P>These limited data suggest that akathisia and parkinsonism may occur more frequently under treatment with risperidone than with sertindole. However, relatively high risperidone dose ranges of 4-10 mg/day and 4-12 mg/day in the two included studies must be taken into account. It is well known that the EPS risk of risperidone is dose related and lower doses (e.g. 2-8mg/day) may produce similar efficacy, but are better tolerated (<LINK REF="REF-Marder-1994" TYPE="REFERENCE">Marder 1994</LINK>).</P>
<P>Conversely cardiac effects (QTc prolongation), male sexual dysfunction and weight change indicated a benefit for risperidone. These differences in tolerability may be considered in drug choice. Due to the known effects of sertindole on the QTc interval, the drug cannot be recommended for people with schizophrenia and cardiac problems. The long-term consequences of weight gain such as diabetes and cardiovascular disease can be dramatic.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Comparison 7. Risperidone versus ziprasidone</HEADING>
<P>Data based on three studies were available for this comparison. Similar to the comparisons with olanzapine and quetiapine, a very high overall attrition of 63.1% clearly limits the interpretation of any findings beyond the outcome leaving the study early.</P>
<SUBSECTION>
<HEADING LEVEL="4">8.1 Leaving the studies early</HEADING>
<P>As fewer participants in the risperidone group than in the ziprasidone group left the studies prematurely, risperidone may be more acceptable for people with schizophrenia. As there were no significant differences in specific reasons (adverse events of inefficacy of treatment) for study discontinuation, the reason for this better acceptability is unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>A statistically significant, but numerically small benefit (4 points difference on the PANSS total score) for risperidone was present in general mental state and in positive symptoms. Although the small number of included trials and the high drop-out rates limit the validity of this finding, risperidone maybe somewhat more efficacious for the positive symptoms of schizophrenia than ziprasidone. Whether the numerically small difference is clinically important is again difficult to say. Unfortunately dichotomous data on response to treatment which can be more intuitively understood were only reported by a single study which did not find a significant difference. It cannot be excluded that selective reporting played a role.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8.3 Adverse effects</HEADING>
<P>Ziprasidone was more tolerable than risperidone concerning a number of adverse events: certain extrapyramidal side effects, glucose levels, cholesterol increase, prolactin increase, and weight gain.</P>
<P>In treatment decisions this better tolerability profile of ziprasidone needs to be weighted with the somewhat lower efficacy, always keeping in mind the small amount of available data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9. Summary</HEADING>
<P>The review currently includes 45 at least single blind studies and 7760 participants. The number of RCTs available for each comparison varied: four studies compared risperidone with amisulpride, two with aripiprazole, 11 with clozapine, 23 with olanzapine, 11 with quetiapine, two with sertindole, three with ziprasidone and none with zotepine. Attrition from these studies was high (46.9%). This high attrition makes the interpretation of the results problematic, because half of the results must be estimated by statistical modelling. Furthermore, 60% were industry sponsored, which can be a source of bias.</P>
<P>Risperidone was slightly less acceptable than olanzapine, and slightly more acceptable than ziprasidone in terms of leaving the studies early due to any reason. The results of all other comparisons were equivocal. There were also only few differences in efficacy-related outcome; risperidone may be somewhat more efficacious than quetiapine and ziprasidone, but slightly less efficacious than olanzapine and clozapine. Whether the differences are clinically meaningful is difficult to say, because most studies reported the mean scores of rating scales, whereas only a few reported more intuitive data on response to treatment and used different definitions for this.</P>
<P>It was the best documented tolerability difference of the review that risperidone produced somewhat more extrapyramidal side effects than a number of other SGA drugs (all except for amisulpride and aripiprazole compared to which only a few RCTs were available). Risperidone also increased prolactin levels clearly more than all comparators, except for amisulpride and sertindole for which no data were available.</P>
<P>Other differences in adverse effects were less well documented, but risperidone may well produce more weight gain and/or associated metabolic problems than amisulpride, aripiprazole and ziprasidone, but less than clozapine, olanzapine, quetiapine and sertindole. It may be less sedating than clozapine and quetiapine, lengthen the QTc interval less than sertindole, produce fewer seizures than clozapine and less sexual dysfunction in men than sertindole.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-11-17 15:35:44 +0000" MODIFIED_BY="[Empty name]">
<P>The amount of RCTs comparing risperidone with the other SGA drugs varied substantially. A high number of studies compared risperidone with olanzapine with risperidone (N = 23). A reasonable amount of trials comparing olanzapine with clozapine (N = 11) and quetiapine (N = 11) was available. In contrast, few trials compared olanzapine with amisulpride (N = 4), aripiprazole (N = 2), sertindole (N = 2) and ziprasidone (N = 3). We did not identify any RCT comparing risperidone with zotepine. Therefore the evidence is incomplete.</P>
<P>Furthermore, it is also obvious that most of the studies reported on leaving the studies early due to any reason and overall symptoms of schizophrenia. All other outcomes were usually based on much smaller numbers. Very little information is available on general functioning, satisfaction with care or cognition. These outcomes may be more important for people suffering from schizophrenia than the improvement of symptoms. Only three included studies reported on service use, although such data would be crucial for policy makers.</P>
<P>Most of the included studies had tight inclusion criteria limiting external validity. Further effectiveness studies are needed.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-11-17 15:36:31 +0000" MODIFIED_BY="[Empty name]">
<P>A major threat for the quality of the evidence is the high overall attrition of 47% in the studies. It is questionable whether even a sophisticated statistical method can account for such a high percentage of participants leaving the studies before their end. Most studies used the last observation carried forward method which is based on the assumption that a participant leaving a study early would not have changed if he had stayed in the study. This assumption can obviously be wrong.</P>
<P>All included studies were stated to be randomised and all but seven studies were double-blind. The remaining seven trials described blinded raters. Nevertheless, the randomisation and blinding methods were rarely described. The study authors did also not make attempts to verify whether blinding was successful.</P>
<P>The majority of the trials fell in the short-term category, which is problematic in a chronic disease such as schizophrenia. All these factors limit the overall quality of the evidence.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-01-06 19:37:08 +0000" MODIFIED_BY="[Empty name]">
<P>We are not aware of obvious flaws in our review process. Nevertheless, we admit that we present only a selection of outcomes. Although these outcomes were defined a priori in the protocols and although we think that we made a meaningful selection, other people may have different opinions and differences in other outcomes may have been missed.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-11-17 15:36:55 +0000" MODIFIED_BY="[Empty name]">
<P>Many new RCTs have compared risperidone with other SGA drugs since the publication of a previous Cochrane review on the same topic (<LINK REF="REF-Gilbody-2000" TYPE="REFERENCE">Gilbody 2000</LINK>). <LINK REF="REF-Gilbody-2000" TYPE="REFERENCE">Gilbody 2000</LINK> included only nine RCTs which compared risperidone with clozapine, olanzapine and amisulpride. Due to this large difference in sample size the reviews are hardly comparable. Nevertheless, as in our review risperidone was overall as acceptable as clozapine for people with schizophrenia (leaving the study early due to any reason), but slightly less acceptable than olanzapine. Efficacy data tended to favour clozapine and olanzapine, but statistically significant effects were rare which is not surprising, because even in the current much larger review the differences were small. Risperidone also produced more extrapyramidal side effects but less weight gain than olanzapine, while very few side effect data compared to clozapine were available. As in the current review there were no major differences between risperidone and amisulpride and the evidence base has grown only slightly (from one to four RCTs).</P>
<P>Another more recent review specifically compared risperidone with olanzapine (<LINK REF="REF-Jayaram-2006" TYPE="REFERENCE">Jayaram 2006</LINK>). Again, more participants in the risperidone group left the studies early due to any reason, but there were no clear differences in the efficacy of both compounds. Risperidone produced more extrapyramidal side effects, but less weight gain and associated metabolic effects than olanzapine. Overall, we believe that many findings of the previous reviews are compatible with the current report. Therefore, the evidence has become more robust, although still insufficient in quality, over time.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-17 15:40:29 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-17 15:39:14 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. For people with schizophrenia</HEADING>
<P>People with schizophrenia need to know that risperidone differs in adverse effects from other SGA drugs. It seems to produce somewhat more movement disorders and clearly more prolactin increase than most other SGA drugs. Its risk for weight gain and associated metabolic problems was intermediate - less than clozapine, olanzapine, quetiapine and sertindole, but more than amisulpride, aripiprazole and ziprasidone. Differences in efficacy were less clear, but risperidone may be overall slightly less efficacious than olanzapine and clozapine, but slightly more efficacious than quetiapine and ziprasidone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. For clinicians</HEADING>
<P>Attrition was very high (overall 47%). Almost half of the results had to be estimated by statistical modelling which calls the validity of the findings in question. It is also important to know that risperidone has been compared in many RCTs with olanzapine and in a reasonable amount of trials with clozapine and quetiapine, but few comparisons with the other SGA drugs are available. Differences in side effects should be considered in choice of drug. Risperidone seems to produce somewhat more extrapyramidal side effects, clearly more prolactin increase and intermediate weight gain compared to other SGA drugs.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. For managers/policy makers</HEADING>
<P>There is insufficient information to guide the decisions of managers and policy makers. Service use was reported by only three of 45 included studies and the results were equivocal. The evidence base is too limited for making any recommendation. Nevertheless, in some countries risperidone is now available as a generic and could therefore be cheaper than other SGA drugs.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-17 15:40:29 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. General</HEADING>
<P>There is room for improvement in the conduct and reporting of RCTs for schizophrenia. Rating scale derived efficacy outcomes dominate the trials and even in this regard authors keep using different definitions for response to treatment, making a comparison of the results difficult. Potentially important outcomes such as satisfaction with care, functioning in the community or service use are rarely examined. Simple descriptions of the randomisation or blinding methods are usually not presented. Strict adherence to the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would improve the reporting and conduct of future trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Specific</HEADING>
<P>Comparisons of risperidone with most SGA drugs are currently based on small numbers and no RCT which compares risperidone to zotepine is available. These gaps need to be filled by future trials (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-23 21:13:18 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank all members of the Cochrane Schizophrenia Group for their editorial assistance. We also thank Simon Gilbody, Anne-Marie Bagnall, Lorna Duggan and Arja Tuunainen for their work on a previous version of this review, and additionally the following authors and pharmaceutical companies for providing additional information on their studies: D. Addington, R. Conley, D. Daniel, S. Dollfus, H. Heinrich, T. Hwang, D. Jeste, J. Kane, R. Keefe, S. McGurk, K. Mori, Q. Ren, M. Riedel, N. Schooler, D. Sechter, J. Svestka, J. Volavka, K. Zhong, Astra Zeneca, Eli Lilly, Lundbeck, Pfizer and Sanofi Aventis.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-12-07 14:19:51 +0000" MODIFIED_BY="[Empty name]">
<P>Katja Komossa: none known.<BR/>Stefan Leucht: has received speaker/consultancy/advisory board honoraria from SanofiAventis, BMS, EliLilly, Essex Pharma, GlaxoSmithKline, Janssen/Johnson and Johnson, Lundbeck and Pfizer including the fees and travel expenses for attending these functions; and he has received funding for research projects from EliLilly and SanofiAventis.<BR/>Christine Rummel received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer.<BR/>Werner Kissling: received speaker or consultancy honoraria from SanofiAventis, BMS, Lilly, Janssen, Lundbeck, Bayer and Pfizer.<BR/>Heike Hunger: none known.<BR/>Franziska Schmid: none known.<BR/>Sandra Schwarz: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-09-18 14:56:58 +0100" MODIFIED_BY="[Empty name]">
<P>Katja Komossa: protocol development, searching, study selection, data extraction, report writing.<BR/>Christine Rummel: protocol development, searching, study selection, data extraction.<BR/>Stefan Leucht: protocol development, searching, study selection, data extraction, report writing.<BR/>Werner Kissling: protocol development.<BR/>Heike Hunger: helped with data extraction and writing.<BR/>Franziska Schmid: helped with data extraction and writing.<BR/>Sandra Schwarz: helped with data extraction and writing.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-12-19 10:55:54 +0000" MODIFIED_BY="[Empty name]">
<P>The review was slightly adapted to new functions available in Review Manager 5, namely the risk of bias table. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-23 21:16:47 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-11-23 21:16:47 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-11-23 21:16:47 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Addington-2004" MODIFIED="2010-01-11 11:04:31 +0000" MODIFIED_BY="[Empty name]" NAME="Addington 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 10:51:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addington D, Pantelis C, Benattia I</AU>
<TI>Ziprasidone vs risperidone in schizophrenia: efficacy and safety in an 8-week trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>125</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:19:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:04:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ</AU>
<TI>Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>12</NO>
<PG>1624-33</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2010-01-11 11:04:31 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-11 11:04:31 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15641867"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atmaca-2003" MODIFIED="2009-11-04 10:53:44 +0000" MODIFIED_BY="[Empty name]" NAME="Atmaca 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 10:53:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atmaca M, Kuloglu M, Tezcan E, Ustundag B</AU>
<TI>Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>5</NO>
<PG>598-604</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:19:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azorin-2001" MODIFIED="2010-01-11 11:05:33 +0000" MODIFIED_BY="[Empty name]" NAME="Azorin 2001" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 11:05:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I</AU>
<TI>A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>8</NO>
<PG>1305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azorin-2006" MODIFIED="2009-02-06 14:19:36 +0000" MODIFIED_BY="[Empty name]" NAME="Azorin 2006" YEAR="2005">
<REFERENCE MODIFIED="2009-02-06 14:19:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azorin J-M, Strub N, Loft H</AU>
<TI>A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>1</NO>
<PG>49-56</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:19:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bondolfi-1998" MODIFIED="2009-11-04 10:54:43 +0000" MODIFIED_BY="[Empty name]" NAME="Bondolfi 1998" YEAR="1996">
<REFERENCE MODIFIED="2009-11-04 10:54:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Baumann P, Dufour H</AU>
<TI>Treatment-resistant schizophrenia - clinical experience with new antipsychotics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>21-5</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:19:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 09:46:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P</AU>
<TI>Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomised double-blind study. The Risperidone Study Group</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>4</NO>
<PG>499-504</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:19:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-1999" MODIFIED="2010-01-11 11:06:40 +0000" MODIFIED_BY="[Empty name]" NAME="Breier 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-06 14:19:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clifton A, Pickar D</AU>
<TI>Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>2</NO>
<PG>294-8</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:19:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:06:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Su T-P, Elman I, Malhotra AK, Adler CM, Pickar D, Breier AF</AU>
<TI>Comparison of weight gain during risperidone and clozapine treatment in chronic schizophrenia</TI>
<SO>Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 Oct 2 - May 9; New York, New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:19:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canive-2000" MODIFIED="2010-01-11 11:07:09 +0000" MODIFIED_BY="[Empty name]" NAME="Canive 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 11:07:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canive JM, Edgar JC, LaNoue MD, Miller GA, Weisend MP, Tuason VB</AU>
<TI>A magnetoencephalographic examination on the effects of olanzapine and risperidone in patients with schizophrenia</TI>
<SO>Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - Jun 2; Boca Raton, Florida, USA</SO>
<YR>2000</YR>
<CY>USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 10:55:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canive JM, Miller GA, Irwin JG, Moses SN, Thoma RJ, Edgar JC, Sherwood A, Torres F, LaNoue M, Lewis S, Hanlos F, Weisend MP, Mead V, Tuason VB</AU>
<TI>Efficacy of Olanzapine and Risperidone in Schizophrenia: A Randomized Double-Blind Crossover Design</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>1</NO>
<PG>105-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2007" MODIFIED="2010-11-23 21:15:41 +0000" MODIFIED_BY="[Empty name]" NAME="Chan 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-23 21:15:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG</AU>
<TI>Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:09:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hwang TJ, Chan HY, Lin WW, Lin SK, Hwu HG, Cheng MY, Forbes RA</AU>
<TI>Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomised controlled trial</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>497</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-2001" MODIFIED="2010-01-11 11:09:39 +0000" MODIFIED_BY="[Empty name]" NAME="Conley 2001" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 11:09:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Mahmoud R, Risperidone Study Group</AU>
<TI>Risperidone versus olanzapine in patients with schizophrenia and schizoaffective psychosis</TI>
<TO>Risperidon versus olanzapin bei patienten mit schizophrenie und schizoaffektiven psychosen</TO>
<SO>Nervenheilkunde</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>5</NO>
<PG>110-2</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:20:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Conley RR, Mahmoud R</AU>
<TI>A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>5</NO>
<PG>765-74</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:09:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Conley RR, Mahmoud RA</AU>
<TI>Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 09:47:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Green MF, McGurk SR, Meltzer HY</AU>
<TI>Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomised study</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>3-4</NO>
<PG>404-11</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-2005" MODIFIED="2010-11-23 21:16:14 +0000" MODIFIED_BY="[Empty name]" NAME="Conley 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-23 21:16:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Kelly DL, Pharm D, BCPP, Nelson MW, Richardson CM, Feldman S, Benham R, Steiner P, Yu Y, Khan I, McMullen R, Gale E, Mackowick M, Love RC</AU>
<TI>Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>4</NO>
<PG>163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 09:47:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR</AU>
<TI>A randomised double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>3</NO>
<PG>340-6</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:12:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR</AU>
<TI>Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine</TI>
<SO>Journal of Clinic Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>80-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 10:56:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richardson CM, Kelly DL, Gold JM, McMahon R, Yu Y, Conley RR</AU>
<TI>Risperidone vs quetiapine vs fluphenazine in treatment - resistant schizophrenia: neuropsychological outcome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>501-2</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1996" MODIFIED="2009-02-06 14:20:47 +0000" MODIFIED_BY="[Empty name]" NAME="Daniel 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-02-06 14:20:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS</AU>
<TI>Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>3</NO>
<PG>417-9</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dollfus-2005" MODIFIED="2009-11-04 10:56:50 +0000" MODIFIED_BY="[Empty name]" NAME="Dollfus 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-06 14:20:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dollfus S, Olivier V, Chabot B, Deal C, Perrin E</AU>
<TI>Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>78</VL>
<NO>2-3</NO>
<PG>157-9</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 10:56:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dollfus S</AU>
<TI>The treatment of post-psychotic depression</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>165</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:20:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolnak-2001" MODIFIED="2010-01-11 11:13:27 +0000" MODIFIED_BY="[Empty name]" NAME="Dolnak 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 11:13:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolnak R, Rapaport MH</AU>
<TI>A prospective, randomised, double blind study examining functioning in schizophrenic patients treated with olanzapine and risperidone</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1, 2</NO>
<PG>225-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gureje-2003" MODIFIED="2009-11-04 10:57:03 +0000" MODIFIED_BY="[Empty name]" NAME="Gureje 2003" YEAR="2002">
<REFERENCE MODIFIED="2009-11-04 10:57:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM</AU>
<TI>Olanzapine versus risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>61</VL>
<PG>303-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heinrich-1994" MODIFIED="2010-01-11 11:14:00 +0000" MODIFIED_BY="[Empty name]" NAME="Heinrich 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-02-06 14:21:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H</AU>
<TI>Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>1</NO>
<PG>129-37</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:14:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E</AU>
<TI>Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia</TI>
<SO>Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan</SO>
<YR>1991</YR>
<PG>37-9</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 10:57:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K</AU>
<TI>Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1 Suppl 1</NO>
<PG>45-51</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hwang-2003" MODIFIED="2009-02-06 14:21:17 +0000" MODIFIED_BY="[Empty name]" NAME="Hwang 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-06 14:21:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hwang TJ, Lee S-M, Sun HJ, Lin H-N, Tsai S-J, Lee Y-C, Chen Y-S</AU>
<TI>Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>1</NO>
<PG>30-6</PG>
<CY>Taiwan</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeste-2003" MODIFIED="2010-01-11 11:16:32 +0000" MODIFIED_BY="[Empty name]" NAME="Jeste 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 10:57:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeste D, Madhusoodanan S, Barak Y, Martinez RA, Mahmoud R, Kershaw P</AU>
<TI>Risperidone and olanzapine in elderly patients with schizophrenia and schizoaffective disorder</TI>
<SO>International Psychogeriatrics</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>295</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:16:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Barak Y, Madhusoodanan S, Gossman F, Gharabawi G</AU>
<TI>International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>6</NO>
<PG>638-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:21:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jeste DV, Madhusoodanan S, Barak F, Martinez RA</AU>
<TI>Risperidone versus olanzapine in elderly patients with schizophrenia</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:16:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jeste DV, Madhusoodanan S, Barak F, Martinez RA</AU>
<TI>Risperidone versus olanzapine in elderly patients with schizophrenia</TI>
<SO>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS MODIFIED="2010-01-11 11:16:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2005" MODIFIED="2009-02-06 14:21:33 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-06 14:21:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Potkin S, Buckley P, Daniel DG</AU>
<TI>Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>490</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keefe-2006" MODIFIED="2010-01-11 11:18:18 +0000" MODIFIED_BY="[Empty name]" NAME="Keefe 2006" YEAR="2005">
<REFERENCE MODIFIED="2009-11-04 10:58:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe R</AU>
<TI>Neurocognitive efficacy in patients with chronic schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>577</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:21:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Young CA, Rock SL, Purdon SE, Gold JM, Breier A</AU>
<TI>One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>1</NO>
<PG>1-15</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:17:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Namjoshi M, Young C, Huang L, Edgell ET, Breier A</AU>
<TI>Conical and quality-of-life outcomes associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: results from a US random study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>127</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 10:59:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Namjoshi M, Young C, Huang L, Edgell ET, Breier A</AU>
<TI>Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: results from a U.S. randomized controlled trial</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>315</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:21:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:18:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Namjoshi M, Young CA, Huang L, Edgell E, Breier A</AU>
<TI>Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: results from a U.S. randomized controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>296</PG>
<EN>1</EN>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2005" MODIFIED="2009-02-06 14:22:13 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-06 14:22:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Keefe R, Perkins DO, Davis S, Davis CE, Lebowitz B, Hsiao J</AU>
<TI>CATIE trial results</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S184</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-2006" MODIFIED="2009-02-06 14:22:22 +0000" MODIFIED_BY="[Empty name]" NAME="McEvoy 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-06 14:22:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>600-10</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-2007" MODIFIED="2010-01-11 11:20:19 +0000" MODIFIED_BY="[Empty name]" NAME="McEvoy 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-11 11:18:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keefe RSE, Gu H, Sweeney JA, Perkins DO, McEvoy JP, Hamer RM, Lieberman JA</AU>
<TI>The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first-episode psychosis: a double-blind 52-week comparison</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:19:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman J, McEvoy JP, Perkins D, Hamer RH</AU>
<TI>Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>525</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:19:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Perkins DO,Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD</AU>
<TI>Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>1050-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 11:00:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Perkins DO, Gu H, Hamer RM, Lieberman JA</AU>
<TI>Clinical effectiveness and predictors of treatment non-adherence: comparison of olanzapine, quetiapine, and risperidone in first-episode psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>Suppl 1</NO>
<PG>130</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:20:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McEvoy JP</AU>
<TI>Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGurk-2005" MODIFIED="2010-01-11 11:21:06 +0000" MODIFIED_BY="[Empty name]" NAME="McGurk 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-06 14:22:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y</AU>
<TI>Do clozapine and risperidone affect social competence and problem solving?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>2</NO>
<PG>364-7</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:22:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, Schooler NR, Kane JM</AU>
<TI>The effects of clozapine and risperidone on spatial working memory in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>5</NO>
<PG>1013-6</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:22:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-2004" MODIFIED="2009-11-04 11:01:32 +0000" MODIFIED_BY="[Empty name]" NAME="Mori 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-06 14:23:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S</AU>
<TI>Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>4</NO>
<PG>659-65</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:23:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 11:01:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mori K, Nagao M, Yamashita H, Yamawaki S</AU>
<TI>Effects of switching to atypical antipsychotics on memory in chronic schizophrenic patients</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>80</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:23:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-2005" MODIFIED="2010-01-11 11:21:49 +0000" MODIFIED_BY="[Empty name]" NAME="Möller 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:21:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Riedel M, Eich FX</AU>
<TI>A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>511</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:23:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peuskens-1999" MODIFIED="2009-02-06 14:36:05 +0000" MODIFIED_BY="[Empty name]" NAME="Peuskens 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-06 14:36:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W</AU>
<TI>Amisulpride versus risperidone in the treatment of acute exacerbation of schizophrenia</TI>
<SO>Journal of Medical Economics</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-2003" MODIFIED="2009-02-06 14:23:43 +0000" MODIFIED_BY="[Empty name]" NAME="Potkin 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-06 14:23:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR</AU>
<TI>Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>7</NO>
<PG>681-90</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:23:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-2006" MODIFIED="2010-01-11 11:23:16 +0000" MODIFIED_BY="[Empty name]" NAME="Potkin 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-06 14:23:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gharabawi GM, Greenspan A, Rupnow MFT, Kosik-Gonzalez C, Bossie CA, Zhu Y, Kalali AH, Awad AG</AU>
<TI>Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial</TI>
<SO>BMC Psychiatry</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>45</NO>
<PG>1-7</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:23:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:23:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MFT, Zhu Y, Gharabawi GM</AU>
<TI>Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>503</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:23:54 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:24:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MFT, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK</AU>
<TI>A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>1-3</NO>
<PG>254-65</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:24:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Greenspan A, Kosik-Gonzalez C, Bossie C, Rupnow M, Zhu Y, Gharabawi G</AU>
<TI>A placebo - controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>501</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purdon-2000" MODIFIED="2010-01-11 11:23:42 +0000" MODIFIED_BY="[Empty name]" NAME="Purdon 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 11:23:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purdon SE, Canadian Cognition and Outcome Study Group</AU>
<TI>Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1, 2</NO>
<PG>132-3</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:24:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD</AU>
<TI>Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>3</NO>
<PG>249-58</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:24:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purdon SE, Woodward N, Lindborg SR, Stip E</AU>
<TI>Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>3-4</NO>
<PG>390-7</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2002" MODIFIED="2010-01-11 11:24:48 +0000" MODIFIED_BY="[Empty name]" NAME="Ren 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 11:24:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren Q, Lu Y, Tian M</AU>
<TI>Comparison of quality of life of schizophrenic outpatients treated with risperdal or clozapine</TI>
<SO>Nervous Disease and Mental Hygiene</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>2</NO>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riedel-2005" MODIFIED="2010-01-11 11:25:24 +0000" MODIFIED_BY="[Empty name]" NAME="Riedel 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:25:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riedel M, Möller H-J, Strassnig M, Spellmann I, Müller-Arends A, Dehning S, Sadowsky N, Müller N</AU>
<TI>Efficacy of quetiapine against negative symptoms in schizophrenia</TI>
<SO>Proceedings of the XIII World Congress of Psychiatry; 2005 10-15th Sept; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:24:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ, Moller H-J</AU>
<TI>Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2005</YR>
<VL>255</VL>
<NO>6</NO>
<PG>432-7</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2005" MODIFIED="2010-01-11 11:28:59 +0000" MODIFIED_BY="[Empty name]" NAME="Robinson 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:28:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Porello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM</AU>
<TI>Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>12</NO>
<PG>2096-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2004" MODIFIED="2010-01-11 11:29:46 +0000" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-06 14:24:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzo a, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>150</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:24:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 11:02:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>350</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:29:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine, and risperidone in schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>286</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sechter-2002" MODIFIED="2010-01-11 11:30:25 +0000" MODIFIED_BY="[Empty name]" NAME="Sechter 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 11:30:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y/Amisulpride Study Group</AU>
<TI>Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1071-81</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sikich-2004" MODIFIED="2010-01-11 11:32:09 +0000" MODIFIED_BY="[Empty name]" NAME="Sikich 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-06 14:25:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA</AU>
<TI>A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>1</NO>
<PG>133-45</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:30:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sikich L, Hooper SR, Malekpour AH, Sheitman BB, Lieberman JA</AU>
<TI>A double blind comparison of typical versus atypical antipsychotic agents on selected neurocognitive functions in children and adolescents with psychotic disorders</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1, 2</NO>
<PG>245</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:30:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L, Horrigan JP, Lieberman JA, Barnhill LJ, Sheitman BB, Courvoisie HE</AU>
<TI>Comparative use of olanzapine and risperidone in psychotic youth</TI>
<SO>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:31:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L, Horrigan JP, Lieberman JA, Barnhill LJJr, Sheitman BB, Courvoisie HE</AU>
<TI>Comparative use of olanzapine and risperidone in psychotic youth</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:31:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S, Sheitman B, Lieberman JA</AU>
<TI>Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth</TI>
<SO>Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico</SO>
<YR>1999</YR>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:32:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L</AU>
<TI>Critical decisions in the treatment of adolescent and pediatric psychosis</TI>
<SO>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroup-2006" MODIFIED="2009-02-06 14:25:48 +0000" MODIFIED_BY="[Empty name]" NAME="Stroup 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-06 14:25:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>611-22</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-2003" MODIFIED="2009-11-04 10:41:47 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 10:41:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Synek O, Zourkova A</AU>
<TI>Olanzapine versus risperidone in first-episode schizophrenic and schizoform disorders: a double-blind comparison</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>291</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:25:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-1997" MODIFIED="2010-01-11 11:34:39 +0000" MODIFIED_BY="[Empty name]" NAME="Tran 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-11 11:32:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ahmed S, Zhang F, Walker D, Beglinger L, Earley WR, Tran PV</AU>
<TI>Olanzapine versus risperidone for treatment of negative symptoms in schizophrenia</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 11:03:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A</AU>
<TI>Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>92</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:26:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A</AU>
<TI>Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>9</NO>
<PG>998-1004</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:26:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glick ID, Berg PH</AU>
<TI>Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>2</NO>
<PG>65-8</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:33:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Tran PV, Hamilton S, Kuntz A</AU>
<TI>Olanzapine versus risperidone in the treatment of psychosis. Preliminary report</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1, 2</NO>
<PG>191</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:26:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD</AU>
<TI>Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>5</NO>
<PG>407-18</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:34:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tran PV, Tollefson GD, Andersen SW, Kuntz AJ, Hamilton SH</AU>
<TI>Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders</TI>
<SO>Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Nimwegen-2006" MODIFIED="2010-01-11 11:36:01 +0000" MODIFIED_BY="[Empty name]" NAME="Van Nimwegen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 11:35:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van de Brink W, Linszen D</AU>
<TI>Obsessive compulsive symptoms in a randomized double blind</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 6-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-11 11:36:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van de Brink W, Linszen D</AU>
<TI>Subjective well-being and craving for cannabis in first psychosis, a randomized double blind comparison of olanzapine versus risperidone</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 6-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-2002" MODIFIED="2009-02-06 14:27:12 +0000" MODIFIED_BY="[Empty name]" NAME="Volavka 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-06 14:26:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, Chakos M, Lieberman JA</AU>
<TI>Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>194</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:26:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA</AU>
<TI>Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>6</NO>
<PG>1018-28</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:26:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Lieberman JA</AU>
<TI>Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>256</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:26:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, McEvoy J, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia</TI>
<SO>Psychiatric Services</SO>
<YR>2001</YR>
<VL>52</VL>
<NO>11</NO>
<PG>1510-4</PG>
<PB>American Psychiatric Association, US</PB>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:26:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>2</NO>
<PG>290-6</PG>
<EN>2</EN>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:26:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:27:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M</AU>
<TI>Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>4</NO>
<PG>551-6</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:27:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA</AU>
<TI>Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>57-61</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:27:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome LMJP, Cooper TB, Lieberman JA</AU>
<TI>Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2</NO>
<PG>225-8</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:27:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>2</NO>
<PG>255-62</PG>
<EN>2</EN>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wahlbeck-2000" MODIFIED="2009-11-04 11:03:47 +0000" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-04 11:03:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R</AU>
<TI>Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>122</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:27:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R</AU>
<TI>Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>6</NO>
<PG>911-22</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:27:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Cheine M, Tuisku K, Joffe G</AU>
<TI>Risperidone versus clozapine in treatment resistant schizophrenia: a randomised pilot trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>197</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2009-02-06 14:27:33 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-06 14:27:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH</AU>
<TI>Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>7</NO>
<PG>669-76</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wynn-2007" MODIFIED="2009-01-04 21:07:42 +0000" MODIFIED_BY="[Empty name]" NAME="Wynn 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-01-04 21:07:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL</AU>
<TI>Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2007</YR>
<VL>5</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2006" MODIFIED="2009-02-06 14:27:47 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-06 14:27:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong K, Harvey P, Brecher M, Sweitzer D</AU>
<TI>A randomized double - blind study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>508</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-06 14:27:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA</AU>
<TI>Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>7</NO>
<PG>1093-103</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-02-06 14:27:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2000" MODIFIED="2010-11-23 21:16:47 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-23 21:16:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Z, Shu Z, Yu Y</AU>
<TI>A control study of risperidone and clozapine in the treatment of the negative symptoms of schizophrenia</TI>
<SO>Aerospace Medicine</SO>
<YR>2000</YR>
<VL>11</VL>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-22 17:49:11 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akdede-2006" MODIFIED="2009-01-09 14:12:16 +0000" MODIFIED_BY="[Empty name]" NAME="Akdede 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:12:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akdede BB, Anil Yaciolu AE, Alptekin K, Turgut TI, Tumuklu M, Yazici MK, Jayathilake K, Tunca Z, Gogus A, Meltzer HY</AU>
<TI>A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>12</NO>
<PG>1912-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:12:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Almond-1999" MODIFIED="2009-11-04 11:04:15 +0000" MODIFIED_BY="[Empty name]" NAME="Almond 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-11-04 11:04:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Almond S, O'Donnell O, McKendrick J</AU>
<TI>The cost-analysis of olanzapine compared with haloperidol and risperidone in the treatment of schizophrenia in the UK</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>289</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:12:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-2006" MODIFIED="2009-01-09 14:12:32 +0000" MODIFIED_BY="[Empty name]" NAME="Alvarez 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:12:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez E, Ciudad A, Olivares JM, Bousono M, Gomez JC</AU>
<TI>A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>238-49</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:12:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez_x002d_Jimenez-2006" MODIFIED="2009-01-09 14:12:51 +0000" MODIFIED_BY="[Empty name]" NAME="Alvarez-Jimenez 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:12:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, Ramirez-Bonilla ML, Crespo-Facorro B</AU>
<TI>Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>8</NO>
<PG>1253-60</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:12:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antonova-2005" MODIFIED="2009-01-09 14:13:01 +0000" MODIFIED_BY="[Empty name]" NAME="Antonova 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:13:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Antonova E, Kumari V, Halari R, Zachariah E, Mehrotra R, Kumar A, Sharma T</AU>
<TI>Superior cognitive efficacy of atypical antipsychotics olanzapine, risperidone, and quetiapine, as a group, relative to low doses of conventional antipsychotics</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>474</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:13:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apiquian-2003" MODIFIED="2009-01-09 14:13:08 +0000" MODIFIED_BY="[Empty name]" NAME="Apiquian 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-09 14:13:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Apiquian R, Fresan A, Herrera K, Ulloa RE, Loyzaga C, De LaFuente-Sandoval C, Gutierrez D, Nicolini H</AU>
<TI>Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>4</NO>
<PG>403-8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:13:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aquila-2000" MODIFIED="2010-01-11 11:42:26 +0000" MODIFIED_BY="[Empty name]" NAME="Aquila 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 11:42:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Aquila R, Weiden PJ, Kinon BJ, Milton DR, Zygmunt A, Swindle RW, Stauffer VL</AU>
<TI>Effectiveness of olanzapine upon psychiatric and vocational rehabilitation outcomes</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2010-01-11 11:42:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ascher_x002d_Svanum-2006" MODIFIED="2009-07-30 16:48:58 +0100" MODIFIED_BY="[Empty name]" NAME="Ascher-Svanum 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-30 16:48:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J</AU>
<TI>Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia</TI>
<SO>BMC Psychiatry</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>8</NO>
<PG>1-16</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:13:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2003" MODIFIED="2009-11-04 11:04:41 +0000" MODIFIED_BY="[Empty name]" NAME="Bai 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 11:04:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai YM, Yu SC, Lin CC</AU>
<TI>Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<PG>1342-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:13:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baloescu-2006" MODIFIED="2010-01-11 11:43:01 +0000" MODIFIED_BY="[Empty name]" NAME="Baloescu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 11:43:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baloescu A, Vasile D, Gheorghe MD, Grigorescu G</AU>
<TI>Side effects of atypical antipsychotics - prediction factor for compliance</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>403</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:13:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basson-2001" MODIFIED="2009-01-09 14:13:50 +0000" MODIFIED_BY="[Empty name]" NAME="Basson 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:13:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD</AU>
<TI>Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>4</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:13:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-2001" MODIFIED="2009-11-04 11:05:23 +0000" MODIFIED_BY="[Empty name]" NAME="Beasley 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-04 11:05:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Berg PH, Dananberg J, Kwong KC, Taylor CCM, Breier A</AU>
<TI>Treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>8</NO>
<PG>121</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-2003" MODIFIED="2010-01-11 11:43:28 +0000" MODIFIED_BY="[Empty name]" NAME="Beasley 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 11:43:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Sowell MO, Carlson C, Mukhopadhyay N, Dananberg J, Henry R, Breier A, Cavazzoni P</AU>
<TI>Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>309</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bera-2001" MODIFIED="2010-01-11 11:43:41 +0000" MODIFIED_BY="[Empty name]" NAME="Bera 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 11:43:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bera RB</AU>
<TI>A comparison of patient satisfaction between seroquel, olanzapine and risperidal</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1, 2</NO>
<PG>220</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2005" MODIFIED="2010-01-11 11:44:20 +0000" MODIFIED_BY="[Empty name]" NAME="Beuzen 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:44:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, Carson W</AU>
<TI>Naturalistic study of aripiprazole treatment</TI>
<SO>Proceedings of the XIII World Congress of Psychiatry; 2005 Sept 10-15; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bitter-2004" MODIFIED="2010-01-11 11:45:00 +0000" MODIFIED_BY="[Empty name]" NAME="Bitter 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 11:45:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bitter I, Basson BR, Dossenbach MR</AU>
<TI>Antipsychotic treatment and sexual functioning in first-time neuroleptic treated schizophrenic patients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boylan-2004" MODIFIED="2009-01-09 14:14:25 +0000" MODIFIED_BY="[Empty name]" NAME="Boylan 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:14:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boylan LS, Labovitz DL</AU>
<TI>Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>3</NO>
<PG>636</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briken-2002" MODIFIED="2009-11-04 11:05:43 +0000" MODIFIED_BY="[Empty name]" NAME="Briken 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-04 11:05:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Briken P, Nika E, Moritz S, Haasen C, Perro C, Yagdiran O, Naber D, Krausz M</AU>
<TI>Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>311-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-2006" MODIFIED="2010-01-11 11:45:32 +0000" MODIFIED_BY="[Empty name]" NAME="Byerly 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 11:45:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Byerly MJ, Nakonezny P, Bugno R, Boles J</AU>
<TI>A randomized, double-blind pilot trial of switching to quetiapine vs. Risperidone continuation in outpatients with risperidone-associated sexual dysfunction</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cai-2000" MODIFIED="2009-01-09 14:14:41 +0000" MODIFIED_BY="[Empty name]" NAME="Cai 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-09 14:14:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cai C, Wan C, Cheng F</AU>
<TI>The controlled investigation of risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>2</NO>
<PG>152-4</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canas-2006" MODIFIED="2010-01-11 11:45:58 +0000" MODIFIED_BY="[Empty name]" NAME="Canas 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 11:45:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Canas F, Perez V, Tafalla M</AU>
<TI>Quetiapine and risperidone in the treatment of schizophrenia: a short- and long-term, non-randomized study</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2001" MODIFIED="2009-01-09 14:14:52 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:14:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cao D, Xie S</AU>
<TI>Different effects of clozapine and risperidone on levels of blood glucose in patients with schizophrenia</TI>
<SO>Modern Rehabilitation</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>12</NO>
<PG>144-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:14:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2003" MODIFIED="2009-11-04 11:06:10 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 11:06:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao W, Liu X-L, Wei H-Y</AU>
<TI>A comparative study of the therapeutic effects of clozapine and risperidone in the treatment of schizophrenia</TI>
<SO>Herald of Medicine</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>10</NO>
<PG>679-80</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2005" MODIFIED="2010-01-11 11:46:43 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2005" YEAR="">
<REFERENCE MODIFIED="2010-01-11 11:46:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao D, Xie S, Chen Q, Yuan Y, Fan Q</AU>
<TI>Comparison of the effects of chlorpromazine, risperidone and quetiapine on hypothalamic-pituary -gonodal axis and sexual function in male patiens with schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>148-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cha-2002" MODIFIED="2009-01-09 14:15:06 +0000" MODIFIED_BY="[Empty name]" NAME="Cha 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:15:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cha A, Xu Y, Zhu XH</AU>
<TI>The curative effect comparison of risperidone and clozapine to treat recurrent schizophrenia</TI>
<SO>Chinese Medical Journal of Metallurgical Industry</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>3</NO>
<PG>143-4</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhry-2006" MODIFIED="2009-11-04 11:06:25 +0000" MODIFIED_BY="[Empty name]" NAME="Chaudhry 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-04 11:06:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhry HR, Niaz S, Arshad N, Peracha F, Ayub A, Mufti KA</AU>
<TI>Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>241</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1999" MODIFIED="2009-01-12 21:47:24 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-09 14:15:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen ZA, Lan LM, Zhu PJ</AU>
<TI>Risperidone vs clozapine in treatment of schizophrenia</TI>
<SO>Chinese Journal of New Drugs And Clinical Remedies</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>5</NO>
<PG>277-80</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2002" MODIFIED="2010-01-11 11:47:13 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 11:47:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen L</AU>
<TI>A comparative stndy of EEg changes in patients treated by risperidone, chlorpromazine and clozpine</TI>
<SO>Journal of Qiqihar Medical</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>5</NO>
<PG>485-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" MODIFIED="2010-01-11 11:47:51 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 11:47:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen C-Q</AU>
<TI>A study of risperidone and clozapine in treatment of first episode schizophrenia</TI>
<SO>HuaXia medicine</SO>
<YR>2003</YR>
<VL>27</VL>
<PG>578-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004" MODIFIED="2010-01-11 11:48:20 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 11:48:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Y-H, Li Y-M, Li S</AU>
<TI>A study of risperidone with haloperidol and clozapine in treatment of positive symptom schizophrenia</TI>
<SO>Suzhou University Journal of Medical Science</SO>
<YR>2004</YR>
<VL>24</VL>
<PG>912-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004a" MODIFIED="2010-01-11 11:48:46 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 11:48:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Q, Huang C-F</AU>
<TI>The influence of risperidone and clozapine in the quality of life of schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>18</NO>
<PG>3640-1</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2009-11-04 11:07:33 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-04 11:07:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Q, Tang Y-L, Mao P-X, Cai Z-J</AU>
<TI>Effects of clozapine and risperidone on the glucose-regulating mechanism of patients with schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>4</NO>
<PG>116-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005a" MODIFIED="2010-01-11 11:49:04 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:49:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen B, Liu X, Zhang X</AU>
<TI>A study of risperidone combination with clozapine in the treatment of the schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>2</NO>
<PG>116-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005b" MODIFIED="2010-01-11 11:49:27 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2005b" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:49:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Q, Yuan Y, Fang Q</AU>
<TI>Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia</TI>
<SO>Chinese Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>63-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2002" MODIFIED="2010-01-11 11:50:10 +0000" MODIFIED_BY="[Empty name]" NAME="Cheng 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 11:50:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng S-Z, Chi X-Z, Li Q-H, Jiang Y-Q</AU>
<TI>A study of risperidone and clozapine in treatment of resistant schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>1</NO>
<PG>44-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:15:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chou-1999" MODIFIED="2009-01-09 14:16:02 +0000" MODIFIED_BY="[Empty name]" NAME="Chou 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-09 14:16:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou X, Chen Q, Li J</AU>
<TI>A clinical controlled study between risperidone and clozapine in the treatment of chronic schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>4</NO>
<PG>244-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chowdhury-1999" MODIFIED="2009-01-09 14:16:06 +0000" MODIFIED_BY="[Empty name]" NAME="Chowdhury 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-09 14:16:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chowdhury AN, Mukherjee A, Ghosh K, Chowdhury S, Das Sen K</AU>
<TI>Horizon of a new hope: Recovery of schizophrenia in India</TI>
<SO>International Medical Journal</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>3</NO>
<PG>181-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Citrome-2004" MODIFIED="2009-01-09 14:16:17 +0000" MODIFIED_BY="[Empty name]" NAME="Citrome 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:16:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA</AU>
<TI>Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone</TI>
<SO>Psychiatric Services</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>3</NO>
<PG>290-4</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciudad-2004" MODIFIED="2010-01-11 11:51:25 +0000" MODIFIED_BY="[Empty name]" NAME="Ciudad 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 11:51:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciudad A, Alvarez E, Bousono M, Cuesta M, Gomez JC, Olivares JM</AU>
<TI>Olanzapine versus risperidone: results of a one year randomized trial in outpatients with schizophrenia with prominent negative symptoms</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>161-2</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-1999" MODIFIED="2009-01-09 14:16:31 +0000" MODIFIED_BY="[Empty name]" NAME="Conley 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-09 14:16:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Conley J, Goldman RS, Bilder RM, Bates J, Reiter G, Pappadopulos E, Robinson D, Alvir JMA, Liebrman J, Schooler N</AU>
<TI>A comparison of the neurocognitive effects of treatment with typical and atypical neuroleptics in first-episode schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>1-3</NO>
<PG>128</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornblatt-2002" MODIFIED="2009-01-09 14:16:37 +0000" MODIFIED_BY="[Empty name]" NAME="Cornblatt 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:16:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G, Green MF</AU>
<TI>Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>27</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crespo_x002d_Facorro-2006" MODIFIED="2009-01-09 14:16:43 +0000" MODIFIED_BY="[Empty name]" NAME="Crespo-Facorro 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:16:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Vazquez-Barquero JL</AU>
<TI>A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>10</NO>
<PG>1511-21</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2002" MODIFIED="2009-07-31 09:42:49 +0100" MODIFIED_BY="[Empty name]" NAME="Cui 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-31 09:42:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui B, Shen J, Tian H, Wang Y, Guo X</AU>
<TI>A comparative study of the effects of risperidone, chlorpromazine and clozapine to patients with schizophrenia by the electrocardiograms</TI>
<SO>Tianjin Pharmacy</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>3</NO>
<PG>54-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czekalla-2001" MODIFIED="2009-01-09 14:16:52 +0000" MODIFIED_BY="[Empty name]" NAME="Czekalla 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:16:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S</AU>
<TI>Analysis of the qtc interval during olanzapine treatment of patients with schizophrenia and related psychosis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>3</NO>
<PG>191-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-David-1999" MODIFIED="2009-11-04 11:08:22 +0000" MODIFIED_BY="[Empty name]" NAME="David 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-11-04 11:08:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Meehan KM, Sutton VK, Taylor CC</AU>
<TI>Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>292</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:16:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-David-2000" MODIFIED="2009-01-09 14:17:04 +0000" MODIFIED_BY="[Empty name]" NAME="David 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-09 14:17:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Taylor CC, Kinon BJ, Breier A</AU>
<TI>The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1085-96</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:17:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Haan-2002" MODIFIED="2010-01-11 11:52:59 +0000" MODIFIED_BY="[Empty name]" NAME="De Haan 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 11:52:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D</AU>
<TI>Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>2</NO>
<PG>104-7</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:17:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2004" MODIFIED="2010-01-11 11:53:11 +0000" MODIFIED_BY="[Empty name]" NAME="Ding 2004" YEAR="">
<REFERENCE MODIFIED="2010-01-11 11:53:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding Y, An B, Li G</AU>
<TI>A comparative study of risperidone and quetiapine in the treatment of schizophrenia and relationship between efficacy and the serum levels of IL-2, SIL-2R</TI>
<SO>Shangdong Arch Psychiatry</SO>
<YR>2004</YR>
<VL>17</VL>
<PG>76-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2005" MODIFIED="2010-01-11 11:53:42 +0000" MODIFIED_BY="[Empty name]" NAME="Ding 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:53:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding Z, Yu Z, Xu G</AU>
<TI>Control studies of increase of blood sugar induced by neo-antipsychotics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>309-10</PG>
<IDENTIFIERS MODIFIED="2010-01-11 11:53:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dossenbach-2005" MODIFIED="2010-01-11 11:54:52 +0000" MODIFIED_BY="[Empty name]" NAME="Dossenbach 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:54:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dossenbach M, Arango-Davila C, Ibarra HS, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S</AU>
<TI>Response and relapse in patients With schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the intercontinental schizophrenia outpatients health outcomes (IC-SOHO) study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>8</NO>
<PG>1021-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2003" MODIFIED="2010-01-11 11:55:57 +0000" MODIFIED_BY="[Empty name]" NAME="Du 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 11:55:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du W-J, Yu J-L, Zheng H-B, Zhong X-Q, Ma C</AU>
<TI>The influence of chlorpromazine, clozapine and risperidone on the cognitive function of schizophrenia</TI>
<SO>International Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<PG>86-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2004" MODIFIED="2009-11-04 11:08:52 +0000" MODIFIED_BY="[Empty name]" NAME="Du 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:08:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du Z-H, Wu H-L</AU>
<TI>Comparison of chlorpromazine, clozapine and risperidone in the effect on indices of liver function</TI>
<SO>Journal of Practical Medical Techniques</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>6A</NO>
<PG>885-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2004a" MODIFIED="2009-11-04 11:09:10 +0000" MODIFIED_BY="[Empty name]" NAME="Du 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:09:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du Z-H</AU>
<TI>A study on the change of serum thyroxin treated with risperdal or clozapine</TI>
<SO>Journal of Practical Medical Techniques</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>68</NO>
<PG>1020-1</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2005" MODIFIED="2009-01-09 14:18:18 +0000" MODIFIED_BY="[Empty name]" NAME="Du 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:18:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du Z, Wu H</AU>
<TI>Effects of clozapine and risperidone on the glucose metabolism in schizophrenic patients</TI>
<SO>Qilu Journal of Medicall Aboratory Sciences</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>1</NO>
<PG>8-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Earnst-1999" MODIFIED="2009-01-09 14:18:30 +0000" MODIFIED_BY="[Empty name]" NAME="Earnst 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-09 14:18:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Earnst KS, Taylor SF, Smet IC, Goldman RS, Tandon R, Berent S</AU>
<TI>The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>40</VL>
<NO>3</NO>
<PG>255-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ertugrul-2006" MODIFIED="2009-11-04 11:09:27 +0000" MODIFIED_BY="[Empty name]" NAME="Ertugrul 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-04 11:09:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ertugrul A, Anil Yagcioglu AE, Woodward ND, Jayathilake K, Meltzer HY</AU>
<TI>Genetic predictors of cognitive function and response to treatment in schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>406</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Estrella-1996" MODIFIED="2010-01-11 11:57:04 +0000" MODIFIED_BY="[Empty name]" NAME="Estrella 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-01-11 11:57:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Estrella MH, Soria FL, Gonzalez CJC, Butron MAL, Torres JA, Escareño RR</AU>
<TI>Cost-effectiveness of clozapine vs respiridona for treatment-resistant schizophrenic patients</TI>
<SO>Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2003" MODIFIED="2009-01-09 14:18:44 +0000" MODIFIED_BY="[Empty name]" NAME="Fan 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-09 14:18:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan C, Leiying, Wang K</AU>
<TI>The effect of clozapine and risperidone on blood sugar of patients with schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>131-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-2004" MODIFIED="2010-11-22 16:08:20 +0000" MODIFIED_BY="[Empty name]" NAME="Feng 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-22 16:08:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng Y-P</AU>
<TI>The influence of clozapine and risperidone on the weight</TI>
<SO>Jounal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>14</VL>
<PG>101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gan-1999" MODIFIED="2009-11-04 10:48:36 +0000" MODIFIED_BY="[Empty name]" NAME="Gan 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-11-04 10:48:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gan JL</AU>
<TI>A control study of risperidone and clozapine in the freatment of first episode schizophrenia</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>1</NO>
<PG>61</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:18:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garc_x00ed_a-2006" MODIFIED="2009-11-04 11:09:43 +0000" MODIFIED_BY="[Empty name]" NAME="García 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-04 11:09:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>García MC, Vidal M, Ramos R</AU>
<TI>Sexual side effects of antipsychoticcs and treatment adherence</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>378</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ge-2004" MODIFIED="2009-01-09 14:19:04 +0000" MODIFIED_BY="[Empty name]" NAME="Ge 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:19:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ge Q, Xiong L, Liang X</AU>
<TI>A comparative study of risperidone, clozapine and haloperidol in the treatment of patients with schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>2</NO>
<PG>79-81</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-2000" MODIFIED="2009-01-09 14:19:11 +0000" MODIFIED_BY="[Empty name]" NAME="Goldberg 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-09 14:19:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg TE, Dodge M, Aloia M, Egan MF, Weinberger DR</AU>
<TI>Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning</TI>
<SO>Psychological Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>5</NO>
<PG>1123-30</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guan-2005" MODIFIED="2009-01-09 14:42:29 +0000" MODIFIED_BY="[Empty name]" NAME="Guan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:42:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guan D-H, Song H-F</AU>
<TI>A control study of social function improvement in schizophrenia patients with risperdal and clozapine</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>9</NO>
<PG>506-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2001" MODIFIED="2009-01-09 14:19:22 +0000" MODIFIED_BY="[Empty name]" NAME="Guo 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:19:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo HR, Zhang SR, Sun FG</AU>
<TI>Clinical controlled study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Xinxiang Medical College</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>3</NO>
<PG>174-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2003" MODIFIED="2009-01-12 21:48:23 +0000" MODIFIED_BY="[Empty name]" NAME="Guo 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-09 14:42:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo S, Lu L, Cheng W</AU>
<TI>Effect of clozapine and risperidone on interleukin-2 on schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>1</NO>
<PG>35-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagger-1997" MODIFIED="2010-01-11 11:58:22 +0000" MODIFIED_BY="[Empty name]" NAME="Hagger 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-11 11:58:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Hagger C, Mitchell D, Wise AL, Schulz SC</AU>
<TI>Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data</TI>
<SO>Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2000" MODIFIED="2010-11-22 16:09:13 +0000" MODIFIED_BY="[Empty name]" NAME="Han 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-22 16:09:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han P</AU>
<TI>A study of risperidone and clozapine in treatment of resistant schizophrenia</TI>
<SO>Journal of Jining Medical College</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>75</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2005" MODIFIED="2010-01-11 11:58:58 +0000" MODIFIED_BY="[Empty name]" NAME="Han 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:58:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han Z-Y, Wang L-J, Wang J</AU>
<TI>Analysis of risperidone clonazepam in treatment of positive symptom schizophrenia</TI>
<SO>Ningxia Medical Journal</SO>
<YR>2005</YR>
<VL>27</VL>
<PG>631-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrigan-2004" MODIFIED="2009-01-09 14:19:51 +0000" MODIFIED_BY="[Empty name]" NAME="Harrigan 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:19:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M</AU>
<TI>A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>62-9</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2005" MODIFIED="2009-01-09 14:19:56 +0000" MODIFIED_BY="[Empty name]" NAME="He 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:19:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He Y-Q, Ma S-H, Du J</AU>
<TI>A controlled study on hostility and side effects in clozapine and risperidone for treatment of patients with schizophrenia</TI>
<SO>Journal of Xinxiang Medical College</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>2</NO>
<PG>118-20</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:19:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heresco_x002d_Levy-2005" MODIFIED="2009-01-09 14:20:01 +0000" MODIFIED_BY="[Empty name]" NAME="Heresco-Levy 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:20:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar GCS, Ermilov M</AU>
<TI>D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>6</NO>
<PG>577-85</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hou-2001" MODIFIED="2009-01-09 14:20:07 +0000" MODIFIED_BY="[Empty name]" NAME="Hou 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:20:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hou J, Xu G, Ma C</AU>
<TI>The effects of clozapine and risperidone on serum prolactin levels of female schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>1</NO>
<PG>1-3</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hrdlicka-2001" MODIFIED="2009-01-09 14:20:12 +0000" MODIFIED_BY="[Empty name]" NAME="Hrdlicka 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:20:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hrdlicka M, Rosillon D, Duchesne I</AU>
<TI>Czech results of the RODOS study: comparison of risperidone and olanzapine from the point of view of efficacy, tolerability and treatment costs</TI>
<TO>Ceske vysledky studie RODOS: Porovnani risperidonu a olanzapinu z hlediska ucinnosti, snasenlivosti a nakladu lecby</TO>
<SO>Ceska A Slovenská Psychiatrie</SO>
<YR>2001</YR>
<VL>97</VL>
<NO>7</NO>
<PG>343-9</PG>
<PB>Czech Medical Society JEv Purkyne, Czech Republic</PB>
<CY>Czech Republic</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2000" MODIFIED="2010-01-11 12:00:12 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:00:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu X-C, Tao R-F</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Handan Medical College</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>91</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2005" MODIFIED="2010-01-11 12:00:29 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:00:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu T-S</AU>
<TI>A study of risperidone in treatment of dominant positive symptoms in schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>5</NO>
<PG>428</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2000" MODIFIED="2010-01-11 12:01:10 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:01:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang Y-H, Luo B-M</AU>
<TI>A study of risperidone and chlorpromazine clozapine</TI>
<SO>Health Psychology Journal</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>321-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2001" MODIFIED="2010-01-11 12:01:51 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:01:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang Q-M, Li J, Zhu X-W, Mel Q-Y</AU>
<TI>A study of risperidone and clozapine in treatment of the behaviors in schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>152-4</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-2004" MODIFIED="2010-11-22 16:10:06 +0000" MODIFIED_BY="[Empty name]" NAME="Huber 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-22 16:10:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huber TJ, Borsutzky M, Schneider U, Emrich HM</AU>
<TI>Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2004</YR>
<VL>109</VL>
<NO>4</NO>
<PG>269-74</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssen_x002d_Ortho-2006" MODIFIED="2010-01-11 12:02:52 +0000" MODIFIED_BY="[Empty name]" NAME="Janssen-Ortho 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:02:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Janssen-Ortho Inc</AU>
<TI>Pragmatic randomised trial of RISPERDAL ® CONSTA &#8482; versus oral atypical antipsychotics in poorly adherent subjects with schizophrenia in a routine care setting: UK Revised Protocol V2</TI>
<SO>Unpublished report</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2006" MODIFIED="2010-01-11 12:03:28 +0000" MODIFIED_BY="[Empty name]" NAME="Jones 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:03:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW</AU>
<TI>Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1079-87</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karow-2002" MODIFIED="2009-01-09 14:20:55 +0000" MODIFIED_BY="[Empty name]" NAME="Karow 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:20:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karow A, Naber D</AU>
<TI>Subjective well-being and quality of life under atypical antipsychotic treatment</TI>
<SO>Psychopharmacology</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>3-10</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:20:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keks-2006" MODIFIED="2010-01-11 12:07:09 +0000" MODIFIED_BY="[Empty name]" NAME="Keks 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:07:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keks NA, Tonso M, Tabone K, McHugh M, Thomas R, Tune P, Gelman M</AU>
<TI>Clinical experience with atypical antipsychotics in an acute inpatient unit: Focus on quetiapine</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>138-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelemen-2006" MODIFIED="2010-01-11 12:07:41 +0000" MODIFIED_BY="[Empty name]" NAME="Kelemen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:07:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S</AU>
<TI>Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>430</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:21:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2004" MODIFIED="2010-01-11 12:07:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:07:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kim JG, Cho DH, Choi HK, Kim HJ, Cho JH, Kang SH, Lee SJ, Lee JG, Kim HT</AU>
<TI>The comparison of risperidone, olanzapine and quetiapine in the treatment of chronic schizophrenia and schizoaffective disorder</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>245</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:21:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knegtering-2004" MODIFIED="2009-01-09 14:21:51 +0000" MODIFIED_BY="[Empty name]" NAME="Knegtering 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:21:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, Van Den Bosch RJ</AU>
<TI>A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>56-61</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:21:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koenigsberg-2000" MODIFIED="2010-01-11 14:55:34 +0000" MODIFIED_BY="[Empty name]" NAME="Koenigsberg 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 14:55:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Koenigsberg HW, Goodman M, Mitropoulou V, New AS, Siever LJ</AU>
<TI>Risperidone in the treatment of schizotypal personality</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2010-01-11 12:08:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolff-2000" MODIFIED="2010-01-11 12:09:12 +0000" MODIFIED_BY="[Empty name]" NAME="Kolff 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:09:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kolff M, Coenen A, Van Dis H, Duigemans P</AU>
<TI>Differential effects of antipsychotic drugs on clinical symptoms and cognitive functions in the treatment of schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 2</NO>
<PG>S59</PG>
<IDENTIFIERS MODIFIED="2010-01-11 12:09:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kong-2001" MODIFIED="2010-01-11 12:11:15 +0000" MODIFIED_BY="[Empty name]" NAME="Kong 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:11:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kong Q-R, Yang R-X, Li S-C, Lu Z-S, Li J-Y, Chen X</AU>
<TI>A study of clozapine with risperidone and clozapine with sulpiride in treatment of resistant schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2001</YR>
<VL>14</VL>
<PG>119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kores-2003" MODIFIED="2009-01-09 14:22:10 +0000" MODIFIED_BY="[Empty name]" NAME="Kores 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-09 14:22:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kores Plesnicar B, Zalar B, Tomori M, Krajnc I</AU>
<TI>Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>2003</YR>
<VL>115</VL>
<NO>1-2</NO>
<PG>58-62</PG>
<CY>Austria</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005" MODIFIED="2010-01-11 12:11:39 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:11:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee JN, Yang BH, Nam CW</AU>
<TI>The influences of risperidone and clozapine on body weight and glucose level in patients with chronic schizophrenia - comparison with haloperidol</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>457</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2006" MODIFIED="2009-01-09 14:22:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:22:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee C, Wu K-H, Habil H, Dyachkova Y, Lee P</AU>
<TI>Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>5</NO>
<PG>437-45</PG>
<CY>Australia</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lei-2002" MODIFIED="2010-01-11 12:11:58 +0000" MODIFIED_BY="[Empty name]" NAME="Lei 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:11:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lei X, Liang T, Zhang X</AU>
<TI>A controlled study on risperidone and clozapine in treatment of schizophrenia</TI>
<SO>China Pharmacist</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>3</NO>
<PG>169-71</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-2004" MODIFIED="2010-01-11 12:12:28 +0000" MODIFIED_BY="[Empty name]" NAME="Lewis 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:12:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Lloyd H, Markwick A</AU>
<TI>A randomised, controlled trial of new atypical drugs versus clozapine in treatment-resistant schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>6-7</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" MODIFIED="2010-01-11 12:12:45 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:12:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X-X</AU>
<TI>A study of risperidone and clozapine in treatment of chronic schizophrenia</TI>
<SO>He Nan Medical Information</SO>
<YR>2000</YR>
<VL>8</VL>
<PG>52-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2001" MODIFIED="2009-01-12 21:49:29 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:22:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Dai X</AU>
<TI>A comparative study of rispredone and sulpride in treating schizophrenia</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>136-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003" MODIFIED="2010-11-22 16:11:53 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-22 16:11:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li T, Xue XM, Gong CF</AU>
<TI>A comparison study on the efficacy of risperidone vs dozapine in cognition of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>11</NO>
<PG>653-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003a" MODIFIED="2009-07-31 09:43:50 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2003a" YEAR="2003">
<REFERENCE MODIFIED="2009-07-31 09:43:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Lao G</AU>
<TI>Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia</TI>
<SO>Chinese Journal of Behavioural Medical Science</SO>
<YR>2003</YR>
<VL>12</VL>
<PG>45-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" MODIFIED="2010-01-11 12:13:16 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:13:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Z</AU>
<TI>A comparative study of clozapine and risperdone lead to putting on weight</TI>
<SO>Heath Psychology Journal</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>5</NO>
<PG>396-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:22:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005" MODIFIED="2010-01-11 12:13:47 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:13:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li G, Chen Q, Zhang Q</AU>
<TI>A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2005</YR>
<VL>14</VL>
<PG>1007-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang--2005" MODIFIED="2010-01-11 12:14:14 +0000" MODIFIED_BY="[Empty name]" NAME="Liang  2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:14:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang Z-Y, Huang X-S</AU>
<TI>A study of risperidone and clozapine in treatment of first episode schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>9</NO>
<PG>509-10</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liao-2004" MODIFIED="2010-01-11 12:14:23 +0000" MODIFIED_BY="[Empty name]" NAME="Liao 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:14:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liao C, Yang H, Gao H</AU>
<TI>Effects of clozapine and risperidone on blood routine examinations of patients with schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>3</NO>
<PG>156-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005" MODIFIED="2010-01-11 14:20:35 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 14:20:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin Z, Li F, Yu Y, Zhong T</AU>
<TI>A controlled study of olanzapine and risperidone in the treatment of elderly patients with schizophrenia</TI>
<SO>Hainan Medical Journal</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>8</NO>
<PG>37-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipkovich-2005" MODIFIED="2009-01-09 14:23:22 +0000" MODIFIED_BY="[Empty name]" NAME="Lipkovich 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:23:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lipkovich I, Baron D, Houston J, Ahl J, Rotelli M</AU>
<TI>Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>381-6</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Littrell-1999" MODIFIED="2010-01-11 12:18:25 +0000" MODIFIED_BY="[Empty name]" NAME="Littrell 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-11 12:18:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Littrell KH</AU>
<TI>Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1999" MODIFIED="2009-01-09 14:43:28 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-09 14:43:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Q, Man C, Li X</AU>
<TI>A control study of risperidone and colzapine to treating the positive symptoms of schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>2</NO>
<PG>98-9, 100</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2001" MODIFIED="2009-01-09 14:23:39 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:23:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Q, Li X</AU>
<TI>A comparative study on the efficacy of combining risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>1</NO>
<PG>28-30</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" MODIFIED="2010-11-22 16:12:36 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-22 16:12:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu F, Dai M</AU>
<TI>The effects of risperidone and clozapine to patients with schizophrenia's life quality</TI>
<SO>Sichuan Mental Health</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>4</NO>
<PG>203-4</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003a" MODIFIED="2010-01-11 12:19:04 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 12:19:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Li H, Wang H</AU>
<TI>Effect and related factors of clozapine and risperidone on glucose-insulin homeostasis in schizophrenic patients</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>4</NO>
<PG>257-59</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:24:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004" MODIFIED="2009-01-09 14:23:52 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:23:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu TF, Yang JZ</AU>
<TI>Risperidone vs clozapine for treatment of schizophrenia in 30 patients each</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>3</NO>
<PG>147-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:23:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004a" MODIFIED="2010-01-11 12:19:25 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:19:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu J-B, Wu J</AU>
<TI>The influence of clozapine, risperidone and chlorpromazine on the Glu.TG.TC and the weight in the first-episode schizophrenia</TI>
<SO>Chinese Journal of Nerval and Mental Diseases</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>4</NO>
<PG>293-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004b" MODIFIED="2010-01-11 12:19:56 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:19:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu N-H, Zhang J-Y</AU>
<TI>A study of risperidone with clonazepam in treatment of schizophrenia</TI>
<SO>Journal of Hai Nan Medical College</SO>
<YR>2004</YR>
<VL>10</VL>
<PG>394-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004c" MODIFIED="2009-11-04 11:14:32 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2004c" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:14:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Li H-F, Wang H-F, Wang K-X, Gao Z-S, Gu N-F</AU>
<TI>Influence of clozapine and risperidone on body weight, leptin level and lipid metabolism in schizophrenic patients</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>23</NO>
<PG>579-82</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:24:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005" MODIFIED="2010-01-11 12:20:30 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:20:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu K, Jiao Z-A</AU>
<TI>A study of the influence of clozapine and risperidone on the weight in schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>513-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005a" MODIFIED="2010-01-11 12:20:59 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:20:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu G-F, Zhou J-S</AU>
<TI>The influence of risperidone and clozapine in the quality of life of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>289-90</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:24:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005c" MODIFIED="2009-01-12 21:51:45 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2005c" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:24:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y</AU>
<TI>A comparative study of risperidone and clozapine in the treatment of refractory schizophrenia</TI>
<SO>Journal of Heze Medical College</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>1</NO>
<PG>13-4</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:24:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loza-2005" MODIFIED="2010-01-11 12:21:43 +0000" MODIFIED_BY="[Empty name]" NAME="Loza 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:21:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loza B, Bartyzel M, Matysiewicz W, Mazurek I, Mosiolek A, Opielak G, Varghese S</AU>
<TI>Hyperprolactinemia during schizophrenia treatment with atypical antipsychotics: oral risperidone, depot risperidone, and oral olanzapine</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>522</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:24:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002" MODIFIED="2009-11-04 11:15:13 +0000" MODIFIED_BY="[Empty name]" NAME="Lu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-04 11:15:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu Y, Ren Q, Tian M</AU>
<TI>A comparison of cognitive function in the first-onset schizophrenia treated with risperidone and clozapine</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>4</NO>
<PG>206-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:25:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2004" MODIFIED="2009-11-04 11:15:24 +0000" MODIFIED_BY="[Empty name]" NAME="Lu 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:15:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu L-X, Guo S-Q, Chen W, Li Q, Cheng J, Zhang H-Y, Shi T-Y, Shi Y</AU>
<TI>Effects of clozapine and risperidone on serum interleukin-2,-10,-18 in adolescent schizophrenia patients</TI>
<SO>Journal of Applied Clinical Pediatrics</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>11</NO>
<PG>983-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:24:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2005" MODIFIED="2009-11-04 11:15:38 +0000" MODIFIED_BY="[Empty name]" NAME="Lu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-04 11:15:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu S, Zhang S-A, Ren Y</AU>
<TI>Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine</TI>
<SO>Journal of Nursing Science</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>3</NO>
<PG>57-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:25:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-1999" MODIFIED="2010-01-11 12:23:53 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-11 12:23:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma Q-M, Guan H-Y, Jiang L, Zhang Y-Y, Yi X-R, Guo J-M, Sun S-G, Liu K-H, Gao S-Q, Wu H-R, Xu S-W</AU>
<TI>A study of risperidone in treatment of chronic schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>3</NO>
<PG>290-3</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:25:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mai-2005" MODIFIED="2010-01-11 12:24:24 +0000" MODIFIED_BY="[Empty name]" NAME="Mai 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:24:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mai G, Cai GH, Huang JM</AU>
<TI>Comparative Study on the effect of aripiprazole and risperidone on schizophrenia</TI>
<SO>Chinese Journal of Rehabilitation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>3</NO>
<PG>184-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malla-2004" MODIFIED="2009-11-04 11:16:05 +0000" MODIFIED_BY="[Empty name]" NAME="Malla 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:16:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malla A, Norman R, Scholten D, Townsend L, Manchanda R, Takhar J, Haricharan R</AU>
<TI>A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition</TI>
<SO>Psychiatry Research</SO>
<YR>2004</YR>
<VL>129</VL>
<PG>159-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malyarov-1999" MODIFIED="2010-01-11 12:24:45 +0000" MODIFIED_BY="[Empty name]" NAME="Malyarov 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-11 12:24:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malyarov S, Dzub G</AU>
<TI>Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>296</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:25:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malykhin-2003" MODIFIED="2010-01-11 12:24:59 +0000" MODIFIED_BY="[Empty name]" NAME="Malykhin 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 12:24:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malykhin N</AU>
<TI>Comparative efficacy of risperidone, clozapine and haloperidol in the treatment of schizoaffective disorders with manic symptoms</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>304</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:25:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mao-2000" MODIFIED="2010-01-11 12:25:26 +0000" MODIFIED_BY="[Empty name]" NAME="Mao 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:25:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mao Y, Da Z</AU>
<TI>Study of cost-effectiveness on risperidone vs clozapine in the treatment of inpatients with schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>4</NO>
<PG>211-3</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:25:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazurek-2003" MODIFIED="2010-01-11 12:25:38 +0000" MODIFIED_BY="[Empty name]" NAME="Mazurek 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 12:25:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mazurek I, Loza B, Lecyk A</AU>
<TI>Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>347</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mei-2001" MODIFIED="2009-07-31 09:45:08 +0100" MODIFIED_BY="[Empty name]" NAME="Mei 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-31 09:45:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mei Q, Zhu X, Shen J</AU>
<TI>A comparative study of social function in schizophrenic patients treated with risperidone or clozapine</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2002" MODIFIED="2010-01-11 12:26:24 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:26:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Meltzer HY, Gilliam JH, Nasdahl C</AU>
<TI>Olanzapine causes greater increases in serum lipids than risperidone</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2004" MODIFIED="2009-01-09 14:26:23 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:26:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group</AU>
<TI>Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>6</NO>
<PG>975-84</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mintzer-2004" MODIFIED="2009-01-09 14:26:29 +0000" MODIFIED_BY="[Empty name]" NAME="Mintzer 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-09 14:26:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mintzer JE, Mullen JA, Sweitzer DE</AU>
<TI>A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>9</NO>
<PG>1483-91</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohr-2000" MODIFIED="2010-01-11 12:27:25 +0000" MODIFIED_BY="[Empty name]" NAME="Mohr 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:27:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mohr E, Mendis T, Hildebrand K, De Deyn PP</AU>
<TI>Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot study</TI>
<SO>Movement Disorder</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>6</NO>
<PG>1230-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mu-2002" MODIFIED="2010-01-11 12:27:52 +0000" MODIFIED_BY="[Empty name]" NAME="Mu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:27:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mu Z-Q, Zong Y-S, Luo Y</AU>
<TI>A study of risperidone instead of typical antipsychotics and clozapine in treatment of chronic schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2002</YR>
<VL>10</VL>
<PG>234-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mullen-2001" MODIFIED="2010-01-11 12:28:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mullen 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:28:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mullen J, Jibson MD, Sweitzer D</AU>
<TI>A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1839-54</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musil-2006" MODIFIED="2010-01-11 12:28:35 +0000" MODIFIED_BY="[Empty name]" NAME="Musil 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:28:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Musil RL, Spellmann I, Riedel M, Douhet A, Dehning S, Maino K, Zill P, Müller N, Möller HJ, Bondy B</AU>
<TI>SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>415</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2001" MODIFIED="2009-01-09 14:26:57 +0000" MODIFIED_BY="[Empty name]" NAME="Naber 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:26:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Moritz S, Lambert M, Pajonk F, Holzbach R, Mass R, Andresen B</AU>
<TI>Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>79-88</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:26:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2002" MODIFIED="2009-01-09 14:27:03 +0000" MODIFIED_BY="[Empty name]" NAME="Naber 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:27:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Karow A, Lambert M</AU>
<TI>Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>31-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nan-2001" MODIFIED="2010-01-11 12:29:29 +0000" MODIFIED_BY="[Empty name]" NAME="Nan 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:29:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nan Z, Wang J, Ji H</AU>
<TI>A controlled study of risperidone and clozapine both influences congnitive function of patients with schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>4</NO>
<PG>198-200</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ni-2001" MODIFIED="2010-01-11 12:30:24 +0000" MODIFIED_BY="[Empty name]" NAME="Ni 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:30:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ni J-L, Jiiang L-C, Hong X, Yang H, Zheng X-P</AU>
<TI>A study of clozapine and risperidone in treatment of schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>181-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicholls-2003" MODIFIED="2010-11-22 16:53:50 +0000" MODIFIED_BY="[Empty name]" NAME="Nicholls 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-22 16:53:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nicholls CJ, Hale AS, Freemantle N</AU>
<TI>Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia... first published as: Journal of Medical Economics 2003;6:31-41</TI>
<SO>Journal of Drug Assessment</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>2</NO>
<PG>79-89</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opjordsmoen-2000" MODIFIED="2010-01-11 12:31:07 +0000" MODIFIED_BY="[Empty name]" NAME="Opjordsmoen 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:31:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Opjordsmoen S, Brunsvik S, Melle I, Dahl A, Friis S, Haahr U, Hustoft K, Johannessen JO, Larsen TK, McGlashan TH, Simonsen E, Vaglum P</AU>
<TI>A comparison between novel and traditional antipsychotics as first-line medication in early psychosis</TI>
<SO>Proceedings of the 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2; New York, New York, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega_x002d_Soto-1997" MODIFIED="2010-01-11 12:31:27 +0000" MODIFIED_BY="[Empty name]" NAME="Ortega-Soto 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-11 12:31:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Ortega-Soto H, Apiquian R, Ulloa RE, Salas M, Loyzaga C, Mendizabal A, Brunner E</AU>
<TI>Olanzapine vs risperidone. A double blind trial in Mexican patients</TI>
<SO>Proceedings of the Collegium Internationale Neuro-Psychopharmacologicum Regional Meeting; 1997 Aug 21-23; Acapulco, Mexico</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2004" MODIFIED="2010-01-11 12:32:09 +0000" MODIFIED_BY="[Empty name]" NAME="Pan 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:32:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan M, Zhang S, Zhao Z</AU>
<TI>A comparative study of domestic quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>10</NO>
<PG>597-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2004a" MODIFIED="2010-01-11 12:32:27 +0000" MODIFIED_BY="[Empty name]" NAME="Pan 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:32:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan M, Zhang S-Q, Zhao Z</AU>
<TI>Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia</TI>
<SO>Journal of Xin Xiang Medical College</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>5</NO>
<PG>403-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2001" MODIFIED="2009-01-09 14:44:14 +0000" MODIFIED_BY="[Empty name]" NAME="Peng 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-09 14:44:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng H, Kuang Y, Huang X</AU>
<TI>A control study of risperidone in combination with clozapine in treating refractory schizophrenia</TI>
<SO>Journal of Modern Clinical Medical Bioengineering</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>2</NO>
<PG>100-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2004" MODIFIED="2009-11-04 11:18:47 +0000" MODIFIED_BY="[Empty name]" NAME="Peng 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:18:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng J-F, Xu Y-M, Wang Y-B</AU>
<TI>Effects of clozapine and risperidone on the serum prolactin levels and body weight regulation</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>5</NO>
<PG>268-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perro-1999" MODIFIED="2010-01-11 12:32:56 +0000" MODIFIED_BY="[Empty name]" NAME="Perro 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-11 12:32:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Perro C, Naber D, Lambert M, Moritz S, Krause M</AU>
<TI>A prospective clinical comparative-study of four atypical antipsychotic agents in the treatment of schizophrenia</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peuskens-2004" MODIFIED="2010-01-11 12:33:21 +0000" MODIFIED_BY="[Empty name]" NAME="Peuskens 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:33:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peuskens J, Deberdt W, Van Brunt D, Hill A, Liu-Seifert H, Csernansky J, Buckley P</AU>
<TI>Medication-specific correlates of relapse risk in schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>238</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:27:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qi-2004a" MODIFIED="2010-01-11 12:33:41 +0000" MODIFIED_BY="[Empty name]" NAME="Qi 2004a" YEAR="">
<REFERENCE MODIFIED="2010-01-11 12:33:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qi F, Wang L, Zhen Y</AU>
<TI>Comparison of efficacy and safety of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>16</VL>
<PG>78-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qian-2004" MODIFIED="2009-11-04 11:19:09 +0000" MODIFIED_BY="[Empty name]" NAME="Qian 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:19:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qian D, Pan B, Yang G</AU>
<TI>Cost-effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia</TI>
<SO>Evaluation and Analysis of Drug-use in Hospital of China</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>2</NO>
<PG>110-1</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2005" MODIFIED="2009-01-09 14:44:41 +0000" MODIFIED_BY="[Empty name]" NAME="Qin 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:44:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin Y, Kang W, Song L</AU>
<TI>A comparative study of risperidone combining alprazolam and clozapine in the treatment of patients with schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>6</NO>
<PG>444-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabinowitz-2005" MODIFIED="2010-01-11 12:34:16 +0000" MODIFIED_BY="[Empty name]" NAME="Rabinowitz 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:34:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Rabinowitz J</AU>
<TI>Pattern mixture approach to comparing outcomes - of benefit in guideline development</TI>
<SO>Proceedings of the 18th European College of Neuropsychopharmacology Congress; 2005 October 22-26, Amsterdam, Netherlands</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2000" MODIFIED="2010-01-11 12:34:46 +0000" MODIFIED_BY="[Empty name]" NAME="Ren 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:34:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren J-J, Su J-L, Li B-Q</AU>
<TI>A study of risperidone and clozapine in treatment of resistant schizophrenia</TI>
<SO>Baotou Medical Journal</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>2</NO>
<PG>6-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2004" MODIFIED="2010-01-11 12:35:35 +0000" MODIFIED_BY="[Empty name]" NAME="Ren 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:35:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren K, Zhao X, Jiang X</AU>
<TI>Effects of risperidone and clozapine on life quality of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>1</NO>
<PG>3-4</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roerig-2004" MODIFIED="2010-01-11 12:35:59 +0000" MODIFIED_BY="[Empty name]" NAME="Roerig 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:35:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Roerig JL, Mitchell JE, De Zwaan M, Crosby RD, Gosnell BA, Pederson K</AU>
<TI>A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors and ghrelin plasma levels in normal human subjects</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryu-2006" MODIFIED="2010-01-11 12:36:22 +0000" MODIFIED_BY="[Empty name]" NAME="Ryu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:36:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ryu SH, Jang WS, Cho EY, Kim SK, Lee DS, Hong KS</AU>
<TI>Association of leptin gene polymorphism with antipsychotic drug-induced weight gain</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>419</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sajatovic-2002" MODIFIED="2010-01-11 12:36:57 +0000" MODIFIED_BY="[Empty name]" NAME="Sajatovic 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:36:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Sajatovic M, Mullen JA, Sweitzer D</AU>
<TI>Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shao-1999" MODIFIED="2010-01-11 12:37:13 +0000" MODIFIED_BY="[Empty name]" NAME="Shao 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-11 12:37:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shao Y-Q</AU>
<TI>The extrapyramidal side effects of risperidone</TI>
<SO>Journal of Southeast China National Defense Medicinal Science</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>1</NO>
<PG>28-29</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:28:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheng-2003" MODIFIED="2009-11-04 11:19:38 +0000" MODIFIED_BY="[Empty name]" NAME="Sheng 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 11:19:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheng Y, Liu T, Li Y</AU>
<TI>A comparison study of the blood sugar in the treatment of schizophrenic patients with risperidone, clozapine and chlorpromazine</TI>
<SO>Qilu Journal of Medicall Aboratory Sciences</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>1</NO>
<PG>11-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheng-2005" MODIFIED="2010-11-22 16:57:20 +0000" MODIFIED_BY="[Empty name]" NAME="Sheng 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-22 16:57:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheng Y</AU>
<TI>Effects of clozapine and risperidone on serum interleukin-2 and interleukin-6 of patients with first episode schizophrenia</TI>
<SO>Qilu Journal of Medical Laboratory Sciences</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>5</NO>
<PG>14-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2000" MODIFIED="2009-11-04 11:19:51 +0000" MODIFIED_BY="[Empty name]" NAME="Shi 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-04 11:19:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi F, Cheng X, Zhang Y</AU>
<TI>Controlled study of risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>1</NO>
<PG>27-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2001" MODIFIED="2010-01-11 12:37:43 +0000" MODIFIED_BY="[Empty name]" NAME="Shi 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:37:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi X-H</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Medical Journal of Communications</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>6</NO>
<PG>652-3</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2004" MODIFIED="2010-01-11 12:37:56 +0000" MODIFIED_BY="[Empty name]" NAME="Shi 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:37:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi T, Zhang R, Guo X</AU>
<TI>Influences of risperidone and clozapine on plasma levels of cytokine in first-episode schizophrenics</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>5</NO>
<PG>339-41</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-2004" MODIFIED="2009-11-04 11:20:32 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:20:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Fayek M, Weiden PJ, Murray S, Warrington L, Loebel A</AU>
<TI>Ziprasidone: long-term post-switch efficacy in schizophrenia</TI>
<SO>World Psychiatry</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>S1</NO>
<PG>220</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sowell-2002" MODIFIED="2009-11-04 11:20:44 +0000" MODIFIED_BY="[Empty name]" NAME="Sowell 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-04 11:20:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sowell M, Cavazzoni P, Roychowdhury SM, Breier A</AU>
<TI>Antipsychotics and diabetes: lack of evidence for a causal relationship</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>170</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2004" MODIFIED="2009-01-12 21:54:42 +0000" MODIFIED_BY="[Empty name]" NAME="Su 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun D, Jiang Q, Su S</AU>
<TI>Effect of risperidone and clozapine on blood fat in patients with schizophrenia</TI>
<SO>Journal of Hebei Medical College for Continuing Education</SO>
<YR>2004</YR>
<VL>21, 2</VL>
<PG>8-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2005" MODIFIED="2009-01-09 14:29:40 +0000" MODIFIED_BY="[Empty name]" NAME="Su 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:29:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Su K-P, Wu P-L, Pariante CM</AU>
<TI>A crossover study on lipid and weight changes associated with olanzapine and risperidone</TI>
<SO>Psychopharmacology</SO>
<YR>2005</YR>
<VL>183</VL>
<NO>3</NO>
<PG>383-6</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2000" MODIFIED="2010-01-11 14:21:58 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 14:21:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun T</AU>
<TI>A controlled study comparing risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>3</NO>
<PG>290-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2001" MODIFIED="2010-01-11 12:39:33 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:39:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun Q-Z, Liang J-S, Yu G-H, Huang X</AU>
<TI>A study of risperidone and clozapine in treatment of negative symptoms of resistant schizophrenia</TI>
<SO>Journal of Qiqihar Medical</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>11</NO>
<PG>1247-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swanson-2006" MODIFIED="2010-01-11 12:39:51 +0000" MODIFIED_BY="[Empty name]" NAME="Swanson 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:39:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Swanson JW, Swartz MS, Van Dorn RA</AU>
<TI>Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:29:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tandon-2006" MODIFIED="2009-01-09 14:30:30 +0000" MODIFIED_BY="[Empty name]" NAME="Tandon 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:30:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT</AU>
<TI>A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>1</NO>
<PG>77-89</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:30:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2002" MODIFIED="2010-11-22 16:58:23 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-22 16:58:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang M, Wang H, Huang J</AU>
<TI>Influences of treating schizophrenics with risperidone and clozapine on the quality of life of their spouses and parents</TI>
<SO>Nervous Diseases and Mental Hygiene</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>2</NO>
<PG>67-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:30:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2002a" MODIFIED="2010-11-22 16:58:39 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2002a" YEAR="2002">
<REFERENCE MODIFIED="2010-11-22 16:58:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang M, Zhao G, Wang H</AU>
<TI>Comparison of quality of life of family with schizophrenic outpatients</TI>
<SO>Nervous Disease and Mental Hygiene</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>67-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-2005" MODIFIED="2010-01-11 12:41:34 +0000" MODIFIED_BY="[Empty name]" NAME="Tian 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:41:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tian R-F</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia in children</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>261</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:30:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-2005" MODIFIED="2010-01-11 12:42:00 +0000" MODIFIED_BY="[Empty name]" NAME="Tong 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:42:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tong S-N, Gan H-Q, Liu Y-Y</AU>
<TI>A study of clozapine and risperidone influencing on IQ and memory in schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>7</NO>
<PG>634</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:30:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tunis-2006" MODIFIED="2009-01-09 14:30:56 +0000" MODIFIED_BY="[Empty name]" NAME="Tunis 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:30:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R</AU>
<TI>Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial</TI>
<SO>Value in Health</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>2</NO>
<PG>77-89</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:30:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Bruggen-2003" MODIFIED="2010-01-11 12:42:35 +0000" MODIFIED_BY="[Empty name]" NAME="Van Bruggen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 12:42:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Bruggen J, Tijssen J, Dingemans P, Gersons B, Linszen D</AU>
<TI>Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>6</NO>
<PG>341-6</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaughan-2000" MODIFIED="2010-01-11 12:43:05 +0000" MODIFIED_BY="[Empty name]" NAME="Vaughan 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:43:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan K, McConaghy N, Wolf C, Myhr C, Black T</AU>
<TI>Community treatment orders: Relationship to clinical care, medication compliance, behavioural disturbance and readmission</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>5</NO>
<PG>801-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000a" MODIFIED="2010-01-11 12:45:32 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2000a" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 12:45:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang M, Liu L</AU>
<TI>A controlled study on seroquel and risperidone in the treatment of schizophrenic patients</TI>
<SO>Journal of Clinical Psychology in Medical Settings</SO>
<YR>2000</YR>
<VL>10, 4</VL>
<PG>200-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2001" MODIFIED="2010-11-22 17:00:29 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-22 17:00:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Nan Z, Bai J</AU>
<TI>The relationship of schizophrenic cognitive function impairment with positive and negative symptoms</TI>
<SO>Journal of Clinical Psychology in Medical Settings</SO>
<YR>2001</YR>
<VL>11</VL>
<PG>346-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" MODIFIED="2009-01-12 21:56:04 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:45:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang G, Chen Z, Wang H</AU>
<TI>Comparative study on quality of life of schizophrenics treated with risperidone or clozapine</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>200-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002a" MODIFIED="2009-11-04 11:21:33 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2002a" YEAR="2002">
<REFERENCE MODIFIED="2009-11-04 11:21:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang R, Geng Y, Pan D</AU>
<TI>A comparative trial on the efficacy of risperidone and clozapine in treatment-resistant schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>4</NO>
<PG>221-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2010-11-22 17:00:49 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-22 17:00:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Zhao J, Wang J</AU>
<TI>A comparative study of risperidone and clozapine on life quality of schizophrenia</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>149-50</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003a" MODIFIED="2010-01-11 12:51:08 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 12:51:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J-J</AU>
<TI>A study of risperidone and clozapine with sulpiride in treatment of schizophrenia</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>234-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2009-01-12 21:55:56 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:45:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang C-H, Li Y, Ma J-D, Wang L-H, Pan M, Mu J-L</AU>
<TI>Comparison of cognitive function and p300 potentials in first-episode schizophrenia treated with risperidone and clozapine</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>4</NO>
<PG>267-71</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005a" MODIFIED="2010-01-11 12:47:24 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:47:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang S-Y, Liu Z, Bian J, Xu J-G</AU>
<TI>The influence of risperidone in the quality of life in schizophrenia</TI>
<SO>Nervous Diseases and Mental Hygiene</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>2</NO>
<PG>153-4</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005b" MODIFIED="2010-01-11 14:24:21 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 14:24:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Yang J, Guo H</AU>
<TI>Clinical study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>2</NO>
<PG>118-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weickert-2003" MODIFIED="2009-01-09 14:31:55 +0000" MODIFIED_BY="[Empty name]" NAME="Weickert 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-09 14:31:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR</AU>
<TI>Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1491-500</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weng-1998" MODIFIED="2009-01-09 14:31:59 +0000" MODIFIED_BY="[Empty name]" NAME="Weng 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-01-09 14:31:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weng Y</AU>
<TI>A controlled trial of risperidone versus clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:31:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-2002" MODIFIED="2010-01-11 12:50:05 +0000" MODIFIED_BY="[Empty name]" NAME="Wolf 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:50:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Wolf K, Wolf K, Mass R, Kiefer F, Wiedemann K, Naber D</AU>
<TI>Improvement of facial expression of emotions (fee) of schizophrenic patients under olanzapine versus risperidone. A prospective facial-emg study</TI>
<SO>Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-2005" MODIFIED="2009-01-09 14:32:09 +0000" MODIFIED_BY="[Empty name]" NAME="Wolf 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:32:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolf K, Mass R, Kiefer F, Eckert K, Stritzky AV, Haasen C, Wiedemann K, Naber D</AU>
<TI>The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia-preliminary results of a facial electromyogram study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>278-81</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2001" MODIFIED="2010-01-11 12:51:32 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:51:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu T, Li Y, Li M</AU>
<TI>Efficacy of low dosage risperidone in the treatment of first episode schizophrenia</TI>
<SO>Journal of Clinical Psychology in Medical Settings</SO>
<YR>2001</YR>
<VL>11</VL>
<PG>152-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2002" MODIFIED="2010-01-11 12:51:41 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:51:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu L</AU>
<TI>A control study of risperidone and clozapine combination for the treatment of refractory schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>2</NO>
<PG>135-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2004" MODIFIED="2010-01-11 12:52:04 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:52:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu J-F, Li Z-G</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>4</NO>
<PG>213-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2006" MODIFIED="2009-01-09 14:32:27 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:32:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wu R-R, Zhao J-P, Liu Z-N, Zhai J-G, Guo X-F, Guo W-B, Tang J-S</AU>
<TI>Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>186</VL>
<NO>4</NO>
<PG>572-8</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wyszogrodzka-2006" MODIFIED="2009-11-04 11:22:34 +0000" MODIFIED_BY="[Empty name]" NAME="Wyszogrodzka 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-04 11:22:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wyszogrodzka-Kucharska A, Rabe-Jablonska J</AU>
<TI>Vitamin D deficiency and impaired parathormone metabolism as a risk factor of low bone mineral density in patients with diagnosis of schizophrenia treated with second generation antipsychotics</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>373</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2003" MODIFIED="2010-01-12 21:38:14 +0000" MODIFIED_BY="[Empty name]" NAME="Xiao 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 21:38:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao X-M, Song X-C, Jiang H-Y</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychology Medicine</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2005" MODIFIED="2010-01-11 12:53:24 +0000" MODIFIED_BY="[Empty name]" NAME="Xie 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 12:53:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie B-Q, Wang Z-M, Han Q-L</AU>
<TI>A control study of risperidone and clozapine in the treatment the chronic schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>76-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xin-2001" MODIFIED="2009-07-31 09:44:11 +0100" MODIFIED_BY="[Empty name]" NAME="Xin 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-31 09:44:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xin X, Du B, Zeng Z</AU>
<TI>A controlled clinical study of risperidone and low dose of clozapine in treating schizophrenia</TI>
<SO>Herald of Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>8</NO>
<PG>501-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2001" MODIFIED="2010-01-11 12:53:39 +0000" MODIFIED_BY="[Empty name]" NAME="Xu 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 12:53:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu C, Tang J, Zhang X</AU>
<TI>The effect of risperidone and clozapine treatment on serum interleukin 8, interleukin 15 in schizophrenis</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>132-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:32:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2005" MODIFIED="2010-11-22 17:46:12 +0000" MODIFIED_BY="[Empty name]" NAME="Xu 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-22 17:46:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu X, Zhang X , Zhaao C, Dai X</AU>
<TI>Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Medicine in Practice</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagdiran-2000" MODIFIED="2009-11-04 11:22:52 +0000" MODIFIED_BY="[Empty name]" NAME="Yagdiran 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-04 11:22:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yagdiran O, Krausz M</AU>
<TI>Depressive symptoms under atypical neuroleptic treatment in schizophrenia</TI>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>Suppl 1</NO>
<PG>135-6</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:33:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamashita-2005" MODIFIED="2009-01-09 14:33:35 +0000" MODIFIED_BY="[Empty name]" NAME="Yamashita 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:33:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S</AU>
<TI>Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>5</NO>
<PG>377-84</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:33:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yan-2002" MODIFIED="2010-01-11 12:54:23 +0000" MODIFIED_BY="[Empty name]" NAME="Yan 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:54:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yan M, Wu B-Q</AU>
<TI>A study of risperidone and clozapine in treatment of chronic schizophrenia</TI>
<SO>Journal of Chinese Politic Medicine</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>6</NO>
<PG>350-1</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:33:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-1998" MODIFIED="2009-01-09 14:33:46 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-01-09 14:33:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Z, Xu H, Song Y</AU>
<TI>A controlled study of efficacy of risperidone and clozapine on treating schizophrenia whose predominant clinical features were negative symptoms</TI>
<SO>Sichuan Mental Health</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>3</NO>
<PG>151-2, 159</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:33:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2003" MODIFIED="2010-11-22 17:46:47 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-22 17:46:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X, Mei Q</AU>
<TI>A comparison of olanzapine and risperidone in the treatment of first episode schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<PG>338-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2004" MODIFIED="2010-01-11 12:55:34 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:55:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X-N, Mei Q-Y</AU>
<TI>A study of risperidone with clonazepam in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>25</VL>
<PG>274</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2004a" MODIFIED="2009-11-04 11:23:18 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang B, Wang YD, Zhang L</AU>
<TI>Effects of clozapine, risperidone and haloperidol on plasma leptin in first-episode schizophrenic patients</TI>
<SO>Journal of The Fourth Military Medical University</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>14</NO>
<PG>1323-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:33:54 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ye-2005" MODIFIED="2009-01-12 22:00:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ye 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:47:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ye S-C, Zhang W-Y, Zhang Y-M</AU>
<TI>Observation of developments of the level of serum prolactin of first-episode schizophrenia patients during the treatment</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>267-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ye-2005a" MODIFIED="2010-01-11 14:33:41 +0000" MODIFIED_BY="[Empty name]" NAME="Ye 2005a" YEAR="">
<REFERENCE MODIFIED="2010-01-11 14:33:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ye X, Xia X</AU>
<TI>A comparative study between aripiprazole and risperidone in treatment of first-onset schizophrenia</TI>
<SO>Medical Journal of National Defending Forces in Southwest China</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>6</NO>
<PG>616-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yin-2002" MODIFIED="2010-11-22 17:47:12 +0000" MODIFIED_BY="[Empty name]" NAME="Yin 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-22 17:47:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yin Y, Son L</AU>
<TI>The impact of clozapine and risperidone on QTc</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>3</NO>
<PG>154-5</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yin-2004" MODIFIED="2010-01-11 12:57:55 +0000" MODIFIED_BY="[Empty name]" NAME="Yin 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 12:57:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yin H-R, Fang Y-M, Huang R-H, Yang X-Q</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>China Medical Engineering</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>3</NO>
<PG>87-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1999" MODIFIED="2010-01-11 12:58:09 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-11 12:58:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu G-H, Huang X</AU>
<TI>A study of risperidone and clozapine in treatment of resistant patients of schizophrenia</TI>
<SO>Chinese Journal of Nerval and Mental Diseases</SO>
<YR>1999</YR>
<VL>25</VL>
<PG>366-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2002" MODIFIED="2009-01-09 14:34:29 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:34:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu G, Ding G, Li X</AU>
<TI>An economic burden comparison of typical and atypical antipsychotic therapies for schizophrenia</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>3</NO>
<PG>177-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2005" MODIFIED="2009-11-04 11:23:49 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-04 11:23:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu D-S, Xu J, Sun D-H, Zeng Y-Y, Gao X-N, Jiang X-J</AU>
<TI>A comparative study of clozapine vs risperidone on body posture balance</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>2</NO>
<PG>125-8</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yue-2004" MODIFIED="2009-11-04 11:23:58 +0000" MODIFIED_BY="[Empty name]" NAME="Yue 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:23:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yue Y, Song L, Xu Y</AU>
<TI>A comparative study on risperidone in the two-year treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>3</NO>
<PG>165-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zelaschi-2006" MODIFIED="2010-01-11 12:59:00 +0000" MODIFIED_BY="[Empty name]" NAME="Zelaschi 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-11 12:59:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Zelaschi Sr NM, Rodriguez Sr JL, Gaitan Sr S, Palacios Vallejos Sr ME, Zieher Sr LM</AU>
<TI>The effects of the switch of conventional neuroleptics to atypical antipsychotics: a follow-up study of patients with chronic schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-2002" MODIFIED="2009-01-09 14:34:49 +0000" MODIFIED_BY="[Empty name]" NAME="Zeng 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:34:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng Y, Fang Q, Gao X</AU>
<TI>The 4th day serum prolactin level predicting the effective dose taking risperidone or clozapine</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>5</NO>
<PG>277-9</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhan-2002" MODIFIED="2010-01-11 12:59:52 +0000" MODIFIED_BY="[Empty name]" NAME="Zhan 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 12:59:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhan L-Y</AU>
<TI>Analysis of risperidone and clozapine in behavioral change in schizophrenia</TI>
<SO>Modern Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>19</NO>
<PG>2943</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:34:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1999" MODIFIED="2010-11-22 17:47:49 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-22 17:47:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang B-S, Liu B-Q, Shang F-Z, Song C-A, Huang C-B, Zhang R-F, Liu X-F</AU>
<TI>A double-blinded study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Psychiatry Medicine of Shandong</SO>
<YR>1999</YR>
<VL>12</VL>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2000" MODIFIED="2010-01-11 14:32:27 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2000" YEAR="1997">
<REFERENCE MODIFIED="2010-01-11 14:32:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang C</AU>
<TI>A controlled study comparing risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>74-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" MODIFIED="2009-01-12 22:02:03 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-09 14:35:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Q</AU>
<TI>A comparison of cognitive function in the first-onset schizophrenia treated with risperidone and clozapine</TI>
<SO>Journal of Qiqihar Medical</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>8</NO>
<PG>852-3</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:35:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002a" MODIFIED="2009-11-04 11:24:23 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2002a" YEAR="2002">
<REFERENCE MODIFIED="2009-11-04 11:24:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XZ, Yu J-L</AU>
<TI>Control studies of relapses between risperidone and clozapine in schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>145-7</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:35:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2003" MODIFIED="2010-11-22 17:48:13 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2003" YEAR="">
<REFERENCE MODIFIED="2010-11-22 17:48:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Wu Y, Guo C</AU>
<TI>A comparative study between quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2003</YR>
<VL>11</VL>
<PG>262-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2009-01-12 22:01:28 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:47:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J-X, Zhu F-Y, Shi X-M, Zhang X-M, Wei Li-H, Ji Z-F, Lin R-M</AU>
<TI>Controlled study of risperidone versus clozapine in treatment of refractory schizophrenia with depressive symptoms</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>4</NO>
<PG>201-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:35:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2004" MODIFIED="2010-01-11 14:23:34 +0000" MODIFIED_BY="[Empty name]" NAME="Zhao 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-11 14:23:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao F, Zhang ZH, Li H</AU>
<TI>Control studies of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<PG>25-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2005" MODIFIED="2010-01-11 13:02:00 +0000" MODIFIED_BY="[Empty name]" NAME="Zhao 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 13:02:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao L, Li Y, Qi F</AU>
<TI>Control study of quetiapine and risperidone in treatment of schizophrenics</TI>
<SO>Chinese Journal of Health Psychology</SO>
<YR>2005</YR>
<VL>13</VL>
<PG>79-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2001" MODIFIED="2010-01-11 13:02:29 +0000" MODIFIED_BY="[Empty name]" NAME="Zheng 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 13:02:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng X-X, Huang J-H, Huang Z-Z</AU>
<TI>A study of risperidone and clozapine in treatment of the side-effects in schizophrenia</TI>
<SO>Strait Pharmaceutical Journal</SO>
<YR>2001</YR>
<VL>13</VL>
<PG>79-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2003" MODIFIED="2009-01-09 14:36:06 +0000" MODIFIED_BY="[Empty name]" NAME="Zheng 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-09 14:36:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng YJ, Wang GH, Cheng ZL</AU>
<TI>Effects of clozapine and risperidone on the glucose metabolism in first-episode schizophrenic patients</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>4</NO>
<PG>207-10</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:36:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhi-2005" MODIFIED="2009-01-09 14:48:53 +0000" MODIFIED_BY="[Empty name]" NAME="Zhi 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhi S</AU>
<TI>Comparison study of aripiprazole and risperidone on schizophrenia</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2005</YR>
<VL>14</VL>
<PG>2787-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2003" MODIFIED="2010-01-11 13:03:15 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 13:03:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong H, Wang M</AU>
<TI>The influence of risperidone, chlorpromazine and clozapine on ECG</TI>
<TO>2003</TO>
<SO>Journal of Gannan Medical College</SO>
<YR>2003</YR>
<VL>23</VL>
<PG>644-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2006a" MODIFIED="2009-01-12 22:03:09 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2006a" YEAR="2006">
<REFERENCE MODIFIED="2009-01-09 14:36:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong Z-Y, Tao J, Wang X-L, Wu X-L, Zhang J-B</AU>
<TI>Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia</TI>
<SO>Zhongguo Linchuang Kangfu</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>30-2</PG>
<CY>China</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:36:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2005" MODIFIED="2009-01-09 14:36:28 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-09 14:36:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou B, Tang Y, Zhu L</AU>
<TI>Effects of risperidone vs clozapine on blood-lipid of first-episode schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>315-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:36:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-1999" MODIFIED="2009-01-09 14:36:32 +0000" MODIFIED_BY="[Empty name]" NAME="Zhu 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-09 14:36:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu X, Mei Q</AU>
<TI>A controlled study comparing drug compliance with risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>3</NO>
<PG>151-2</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:36:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2002" MODIFIED="2010-01-11 13:03:42 +0000" MODIFIED_BY="[Empty name]" NAME="Zhu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-11 13:03:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu H, Ma C, Hou J, Yin Q, Hu H, Guo Y</AU>
<TI>Study of serum il-6 and a-ifn in the pre-and post-treatment of 68 patients with first episode schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>5</NO>
<PG>324-6</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:36:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2003" MODIFIED="2010-11-22 17:49:11 +0000" MODIFIED_BY="[Empty name]" NAME="Zhu 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-22 17:49:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu F, Lin R, Zhang J</AU>
<TI>Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized controlled study</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>168-71</PG>
<IDENTIFIERS MODIFIED="2009-01-09 14:36:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2003a" MODIFIED="2010-01-11 13:04:24 +0000" MODIFIED_BY="[Empty name]" NAME="Zhu 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-01-11 13:04:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu Q-Y, Zhang S-W, Pi J-F</AU>
<TI>15 cases of risperidone in treatment of resistant schizophrenia</TI>
<SO>Herald of Medicine</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>13-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoccali-2003" MODIFIED="2009-01-09 14:36:50 +0000" MODIFIED_BY="[Empty name]" NAME="Zoccali 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-09 14:36:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zoccali R, Muscatello MR, Torre DL, Malara G, Canale A, Crucitti DDC, Spina E</AU>
<TI>Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia</TI>
<SO>Pharmacological Research</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>4</NO>
<PG>411-4</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-01-09 14:36:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-01-09 15:39:40 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-01-11 11:40:32 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2003" MODIFIED="2009-02-06 14:44:35 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-06 14:44:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Safety study of olanzapine and a comparator in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:44:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2006" MODIFIED="2009-02-06 14:44:38 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-06 14:44:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Efficacy study of early onset of antipsychotic drug action in schizophrenia</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:44:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gafoor-2005" MODIFIED="2010-01-11 11:39:40 +0000" MODIFIED_BY="[Empty name]" NAME="Gafoor 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-11 11:39:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gafoor R, Power P, Craig T, Kerwin R, McGuire P</AU>
<TI>A comparative study of quetiapine and risperidone in patients with first-episode psychosis</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>509</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2001" MODIFIED="2010-01-11 11:39:56 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-11 11:39:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lieberman JA</AU>
<TI>Risperidone and clozapine in chronic schizophrenia</TI>
<SO>CRISP database</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2009-01-09 15:30:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratna-2003" MODIFIED="2009-01-12 23:59:05 +0000" MODIFIED_BY="[Empty name]" NAME="Ratna 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-12 23:59:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ratna L</AU>
<TI>A multi-centre, double-blind, randomised study to compare the safety tolerability and efficacy of quetiapine and risperidone in the treatment of schizophrenia in subjects with inadequate symptom control Improved Response In Schizophrenia - IRIS</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>1</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reveley-2000" MODIFIED="2009-02-06 14:44:55 +0000" MODIFIED_BY="[Empty name]" NAME="Reveley 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-06 14:44:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Reveley M</AU>
<TI>Ris-int-45 an international, multicentre, randomised double-blind parallel-group trial comparing the safety and efficacy of risperidone and olanzapine in the treatment of patients with schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-02-06 14:44:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sireling-2003" MODIFIED="2010-01-11 11:40:32 +0000" MODIFIED_BY="[Empty name]" NAME="Sireling 2003" YEAR="">
<REFERENCE MODIFIED="2010-01-11 11:40:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sireling 2003</AU>
<TI>Study a) Sertindole versus risperidone safety outcome study: a randomised, partially blinded, parallel-group, active-controlled, post marketing study. Study b) Sertindole post-marketing surveillance study</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>2</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-22 17:50:33 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-22 17:50:33 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-02-06 14:45:14 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:45:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1983" MODIFIED="2010-01-11 13:11:24 +0000" MODIFIED_BY="[Empty name]" NAME="Andreasen 1983" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the assessment of negative symptoms</SO>
<YR>1983</YR>
<PB>University of Iowa</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" MODIFIED="2010-01-11 14:11:33 +0000" MODIFIED_BY="[Empty name]" NAME="Andreasen 1984" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the assessment of positive symptoms</SO>
<YR>1984</YR>
<PB>The University of Iowa</PB>
<CY>Iowa City, IA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" MODIFIED="2010-01-11 14:13:30 +0000" MODIFIED_BY="[Empty name]" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2004" MODIFIED="2010-01-11 14:03:55 +0000" MODIFIED_BY="[Empty name]" NAME="APA 2004" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Practice guidelines for the treatment of patients with schizophrenia</SO>
<YR>2004</YR>
<PG>1-114</PG>
<EN>2nd</EN>
<PB>American Psychiatric Publishing, Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2010-11-22 17:50:20 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1984" MODIFIED="2010-11-22 17:50:33 +0000" MODIFIED_BY="[Empty name]" NAME="Carpenter 1984" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs DW, Hanlon ET, Carpenter WT Jr</AU>
<TI>The quality of life scale: an instrument for rating the schizophrenic deficit syndrome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>388-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" MODIFIED="2010-01-11 13:15:38 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L, Jones BD</AU>
<TI>The extrapyramidal symptom rating scale</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtis-1995" NAME="Curtis 1995" TYPE="JOURNAL_ARTICLE">
<AU>Curtis V, Kerwin R</AU>
<TI>A risk benefit assessment of risperidone in schizophrenia</TI>
<SO>Drug Safety</SO>
<YR>1995</YR>
<VL>12</VL>
<PG>139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2010-01-11 13:16:15 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2009-07-30 16:37:14 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-30 16:37:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-30 16:37:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-07-28 10:29:34 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2009-07-30 16:37:50 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Morganti C</AU>
<TI>Aripiprazole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-30 16:37:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-30 16:37:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858. CD004578.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2010-01-11 13:17:43 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving crossover trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS MODIFIED="2010-01-11 13:17:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-11 13:17:43 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11914310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fleischhacker-1989" MODIFIED="2010-01-11 13:18:26 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Bergman KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, Kane JM</AU>
<TI>The Hillside Akathisia Scale: a new rating instrument for neuroleptic induced akathisia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" NAME="Gaebel 2006" TYPE="OTHER">
<AU>Gaebel W, Falkai P, Weinmann S, Wobrock T</AU>
<TI>Treatment guidelines for schizophrenia</TI>
<TO>Behandlungsleitlinie Schizophrenie</TO>
<SO>Steinkopf</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbody-2000" MODIFIED="2010-01-11 13:19:04 +0000" MODIFIED_BY="[Empty name]" NAME="Gilbody 2000" TYPE="COCHRANE_REVIEW">
<AU>Gilbody SM, Bagnall AM, Duggan L, Tuunainen A</AU>
<TI>Risperidone versus other atypical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-07-30 16:36:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-30 16:36:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldman-1992" MODIFIED="2010-01-11 13:19:34 +0000" MODIFIED_BY="[Empty name]" NAME="Goldman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Goldman HH, Skodol AE, Lave TR</AU>
<TI>Revising axis V for DSM-IV: a review of measures of social functioning</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<PG>1148-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-1994" NAME="Gupta 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gupta S, Black D, Smith D</AU>
<TI>Risperidone: review of its pharmacology and therapeutic use in schizophrenia</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>6</VL>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2010-01-11 13:20:06 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy U</AU>
<TI>ECDEU assessment manual for psychopharmacology</TI>
<SO>National Institute of Mental Health</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-01-11 13:23:01 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janssen_x002d_Cilag-2005" NAME="Janssen-Cilag 2005" TYPE="OTHER">
<AU>Janssen-Cilag</AU>
<TI>Risperdal</TI>
<SO>Janssen-Cilag Product Information</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jayaram-2006" MODIFIED="2010-01-11 13:24:22 +0000" MODIFIED_BY="[Empty name]" NAME="Jayaram 2006" TYPE="COCHRANE_REVIEW">
<AU>Jayaram MB, Hosalli P, Stroup S</AU>
<TI>Risperidone versus olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-01-11 13:24:22 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-11 13:24:22 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005237.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" MODIFIED="2009-02-06 14:45:42 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group</AU>
<TI>Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:45:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1993" NAME="Kane 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>46</VL>
<PG>585-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-2006" MODIFIED="2010-01-11 14:16:03 +0000" MODIFIED_BY="[Empty name]" NAME="Lewis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SW, Davies L, Jones P, Barnes TRE, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Marwick A, Lloyd H, Dunn G</AU>
<TI>Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment</TI>
<SO>Health Technology Assessment</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>17</NO>
<PG>iii-iv, ix-xi, 1-165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marder-1994" MODIFIED="2009-01-02 14:39:28 +0000" MODIFIED_BY="[Empty name]" NAME="Marder 1994" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Meibach RC</AU>
<TI>Risperidone in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<PG>825-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2009-07-28 10:29:34 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment - a review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-11-04 09:49:34 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-2000" NAME="Möller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ</AU>
<TI>New assessment of atypical antipsychotics</TI>
<TO>Aktuelle Bewertung neuer/atypischer Neuroleptika</TO>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>329-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenheck-1997" MODIFIED="2009-01-02 17:26:12 +0000" MODIFIED_BY="[Empty name]" NAME="Rosenheck 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck R, Cramer J, Xu WC, Thomas J, Henderson W, Frisman L, Fye C, Charney D</AU>
<TI>A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>809-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2009-07-28 10:29:34 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2008-12-12 14:45:58 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrapyrmidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1999" MODIFIED="2009-01-02 17:26:26 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Josiassen RC, Stanilla JK, De Leon J, Nair C, Abraham G, Odom WA, Turner RM</AU>
<TI>Double-blind study of clozapine dose response in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>1744-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tandon-2008" MODIFIED="2009-07-28 10:30:30 +0100" MODIFIED_BY="[Empty name]" NAME="Tandon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Keshavan MS, Nasralllah HA</AU>
<TI>Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology</TI>
<SO>Schizophrenia research</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarnow_x002d_Mordi-1999" MODIFIED="2009-01-02 12:36:20 +0000" MODIFIED_BY="[Empty name]" NAME="Tarnow-Mordi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Tarnow-Mordi WO, Healy MJ</AU>
<TI>Distinguishing between "no evidence of effect" and "evidence of no effect" in randomised controlled trials and other comparisons</TI>
<SO>Archives of Diseases in Children</SO>
<YR>1999</YR>
<VL>80</VL>
<PG>210-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2009-07-28 10:30:30 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-02-06 14:46:01 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>3-92</PG>
<IDENTIFIERS MODIFIED="2009-02-06 14:46:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Van-Os-2006" MODIFIED="2010-01-11 13:27:03 +0000" MODIFIED_BY="[Empty name]" NAME="Van Os 2006" TYPE="JOURNAL_ARTICLE">
<AU>Van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM</AU>
<TI>Standardized remission criteria in schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" MODIFIED="2009-11-04 11:26:42 +0000" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Drop-out rates in randomised antipsychotic drug trials</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2010-01-11 14:01:47 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="BOOK">
<AU>WHO</AU>
<SO>The World Health Report 2001 - Mental Health: New Understanding, New Hope</SO>
<YR>2001</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2010-01-11 14:00:00 +0000" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-01-11 14:17:43 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2010-01-11 14:17:43 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM</AU>
<TI>A meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>166</VL>
<NO>2</NO>
<PG>152-63</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-12-07 13:29:52 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Included studies check the layout is the same for each study&lt;/p&gt;&lt;p&gt;Diagnosis:&lt;br&gt;N=&lt;br&gt;Age:&lt;br&gt;Sex:&lt;br&gt;History&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Excluded tables&lt;/p&gt;&lt;p&gt;randomised not randomized&lt;br&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-12-07 13:29:52 +0000" NOTES_MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-12-07 13:29:52 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-17 15:43:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addington-2004">
<CHAR_METHODS MODIFIED="2009-07-30 12:31:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 15:42:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R) schizophrenia (n = 260) or schizoaffective disorder (n = 36), acute exacerbation, PANSS total score of 60 or more.<BR/>N = 296.<BR/>Age: 18-64 years.<BR/>Sex: 215 M, 81 F.<BR/>History: duration not reported, age at onset mean risperidone = 24.6 years, mean ziprasidone = 25.2 years.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 15:42:26 +0000" MODIFIED_BY="[Empty name]">
<P>1. Risperidone: flexible dose, allowed dose range: 6-10 mg/day, mean dose = 7.4 mg/day. N = 147.<BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose = 114.2 mg/day. N = 149.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 15:43:17 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS derived BPRS, BPRS positive subscore, PANSS negative subscore, depression MADRS.<BR/>General functioning: GAF.<BR/>Adverse effects: open interviews, EPS (akathisia, tremor, use of antiparkinson medication, AIMS, BAS, SAS), cardiac effects (ECG),<BR/>prolactin-associated side effects, sedation, weight gain, laboratory (urine, blood chemistry).<BR/>
</P>
<P>Unable to use:<BR/>GAF total score (no usable data).<BR/>QTc abnormalities in ms (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 12:31:03 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:13:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Atmaca-2003">
<CHAR_METHODS MODIFIED="2009-07-30 12:32:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 15:44:16 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia.<BR/>N=56.<BR/>Sex: 24 M, 29 F (3 not reported)<BR/>Age: 19-46 years (mean clozapine = 31.3 years, mean olanzapine = 29.6 years, mean quetiapine = 30.1 years, mean risperidone = 27.9 years, mean control group = 32.1 years).<BR/>History: duration ill mean clozapine = 6.6 years, mean olanzapine = 6.3 years, mean quetiapine = 5.9 years, mean risperidone = 5.6, age at onset: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 15:45:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: not reported. Mean dose: 207.1 mg/day. N = 14.<BR/>2. Olanzapine: flexible dose. Allowed dose range: not reported. Mean dose: 15.7 mg/day. N = 14.<BR/>3. Quetiapine: flexible dose. Allowed dose range: not reported. Mean dose: 535.7 mg/day. N = 14.<BR/>4. Risperidone: flexible dose. Allowed dose range: not reported. Mean dose: 6.7 mg/day. N = 14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 21:13:24 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score.<BR/>Adverse effects: EPS (use of antiparkinson medication), weight gain (BMI), laboratory (serum leptin, triglyceride levels).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 12:32:03 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 13:23:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azorin-2001">
<CHAR_METHODS MODIFIED="2010-11-17 15:46:18 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicenter.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 13:23:40 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised (n = 46), catatonic (n = 4), paranoid (n = 140), residual (n = 15) or undifferentiated (n = 51) of intent to treat population, poor previous treatment response, CGI of 4 or more, BPRS of 45 or more.<BR/>N = 273.<BR/>Sex: 182 M, 74 F (of intent-to-treat population, n = 256).<BR/>Age: 18-65 years (mean clozapine = 37.8, mean risperidone = 39.5) (of intent-to-treat population).<BR/>History: duration ill mean clozapine = 13.0 years, mean risperidone = 15.5 years (of intent-to-treat population), age at onset: not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 15:47:32 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-900 mg/day. Mean dose: 642 mg/day. N = 138.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-15 mg/day. Mean dose: 9 mg/day. N = 135.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 21:13:38 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, Calgary depression scale, psychotic depression scale, psychotic anxiety scale.<BR/>Adverse effects: open interviews, death, EPS,<BR/>sedation, seizures, constipation, hypotension, sialorrhoea, tachycardia, agitation, anxiety, insomnia, nausea, headache, fatigue, fever, weight gain, laboratory (white blood cell count).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 16:22:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azorin-2006">
<CHAR_METHODS MODIFIED="2010-11-17 16:22:00 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 16:22:05 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N = 187.<BR/>Sex: 113 M, 73 F (intent-to-treat group).<BR/>Age: 18-65 years (mean ~ 36 years).<BR/>History: duration ill unclear, age at onset unclear, at least moderately ill on CGI-S.<BR/>Setting: inpatient and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 16:22:20 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: flexible dose (permitted range 12-24 mg/day, mean 16.2). N = 98.</P>
<P>2. Risperidone: flexible dose (permitted range 4-10 mg/day, mean 6.6). N = 89.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 12:45:03 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving study early: any reason, adverse effects, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS (total, positive, negative sub-score).<BR/>Functioning: GAF.<BR/>Attitude: Drug attitude inventory.<BR/>Adverse effect/event: at least one adverse effect, QTc prolongation, death, extrapyramidal side effects (tremor, AIMS, BAS, SAS), prolactin associated effects (amenorrhoea, sexual dysfunction), sedation, weight change.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 12:45:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 16:23:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bondolfi-1998">
<CHAR_METHODS MODIFIED="2010-11-17 16:23:10 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicenter.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 16:23:30 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R) chronic schizophrenia, non-responders or intolerance, PANSS between 60 and 120.<BR/>N = 86.<BR/>Sex: 61 M, 25 F.<BR/>Age: 18-65 years (mean = 37.3).<BR/>History: age at first hospitalisation mean clozapine = 25.0, mean risperidone = 26.0, age at onset mean clozapine = 23.5, mean risperidone = 22.4.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 16:23:38 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 150-400 mg/day. Mean dose: 291.2 mg/day. N = 43.<BR/>2. Risperidone: flexible dose. Allowed dose range: 3-10 mg/day. Mean dose: 6.4 mg/day. N = 43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 16:23:57 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore).<BR/>Adverse effects: cardiac effects, EPS (akinesia, dystonia, parkinsonism, use of antiparkinson medication), prolactin associated side effects (sexual dysfunction), sedation, failing memory, concentration difficulties, nausea, weight gain, laboratory (hematology).</P>
<P>Unable to use:<BR/>Change of weight in kg (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 16:25:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breier-1999">
<CHAR_METHODS MODIFIED="2010-11-17 16:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 16:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia, BPRS (positive subscale) of 8 or more, SANS of 20 or more.<BR/>N = 29.<BR/>Sex: 19 M, 10 F.<BR/>Age: 18-55 years (mean clozapine = 37.7, mean risperidone = 32.4).<BR/>History: duration ill mean clozapine = 13.9 years, mean risperidone = 11.1 years, age at onset mean clozapine = 23.7, mean risperidone = 21.3.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 16:25:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-600 mg/day. Mean dose: 403.6 mg/day. N = 14.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-9 mg/day. Mean dose: 5.9 mg/day. N = 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 12:52:59 +0100" MODIFIED_BY="[Empty name]">
<P>Mental State: BPRS total score, BPRS positive subscore, SANS.<BR/>Adverse effects: EPS (use of antiparkinson medication, Simpson Angus Scale), laboratory (prolactin).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 16:26:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canive-2000">
<CHAR_METHODS MODIFIED="2009-11-04 10:00:53 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 16 weeks (first 8 weeks observed).<BR/>Design: crossover.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 16:25:46 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N = 8.<BR/>Sex: not reported.<BR/>Age: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 16:26:02 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N = not reported.<BR/>2. Risperidone: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N = not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 16:26:14 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore depression Calgary depression scale.</P>
<P>Unable to use:<BR/>CGI (no usable data).<BR/>Mental State (no usable data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 12:53:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 18:24:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chan-2007">
<CHAR_METHODS MODIFIED="2009-07-30 12:55:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, permuted block randomisation stratified by centre.<BR/>Blindness: double, identical capsules.<BR/>Duration: 4 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 18:24:26 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 80) or schizoaffective disorder (n = 3), acute relapse. PANSS total score of 60 or more.<BR/>N = 83.<BR/>Age: 18-65 years (mean aripiprazole = 35.2 years, mean risperidone = 35.1 years).<BR/>Sex: 45 M, 38 F.<BR/>History: duration illness not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 18:24:42 +0000" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole: fixed dose: 15 mg/day. N = 49.<BR/>2. Risperidone: fixed dose: 6 mg/day. N = 34.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 18:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: at least one adverse effect, cardiac effects (QTc), extrapyramidal side effects (use of antiparkinson medication, extrapyramidal symptoms, AIMS, BAS, SAS), cholesterol increase, glucose elevation, prolactin increase, weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 12:54:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 18:26:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-2001">
<CHAR_METHODS MODIFIED="2009-07-30 12:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, stratified by site.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 18:25:49 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 325) paranoid (n = 213) or schizoaffective disorder (n = 52), PANSS between 60 and 120.<BR/>N = 377.<BR/>Sex: 274 M, 103 F.<BR/>Age: 18-64 years (mean = 40.0 years).<BR/>History: duration ill mean olanzapine = 15.4 years, mean risperidone = 16.5 years, age at onset mean olanzapine = 23.6 years, mean risperidone = 24.5 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 18:25:58 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 13.1 mg/day. N = 189.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-6 mg/day. Mean dose: 4.7 mg/day. N = 188.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 18:26:08 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (suicide attempt), EPS (use of antiparkinson medication, ESRS), prolactin associated side effects (abnormal ejaculation, amenorrhea, decreased libido, galactorrhea, gynecomastia, impotence, orgastic dysfunction, sexual dysfunction) depression, insomnia, dry mouth, agitation, rhinitis, dizziness, anxiety, vision abnormalities, sedation, weight gain, laboratory (liver enzymes, lipids).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 12:56:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:13:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-2005">
<CHAR_METHODS MODIFIED="2009-07-30 12:57:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 21:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, treatment resistance, persistent positive psychotic symptoms, BPRS total score of 35 or more plus CGI score of 4 or more.<BR/>N = 38.<BR/>Sex: 30 M, 8 F.<BR/>Age: 18-65 years (mean fluphenazine = 44.2 years, mean quetiapine = 43.7 years, mean risperidone = 46.3 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 18:27:09 +0000" MODIFIED_BY="[Empty name]">
<P>1. Fluphenazine: flexible dose. Allowed dose range: 10-15 mg/day. Mean dose: 13.2 mg/day. N = 13.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 300-500 mg/day, Mean dose: 463.6 mg/day. N = 12.<BR/>3. Risperidone: flexible dose. Allowed dose range: 3-5 mg/day. Mean dose: 4.31 mg/day. N = 13.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 18:27:17 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS total score, BPRS positive subscore, BPRS negative subscore.<BR/>Cognitive functioning: Neuropsychological testing.<BR/>Quality of life: QLS.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, SAS), prolactin increase, sexual dysfunction, sedation, weight gain, laboratory (thyroidal hormones).</P>
<P>Unable to use:<BR/>Prolactin increase: no useable data.<BR/>Sexual dysfunction: no useable data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 12:56:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:13:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniel-1996">
<CHAR_METHODS MODIFIED="2010-11-17 18:27:39 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 12 weeks (6 weeks observed).<BR/>Design: crossover.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 18:27:57 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R) chronic schizophrenia (n = 16) or schizoaffective disorder (n = 4).<BR/>N = 20.<BR/>Sex: 7 M, 13 F.<BR/>Age: 22-51 years (mean = 33.8 years).<BR/>History: duration ill n.i., age at onset mean = 22.7 years.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 18:28:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 75-800 mg/day. Mean dose: 375 mg/day. N = 10.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-10 mg/day. Mean dose: 6.1 mg/day. N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 21:13:57 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI-S.<BR/>Cognitive functioning: Wechsler memory scale.<BR/>Adverse effects: insomnia, malaise, nausea, vomiting, diarrhoea, anorexia, depressed mood, agitation, weight gain.</P>
<P>Unable to use:<BR/>Weight gain: no useable data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 18:29:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dollfus-2005">
<CHAR_METHODS MODIFIED="2009-07-30 13:00:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 18:28:52 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia with post-psychotic depression, PANSS positive subscore of 28 or less and MADRS score of 16 or more.<BR/>N = 76.<BR/>Sex: 53 M, 23 F.<BR/>Age: 18-65 years (mean olanzapine = 39 years, mean risperidone = 39.6 years).<BR/>History: duration ill mean olanzapine = 13.7 years, mean risperidone = 13.1 years, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 18:28:58 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-15 mg/day. Mean dose: not reported. N = 36.<BR/>2. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: not reported. N = 40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 18:29:13 +0000" MODIFIED_BY="[Empty name]">
<P>Global state: relapse.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, depression MADRS.<BR/>Service use: number of participants rehospitalised.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (natural causes, suicide), EPS (akathisia, akinesia, dystonia, parkinsonism, rigor, tremor, use of antiparkinson medication, continuous: ESRS total score), prolactin associated side effects (abnormally high prolactin value, amenorrhea, sexual dysfunction), sedation, seizures, weight gain.<BR/>Weight (change from baseline in kg).<BR/>
</P>
<P>Unable to use:<BR/>White blood cell count (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:00:42 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 18:29:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolnak-2001">
<CHAR_METHODS MODIFIED="2009-07-30 13:01:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 18:29:35 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia.<BR/>N = 40.<BR/>Sex: not reported.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 18:29:45 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N = 20.<BR/>2. Risperidone:<BR/>fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 18:29:49 +0000" MODIFIED_BY="[Empty name]">
<P>General functioning: scale of functioning.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:01:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:14:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gureje-2003">
<CHAR_METHODS MODIFIED="2009-07-30 13:02:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, double-dummy design.<BR/>Duration: 30 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 20:22:57 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, schizoaffective disorder or schizophreniform disorder, BPRS total score of 36 or more.<BR/>N = 65.<BR/>Sex: 38 M, 27 F.<BR/>Age: 18 years or more (mean olanzapine = 35.6 years, mean risperidone = 34.8 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 20:23:08 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 17.2 mg/day. N = 32.<BR/>2. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: 6.6 mg/day. N = 33.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 21:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, inefficacy.<BR/>Global state: CGI-S.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Quality of life: QLS, SF-36.<BR/>Adverse effects: open interviews, death (suicide attempt), cardiac effects (ECG), EPS (akathisia, dyskinesia, parkinsonism, rigor, tremor, use of antiparkinson medication), prolactin associated side effects (abnormal ejaculation, decreased libido, gynaecomastia, impotence), sedation, weight change,<BR/>laboratory (glucose, leukopenia).<BR/>
</P>
<P>Unable to use:<BR/>Cardiac effects (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:01:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:14:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heinrich-1994">
<CHAR_METHODS MODIFIED="2010-11-17 20:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 4 weeks.<BR/>Design: parallel.<BR/>Location: single-centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 20:25:25 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: acute schizophrenia, disorganised (n = 1), catatonic (n = 1), paranoid (n = 47), unspecified (n = 2) type. Schizoaffective psychosis schizodominant type (n = 8).<BR/>N = 59.<BR/>Sex: 31 M, 28 F.<BR/>Age: 19-65 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 20:25:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed dose: 400 mg/day. N = 20.<BR/>2. Risperidone: fixed dose: 4 mg/day. N = 20.<BR/>3. Risperidone: fixed dose: 8 mg/day. N = 19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 20:26:05 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>General Mental State: BPRS total score.<BR/>Adverse effects: open interviews, cardiac effects (preterminal negative T-wave), EEG, EPS (extrapyramidal symptoms, use of antiparkinson medication, Simpson-Angus Scale), sedation, vital signs, laboratory (agranulocytosis).<BR/>
</P>
<P>Unable to use:<BR/>White blood cell count: agranulocytosis (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-23 21:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>BPRS subscores available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 20:27:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hwang-2003">
<CHAR_METHODS MODIFIED="2009-07-30 13:09:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 20:27:12 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised (n = 9), paranoid (n = 22) or undifferentiated (n = 16) (of intent-to-treat population).<BR/>N = 48.<BR/>Age: 18-65 years (mean amisulpride = 36.3 years, mean risperidone = 34.1 years).<BR/>Sex: 20 M, 27 F (of intent-to-treat population).<BR/>Location: multicentre.<BR/>Setting: not described.<BR/>History: duration ill mean amisulpride = 13.3 years, mean risperidone = 13.4 years, age at onset not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 20:27:20 +0000" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 400-800 mg/day. Mean dose: 630 mg/day. N = 23.<BR/>2. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: 6.88 mg/day. N = 25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 20:27:42 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total, BPRS total, PANSS positive subscore, PANSS negative subscore.<BR/>General Functioning: SOFAS total score.<BR/>Adverse effects: open interviews, cardiac effects (QTc interval of &gt; 500 ms), EPS (akathisia, rigor, tremor, use of antiparkinson medication), weight, laboratory (hematology, blood chemistry, urinanalysis).<BR/>
</P>
<P>Unable to use:<BR/>ESRS: no data.<BR/>Leukopenia: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:08:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 20:29:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jeste-2003">
<CHAR_METHODS MODIFIED="2009-07-30 13:11:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 20:28:52 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 149) or schizoaffective disorder (n = 26), PANSS between 50 and 120.<BR/>N = 176.<BR/>Sex: 62 M, 113 F (of intent-to-treat population).<BR/>Age: 60 years or more (mean olanzapine = 71.4 years, mean risperidone = 70.9 years) (of intent-to-treat population).<BR/>History: duration ill mean = 36.5 years, age at onset mean olanzapine = 33.4 years, mean risperidone = 36.0 years (of intent-to-treat population).<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 20:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 11.1 mg/day. N = 89.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-3 mg/day. Mean dose: 1.9 mg/day. N = 87.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 20:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (natural causes, suicide) EPS (akinesia, dystonia, extrapyramidal symptoms, parkinsonism, tremor, use of antiparkinson medication, ESRS), sedation, seizures, weight change, laboratory (cholesterol, glucose, prolactin).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:10:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 20:30:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2005">
<CHAR_METHODS MODIFIED="2010-11-17 20:29:54 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 20:30:06 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DMS-IV).<BR/>N = 321.<BR/>Sex: 250 M, 71 F.<BR/>Age: 18-55 years (mean ~ 39).<BR/>History: duration ill not specified, mean age at onset ~ 22 years, treatment resistance, PANSS total score &#8807; 60.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 20:30:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: flexible dose (permitted range 12-24 mg/day, mean 18.1). N = 216.<BR/>2. Risperidone: flexible dose (permitted range 6-12 mg/day, mean 9). N = 105.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:12:19 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score.<BR/>Adverse effects/event: at least one adverse effect, QTc prolongation, cholesterol, extrapyramidal effects (akathisia, parkinsonism, AIMS, BAS, SAS), glucose, sexual dysfunction, sedation, weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:11:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 20:31:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keefe-2006">
<CHAR_METHODS MODIFIED="2009-07-30 13:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 20:31:16 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder.<BR/>N = 414.<BR/>Sex: 282 M, 132 F.<BR/>Age: 18-55 years (mean = 39 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 20:31:26 +0000" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: flexible dose. Allowed dose range: 2-19 mg/day. Mean dose: 8.2 mg/day. N = 97.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 12.3 mg/day. N = 159.<BR/>3. Risperidone: flexible dose. Allowed dose range: 2-10 mg/day. Mean dose: 5.2 mg/day. N = 158.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: relapse.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, depression (MADRS), anxiety (Hamilton anxiety scale).<BR/>Cognitive Functioning: Neurocognitive Composite Score.<BR/>Adverse effects: open interviews, EPS (akathisia, tremor, use of antiparkinson medication, AIMS, BAS, SAS), sedation, weight change, laboratory (cholesterol, prolactin, urinanalysis).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:12:46 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:22:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lieberman-2005">
<CHAR_METHODS MODIFIED="2009-07-30 13:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 78 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:21:29 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, previously more than one schizophrenic episode, responder.<BR/>N = 1493.<BR/>Age: 18-65 years (mean = 40.6 years).<BR/>Sex: 1080 M, 380 F.<BR/>History: duration not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:22:15 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 7.5-30 mg/day, mean dose=20.1 mg/day. N = 336.<BR/>2. Perphenazine: flexible dose, allowed dose range: 8-32 mg/day, mean dose=20.8 mg/day. N = 261.<BR/>3. Quetiapine: flexible dose, allowed dose range: 200-800 mg/day, mean dose=543.4 mg/day. N = 337.<BR/>4. Risperidone: flexible dose, allowed dose range: 1.5-6.0 mg/day, mean dose=3.9 mg/day. N = 341.<BR/>5. Ziprasidone: flexible dose, allowed dose range: 40-160 mg/day, mean dose=112.8 mg/day. N = 185.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:22:30 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI-S.<BR/>Mental State: PANSS total score.<BR/>Service use: number of patients re-hospitalised.<BR/>Death: suicide attempt.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, akathisia), cardiac effects (ECG), prolactin-associated side effects, sedation, weight gain, laboratory (prolactin, lipids, glucose).</P>
<P>Unable to use:<BR/>Withdrawal due to "extrapyramidal effects" (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Note: 33 patients were excluded before analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:33:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McEvoy-2006">
<CHAR_METHODS MODIFIED="2009-07-30 13:14:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 52 weeks (26 weeks observed, because of small group sizes).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:23:54 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, inadequate efficacy in previous study, clozapine treatment (n = 49) was open-label.<BR/>N = 99 (observed N = 50).<BR/>Sex: 80 M, 19 F.<BR/>Age: 18-65 years (mean = 39.7 years).<BR/>History: duration ill, age at onset: not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:32:55 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 7.5-30 mg/day. Mean dose: 23.4 mg/day. N = 19.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 642.9 mg/day. N = 15.<BR/>3. Risperidone: flexible dose. Allowed dose range: 1.5-6 mg/day. Mean dose: 4.8 mg/day. N = 16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:33:03 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, amenorrhoea, galactorrhoea, sexual dysfunction, sedation, laboratory (lipids, glucose, prolactin, haemoglobin A1C level), weight gain.</P>
<P>Unable to use:<BR/>Global state CGI: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:14:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:34:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McEvoy-2007">
<CHAR_METHODS MODIFIED="2009-07-30 13:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:34:06 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 231), schizophreniform disorder (n = 115) or schizoaffective disorder (n = 54), first episode, psychotic symptoms for 1 month to 5 years, PANSS psychosis and CGI-S score of 4 or more.<BR/>N = 400.<BR/>Sex: 292 M, 108 F.<BR/>Age: 16-40 years (mean = 24.5 years).<BR/>History: duration ill mean = 1.08 years, age at onset 23.5 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:34:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 11.7 mg/day. N = 133.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 100-800 mg/day. Mean dose: 506 mg/day. N = 134.<BR/>3. Risperidone: flexible dose. Allowed dose range: 0.5-4 mg/day. Mean dose: 2.4 mg/day. N = 133.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total, PANSS positive subscore, PANSS negative subscore, depression Calgary depression scale.<BR/>Adverse effects: open interviews, death (suicide attempt, suicide, EPS (akathisia, akinesia, use of antiparkinson medication, laboratory (cholesterol, fasting glucose, prolactin), prolactin associated side effects (amenorrhoea, galactorrhoea, gynaecomastia, sexual dysfunction), sedation, insomnia, dry mouth, orthostatic faintness, constipation, sialorrhoea, skin rash, gynaecomastia, urinary hesitancy, incontinence, weight gain (BMI, waist circumference).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:15:09 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:35:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGurk-2005">
<CHAR_METHODS MODIFIED="2010-11-17 22:34:54 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, double-dummy protocol.<BR/>Duration: 29 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 93) or schizoaffective disorder (n = 14), treatment resistance, moderate severity score on BPRS or SANS.<BR/>N = 107.<BR/>Sex: 84 M, 23 F.<BR/>Age: 18-60 years (mean = 42 years).<BR/>History: duration ill n.i., age at onset mean clozapine = 23 years, mean risperidone = 22 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:35:38 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 500-800 mg/day. Mean dose: 456.7 mg/day.<BR/>N = 53.<BR/>2. Risperidone: flexible dose. Allowed dose range: 6-16 mg/day. Mean dose: 6.8 mg/day. N = 54.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:19:01 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>General Mental State: BPRS total score, SANS.<BR/>Cognitive functioning: Spatial working memory performance, social skill and problem solving assessment.<BR/>Adverse effects: TESS, laboratory (hematology).</P>
<P>Unable to use:<BR/>SANS (modified version).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:14:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mori-2004">
<CHAR_METHODS MODIFIED="2010-11-23 21:14:46 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks (last 4 weeks observed).<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:36:30 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised (n = 23), paranoid (n = 10), undifferentiated (n = 34). N = 77.<BR/>Sex: 39 M, 38 F.<BR/>Age: 28-84 years (mean = 59.9 years).<BR/>History: duration ill mean = 34.51 years, age at onset: not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:36:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 16.5 mg/day. N = 20.<BR/>2. Perospirone: flexible dose. Allowed dose range: 4-48 mg/day. Mean dose: 37.3 mg/day. N = 18.<BR/>3. Quetiapine: flexible dose. Allowed dose range: 50-750 mg/day. Mean dose: 432.5 mg/day. N = 20.<BR/>4. Risperidone: flexible dose. Allowed dose range: 1-12 mg/day. Mean dose: 7.37 mg/day. N = 19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Cognitive functioning: digit span distractibility test.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:19:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:37:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00f6_ller-2005">
<CHAR_METHODS MODIFIED="2009-07-30 13:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:37:20 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder or shared psychotic disorder.<BR/>N = 36.<BR/>Age: 65 years or more.<BR/>Sex: not described.<BR/>Location: not described.<BR/>Setting: not described.<BR/>History: duration ill, age at onset: not described.<BR/>Excluded:<B> </B>conditions such as: not described.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:37:32 +0000" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 100-400 mg/day. Mean dose: n.i. N = 24.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 1-4 mg/day. Mean dose: n.i. N = 12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:37:53 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: adverse events.<BR/>Cognitive functioning: MMSE.<BR/>Adverse effects: open interviews.<BR/>
</P>
<P>Unable to use:<BR/>Mental state, PANSS total score, BPRS total score: no usable data.<BR/>Cardiac effects (QTc), laboratory tests: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:20:13 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:40:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peuskens-1999">
<CHAR_METHODS MODIFIED="2009-07-30 13:21:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:39:13 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised, paranoid or undifferentiated, BPRS of 36 or more. N = 228.<BR/>Age: 18-65 years (mean amisulpride = 36 years, mean risperidone = 37 years).<BR/>Sex: 137 M, 91 F.<BR/>Setting: in- and outpatient.<BR/>History: duration ill mean amisulpride = 7.9 years, mean risperidone = 10.2 years, age at onset n.i.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:39:35 +0000" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: fixed dose: 800 mg/day. N = 115.<BR/>2. Risperidone: fixed dose: 8 mg/day. N = 113.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:40:17 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS total score, PANSS positive subscore, BPRS positive subscore, PANSS negative subscore.<BR/>General functioning: SOFAS.<BR/>Adverse effects: open interviews, cardiac effects (arrhythmia, ECG, QTc interval of &gt; 500 ms), EPS<BR/>(akathisia, extrapyramidal symptoms, hyperkinesia, parkinsonism, rigor, tremor, use of antiparkinson medication, AIMS, SAS), prolactin associated side effects, weight.</P>
<P>Unable to use:<BR/>General Functioning - SOFAS: no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>Individual BPRS factors are also available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:42:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Potkin-2003">
<CHAR_METHODS MODIFIED="2009-07-30 13:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 4 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:42:15 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 289) or schizoaffective disorder (n = 115), hospitalised due to an acute relapse, response to previous antipsychotic treatment other than clozapine, PANSS of 60 or more.<BR/>N = 404.<BR/>Age: 18-65 years (mean = 38.9 years).<BR/>Sex: 283 M, 121 F.<BR/>History: duration illness not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:42:24 +0000" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole: fixed dose: 20 mg/day. N = 101.<BR/>2. Aripiprazole: fixed dose: 30 mg/day. N = 101.<BR/>3. Risperidone: fixed dose: 6 mg/day. N = 99.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:42:38 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: At least one adverse effect, cardiac effects (ECG, QTc prolongation, QTc abnormalities in ms), extrapyramidal side effects (akathisia, dystonia, parkinsonism, rigor, tremor, AIMS, BAS, SAS), prolactin-associated side effects (dysmenorrhoea, increase of prolactin level above 23 ng/ml, change from baseline in ng/ml), sedation, weight gain.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-17 22:42:40 +0000" MODIFIED_BY="[Empty name]">
<P>Note: There is a placebo group (n = 103), which is not relevant for this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:44:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Potkin-2006">
<CHAR_METHODS MODIFIED="2009-07-30 13:23:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 6 weeks (2 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:43:56 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 341) disorganised, paranoid or undifferentiated or schizoaffective disorder (n = 30) plus (n = 11), CGI-S of 5 or more, recent exacerbation.<BR/>N = 382.<BR/>Sex: 251 M, 131 F.<BR/>Age: 18-65 years (mean = 34.8 years).<BR/>History: duration ill, age at onset: not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:44:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine: flexible dose. Allowed dose range: 50-800 mg/day. Mean dose: 523.8 mg/day (after 2 weeks). (579.5 mg/day, after 6 weeks). N = 156.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-6 mg/day. Mean dose: 4.32 mg/day (after 2 weeks). (4.7 mg/day, after 6 weeks). N = 153.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:44:27 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, Depression Hamilton Rating Scale for Depression, Readiness for Discharge Questionnaire.<BR/>Satisfaction of treatment: Study Medication Satisfaction.<BR/>Adverse effects: open interviews, death (natural cause), cardiac effects (ECG), EPS (akathisia, rigor, AIMS, BAS, SAS), prolactin associated side effects (amenorrhoea, decreased libido), sedation, headache , insomnia, constipation, laboratory (prolactin).</P>
<P>Unable to use:<BR/>BAS: no data.<BR/>Cardiac effects - QTc-prolongation: no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-17 22:44:29 +0000" MODIFIED_BY="[Empty name]">
<P>There was a placebo group (n = 73).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:46:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Purdon-2000">
<CHAR_METHODS MODIFIED="2009-07-30 13:24:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, no further details.<BR/>Duration: 54 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:46:16 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, in early phase.<BR/>N = 65.<BR/>Sex: 46 M, 19 F.<BR/>Age: 18-65 years (mean haloperidol = 28.83 years, mean olanzapine = 26.01 years, mean risperidone = 31.77 years).<BR/>History: duration ill mean haloperidol = 2.45 years, mean olanzapine = 2.79 years, mean risperidone = 2.67 years, age at onset mean haloperidol = 24.25 years, mean olanzapine = 23.37 years, mean risperidone = 28.86 years.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:46:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 9.70 mg/day. N = 23.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 11.00 mg/day. N = 21.<BR/>3. Risperidone: flexible dose. Allowed dose range: 4-10 mg/day. Mean dose: 6.00 mg/day. N = 21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:46:39 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS positive subscore, PANSS negative subscore.<BR/>Cognitive functioning: Cognitive test battery (finger tapping, digit span, Peabody picture vocabulary test, trailmaking test).<BR/>Adverse effects: EPS (use of antiparkinson medication, ESRS).</P>
<P>Unable to use:<BR/>Cognitive Functioning (no overall score).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:24:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 13:29:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2002">
<CHAR_METHODS MODIFIED="2010-11-17 22:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation:random, ball drawing out of box.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 13:29:32 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N:120.<BR/>Sex: not reported.<BR/>Age mean: 29.45<BR/>History duration ill: clozapine = 6.2 years, risperidone = 6.4 years.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 13:29:52 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: mean dose: 350 mg/day. N = 60.<BR/>2. Risperidone: mean dose: 3.2 mg/day. N = 60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:48:03 +0000" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS positive subscore, PANSS negative subscore).<BR/>Quality of life: General quality of life inventory.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:49:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riedel-2005">
<CHAR_METHODS MODIFIED="2009-07-30 13:27:07 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:48:46 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV or ICD-10) schizophrenia, predominant negative symptoms, CGI of 4 or more, PANSS negative subscore of 21 or more.<BR/>N = 44.<BR/>Sex: 27 M, 17 F.<BR/>Age: mean quetiapine = 30.6 years, mean risperidone = 39.3 years.<BR/>History: duration ill mean quetiapine = 5.4 years, mean risperidone = 2.5 years, age at onset mean quetiapine = 25.3 years, mean risperidone = 36.9 years.<BR/>Setting: partially in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine: flexible dose. Allowed dose range: 50-800 mg/day, Mean dose: 589.7 mg/day. N = 22.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-8 mg/day. Mean dose: 4.9 mg/day. N = 22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:49:16 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>Cognitive functioning: auditory verbal memory test, Trail Making Test, Wechsler visual memory scale.<BR/>Adverse effects: open interviews, cardiac effects (ECG), EPS (akathisia, parkinsonism, use of antiparkinson medication, SAS), sedation, headache, nausea, insomnia, dizziness, weight gain, laboratory (prolactin).</P>
<P>Unable to use:<BR/>SANS total score: no data.<BR/>Prolactin change from baseline in ng/ml: no data.<BR/>Cardiac effects: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:26:46 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:50:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-2005">
<CHAR_METHODS MODIFIED="2009-07-30 13:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 16 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:50:11 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) first episode schizophrenia (n = 84), schizophreniform disorder (n = 19) or schizoaffective disorder (n = 9) (of intent-to-treat population).<BR/>N = 120.<BR/>Sex: 78 M, 34 F (of intent-to-treat population).<BR/>Age: 16-40 years (mean = 23.3 years) (of intent-to-treat population).<BR/>History: duration ill mean = 2.2 years (of intent-to-treat population), age at onset mean = 20.7 years (of intent-to-treat population).<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:50:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 11.8 mg/day. N = 60.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-6 mg/day. Mean dose: 3.9 mg/day. N = 60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:50:25 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: inefficacy.<BR/>Global State.<BR/>Adverse effects: EPS (parkinsonism, use of antiparkinson medication, Simpson-Angus), weight gain.</P>
<P>Unable to use:<BR/>Leaving the study early: incomplete data.<BR/>Weight gain: no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:27:26 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-17 22:51:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2004">
<CHAR_METHODS MODIFIED="2009-07-30 13:28:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single (rater-blinded).<BR/>Duration: 16 weeks (8 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:51:15 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, PANSS total score of 70 or more, PANSS positive subscore of 4 or more on at least 2 items.<BR/>N = 75.<BR/>Sex: M, F: not reported.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:51:24 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 14.6 mg/day. N = 25.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 400-800 mg/day. Mean dose: 602.4 mg/day. N = 25.<BR/>3. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: 4.3 mg/day. N = 25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-17 22:51:32 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental State: PANSS total score, BPRS hostility cluster score, PANSS positive subscore, PANSS negative subscore).<BR/>Adverse effects: EPS (BAS, SAS), weight gain.</P>
<P>Unable to use:<BR/>Mental State - PANSS total score, PANSS positive subscore, PANSS negative subscore: no usable data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:28:23 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:14:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sechter-2002">
<CHAR_METHODS MODIFIED="2009-07-30 13:29:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 21:14:54 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia disorganised (n = 37), paranoid (n = 227), residual (n = 19) or undifferentiated (n = 27), PANSS between 60 and 120, recent worsening of symptoms.<BR/>N = 310.<BR/>Age: 18-65 years (mean = 38.4 years).<BR/>Sex: 170 M, 140 F.<BR/>Setting: in- and outpatient.<BR/>History: duration ill mean = 11.8 years, age at onset not described.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:53:15 +0000" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 400-1000 mg/day. Mean dose: 683 mg/day. N = 152.<BR/>2. Risperidone: flexible dose. Allowed dose range: 4-10 mg/day. Mean dose: 6.92 mg/day. N = 158.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI, relapse.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>General Functioning: SOFAS total score.<BR/>Adverse effects: open interviews, death (natural causes, suicide), EPS (akathisia, hyperkinesia, parkinsonism, tremor, use of antiparkinson medication, AIMS, SAS), prolactin associated side effects (amenorrhea, galactorrhea, sexual dysfunction), sedation, seizures, weight.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:29:15 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:14:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sikich-2004">
<CHAR_METHODS MODIFIED="2009-07-30 13:30:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-17 22:58:17 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: children and adolescents with (K-SADS-P or DSM-IV) schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, major depression with psychotic features or bipolar affective disorder with psychotic features, schizophrenia spectrum (n = 26), affective disorders (n = 24) subjects selected because of prominent positive psychotic symptoms (of intent-to-treat population).<BR/>N = 51.<BR/>Sex: 30 M, 21 F.<BR/>Age: 8-19 years (mean = 14.8 years).<BR/>History: duration ill not reported, age at onset mean = 12.4 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-17 22:58:33 +0000" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: flexible dose. Allowed dose range: 1-8 mg/day. Mean dose: 5.0 mg/day. N = 15.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 12.3 mg/day. N = 16.<BR/>3. Risperidone: flexible dose. Allowed dose range: 0.5-6 mg/day. Mean dose: 4.0 mg/day. N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 21:14:56 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS-C total score, CPRS.<BR/>Adverse effects: open interviews, cardiac effects (QTc, vital signs), EPS (akathisia, use of antiparkinson medication, Simpson-Angus), prolactin associated side effects (amenorrhea, galactorrhea, gynaecomastia), sedation, gastrointestinal malfunction, weight (BMI), laboratory (glucose, prolactin).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>There is a Haloperidol Group (N = 15).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-18 04:26:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stroup-2006">
<CHAR_METHODS MODIFIED="2009-07-30 13:32:07 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, 2 steps of randomisation before and after availability of ziprasidone, subjects received other medication than in previous phase 1 treatment. Re-randomised.<BR/>Blindness: double, identical capsules.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-18 04:26:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia.<BR/>N = 444.<BR/>Sex: 308 M, 136 F.<BR/>Age: 18-65 years (mean olanzapine = 40.0 years, mean quetiapine = 40.1 years, mean risperidone = 41.8 years, mean ziprasidone = 41.3 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-18 04:26:41 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 7.5-30 mg/day, mean dose = 20.5 mg/day. N = 108.<BR/>2. Quetiapine: flexible dose, allowed dose range: 200-800 mg/day, mean dose = 565.2 mg/day. N = 95.<BR/>3. Risperidone: flexible dose, allowed dose range: 1.5-6.0 mg/day, mean dose = 4.1 mg/day. N = 104.<BR/>4. Ziprasidone: flexible dose, allowed dose range: 40-160 mg/day, mean dose = 115.9 mg/day. N = 137.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-18 04:26:49 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score.<BR/>Adverse effects: open interviews, death (suicide), EPS (akathisia), cardiac effects (ECG),<BR/>prolactin-associated side effects, weight gain, laboratory (prolactin, glucose, cholesterol).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:31:15 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-18 04:27:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-2003">
<CHAR_METHODS MODIFIED="2009-07-30 13:32:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-18 04:27:21 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder, first episode.<BR/>N = 42.<BR/>Sex: not reported.<BR/>Age: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-18 04:27:31 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N = 21.<BR/>2. Risperidone: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N = 21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:32:41 +0100" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:32:24 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:15:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tran-1997">
<CHAR_METHODS MODIFIED="2009-07-30 13:33:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 28 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: in- and outpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-18 04:28:00 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 277), schizophreniform disorder or schizoaffective disorder, BPRS score of 42 or more.<BR/>N = 339.<BR/>Sex: 220 M, 119 F.<BR/>Age: 18-65 years (mean = 36.21 years).<BR/>History: duration ill not reported, age at onset mean = 23.7 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-18 04:28:07 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 17.2 mg/day. N = 172.<BR/>2. Risperidone: flexible dose. Allowed dose range: 4-12 mg/day. Mean dose: 7.2 mg/day. N = 167.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 21:15:08 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>Quality of life: QLS total score.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (any reason, suicide attempt), EPS (akathisia, akinesia, dyskinesia, dystonia, extrapyramidal symptoms, parkinsonism, tremor, use of antiparkinson medication), Prolactin associated side effects (abnormal ejaculation, abnormally high prolactin value, amenorrhea, decreased libido, galactorrhea, gynaecomastia, impotence), sedation, backache, blurred vision, breathing difficulties, early wakening, nightmares, seizures, weight gain, laboratory (glucose, white blood cell count).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:33:02 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-18 04:29:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Nimwegen-2006">
<CHAR_METHODS MODIFIED="2009-07-30 13:34:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-18 04:29:19 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, schizophreniform disorder or schizoaffective disorder, cannabis positive last month olanzapine (n = 20), risperidone (n = 23).<BR/>N = 131.<BR/>Sex: 106 M, 25 F.<BR/>Age: mean olanzapine = 24.4 years, mean risperidone = 25.1 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-18 04:29:28 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 10.95 mg/day. N = 64.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-5 mg/day. Mean dose: 2.96 mg/day. N = 67.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-18 04:29:34 +0000" MODIFIED_BY="[Empty name]">
<P>Quality of life: Subject well being.<BR/>Adverse effects: EPS (BAS).<BR/>Cannabis use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:34:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-18 04:30:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volavka-2002">
<CHAR_METHODS MODIFIED="2009-07-30 13:35:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 14 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-18 04:30:31 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia (n = 135) or schizoaffective disorder (n = 22), suboptimal response to previous treatment, PANSS of 60 or more.<BR/>N = 167.<BR/>Sex: 133 M, 24 F (of intent-to-treat population).<BR/>Age: 18-60 years (mean = 40.8 years) (of intent-to-treat population).<BR/>History: duration ill mean = 19.5 years (of intent-to-treat population), age at onset not reported.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-18 04:30:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 526.6 mg/day (at the end of the last 6 weeks). N = 40.<BR/>2. Haloperidol: flexible dose. Allowed dose range: 10-30 mg/day. Mean dose: 25.7 mg/day (at the end of the last 6 weeks). N = 37.<BR/>3. Olanzapine: flexible dose. Allowed dose range: 10-40 mg/day. Mean dose: 30.4 mg/day (at the end of the last 6 weeks). N = 39.<BR/>4. Risperidone: flexible dose. Allowed dose range: 4-16 mg/day. Mean dose: 11.6 mg/day (at the end of the last 6 weeks). N = 41.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-18 04:30:58 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early. any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Quality of life: Quality of life scale, Nurses`observation scale for inpatient evaluation.<BR/>Cognitive Functioning: Global Neurocognitive Score.<BR/>Adverse effects: EPS (Use of antiparkinson medication, ESRS), seizures, weight gain, laboratory (cholesterol, glucose, prolactin, white blood cell count).</P>
<P>Unable to use:<BR/>Quality of life scale: no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:35:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-19 04:14:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wahlbeck-2000">
<CHAR_METHODS MODIFIED="2010-11-19 04:12:42 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 10 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: in- and outpatient (initially inpatient).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-19 04:13:07 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, resistance to previous treatment. N = 20.<BR/>Sex: 10 M, 9 F (of intent-to-treat population).<BR/>Age: 24-55 years (mean clozapine = 35.7 years, mean risperidone = 36.8 years) (of intent-to-treat population).<BR/>History: duration ill mean clozapine = 12.6 years, mean risperidone = 13.1 years (of intent-to-treat population), age at onset not reported.<BR/>Setting: in- and outpatient (initially inpatient).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-19 04:14:27 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 25-600 mg/day. Mean dose: 385 mg/day. N = 11.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-10 mg/day. Mean dose: 7.8 mg/day. N = 9.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:38:54 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>General Functioning: GAF, social functioning scale, patient global impression scale.<BR/>Satisfaction with treatment: Drug attitude inventory.<BR/>Adverse effects: death (natural causes, suicide), EPS (use of antiparkinson medication), sedation, laboratory (white blood cell count).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-19 04:16:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_METHODS MODIFIED="2009-07-30 13:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 22 weeks (last 12 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-19 04:16:08 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n = 24) or schizoaffective disorder (n = 12). N = 36.<BR/>Sex: 17 M, 19 F.<BR/>Age: mean = 47.0 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-19 04:16:40 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: not reported. Mean dose: 13.8 mg/day. N = 17.<BR/>2. Risperidone: flexible dose. Allowed dose range: not reported. Mean dose: 5.3 mg/day. N = 19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-19 04:16:43 +0000" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: EPS (SAS), weight gain.</P>
<P>Unable to use:<BR/>Leaving the study early: no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:39:24 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-19 04:18:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wynn-2007">
<CHAR_METHODS MODIFIED="2009-07-30 13:41:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, 33 participants were assigned to a three-arm randomisation (1:1:1, blocks of 15) and 18 participants with a history of adverse experiences with haloperidol were assigned to a two-arm randomisation (1:1) for risperidone and olanzapine only.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-19 04:18:05 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder. N = 51.<BR/>Sex: 43 M, 8 F.<BR/>Age: 18-60 years (mean = 48.8 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-19 04:18:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: fixed dose: 8 mg/day. N = 11.<BR/>2. Olanzapine: fixed dose: 15 mg/day. N = 21.<BR/>3. Risperidone: fixed dose: 4 mg/day. N = 19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:41:10 +0100" MODIFIED_BY="[Empty name]">
<P>Neurological functioning: Prepulse inhibition, EMG.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:40:47 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:15:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2006">
<CHAR_METHODS MODIFIED="2009-07-30 13:42:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-19 04:19:26 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, PANSS of 60 or more, CGI-S of 4 or more. N = 673.<BR/>Sex: 510 M, 163 F.<BR/>Age: 18-65 years (mean quetiapine = 40.2 years, mean risperidone = 39.6 years).<BR/>History: duration ill, age at onset: not reported.<BR/>Setting: in- and outpatient, initially inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-19 04:19:37 +0000" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine:flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 525 mg/day. N = 338.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-8 mg/day. Mean dose: 5.2 mg/day. N = 335.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-23 21:15:18 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (QTc), death (natural causes, suicide), EPS (akathisia, dystonia, parkinsonism, use of antiparkinson medication, AIMS, BAS, SAS), sedation, prolactin associated side effects (dysmenorrhoea, galactorrhea, sexual dysfunction) weight gain, laboratory (cholesterol, glucose, prolactin, white blood cell count).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-30 13:41:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-23 21:15:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2000">
<CHAR_METHODS MODIFIED="2010-11-23 21:15:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-19 04:20:49 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (CCMD-2) schizophrenia.<BR/>N = 40.<BR/>Sex: 23 M, 17 F.<BR/>Age: mean clozapine = 27.6 years, mean risperidone = 29 years.<BR/>History: duration ill mean clozapine = 2.7 years, mean risperidone = 3.2 years, age at onset: not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-19 04:21:00 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed and flexible dose (first 2 weeks).<BR/>Allowed dose range: 25-300 mg/day (first 2 weeks), then 300 mg/day fixed. Mean dose: not reported. N = 20.<BR/>2. Risperidone: fixed and flexible dose (first 2 weeks).<BR/>Allowed dose range: 1-6 mg/day (first 2 weeks), then 6 mg/day fixed. Mean dose: not reported. N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 13:44:10 +0100" MODIFIED_BY="[Empty name]">
<P>Mental State: SANS.<BR/>Advers effects: EPS (akathisia, tremor, treatment emergent symptom scale), vital signs, dry mouth hypersalivation, weight gain, sedation.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tool<BR/>DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.<BR/>ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.<BR/>BMI - Body Mass Index.</P>
<P>Rating Scales:</P>
<P>Global rating scales:<BR/>CGI - Clinical Global Impressions.<BR/>CGI-S - Clinical Global Impression-Severity.<BR/>CGI-I - Clinical Global Impression-Improvement.<BR/>
</P>
<P>Mental state:<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>MADRS - Montgomery-Asberg Depression Rating Scale.<BR/>MMSE - Wiing Mini Mental State Examination.<BR/>PANSS - Positive and Negative Syndrome Scale.<BR/>SANS - Scale for the Assessment of Negative Symptoms.</P>
<P>Side effects:<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BAS - Barnes Akathisia Scale.<BR/>BMI - Body mass index.<BR/>ESRS - Extrapyramidal Syndrome Rating Scale.<BR/>HAS - Hillside Akathisia Scale.<BR/>SAS - Simpson-Angus Index - for neurological side effects.<BR/>TESS - Treatment Emergent Symptom Scale.<BR/>UKU - Udvalg for kliniske ndersogelser Side Effect Rating Scale -side effect rating scale.</P>
<P>Quality of Life:<BR/>QoL - Quality of Life Scale.<BR/>SWN -Subjective Well-being List.</P>
<P>CCMD-2:<BR/>ECG:<BR/>EEG:<BR/>EPS:<BR/>GAF:<BR/>LOCF: last observation carried forward<BR/>QLS:<BR/>QTc:<BR/>SOFAS:<BR/>TESS:<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-11-19 04:32:20 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:25:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akdede-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:25:48 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: patients with schizophrenia.<BR/>3. Interventions: inappropriate (olanzapine and adjunctive treatment with risperidone or placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:25:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Almond-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:25:54 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: pooled analysis.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:26:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez_x002d_Jimenez-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:26:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: drug-naive first-episode psychosis patients.<BR/>3. Interventions: risperidone versus olanzapine versus haloperidol.<BR/>4. Outcomes: no usable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:26:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antonova-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:26:23 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: patients with chronic schizophrenia (DSM-IV).<BR/>3. Interventions: olanzapine versus risperidone versus quetiapine.<BR/>4. Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:26:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apiquian-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:26:30 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:26:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aquila-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:26:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:26:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ascher_x002d_Svanum-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:26:46 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:26:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bai-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:26:52 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: DSM-IV schizophrenia patients.<BR/>3. Interventions: inappropriate (risperidone versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:27:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baloescu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:27:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomised, controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:27:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:27:13 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: patients with schizophrenia.<BR/>3. Interventions: olanzapine versus haloperidol versus risperidone.<BR/>4. Outcomes: no usable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:27:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:27:21 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: patients with schizophrenia.<BR/>3. Interventions: olanzapine versus clozapine versus risperidone versus haloperidol versus placebo.<BR/>4. Outcomes: no usable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:27:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:27:34 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:27:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bera-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:27:41 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:27:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:27:55 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:28:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bitter-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:28:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:28:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boylan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:28:23 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: patients with schizophrenia.<BR/>3. Interventions: inappropriate (risperidone versus risperidone/divalproex, olanzapine versus olanzapine/divalproex or antipsychotic monotherapy versus antipsychotic/divalproex).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Briken-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:28:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Byerly-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:28:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: double-blind.<BR/>3. Participants: patients with schizophrenia/schizoaffective disorder.<BR/>4. Interventions: quetiapine versus risperidone.<BR/>5. Outomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cai-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:28:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canas-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:28:54 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:29:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: inadequate randomisation.<BR/>2: Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cha-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:30:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaudhry-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:30:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:30:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:30:12 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:30:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:30:21 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomisation not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:30:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:30:29 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:30:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:30:36 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:30:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:30:45 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:31:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:31:12 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomisation not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:31:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:31:33 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:31:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:31:40 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:31:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:31:50 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:31:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chou-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:31:56 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:32:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chowdhury-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:32:05 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-19 04:32:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Citrome-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-19 04:32:20 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomised.<BR/>2. Participants: patients with schizophrenia.<BR/>3. Interventions: inappropriate (olanzapine versus risperidone, additive divalproex).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ciudad-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:56:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:56:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornblatt-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crespo_x002d_Facorro-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:56:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 12:50:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czekalla-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 12:50:50 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Participants: patients with schizophrenia and related psychosis (DSM-III-R and DSM-IV).<BR/>3. Interventions: olanzapine versus placebo versus haloperidol versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 12:51:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-David-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 12:51:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Participants: patients with schizophrenia.<BR/>3. Interventions: olanzapine versus risperidone versus clozapine.<BR/>4. Outcomes: no usable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-David-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized,<BR/>2. Blindness: double-blind.<BR/>2. Participants: patients with schizophrenia<BR/>3. Interventions: olanzapine versus risperidone versus haloperidol<BR/>4. Outcomes: no usable data (pooled analysis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Haan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:56:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ding-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:56:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:56:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ding-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:56:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:56:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dossenbach-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:56:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:56:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:57:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:57:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:57:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:57:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:07:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Earnst-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:07:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:58:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ertugrul-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:58:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized, controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Estrella-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:58:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:58:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:58:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:58:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:58:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gan-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:58:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garc_x00ed_a-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ge-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: double-blind.<BR/>3. Participants: patients with schizophrenia<BR/>4. Interventions: inappopriate (risperidone versus olanzapine versus clozapine and in crossover fashion placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:58:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:58:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:59:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:59:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:59:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:59:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hagger-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:59:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:59:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrigan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heresco_x002d_Levy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: double-blind.<BR/>3. Participants: patients with schizophrenia<BR/>4. Interventions: inappropriate (risperidone versus olanzapine, placebo-controlled).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hou-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:59:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hrdlicka-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:00:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:00:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>3. Participants: patients with schizophrenia, brief psychotic, schizoaffective disorder, delusional disorder<BR/>4. Interventions: inclusion into the study was independent of medication<BR/>5. Outcomes: no usable data (other aims)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janssen_x002d_Ortho-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: not mentioned<BR/>3. Participants: patients with schizophrenia and related disorders<BR/>4. Interventions: FGA's or SGA's other than cozapine<BR/>5. Outcomes: no usable data (pooled analysis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karow-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>3. Participants: patients with schizophrenia.<BR/>4. Interventions: atypical and typical neuroleptics.<BR/>5. Outcomes: no usable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keks-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelemen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:00:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:00:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized, controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knegtering-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koenigsberg-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: double-blind.<BR/>3. Participants: patients with schizotypical personality disorder.<BR/>4. Interventions: inappropriate (risperidone versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolff-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kong-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kores-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: double-blind<BR/>3. Participants: patients with schizophrenia<BR/>4. Interventions: risperidone versus olanzapine<BR/>5. Outcomes: no usable data (pooled analysis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lei-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: single-blind.<BR/>3. Participants: patients with schizophrenia.<BR/>4. Interventions: new atypical drugs versus clozapine.<BR/>5. Outcomes: no usable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang--2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liao-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 13:05:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 13:05:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized (inadequate randomization).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lipkovich-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: double-blind<BR/>3. Participants: patients with schizophrenia<BR/>4. Interventions: inappropriate (3 trials: olanzapine versus haloperidol, olanzapine versus risperidone, olanzapine versus placebo).<BR/>5. OUtcomes nousable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Littrell-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:44:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:44:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:41:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:41:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness. not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness : not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loza-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:10 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:10 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mai-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:01:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malla-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:01:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized, controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 13:12:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malyarov-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 13:12:09 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malykhin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mao-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mazurek-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mei-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: double-blind.<BR/>2. Participants: Patients with schizophrenia<BR/>and schizoaffective disorder<BR/>3. Interventions: inappropriate (investigational drugs versus placebo versus haloperidol)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mintzer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohr-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mullen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musil-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:02:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naber-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized, pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naber-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization and Blindness not mentioned.<BR/>2. Participants: Patients with schizophrenia<BR/>3. Interventions: atypical and typical neuroleptics<BR/>4. Outcomes: no usable data (pooled analysis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ni-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nicholls-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opjordsmoen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega_x002d_Soto-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: double-blind.<BR/>3. Participants: Patients with schizophrenia<BR/>4. Interventions: olanzapine versus risperidone<BR/>5. Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 13:19:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 13:19:27 +0000" MODIFIED_BY="[Empty name]">
<P>1.Allocation: not randomized (inadequate randomization).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perro-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peuskens-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qi-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qian-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabinowitz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.<BR/>3. Participants: patients with schizophrenia.<BR/>4. Interventions: inappropriate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roerig-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: double-blind.<BR/>3. Participants: inadequate diagnosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness. not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sajatovic-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shao-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheng-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: open-label.<BR/>3. Participants: patients with schizophrenia.<BR/>4. Interventions: switch to ziprasidone from conventionals, olanzapine or risperidone.<BR/>5. Outcomes: no usable data (pooled analysis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sowell-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 13:33:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 13:33:17 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 13:33:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 13:33:13 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swanson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tandon-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 13:34:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 13:34:54 +0000" MODIFIED_BY="[Empty name]">
<P>1. Allocation: inadequate randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tian-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tong-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tunis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Bruggen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaughan-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: unclear.<BR/>2. Blindness: unclear.<BR/>3. Outcomes: no usable data (other aims).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weickert-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: double-blind.<BR/>3. Participants: patients with schizophrenia.<BR/>4. Interventions: inappropriate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weng-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wyszogrodzka-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xin-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yagdiran-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: inadequate randomization.<BR/>2. Blindness not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamashita-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ye-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ye-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2 Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yue-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:04:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zelaschi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:04:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zeng-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:04:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:04:44 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: not randomized- inadequate randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-09 13:48:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-09 13:48:32 +0000" MODIFIED_BY="[Empty name]">
<P>1.Allocation: inadequate randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomized.<BR/>2. Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zoccali-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 15:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Allocation: randomization not mentioned.<BR/>2. Blindness: not mentioned.<BR/>3. Participants: patients with schizophrenia.<BR/>3. Interventions: inappropriate (additional mirtazepine with clozapine, risperidone or olanzapine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-01-09 15:39:40 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-11-23 21:15:29 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-09-30 15:38:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2003">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:55:05 +0000" MODIFIED_BY="[Empty name]">
<P>Trial 5296<BR/>F1D-MC-S014</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-30 15:28:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness.: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Setting: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-30 15:38:14 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. N=not reported.<BR/>Sex: not reported. M, not reported. F.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported., age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 15:22:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported, Mean dose: not reported, N=not reported.<BR/>2. Risperidone: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:22:00 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI-S.<BR/>Mental State: BPRS.<BR/>Adverse effects: EPS (AIMS, BAS, SAS), Eating Behavior Assessment Scale, Insuline sensitivity index, weight, BMI, waist circumference, visceral fat area, subcutaneous fat area, ratio of visceral fat area to subcutaneous fat area.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 23:55:05 +0000" MODIFIED_BY="[Empty name]">
<P>October 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-12 23:55:05 +0000" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-12 23:55:05 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-09-30 15:38:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2006">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:56:03 +0000" MODIFIED_BY="[Empty name]">
<P>Trial 10769<BR/>F1D-US-HGMN</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-30 15:28:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness.: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-30 15:38:14 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder or schizophreniform disorder. N=not reported.<BR/>Sex: not reported. M, not reported. F.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported., age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 15:21:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N=not reported.<BR/>2. Risperidone: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:20:36 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: Response, remission.<BR/>Mental State: PANSS.<BR/>Service use: Psychiatric hospitalisations.<BR/>Adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 23:56:03 +0000" MODIFIED_BY="[Empty name]">
<P>June 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-07-30 15:12:39 +0100" MODIFIED_BY="[Empty name]">
<P>not reported.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-12 23:56:03 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-07-30 15:28:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gafoor-2005">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:59:36 +0000" MODIFIED_BY="[Empty name]">
<P>A comparative study of quetiapine and risperidone in patients with first episode psychosis.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-30 15:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness.: rater-blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-12 23:59:36 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: first episode of schizophreniform psychosis (ICD-10 criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 15:18:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine <BR/>2. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:19:23 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI.<BR/>Mental state: PANSS positive subscale, PANSS negative subscale, Calgary Depression Scale for Schizophrenia, Calgary Anxiety Scale Schizophrenia.<BR/>General functioning: GAF.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-07-30 15:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-12 23:59:36 +0000" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2009-01-12 23:59:36 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-11-23 21:15:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lieberman-2001">
<CHAR_STUDY_NAME MODIFIED="2009-01-13 00:01:33 +0000" MODIFIED_BY="[Empty name]">
<P>Risperidone and clozapine in chronic schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-30 15:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness.: double, no further details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-23 21:15:29 +0000" MODIFIED_BY="[Empty name]">
<P>Severely ill treatment resistant patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 15:16:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine<BR/>2. Haloperidole, <BR/>3. Risperidone 6mg, risperidone 16mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:17:53 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI.<BR/>Mental state: PANSS, Overt Agression Scale.<BR/>General functioning: Social functioning and activities of daily living.<BR/>Quality of life interview.<BR/>Cognitive functioning: Cognitive test battery.<BR/>Adverse effects: EPS (ESRS).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-07-30 15:23:10 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-07-30 15:28:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratna-2003">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:59:05 +0000" MODIFIED_BY="[Empty name]">
<P>Improved response in Schizophrenia -IRIS.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-30 15:28:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness.: double, no further details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-12 23:59:05 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 15:15:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine <BR/>2. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:15:29 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI-S.<BR/>Mental state: PANSS, GAS, HAM-D.<BR/>Quality of life - SQLS and care giving inventory scores.<BR/>Adverse effects: EPS (AIMS, SAS, BAS).<BR/>Health Economics.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 23:59:05 +0000" MODIFIED_BY="[Empty name]">
<P>1 October 2002.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-12 23:59:05 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Lawrence Ratna<BR/>Barnet Hospital<BR/>Wellhouse Lane<BR/>Barnet<BR/>EN5 3DJ<BR/>UK<BR/>Telephone: 020 8216 4617<BR/>Fax: 020 8216 4595<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-12 23:59:05 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-09-30 15:38:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reveley-2000">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:56:27 +0000" MODIFIED_BY="[Empty name]">
<P>RIS-INT-45</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-30 15:28:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, using a central randomisation procedure.<BR/>Blindness.: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-30 15:38:14 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, PANSS between 60 and 120. N=not reported.<BR/>Sex: not reported.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported., age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 15:14:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported.<BR/>2. Risperidone: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:13:38 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy.<BR/>Cognitive functioning.<BR/>Adverse effects: Sleepiness, weight gain, safety.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 23:56:27 +0000" MODIFIED_BY="[Empty name]">
<P>1 April 1997</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-12 23:56:27 +0000" MODIFIED_BY="[Empty name]">
<P>Professor Michael Reveley<BR/>Department of Psychiatry<BR/>Clinical Sciences Building<BR/>University of Leicester<BR/>Leicester Royal Infirmary<BR/>PO BOX 65<BR/>LE2 7LX<BR/>United Kingdom<BR/>Telephone: 0116 252 3242</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-12 23:56:27 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-07-30 15:28:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sireling-2003">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:51:02 +0000" MODIFIED_BY="[Empty name]">
<P>Sertindole versus risperidone safety outcome study.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-30 15:28:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness.: partially blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 15:12:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-12 23:51:02 +0000" MODIFIED_BY="[Empty name]">
<P>Sertindole versus risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:23:23 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 23:51:02 +0000" MODIFIED_BY="[Empty name]">
<P>November 2002.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-12 23:51:02 +0000" MODIFIED_BY="[Empty name]">
<P>Lester.sireling@beh-mht.nhs.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-12 23:51:02 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-23 21:17:08 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-17 22:48:06 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 00:13:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:41:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:47:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:45:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:49:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:50:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:56:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 12:14:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Random, permuted block randomisation stratified by centre.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:51:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:48:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:53:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daniel-1996">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:53:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:58:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:54:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:55:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:50:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:56:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:51:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:59:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:38:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:38:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:39:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:02:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:53:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:54:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:55:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:56:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:56:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:06:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:48:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Allocation: random, ball drawing out of a covered box. Probably yes.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:57:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:09:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:58:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:59:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:12:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:00:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Random, 2 steps of randomisation before and after availability of ziprasidone, subjects received other medication than in previous phase 1 treatment. Re-randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:13:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:14:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:15:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:16:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:17:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:17:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:19:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Random, 33 participants were assigned to a three-arm randomisation (1:1:1, blocks of 15) and 18 participants with a history of adverse experiences with haloperidol were assigned to a two-arm randomisation (1:1) for risperidone and olanzapine only.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:01:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:20:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-23 21:14:20 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 00:13:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:41:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:47:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:45:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:49:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:50:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 16:26:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:46:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:51:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:48:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:53:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daniel-1996">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:54:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:58:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:54:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 21:14:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:50:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:57:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:51:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 17:59:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:38:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:38:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:39:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:02:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:53:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:54:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:55:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:56:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2003">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:44:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Quote: were assigned using a centralised interactive voice response system. Probably done.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:06:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 14:03:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:57:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:09:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:58:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:59:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:11:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:00:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:13:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:15:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:16:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:16:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-30 12:36:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:17:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:18:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:01:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-13 18:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-11-19 04:21:11 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 15:43:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 15:45:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:32:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 16:21:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:44:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 16:22:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:45:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 16:24:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-31 09:55:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 16:25:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 16:26:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:54:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 18:24:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:55:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 18:26:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:56:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 18:27:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:57:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 18:28:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daniel-1996">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daniel-1996">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 18:29:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-31 09:55:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 18:29:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-31 09:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 20:24:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Double, double-dummy design. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-31 09:54:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 20:26:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:08:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 20:27:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:10:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 20:29:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 20:30:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined. Both compounds differ substantially in side effects which can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:12:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:20:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:13:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:22:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:33:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:14:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:34:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:15:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:35:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Double, double-dummy protocol. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:19:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:36:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:20:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:38:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:20:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:40:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds in side effects. This may be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:21:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:42:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2003">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:22:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Potkin-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:44:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:23:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:46:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:24:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:48:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:26:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:49:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:50:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2005">
<DESCRIPTION>
<P>Single-blind, rater-blinded. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:28:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:52:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Single: rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:28:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 22:53:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:30:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-18 04:25:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:30:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-18 04:27:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:32:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-18 04:27:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:32:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-18 04:28:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:33:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-18 04:29:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:34:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-18 04:31:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-31 09:53:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-19 04:14:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:39:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-19 04:16:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:39:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-19 04:19:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:41:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-19 04:20:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:42:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-19 04:21:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-30 13:44:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-11-23 21:14:38 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 15:43:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>The overall attrition was rather high (33.3%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Data on study completers were also available. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-10 13:36:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Three subjects in the control groups left the study early (5.4%). Reason for drop-out were not assessed, only completer data were presented. But due to the very low rate we do not think that there was a risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 16:21:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>The overall attrition was moderate (26.7%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 16:22:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Data on reasons for leaving the study early were available, but total number was considerably high (35.8%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 16:24:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>The overall attrition was moderate (20.9%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-30 11:58:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Data on subjects leaving the study early were not available. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-10 10:59:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Data on leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 18:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Total number of participants leaving the study early was possibly acceptable (25%).<BR/>The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 18:26:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>The overall attrition was moderate (25.5%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias in a study with moderate attrition.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 17:47:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>The drop-out rate was considerable (36%). The analysis was based on the intention-to-treat sample and a mixed effects model. It is unclear whether any statistical method can account for higher drop-out rates.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 17:48:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daniel-1996">
<DESCRIPTION>
<P>The overall attrition was moderate (15%). Further details were not provided.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:55:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Data on leaving the study early were not published separately for each group, the overall attrition was moderate (25%). (Data on both treatment attrition were provided from contact of the author).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-10 10:58:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>No data on leaving the study early available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 20:24:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>The overall attrition was high (55.4%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 20:26:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>The overall attrition was high (48.3%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 20:28:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>The rate of participants leaving the study early was below 10% and data on reasons for drop-out were available. The data were analysed on an intent-to-treat basis with the LOCF method. This method is not perfect, but due to the very low attrition the risk of bias was low.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 20:29:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Number of participants leaving the study early was moderate (23.9%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 20:30:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Data on reason for drop-out were available but total numbers was considerably high (32.4%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:21:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>The overall attrition was high (62.8%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-23 21:14:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>The overall attrition was high (75%), and it is unclear whether any statistical method can account for such a high drop-out rate. Efficacy outcomes were evaluated based on mixed effects model analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 17:56:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>The overall attrition was high (74%). It is doubtful that the validity was not affected by this high rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 17:57:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>The attrition was high (70.3.%). The primary analysis was based on a mixed effect model, secondary approaches used the last-observation-carried forward approach or included only study completers. Nevertheless, it is unclear whether any statistical method can account for such a high attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 17:59:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>The overall attrition was high 63.9%. The analysis was based on mixed effect models, but it is unclear whether any statistical method can account for such a high drop-out rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 18:27:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>There was no data on attrition available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 18:28:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>Numbers of participants leaving the study early were only reported for the category "due to adverse effects". The statistical method used to account for incomplete data was not described.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:48:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>The rate of leaving the study early was moderate (30.3%). The statistical analysis was based on a last-observation-carried-forward method to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:43:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2003">
<DESCRIPTION>
<P>The overall drop-out rate was high (36.9%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:45:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>The overall attrition was rather low (12%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Nevertheless, due to the overall low attrition it is unlikely that the results have been affected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:46:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>The overall attrition was high (54.8%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 18:32:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Data on leaving the study early were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:49:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>The overall attrition was high (45.2%). The data were analysed using both a LOCF method and a study completer approach. Nevertheless, it is questionable whether any statistical method can account for such a high attrition.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:50:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2005">
<DESCRIPTION>
<P>The overall attrition was possibly acceptable (28%), but data on leaving the study early were incompletely reported. Eight patients were excluded from the analysis for various reasons. The statistical analysis was based on mixed model approach.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:52:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>The overall attrition was moderate (18.6%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 22:53:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>The rate of participants leaving the study early was high (40%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-18 04:25:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>The overall attrition was high (33.3%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 18:39:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>The overall attrition was high (72.5%). The main statistical analysis used a mixed effects model approach. It is unclear whether any statistical method can account for such high rates of leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-01 11:07:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003">
<DESCRIPTION>
<P>Data on subjects leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-18 04:28:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>The overall attrition was high 47.5 %. The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-01 11:09:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Data on leaving the study early were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-18 04:31:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>The overall attrition was high (41.7%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-19 04:15:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>The overall attrition was high (35%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-01 11:11:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Data on leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-01 11:13:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Data on leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-19 04:20:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>The overall attrition was high (52.1%). The LOCF method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Data on study completers were also available. Nevertheless it is unclear whether any statistical method can account for such a degree of attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 18:45:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>No participant left the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-11-23 21:17:08 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-30 11:24:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>Reporting on secondary outcomes was incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:17:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Probably free of bias. The study focused on serum leptin and triglyceride levels which were adequately described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:42:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:42:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 21:13:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Secondary outcomes were not fully reported. For treatment emergent adverse events there was an incidence of at lest 5% occurrence for being reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:44:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Exclusion of 5 participants after randomisation, incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:56:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Data were only presented as a poster, data on primary outcomes were missing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:46:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>Only adverse events with an incidence of at least 5% in any treatment group were reported, therefore important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:44:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:48:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Not all of the predefined adverse effects were assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 18:28:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daniel-1996">
<DESCRIPTION>
<P>Outcomes were reported incompletely. Six weeks' interim data before crossover were hardly reported. The study was only published as an abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 10:38:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Data on efficacy outcomes were incompletely reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:58:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Insufficient data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:45:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 21:17:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Acutely ill subjects were included but data on the reduction of positive symptoms were not available. Secondary outcome data in terms of adverse effects were reported incompletely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:52:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>Data on the extrapyramidal symptom scale have not been presented. Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:45:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:46:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:46:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:55:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>There was no evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:22:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Due to small numbers and the very high attrition only data on 26 weeks treatment (rather than 52 weeks) were presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:39:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Adverse events were presented only in case of moderate or worse severity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:36:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Outcome reporting was incomplete. Quote: "...adverse events data have been reported elsewhere (unpublished study of N.R. Schooler et al.).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:26:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Adverse events were not reported. Numbers on use of antiparkinson medication have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:28:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>The study is only available as an abstract. The data for primary outcomes were either not available or only available in percentage change without a standard deviation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:48:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>Data on general functioning (secondary outcome) were not available. Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:43:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2003">
<DESCRIPTION>
<P>For efficacy outcomes standard deviations or standard errors had not been indicated which had to be back calculated from P values. Only adverse events with an incidence of more than 5% were reported. This procedure may have missed important adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:49:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Data on some adverse effects were not available. Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:32:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>The study focused on neuropsychological changes, but data for efficacy and some side effects were also presented. Probably no bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:33:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Secondary outcomes were poorly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:38:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Data on negative symptoms (SANS) and some adverse effects were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:36:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robinson-2005">
<DESCRIPTION>
<P>Data on the general mental state (PANSS total score) were not presented. The data available for adverse effects were incomplete. Data on weight gain were missing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:52:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Efficacy data (PANSS) were only presented as percentage change without standard deviations, standard errors, P values or ranges. Only interim data after recruitment of half the patients have been presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:51:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:39:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>No evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:43:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Use of antiparkinson medication was permitted but data on this outcome have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 14:05:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003">
<DESCRIPTION>
<P>Allowed study medication dose ranges were not indicated. A publication was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:40:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Adverse effects were only reported in the case of a significant difference between groups. Important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:40:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Outcome reporting was incomplete, standard deviations were not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:41:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Some outcomes were reported on subgroup from the entire sample. Quality of life data were not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:42:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>No evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:43:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Standard deviations for the primary outcome were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:43:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Efficay outcomes such as the general mental state (PANSS total score) were not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:53:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:45:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>No clear evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-11-23 21:15:00 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:24:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addington-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of ziprasidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:17:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Data on the allowed dose range have not been presented. Furthermore, the pre-study treatment was quite heterogeneous as 19 participants had never taken any psychotropic drugs while most other participants had a long history of previous treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:42:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of clozapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:28:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>The study was industry sponsored by the manufacturer of sertindole.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:10:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:45:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>One of the authors is an employee of a pharmaceutical company producing olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:01:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:46:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chan-2007">
<DESCRIPTION>
<P>The study was industry sponsored by the manufacturer of aripiprazole.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 18:26:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone. The total number of participants was very low (n = 13), which may limit the validity of results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:47:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>There was a slight baseline imbalance in terms of mean age and previous numbers of hospitalizations (14 in the risperidone and 9.7 in the quetiapine group).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daniel-1996">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:02:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:58:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Insufficient data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:50:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 10:32:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Fixed doses of 4mg/day and 8mg/day of risperidone were compared with a fixed dose of 400mg of clozapine, for a fixed dose regimen it might be difficult to decide which doses are appropriate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:17:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 17:54:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone. The mean age of included subjects was about 71 years. Probably due to this reason the upper dose range limit of risperidone was rather low (3mg/day), compared to that of olanzapine (20mg/day).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:17:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of sertindole.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:03:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:23:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6mg /day. There was no wash-out period. An overlap in the administration of formerly given antipsychotics was permitted for the first four weeks after randomisation. Allocation to ziprasidone treatment was not possible from the start of the study due to the later availability of ziprasidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:33:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6mg /day. Patients had a history of former inefficacy to one of the medications. It was excluded that the same medication could be given again but still this might implicate a risk of bias due to baseline imbalance in terms of former treatment. There was no wash-out period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:39:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-30 12:21:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Review authors did not find other sources of bias. Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:37:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>There was no wash-out period. The previous antipsychotic treatment was gradually tapered over 4 weeks. Thus, during a period of 4 weeks the participants were on two drugs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:28:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-M_x00f6_ller-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride. Whether there was a baseline imbalance could not be judged due to insufficient data.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:55:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peuskens-1999">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:43:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of aripiprazole. The study used a fixed-dose regimen. It is difficult to say whether the chosen doses were appropriate.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:56:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:06:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:33:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>The allowed dose ranges were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:57:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-17 22:51:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2005">
<DESCRIPTION>
<P>Quote: ".. the study was designed to detect differences in our primary analysis at alpha = 0.05 with 80% power based upon 130 subjects, the stability analysis included only 47 subjects and therefore might lack adequate power."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:58:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:59:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sechter-2002">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-23 21:15:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Quote: "...this study has a number of limitations including limited sample size, differences in the diagnosis of participants, use of concomitant medication, variations in age and pupertal status".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:00:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Patients had a history of former intolerance to atypical antipsychotic treatment but baseline data on this was not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 14:05:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003">
<DESCRIPTION>
<P>Insufficient information. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:10:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:52:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Additional usage of cannabis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Quote: "The olanzapine arm was added in November 1997 and required a modified randomization procedure"...It entails the potential for a bias that could be manifested as a cohort effect."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:42:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>The number of participants included was rather low. Quote: "...readers have to bear in mind, that the statistical power of this study may hide some clinically relevant differences in drug efficacy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:11:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Dose ranges were not indicated. The study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 11:11:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 11:01:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 18:46:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>The description of blinding differed between the abstract (double-blind) and the method section (single-blind).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-07-30 15:28:57 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-07-30 15:28:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-01-06 11:10:22 +0000" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blindness.: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N=2700.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Risperidone: dose ~ 4-8 mg/day. N=300.<BR/>2. Amisulpride: dose ~ 400-800 mg/day. N=300.<BR/>3. Aripiprazole: dose ~ 10-30 mg/day. N=300.<BR/>4. Clozapine: dose ~ 300-800 mg/day. N=300.<BR/>5. Olanzapine: dose ~ 10-20 mg/day. N=300.<BR/>6. Quetiapine: dose ~300-800 mg/day. N=300.<BR/>7. Sertindole: dose ~ 12-24 mg/day. N=300.<BR/>8. Ziprasidone: dose ~ 120-160 mg/day. N=300.<BR/>9. Zotepine: dose ~ 100-300 mg/day. N=300.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: CGI**, relapse.<BR/>Mental state: PANSS.<BR/>Adverse events: UKU.<BR/>Employment, family satisfaction, patient satisfaction.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>
<BR/>** Primary outcome<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-11-23 17:54:45 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-11-22 18:37:37 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>RISPERIDONE versus AMISULPRIDE</NAME>
<DICH_OUTCOME CHI2="4.3488673694068245" CI_END="1.5003493595350392" CI_START="0.8333297151782959" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.118161752363795" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="125" I2="54.011014130495425" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.17619239722378913" LOG_CI_START="-0.07918313166543921" LOG_EFFECT_SIZE="0.04850463277917494" METHOD="MH" MODIFIED="2009-09-21 10:35:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11367259034651489" P_Q="0.0" P_Z="0.45655608429056715" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03594042366089356" TOTALS="YES" TOTAL_1="296" TOTAL_2="290" WEIGHT="100.0" Z="0.7445297029361044">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.175156416008803" CI_START="0.3674717074349383" EFFECT_SIZE="0.6571428571428571" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.07009567604472877" LOG_CI_START="-0.4347760927100943" LOG_EFFECT_SIZE="-0.18234020833268275" ORDER="11" O_E="0.0" SE="0.29656417612214425" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.0879503105590062" WEIGHT="18.163307498052575"/>
<DICH_DATA CI_END="1.8010798531252876" CI_START="0.91753176191543" EFFECT_SIZE="1.2855146716348393" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.25553296823479055" LOG_CI_START="-0.03737889297685246" LOG_EFFECT_SIZE="0.10907703762896903" ORDER="12" O_E="0.0" SE="0.1720578772128164" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.029603913110980602" WEIGHT="34.3319592908164"/>
<DICH_DATA CI_END="1.5275306834762217" CI_START="1.0045997049530728" EFFECT_SIZE="1.2387723252991156" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="73" LOG_CI_END="0.18398994266619356" LOG_CI_START="0.001993046272991792" LOG_EFFECT_SIZE="0.09299149446959266" ORDER="13" O_E="0.0" SE="0.10690587784053336" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.011428866716855043" WEIGHT="47.50473321113103"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.478284851222845" CI_END="1.5349513878836691" CI_START="0.8160771384271033" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.11921344534848" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="111" I2="55.3400449849929" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.18609462586650682" LOG_CI_START="-0.0882687882928564" LOG_EFFECT_SIZE="0.048912918786825195" METHOD="MH" MODIFIED="2009-09-21 10:35:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10654995383271193" P_Q="0.0" P_Z="0.48465433323825446" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04227546567585507" TOTALS="YES" TOTAL_1="296" TOTAL_2="290" WEIGHT="99.99999999999999" Z="0.6988363189359172">
<NAME>Global state: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.852675870956527" CI_END="1.8457493938625253" CI_START="0.49900748642891923" DF="1" EFFECT_SIZE="0.9597097298709856" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="52" I2="74.04401425153567" ID="CMP-001.02.01" LOG_CI_END="0.26617273447377726" LOG_CI_START="-0.3018929387646271" LOG_EFFECT_SIZE="-0.0178601021454249" MODIFIED="2009-09-21 10:35:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.049666743462345786" P_Z="0.9019144025948918" STUDIES="2" TAU2="0.167672048696199" TOTAL_1="138" TOTAL_2="138" WEIGHT="56.07944698524126" Z="0.1232433453184505">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.175156416008803" CI_START="0.3674717074349383" EFFECT_SIZE="0.6571428571428571" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.07009567604472877" LOG_CI_START="-0.4347760927100943" LOG_EFFECT_SIZE="-0.18234020833268275" ORDER="14" O_E="0.0" SE="0.29656417612214425" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.0879503105590062" WEIGHT="19.94484411630017"/>
<DICH_DATA CI_END="1.8010798531252876" CI_START="0.91753176191543" EFFECT_SIZE="1.2855146716348393" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.25553296823479055" LOG_CI_START="-0.03737889297685246" LOG_EFFECT_SIZE="0.10907703762896903" ORDER="15" O_E="0.0" SE="0.1720578772128164" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.029603913110980602" WEIGHT="36.134602868941094"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.238709125914315E-30" CI_END="1.6404368578269557" CI_START="0.9860493825796046" DF="0" EFFECT_SIZE="1.271830079382107" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="59" I2="100.0" ID="CMP-001.02.02" LOG_CI_END="0.21495951858364618" LOG_CI_START="-0.0061013345062738596" LOG_EFFECT_SIZE="0.10442909203868615" MODIFIED="2009-09-21 10:35:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.06405842660611523" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="152" WEIGHT="43.920553014758724" Z="1.8517729980060074">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.6404368578269557" CI_START="0.9860493825796046" EFFECT_SIZE="1.271830079382107" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="59" LOG_CI_END="0.21495951858364618" LOG_CI_START="-0.0061013345062738596" LOG_EFFECT_SIZE="0.10442909203868615" ORDER="16" O_E="0.0" SE="0.12985223937388995" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.016861604070414017" WEIGHT="43.920553014758724"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3878312654011733" CI_START="0.9387557641860125" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4971941638608306" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.37800363439440177" LOG_CI_START="-0.02744738330709102" LOG_EFFECT_SIZE="0.17527812554365538" METHOD="MH" MODIFIED="2009-09-21 10:36:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.09015117159826876" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="92" WEIGHT="100.0" Z="1.6946008190620943">
<NAME>Global state: 1c. Relapse - medium term (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3878312654011733" CI_START="0.9387557641860125" EFFECT_SIZE="1.4971941638608306" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.37800363439440177" LOG_CI_START="-0.02744738330709102" LOG_EFFECT_SIZE="0.17527812554365538" MODIFIED="2009-09-21 10:36:17 +0100" MODIFIED_BY="[Empty name]" ORDER="927" O_E="0.0" SE="0.2381639348127632" STUDY_ID="STD-Sechter-2002" TOTAL_1="81" TOTAL_2="92" VAR="0.05672205984549813" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.352968351575502" CI_END="1.378865104144681" CI_START="0.8196071758583723" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0630746605472647" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="151" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.13952178075801314" LOG_CI_START="-0.08639424790133139" LOG_EFFECT_SIZE="0.0265637664283408" METHOD="MH" MODIFIED="2009-09-21 10:37:01 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6077584781421395" P_Q="0.0" P_Z="0.6448597033362876" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="900" TOTAL_2="894" WEIGHT="300.0" Z="0.4609148434685776">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9371029556335126" CI_END="1.5285942620073611" CI_START="0.6804394135299416" DF="2" EFFECT_SIZE="1.0198606685060088" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="94" I2="49.20122682750156" ID="CMP-001.04.01" LOG_CI_END="0.18429222501003237" LOG_CI_START="-0.16721053841218075" LOG_EFFECT_SIZE="0.008540843298925866" MODIFIED="2009-09-21 10:36:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13965918262670762" P_Z="0.9241188496100194" STUDIES="3" TAU2="0.05769021251628022" TOTAL_1="296" TOTAL_2="290" WEIGHT="100.0" Z="0.09524673490767228">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="2.4225772069595117" CI_START="0.0071779773013779654" EFFECT_SIZE="0.13186813186813187" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3842776268052258" LOG_CI_START="-2.1439979193521634" LOG_EFFECT_SIZE="-0.8798601462734688" ORDER="1" O_E="0.0" SE="1.4851215709786458" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="2.2055860805860807" WEIGHT="1.8836279107436338"/>
<DICH_DATA CI_END="1.3072486782108412" CI_START="0.5926210735221579" EFFECT_SIZE="0.8801722076058359" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="37" LOG_CI_END="0.11635821137679124" LOG_CI_START="-0.2272229091305854" LOG_EFFECT_SIZE="-0.05543234887689707" ORDER="2" O_E="0.0" SE="0.20182125094000902" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.04073181733099009" WEIGHT="43.315204959982175"/>
<DICH_DATA CI_END="1.6230433402119737" CI_START="0.9310082873034944" EFFECT_SIZE="1.2292545710267229" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="54" LOG_CI_END="0.21033011696954332" LOG_CI_START="-0.03104645316026992" LOG_EFFECT_SIZE="0.0896418319046367" ORDER="3" O_E="0.0" SE="0.14178579212754444" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.02010321084923524" WEIGHT="54.80116712927419"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7928365025351387" CI_END="1.4246937688059509" CI_START="0.6059048462865414" DF="3" EFFECT_SIZE="0.9291011026760021" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="38" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.15372152482873266" LOG_CI_START="-0.21759557381625216" LOG_EFFECT_SIZE="-0.03193702449375974" MODIFIED="2009-09-21 10:36:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8511797179541631" P_Z="0.7360012377532059" STUDIES="4" TAU2="0.0" TOTAL_1="308" TOTAL_2="314" WEIGHT="100.0" Z="0.33715343575378903">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="7.195817676132172" CI_START="0.01315688646851686" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440404" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="4" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="2.5865384615384617" WEIGHT="1.8392728494846913"/>
<DICH_DATA CI_END="29.28098695884011" CI_START="0.13660741714829308" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.466585711168944" LOG_CI_START="-0.8645257198409816" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="5" O_E="0.0" SE="1.3693063937629153" STUDY_ID="STD-M_x00f6_ller-2005" TOTAL_1="12" TOTAL_2="24" VAR="1.875" WEIGHT="2.5372533154429844"/>
<DICH_DATA CI_END="1.875841034127659" CI_START="0.48096814674141203" EFFECT_SIZE="0.9498525073746312" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.2731960318434951" LOG_CI_START="-0.3178836848579976" LOG_EFFECT_SIZE="-0.022343826507251273" ORDER="6" O_E="0.0" SE="0.3472031514822427" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.12055002839920115" WEIGHT="39.46369842984725"/>
<DICH_DATA CI_END="1.6208420809306776" CI_START="0.5179092889382734" EFFECT_SIZE="0.9162145871006631" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.2097407034843361" LOG_CI_START="-0.28574629964351234" LOG_EFFECT_SIZE="-0.038002798079588146" ORDER="7" O_E="0.0" SE="0.2910515183375203" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.08471098632657592" WEIGHT="56.159775405225076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1331397610162478" CI_END="2.5319386832879363" CI_START="0.8283150983127991" DF="1" EFFECT_SIZE="1.4481861204174091" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="19" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.4034531840340448" LOG_CI_START="-0.08180442236173878" LOG_EFFECT_SIZE="0.16082438083615305" MODIFIED="2009-09-21 10:37:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7151986754937413" P_Z="0.19389417553582186" STUDIES="3" TAU2="0.0" TOTAL_1="296" TOTAL_2="290" WEIGHT="100.0" Z="1.2991449907030346">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1061893302850443" CI_START="0.520991809936414" EFFECT_SIZE="1.2721238938053097" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.49222792357286316" LOG_CI_START="-0.2831691038163664" LOG_EFFECT_SIZE="0.10452940987824834" ORDER="9" O_E="0.0" SE="0.455472052165622" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.20745479030396308" WEIGHT="39.164847502725124"/>
<DICH_DATA CI_END="3.22211682016001" CI_START="0.7691151388233823" EFFECT_SIZE="1.574223245109321" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.5081412820270699" LOG_CI_START="-0.11400864015620799" LOG_EFFECT_SIZE="0.19706632093543092" ORDER="10" O_E="0.0" SE="0.3654539439822408" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.13355658517217478" WEIGHT="60.835152497274876"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5275306834762217" CI_START="1.0045997049530728" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2387723252991156" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.18398994266619356" LOG_CI_START="0.001993046272991792" LOG_EFFECT_SIZE="0.09299149446959266" METHOD="MH" MODIFIED="2009-09-21 10:49:50 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.04518898092338836" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="152" WEIGHT="100.00000000000001" Z="2.002891078265282">
<NAME>Mental state: 1a. General - no clinically important change - medium term (less than 50% PANSS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5275306834762217" CI_START="1.0045997049530728" EFFECT_SIZE="1.2387723252991156" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="73" LOG_CI_END="0.18398994266619356" LOG_CI_START="0.001993046272991792" LOG_EFFECT_SIZE="0.09299149446959266" MODIFIED="2009-09-21 10:47:30 +0100" MODIFIED_BY="[Empty name]" ORDER="928" O_E="0.0" SE="0.10690587784053336" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.011428866716855043" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6874561734434126" CI_START="0.282140660891046" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.69" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.22723250216744473" LOG_CI_START="-0.5495343206929342" LOG_EFFECT_SIZE="-0.16115090926274472" METHOD="MH" MODIFIED="2009-09-21 10:50:01 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.41607892373320954" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.8132427105158038">
<NAME>Mental state: 1b. General - no clinically important change - short term (less than 20% PANSS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6874561734434126" CI_START="0.282140660891046" EFFECT_SIZE="0.69" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.22723250216744473" LOG_CI_START="-0.5495343206929342" LOG_EFFECT_SIZE="-0.16115090926274472" MODIFIED="2009-09-21 10:48:07 +0100" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.0" SE="0.456276676805972" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.20818840579710143" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6233152184327608" CI_START="1.021367263262778" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2876338851022395" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.21040286014265902" LOG_CI_START="0.00918193378956674" LOG_EFFECT_SIZE="0.10979239696611287" METHOD="MH" MODIFIED="2009-09-21 10:50:09 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.03244906291669766" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="152" WEIGHT="99.99999999999999" Z="2.1388346404121297">
<NAME>Mental state: 1c. General - no clinically important change - medium term (less than 50% BPRS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6233152184327608" CI_START="1.021367263262778" EFFECT_SIZE="1.2876338851022395" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="65" LOG_CI_END="0.21040286014265902" LOG_CI_START="0.00918193378956674" LOG_EFFECT_SIZE="0.10979239696611287" MODIFIED="2009-09-21 10:48:35 +0100" MODIFIED_BY="[Empty name]" ORDER="930" O_E="0.0" SE="0.11819816819945612" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.01397080696570692" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8010798531252876" CI_START="0.91753176191543" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2855146716348393" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.25553296823479055" LOG_CI_START="-0.03737889297685246" LOG_EFFECT_SIZE="0.10907703762896903" METHOD="MH" MODIFIED="2009-09-21 14:06:49 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.14436251060826044" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="115" WEIGHT="100.0" Z="1.4597364846118543">
<NAME>Mental state: 1d. General - no clinically important change - short term (less than 40% BPRS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8010798531252876" CI_START="0.91753176191543" EFFECT_SIZE="1.2855146716348393" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="38" LOG_CI_END="0.25553296823479055" LOG_CI_START="-0.03737889297685246" LOG_EFFECT_SIZE="0.10907703762896903" MODIFIED="2009-09-21 10:50:35 +0100" MODIFIED_BY="[Empty name]" ORDER="931" O_E="0.0" SE="0.1720578772128164" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.029603913110980602" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7246945687566685" CI_END="4.571830764932009" CI_START="-5.332376864814948" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3802730499414693" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2009-09-21 10:51:32 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.39460833516818805" P_Q="0.39460833516818805" P_Z="0.8803653942226284" Q="0.7246945687566685" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="143" UNITS="" WEIGHT="100.0" Z="0.15050602936431445">
<NAME>Mental state: 1e. General - average endpoint score - (PANSS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.993986237406125" CI_START="-14.593986237406119" DF="0" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2009-09-21 10:51:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41294881183983856" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="22" WEIGHT="23.14260882238183" Z="0.8187154071468699">
<NAME>short term</NAME>
<CONT_DATA CI_END="5.993986237406125" CI_START="-14.593986237406119" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="-28.4" MEAN_2="-24.1" ORDER="20" SD_1="18.8" SD_2="17.2" SE="5.252130303721788" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="22" WEIGHT="23.14260882238183"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.448679332467792" CI_START="-4.848679332467784" DF="0" EFFECT_SIZE="0.8000000000000043" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2009-09-21 10:51:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7813333220870281" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="121" WEIGHT="76.85739117761817" Z="0.27758190814967687">
<NAME>medium term</NAME>
<CONT_DATA CI_END="6.448679332467792" CI_START="-4.848679332467784" EFFECT_SIZE="0.8000000000000043" ESTIMABLE="YES" MEAN_1="-31.4" MEAN_2="-32.2" ORDER="21" SD_1="21.0" SD_2="23.9" SE="2.8820322092772366" STUDY_ID="STD-Sechter-2002" TOTAL_1="123" TOTAL_2="121" WEIGHT="76.85739117761817"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1367011695090135" CI_END="3.1439307857566456" CI_START="-1.7867673486150508" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6785817185707975" ESTIMABLE="YES" I2="6.397767336853455" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2009-09-21 10:52:13 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.34357495068042654" P_Q="0.6991515371659666" P_Z="0.5895587137949574" Q="0.1493561716952756" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.327143601403669" TOTALS="YES" TOTAL_1="261" TOTAL_2="258" UNITS="" WEIGHT="100.00000000000001" Z="0.5394756250417002">
<NAME>Mental state: 1f. General - average endpoint score - BPRS total score (high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9873449978137379" CI_END="5.533509771738746" CI_START="-4.5403501186989494" DF="1" EFFECT_SIZE="0.49657982651989846" ESTIMABLE="YES" I2="49.681610334386235" ID="CMP-001.10.01" MODIFIED="2009-09-21 10:52:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15861909962329912" P_Z="0.8467799951604105" STUDIES="2" TAU2="6.977782171464546" TOTAL_1="138" TOTAL_2="137" WEIGHT="54.500295648994395" Z="0.1932285312707206">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.5492218490058542" CI_START="-9.149221849005851" EFFECT_SIZE="-2.799999999999999" ESTIMABLE="YES" MEAN_1="-17.7" MEAN_2="-14.9" ORDER="24" SD_1="11.5" SD_2="10.7" SE="3.2394584283628194" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="22" WEIGHT="14.621227950114593"/>
<CONT_DATA CI_END="6.239550032088791" CI_START="-1.2395500320887907" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="-15.2" MEAN_2="-17.7" ORDER="25" SD_1="13.9" SD_2="14.9" SE="1.9079687492147224" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" WEIGHT="39.8790676988798"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6787212094533044" CI_START="-3.278721209453306" DF="0" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" MODIFIED="2009-09-21 10:52:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9102818669443643" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="121" WEIGHT="45.49970435100562" Z="0.11268301577107775">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.6787212094533044" CI_START="-3.278721209453306" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="-19.6" MEAN_2="-19.8" ORDER="26" SD_1="12.6" SD_2="15.0" SE="1.7748903739522839" STUDY_ID="STD-Sechter-2002" TOTAL_1="123" TOTAL_2="121" WEIGHT="45.49970435100562"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7224343951287495" CI_END="1.2949231479493928" CI_START="-1.2394024252719762" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.02776036133870829" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2009-09-21 10:53:06 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.4226476557023281" P_Q="0.6188040550776852" P_Z="0.9657510371368454" Q="0.24755209235640896" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="261" TOTAL_2="258" UNITS="" WEIGHT="100.0" Z="0.04293789953161146">
<NAME>Mental state: 2a. Positive symptoms - average endpoint score - (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4748823027723406" CI_END="2.4719296130574895" CI_START="-2.1671692143027252" DF="1" EFFECT_SIZE="0.1523801993773823" ESTIMABLE="YES" I2="32.197979586554325" ID="CMP-001.11.01" MODIFIED="2009-09-21 10:52:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2245772796582285" P_Z="0.8975494267697337" STUDIES="2" TAU2="1.0061868620798236" TOTAL_1="138" TOTAL_2="137" WEIGHT="50.93690542251359" Z="0.12875763757188521">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.9646285274893955" CI_START="-4.964628527489397" EFFECT_SIZE="-1.5000000000000009" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-6.8" ORDER="27" SD_1="6.1" SD_2="6.0" SE="1.7677000979701383" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="22" WEIGHT="13.37677636615875"/>
<CONT_DATA CI_END="3.067611182654708" CI_START="-1.0676111826547081" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-8.6" MEAN_2="-9.6" ORDER="28" SD_1="7.4" SD_2="8.5" SE="1.0549230490783306" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" WEIGHT="37.56012905635484"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5090682086866545" CI_START="-2.1090682086866526" DF="0" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" MODIFIED="2009-09-21 10:52:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7451634896919006" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="121" WEIGHT="49.06309457748641" Z="0.32502323159439206">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.5090682086866545" CI_START="-2.1090682086866526" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="-12.1" MEAN_2="-11.8" ORDER="29" SD_1="6.9" SD_2="7.5" SE="0.9230109445665087" STUDY_ID="STD-Sechter-2002" TOTAL_1="123" TOTAL_2="121" WEIGHT="49.06309457748641"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.888879336880697" CI_START="-0.8888793368806971" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2009-09-21 10:53:56 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.4804419759947307" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="0.7055918871044492">
<NAME>Mental state: 2b. Positive symptoms -average endpoint score - short term (BPRS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.888879336880697" CI_START="-0.8888793368806971" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-7.2" MODIFIED="2009-09-21 10:53:56 +0100" MODIFIED_BY="[Empty name]" ORDER="932" SD_1="5.3" SD_2="5.4" SE="0.7086249277211214" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.245300491845032" CI_END="2.1133406090333064" CI_START="-0.11131794552892638" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.00101133175219" ESTIMABLE="YES" I2="10.925062936385018" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2009-09-21 10:55:11 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.3254165350437169" P_Q="0.7236111191640475" P_Z="0.07776266275057028" Q="0.12505902597753904" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.11441183936315624" TOTALS="YES" TOTAL_1="261" TOTAL_2="258" UNITS="" WEIGHT="100.0" Z="1.763817781679166">
<NAME>Mental state: 3a. Negative symptoms - average endpoint score (PANSS negative, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.120241465867493" CI_END="2.9200947446102563" CI_START="-1.7169958341901652" DF="1" EFFECT_SIZE="0.6015494552100457" ESTIMABLE="YES" I2="52.83556066144326" ID="CMP-001.13.01" MODIFIED="2009-09-21 10:54:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1453636836796356" P_Z="0.6110921610222178" STUDIES="2" TAU2="1.5216641470495669" TOTAL_1="138" TOTAL_2="137" WEIGHT="49.02837336928738" Z="0.5085150902686838">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.8601083966327514" CI_START="-3.460108396632753" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-5.6" ORDER="31" SD_1="4.8" SD_2="4.5" SE="1.3572231008402948" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="22" WEIGHT="16.46259007187331"/>
<CONT_DATA CI_END="3.432977306386249" CI_START="-0.23297730638624792" EFFECT_SIZE="1.6000000000000005" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-6.9" ORDER="32" SD_1="6.6" SD_2="7.5" SE="0.9352096879557683" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" WEIGHT="32.565783297414065"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6099199552360153" CI_START="-0.2099199552360156" DF="0" EFFECT_SIZE="1.1999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" MODIFIED="2009-09-21 10:54:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09528612140585256" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="121" WEIGHT="50.97162663071263" Z="1.6681491546478293">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.6099199552360153" CI_START="-0.2099199552360156" EFFECT_SIZE="1.1999999999999997" ESTIMABLE="YES" MEAN_1="-3.9" MEAN_2="-5.1" ORDER="33" SD_1="6.1" SD_2="5.1" SE="0.7193601343480207" STUDY_ID="STD-Sechter-2002" TOTAL_1="123" TOTAL_2="121" WEIGHT="50.97162663071263"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.733862360348889" CI_START="-2.3338623603488866" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.700000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2009-09-21 10:56:02 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.29313878749752686" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="121" UNITS="" WEIGHT="100.0" Z="1.0512609164568767">
<NAME>Mental state: 3b. Negative symptoms - average endpoint scale (SANS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.733862360348889" CI_START="-2.3338623603488866" DF="0" EFFECT_SIZE="2.700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" MODIFIED="2009-09-21 10:56:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.29313878749752686" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="121" WEIGHT="100.0" Z="1.0512609164568767">
<NAME>medium term</NAME>
<CONT_DATA CI_END="7.733862360348889" CI_START="-2.3338623603488866" EFFECT_SIZE="2.700000000000001" ESTIMABLE="YES" MEAN_1="-12.1" MEAN_2="-14.8" ORDER="34" SD_1="19.6" SD_2="20.5" SE="2.568344316556504" STUDY_ID="STD-Sechter-2002" TOTAL_1="123" TOTAL_2="121" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2455544711959707" CI_START="0.98342239617221" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1067547888428364" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="113" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.09536272506605847" LOG_CI_START="-0.007259905438524481" LOG_EFFECT_SIZE="0.04405140981376699" METHOD="MH" MODIFIED="2009-09-21 10:56:36 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.09244214116513576" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="152" WEIGHT="100.0" Z="1.6826537436952926">
<NAME>General functioning: General 1a. No clinically important change - medium term (less than 50% SOFAS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2455544711959707" CI_START="0.98342239617221" EFFECT_SIZE="1.1067547888428364" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="113" LOG_CI_END="0.09536272506605847" LOG_CI_START="-0.007259905438524481" LOG_EFFECT_SIZE="0.04405140981376699" MODIFIED="2009-09-21 10:56:36 +0100" MODIFIED_BY="[Empty name]" ORDER="933" O_E="0.0" SE="0.060281041148605774" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.003633803921959902" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.1052377638977139" CI_END="5.896970929891035" CI_START="-1.2813448791383917" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.3078130253763214" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2009-09-21 10:57:44 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.7456324471943845" P_Q="0.7456324471943845" P_Z="0.2075798020787717" Q="0.1052377638977139" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="143" UNITS="" WEIGHT="100.0" Z="1.2602483738874661">
<NAME>General functioning: General 1b. average endpoint score - (SOFAS total score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.232194723685735" CI_START="-7.032194723685736" DF="0" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" MODIFIED="2009-09-21 10:57:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7909214808776569" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="22" WEIGHT="19.47913164157855" Z="0.26511421040062333">
<NAME>short term</NAME>
<CONT_DATA CI_END="9.232194723685735" CI_START="-7.032194723685736" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="-10.0" MEAN_2="-11.1" ORDER="36" SD_1="14.52" SD_2="13.9" SE="4.14915518235613" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="22" WEIGHT="19.47913164157855"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.599800594266679" CI_START="-1.399800594266679" DF="0" EFFECT_SIZE="2.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" MODIFIED="2009-09-21 10:57:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20264922964941323" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="121" WEIGHT="80.52086835842145" Z="1.2740401026762738">
<NAME>medium term</NAME>
<CONT_DATA CI_END="6.599800594266679" CI_START="-1.399800594266679" EFFECT_SIZE="2.5999999999999996" ESTIMABLE="YES" MEAN_1="-11.9" MEAN_2="-14.5" ORDER="37" SD_1="14.3" SD_2="17.4" SE="2.040752088210087" STUDY_ID="STD-Sechter-2002" TOTAL_1="123" TOTAL_2="121" WEIGHT="80.52086835842145"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.9284145454048067" CI_END="1.0973039056362257" CI_START="0.9030215925323725" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9954341366256316" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="223" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.040326924987787775" LOG_CI_START="-0.04430186496274682" LOG_EFFECT_SIZE="-0.001987469987479532" METHOD="MH" MODIFIED="2009-09-21 10:58:24 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.4027945950266275" P_Q="0.0" P_Z="0.9266521264006161" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="314" WEIGHT="100.0" Z="0.09205778785425131">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4919682226907156" CI_START="0.6454662347796825" EFFECT_SIZE="0.9813333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.17375957323246702" LOG_CI_START="-0.19012647134086944" LOG_EFFECT_SIZE="-0.008183449054201215" ORDER="38" O_E="0.0" SE="0.2137484638473489" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.04568840579710143" WEIGHT="5.408856530897172"/>
<DICH_DATA CI_END="2.2702994966838874" CI_START="0.4404705200616261" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.3560831528659938" LOG_CI_START="-0.3560831528659938" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.41833001326703784" STUDY_ID="STD-M_x00f6_ller-2005" TOTAL_1="12" TOTAL_2="24" VAR="0.17500000000000007" WEIGHT="1.4121258976110407"/>
<DICH_DATA CI_END="1.0487507585331768" CI_START="0.7536248060661426" EFFECT_SIZE="0.8890245142915268" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="87" LOG_CI_END="0.020672287950371834" LOG_CI_START="-0.12284481488564218" LOG_EFFECT_SIZE="-0.05108626346763519" ORDER="40" O_E="0.0" SE="0.08430265662699121" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.0071069379143683855" WEIGHT="34.771941877009446"/>
<DICH_DATA CI_END="1.2109778404284413" CI_START="0.938428245862367" EFFECT_SIZE="1.0660280533698254" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="111" LOG_CI_END="0.08313619610118511" LOG_CI_START="-0.02759892881500432" LOG_EFFECT_SIZE="0.027768633643090384" ORDER="41" O_E="0.0" SE="0.06504636052347844" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.004231029017350334" WEIGHT="58.40707569448235"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.039729501925016036" CI_END="2.817965129171913" CI_START="0.06137323903530832" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41586974819747513" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.449935614642068" LOG_CI_START="-1.212020955776838" LOG_EFFECT_SIZE="-0.38104267056738494" METHOD="MH" MODIFIED="2009-09-21 10:58:42 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.8420104891469854" P_Q="0.0" P_Z="0.3687934281112105" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="304" WEIGHT="99.99999999999999" Z="0.8987357722552188">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.813268069803093" CI_START="0.013167804758072114" DF="0" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.8928327250185286" LOG_CI_START="-1.8804866214635592" LOG_EFFECT_SIZE="-0.49382694822251516" MODIFIED="2009-09-21 10:58:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4851796428367121" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="152" WEIGHT="35.91199889494074" Z="0.6979960921840468">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="7.813268069803093" CI_START="0.013167804758072114" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8928327250185286" LOG_CI_START="-1.8804866214635592" LOG_EFFECT_SIZE="-0.49382694822251516" ORDER="44" O_E="0.0" SE="1.6290615122757481" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="2.6538414107781474" WEIGHT="35.91199889494074"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.250080548158111" CI_START="0.04407040525437145" DF="0" EFFECT_SIZE="0.4810126582278481" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.7201659665206702" LOG_CI_START="-1.3558529558679329" LOG_EFFECT_SIZE="-0.31784349467363127" MODIFIED="2009-09-21 10:58:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5484060034886087" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="152" WEIGHT="64.08800110505925" Z="0.6001504086137186">
<NAME>suicide</NAME>
<DICH_DATA CI_END="5.250080548158111" CI_START="0.04407040525437145" EFFECT_SIZE="0.4810126582278481" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7201659665206702" LOG_CI_START="-1.3558529558679329" LOG_EFFECT_SIZE="-0.31784349467363127" ORDER="45" O_E="0.0" SE="1.2194637914704678" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="1.4870919387075283" WEIGHT="64.08800110505925"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-09-21 10:58:59 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="138" TOTAL_2="138" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42" O_E="0.0" SE="0.0" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="43" O_E="0.0" SE="0.0" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4321624553631698" CI_START="0.6067191234275194" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4430379746835442" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.5355678362273648" LOG_CI_START="-0.21701231613530247" LOG_EFFECT_SIZE="0.15927776004603114" METHOD="MH" MODIFIED="2009-09-21 10:59:30 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.4067523202871539" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="152" WEIGHT="99.99999999999999" Z="0.8296223923747471">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4321624553631698" CI_START="0.6067191234275194" EFFECT_SIZE="1.4430379746835442" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5355678362273648" LOG_CI_START="-0.21701231613530247" LOG_EFFECT_SIZE="0.15927776004603114" ORDER="71" O_E="0.0" SE="0.4420693068296663" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.19542527204086163" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-09-21 10:59:55 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="158" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.366084337164137" CI_END="1.210759985925801" CI_START="0.8954745465782508" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0412515303287655" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="261" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.08305805964266341" LOG_CI_START="-0.04794675424567663" LOG_EFFECT_SIZE="0.017555652698493424" METHOD="MH" MODIFIED="2009-09-21 11:00:42 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5740444656938072" P_Q="0.0" P_Z="0.5993743131407367" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1681" TOTAL_2="1657" WEIGHT="100.0" Z="0.5253004983995165">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8772218360608266" CI_END="1.736445659823464" CI_START="0.9027365472790041" DF="2" EFFECT_SIZE="1.2520195523579678" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="50" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="0.23966119708641614" LOG_CI_START="-0.04443897477710075" LOG_EFFECT_SIZE="0.09761111115465768" MODIFIED="2009-09-21 11:00:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6449316851268718" P_Z="0.17804191828818736" STUDIES="3" TAU2="0.0" TOTAL_1="296" TOTAL_2="290" WEIGHT="21.263341590576744" Z="1.3468084943360987">
<NAME>akathisia (Barnes)</NAME>
<DICH_DATA CI_END="9.114763925275941" CI_START="0.371441326155631" EFFECT_SIZE="1.84" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9597454247981604" LOG_CI_START="-0.4301097787790874" LOG_EFFECT_SIZE="0.2648178230095365" ORDER="46" O_E="0.0" SE="0.8164078264754906" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.6665217391304348" WEIGHT="0.8884549148202893"/>
<DICH_DATA CI_END="1.9697760622230749" CI_START="0.44802033438932226" EFFECT_SIZE="0.9394145677331518" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.29441685536519385" LOG_CI_START="-0.3487022741432338" LOG_EFFECT_SIZE="-0.027142709389019984" ORDER="47" O_E="0.0" SE="0.37777136016428414" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.14271120056037329" WEIGHT="4.149460677506423"/>
<DICH_DATA CI_END="1.9185546311197805" CI_START="0.9072881063073267" EFFECT_SIZE="1.3193490054249548" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="35" LOG_CI_END="0.28297417030840716" LOG_CI_START="-0.042254782277084145" LOG_EFFECT_SIZE="0.12035969401566152" ORDER="48" O_E="0.0" SE="0.19104109665799718" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.03649670061229022" WEIGHT="16.22542599825003"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.992472801291283E-31" CI_END="1.3019884730037057" CI_START="0.5999186191798769" DF="0" EFFECT_SIZE="0.883791336748952" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" I2="100.0" ID="CMP-001.22.02" LOG_CI_END="0.11460713927591817" LOG_CI_START="-0.22190765901337958" LOG_EFFECT_SIZE="-0.053650259868730704" MODIFIED="2009-09-21 11:00:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.5320034276880947" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="115" WEIGHT="15.155357125750706" Z="0.6249506864986567">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.3019884730037057" CI_START="0.5999186191798769" EFFECT_SIZE="0.883791336748952" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" LOG_CI_END="0.11460713927591817" LOG_CI_START="-0.22190765901337958" LOG_EFFECT_SIZE="-0.053650259868730704" ORDER="49" O_E="0.0" SE="0.1976704582902503" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.03907361008067758" WEIGHT="15.155357125750706"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03942670534916158" CI_END="1.1427914565144575" CI_START="0.49381432986894047" DF="1" EFFECT_SIZE="0.7512168776582681" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="43" I2="0.0" ID="CMP-001.22.03" LOG_CI_END="0.05796698494618255" LOG_CI_START="-0.30643631154319345" LOG_EFFECT_SIZE="-0.12423466329850542" MODIFIED="2009-09-21 11:00:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8426057924326487" P_Z="0.18141644530717055" STUDIES="2" TAU2="0.0" TOTAL_1="271" TOTAL_2="267" WEIGHT="12.924385841047553" Z="1.3364064927092654">
<NAME>hyperkinesia</NAME>
<DICH_DATA CI_END="1.6856984298129047" CI_START="0.3793046880352836" EFFECT_SIZE="0.7996207332490518" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.22677988228000176" LOG_CI_START="-0.42101178957964386" LOG_EFFECT_SIZE="-0.09711595364982104" ORDER="50" O_E="0.0" SE="0.3805160346708472" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.14479245264162538" WEIGHT="4.0898161759210465"/>
<DICH_DATA CI_END="1.2122363912048426" CI_START="0.43937470470601886" EFFECT_SIZE="0.7298123090353558" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.08358731734287918" LOG_CI_START="-0.35716494951567895" LOG_EFFECT_SIZE="-0.1367888160863999" ORDER="51" O_E="0.0" SE="0.25890006331162496" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.06702924278276343" WEIGHT="8.834569665126505"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5383720263751324" CI_END="1.9480667936056772" CI_START="0.6607299188968987" DF="1" EFFECT_SIZE="1.134524576439321" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="34" I2="34.99621789429563" ID="CMP-001.22.04" LOG_CI_END="0.2896038435061821" LOG_CI_START="-0.17997602720464162" LOG_EFFECT_SIZE="0.054813908150770266" MODIFIED="2009-09-21 11:00:27 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.21486074240793773" P_Z="0.647260009370991" STUDIES="2" TAU2="0.05425777846804982" TOTAL_1="271" TOTAL_2="267" WEIGHT="12.290239962416162" Z="0.45757193835744986">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="1.6391014287882564" CI_START="0.41713795162048095" EFFECT_SIZE="0.8268805309734514" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.21460582886036847" LOG_CI_START="-0.37972029581816047" LOG_EFFECT_SIZE="-0.08255723347889601" ORDER="52" O_E="0.0" SE="0.34911010759793243" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.12187786722703997" WEIGHT="4.8587535082302535"/>
<DICH_DATA CI_END="2.5093356147771884" CI_START="0.8298445947668438" EFFECT_SIZE="1.4430379746835442" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.39955875055263046" LOG_CI_START="-0.0810032304605683" LOG_EFFECT_SIZE="0.15927776004603114" ORDER="53" O_E="0.0" SE="0.2822844864673241" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.0796845313001209" WEIGHT="7.431486454185909"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.274695900078324" CI_END="4.36201708838141" CI_START="0.26526108368237217" DF="1" EFFECT_SIZE="1.0756734541230801" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="21.549916341728665" ID="CMP-001.22.05" LOG_CI_END="0.639687362612515" LOG_CI_START="-0.5763264604651646" LOG_EFFECT_SIZE="0.031680451073675196" MODIFIED="2009-09-21 11:00:31 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.25888768052268873" P_Z="0.9186576700635735" STUDIES="2" TAU2="0.35627965555597685" TOTAL_1="138" TOTAL_2="138" WEIGHT="2.415525011563369" Z="0.10212473236732317">
<NAME>rigor</NAME>
<DICH_DATA CI_END="91.34475988701922" CI_START="0.23320193927135308" EFFECT_SIZE="4.615384615384615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9606836385257036" LOG_CI_START="-0.6322678423720901" LOG_EFFECT_SIZE="0.6642078980768068" ORDER="54" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="2.319871794871795" WEIGHT="0.25526174173677874"/>
<DICH_DATA CI_END="2.129810330523225" CI_START="0.2735397157574191" EFFECT_SIZE="0.7632743362831859" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.32834092922518743" LOG_CI_START="-0.5629796087014034" LOG_EFFECT_SIZE="-0.11731933973810799" ORDER="55" O_E="0.0" SE="0.5235660960858998" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.2741214569706297" WEIGHT="2.1602632698265904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6705428758432243" CI_END="3.209938918592022" CI_START="0.6636200945079131" DF="2" EFFECT_SIZE="1.459513606829572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-001.22.06" LOG_CI_END="0.5064967683641175" LOG_CI_START="-0.17808047195181262" LOG_EFFECT_SIZE="0.16420814820615245" MODIFIED="2009-09-21 11:00:36 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7151440133277758" P_Z="0.3470815886972781" STUDIES="3" TAU2="0.0" TOTAL_1="296" TOTAL_2="290" WEIGHT="3.662094915283078" Z="0.9402651373672467">
<NAME>tremor</NAME>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="56" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="0.7897186225857191"/>
<DICH_DATA CI_END="6.569944649295559" CI_START="0.6305754730356189" EFFECT_SIZE="2.0353982300884956" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8175617107155239" LOG_CI_START="-0.2002629256471775" LOG_EFFECT_SIZE="0.3086493925341732" ORDER="57" O_E="0.0" SE="0.5978752297126576" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.35745479030396304" WEIGHT="1.6566417097430521"/>
<DICH_DATA CI_END="3.7779555651367973" CI_START="0.24497183557217694" EFFECT_SIZE="0.9620253164556962" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.57725684561086" LOG_CI_START="-0.6108838436301601" LOG_EFFECT_SIZE="-0.016813499009650065" ORDER="58" O_E="0.0" SE="0.6979197222514408" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.4870919387075283" WEIGHT="1.2157345829543065"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7466097365824744" CI_END="1.5699472733978657" CI_START="0.7233399563927623" DF="2" EFFECT_SIZE="1.065647968270267" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="78" I2="46.61840595587813" ID="CMP-001.22.07" LOG_CI_END="0.19588506689529686" LOG_CI_START="-0.14065754435731498" LOG_EFFECT_SIZE="0.027613761268990938" MODIFIED="2009-09-21 11:00:42 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.15361524365849133" P_Z="0.7477290630668618" STUDIES="3" TAU2="0.05426114906844892" TOTAL_1="296" TOTAL_2="290" WEIGHT="32.28905555336238" Z="0.3216352150086861">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="3.090777295202042" CI_START="0.676234356698204" EFFECT_SIZE="1.4457142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.49006771326475906" LOG_CI_START="-0.16990276828571202" LOG_EFFECT_SIZE="0.16008247248952348" ORDER="59" O_E="0.0" SE="0.3876699277693184" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="23" VAR="0.15028797289666854" WEIGHT="3.9402655019650505"/>
<DICH_DATA CI_END="1.1691807803183225" CI_START="0.48884112334421215" EFFECT_SIZE="0.7560050568900126" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="35" LOG_CI_END="0.06788166755582084" LOG_CI_START="-0.31083226657435226" LOG_EFFECT_SIZE="-0.12147529950926571" ORDER="60" O_E="0.0" SE="0.2224584395722718" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.049487757336930095" WEIGHT="11.966081043706803"/>
<DICH_DATA CI_END="1.823114132662282" CI_START="0.8652664380206382" EFFECT_SIZE="1.2559774964838255" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="36" LOG_CI_END="0.26081385770262905" LOG_CI_START="-0.06285014138506888" LOG_EFFECT_SIZE="0.09898185815878009" ORDER="61" O_E="0.0" SE="0.1901218352267486" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.036146312229986946" WEIGHT="16.38270900769053"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.43473560959096785" CI_END="0.12165735445258948" CI_START="-0.06382381638125968" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0289167690356649" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.23" MODIFIED="2010-11-22 18:37:28 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.9329770728442052" P_Q="0.7279822536854461" P_Z="0.5411187209722037" Q="0.1209724308002722" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="542" TOTAL_2="534" UNITS="" WEIGHT="200.0" Z="0.611122148996304">
<NAME>Adverse effects: 5b Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.29681460617494604" CI_END="0.550911258129709" CI_START="-0.7153645076523355" DF="1" EFFECT_SIZE="-0.08222662476131323" ESTIMABLE="YES" I2="0.0" ID="CMP-001.23.01" MODIFIED="2010-11-22 18:36:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5858863873339073" P_Z="0.7990755922627116" STUDIES="2" TAU2="0.0" TOTAL_1="271" TOTAL_2="267" WEIGHT="100.0" Z="0.25454364279479225">
<NAME>abnormal involuntary movement: AIMS (high = poor)</NAME>
<CONT_DATA CI_END="0.7073006128888917" CI_START="-1.3073006128888918" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.0" ORDER="62" SD_1="3.88" SD_2="3.88" SE="0.513938327864364" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" WEIGHT="39.50739576703145"/>
<CONT_DATA CI_END="0.8740426491390378" CI_START="-0.7540426491390377" EFFECT_SIZE="0.06" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.16" ORDER="63" SD_1="4.1" SD_2="3.17" SE="0.4153355141013316" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" WEIGHT="60.49260423296855"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.01694857261574963" CI_END="0.12510551185088395" CI_START="-0.06239807805824446" DF="1" EFFECT_SIZE="0.031353716896319744" ESTIMABLE="YES" I2="0.0" ID="CMP-001.23.02" MODIFIED="2010-11-22 18:37:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8964187345596554" P_Z="0.5121606213331449" STUDIES="2" TAU2="0.0" TOTAL_1="271" TOTAL_2="267" WEIGHT="100.0" Z="0.6554771130305697">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="0.5013430520389472" CI_START="-0.3813430520389473" EFFECT_SIZE="0.06" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.29" ORDER="64" SD_1="1.7" SD_2="1.7" SE="0.22517916427046872" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" WEIGHT="4.512389654399158"/>
<CONT_DATA CI_END="0.12594140606230125" CI_START="-0.06594140606230124" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="-0.07" MEAN_2="-0.1" ORDER="65" SD_1="0.41" SD_2="0.45" SE="0.048950596449258664" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" WEIGHT="95.48761034560084"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.1689795571738815" CI_END="10.920843609776242" CI_START="0.5013288571704012" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.339857697858099" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" I2="44.204053476519334" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="1.0382561879034735" LOG_CI_START="-0.2998772960867916" LOG_EFFECT_SIZE="0.369189445908341" METHOD="MH" MODIFIED="2010-11-22 18:37:37 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.12722341562211825" P_Q="0.0" P_Z="0.27947322502217375" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.3405019693030882" TOTALS="YES" TOTAL_1="342" TOTAL_2="336" WEIGHT="100.0" Z="1.0815034914079036">
<NAME>Adverse effects: 6. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.23141940682358" CI_START="0.06200705528221281" DF="0" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="1.182740376863771" LOG_CI_START="-1.207558892827411" LOG_EFFECT_SIZE="-0.012409257981819953" MODIFIED="2009-09-21 11:01:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9837639003756424" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="18.654930057804233" Z="0.020350337740240858">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="15.23141940682358" CI_START="0.06200705528221281" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.182740376863771" LOG_CI_START="-1.207558892827411" LOG_EFFECT_SIZE="-0.012409257981819953" ORDER="66" O_E="0.0" SE="1.404073623188812" STUDY_ID="STD-Sechter-2002" TOTAL_1="71" TOTAL_2="69" VAR="1.971422739334558" WEIGHT="18.654930057804233"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.008642987698255" CI_END="3.0250501911790586" CI_START="0.1582352263405629" DF="1" EFFECT_SIZE="0.6918594522681477" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.8568926571311901" ID="CMP-001.24.02" LOG_CI_END="0.4807325847971726" LOG_CI_START="-0.8006968273977021" LOG_EFFECT_SIZE="-0.15998212130026476" MODIFIED="2009-09-21 11:01:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.315228426210313" P_Z="0.6245658085053425" STUDIES="2" TAU2="0.014453185163258938" TOTAL_1="118" TOTAL_2="113" WEIGHT="45.71744702615611" Z="0.48938972827502475">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="2.4296001069621895" CI_START="0.09018095866464097" EFFECT_SIZE="0.46808510638297873" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.385534798029853" LOG_CI_START="-1.0448851522568756" LOG_EFFECT_SIZE="-0.32967517711351124" ORDER="67" O_E="0.0" SE="0.8402357594913742" STUDY_ID="STD-Peuskens-1999" TOTAL_1="47" TOTAL_2="44" VAR="0.7059961315280464" WEIGHT="30.189973678087956"/>
<DICH_DATA CI_END="70.39317592451235" CI_START="0.1208489932826308" EFFECT_SIZE="2.9166666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.847530559682231" LOG_CI_START="-0.9177569630769294" LOG_EFFECT_SIZE="0.4648867983026508" ORDER="68" O_E="0.0" SE="1.624343579262732" STUDY_ID="STD-Sechter-2002" TOTAL_1="71" TOTAL_2="69" VAR="2.6384920634920634" WEIGHT="15.527473348068156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0032993496960563038" CI_END="99.4215697448685" CI_START="1.7439236202405182" DF="1" EFFECT_SIZE="13.16752155264863" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="1.997480615835293" LOG_CI_START="0.24152745993457927" LOG_EFFECT_SIZE="1.119504037884936" MODIFIED="2009-09-21 11:01:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9541947604817921" P_Z="0.012449463348162014" STUDIES="2" TAU2="0.0" TOTAL_1="153" TOTAL_2="154" WEIGHT="35.62762291603965" Z="2.499141377921479">
<NAME>sexual dysfunction (men)</NAME>
<DICH_DATA CI_END="243.24233846921584" CI_START="0.8023482729189022" EFFECT_SIZE="13.970149253731343" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.386039169956037" LOG_CI_START="-0.0956370778814795" LOG_EFFECT_SIZE="1.1452010460372788" ORDER="69" O_E="0.0" SE="1.4577489124753058" STUDY_ID="STD-Peuskens-1999" TOTAL_1="66" TOTAL_2="71" VAR="2.1250318918229367" WEIGHT="17.82805370606713"/>
<DICH_DATA CI_END="216.86835826461828" CI_START="0.7100415128434394" EFFECT_SIZE="12.409090909090908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3361961917859206" LOG_CI_START="-0.1487162593488214" LOG_EFFECT_SIZE="1.0937399662185499" ORDER="70" O_E="0.0" SE="1.459649874311561" STUDY_ID="STD-Sechter-2002" TOTAL_1="87" TOTAL_2="83" VAR="2.1305777555777556" WEIGHT="17.799569209972518"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05459016225550796" CI_END="2.8746201443698487" CI_START="1.0656798415289797" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7502641914602701" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.45858046464191876" LOG_CI_START="0.027626750711831717" LOG_EFFECT_SIZE="0.24310360767687528" METHOD="MH" MODIFIED="2009-09-21 11:02:58 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.8152602984324181" P_Q="0.0" P_Z="0.02701817136179922" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="271" TOTAL_2="267" WEIGHT="100.0" Z="2.211255177328525">
<NAME>Adverse effects: 8a. Metabolic effects - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9137708760370433" CI_START="1.0038586147996496" DF="0" EFFECT_SIZE="1.710267229254571" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="18" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="0.4644553980911259" LOG_CI_START="0.00167255032277378" LOG_EFFECT_SIZE="0.23306397420694983" MODIFIED="2009-09-21 11:02:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04836684309255186" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="152" WEIGHT="86.71749962874856" Z="1.9741310540880088">
<NAME>weight gain of 7 % or more of total body weight</NAME>
<DICH_DATA CI_END="2.9137708760370433" CI_START="1.0038586147996496" EFFECT_SIZE="1.710267229254571" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="18" LOG_CI_END="0.4644553980911259" LOG_CI_START="0.00167255032277378" LOG_EFFECT_SIZE="0.23306397420694983" ORDER="73" O_E="0.0" SE="0.2718409355911723" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" VAR="0.07389749426308387" WEIGHT="86.71749962874856"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.941182551451686" CI_START="0.5216913133787674" DF="0" EFFECT_SIZE="2.0353982300884956" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.8998851796725493" LOG_CI_START="-0.28258639460420304" LOG_EFFECT_SIZE="0.3086493925341732" MODIFIED="2009-09-21 11:02:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3062219136621168" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="115" WEIGHT="13.28250037125144" Z="1.0231817937562724">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="7.941182551451686" CI_START="0.5216913133787674" EFFECT_SIZE="2.0353982300884956" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8998851796725493" LOG_CI_START="-0.28258639460420304" LOG_EFFECT_SIZE="0.3086493925341732" ORDER="74" O_E="0.0" SE="0.6945896560588583" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" VAR="0.48245479030396304" WEIGHT="13.28250037125144"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.4537719321162571" CI_END="1.6116863973251534" CI_START="0.36592684074728055" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.988806619036217" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2009-09-21 11:03:13 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.7970118195269869" P_Q="1.0" P_Z="0.0018620534365205292" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="289" UNITS="" WEIGHT="100.0" Z="3.1113955349611744">
<NAME>Adverse effects: 8b Metabolic effects - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.262442510385309" CI_START="-0.26244251038530897" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="0.1" ORDER="75" SD_1="2.8" SD_2="3.3" SE="0.8992218858546537" STUDY_ID="STD-Hwang-2003" TOTAL_1="25" TOTAL_2="22" WEIGHT="12.490463210455559"/>
<CONT_DATA CI_END="1.8748976972772073" CI_START="0.12510230272279255" EFFECT_SIZE="0.9999999999999999" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="0.4" ORDER="76" SD_1="3.37" SD_2="3.37" SE="0.44638457858322333" STUDY_ID="STD-Peuskens-1999" TOTAL_1="113" TOTAL_2="115" WEIGHT="50.686688281514165"/>
<CONT_DATA CI_END="1.8264682985907412" CI_START="-0.22646829859074114" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="1.3" ORDER="77" SD_1="5.0" SD_2="4.2" SE="0.5237179390475499" STUDY_ID="STD-Sechter-2002" TOTAL_1="158" TOTAL_2="152" WEIGHT="36.82284850803027"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-11-22 20:41:08 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>RISPERIDONE versus ARIPIPRAZOLE - all data short term</NAME>
<DICH_OUTCOME CHI2="1.6974822155050011" CI_END="1.235109144466341" CI_START="0.6241007152199726" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8779706717403332" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="152" I2="41.0892207961955" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.09170533714632031" LOG_CI_START="-0.20474531971697094" LOG_EFFECT_SIZE="-0.05651999128532528" METHOD="MH" MODIFIED="2009-09-21 10:25:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19261766429162663" P_Q="0.0" P_Z="0.4548484642363553" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03205288835426286" TOTALS="YES" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.7473563964936021">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.160824106665304" CI_START="0.3758640546437574" EFFECT_SIZE="0.6605392156862745" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="0.06476641845363681" LOG_CI_START="-0.4249692055878817" LOG_EFFECT_SIZE="-0.18010139356712243" ORDER="84" O_E="0.0" SE="0.2876731297924245" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.08275582960456909" WEIGHT="26.412236092427012"/>
<DICH_DATA CI_END="1.1729459589097286" CI_START="0.8061095700428371" EFFECT_SIZE="0.9723800505050505" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="128" LOG_CI_END="0.06927800334489588" LOG_CI_START="-0.09360592292095081" LOG_EFFECT_SIZE="-0.012163959788027482" ORDER="85" O_E="0.0" SE="0.09567882457699702" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.009154437472435769" WEIGHT="73.58776390757299"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6974822155050011" CI_END="1.235109144466341" CI_START="0.6241007152199726" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8779706717403332" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="152" I2="41.0892207961955" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.09170533714632031" LOG_CI_START="-0.20474531971697094" LOG_EFFECT_SIZE="-0.05651999128532528" METHOD="MH" MODIFIED="2009-09-21 10:26:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19261766429162663" P_Q="0.0" P_Z="0.4548484642363553" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03205288835426286" TOTALS="YES" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.7473563964936021">
<NAME>Global state: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.160824106665304" CI_START="0.3758640546437574" EFFECT_SIZE="0.6605392156862745" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="0.06476641845363681" LOG_CI_START="-0.4249692055878817" LOG_EFFECT_SIZE="-0.18010139356712243" MODIFIED="2009-09-21 10:26:35 +0100" MODIFIED_BY="[Empty name]" ORDER="922" O_E="0.0" SE="0.2876731297924245" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.08275582960456909" WEIGHT="26.412236092427012"/>
<DICH_DATA CI_END="1.1729459589097286" CI_START="0.8061095700428371" EFFECT_SIZE="0.9723800505050505" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="128" LOG_CI_END="0.06927800334489588" LOG_CI_START="-0.09360592292095081" LOG_EFFECT_SIZE="-0.012163959788027482" MODIFIED="2009-09-21 10:26:35 +0100" MODIFIED_BY="[Empty name]" ORDER="921" O_E="0.0" SE="0.09567882457699702" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.009154437472435769" WEIGHT="73.58776390757299"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8455203904999375" CI_END="1.2900406404737346" CI_START="0.7788963447021858" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0024010870815427" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.11060339220271159" LOG_CI_START="-0.1085203342647236" LOG_EFFECT_SIZE="0.0010415289689940177" METHOD="MH" MODIFIED="2009-09-21 10:27:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8700805960378476" P_Q="0.0" P_Z="0.9851346557865838" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="399" TOTAL_2="753" WEIGHT="300.0" Z="0.01863202402581209">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.37688202680019905" CI_END="1.4137665488159872" CI_START="0.7947697514487402" DF="1" EFFECT_SIZE="1.060008909683794" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="85" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.1503777015886142" LOG_CI_START="-0.099758670285026" LOG_EFFECT_SIZE="0.02530951565179413" MODIFIED="2009-09-21 10:26:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5392769702799086" P_Z="0.691640654440947" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.3966295566862085">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="2.7355925825789025" CI_START="0.6274766050778275" EFFECT_SIZE="1.3101604278074865" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.43705141749503973" LOG_CI_START="-0.20240246183897273" LOG_EFFECT_SIZE="0.11732447782803347" ORDER="78" O_E="0.0" SE="0.3756183740685517" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.14108916293790244" WEIGHT="15.30154344678855"/>
<DICH_DATA CI_END="1.3950280469264869" CI_START="0.7460869079423822" EFFECT_SIZE="1.02020202020202" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="74" LOG_CI_END="0.14458293915295795" LOG_CI_START="-0.12721058078277273" LOG_EFFECT_SIZE="0.00868617918509262" ORDER="79" O_E="0.0" SE="0.1596528590098702" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.025489035390025488" WEIGHT="84.69845655321144"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1960425614517221" CI_END="1.6082944656081395" CI_START="0.39121674360375974" DF="1" EFFECT_SIZE="0.7932160636240073" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.2063655674725565" LOG_CI_START="-0.40758256620777766" LOG_EFFECT_SIZE="-0.10060849936761063" MODIFIED="2009-09-21 10:26:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6579343287446917" P_Z="0.5206369868831284" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="251" WEIGHT="99.99999999999999" Z="0.6423638235271791">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="2.799837526762036" CI_START="0.11869200834830812" EFFECT_SIZE="0.5764705882352941" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.4471328301715112" LOG_CI_START="-0.9255785215430695" LOG_EFFECT_SIZE="-0.23922284568577912" ORDER="80" O_E="0.0" SE="0.8063374430279245" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.6501800720288115" WEIGHT="20.003450542188173"/>
<DICH_DATA CI_END="1.8935091281609668" CI_START="0.3897963056229852" EFFECT_SIZE="0.8591174906964381" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="0.27726740309317055" LOG_CI_START="-0.40916228131679355" LOG_EFFECT_SIZE="-0.06594743911181151" ORDER="81" O_E="0.0" SE="0.4032121945041511" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.16258007379685335" WEIGHT="79.99654945781181"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5905514684648572" CI_END="1.9269988317811537" CI_START="0.4067485879797971" DF="1" EFFECT_SIZE="0.8853270886320507" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.28488145136995613" LOG_CI_START="-0.39067394603375105" LOG_EFFECT_SIZE="-0.052896247331897454" MODIFIED="2009-09-21 10:26:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.44220609758495777" P_Z="0.7588952331154686" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.3069318669831801">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="5.770265129435703" CI_START="0.014147123438885661" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.761195768373336" LOG_CI_START="-1.8493318570738875" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="82" O_E="0.0" SE="1.5334368495078534" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="2.3514285714285714" WEIGHT="6.69676947739368"/>
<DICH_DATA CI_END="2.1480618033766135" CI_START="0.42920790132354314" EFFECT_SIZE="0.960190136660725" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.33204677259515947" LOG_CI_START="-0.3673322916696724" LOG_EFFECT_SIZE="-0.017642759537256462" ORDER="83" O_E="0.0" SE="0.4108187243313645" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.16877202426124965" WEIGHT="93.30323052260633"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.9551333231470176" CI_START="-5.955133323147018" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2009-09-21 10:28:07 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.50931750465512" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="243" UNITS="" WEIGHT="100.0" Z="0.6599007849070074">
<NAME>Mental state: 1a. General - average endpoint score (PANSS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.162986088039367" CI_START="-9.162986088039368" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-21.1" MEAN_2="-19.6" MODIFIED="2009-09-21 10:27:57 +0100" MODIFIED_BY="[Empty name]" ORDER="923" SD_1="17.1" SD_2="18.1" SE="3.9097586223440954" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="33.800672109006726"/>
<CONT_DATA CI_END="3.975627740929717" CI_START="-6.975627740929717" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-15.7" MEAN_2="-14.2" MODIFIED="2009-09-21 10:27:57 +0100" MODIFIED_BY="[Empty name]" ORDER="924" SD_1="22.31" SD_2="22.31" SE="2.793738958532284" STUDY_ID="STD-Potkin-2003" TOTAL_1="95" TOTAL_2="194" WEIGHT="66.19932789099327"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8148482499855936" CI_END="0.2594996047866247" CI_START="-2.7430047545064333" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2417525748599043" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2009-09-21 10:28:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.36669079443992925" P_Q="1.0" P_Z="0.10498042380049814" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="243" UNITS="" WEIGHT="100.0" Z="1.6211735492755974">
<NAME>Mental state: 2. Positive symptoms average endpoint score (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4446805599931718" CI_START="-5.044680559993171" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="-8.1" MEAN_2="-5.8" MODIFIED="2009-09-21 10:28:56 +0100" MODIFIED_BY="[Empty name]" ORDER="925" SD_1="5.8" SD_2="6.9" SE="1.400372956668011" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="29.917389063569814"/>
<CONT_DATA CI_END="1.0032816906744675" CI_START="-2.5832816906744673" EFFECT_SIZE="-0.79" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-4.41" MODIFIED="2009-09-21 10:28:56 +0100" MODIFIED_BY="[Empty name]" ORDER="926" SD_1="7.3" SD_2="7.32" SE="0.914956450638708" STUDY_ID="STD-Potkin-2003" TOTAL_1="95" TOTAL_2="194" WEIGHT="70.08261093643019"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.11655804286785523" CI_END="1.7774677471479081" CI_START="-0.8704773736924784" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.45349518672771494" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2009-09-22 10:37:27 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7327980249442076" P_Q="1.0" P_Z="0.5020046868893309" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="243" UNITS="" WEIGHT="100.0" Z="0.6713388628435744">
<NAME>Mental state: 3. Negative symptoms - average endpoint score - (PANSS negative, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1895526600478163" CI_START="-1.5895526600478167" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-4.8" MODIFIED="2009-09-22 10:37:27 +0100" MODIFIED_BY="[Empty name]" ORDER="895" SD_1="5.7" SD_2="5.1" SE="1.2191819231864989" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="30.699037345543022"/>
<CONT_DATA CI_END="1.8904109260970223" CI_START="-1.2904109260970227" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-3.4" MODIFIED="2009-09-22 10:37:27 +0100" MODIFIED_BY="[Empty name]" ORDER="896" SD_1="6.48" SD_2="6.48" SE="0.8114490565347021" STUDY_ID="STD-Potkin-2003" TOTAL_1="95" TOTAL_2="194" WEIGHT="69.30096265445698"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.534453881264957" CI_END="1.0879818530027456" CI_START="0.9522846393988718" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.017874455205177" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="224" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.03662165160618952" LOG_CI_START="-0.021233220897338572" LOG_EFFECT_SIZE="0.007694215354425487" METHOD="MH" MODIFIED="2009-09-21 10:30:01 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4647404305337731" P_Q="0.0" P_Z="0.602145464034213" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.5213177155666326">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1722043635773314" CI_START="0.7684061057843267" EFFECT_SIZE="0.9490674318507891" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="41" LOG_CI_END="0.06900333372707856" LOG_CI_START="-0.11440919287605786" LOG_EFFECT_SIZE="-0.022702929574489633" ORDER="94" O_E="0.0" SE="0.10773742603333156" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.011607352968287587" WEIGHT="9.949972825221282"/>
<DICH_DATA CI_END="1.1003646666162261" CI_START="0.9562450244709848" EFFECT_SIZE="1.0257768946293537" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="183" LOG_CI_END="0.041536636479580204" LOG_CI_START="-0.019430811551180868" LOG_EFFECT_SIZE="0.011052912464199689" ORDER="95" O_E="0.0" SE="0.03581258076700408" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.0012825409411931906" WEIGHT="90.05002717477872"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="272.4464422120117" CI_START="0.7411515392183659" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="14.209999999999999" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="2.4352811409691433" LOG_CI_START="-0.1300929851142036" LOG_EFFECT_SIZE="1.1525940779274697" METHOD="MH" MODIFIED="2009-07-29 15:52:16 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.07820793148790327" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="202" WEIGHT="100.0" Z="1.7611800622476528">
<NAME>Adverse effects: 2a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="272.4464422120117" CI_START="0.7411515392183659" EFFECT_SIZE="14.21" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.4352811409691433" LOG_CI_START="-0.1300929851142036" LOG_EFFECT_SIZE="1.1525940779274697" ORDER="96" O_E="0.0" SE="1.5069134604680858" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="2.2707881773399015" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.05591118947867314" CI_END="12.186712126050029" CI_START="2.194870555064173" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="7.190791340557101" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2009-07-29 15:52:24 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8130792589972158" P_Q="1.0" P_Z="0.004786824347839577" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="250" UNITS="" WEIGHT="100.0" Z="2.8210399349724367">
<NAME>Adverse effects: 2b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.806695340351745" CI_START="-6.8066953403517445" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="-1.0" ORDER="97" SD_1="34.0" SD_2="39.0" SE="8.064788672155682" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="9.989618933189057"/>
<CONT_DATA CI_END="12.255859210311565" CI_START="1.724140789688434" EFFECT_SIZE="6.989999999999999" ESTIMABLE="YES" MEAN_1="6.31" MEAN_2="-0.68" ORDER="98" SD_1="22.2" SD_2="21.22" SE="2.6867122313715917" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="201" WEIGHT="90.01038106681095"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="26.306868644372305" CI_END="2.054249525910772" CI_START="0.9867073400712724" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4237075140470707" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="152" I2="73.3909797679494" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.3126531954171793" LOG_CI_START="-0.005811641088659298" LOG_EFFECT_SIZE="0.15342077716426" METHOD="MH" MODIFIED="2009-09-21 10:31:03 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="4.4386720075861863E-4" P_Q="0.0" P_Z="0.05896831266559055" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4424007214619136" TOTALS="SUB" TOTAL_1="597" TOTAL_2="1157" WEIGHT="600.0" Z="1.888429510908228">
<NAME>Adverse effects: 3a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4520415538575353" CI_END="11.446508762188234" CI_START="0.21208730371899265" DF="1" EFFECT_SIZE="1.5580947276620656" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="41" I2="71.03163492100681" ID="CMP-002.10.01" LOG_CI_END="1.058673045058352" LOG_CI_START="-0.6734853290780644" LOG_EFFECT_SIZE="0.19259385799014372" MODIFIED="2009-09-21 10:30:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06317380322893584" P_Z="0.6629485716372265" STUDIES="2" TAU2="1.571215678385594" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.4358458567537142">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="49.35051457820441" CI_START="0.6733837366046713" EFFECT_SIZE="5.764705882352941" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6932916854212496" LOG_CI_START="-0.171737376792808" LOG_EFFECT_SIZE="0.760777154314221" ORDER="100" O_E="0.0" SE="1.0955273031872879" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="1.2001800720288116" WEIGHT="37.35526768440415"/>
<DICH_DATA CI_END="1.2491184953502614" CI_START="0.40828629252574783" EFFECT_SIZE="0.7141414141414142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="40" LOG_CI_END="0.09660363888314588" LOG_CI_START="-0.3890352004844469" LOG_EFFECT_SIZE="-0.14621578080065048" ORDER="101" O_E="0.0" SE="0.2852666581955493" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.08137706627805637" WEIGHT="62.64473231559585"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.131759816746566" CI_START="2.413419250524197" DF="0" EFFECT_SIZE="7.14141414141414" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="1.3249356658586267" LOG_CI_START="0.382632772540072" LOG_EFFECT_SIZE="0.8537842191993494" MODIFIED="2009-09-21 10:30:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.827580016168198E-4" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="202" WEIGHT="100.0" Z="3.55169517586034">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="21.131759816746566" CI_START="2.413419250524197" EFFECT_SIZE="7.141414141414141" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.3249356658586267" LOG_CI_START="0.382632772540072" LOG_EFFECT_SIZE="0.8537842191993494" ORDER="102" O_E="0.0" SE="0.5535133840098687" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.30637706627805633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5398342394253421" CI_END="2.0610387784561586" CI_START="0.6796435345822108" DF="1" EFFECT_SIZE="1.1835420061412885" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="69" I2="35.05794491404512" ID="CMP-002.10.03" LOG_CI_END="0.314086163109194" LOG_CI_START="-0.16771881016898005" LOG_EFFECT_SIZE="0.07318367647010696" MODIFIED="2009-09-21 10:30:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2146429372553288" P_Z="0.5515649502430672" STUDIES="2" TAU2="0.07420731879031607" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.5954167270698816">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="5.038010594719057" CI_START="0.7329135023801496" EFFECT_SIZE="1.9215686274509804" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.7022590764656246" LOG_CI_START="-0.13494727727650754" LOG_EFFECT_SIZE="0.2836558995945585" ORDER="103" O_E="0.0" SE="0.49177915642641684" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.24184673869547815" WEIGHT="25.34290473082436"/>
<DICH_DATA CI_END="1.4340096684242867" CI_START="0.7029469630837486" EFFECT_SIZE="1.0040083373416706" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="63" LOG_CI_END="0.15655207945532473" LOG_CI_START="-0.15307744099579523" LOG_EFFECT_SIZE="0.0017373192297648" ORDER="104" O_E="0.0" SE="0.18187791300383302" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.03307957523862985" WEIGHT="74.65709526917564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3458879890175766" CI_START="0.0078073254975746745" DF="0" EFFECT_SIZE="0.1353333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-002.10.04" LOG_CI_END="0.37030727166999455" LOG_CI_START="-2.1074977139549316" LOG_EFFECT_SIZE="-0.8685952211424683" MODIFIED="2009-09-21 10:30:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.16940075914850453" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="202" WEIGHT="100.0" Z="1.3741318307610693">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="2.3458879890175766" CI_START="0.0078073254975746745" EFFECT_SIZE="0.13533333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.37030727166999455" LOG_CI_START="-2.1074977139549316" LOG_EFFECT_SIZE="-0.8685952211424683" ORDER="105" O_E="0.0" SE="1.455474913888573" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="2.118407224958949" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.903841511419518" CI_START="0.051037906915599396" DF="0" EFFECT_SIZE="0.21477937267410951" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="19" I2="0.0" ID="CMP-002.10.05" LOG_CI_END="-0.043907716372343836" LOG_CI_START="-1.2921071445072039" LOG_EFFECT_SIZE="-0.668007430439774" MODIFIED="2009-09-21 10:30:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.0359179846237295" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="202" WEIGHT="100.0" Z="2.0978546785965104">
<NAME>tremor</NAME>
<DICH_DATA CI_END="0.903841511419518" CI_START="0.051037906915599396" EFFECT_SIZE="0.21477937267410951" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="19" LOG_CI_END="-0.043907716372343836" LOG_CI_START="-1.2921071445072039" LOG_EFFECT_SIZE="-0.668007430439774" ORDER="106" O_E="0.0" SE="0.7331985227732346" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.5375800737968534" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.172550594007753" CI_START="0.8910854420844533" DF="0" EFFECT_SIZE="1.6813725490196079" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-002.10.06" LOG_CI_END="0.5014085566999746" LOG_CI_START="-0.05008065146623128" LOG_EFFECT_SIZE="0.22566395261687172" MODIFIED="2009-09-21 10:31:03 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.10871495207192543" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="49" WEIGHT="100.0" Z="1.6039959193715538">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="3.172550594007753" CI_START="0.8910854420844533" EFFECT_SIZE="1.6813725490196079" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.5014085566999746" LOG_CI_START="-0.05008065146623128" LOG_EFFECT_SIZE="0.22566395261687172" ORDER="107" O_E="0.0" SE="0.32394749079243734" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.10494197679071629" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.727138688132905" CI_END="0.5037559307316044" CI_START="-0.18892123975879593" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.15741734548640424" ESTIMABLE="YES" I2="60.713871966665046" I2_Q="21.7134774643367" ID="CMP-002.11" MODIFIED="2010-11-22 20:41:08 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.02607449612038748" P_Q="0.2787726619225095" P_Z="0.3730149257053922" Q="2.5547181497158764" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1359424740237984" TOTALS="SUB" TOTAL_1="399" TOTAL_2="750" UNITS="" WEIGHT="300.0" Z="0.8908401802150258">
<NAME>Adverse effects: 3b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.089700816873509" CI_END="1.2426504800463678" CI_START="-0.7492881352592144" DF="1" EFFECT_SIZE="0.24668117239357673" ESTIMABLE="YES" I2="67.63440671864446" ID="CMP-002.11.01" MODIFIED="2010-11-22 20:40:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07878955746547622" P_Z="0.6273622201269902" STUDIES="2" TAU2="0.3518341837503883" TOTAL_1="133" TOTAL_2="250" WEIGHT="100.0" Z="0.485442884474987">
<NAME>abnormal involuntary movement: AIMS (high = poor)</NAME>
<CONT_DATA CI_END="1.7036072112342153" CI_START="-0.10360721123421535" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-0.4" ORDER="108" SD_1="1.7" SD_2="2.5" SE="0.461032558945855" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="45.75305611701733"/>
<CONT_DATA CI_END="0.4706769922882893" CI_START="-0.9106769922882892" EFFECT_SIZE="-0.21999999999999997" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.38" MODIFIED="2008-12-12 13:33:42 +0000" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="2.87" SD_2="2.87" SE="0.35239269585373056" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="201" WEIGHT="54.24694388298267"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9774558564556692" CI_END="0.49119042082985287" CI_START="-0.2704878328014688" DF="1" EFFECT_SIZE="0.11035129401419201" ESTIMABLE="YES" I2="49.42997100363246" ID="CMP-002.11.02" MODIFIED="2010-11-22 20:41:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15965900887739048" P_Z="0.5700921374723069" STUDIES="2" TAU2="0.04359723442520381" TOTAL_1="133" TOTAL_2="250" WEIGHT="100.0" Z="0.5679158119168147">
<NAME>akathisia: Barnes Akathisia Scale (high = poor)</NAME>
<CONT_DATA CI_END="0.9475818855608686" CI_START="-0.1475818855608686" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.1" ORDER="110" SD_1="1.4" SD_2="1.0" SE="0.279383646781331" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="31.036022384331428"/>
<CONT_DATA CI_END="0.18696244368220513" CI_START="-0.2269624436822051" EFFECT_SIZE="-0.01999999999999999" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.16" ORDER="111" SD_1="0.86" SD_2="0.86" SE="0.10559502384467187" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="201" WEIGHT="68.96397761566857"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.105263865087851" CI_END="2.2158951700453358" CI_START="-0.820184962588022" DF="1" EFFECT_SIZE="0.6978551037286569" ESTIMABLE="YES" I2="80.41237384734487" ID="CMP-002.11.03" MODIFIED="2010-11-22 20:41:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.023853386623795325" P_Z="0.36758245611442353" STUDIES="2" TAU2="0.9659536408412305" TOTAL_1="133" TOTAL_2="250" WEIGHT="100.0" Z="0.9010110471289103">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="2.5322349908117605" CI_START="0.46776500918823927" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="-0.2" ORDER="112" SD_1="2.4" SD_2="2.3" SE="0.5266601830206568" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="48.24871636959076"/>
<CONT_DATA CI_END="0.8115413353282492" CI_START="-0.9115413353282493" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="-0.13" ORDER="113" SD_1="3.58" SD_2="3.58" SE="0.4395699829813085" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="201" WEIGHT="51.75128363040923"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.349532224727756" CI_END="41.1491029301958" CI_START="9.969851711415403" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="20.25464031455067" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="10" I2="88.02328114815312" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="1.614360371827451" LOG_CI_START="0.9986886987938064" LOG_EFFECT_SIZE="1.3065245353106287" METHOD="MH" MODIFIED="2009-09-21 10:31:52 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0038578754522783365" P_Q="0.0" P_Z="8.906244064462144E-17" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="8.725817667338234" TOTALS="SUB" TOTAL_1="127" TOTAL_2="265" WEIGHT="200.0" Z="8.318528028125879">
<NAME>Adverse effects: 4a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="54.4648791630528" CI_START="12.635858215118438" DF="0" EFFECT_SIZE="26.23376623376624" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="7" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="1.736116544434605" LOG_CI_START="1.101604744113679" LOG_EFFECT_SIZE="1.418860644274142" MODIFIED="2009-09-21 10:31:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.8590183291905387E-18" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="202" WEIGHT="100.0" Z="8.765528900966295">
<NAME>abnormally high prolactin value</NAME>
<DICH_DATA CI_END="54.46487916305278" CI_START="12.635858215118432" EFFECT_SIZE="26.233766233766232" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="7" LOG_CI_END="1.736116544434605" LOG_CI_START="1.1016047441136787" LOG_EFFECT_SIZE="1.4188606442741418" ORDER="115" O_E="0.0" SE="0.37271537239257907" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.13891674881773888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.907391899860082" CI_START="0.01682565923276927" DF="0" EFFECT_SIZE="0.31527093596059114" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.7713957831653793" LOG_CI_START="-1.7740279110240307" LOG_EFFECT_SIZE="-0.5013160639293257" MODIFIED="2009-09-21 10:31:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.44010145779343623" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="63" WEIGHT="100.0" Z="0.7720219092922009">
<NAME>dysmenorrhea</NAME>
<DICH_DATA CI_END="5.907391899860082" CI_START="0.01682565923276927" EFFECT_SIZE="0.31527093596059114" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.7713957831653793" LOG_CI_START="-1.7740279110240307" LOG_EFFECT_SIZE="-0.5013160639293257" ORDER="116" O_E="0.0" SE="1.4951944780173567" STUDY_ID="STD-Potkin-2003" TOTAL_1="28" TOTAL_2="63" VAR="2.235606527093596" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.40006385092943925" CI_END="60.05539953830677" CI_START="49.35923281173196" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="54.707316175019365" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2009-09-21 10:32:00 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5270567036498739" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="250" UNITS="" WEIGHT="99.99999999999999" Z="20.049120799039642">
<NAME>Adverse effects: 4b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="94.90741842290257" CI_START="33.892581577097445" EFFECT_SIZE="64.4" ESTIMABLE="YES" MEAN_1="55.4" MEAN_2="-9.0" ORDER="117" SD_1="42.3" SD_2="96.4" SE="15.56529541539599" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="3.0731617501936968"/>
<CONT_DATA CI_END="59.83220492644999" CI_START="48.96779507355001" EFFECT_SIZE="54.4" ESTIMABLE="YES" MEAN_1="47.9" MEAN_2="-6.5" ORDER="118" SD_1="24.4" SD_2="18.31" SE="2.771584054247187" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="201" WEIGHT="96.9268382498063"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="39.68927241354122" CI_START="4.91072758645878" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="22.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" MODIFIED="2009-09-21 10:32:46 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.011955418806770748" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="2.5134574820512863">
<NAME>Adverse effects: 5a. Metabolic effects - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="39.68927241354122" CI_START="4.91072758645878" EFFECT_SIZE="22.3" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="-3.1" ORDER="99" SD_1="27.9" SD_2="52.3" SE="8.872240791517386" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.09749606231576" CI_START="-19.69749606231576" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.15" MODIFIED="2009-09-21 10:33:05 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.30143552495200954" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="49" UNITS="" WEIGHT="100.00000000000001" Z="1.0333598886541824">
<NAME>Adverse effects: 5b. Metabolic effects - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.09749606231576" CI_START="-19.69749606231576" EFFECT_SIZE="-6.8" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="4.1" ORDER="114" SD_1="27.6" SD_2="32.0" SE="6.580476051626235" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.3158686986995647" CI_END="3.0700606372324946" CI_START="0.5492132342935673" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2985060385118847" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" I2="24.004575761375637" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.48714695337796854" LOG_CI_START="-0.26025900619235026" LOG_EFFECT_SIZE="0.11344397359280912" METHOD="MH" MODIFIED="2009-09-21 10:34:01 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.2513349709369106" P_Q="0.0" P_Z="0.5518562999735747" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12974183661493377" TOTALS="YES" TOTAL_1="133" TOTAL_2="251" WEIGHT="100.0" Z="0.5949808123896817">
<NAME>Adverse effects: 5c. Metabolic effects - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.859529529938705" CI_START="0.5590996983296093" EFFECT_SIZE="2.8823529411764706" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.1720050593716607" LOG_CI_START="-0.2525107420711811" LOG_EFFECT_SIZE="0.45974715865023974" ORDER="119" O_E="0.0" SE="0.836767633234467" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" VAR="0.7001800720288115" WEIGHT="23.224752123744953"/>
<DICH_DATA CI_END="2.019104280517821" CI_START="0.5154821234678159" EFFECT_SIZE="1.02020202020202" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.30515874949536537" LOG_CI_START="-0.2877863911251802" LOG_EFFECT_SIZE="0.00868617918509262" ORDER="120" O_E="0.0" SE="0.34829891072629166" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="202" VAR="0.12131213121312129" WEIGHT="76.77524787625505"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.019667431357376565" CI_END="1.2388410267205887" CI_START="-0.15000097098669296" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5444200278669479" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.17" MODIFIED="2009-09-21 10:34:20 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.8884698873338559" P_Q="1.0" P_Z="0.12439258395890884" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="250" UNITS="" WEIGHT="100.0" Z="1.536594729771997">
<NAME>Adverse effects: 5d. Metabolic effects - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6419177383325336" CI_START="-0.44191773833253356" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="0.9" ORDER="121" SD_1="2.5" SD_2="2.2" SE="0.5316004511057589" STUDY_ID="STD-Chan-2007" TOTAL_1="34" TOTAL_2="49" WEIGHT="44.420027866948"/>
<CONT_DATA CI_END="1.4314588702098219" CI_START="-0.4314588702098219" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.0" ORDER="122" SD_1="3.9" SD_2="3.81" SE="0.47524285015288575" STUDY_ID="STD-Potkin-2003" TOTAL_1="99" TOTAL_2="201" WEIGHT="55.579972133052"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-11-22 20:42:12 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>RISPERIDONE versus CLOZAPINE</NAME>
<DICH_OUTCOME CHI2="1.9544953073698696" CI_END="1.1620636784667" CI_START="0.979643975371602" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0669623618516564" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="184" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.06522992706375132" LOG_CI_START="-0.008931728005706775" LOG_EFFECT_SIZE="0.028149099529022253" METHOD="MH" MODIFIED="2009-09-21 09:50:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8554050130991868" P_Q="0.0" P_Z="0.13678681386300937" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="279" WEIGHT="100.0" Z="1.4878638083911417">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1697181085410069" CI_START="0.9719953441605614" EFFECT_SIZE="1.0662835249042146" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="116" LOG_CI_END="0.06808121332267693" LOG_CI_START="-0.012335815331152864" LOG_EFFECT_SIZE="0.027872698995762026" ORDER="145" O_E="0.0" SE="0.04723736070197147" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.0022313682460881586" WEIGHT="85.04774096513516"/>
<DICH_DATA CI_END="1.6890171601512383" CI_START="0.5157503024025581" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.22763406195770663" LOG_CI_START="-0.28756050871259303" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="146" O_E="0.0" SE="0.3026278410659888" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.09158361018826136" WEIGHT="2.0721265322586904"/>
<DICH_DATA CI_END="1.9816804798978511" CI_START="0.7814791491454108" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.2970336314793739" LOG_CI_START="-0.10708260501766043" LOG_EFFECT_SIZE="0.09497551323085675" ORDER="147" O_E="0.0" SE="0.2373798777259908" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.05634920634920634" WEIGHT="3.367799493307443"/>
<DICH_DATA CI_END="2.3231838258692092" CI_START="0.6725683876588618" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.3660835754489753" LOG_CI_START="-0.17226354943286246" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="148" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.09999999999999999" WEIGHT="1.8977282859113367"/>
<DICH_DATA CI_END="1.4463938386502206" CI_START="0.7577659799271736" EFFECT_SIZE="1.0469135802469136" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" LOG_CI_END="0.1602865631272024" LOG_CI_START="-0.12046489637107426" LOG_EFFECT_SIZE="0.01991083337806409" ORDER="149" O_E="0.0" SE="0.1649147970514257" STUDY_ID="STD-McGurk-2005" TOTAL_1="54" TOTAL_2="53" VAR="0.027196890286512922" WEIGHT="6.977739976590007"/>
<DICH_DATA CI_END="1.7814352539781018" CI_START="0.20963814951427226" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2507700426000194" LOG_CI_START="-0.6785296824901814" LOG_EFFECT_SIZE="-0.21387981994508098" ORDER="150" O_E="0.0" SE="0.5458752586258128" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.297979797979798" WEIGHT="0.6368647467973637"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2811070524175291" CI_END="1.2969904160189027" CI_START="0.878060309523589" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0671625022172988" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.11293676692025317" LOG_CI_START="-0.056475653577064744" LOG_EFFECT_SIZE="0.02823055667159421" METHOD="MH" MODIFIED="2009-09-21 09:50:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5959765952572835" P_Q="0.0" P_Z="0.513621435346012" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="158" WEIGHT="100.0" Z="0.6532091823895241">
<NAME>Global state: 1b. No clinically important change - short term (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2880175474568611" CI_START="0.8539679828306013" EFFECT_SIZE="1.0487734487734488" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="77" LOG_CI_END="0.10992177972548182" LOG_CI_START="-0.06855841167710185" LOG_EFFECT_SIZE="0.02068168402418996" MODIFIED="2009-09-21 09:50:40 +0100" MODIFIED_BY="[Empty name]" ORDER="907" O_E="0.0" SE="0.10484014792107384" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.010991456616112644" WEIGHT="90.09702462584222"/>
<DICH_DATA CI_END="2.3231838258692092" CI_START="0.6725683876588618" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.3660835754489753" LOG_CI_START="-0.17226354943286246" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-09-21 09:50:40 +0100" MODIFIED_BY="[Empty name]" ORDER="908" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.09999999999999999" WEIGHT="9.902975374157773"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.10648605386317" CI_END="1.3894108775856404" CI_START="0.9126919530416839" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1261012953731109" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="156" I2="39.58887703315703" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.14283069460809883" LOG_CI_START="-0.03967577851006597" LOG_EFFECT_SIZE="0.05157745804901646" METHOD="MH" MODIFIED="2009-09-21 09:51:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03284385996912165" P_Q="0.0" P_Z="0.26794999419790855" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13936136110393776" TOTALS="SUB" TOTAL_1="1010" TOTAL_2="959" WEIGHT="300.0" Z="1.1077958875984253">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.126091992912368" CI_END="1.4118858369673013" CI_START="0.8615116133095441" DF="7" EFFECT_SIZE="1.1028853273185728" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="103" I2="13.85773129192425" ID="CMP-003.03.01" LOG_CI_END="0.1497995817160804" LOG_CI_START="-0.06473886381983286" LOG_EFFECT_SIZE="0.042530358948123737" MODIFIED="2009-09-21 09:51:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32160689015836574" P_Z="0.43710495703396224" STUDIES="8" TAU2="0.017562483548316837" TOTAL_1="346" TOTAL_2="329" WEIGHT="100.0" Z="0.7770912255810994">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="14.45413717356195" CI_START="0.06918434410800384" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1599921719703592" LOG_CI_START="-1.1599921719703592" LOG_EFFECT_SIZE="0.0" ORDER="123" O_E="0.0" SE="1.3627702877384937" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="1.8571428571428572" WEIGHT="0.8471346513138316"/>
<DICH_DATA CI_END="1.360663708067324" CI_START="0.6147952102301713" EFFECT_SIZE="0.9146198830409357" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.13375080134037534" LOG_CI_START="-0.21126952467702462" LOG_EFFECT_SIZE="-0.038759361668324645" ORDER="124" O_E="0.0" SE="0.20266664738077883" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.04107376996056495" WEIGHT="27.084401885636126"/>
<DICH_DATA CI_END="2.274078044403178" CI_START="0.4397386459365979" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.35680536522068085" LOG_CI_START="-0.35680536522068085" LOG_EFFECT_SIZE="0.0" ORDER="125" O_E="0.0" SE="0.41917847549134185" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.1757105943152455" WEIGHT="8.217015389094732"/>
<DICH_DATA CI_END="120.15725297777159" CI_START="0.4077989366906108" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.079749990979728" LOG_CI_START="-0.3895539109512146" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="126" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Daniel-1996" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.7486018650101047"/>
<DICH_DATA CI_END="3.939724357120538" CI_START="0.9324538414652127" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.5954658374679114" LOG_CI_START="-0.030372657527975314" LOG_EFFECT_SIZE="0.28254658996996806" ORDER="127" O_E="0.0" SE="0.3676206299110972" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.13514492753623186" WEIGHT="10.39980865253033"/>
<DICH_DATA CI_END="1.7549174860818295" CI_START="0.8440164060515978" EFFECT_SIZE="1.2170370370370371" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="25" LOG_CI_END="0.2442567013250373" LOG_CI_START="-0.07364911144492599" LOG_EFFECT_SIZE="0.08530379494005565" ORDER="128" O_E="0.0" SE="0.18673944808022927" STUDY_ID="STD-McGurk-2005" TOTAL_1="54" TOTAL_2="53" VAR="0.03487162146930864" WEIGHT="30.288070227741162"/>
<DICH_DATA CI_END="1.65636932024269" CI_START="0.6402613457749663" EFFECT_SIZE="1.029810298102981" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.21915717777534102" LOG_CI_START="-0.19364271685984139" LOG_EFFECT_SIZE="0.01275723045774981" ORDER="129" O_E="0.0" SE="0.24248070150113998" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.05879689060048495" WEIGHT="20.798073226841872"/>
<DICH_DATA CI_END="1.3964281208304248" CI_START="0.02971524153919933" EFFECT_SIZE="0.2037037037037037" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14501858591592467" LOG_CI_START="-1.5270207352454117" LOG_EFFECT_SIZE="-0.6910010746647435" ORDER="130" O_E="0.0" SE="0.982164173978294" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.9646464646464646" WEIGHT="1.6168941018318381"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.360649389987162" CI_END="0.9784401341290687" CI_START="0.3138365320244273" DF="6" EFFECT_SIZE="0.5541392049734276" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="38" I2="5.670008954665713" ID="CMP-003.03.02" LOG_CI_END="-0.009465741506001381" LOG_CI_START="-0.5032965039193569" LOG_EFFECT_SIZE="-0.25638112271267915" MODIFIED="2009-09-21 09:51:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3840254267951728" P_Z="0.04184070014776195" STUDIES="7" TAU2="0.039301059608376106" TOTAL_1="332" TOTAL_2="315" WEIGHT="100.0" Z="2.0351011118751856">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.5591965417608036" CI_START="0.3769747828673346" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.19290086286183178" LOG_CI_START="-0.4236877002659708" LOG_EFFECT_SIZE="-0.11539341870206953" ORDER="131" O_E="0.0" SE="0.36218717414388335" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.1311795491143317" WEIGHT="49.357879897848946"/>
<DICH_DATA CI_END="15.477505790203258" CI_START="0.06460989345149956" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1897009751564562" LOG_CI_START="-1.1897009751564562" LOG_EFFECT_SIZE="0.0" ORDER="132" O_E="0.0" SE="1.3976724838434158" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="1.9534883720930232" WEIGHT="4.222504031980652"/>
<DICH_DATA CI_END="92.62160011346378" CI_START="0.2699154405600246" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="133" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Daniel-1996" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="3.7274087405191922"/>
<DICH_DATA CI_END="1.5167593390499818" CI_START="0.09271411513976904" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.1809166776793044" LOG_CI_START="-1.0328541422238666" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="134" O_E="0.0" SE="0.7129749878735812" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.5083333333333332" WEIGHT="15.365290271575844"/>
<DICH_DATA CI_END="1.1009028751393783" CI_START="0.017857437286054403" EFFECT_SIZE="0.1402116402116402" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.041749005936669976" LOG_CI_START="-1.7481808664095428" LOG_EFFECT_SIZE="-0.8532159302364364" ORDER="135" O_E="0.0" SE="1.0514136673119303" STUDY_ID="STD-McGurk-2005" TOTAL_1="54" TOTAL_2="53" VAR="1.1054706998103223" WEIGHT="7.350427140620943"/>
<DICH_DATA CI_END="1.078981046200928" CI_START="0.055133869099465604" EFFECT_SIZE="0.24390243902439024" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.033013815764795014" LOG_CI_START="-1.258581529204266" LOG_EFFECT_SIZE="-0.6127838567197355" ORDER="136" O_E="0.0" SE="0.758689499134897" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.5756097560975609" WEIGHT="13.684198090722159"/>
<DICH_DATA CI_END="5.700131491522857" CI_START="0.06551722371297147" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7558848741609341" LOG_CI_START="-1.183644514051096" LOG_EFFECT_SIZE="-0.21387981994508098" ORDER="137" O_E="0.0" SE="1.1392891634610582" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="1.297979797979798" WEIGHT="6.292291826732271"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.464840377113116" CI_END="4.4010623600831416" CI_START="1.42997516552009" DF="5" EFFECT_SIZE="2.5086669521529017" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="15" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.6435575222662233" LOG_CI_START="0.15532849510755037" LOG_EFFECT_SIZE="0.39944300868688687" MODIFIED="2009-09-21 09:51:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.48460169311270596" P_Z="0.0013409134954203133" STUDIES="7" TAU2="0.0" TOTAL_1="332" TOTAL_2="315" WEIGHT="100.00000000000001" Z="3.207076463514653">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="71.63030182636417" CI_START="1.1816228305888203" EFFECT_SIZE="9.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.8550967811355628" LOG_CI_START="0.0724788735555476" LOG_EFFECT_SIZE="0.9637878273455552" ORDER="138" O_E="0.0" SE="1.0471185830134568" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="1.0964573268921096" WEIGHT="7.501198581035255"/>
<DICH_DATA CI_END="10.35067319986737" CI_START="0.3864482940154323" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0149685968924291" LOG_CI_START="-0.4129086055644666" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="139" O_E="0.0" SE="0.8387421368293256" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.7034883720930232" WEIGHT="11.691371841980114"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="140" O_E="0.0" SE="0.0" STUDY_ID="STD-Daniel-1996" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.37021641051294" CI_START="0.6873756184957331" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.5607458852068146" LOG_CI_START="-0.16280587653477713" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="141" O_E="0.0" SE="1.0124228365658294" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="1.0250000000000001" WEIGHT="8.024140628925657"/>
<DICH_DATA CI_END="5.297026599415112" CI_START="1.2531142863286837" EFFECT_SIZE="2.576388888888889" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="8" LOG_CI_END="0.7240321537832851" LOG_CI_START="0.09799068125630722" LOG_EFFECT_SIZE="0.4110114175197962" ORDER="142" O_E="0.0" SE="0.36773985991761515" STUDY_ID="STD-McGurk-2005" TOTAL_1="54" TOTAL_2="53" VAR="0.13523260457222722" WEIGHT="60.81923934442892"/>
<DICH_DATA CI_END="6.594638368544499" CI_START="0.1443315528464402" EFFECT_SIZE="0.975609756097561" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.819190985045122" LOG_CI_START="-0.8406387158286682" LOG_EFFECT_SIZE="-0.010723865391773113" ORDER="143" O_E="0.0" SE="0.9749921825827943" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.9506097560975609" WEIGHT="8.65207209571779"/>
<DICH_DATA CI_END="8.778778178034305" CI_START="0.01822577091654301" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9434340754206604" LOG_CI_START="-1.7393140927647355" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="144" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="2.483333333333333" WEIGHT="3.3119775079122693"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4605551372504001" CI_END="1.4193555512966234" CI_START="0.5029297920547208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8448882720604686" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.1520912006893585" LOG_CI_START="-0.2984926373125736" LOG_EFFECT_SIZE="-0.07320071831160756" METHOD="MH" MODIFIED="2009-09-21 09:53:39 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.497364674630725" P_Q="0.0" P_Z="0.5242410261424035" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="54" WEIGHT="100.0" Z="0.6368216497485524">
<NAME>Mental state: 1a.General - no clinically important change - short term (less than 20 % PANSS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6890171601512383" CI_START="0.5157503024025581" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.22763406195770663" LOG_CI_START="-0.28756050871259303" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2009-09-21 09:51:46 +0100" MODIFIED_BY="[Empty name]" ORDER="910" O_E="0.0" SE="0.3026278410659888" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.09158361018826136" WEIGHT="76.49070516685906"/>
<DICH_DATA CI_END="1.7814352539781018" CI_START="0.20963814951427226" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2507700426000194" LOG_CI_START="-0.6785296824901814" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2009-09-21 09:51:46 +0100" MODIFIED_BY="[Empty name]" ORDER="909" O_E="0.0" SE="0.5458752586258128" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.297979797979798" WEIGHT="23.50929483314095"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2880175474568611" CI_START="0.8539679828306013" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0487734487734488" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.10992177972548182" LOG_CI_START="-0.06855841167710185" LOG_EFFECT_SIZE="0.02068168402418996" METHOD="MH" MODIFIED="2009-09-21 09:53:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6496646879123125" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="138" WEIGHT="99.99999999999999" Z="0.45422806316491837">
<NAME>Mental state: 1b. General - no clinically important change - short term (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2880175474568611" CI_START="0.8539679828306013" EFFECT_SIZE="1.0487734487734488" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="77" LOG_CI_END="0.10992177972548182" LOG_CI_START="-0.06855841167710185" LOG_EFFECT_SIZE="0.02068168402418996" MODIFIED="2009-09-21 09:52:14 +0100" MODIFIED_BY="[Empty name]" ORDER="911" O_E="0.0" SE="0.10484014792107384" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.010991456616112644" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4463938386502206" CI_START="0.7577659799271736" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0469135802469136" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.1602865631272024" LOG_CI_START="-0.12046489637107426" LOG_EFFECT_SIZE="0.01991083337806409" METHOD="MH" MODIFIED="2009-09-21 09:53:50 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.7810120120890462" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="53" WEIGHT="100.0" Z="0.2780004520220358">
<NAME>Mental State: 1c. General - no clinically important change - long term (less than 40% BPRS reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4463938386502206" CI_START="0.7577659799271736" EFFECT_SIZE="1.0469135802469136" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" LOG_CI_END="0.1602865631272024" LOG_CI_START="-0.12046489637107426" LOG_EFFECT_SIZE="0.01991083337806409" MODIFIED="2009-09-21 09:52:50 +0100" MODIFIED_BY="[Empty name]" ORDER="912" O_E="0.0" SE="0.1649147970514257" STUDY_ID="STD-McGurk-2005" TOTAL_1="54" TOTAL_2="53" VAR="0.027196890286512922" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9816804798978511" CI_START="0.7814791491454108" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.2970336314793739" LOG_CI_START="-0.10708260501766043" LOG_EFFECT_SIZE="0.09497551323085675" METHOD="MH" MODIFIED="2009-09-21 09:54:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.35691335822343995" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="14" WEIGHT="99.99999999999999" Z="0.921262589987783">
<NAME>Mental State: 1d. General - no clinically important change - short term (less than 20% BPRS reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9816804798978511" CI_START="0.7814791491454108" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.2970336314793739" LOG_CI_START="-0.10708260501766043" LOG_EFFECT_SIZE="0.09497551323085675" MODIFIED="2009-09-21 09:53:31 +0100" MODIFIED_BY="[Empty name]" ORDER="913" O_E="0.0" SE="0.2373798777259908" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.05634920634920634" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.406945784465131" CI_END="6.424713485439984" CI_START="-3.4367699178116253" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4939717838141795" ESTIMABLE="YES" I2="52.420295044706435" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2009-09-21 14:51:30 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.07775867031577577" P_Q="0.7597730921227926" P_Z="0.5526110994333546" Q="0.09350067280252539" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="14.919528982437495" TOTALS="YES" TOTAL_1="236" TOTAL_2="232" UNITS="" WEIGHT="100.00000000000001" Z="0.5938520140345953">
<NAME>Mental state: 1e. General - average endpoint score (PANSS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.313445111662606" CI_END="6.850822336186013" CI_START="-5.346233867450623" DF="3" EFFECT_SIZE="0.7522942343676949" ESTIMABLE="YES" I2="63.91387734320376" ID="CMP-003.08.01" MODIFIED="2009-09-21 10:04:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03995905902382335" P_Z="0.8089547691275619" STUDIES="4" TAU2="22.003392943116005" TOTAL_1="195" TOTAL_2="192" WEIGHT="83.97861550174002" Z="0.2417746676773029">
<NAME>short term</NAME>
<CONT_DATA CI_END="5.013814557623813" CI_START="-2.613814557623807" EFFECT_SIZE="1.2000000000000028" ESTIMABLE="YES" MEAN_1="78.26" MEAN_2="77.06" ORDER="155" SD_1="4.62" SD_2="5.28" SE="1.9458595095148137" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="33.83372040677325"/>
<CONT_DATA CI_END="13.284497103791601" CI_START="1.9155028962084009" EFFECT_SIZE="7.600000000000001" ESTIMABLE="YES" MEAN_1="-29.9" MEAN_2="-37.5" ORDER="156" SD_1="23.9" SD_2="22.5" SE="2.900306918203696" STUDY_ID="STD-Azorin-2001" TOTAL_1="130" TOTAL_2="126" WEIGHT="27.12621587660574"/>
<CONT_DATA CI_END="5.342138179576507" CI_START="-13.742138179576505" EFFECT_SIZE="-4.199999999999999" ESTIMABLE="YES" MEAN_1="-27.4" MEAN_2="-23.2" ORDER="157" SD_1="23.6" SD_2="21.5" SE="4.868527307054453" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="16.386740781368598"/>
<CONT_DATA CI_END="4.586361702798641" CI_START="-30.58636170279864" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="76.0" ORDER="158" SD_1="17.0" SD_2="22.0" SE="8.972798399112238" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="6.631938436992428"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.022322760417206E-33" CI_END="13.317806489596327" CI_START="-6.117806489596328" DF="0" EFFECT_SIZE="3.5999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-003.08.02" MODIFIED="2009-09-21 10:04:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.4677919165143951" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="16.02138449825999" Z="0.726076440387865">
<NAME>medium term</NAME>
<CONT_DATA CI_END="13.317806489596327" CI_START="-6.117806489596328" EFFECT_SIZE="3.6" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-6.7" ORDER="159" SD_1="22.31" SD_2="22.31" SE="4.958155642781778" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" WEIGHT="16.02138449825999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.8144346224031525" CI_END="6.156530156090894" CI_START="-0.007364628121953487" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0745827639844703" ESTIMABLE="YES" I2="37.68738729901928" I2_Q="77.14700686745147" ID="CMP-003.09" MODIFIED="2009-09-21 10:05:44 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.1859005857611742" P_Q="0.0364528673938499" P_Z="0.050549977369963126" Q="4.375794427451796" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.6550715510879286" TOTALS="YES" TOTAL_1="207" TOTAL_2="190" UNITS="" WEIGHT="100.00000000000001" Z="1.9552804503838486">
<NAME>Mental state: 1f. General - average endpoint score (BPRS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.43864019495135687" CI_END="7.639172047741103" CI_START="2.166100804891829" DF="2" EFFECT_SIZE="4.902636426316466" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" MODIFIED="2009-09-21 10:05:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8030647461821679" P_Z="4.458023781339924E-4" STUDIES="3" TAU2="0.0" TOTAL_1="185" TOTAL_2="160" WEIGHT="67.7031393563538" Z="3.5113706357938814">
<NAME>short term</NAME>
<CONT_DATA CI_END="8.782940477763663" CI_START="2.217059522236337" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="-17.7" MEAN_2="-23.2" ORDER="163" SD_1="13.6" SD_2="13.2" SE="1.6750004100376732" STUDY_ID="STD-Azorin-2001" TOTAL_1="130" TOTAL_2="126" WEIGHT="38.27144187753954"/>
<CONT_DATA CI_END="9.815255810077117" CI_START="-2.2152558100771227" EFFECT_SIZE="3.799999999999997" ESTIMABLE="YES" MEAN_1="35.8" MEAN_2="32.0" ORDER="165" SD_1="9.89" SD_2="6.37" SE="3.069064461145557" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="18.91203220533264"/>
<CONT_DATA CI_END="11.732183968593883" CI_START="-5.732183968593887" EFFECT_SIZE="2.9999999999999982" ESTIMABLE="YES" MEAN_1="-13.9" MEAN_2="-16.9" ORDER="164" SD_1="16.6" SD_2="16.1" SE="4.45527776911833" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" WEIGHT="10.51966527348162"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.720314003583877" CI_START="-4.120314003583875" DF="0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" MODIFIED="2009-09-21 10:05:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9203521430657307" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="30" WEIGHT="32.29686064364621" Z="0.0999901529698022">
<NAME>long term</NAME>
<CONT_DATA CI_END="3.720314003583877" CI_START="-4.120314003583875" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="31.3" MEAN_2="31.5" ORDER="166" SD_1="6.5" SD_2="7.9" SE="2.0001969599986595" STUDY_ID="STD-McGurk-2005" TOTAL_1="22" TOTAL_2="30" WEIGHT="32.29686064364621"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.909115694207092" CI_END="2.3508290186879233" CI_START="0.17769461808086762" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2642618183843954" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2009-09-21 10:07:45 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.4270724653860002" P_Q="0.5708191118274315" P_Z="0.02257853436076042" Q="0.3213141091423397" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="298" TOTAL_2="293" UNITS="" WEIGHT="100.0" Z="2.2804918373850613">
<NAME>Mental state: 2a. Positive symptoms - average endpoint score (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.587801585064752" CI_END="2.5736549707195415" CI_START="-0.005259747578021612" DF="4" EFFECT_SIZE="1.28419761157076" ESTIMABLE="YES" I2="12.812271284318323" ID="CMP-003.10.01" MODIFIED="2009-09-21 10:06:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3322632108016377" P_Z="0.05094185980992215" STUDIES="5" TAU2="0.29358164325209074" TOTAL_1="257" TOTAL_2="253" WEIGHT="88.32303149084301" Z="1.9519692139122768">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.816446284130797" CI_START="0.38355371586920217" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-10.4" ORDER="167" SD_1="7.4" SD_2="6.6" SE="0.8757539922518509" STUDY_ID="STD-Azorin-2001" TOTAL_1="130" TOTAL_2="126" WEIGHT="40.073082314000345"/>
<CONT_DATA CI_END="2.2381698628517928" CI_START="-5.438169862851794" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-6.7" ORDER="168" SD_1="10.7" SD_2="7.1" SE="1.9582859139896382" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="8.014285322234896"/>
<CONT_DATA CI_END="4.758906929087491" CI_START="-0.5589069290874913" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="9.53" MEAN_2="7.43" ORDER="171" SD_1="4.73" SD_2="2.21" SE="1.3566100959306444" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="16.699632367442184"/>
<CONT_DATA CI_END="3.5213026253477744" CI_START="-1.3213026253477715" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="20.8" MEAN_2="19.7" ORDER="170" SD_1="7.9" SD_2="5.4" SE="1.2353811827394274" STUDY_ID="STD-Ren-2002" TOTAL_1="60" TOTAL_2="60" WEIGHT="20.137939707630473"/>
<CONT_DATA CI_END="3.8943923257100126" CI_START="-7.894392325710013" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="17.0" ORDER="169" SD_1="7.0" SD_2="6.0" SE="3.007398284970656" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="3.3980917795351147"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.5797394609615947" CI_START="-2.779739460961595" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" MODIFIED="2009-09-21 10:06:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8052514342014075" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="11.676968509156993" Z="0.24655655076184577">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.5797394609615947" CI_START="-2.779739460961595" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.3" ORDER="172" SD_1="7.3" SD_2="7.3" SE="1.622345862496951" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" WEIGHT="11.676968509156993"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.758906929087491" CI_START="-0.5589069290874917" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2009-09-21 10:07:52 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.12162805182197306" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="1.5479760959315167">
<NAME>Mental state: 2b. Positive symptoms -average endpoint score - short term (BPRS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.758906929087491" CI_START="-0.5589069290874913" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="9.53" MEAN_2="7.43" MODIFIED="2009-09-21 10:07:28 +0100" MODIFIED_BY="[Empty name]" ORDER="914" SD_1="4.73" SD_2="2.21" SE="1.3566100959306444" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.140405753104814" CI_END="1.7088351683023213" CI_START="-1.9596597681834307" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.12541229994055478" ESTIMABLE="YES" I2="60.55384668630966" I2_Q="0.0" ID="CMP-003.12" MODIFIED="2009-09-21 10:09:13 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.03812793050080254" P_Q="0.4124951997178241" P_Z="0.8933963534688238" Q="0.6715984545688052" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.5766236672979006" TOTALS="YES" TOTAL_1="283" TOTAL_2="279" UNITS="" WEIGHT="100.0" Z="0.13400786718124277">
<NAME>Mental state: 3a. Negative symptoms - average endpoint score (PANSS negative, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.468807298536008" CI_END="1.7066720332585588" CI_START="-2.7999844113756165" DF="3" EFFECT_SIZE="-0.5466561890585288" ESTIMABLE="YES" I2="68.31702340733203" ID="CMP-003.12.01" MODIFIED="2009-09-21 10:08:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02366559482388908" P_Z="0.6344404785964517" STUDIES="4" TAU2="3.516250165792604" TOTAL_1="242" TOTAL_2="239" WEIGHT="81.16713850761606" Z="0.4754861861086939">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.4151122384898853" CI_START="-0.015112238489882968" EFFECT_SIZE="1.700000000000001" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-8.8" ORDER="174" SD_1="7.2" SD_2="6.8" SE="0.8750733442137052" STUDY_ID="STD-Azorin-2001" TOTAL_1="130" TOTAL_2="126" WEIGHT="26.203797656569826"/>
<CONT_DATA CI_END="2.764330789454674" CI_START="-2.5643307894546745" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-6.1" ORDER="175" SD_1="6.5" SD_2="6.1" SE="1.3593774224784616" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.79486148985024"/>
<CONT_DATA CI_END="1.2586101839865305" CI_START="-3.8586101839865248" EFFECT_SIZE="-1.2999999999999972" ESTIMABLE="YES" MEAN_1="18.6" MEAN_2="19.9" ORDER="177" SD_1="7.2" SD_2="7.1" SE="1.305437346894391" STUDY_ID="STD-Ren-2002" TOTAL_1="60" TOTAL_2="60" WEIGHT="20.459533035643393"/>
<CONT_DATA CI_END="-0.39783478463451827" CI_START="-7.602165215365481" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="21.0" ORDER="176" SD_1="4.0" SD_2="4.0" SE="1.837873166945363" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="14.7089463255526"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.222563247538512" CI_START="-1.422563247538512" DF="0" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" MODIFIED="2009-09-21 10:08:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3309768741358846" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="18.832861492383937" Z="0.9721481283896852">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.222563247538512" CI_START="-1.422563247538512" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.6" ORDER="178" SD_1="6.48" SD_2="6.48" SE="1.4401097519151018" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" WEIGHT="18.832861492383937"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.060489605824938286" CI_END="2.509754284760078" CI_START="-3.739880911986222" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6150633136130722" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.13" MODIFIED="2009-09-21 10:10:11 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.8057237681273618" P_Q="1.0" P_Z="0.6996572842650508" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="34" UNITS="" WEIGHT="99.99999999999999" Z="0.3857831393170268">
<NAME>Mental state: 3b. Negative symptoms - average endpoint score - short term (SANS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.1680489654878015" CI_START="-7.828048965487798" EFFECT_SIZE="-1.3299999999999983" ESTIMABLE="YES" MEAN_1="47.6" MEAN_2="48.93" MODIFIED="2009-09-21 10:10:11 +0100" MODIFIED_BY="[Empty name]" ORDER="915" SD_1="9.42" SD_2="8.43" SE="3.3153920259472014" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="23.12508748527674"/>
<CONT_DATA CI_END="3.163956171254795" CI_START="-3.963956171254792" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="34.5" MEAN_2="34.9" MODIFIED="2009-09-21 10:10:11 +0100" MODIFIED_BY="[Empty name]" ORDER="916" SD_1="5.7" SD_2="5.8" SE="1.818378398463862" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="76.87491251472325"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="18.442697046707007" CI_START="-0.44269704670700705" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.14" MODIFIED="2009-09-21 10:11:37 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.06175147633737428" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.8680760140464372">
<NAME>General functioning: 1a. General - average endpoint score - short term (GAF total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.442697046707007" CI_START="-0.44269704670700705" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="35.0" MODIFIED="2009-09-21 10:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="917" SD_1="10.0" SD_2="11.0" SE="4.817791102892602" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="93.55069194709738" CI_START="0.449308052902623" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="47.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.15" MODIFIED="2009-09-21 10:12:48 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.04782933953806504" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.9788815895168772">
<NAME>General functioning: 1b. Social functioning - average endpoint score - short term (SFS, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="93.55069194709738" CI_START="0.449308052902623" EFFECT_SIZE="47.0" ESTIMABLE="YES" MEAN_1="734.0" MEAN_2="687.0" MODIFIED="2009-09-21 10:12:48 +0100" MODIFIED_BY="[Empty name]" ORDER="918" SD_1="54.0" SD_2="49.0" SE="23.7507894605632" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.04819153720404" CI_START="0.5994574466444121" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7926829268292683" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.020440649012421073" LOG_CI_START="-0.22224164049414327" LOG_EFFECT_SIZE="-0.10090049574086109" METHOD="MH" MODIFIED="2009-09-21 10:14:26 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.10314457536004235" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.6297962086679227">
<NAME>Cognitive functioning: 1a. Global - no clinically important change in global neurocognitive score - medium term (less than 1/2 SD)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.04819153720404" CI_START="0.5994574466444121" EFFECT_SIZE="0.7926829268292683" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.020440649012421073" LOG_CI_START="-0.22224164049414327" LOG_EFFECT_SIZE="-0.10090049574086109" MODIFIED="2009-09-21 10:13:49 +0100" MODIFIED_BY="[Empty name]" ORDER="919" O_E="0.0" SE="0.1425527781528632" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.020321294559099437" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.824090399073146E-32" CI_END="0.7189657802029328" CI_START="-0.05896578020293303" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3299999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.17" MODIFIED="2009-09-21 10:17:09 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="1.0" P_Z="0.09634433508384699" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.6628406605865753">
<NAME>Cognitive functioning: 1b. Global - average endpoint score - medium term - (global neurocognitive score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7189657802029329" CI_START="-0.05896578020293297" EFFECT_SIZE="0.32999999999999996" ESTIMABLE="YES" MEAN_1="0.29" MEAN_2="-0.04" MODIFIED="2009-09-21 10:15:47 +0100" MODIFIED_BY="[Empty name]" ORDER="920" SD_1="0.68" SD_2="0.72" SE="0.19845557534273353" STUDY_ID="STD-Volavka-2002" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.739343963124061" CI_END="1.4157842035501478" CI_START="0.5118092980879376" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8512411641027419" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="122" I2="82.57640583270295" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.1509970624289975" LOG_CI_START="-0.29089182850822565" LOG_EFFECT_SIZE="-0.06994738303961404" METHOD="MH" MODIFIED="2009-09-21 10:17:25 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.01658901584554584" P_Q="0.0" P_Z="0.5349336525964155" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11374251292399878" TOTALS="YES" TOTAL_1="175" TOTAL_2="158" WEIGHT="100.0" Z="0.6204924105681926">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.194725733287505" CI_START="0.94124096390986" EFFECT_SIZE="1.060436137071651" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="107" LOG_CI_END="0.0772682180952292" LOG_CI_START="-0.026299180079872857" LOG_EFFECT_SIZE="0.02548451900767818" ORDER="185" O_E="0.0" SE="0.06083600235494408" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.003701019182530762" WEIGHT="57.3683378345308"/>
<DICH_DATA CI_END="0.9567225232664646" CI_START="0.4192554281482034" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="-0.019214001708750993" LOG_CI_START="-0.377521305824916" LOG_EFFECT_SIZE="-0.1983676537668335" ORDER="186" O_E="0.0" SE="0.21047148408759575" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.04429824561403507" WEIGHT="42.6316621654692"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.177372703485034" CI_START="0.06459258192029108" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0222222222222221" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="1.2089079911311467" LOG_CI_START="-1.1898173553186862" LOG_EFFECT_SIZE="0.009545317906230361" METHOD="MH" MODIFIED="2009-09-21 10:18:00 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.9875545555862577" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="153" TOTAL_2="160" WEIGHT="100.0" Z="0.015598683980127826">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.177372703485034" CI_START="0.06459258192029108" DF="0" EFFECT_SIZE="1.0222222222222221" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.19.01" LOG_CI_END="1.2089079911311467" LOG_CI_START="-1.1898173553186862" LOG_EFFECT_SIZE="0.009545317906230361" MODIFIED="2009-09-21 10:17:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9875545555862577" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="138" WEIGHT="100.0" Z="0.015598683980127826">
<NAME>any reason</NAME>
<DICH_DATA CI_END="16.177372703485034" CI_START="0.06459258192029108" EFFECT_SIZE="1.0222222222222221" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2089079911311467" LOG_CI_START="-1.1898173553186862" LOG_EFFECT_SIZE="0.009545317906230361" ORDER="190" O_E="0.0" SE="1.4090231423865962" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="1.9853462157809985" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.19.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-21 10:17:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="191" O_E="0.0" SE="0.0" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.19.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-21 10:18:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="192" O_E="0.0" SE="0.0" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="36.11328941979413" CI_START="0.06538021389049867" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="1.557667048432407" LOG_CI_START="-1.1845536629647144" LOG_EFFECT_SIZE="0.1865566927338462" METHOD="MH" MODIFIED="2009-09-21 10:18:46 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.789717413732514" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="63" WEIGHT="100.0" Z="0.26667758529688396">
<NAME>Adverse effects: 3. Cardiac effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="36.11328941979413" CI_START="0.06538021389049867" DF="0" EFFECT_SIZE="1.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.20.01" LOG_CI_END="1.557667048432407" LOG_CI_START="-1.1845536629647144" LOG_EFFECT_SIZE="0.1865566927338462" MODIFIED="2009-09-21 10:18:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.789717413732514" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="20" WEIGHT="100.0" Z="0.26667758529688396">
<NAME>preterminal negative T-wave</NAME>
<DICH_DATA CI_END="36.11328941979413" CI_START="0.06538021389049867" EFFECT_SIZE="1.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.557667048432407" LOG_CI_START="-1.1845536629647144" LOG_EFFECT_SIZE="0.1865566927338462" ORDER="187" O_E="0.0" SE="1.6107940200861126" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="2.59465737514518" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.20.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-21 10:18:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>any significant cardiac effect</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="188" O_E="0.0" SE="0.0" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8244699457057016" CI_END="0.8094977248414443" CI_START="0.413093278869625" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5782716225030013" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="-0.09178436752851324" LOG_CI_START="-0.3839518710451517" LOG_EFFECT_SIZE="-0.2378681192868325" METHOD="MH" MODIFIED="2009-09-21 10:19:24 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.768002562423534" P_Q="0.0" P_Z="0.0014158088131799842" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="232" WEIGHT="100.0" Z="3.1914086355323836">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.982220622951789" CI_START="0.35266382170696214" EFFECT_SIZE="0.5885521885521886" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="33" LOG_CI_END="-0.007790951552270662" LOG_CI_START="-0.4526390904853854" LOG_EFFECT_SIZE="-0.23021502101882807" ORDER="213" O_E="0.0" SE="0.2613059988431133" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.06828082503139711" WEIGHT="43.13603901470431"/>
<DICH_DATA CI_END="1.1331511242283545" CI_START="0.372854062416177" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.05428783399550992" LOG_CI_START="-0.4284611207097987" LOG_EFFECT_SIZE="-0.1870866433571444" ORDER="214" O_E="0.0" SE="0.28356912563976383" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.08041144901610017" WEIGHT="36.62866878472513"/>
<DICH_DATA CI_END="3.1411228557862287" CI_START="0.22108159289765303" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.4970849228826155" LOG_CI_START="-0.6554474149778653" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="215" O_E="0.0" SE="0.67700320038633" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.4583333333333333" WEIGHT="6.426249452750279"/>
<DICH_DATA CI_END="8.778778178034305" CI_START="0.01822577091654301" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9434340754206604" LOG_CI_START="-1.7393140927647355" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="216" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="2.483333333333333" WEIGHT="1.1860527513465282"/>
<DICH_DATA CI_END="0.859108772287196" CI_START="0.12933299565234468" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.06595184639751821" LOG_CI_START="-0.8882906630418067" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="217" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.23333333333333334" WEIGHT="12.622989996473763"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.28986475495723596" CI_END="0.7001700902077725" CI_START="0.07138370045851408" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2235637090169208" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="-0.15479644532071588" LOG_CI_START="-1.1464009424120545" LOG_EFFECT_SIZE="-0.6505986938663851" METHOD="MH" MODIFIED="2009-09-21 10:19:17 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5903072863203875" P_Q="0.0" P_Z="0.010114433733367949" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="178" WEIGHT="100.0" Z="2.5718923464088705">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8854933183791365" CI_START="0.07375396360398719" EFFECT_SIZE="0.25555555555555554" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.052814711494820185" LOG_CI_START="-1.1322146353486437" LOG_EFFECT_SIZE="-0.592514673421732" ORDER="218" O_E="0.0" SE="0.6340448583875317" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.40201288244766503" WEIGHT="84.39412392058226"/>
<DICH_DATA CI_END="1.9514249115907354" CI_START="0.006028819325784057" EFFECT_SIZE="0.10846560846560846" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2903518448259808" LOG_CI_START="-2.2197677310609607" LOG_EFFECT_SIZE="-0.9647079431174899" ORDER="219" O_E="0.0" SE="1.4744566641682826" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="2.1740224545102595" WEIGHT="15.605876079417746"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.36302748177824" CI_END="1.3436708674961177" CI_START="0.7486472507774737" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.00296335970002" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="85" I2="61.73838763820891" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="0.1282929012062973" LOG_CI_START="-0.12572276591472206" LOG_EFFECT_SIZE="0.0012850676457876217" METHOD="MH" MODIFIED="2009-09-21 10:20:06 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0017337808128784493" P_Q="0.0" P_Z="0.9841782262781248" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.381902121953176" TOTALS="SUB" TOTAL_1="506" TOTAL_2="469" WEIGHT="700.0" Z="0.019830952413194124">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9371598241474748" CI_START="0.006373082312802401" DF="0" EFFECT_SIZE="0.11111111111111109" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-003.23.01" LOG_CI_END="0.2871654533891674" LOG_CI_START="-2.195650472267817" LOG_EFFECT_SIZE="-0.954242509439325" MODIFIED="2009-09-21 10:19:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.13191823498596858" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.5065804369071778">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.9371598241474748" CI_START="0.006373082312802401" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2871654533891674" LOG_CI_START="-2.195650472267817" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="193" O_E="0.0" SE="1.4584183648679576" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="2.1269841269841274" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6080061992060575" CI_START="0.38343467139933374" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-003.23.02" LOG_CI_END="0.41630861937498354" LOG_CI_START="-0.41630861937498354" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-21 10:19:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="2.6080061992060575" CI_START="0.38343467139933374" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41630861937498354" LOG_CI_START="-0.41630861937498354" LOG_EFFECT_SIZE="0.0" ORDER="194" O_E="0.0" SE="0.4890834875635335" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.23920265780730898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.24440546987425" CI_START="0.18828486425154256" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.23.03" LOG_CI_END="1.3272445817533365" LOG_CI_START="-0.7251845904253741" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-09-21 10:19:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5653344259186854" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.5749362343562306">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="21.24440546987425" CI_START="0.18828486425154256" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3272445817533365" LOG_CI_START="-0.7251845904253741" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="195" O_E="0.0" SE="1.2056070554260303" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="1.4534883720930232" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.262685996981284" CI_END="3.848626324081127" CI_START="0.43821318899002903" DF="1" EFFECT_SIZE="1.298660392368445" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="25" I2="80.99829629634739" ID="CMP-003.23.04" LOG_CI_END="0.5853057460471123" LOG_CI_START="-0.3583145555306908" LOG_EFFECT_SIZE="0.1134955952582107" MODIFIED="2009-09-21 10:19:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.02178742272059897" P_Z="0.6373006798236327" STUDIES="2" TAU2="0.5010248237837348" TOTAL_1="175" TOTAL_2="158" WEIGHT="100.0" Z="0.4714762468295343">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="3.58708690105496" CI_START="1.2982876347771937" EFFECT_SIZE="2.1580246913580248" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="18" LOG_CI_END="0.5547418980563633" LOG_CI_START="0.11337092078310562" LOG_EFFECT_SIZE="0.3340564094197345" ORDER="196" O_E="0.0" SE="0.25926349687188543" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.06721756081023815" WEIGHT="54.067480441495235"/>
<DICH_DATA CI_END="1.594455518257444" CI_START="0.31998640024166203" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.20261240790334178" LOG_CI_START="-0.49486847925981775" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="197" O_E="0.0" SE="0.40970372570571395" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="0.16785714285714287" WEIGHT="45.93251955850477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9731423071962342" CI_START="0.40737461271181147" DF="0" EFFECT_SIZE="0.6296296296296297" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" I2="0.0" ID="CMP-003.23.05" LOG_CI_END="-0.011823646154104195" LOG_CI_START="-0.3900060394073226" LOG_EFFECT_SIZE="-0.20091484278071337" MODIFIED="2009-09-21 10:19:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.03729516350761737" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="2.0825181861179853">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="0.9731423071962342" CI_START="0.40737461271181147" EFFECT_SIZE="0.6296296296296297" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.011823646154104195" LOG_CI_START="-0.3900060394073226" LOG_EFFECT_SIZE="-0.20091484278071337" ORDER="198" O_E="0.0" SE="0.22214620982997885" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.049348938541824997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.397474395146152" CI_START="0.17889415424592042" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-003.23.06" LOG_CI_END="0.14534385938593308" LOG_CI_START="-0.7474038507138954" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-09-21 10:20:01 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.1862414830200649" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.321779811009935">
<NAME>tremor</NAME>
<DICH_DATA CI_END="1.397474395146152" CI_START="0.17889415424592042" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.14534385938593308" LOG_CI_START="-0.7474038507138954" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="199" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6985184156459976" CI_END="4.484490994248323" CI_START="1.4746920208425789" DF="5" EFFECT_SIZE="2.5716226563705655" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="13" I2="0.0" ID="CMP-003.23.07" LOG_CI_END="0.6517131562019182" LOG_CI_START="0.1687013304061167" LOG_EFFECT_SIZE="0.4102072433040174" MODIFIED="2009-09-21 10:20:06 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7463450964263516" P_Z="8.713477341346715E-4" STUDIES="6" TAU2="0.0" TOTAL_1="162" TOTAL_2="142" WEIGHT="99.99999999999999" Z="3.3290755221104242">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="124.13532946180445" CI_START="0.39473049463389837" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.093895401214321" LOG_CI_START="-0.4036993211858073" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="200" O_E="0.0" SE="1.4670995032311038" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.152380952380952" WEIGHT="3.7399999101839483"/>
<DICH_DATA CI_END="4.680805125661779" CI_START="0.21363846029770756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" ORDER="201" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="12.980471116845573"/>
<DICH_DATA CI_END="17.681283431552767" CI_START="1.2316853503357512" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2475137859604954" LOG_CI_START="0.09049977595665581" LOG_EFFECT_SIZE="0.6690067809585756" ORDER="202" O_E="0.0" SE="0.6796357567879738" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.46190476190476193" WEIGHT="17.427628447455092"/>
<DICH_DATA CI_END="50.95043024524692" CI_START="0.12872503808498176" EFFECT_SIZE="2.5609756097560976" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.707147855709426" LOG_CI_START="-0.8903369710090208" LOG_EFFECT_SIZE="0.4084054423502026" ORDER="203" O_E="0.0" SE="1.5257754449716752" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" VAR="2.3279907084785134" WEIGHT="3.4578765882822244"/>
<DICH_DATA CI_END="6.460647389420107" CI_START="0.9959164972847193" EFFECT_SIZE="2.5365853658536586" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8102760386708763" LOG_CI_START="-0.0017770735127865752" LOG_EFFECT_SIZE="0.40424948257904486" ORDER="204" O_E="0.0" SE="0.4770040178244182" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.2275328330206379" WEIGHT="35.37908996129913"/>
<DICH_DATA CI_END="7.125741015912406" CI_START="0.8385525980570889" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8528300339279817" LOG_CI_START="-0.07646969116221906" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="205" O_E="0.0" SE="0.5458752586258128" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.297979797979798" WEIGHT="27.014933975934017"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.9392530888476087" CI_END="1.3383900497292167" CI_START="-0.24916090142677128" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5446145741512227" ESTIMABLE="YES" I2="0.0" I2_Q="28.07744224407858" ID="CMP-003.24" MODIFIED="2010-11-22 20:42:12 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.3792247193414703" P_Q="0.23834040500559484" P_Z="0.17870786213940718" Q="1.3903843678552568" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="74" UNITS="" WEIGHT="99.99999999999999" Z="1.3447441797250808">
<NAME>Adverse effects: 5b. Extrapyramidal symptoms - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.548868720992352" CI_END="1.7264902618796008" CI_START="-0.09724654976517166" DF="1" EFFECT_SIZE="0.8146218560572145" ESTIMABLE="YES" I2="0.0" ID="CMP-003.24.01" MODIFIED="2010-11-22 20:42:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.45878039718324937" P_Z="0.07995574841565393" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="34" WEIGHT="75.77588484931591" Z="1.7509428868207813">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="1.9702365689144692" CI_START="-0.03023656891446791" EFFECT_SIZE="0.9700000000000006" ESTIMABLE="YES" MEAN_1="12.33" MEAN_2="11.36" ORDER="206" SD_1="1.63" SD_2="1.08" SE="0.5103341575683058" STUDY_ID="STD-Breier-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="62.978149693327886"/>
<CONT_DATA CI_END="2.2688662156503305" CI_START="-2.168866215650331" EFFECT_SIZE="0.04999999999999999" ESTIMABLE="YES" MEAN_1="0.15" MEAN_2="0.1" ORDER="207" SD_1="3.58" SD_2="3.58" SE="1.1320954023402798" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.797735155988033"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3127747511913235" CI_START="-1.9127747511913231" DF="0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.24.02" MODIFIED="2010-11-22 20:42:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7154231989123513" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="24.22411515068407" Z="0.36458234166158693">
<NAME>extrapyramidal symptoms: ESRS total score (high = poor)</NAME>
<CONT_DATA CI_END="1.3127747511913235" CI_START="-1.9127747511913231" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="5.1" ORDER="208" SD_1="3.6" SD_2="3.8" SE="0.8228593810461237" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" WEIGHT="24.22411515068407"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.3385597634379365" CI_END="5.583986519238538" CI_START="0.509323045285179" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6864320380050772" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.25" LOG_CI_END="0.7469443611503157" LOG_CI_START="-0.2930066729034246" LOG_EFFECT_SIZE="0.22696884412344548" METHOD="MH" MODIFIED="2009-09-21 10:21:34 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.5051743036524214" P_Q="0.0" P_Z="0.3922619562623453" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="282" TOTAL_2="285" WEIGHT="100.0" Z="0.8555225112101783">
<NAME>Adverse effects: 6. Haematological - white blood cells - significant low white blood cell count (as def. by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="43.176669526805036" CI_START="0.6050364022149839" EFFECT_SIZE="5.111111111111111" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6352491395750017" LOG_CI_START="-0.21821849509050348" LOG_EFFECT_SIZE="0.7085153222422492" ORDER="225" O_E="0.0" SE="1.088736063415279" STUDY_ID="STD-Azorin-2001" TOTAL_1="135" TOTAL_2="138" VAR="1.1853462157809984" WEIGHT="31.48152548895515"/>
<DICH_DATA CI_END="71.65227627955493" CI_START="0.12560661666750186" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8552299918017103" LOG_CI_START="-0.9009874823623858" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="226" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="14.23635531186612"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="227" O_E="0.0" SE="0.0" STUDY_ID="STD-McGurk-2005" TOTAL_1="54" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.594638368544499" CI_START="0.1443315528464402" EFFECT_SIZE="0.975609756097561" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.819190985045122" LOG_CI_START="-0.8406387158286682" LOG_EFFECT_SIZE="-0.010723865391773113" ORDER="228" O_E="0.0" SE="0.9749921825827943" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.9506097560975609" WEIGHT="39.255337814475624"/>
<DICH_DATA CI_END="8.778778178034305" CI_START="0.01822577091654301" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9434340754206604" LOG_CI_START="-1.7393140927647355" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="229" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="11" VAR="2.483333333333333" WEIGHT="15.026781384703105"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.35067319986737" CI_START="0.3864482940154323" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="1.0149685968924291" LOG_CI_START="-0.4129086055644666" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2009-09-21 10:21:45 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.40857001147857763" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.8264127317845636">
<NAME>Adverse effects: 7a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.35067319986737" CI_START="0.3864482940154323" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-003.26.01" LOG_CI_END="1.0149685968924291" LOG_CI_START="-0.4129086055644666" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-09-21 10:21:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.40857001147857763" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.8264127317845636">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="10.35067319986737" CI_START="0.3864482940154323" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0149685968924291" LOG_CI_START="-0.4129086055644666" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="210" O_E="0.0" SE="0.8387421368293256" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.7034883720930232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.5479563203142783" CI_END="46.6907226802043" CI_START="10.519602535120914" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="28.605162607662606" ESTIMABLE="YES" I2="71.81476011205741" I2_Q="71.81476011205741" ID="CMP-003.27" MODIFIED="2009-09-21 10:21:58 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.05961898489604256" P_Q="0.05961898489604256" P_Z="0.0019352598007844725" Q="3.5479563203142783" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="122.89300824175825" TOTALS="YES" TOTAL_1="30" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="3.0999918309442402">
<NAME>Adverse effects: 7b. Prolactin associated side effects - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="53.70223212296273" CI_START="23.297767877037273" DF="0" EFFECT_SIZE="38.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.27.01" MODIFIED="2009-09-21 10:21:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="6.917930125635593E-7" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="46.514392473851935" Z="4.963653547350659">
<NAME>change from baseline in ng/ml</NAME>
<CONT_DATA CI_END="53.70223212296273" CI_START="23.297767877037273" EFFECT_SIZE="38.5" ESTIMABLE="YES" MEAN_1="50.7" MEAN_2="12.2" ORDER="211" SD_1="27.9" SD_2="7.7" SE="7.756383404427834" STUDY_ID="STD-Breier-1999" TOTAL_1="14" TOTAL_2="13" WEIGHT="46.514392473851935"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="31.80908797656485" CI_START="8.19091202343515" DF="0" EFFECT_SIZE="20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.27.02" MODIFIED="2009-09-21 10:21:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.020582634625157E-4" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="53.485607526148065" Z="3.3194163485437747">
<NAME>change fom baseline in mg/ml - of men only</NAME>
<CONT_DATA CI_END="31.80908797656485" CI_START="8.19091202343515" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="12.0" ORDER="212" SD_1="12.2" SD_2="18.0" SE="6.025155599650518" STUDY_ID="STD-Volavka-2002" TOTAL_1="16" TOTAL_2="12" WEIGHT="53.485607526148065"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="19.805896616119185" CI_START="-34.00589661611919" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.28" MODIFIED="2009-09-21 10:22:52 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.6050161763660028" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="0.5172005411593508">
<NAME>Adverse effects: 3a. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.805896616119185" CI_START="-34.00589661611919" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="16.3" ORDER="189" SD_1="36.7" SD_2="39.6" SE="13.727750524167517" STUDY_ID="STD-Volavka-2002" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.6399974110196" CI_START="-12.039997411019602" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.29" MODIFIED="2009-09-21 10:23:14 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.7472724953160583" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="0.32223787311273017">
<NAME>Adverse effects: 3b. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.6399974110196" CI_START="-12.039997411019602" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="4.4" ORDER="209" SD_1="12.2" SD_2="17.1" SE="5.275605823668282" STUDY_ID="STD-Volavka-2002" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.028709652466532093" CI_END="1.0814186244702177" CI_START="0.340959047218256" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6072227464805995" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="0.03399384483549301" LOG_CI_START="-0.4672977812280432" LOG_EFFECT_SIZE="-0.2166519681962751" METHOD="MH" MODIFIED="2009-09-21 13:14:51 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.8654511990882339" P_Q="0.0" P_Z="0.09023795747954544" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="83" WEIGHT="100.0" Z="1.6941438187543019">
<NAME>Adverse effects: 3c. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7583028504986467" CI_START="0.17675938900069665" DF="0" EFFECT_SIZE="0.5574912891986062" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-003.30.01" LOG_CI_END="0.24509368016476846" LOG_CI_START="-0.7526175083209035" LOG_EFFECT_SIZE="-0.2537619140780676" NO="1" P_CHI2="1.0" P_Z="0.31875947839677654" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="25.24475817385381" Z="0.997010393350125">
<NAME>10% of total body weight or more</NAME>
<DICH_DATA CI_END="1.7583028504986467" CI_START="0.17675938900069665" EFFECT_SIZE="0.5574912891986062" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.24509368016476846" LOG_CI_START="-0.7526175083209035" LOG_EFFECT_SIZE="-0.2537619140780676" ORDER="220" O_E="0.0" SE="0.5860604908665178" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.3434668989547038" WEIGHT="25.24475817385381"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2183562226463915" CI_START="0.32061641147243736" DF="0" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" I2="0.0" ID="CMP-003.30.02" LOG_CI_END="0.0857742857607916" LOG_CI_START="-0.4940142510726412" LOG_EFFECT_SIZE="-0.2041199826559248" NO="2" P_CHI2="1.0" P_Z="0.16757206893463933" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="74.75524182614619" Z="1.3800473417965777">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="1.2183562226463915" CI_START="0.32061641147243736" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.0857742857607916" LOG_CI_START="-0.4940142510726412" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="221" O_E="0.0" SE="0.34057065653550256" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.11598837209302325" WEIGHT="74.75524182614619"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.515619597778661" CI_END="-0.9460844276996805" CI_START="-5.65174080339041" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2989126155450457" ESTIMABLE="YES" I2="84.01996813361944" I2_Q="0.0" ID="CMP-003.31" MODIFIED="2009-09-21 10:23:51 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.0019154495861043452" P_Q="1.0" P_Z="0.0059946171216200056" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="3.6155804969511083" TOTALS="YES" TOTAL_1="186" TOTAL_2="187" UNITS="" WEIGHT="100.0" Z="2.7480756767599845">
<NAME>Adverse effects: 3d. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.085467795398046" CI_START="-7.8745322046019535" EFFECT_SIZE="-5.9799999999999995" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="6.52" ORDER="222" SD_1="0.72" SD_2="3.41" SE="0.9666158253650485" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="31.672318173929305"/>
<CONT_DATA CI_END="-0.9045879000346444" CI_START="-3.495412099965355" EFFECT_SIZE="-2.1999999999999997" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="2.4" ORDER="223" SD_1="5.43" SD_2="5.43" SE="0.6609366856653492" STUDY_ID="STD-Azorin-2001" TOTAL_1="134" TOTAL_2="136" WEIGHT="35.56067801624339"/>
<CONT_DATA CI_END="-0.16641054774029818" CI_START="-3.6335894522597023" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="4.2" ORDER="224" SD_1="2.8" SD_2="4.7" SE="0.8845006673255399" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="38" WEIGHT="32.76700380982731"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-11-23 15:33:43 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>RISPERIDONE versus OLANZAPINE</NAME>
<DICH_OUTCOME CHI2="5.2419986846309214" CI_END="1.1337029137031271" CI_START="0.9902687988829304" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0595615237648421" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="397" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.05449926280811906" LOG_CI_START="-0.004246904365599686" LOG_EFFECT_SIZE="0.025126179221259672" METHOD="MH" MODIFIED="2009-09-18 15:08:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5131707947171114" P_Q="0.0" P_Z="0.0936240950322415" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="685" TOTAL_2="691" WEIGHT="100.0" Z="1.6765827869975143">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.206689526932974" CI_START="0.8531351806708314" EFFECT_SIZE="1.014627659574468" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="108" LOG_CI_END="0.08159554343240076" LOG_CI_START="-0.06898214870592426" LOG_EFFECT_SIZE="0.006306697363238227" ORDER="273" O_E="0.0" SE="0.0884500817336494" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.00782341695868926" WEIGHT="15.220811255371538"/>
<DICH_DATA CI_END="1.1927921689918466" CI_START="0.8892271924446544" EFFECT_SIZE="1.0298850574712644" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.07656477919175833" LOG_CI_START="-0.05098726510474498" LOG_EFFECT_SIZE="0.012788757043506667" ORDER="274" O_E="0.0" SE="0.07492470221256828" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" VAR="0.005613711001642034" WEIGHT="21.212127390499976"/>
<DICH_DATA CI_END="1.467815270972078" CI_START="0.7509864949770175" EFFECT_SIZE="1.0499092558983667" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.16667140173423725" LOG_CI_START="-0.12436787286227054" LOG_EFFECT_SIZE="0.02115176443598335" ORDER="275" O_E="0.0" SE="0.17095791056563267" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.029226607184966856" WEIGHT="4.0743269359548515"/>
<DICH_DATA CI_END="1.3517940730655456" CI_START="0.7092554851471244" EFFECT_SIZE="0.9791666666666666" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="48" LOG_CI_END="0.13091053794963226" LOG_CI_START="-0.14919729682937186" LOG_EFFECT_SIZE="-0.009143379439869771" ORDER="276" O_E="0.0" SE="0.16453672870533126" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.027072335093051778" WEIGHT="4.398540151449444"/>
<DICH_DATA CI_END="1.1552758045619502" CI_START="0.6011070617961737" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" LOG_CI_END="0.06268567782151785" LOG_CI_START="-0.22104816991676746" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="277" O_E="0.0" SE="0.16666666666666666" STUDY_ID="STD-Robinson-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.027777777777777773" WEIGHT="4.286835104410155"/>
<DICH_DATA CI_END="10.324424584242683" CI_START="0.5579003413702117" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0138658562749796" LOG_CI_START="-0.2534433728517676" LOG_EFFECT_SIZE="0.38021124171160603" ORDER="278" O_E="0.0" SE="0.7444237144709097" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.5541666666666666" WEIGHT="0.21487895260201276"/>
<DICH_DATA CI_END="1.2242955361714047" CI_START="1.0122657394788768" EFFECT_SIZE="1.1132441000352236" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="136" LOG_CI_END="0.08788626604144172" LOG_CI_START="0.005294538234406676" LOG_EFFECT_SIZE="0.046590402137924175" ORDER="279" O_E="0.0" SE="0.04851478974949865" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.0023536848244380595" WEIGHT="50.59248020971203"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.339223756729817" CI_END="1.0870264767924693" CI_START="0.8756063112556131" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9756060903773814" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="267" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.036240122361206314" LOG_CI_START="-0.05769111675507847" LOG_EFFECT_SIZE="-0.010725497196936076" METHOD="MH" MODIFIED="2009-09-18 15:26:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5027419009099162" P_Q="0.0" P_Z="0.6544453332872424" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="488" TOTAL_2="487" WEIGHT="100.00000000000001" Z="0.44759524988818183">
<NAME>Global state: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.342936210323415" CI_END="1.1608350521083963" CI_START="0.8689583490404394" DF="2" EFFECT_SIZE="1.0043491974350278" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="183" I2="14.637027197427484" ID="CMP-004.02.01" LOG_CI_END="0.06477051340919397" LOG_CI_START="-0.06100103967954118" LOG_EFFECT_SIZE="0.001884736864826378" MODIFIED="2009-09-18 15:26:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.30991167328278546" P_Z="0.9531578580968081" STUDIES="3" TAU2="0.0029265494517414143" TOTAL_1="295" TOTAL_2="294" WEIGHT="77.7950593665096" Z="0.058741683388268684">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1041026417248445" CI_START="0.8149422124167727" EFFECT_SIZE="0.9485672614962252" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="124" LOG_CI_END="0.04300944899339249" LOG_CI_START="-0.0888731860064107" LOG_EFFECT_SIZE="-0.022931868506509117" ORDER="280" O_E="0.0" SE="0.07746851262845636" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.0060013704488653015" WEIGHT="50.727664926327066"/>
<DICH_DATA CI_END="1.328465254500316" CI_START="0.8728590062861297" EFFECT_SIZE="1.0768300060496068" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="57" LOG_CI_END="0.1233502000890771" LOG_CI_START="-0.059055902614184135" LOG_EFFECT_SIZE="0.032147148737446486" ORDER="281" O_E="0.0" SE="0.1071462476526662" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.011480318386046476" WEIGHT="26.51803713029598"/>
<DICH_DATA CI_END="10.324424584242683" CI_START="0.5579003413702117" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0138658562749796" LOG_CI_START="-0.2534433728517676" LOG_EFFECT_SIZE="0.38021124171160603" ORDER="282" O_E="0.0" SE="0.7444237144709097" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.5541666666666666" WEIGHT="0.5493573098865566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1552758045619502" CI_START="0.6011070617961737" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.06268567782151785" LOG_CI_START="-0.22104816991676746" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2009-09-18 15:26:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.27398598632828397" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="10.959678332236805" Z="1.0939293407637276">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.1552758045619502" CI_START="0.6011070617961737" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" LOG_CI_END="0.06268567782151785" LOG_CI_START="-0.22104816991676746" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="283" O_E="0.0" SE="0.16666666666666666" STUDY_ID="STD-Robinson-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.027777777777777773" WEIGHT="10.959678332236805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3517940730655456" CI_START="0.7092554851471244" DF="0" EFFECT_SIZE="0.9791666666666666" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="48" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="0.13091053794963226" LOG_CI_START="-0.14919729682937186" LOG_EFFECT_SIZE="-0.009143379439869771" MODIFIED="2009-09-18 15:26:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8981840459845761" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="133" WEIGHT="11.245262301253602" Z="0.1279556811630607">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.3517940730655456" CI_START="0.7092554851471244" EFFECT_SIZE="0.9791666666666666" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="48" LOG_CI_END="0.13091053794963226" LOG_CI_START="-0.14919729682937186" LOG_EFFECT_SIZE="-0.009143379439869771" ORDER="284" O_E="0.0" SE="0.16453672870533126" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.027072335093051778" WEIGHT="11.245262301253602"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.431959031561414" CI_END="2.7128912813130897" CI_START="0.5714963769677229" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2451536203929836" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" I2="30.16559985591236" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.4334323898279884" LOG_CI_START="-0.24298651849339445" LOG_EFFECT_SIZE="0.09522293566729696" METHOD="MH" MODIFIED="2009-09-18 15:26:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23144524816894074" P_Q="0.0" P_Z="0.5810660466023532" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10101630162919864" TOTALS="YES" TOTAL_1="115" TOTAL_2="96" WEIGHT="100.0" Z="0.5518282298560541">
<NAME>Global state: 1c. Relapse (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.835416665224275E-32" CI_END="2.2488145006967986" CI_START="0.2501317915842808" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="100.0" ID="CMP-004.03.01" LOG_CI_END="0.3519536330050671" LOG_CI_START="-0.601831106221667" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2009-09-18 15:26:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6076145288601198" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="36" WEIGHT="38.05027627495315" Z="0.5134815309054594">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.2488145006967986" CI_START="0.2501317915842808" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3519536330050671" LOG_CI_START="-0.601831106221667" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="285" O_E="0.0" SE="0.5602578771323871" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.3138888888888889" WEIGHT="38.05027627495315"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6668494971517296" CI_START="0.788142519142071" DF="0" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.5642930850634462" LOG_CI_START="-0.10339524230689837" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2009-09-18 15:26:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.17607435584406747" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="60" WEIGHT="61.94972372504686" Z="1.3529413879568757">
<NAME>long term</NAME>
<DICH_DATA CI_END="3.6668494971517296" CI_START="0.788142519142071" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.5642930850634462" LOG_CI_START="-0.10339524230689837" LOG_EFFECT_SIZE="0.2304489213782739" ORDER="286" O_E="0.0" SE="0.39220342860786506" STUDY_ID="STD-Keefe-2006" TOTAL_1="75" TOTAL_2="60" VAR="0.15382352941176472" WEIGHT="61.94972372504686"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="50.364307770848015" CI_END="1.2110703399603484" CI_START="1.0727322604096876" CI_STUDY="95" CI_TOTAL="95" DF="42" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1398044671349528" ESTIMABLE="YES" EVENTS_1="1105" EVENTS_2="959" I2="16.607609914752892" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.08316936805592219" LOG_CI_START="0.03049134141036306" LOG_EFFECT_SIZE="0.056830354733142664" METHOD="MH" MODIFIED="2009-09-18 15:56:44 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.17620722924702614" P_Q="0.0" P_Z="2.3482103794871044E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.009003131140667203" TOTALS="SUB" TOTAL_1="4049" TOTAL_2="4028" WEIGHT="300.0" Z="4.2289149992290005">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.067383732253985" CI_END="1.2135371322634023" CI_START="1.0669981909400834" DF="15" EFFECT_SIZE="1.1379112112830538" ESTIMABLE="YES" EVENTS_1="762" EVENTS_2="653" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.08405306957637863" LOG_CI_START="0.028163683093255985" LOG_EFFECT_SIZE="0.05610837633481727" MODIFIED="2009-09-18 15:56:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.747803231511659" P_Z="8.309722507065404E-5" STUDIES="16" TAU2="0.0" TOTAL_1="1373" TOTAL_2="1365" WEIGHT="100.0" Z="3.93528731543582">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="14.45413717356195" CI_START="0.06918434410800384" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1599921719703592" LOG_CI_START="-1.1599921719703592" LOG_EFFECT_SIZE="0.0" ORDER="230" O_E="0.0" SE="1.3627702877384937" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="1.8571428571428572" WEIGHT="0.058034811240202516"/>
<DICH_DATA CI_END="1.754757985823653" CI_START="0.8749948770718524" EFFECT_SIZE="1.2391142998515587" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="43" LOG_CI_END="0.24421722754315042" LOG_CI_START="-0.05799448968161673" LOG_EFFECT_SIZE="0.09311136893076684" ORDER="231" O_E="0.0" SE="0.17752065866995523" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.03151358425461475" WEIGHT="3.420078601328673"/>
<DICH_DATA CI_END="2.1812359076767756" CI_START="0.458455683991144" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3387026384634917" LOG_CI_START="-0.3387026384634917" LOG_EFFECT_SIZE="0.0" ORDER="245" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.15833333333333333" WEIGHT="0.6807090641707965"/>
<DICH_DATA CI_END="2.1292692189916784" CI_START="0.8655607854182742" EFFECT_SIZE="1.3575757575757577" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.328230575919607" LOG_CI_START="-0.06270242767909391" LOG_EFFECT_SIZE="0.13276407412025656" ORDER="232" O_E="0.0" SE="0.2296359814634544" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.05273268398268398" WEIGHT="2.0438734959094416"/>
<DICH_DATA CI_END="2.3287874119778644" CI_START="0.7988939575320245" EFFECT_SIZE="1.3639846743295019" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" LOG_CI_END="0.3671298449027026" LOG_CI_START="-0.09751086363351419" LOG_EFFECT_SIZE="0.1348094906345942" ORDER="233" O_E="0.0" SE="0.27293225220277506" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.07449201429247922" WEIGHT="1.4468522053545485"/>
<DICH_DATA CI_END="1.3058109256384625" CI_START="0.9294354749981366" EFFECT_SIZE="1.1016655562958029" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="95" LOG_CI_END="0.11588029799845301" LOG_CI_START="-0.03178075524653006" LOG_EFFECT_SIZE="0.04204977137596148" ORDER="234" O_E="0.0" SE="0.08673683361010498" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.007523278304707037" WEIGHT="14.326059836566568"/>
<DICH_DATA CI_END="1.2772133684516094" CI_START="1.0428933092943877" EFFECT_SIZE="1.1541218637992832" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="216" LOG_CI_END="0.10626345560369044" LOG_CI_START="0.01823988124077624" LOG_EFFECT_SIZE="0.062251668422233356" ORDER="235" O_E="0.0" SE="0.05170548330449618" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.0026734570037515335" WEIGHT="40.3144449337076"/>
<DICH_DATA CI_END="1.8529674146119626" CI_START="0.7610259300190158" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2678677820935081" LOG_CI_START="-0.11860054549969974" LOG_EFFECT_SIZE="0.07463361829690418" ORDER="236" O_E="0.0" SE="0.22701340867732514" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.05153508771929824" WEIGHT="2.0913699758779365"/>
<DICH_DATA CI_END="1.222336069837592" CI_START="0.8916076753401853" EFFECT_SIZE="1.043956043956044" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="91" LOG_CI_END="0.08719062751858053" LOG_CI_START="-0.04982620158307213" LOG_EFFECT_SIZE="0.018682212967754193" ORDER="237" O_E="0.0" SE="0.08048436365855338" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.006477732793522269" WEIGHT="16.638373115383057"/>
<DICH_DATA CI_END="2.7758033875549644" CI_START="0.8717307202910959" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.4433887014355833" LOG_CI_START="-0.05961764895775695" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="238" O_E="0.0" SE="0.2954684201426394" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.0873015873015873" WEIGHT="1.2345587118370354"/>
<DICH_DATA CI_END="3.030486172073819" CI_START="0.32998005706644784" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.481512306690943" LOG_CI_START="-0.48151230669094314" LOG_EFFECT_SIZE="0.0" ORDER="239" O_E="0.0" SE="0.5656854249492381" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.32000000000000006" WEIGHT="0.3368091723761753"/>
<DICH_DATA CI_END="15.71734278975809" CI_START="1.0179837784301613" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.1963791250819027" LOG_CI_START="0.007740857574021869" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="240" O_E="0.0" SE="0.698212002188447" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.48749999999999993" WEIGHT="0.22108499520077154"/>
<DICH_DATA CI_END="1.2078440823886156" CI_START="0.7476876955614661" EFFECT_SIZE="0.9503105590062112" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="46" LOG_CI_END="0.08201087590051492" LOG_CI_START="-0.12627976632901672" LOG_EFFECT_SIZE="-0.0221344452142509" ORDER="241" O_E="0.0" SE="0.12235095430093455" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="68" VAR="0.014969756018349375" WEIGHT="7.199779009642152"/>
<DICH_DATA CI_END="1.5559315196007546" CI_START="0.9907249423830752" EFFECT_SIZE="1.2415716512181116" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="73" LOG_CI_END="0.19199047869866934" LOG_CI_START="-0.004046903119312673" LOG_EFFECT_SIZE="0.09397178778967832" ORDER="242" O_E="0.0" SE="0.11515332848057307" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.013260289060154761" WEIGHT="8.12794763910812"/>
<DICH_DATA CI_END="2.4161779017285103" CI_START="0.7999320360004105" EFFECT_SIZE="1.3902439024390243" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.3831289079683722" LOG_CI_START="-0.09694691006286048" LOG_EFFECT_SIZE="0.14309099895275587" ORDER="243" O_E="0.0" SE="0.2819989119251716" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="0.0795233863269807" WEIGHT="1.355311187544448"/>
<DICH_DATA CI_END="3.541305124184403" CI_START="0.5787183568432211" EFFECT_SIZE="1.431578947368421" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.549163347837079" LOG_CI_START="-0.23753274167433938" LOG_EFFECT_SIZE="0.15581530308136976" ORDER="244" O_E="0.0" SE="0.4621091771874552" STUDY_ID="STD-Wang-2006" TOTAL_1="19" TOTAL_2="17" VAR="0.21354489164086687" WEIGHT="0.504713244752468"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.27606376458574" CI_END="1.3011670382917597" CI_START="0.7054316377769921" DF="12" EFFECT_SIZE="0.9580628344965659" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="153" I2="30.539733104025466" ID="CMP-004.04.02" LOG_CI_END="0.11433305301949992" LOG_CI_START="-0.15154506663642134" LOG_EFFECT_SIZE="-0.018606006808460716" MODIFIED="2009-09-18 15:56:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13950461776426915" P_Z="0.7838429917301708" STUDIES="13" TAU2="0.08239183444893516" TOTAL_1="1301" TOTAL_2="1294" WEIGHT="100.0" Z="0.27431443616257656">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="2.3702261195993795" CI_START="0.7141108785259557" EFFECT_SIZE="1.3010012515644556" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.374789779685147" LOG_CI_START="-0.1462343509781538" LOG_EFFECT_SIZE="0.11427771435349658" ORDER="246" O_E="0.0" SE="0.306052153462665" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.09366792063913466" WEIGHT="13.854163480009685"/>
<DICH_DATA CI_END="2.813925188531191" CI_START="0.16191795071773982" EFFECT_SIZE="0.675" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.44931254702908296" LOG_CI_START="-0.790705001367033" LOG_EFFECT_SIZE="-0.17069622716897506" ORDER="258" O_E="0.0" SE="0.7283924461137385" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.5305555555555554" WEIGHT="3.9793963870581393"/>
<DICH_DATA CI_END="3.4095593066557197" CI_START="0.30693277012307135" EFFECT_SIZE="1.0229885057471264" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.532698249064069" LOG_CI_START="-0.5129567410114806" LOG_EFFECT_SIZE="0.009870754026294247" ORDER="247" O_E="0.0" SE="0.6142229172460574" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.377269792070257" WEIGHT="5.306426485306674"/>
<DICH_DATA CI_END="2.9525909016374414" CI_START="0.8780449772171399" EFFECT_SIZE="1.610126582278481" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="0.47020327714815136" LOG_CI_START="-0.05648323710424406" LOG_EFFECT_SIZE="0.2068600200219536" ORDER="248" O_E="0.0" SE="0.30937826561215004" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.09571491123318207" WEIGHT="13.694936819484482"/>
<DICH_DATA CI_END="0.7982292495847949" CI_START="0.36577718581478236" EFFECT_SIZE="0.5403462302525778" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="62" LOG_CI_END="-0.097872362369417" LOG_CI_START="-0.4367833857478879" LOG_EFFECT_SIZE="-0.26732787405865244" ORDER="249" O_E="0.0" SE="0.19907801276913606" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.039632055168108304" WEIGHT="19.989205694848632"/>
<DICH_DATA CI_END="9.011735600766475" CI_START="0.017065192745446014" EFFECT_SIZE="0.39215686274509803" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9548084412838611" LOG_CI_START="-1.7678888021517716" LOG_EFFECT_SIZE="-0.4065401804339552" ORDER="250" O_E="0.0" SE="1.599325838362809" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" VAR="2.557843137254902" WEIGHT="0.9238422547166358"/>
<DICH_DATA CI_END="1.8993618146840907" CI_START="0.45396558533140546" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2786077025744926" LOG_CI_START="-0.3429770693172951" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="251" O_E="0.0" SE="0.36512197190348045" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.13331405436668595" WEIGHT="11.307807323357347"/>
<DICH_DATA CI_END="8.07940769350109" CI_START="0.2784857610057052" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9073795235378425" LOG_CI_START="-0.55519700542648" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="252" O_E="0.0" SE="0.8591246929842244" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.7380952380952379" WEIGHT="2.9728203049893485"/>
<DICH_DATA CI_END="126.06834462038681" CI_START="0.42105441150115064" EFFECT_SIZE="7.285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.100606050232446" LOG_CI_START="-0.37566177806508694" LOG_EFFECT_SIZE="0.8624721360836796" ORDER="253" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="2.1157796451914104" WEIGHT="1.1096316424047454"/>
<DICH_DATA CI_END="1.231302954586414" CI_START="0.22221133023068623" EFFECT_SIZE="0.5230769230769231" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.09036492158902208" LOG_CI_START="-0.653233800790223" LOG_EFFECT_SIZE="-0.28143443960060044" ORDER="254" O_E="0.0" SE="0.43679357039860867" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="68" VAR="0.1907886231415643" WEIGHT="8.928752264178849"/>
<DICH_DATA CI_END="1.9486800225871013" CI_START="0.5443565069671749" EFFECT_SIZE="1.029940119760479" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.28974053289224505" LOG_CI_START="-0.2641165813723138" LOG_EFFECT_SIZE="0.012811975759965595" ORDER="255" O_E="0.0" SE="0.32533841055593404" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.1058450813830615" WEIGHT="12.957929205648277"/>
<DICH_DATA CI_END="20.150326280025773" CI_START="0.1796136792638711" EFFECT_SIZE="1.9024390243902438" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.304282082758394" LOG_CI_START="-0.7456605908169043" LOG_EFFECT_SIZE="0.27931074597074484" ORDER="256" O_E="0.0" SE="1.2041464738380192" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="1.4499687304565354" WEIGHT="1.5917667715437815"/>
<DICH_DATA CI_END="8.568641858362714" CI_START="0.3737133748164229" EFFECT_SIZE="1.7894736842105263" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9329119910992828" LOG_CI_START="-0.4274613589204303" LOG_EFFECT_SIZE="0.25272531608942617" ORDER="257" O_E="0.0" SE="0.7990900397582659" STUDY_ID="STD-Wang-2006" TOTAL_1="19" TOTAL_2="17" VAR="0.6385448916408669" WEIGHT="3.383321366453395"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.604479551184511" CI_END="1.6015135872998887" CI_START="1.020241141177999" DF="13" EFFECT_SIZE="1.2782527331943825" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="153" I2="10.986215192135196" ID="CMP-004.04.03" LOG_CI_END="0.20453062758574994" LOG_CI_START="0.008702832453674628" LOG_EFFECT_SIZE="0.10661673001971225" MODIFIED="2009-09-18 15:56:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.33269049866029465" P_Z="0.032828827186685505" STUDIES="14" TAU2="0.019748484766757435" TOTAL_1="1375" TOTAL_2="1369" WEIGHT="100.00000000000001" Z="2.134170492468966">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="2.046974166120395" CI_START="0.07899789712603944" EFFECT_SIZE="0.4021276595744681" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31111236167464223" LOG_CI_START="-1.1023844691995888" LOG_EFFECT_SIZE="-0.3956360537624733" ORDER="259" O_E="0.0" SE="0.830295035377681" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.6893898457728245" WEIGHT="1.8659195356745362"/>
<DICH_DATA CI_END="7.627150039521771" CI_START="0.23894901641587124" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8823622898127927" LOG_CI_START="-0.6216947528227804" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="272" O_E="0.0" SE="0.8834905520465713" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.7805555555555554" WEIGHT="1.653365468349418"/>
<DICH_DATA CI_END="4.233916692624244" CI_START="0.746470480315845" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6267423085040044" LOG_CI_START="-0.1269873620708047" LOG_EFFECT_SIZE="0.24987747321659987" ORDER="260" O_E="0.0" SE="0.4427445395176854" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.19602272727272727" WEIGHT="6.13239853427387"/>
<DICH_DATA CI_END="28.93749616114478" CI_START="0.32547907025429557" EFFECT_SIZE="3.0689655172413794" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4614609507484215" LOG_CI_START="-0.4874769332565079" LOG_EFFECT_SIZE="0.4869920087459567" ORDER="261" O_E="0.0" SE="1.1448157604626126" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="1.3106031254035901" WEIGHT="0.9946205607102631"/>
<DICH_DATA CI_END="1.6461764273469812" CI_START="0.49829750788148286" EFFECT_SIZE="0.9056962025316456" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.21647637845656154" LOG_CI_START="-0.302511284845854" LOG_EFFECT_SIZE="-0.04301745319464624" ORDER="262" O_E="0.0" SE="0.30485592245420506" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.09293713345540429" WEIGHT="11.742359720126213"/>
<DICH_DATA CI_END="2.5609962663133676" CI_START="1.362577337296342" EFFECT_SIZE="1.8680351906158357" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="48" LOG_CI_END="0.4084089453092405" LOG_CI_START="0.13436116137646495" LOG_EFFECT_SIZE="0.2713850533428527" ORDER="263" O_E="0.0" SE="0.1609770248405211" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.02591360252650575" WEIGHT="28.977980265143326"/>
<DICH_DATA CI_END="2.9665213923019347" CI_START="0.4753568451113577" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.47224748448712073" LOG_CI_START="-0.3229802478933124" LOG_EFFECT_SIZE="0.07463361829690418" ORDER="264" O_E="0.0" SE="0.4671207064410278" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.2182017543859649" WEIGHT="5.560805776707681"/>
<DICH_DATA CI_END="1.6436065176478245" CI_START="0.389387601672393" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.2157978547685103" LOG_CI_START="-0.40961788078462313" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="265" O_E="0.0" SE="0.3673722989217309" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.1349624060150376" WEIGHT="8.552695015606062"/>
<DICH_DATA CI_END="32.86698604505921" CI_START="0.48681068528963045" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.516759880412206" LOG_CI_START="-0.3126398977562814" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="266" O_E="0.0" SE="1.0745984853711197" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="1.1547619047619047" WEIGHT="1.126592898833733"/>
<DICH_DATA CI_END="3.2087008039370097" CI_START="0.1753045965862022" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5063292230920509" LOG_CI_START="-0.7562066963086507" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="267" O_E="0.0" SE="0.7416198487095662" STUDY_ID="STD-Robinson-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.5499999999999998" WEIGHT="2.3224196287088326"/>
<DICH_DATA CI_END="7.651558684015131" CI_START="0.3345723539111183" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.8837499134430681" LOG_CI_START="-0.47550994813121833" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="268" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.6375" WEIGHT="2.013234104174473"/>
<DICH_DATA CI_END="2.1207787517491132" CI_START="0.6407503822818021" EFFECT_SIZE="1.1657142857142857" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.32649536351589986" LOG_CI_START="-0.19331112603669118" LOG_EFFECT_SIZE="0.06659211873960431" ORDER="269" O_E="0.0" SE="0.30533690504681343" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="68" VAR="0.09323062558356675" WEIGHT="11.71185593820385"/>
<DICH_DATA CI_END="1.9848961744870182" CI_START="0.7274107853490765" EFFECT_SIZE="1.2015968063872255" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.29773779471291256" LOG_CI_START="-0.1382202639317549" LOG_EFFECT_SIZE="0.07975876539057883" ORDER="270" O_E="0.0" SE="0.25608392167507216" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.06557897494048448" WEIGHT="15.50725955031719"/>
<DICH_DATA CI_END="2.4513264633872436" CI_START="0.09227846371087259" EFFECT_SIZE="0.47560975609756095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3894011536862331" LOG_CI_START="-1.0348996444006682" LOG_EFFECT_SIZE="-0.3227492453572175" ORDER="271" O_E="0.0" SE="0.8366413391989038" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="0.6999687304565353" WEIGHT="1.838493003170572"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3498613830313873" CI_END="1.177038828983094" CI_START="1.0034677674269534" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0867936905846027" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="167" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.07079078989096638" LOG_CI_START="0.0015034269944736453" LOG_EFFECT_SIZE="0.036147108442720066" METHOD="MH" MODIFIED="2009-09-18 15:26:58 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5091917544019042" P_Q="0.0" P_Z="0.040852860038810834" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="235" TOTAL_2="237" WEIGHT="99.99999999999999" Z="2.045020267226283">
<NAME>Mental state: 1a. General - no clinically important change (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.57446901680259" CI_START="0.04121544609241175" DF="0" EFFECT_SIZE="0.43421052631578944" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.6603406904339929" LOG_CI_START="-1.3849399952398005" LOG_EFFECT_SIZE="-0.3622996524029039" MODIFIED="2009-09-18 15:26:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48744806426416787" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="33" WEIGHT="0.11476308920712967" Z="0.6943734180789372">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.57446901680259" CI_START="0.04121544609241175" EFFECT_SIZE="0.4342105263157895" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6603406904339929" LOG_CI_START="-1.3849399952398005" LOG_EFFECT_SIZE="-0.36229965240290385" ORDER="287" O_E="0.0" SE="1.201407999067463" STUDY_ID="STD-Dollfus-2005" TOTAL_1="38" TOTAL_2="33" VAR="1.4433811802232854" WEIGHT="0.11476308920712967"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8198934526967077" CI_END="1.1783341957974973" CI_START="1.0044800739196942" DF="1" EFFECT_SIZE="1.0879398972814507" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="165" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.07126848128874956" LOG_CI_START="0.0019413259796828993" LOG_EFFECT_SIZE="0.03660490363421622" MODIFIED="2009-09-18 15:26:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3652113814808515" P_Z="0.03847751086027542" STUDIES="2" TAU2="0.0" TOTAL_1="197" TOTAL_2="204" WEIGHT="99.88523691079286" Z="2.06973133286028">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.1927921689918466" CI_START="0.8892271924446544" EFFECT_SIZE="1.0298850574712644" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.07656477919175833" LOG_CI_START="-0.05098726510474498" LOG_EFFECT_SIZE="0.012788757043506667" ORDER="288" O_E="0.0" SE="0.07492470221256828" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" VAR="0.005613711001642034" WEIGHT="29.507554467517938"/>
<DICH_DATA CI_END="1.2242955361714047" CI_START="1.0122657394788768" EFFECT_SIZE="1.1132441000352236" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="136" LOG_CI_END="0.08788626604144172" LOG_CI_START="0.005294538234406676" LOG_EFFECT_SIZE="0.046590402137924175" ORDER="289" O_E="0.0" SE="0.04851478974949865" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.0023536848244380595" WEIGHT="70.37768244327492"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03202318296622768" CI_END="1.1920939205414345" CI_START="0.8761374356514878" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0219775489700842" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="146" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.07631047316095281" LOG_CI_START="-0.05742776270936476" LOG_EFFECT_SIZE="0.009441355225794009" METHOD="MH" MODIFIED="2009-09-18 15:27:03 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8579768296292944" P_Q="0.0" P_Z="0.7819871453494917" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="278" WEIGHT="100.00000000000001" Z="0.276730376879636">
<NAME>Mental state: 1b. General - no clinically important change - short term (less than 20% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.206689526932974" CI_START="0.8531351806708314" EFFECT_SIZE="1.014627659574468" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="108" LOG_CI_END="0.08159554343240076" LOG_CI_START="-0.06898214870592426" LOG_EFFECT_SIZE="0.006306697363238227" MODIFIED="2009-09-18 15:27:03 +0100" MODIFIED_BY="[Empty name]" ORDER="1820" O_E="0.0" SE="0.0884500817336494" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.00782341695868926" WEIGHT="78.88417851401368"/>
<DICH_DATA CI_END="1.467815270972078" CI_START="0.7509864949770175" EFFECT_SIZE="1.0499092558983667" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.16667140173423725" LOG_CI_START="-0.12436787286227054" LOG_EFFECT_SIZE="0.02115176443598335" MODIFIED="2009-09-18 15:27:03 +0100" MODIFIED_BY="[Empty name]" ORDER="1819" O_E="0.0" SE="0.17095791056563267" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.029226607184966856" WEIGHT="21.115821485986327"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.446175010973944" CI_END="3.3080845656443625" CI_START="0.5755430634914973" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9418138145679298" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2010-11-22 20:42:49 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.650684583534678" P_Q="0.3925986457191776" P_Z="0.00534285958744282" Q="1.8699352005882606" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1189" TOTAL_2="1201" UNITS="" WEIGHT="99.99999999999999" Z="2.785600978603231">
<NAME>Mental state: 1c. General - average endpoint score (PANSS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.3261547316405085" CI_END="3.046666922386055" CI_START="-1.0978889966709162" DF="6" EFFECT_SIZE="0.9743889628575696" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" MODIFIED="2009-09-18 15:27:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8873939186314329" P_Z="0.35674837210847365" STUDIES="7" TAU2="0.0" TOTAL_1="360" TOTAL_2="368" WEIGHT="43.46878750650934" Z="0.9215787222717509">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.69518404569392" CI_START="-0.8951840456939086" EFFECT_SIZE="3.4000000000000057" ESTIMABLE="YES" MEAN_1="78.26" MEAN_2="74.86" ORDER="292" SD_1="4.62" SD_2="6.41" SE="2.191460700081113" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="10.118356729092273"/>
<CONT_DATA CI_END="3.4242792035423495" CI_START="-3.22427920354235" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="-12.8" MEAN_2="-12.9" ORDER="293" SD_1="15.9" SD_2="16.1" SE="1.6960919842220774" STUDY_ID="STD-Conley-2001" TOTAL_1="175" TOTAL_2="181" WEIGHT="16.89190214420437"/>
<CONT_DATA CI_END="9.097000872241495" CI_START="-7.897000872241492" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" MEAN_1="-16.9" MEAN_2="-17.5" ORDER="294" SD_1="18.8" SD_2="17.7" SE="4.3352841885181315" STUDY_ID="STD-Dollfus-2005" TOTAL_1="38" TOTAL_2="33" WEIGHT="2.5854861553621022"/>
<CONT_DATA CI_END="5.077521730134338" CI_START="-5.077521730134338" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-12.3" MEAN_2="-12.3" ORDER="295" SD_1="18.04" SD_2="15.67" SE="2.59061991454189" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="7.240523389520455"/>
<CONT_DATA CI_END="9.277576336221415" CI_START="-5.077576336221427" EFFECT_SIZE="2.0999999999999943" ESTIMABLE="YES" MEAN_1="71.5" MEAN_2="69.4" ORDER="296" SD_1="12.0" SD_2="10.8" SE="3.6620960348441236" STUDY_ID="STD-Mori-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="3.6234135334755866"/>
<CONT_DATA CI_END="8.920920679524045" CI_START="-8.54092067952405" EFFECT_SIZE="0.18999999999999773" ESTIMABLE="YES" MEAN_1="49.48" MEAN_2="49.29" ORDER="297" SD_1="17.7" SD_2="10.17" SE="4.4546332220349125" STUDY_ID="STD-Svestka-2003" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.4488007911826855"/>
<CONT_DATA CI_END="12.252594840357954" CI_START="-24.252594840357954" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-15.0" MEAN_2="-9.0" ORDER="298" SD_1="22.31" SD_2="22.31" SE="9.312719511344133" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.5603047636718635"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7999604544536205" CI_END="8.928299336757078" CI_START="-0.7147127623588334" DF="2" EFFECT_SIZE="4.106793287199123" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.02" MODIFIED="2009-09-18 15:27:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40657774134073776" P_Z="0.09503218860734909" STUDIES="3" TAU2="0.0" TOTAL_1="116" TOTAL_2="115" WEIGHT="8.029862528877242" Z="1.6694300187799413">
<NAME>medium term</NAME>
<CONT_DATA CI_END="15.586754939148312" CI_START="-0.7867549391483113" EFFECT_SIZE="7.4" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-7.7" ORDER="299" SD_1="6.86" SD_2="9.8" SE="4.176992538497845" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="10" WEIGHT="2.785158794202662"/>
<CONT_DATA CI_END="7.728666030926336" CI_START="-7.328666030926337" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-8.2" ORDER="300" SD_1="22.31" SD_2="22.31" SE="3.8412267216701395" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="66" WEIGHT="3.2933468886935087"/>
<CONT_DATA CI_END="15.780665875938874" CI_START="-3.7806658759388743" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-9.1" ORDER="301" SD_1="22.31" SD_2="22.31" SE="4.990227347587771" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" WEIGHT="1.9513568459810722"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.450124624291555" CI_END="4.980614052622716" CI_START="0.20196365546916306" DF="4" EFFECT_SIZE="2.59128885404594" ESTIMABLE="YES" I2="26.607182849145442" ID="CMP-004.07.03" MODIFIED="2009-09-18 15:27:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24414868007685187" P_Z="0.03353367836301015" STUDIES="5" TAU2="1.9590283502343937" TOTAL_1="713" TOTAL_2="718" WEIGHT="48.50134996461341" Z="2.125634815426282">
<NAME>long term</NAME>
<CONT_DATA CI_END="21.171340952533527" CI_START="2.628659047466469" EFFECT_SIZE="11.899999999999999" ESTIMABLE="YES" MEAN_1="-16.3" MEAN_2="-28.2" ORDER="302" SD_1="16.3" SD_2="20.8" SE="4.730362917719246" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" WEIGHT="2.1716430242428295"/>
<CONT_DATA CI_END="6.458570018242206" CI_START="-0.6585700182422052" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="-9.5" MEAN_2="-12.4" ORDER="303" SD_1="15.5" SD_2="16.0" SE="1.8156303107157843" STUDY_ID="STD-Keefe-2006" TOTAL_1="148" TOTAL_2="153" WEIGHT="14.740849474522134"/>
<CONT_DATA CI_END="5.356450885289281" CI_START="-1.436450885289283" EFFECT_SIZE="1.959999999999999" ESTIMABLE="YES" MEAN_1="-9.31" MEAN_2="-11.27" ORDER="304" SD_1="22.31" SD_2="22.31" SE="1.7329149474582457" STUDY_ID="STD-Lieberman-2005" TOTAL_1="333" TOTAL_2="330" WEIGHT="16.18165228115687"/>
<CONT_DATA CI_END="4.374988808061811" CI_START="-4.574988808061814" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="-18.5" MEAN_2="-18.4" ORDER="305" SD_1="9.91" SD_2="9.73" SE="2.283199509460354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="9.321582235078772"/>
<CONT_DATA CI_END="8.738399132890404" CI_START="-2.338399132890399" EFFECT_SIZE="3.200000000000003" ESTIMABLE="YES" MEAN_1="-24.9" MEAN_2="-28.1" ORDER="306" SD_1="23.2" SD_2="28.0" SE="2.8257657674205174" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="6.085622949612798"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3650603675872914" CI_END="8.294738027049467" CI_START="0.03244567972542889" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="4.163591853387448" ESTIMABLE="YES" I2="40.56570220064206" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2010-11-22 20:43:17 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.18590324079798037" P_Q="0.7683986827244544" P_Z="0.04822760591623386" Q="0.08671266959850987" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.5675983992881095" TOTALS="YES" TOTAL_1="214" TOTAL_2="214" UNITS="" WEIGHT="100.0" Z="1.9753573792645482">
<NAME>Mental state: 1d. General - average endpoint score (BPRS total score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.744577547024276" CI_START="-5.744577547024276" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.08.01" MODIFIED="2009-09-18 15:27:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3617312392529196" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="16" WEIGHT="12.47234808587206" Z="0.9120712173010788">
<NAME>short term</NAME>
<CONT_DATA CI_END="15.744577547024276" CI_START="-5.744577547024276" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.0" ORDER="307" SD_1="20.0" SD_2="12.0" SE="5.482028053462274" STUDY_ID="STD-Sikich-2004" TOTAL_1="19" TOTAL_2="16" WEIGHT="12.47234808587206"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.2783476979887816" CI_END="9.907846603522582" CI_START="-1.3418164287482535" DF="1" EFFECT_SIZE="4.283015087387165" ESTIMABLE="YES" I2="69.4968291309221" ID="CMP-004.08.02" MODIFIED="2009-09-18 15:27:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07019963163782827" P_Z="0.1355916711670666" STUDIES="2" TAU2="11.689366659821088" TOTAL_1="195" TOTAL_2="198" WEIGHT="87.52765191412794" Z="1.4924100912960423">
<NAME>long term</NAME>
<CONT_DATA CI_END="12.985140002837866" CI_START="2.2148599971621286" EFFECT_SIZE="7.599999999999998" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-16.4" ORDER="308" SD_1="9.2" SD_2="12.3" SE="2.74757089687115" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" WEIGHT="33.87028818344038"/>
<CONT_DATA CI_END="5.027770213412124" CI_START="-1.4277702134121224" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="-15.2" MEAN_2="-17.0" ORDER="309" SD_1="13.3" SD_2="16.5" SE="1.6468517987434272" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="53.65736373068756"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0371011391622011" CI_START="0.9312049812676473" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9827277073870427" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="178" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.015821111295707502" LOG_CI_START="-0.03095470952916746" LOG_EFFECT_SIZE="-0.007566799116729997" METHOD="MH" MODIFIED="2009-09-18 15:27:41 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.5260049705800998" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.0" Z="0.6341162372143129">
<NAME>Mental state: 2a. Positive symptoms - no clinically important change - short term (less than 50% PANSS positive subscore reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0371011391622011" CI_START="0.9312049812676473" EFFECT_SIZE="0.9827277073870427" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="178" LOG_CI_END="0.015821111295707502" LOG_CI_START="-0.03095470952916746" LOG_EFFECT_SIZE="-0.007566799116729997" MODIFIED="2009-09-18 15:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1821" O_E="0.0" SE="0.027476348696578903" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="7.549497376959933E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.453158868349167" CI_END="1.0189225853228443" CI_START="-0.09456044751508613" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="0.46218106890387906" ESTIMABLE="YES" I2="0.0" I2_Q="62.370325718250086" ID="CMP-004.10" MODIFIED="2010-11-22 20:43:34 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7487913022891728" P_Q="0.0701250619893915" P_Z="0.10372191500930172" Q="5.3149543230832155" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="844" TOTAL_2="858" UNITS="" WEIGHT="100.0" Z="1.6270714912989208">
<NAME>Mental state: 2b. Positive symptoms - average endpoint score (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3345674388777735" CI_END="0.5680793541087904" CI_START="-1.5309078913271121" DF="4" EFFECT_SIZE="-0.4814142686091608" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.01" MODIFIED="2009-09-18 15:27:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8554840019175778" P_Z="0.3686222900369711" STUDIES="5" TAU2="0.0" TOTAL_1="327" TOTAL_2="334" WEIGHT="28.14152369510026" Z="0.8990570382638949">
<NAME>short term</NAME>
<CONT_DATA CI_END="9.059970711802848" CI_START="-10.059970711802848" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-4.6" MEAN_2="-4.1" ORDER="311" SD_1="5.3" SD_2="65.4" SE="4.877625704967375" STUDY_ID="STD-Conley-2001" TOTAL_1="175" TOTAL_2="181" WEIGHT="0.3391517735582294"/>
<CONT_DATA CI_END="1.2192352415235201" CI_START="-2.81923524152352" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.1" ORDER="312" SD_1="3.91" SD_2="4.7" SE="1.0302409929218035" STUDY_ID="STD-Dollfus-2005" TOTAL_1="39" TOTAL_2="33" WEIGHT="7.6020965557670985"/>
<CONT_DATA CI_END="2.3258975113126548" CI_START="-1.5258975113126552" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-4.0" ORDER="313" SD_1="7.02" SD_2="5.72" SE="0.9826188269294175" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="8.356816617876799"/>
<CONT_DATA CI_END="0.8805897930204627" CI_START="-2.4805897930204606" EFFECT_SIZE="-0.7999999999999989" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="11.6" ORDER="314" SD_1="2.2" SD_2="3.1" SE="0.8574595279692583" STUDY_ID="STD-Mori-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="10.97447549068658"/>
<CONT_DATA CI_END="3.8323864784676407" CI_START="-8.112386478467641" EFFECT_SIZE="-2.14" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-2.36" ORDER="315" SD_1="7.3" SD_2="7.3" SE="3.047191951269035" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.8689832572115573"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.46690689369471294" CI_END="3.201580707579363" CI_START="-0.034246268075140085" DF="2" EFFECT_SIZE="1.5836672197521116" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.02" MODIFIED="2009-09-18 15:27:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7917946395508001" P_Z="0.05505048530675875" STUDIES="3" TAU2="0.0" TOTAL_1="116" TOTAL_2="115" WEIGHT="11.841224769264828" Z="1.9184775561635172">
<NAME>medium term</NAME>
<CONT_DATA CI_END="5.291568019391902" CI_START="-0.4915680193919023" EFFECT_SIZE="2.4" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-2.9" ORDER="316" SD_1="1.71" SD_2="4.11" SE="1.4753169151067171" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="10" WEIGHT="3.7071519753804214"/>
<CONT_DATA CI_END="3.5634362180978156" CI_START="-1.3634362180978155" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-3.4" ORDER="317" SD_1="7.3" SD_2="7.3" SE="1.256878308749082" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="66" WEIGHT="5.107690478499043"/>
<CONT_DATA CI_END="4.600307525520115" CI_START="-1.800307525520116" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-3.3" ORDER="318" SD_1="7.3" SD_2="7.3" SE="1.6328399658176034" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" WEIGHT="3.0263823153853635"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3367302126934648" CI_END="1.40200505733471" CI_START="-0.03528874229455581" DF="4" EFFECT_SIZE="0.6833581575200771" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.03" MODIFIED="2009-09-18 15:27:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8551136536984457" P_Z="0.06236088332451102" STUDIES="5" TAU2="0.0" TOTAL_1="401" TOTAL_2="409" WEIGHT="60.01725153563491" Z="1.8637210814190848">
<NAME>long term</NAME>
<CONT_DATA CI_END="4.887872227877274" CI_START="-0.6878722278772726" EFFECT_SIZE="2.1000000000000005" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-6.2" ORDER="319" SD_1="5.4" SD_2="5.8" SE="1.4224099268495" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" WEIGHT="3.9880581754770845"/>
<CONT_DATA CI_END="1.8781323726651176" CI_START="-0.4781323726651181" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-4.3" ORDER="320" SD_1="5.5" SD_2="4.9" SE="0.6010989905723144" STUDY_ID="STD-Keefe-2006" TOTAL_1="148" TOTAL_2="153" WEIGHT="22.331558680477617"/>
<CONT_DATA CI_END="1.9263513314482366" CI_START="-0.9263513314482366" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="-7.1" ORDER="321" SD_1="3.16" SD_2="3.1" SE="0.7277436436072876" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="15.23541162458707"/>
<CONT_DATA CI_END="3.2376310753164965" CI_START="-1.3376310753164962" EFFECT_SIZE="0.9500000000000002" ESTIMABLE="YES" MEAN_1="-1.19" MEAN_2="-2.14" ORDER="322" SD_1="3.14" SD_2="4.33" SE="1.1671801591054929" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="5.922911469465866"/>
<CONT_DATA CI_END="1.8722324691910581" CI_START="-1.2722324691910585" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-7.2" ORDER="323" SD_1="6.4" SD_2="8.1" SE="0.8021741631951542" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="12.539311585627273"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.982542033609239" CI_END="0.9620788570154244" CI_START="-0.08055646543853617" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="0.44076119578844414" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.11" MODIFIED="2010-11-22 20:43:48 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.4470828340075008" P_Q="0.3776868790620478" P_Z="0.09749903692444394" Q="1.9473800406291257" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="844" TOTAL_2="858" UNITS="" WEIGHT="100.0" Z="1.6571010993468505">
<NAME>Mental state: 3a. Negative symptoms - average endpoint score (PANSS negative, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.929494190338148" CI_END="1.2190729801955502" CI_START="-0.8452628053190034" DF="4" EFFECT_SIZE="0.18690508743827342" ESTIMABLE="YES" I2="18.855772102540758" ID="CMP-004.11.01" MODIFIED="2009-09-18 15:28:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29460869594128325" P_Z="0.7226566303800492" STUDIES="5" TAU2="0.2776833639276352" TOTAL_1="327" TOTAL_2="334" WEIGHT="38.60202095292707" Z="0.3549105164739615">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.9115246897369582" CI_START="-1.3115246897369577" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-2.6" ORDER="324" SD_1="5.3" SD_2="5.4" SE="0.5671148544077966" STUDY_ID="STD-Conley-2001" TOTAL_1="175" TOTAL_2="181" WEIGHT="21.9971617681255"/>
<CONT_DATA CI_END="2.951744723056502" CI_START="-2.3517447230565023" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-4.9" MEAN_2="-5.2" ORDER="325" SD_1="5.5" SD_2="5.9" SE="1.3529558420323669" STUDY_ID="STD-Dollfus-2005" TOTAL_1="39" TOTAL_2="33" WEIGHT="3.864928374300159"/>
<CONT_DATA CI_END="1.3730277319916189" CI_START="-2.373027731991619" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-3.8" ORDER="326" SD_1="6.38" SD_2="6.1" SE="0.955643954055188" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="7.746695069301624"/>
<CONT_DATA CI_END="5.398066319990228" CI_START="0.20193368000977285" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" MEAN_1="25.6" MEAN_2="22.8" ORDER="327" SD_1="4.8" SD_2="3.3" SE="1.3255683984417281" STUDY_ID="STD-Mori-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="4.026284048794975"/>
<CONT_DATA CI_END="4.611515668557576" CI_START="-5.991515668557577" EFFECT_SIZE="-0.69" ESTIMABLE="YES" MEAN_1="-4.17" MEAN_2="-3.48" ORDER="328" SD_1="6.48" SD_2="6.48" SE="2.704904636194979" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.966951692404809"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.0502516849226375" CI_END="1.5899637311215082" CI_START="-1.5815318340180444" DF="2" EFFECT_SIZE="0.004215948551731909" ESTIMABLE="YES" I2="2.4510007864977656" ID="CMP-004.11.02" MODIFIED="2009-09-18 15:28:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.35875145602683955" P_Z="0.9958423552641053" STUDIES="3" TAU2="0.05198008168757503" TOTAL_1="116" TOTAL_2="115" WEIGHT="11.148755896620404" Z="0.005210858506563763">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.299444197444368" CI_START="-2.8994441974443683" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.7" ORDER="329" SD_1="4.16" SD_2="2.21" SE="1.8364848669854774" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="10" WEIGHT="2.097654636707852"/>
<CONT_DATA CI_END="1.0867214648320336" CI_START="-3.2867214648320338" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.4" ORDER="330" SD_1="6.48" SD_2="6.48" SE="1.1156947179032948" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="66" WEIGHT="5.6835271698016"/>
<CONT_DATA CI_END="4.240820926763062" CI_START="-1.440820926763062" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.6" ORDER="331" SD_1="6.48" SD_2="6.48" SE="1.449425065547681" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" WEIGHT="3.3675740901109523"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.055416117719328" CI_END="1.5444302802010936" CI_START="0.07358240346478284" DF="4" EFFECT_SIZE="0.8090063418329383" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.03" MODIFIED="2009-09-18 15:28:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5485949415257554" P_Z="0.031078432922932532" STUDIES="5" TAU2="0.0" TOTAL_1="401" TOTAL_2="409" WEIGHT="50.249223150452536" Z="2.156067011872669">
<NAME>long term</NAME>
<CONT_DATA CI_END="5.170870539440106" CI_START="-0.7708705394401059" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-6.3" ORDER="332" SD_1="5.3" SD_2="6.6" SE="1.5157781280033478" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" WEIGHT="3.0791966259982084"/>
<CONT_DATA CI_END="2.052592980921428" CI_START="-0.252592980921428" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-2.5" ORDER="333" SD_1="4.9" SD_2="5.3" SE="0.5880684492230134" STUDY_ID="STD-Keefe-2006" TOTAL_1="148" TOTAL_2="153" WEIGHT="20.457517694882853"/>
<CONT_DATA CI_END="1.3263513314482365" CI_START="-1.5263513314482366" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-3.5" ORDER="334" SD_1="3.16" SD_2="3.1" SE="0.7277436436072876" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="13.358320305279731"/>
<CONT_DATA CI_END="5.659077476707927" CI_START="-1.4790774767079276" EFFECT_SIZE="2.09" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="-2.76" ORDER="335" SD_1="5.99" SD_2="5.81" SE="1.8209913574230725" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.1335013657687245"/>
<CONT_DATA CI_END="2.656297827462932" CI_START="-0.45629782746293257" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-7.3" ORDER="336" SD_1="6.6" SD_2="7.8" SE="0.7940440945541912" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="11.220687158523019"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.4269656499287184" CI_START="0.3730343500712814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.12" MODIFIED="2010-11-22 20:44:04 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.007542310847489012" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="2.6719000567804123">
<NAME>Mental state: 3b. Negative symptoms - average endpoint score - long term (SANS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.4269656499287184" CI_START="0.3730343500712814" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-4.3" MODIFIED="2009-09-18 15:28:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1822" SD_1="3.8" SD_2="5.3" SE="0.5239716943930054" STUDY_ID="STD-Tran-1997" TOTAL_1="151" TOTAL_2="157" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.22644424679024605" CI_END="9.104605215151475" CI_START="1.090415333034679" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.097510274093077" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.13" MODIFIED="2010-11-22 20:44:22 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6341730123113762" P_Q="1.0" P_Z="0.012655770513836056" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="2.4933116621904685">
<NAME>Quality of life: General - average endpoint score - long term (QLS total score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.801044691905808" CI_START="-1.8010446919058083" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="-4.9" MEAN_2="-11.9" MODIFIED="2009-09-18 15:28:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1824" SD_1="19.2" SD_2="13.4" SE="4.490411436805638" STUDY_ID="STD-Gureje-2003" TOTAL_1="26" TOTAL_2="30" WEIGHT="20.729594753878224"/>
<CONT_DATA CI_END="9.100638108611587" CI_START="0.099361891388412" EFFECT_SIZE="4.6" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-13.4" MODIFIED="2009-09-18 15:28:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1823" SD_1="16.9" SD_2="18.6" SE="2.296286127761554" STUDY_ID="STD-Tran-1997" TOTAL_1="122" TOTAL_2="118" WEIGHT="79.27040524612177"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9363578570285995" CI_START="0.8750147472918894" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3016688061617459" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="0.28698562206888484" LOG_CI_START="-0.05798462741937942" LOG_EFFECT_SIZE="0.11450049732475272" METHOD="MH" MODIFIED="2009-09-18 15:28:28 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.19323126158382808" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="39" WEIGHT="100.00000000000001" Z="1.3010794484529875">
<NAME>Cognitive functioning: 1a.General - no clinically important change - medium term (less than ½ SD in Global Neurocognitive Score improved)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9363578570285995" CI_START="0.8750147472918894" EFFECT_SIZE="1.3016688061617459" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.28698562206888484" LOG_CI_START="-0.05798462741937942" LOG_EFFECT_SIZE="0.11450049732475272" MODIFIED="2009-09-18 15:28:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1825" O_E="0.0" SE="0.2026372321796817" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="0.04106184786544222" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3860492613983309" CI_START="-0.30604926139833094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.03999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.15" MODIFIED="2010-11-22 20:44:41 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.8207712054789031" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.22655317646050108">
<NAME>Cognitive functioning: 1b. General - average endpoint score - medium term (global neurocognitive score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3860492613983309" CI_START="-0.30604926139833094" EFFECT_SIZE="0.03999999999999998" ESTIMABLE="YES" MEAN_1="0.29" MEAN_2="0.25" MODIFIED="2009-09-18 15:28:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1826" SD_1="0.68" SD_2="0.59" SE="0.1765589899242656" STUDY_ID="STD-Volavka-2002" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.12736439977179595" CI_START="-0.10736439977179599" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.009999999999999981" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.16" MODIFIED="2010-11-22 20:44:54 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.8673714898344678" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="0.1669981688102198">
<NAME>Cognitive functioning: 1c. General - average endpoint score - long term (neurocognitive composite score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.12736439977179592" CI_START="-0.10736439977179597" EFFECT_SIZE="0.009999999999999981" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.17" MODIFIED="2009-09-18 15:28:38 +0100" MODIFIED_BY="[Empty name]" ORDER="1827" SD_1="0.46" SD_2="0.51" SE="0.05988089612745508" STUDY_ID="STD-Keefe-2006" TOTAL_1="131" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.012882338444630007" CI_END="1.8582652637205401" CI_START="0.9634870035573526" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3380636871079108" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-004.17" LOG_CI_END="0.269107708768074" LOG_CI_START="-0.016154139152164695" LOG_EFFECT_SIZE="0.12647678480795466" METHOD="MH" MODIFIED="2009-09-18 15:29:00 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.9935795307118941" P_Q="0.0" P_Z="0.0822140292070722" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="485" TOTAL_2="480" WEIGHT="100.0" Z="1.7379817519328813">
<NAME>Service use - number of patients rehospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.403579164501583" CI_START="0.41386788608040825" DF="0" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-004.17.01" LOG_CI_END="0.6438058081953386" LOG_CI_START="-0.38313827120532623" LOG_EFFECT_SIZE="0.13033376849500614" MODIFIED="2009-09-18 15:28:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6188404144835117" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="36" WEIGHT="7.716027940595987" Z="0.49749445435953277">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.403579164501583" CI_START="0.41386788608040825" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6438058081953386" LOG_CI_START="-0.38313827120532623" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="343" O_E="0.0" SE="0.6032320356951285" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.3638888888888888" WEIGHT="7.716027940595987"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1844421455059403E-31" CI_END="2.7837037360597363" CI_START="0.6887082624774221" DF="0" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="100.0" ID="CMP-004.17.02" LOG_CI_END="0.44462301231746837" LOG_CI_START="-0.16196470672452976" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2009-09-18 15:28:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.36108172859328636" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="108" WEIGHT="22.115672790185076" Z="0.9133058278334829">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.7837037360597363" CI_START="0.6887082624774221" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.44462301231746837" LOG_CI_START="-0.16196470672452976" LOG_EFFECT_SIZE="0.1413291527964693" ORDER="344" O_E="0.0" SE="0.3563126288229052" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="0.12695868945868943" WEIGHT="22.115672790185076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9572372439459644" CI_START="0.8935101379661236" DF="0" EFFECT_SIZE="1.322426300354993" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="38" I2="0.0" ID="CMP-004.17.03" LOG_CI_END="0.29164347128487667" LOG_CI_START="-0.04890051552793164" LOG_EFFECT_SIZE="0.12137147787847251" MODIFIED="2009-09-18 15:29:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1623892878299284" STUDIES="1" TAU2="0.0" TOTAL_1="341" TOTAL_2="336" WEIGHT="70.16829926921893" Z="1.3970807566951227">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.9572372439459644" CI_START="0.8935101379661236" EFFECT_SIZE="1.322426300354993" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="38" LOG_CI_END="0.29164347128487667" LOG_CI_START="-0.04890051552793164" LOG_EFFECT_SIZE="0.12137147787847251" ORDER="345" O_E="0.0" SE="0.20003722357376524" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.04001489081510054" WEIGHT="70.16829926921893"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.116420958269057" CI_END="1.0345329316371477" CI_START="0.8839638945991158" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.956289579228496" ESTIMABLE="YES" EVENTS_1="604" EVENTS_2="621" I2="10.042989218023417" I2_Q="0.0" ID="CMP-004.18" LOG_CI_END="0.014744319845307876" LOG_CI_START="-0.05356547333149489" LOG_EFFECT_SIZE="-0.019410576743093502" METHOD="MH" MODIFIED="2009-09-18 15:16:21 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.34852010976343173" P_Q="0.0" P_Z="0.26533602590485506" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.001823675641069336" TOTALS="YES" TOTAL_1="1287" TOTAL_2="1289" WEIGHT="100.00000000000001" Z="1.1138675603114956">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2322380007075744" CI_START="0.7327667815606596" EFFECT_SIZE="0.9502331681725444" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="73" LOG_CI_END="0.09069459777270614" LOG_CI_START="-0.13503422671997878" LOG_EFFECT_SIZE="-0.0221698144736363" ORDER="346" O_E="0.0" SE="0.13259422888270517" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.017581229532999204" WEIGHT="8.29716296245432"/>
<DICH_DATA CI_END="1.0166111637728859" CI_START="0.5376129899248661" EFFECT_SIZE="0.7392857142857143" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="0.007154874536801463" LOG_CI_START="-0.2695302463074043" LOG_EFFECT_SIZE="-0.13118768588530144" ORDER="347" O_E="0.0" SE="0.16252620959732356" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.02641476880607315" WEIGHT="5.701647652780402"/>
<DICH_DATA CI_END="3.9994628191417827" CI_START="1.1610351968282528" EFFECT_SIZE="2.154882154882155" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6020016637406899" LOG_CI_START="0.06484538559265973" LOG_EFFECT_SIZE="0.3334235246666748" ORDER="348" O_E="0.0" SE="0.315528256750613" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.09955808080808079" WEIGHT="1.5881127545957943"/>
<DICH_DATA CI_END="1.2623041486871702" CI_START="0.8564484100500455" EFFECT_SIZE="1.03975880912003" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="61" LOG_CI_END="0.10116400956886552" LOG_CI_START="-0.06729879254130339" LOG_EFFECT_SIZE="0.016932608513781058" ORDER="349" O_E="0.0" SE="0.09895588386383271" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.009792266951272346" WEIGHT="13.860748640955725"/>
<DICH_DATA CI_END="1.4296917518898593" CI_START="0.6742018381893332" EFFECT_SIZE="0.9817845013893177" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" LOG_CI_END="0.1552424116721971" LOG_CI_START="-0.17121006772368555" LOG_EFFECT_SIZE="-0.007983828025744232" ORDER="350" O_E="0.0" SE="0.1917598023629764" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.03677182180228777" WEIGHT="4.171617705835046"/>
<DICH_DATA CI_END="1.0761690425785022" CI_START="0.8792847625950325" EFFECT_SIZE="0.9727584700817371" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="235" LOG_CI_END="0.031880494836748124" LOG_CI_START="-0.055870452803728654" LOG_EFFECT_SIZE="-0.011994978983490251" ORDER="351" O_E="0.0" SE="0.051545341018212384" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.002656922180683808" WEIGHT="35.933968391124715"/>
<DICH_DATA CI_END="1.2698316568767019" CI_START="0.4589337895151564" EFFECT_SIZE="0.7633928571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.10374614982566258" LOG_CI_START="-0.3382499657096806" LOG_EFFECT_SIZE="-0.11725190794200899" ORDER="352" O_E="0.0" SE="0.25963070618151873" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.06740810359231411" WEIGHT="2.32560339027923"/>
<DICH_DATA CI_END="1.1741196143726293" CI_START="0.7359678285459625" EFFECT_SIZE="0.9295774647887324" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="71" LOG_CI_END="0.06971234326234903" LOG_CI_START="-0.13314116961676228" LOG_EFFECT_SIZE="-0.03171441317720662" ORDER="353" O_E="0.0" SE="0.11915715760627336" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.01419842820880627" WEIGHT="10.048971221808037"/>
<DICH_DATA CI_END="1.1336081375397735" CI_START="0.7251575012759666" EFFECT_SIZE="0.9066666666666666" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.05446295480815421" LOG_CI_START="-0.1395676561790817" LOG_EFFECT_SIZE="-0.042552350685463744" ORDER="354" O_E="0.0" SE="0.11397454136091695" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.012990196078431368" WEIGHT="10.868573965594347"/>
<DICH_DATA CI_END="1.4685700219048934" CI_START="0.5902511934441143" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.166894658657194" LOG_CI_START="-0.22896312613713152" LOG_EFFECT_SIZE="-0.031034233739968786" ORDER="355" O_E="0.0" SE="0.2325288223158244" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="0.05406965320758424" WEIGHT="2.880588145611911"/>
<DICH_DATA CI_END="1.323908150829997" CI_START="0.6330835815805553" EFFECT_SIZE="0.9155023286759814" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="45" LOG_CI_END="0.12185785597121618" LOG_CI_START="-0.19853894934604752" LOG_EFFECT_SIZE="-0.038340546687415655" ORDER="356" O_E="0.0" SE="0.18820266943312552" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.03542024478175432" WEIGHT="4.3230051689604885"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.803872686661311" CI_END="3.220208131375239" CI_START="0.47287413355002433" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.233998837104318" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-004.19" LOG_CI_END="0.5078839423127939" LOG_CI_START="-0.3252544414587301" LOG_EFFECT_SIZE="0.09131475042703188" METHOD="MH" MODIFIED="2009-09-18 15:30:21 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.44958249400794803" P_Q="0.0" P_Z="0.6674595720101649" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1520" TOTAL_2="1525" WEIGHT="400.0" Z="0.42963720212734063">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.30141698747275" CI_START="0.12673979595998175" DF="0" EFFECT_SIZE="3.089285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.19.01" LOG_CI_END="1.8768031486316468" LOG_CI_START="-0.8970869963864565" LOG_EFFECT_SIZE="0.48985807612259497" MODIFIED="2009-09-18 15:30:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4887842146762401" STUDIES="1" TAU2="0.0" TOTAL_1="167" TOTAL_2="172" WEIGHT="100.0" Z="0.6922438427929168">
<NAME>any reason</NAME>
<DICH_DATA CI_END="75.30141698747275" CI_START="0.12673979595998175" EFFECT_SIZE="3.0892857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8768031486316468" LOG_CI_START="-0.8970869963864565" LOG_EFFECT_SIZE="0.489858076122595" ORDER="375" O_E="0.0" SE="1.629396802161302" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="2.6549339388934765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.256100678584414" CI_START="0.014076743100520147" DF="0" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.19.02" LOG_CI_END="0.9167749802965881" LOG_CI_START="-1.8514978151576003" LOG_EFFECT_SIZE="-0.46736141743050624" MODIFIED="2009-09-18 15:30:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5081040050566962" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="125" WEIGHT="100.0" Z="0.6617928315674491">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="376" O_E="0.0" SE="0.0" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.256100678584414" CI_START="0.014076743100520147" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9167749802965881" LOG_CI_START="-1.8514978151576003" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="377" O_E="0.0" SE="1.6260971432211297" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="2.644191919191919" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.524847612512347" CI_END="3.543969506767745" CI_START="0.3745844398097367" DF="4" EFFECT_SIZE="1.1521787328341835" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="27.599813052924077" ID="CMP-004.19.03" LOG_CI_END="0.549489976448795" LOG_CI_START="-0.42645026712395245" LOG_EFFECT_SIZE="0.06151985466242132" MODIFIED="2009-09-18 15:30:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2375542151785931" P_Z="0.804831972067529" STUDIES="5" TAU2="0.4518420210702836" TOTAL_1="862" TOTAL_2="862" WEIGHT="100.0" Z="0.24709852937526988">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="2.046974166120395" CI_START="0.07899789712603944" EFFECT_SIZE="0.4021276595744681" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31111236167464223" LOG_CI_START="-1.1023844691995888" LOG_EFFECT_SIZE="-0.3956360537624733" ORDER="378" O_E="0.0" SE="0.830295035377681" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.6893898457728245" WEIGHT="28.797034559584755"/>
<DICH_DATA CI_END="68.94634076504033" CI_START="0.12297061175900956" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8385112215238748" LOG_CI_START="-0.910198666413285" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="379" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="2.606951871657754" WEIGHT="10.744134669587039"/>
<DICH_DATA CI_END="6.954532655971472" CI_START="0.13960528065116343" EFFECT_SIZE="0.9853372434017595" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8422679507547797" LOG_CI_START="-0.855098153960087" LOG_EFFECT_SIZE="-0.006415101602653666" ORDER="380" O_E="0.0" SE="0.9970412520072384" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.9940912582041614" WEIGHT="22.728637608003105"/>
<DICH_DATA CI_END="5.447985945677765" CI_START="0.04588851779222025" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.736235978544511" LOG_CI_START="-1.3382959698724735" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="381" O_E="0.0" SE="1.2185903355988992" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="1.4849624060150375" WEIGHT="16.96820445595391"/>
<DICH_DATA CI_END="57.96582581126271" CI_START="0.8967017227281517" EFFECT_SIZE="7.209580838323354" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7631720274295022" LOG_CI_START="-0.0473519958810575" LOG_EFFECT_SIZE="0.8579100157742225" ORDER="382" O_E="0.0" SE="1.0635107735310794" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="1.131055165416675" WEIGHT="20.761988706871186"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.59324007323507" CI_START="0.12830215374824344" DF="0" EFFECT_SIZE="3.114285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.19.04" LOG_CI_END="1.878482960446245" LOG_CI_START="-0.8917660532655488" LOG_EFFECT_SIZE="0.4933584535903479" MODIFIED="2009-09-18 15:30:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4851104272141801" STUDIES="4" TAU2="0.0" TOTAL_1="364" TOTAL_2="366" WEIGHT="100.0" Z="0.698106773592778">
<NAME>suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="383" O_E="0.0" SE="0.0" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="384" O_E="0.0" SE="0.0" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="385" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="75.59324007323507" CI_START="0.12830215374824344" EFFECT_SIZE="3.1142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.878482960446245" LOG_CI_START="-0.8917660532655488" LOG_EFFECT_SIZE="0.493358453590348" ORDER="386" O_E="0.0" SE="1.6272579836080852" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="2.6479685452162514" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.49326354928762" CI_END="4.637294201735784" CI_START="0.2301295138496654" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.03304320346408" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="45.38765575176076" I2_Q="0.0" ID="CMP-004.20" LOG_CI_END="0.6662646495160975" LOG_CI_START="-0.6380276799837409" LOG_EFFECT_SIZE="0.014118484766178356" METHOD="MH" MODIFIED="2009-09-18 15:30:29 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.13904218101282872" P_Q="0.0" P_Z="0.9661544955165116" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.0533642948437019" TOTALS="YES" TOTAL_1="635" TOTAL_2="633" WEIGHT="100.0" Z="0.0424317785700669">
<NAME>Adverse effects: 3a. Cardiac effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4970173084698264" CI_END="2.3043938897039284" CI_START="0.07611414584880875" DF="1" EFFECT_SIZE="0.41880421752177777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-004.20.01" LOG_CI_END="0.3625567149873198" LOG_CI_START="-1.1185346219001064" LOG_EFFECT_SIZE="-0.3779889534563933" MODIFIED="2009-09-18 15:30:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48081368152939297" P_Z="0.3171151226082307" STUDIES="2" TAU2="0.0" TOTAL_1="207" TOTAL_2="208" WEIGHT="45.1771997828466" Z="1.000403846646532">
<NAME>abnormal ECG</NAME>
<DICH_DATA CI_END="13.868639738956116" CI_START="0.05840515113567786" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420338667808942" LOG_CI_START="-1.2335488479022445" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="357" O_E="0.0" SE="1.3954290459289653" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="1.9472222222222224" WEIGHT="19.56225568598418"/>
<DICH_DATA CI_END="2.279926993210213" CI_START="0.029079238432066553" EFFECT_SIZE="0.25748502994011974" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.35792094044186373" LOG_CI_START="-1.5364169715778573" LOG_EFFECT_SIZE="-0.5892480155679968" ORDER="358" O_E="0.0" SE="1.112743466644281" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="1.2381980225595322" WEIGHT="25.614944096862423"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8250133865453533" CI_END="60.0042930936099" CI_START="0.12040941608332721" DF="1" EFFECT_SIZE="2.687951244701882" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="73.85630064674957" ID="CMP-004.20.02" LOG_CI_END="1.7781823237197354" LOG_CI_START="-0.9193395496800951" LOG_EFFECT_SIZE="0.42942138701982024" NO="2" P_CHI2="0.05049299117557415" P_Z="0.5326160837260345" STUDIES="2" TAU2="3.796881728167061" TOTAL_1="428" TOTAL_2="425" WEIGHT="54.82280021715339" Z="0.6240175184858142">
<NAME>QTc prolongation</NAME>
<DICH_DATA CI_END="3.328555868129624" CI_START="0.17685127047509014" EFFECT_SIZE="0.7672413793103449" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5222558507624637" LOG_CI_START="-0.752391815926475" LOG_EFFECT_SIZE="-0.11506798258200567" ORDER="359" O_E="0.0" SE="0.7487343490207927" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.5606031254035903" WEIGHT="36.36891297704547"/>
<DICH_DATA CI_END="257.7725257523975" CI_START="0.8475268794237529" EFFECT_SIZE="14.780701754385966" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.411236626942997" LOG_CI_START="-0.07184651920122707" LOG_EFFECT_SIZE="1.1696950538708848" ORDER="360" O_E="0.0" SE="1.4585753315049246" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="2.1274419976747008" WEIGHT="18.453887240107925"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.052493389018493" CI_END="4.665974725609029" CI_START="-2.7410645131374465" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9624551062357914" ESTIMABLE="YES" I2="29.103088451163256" I2_Q="0.0" ID="CMP-004.21" MODIFIED="2009-09-18 15:16:49 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.21676558413467917" P_Q="1.0" P_Z="0.6105088815735213" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="5.980126993950939" TOTALS="YES" TOTAL_1="748" TOTAL_2="770" UNITS="" WEIGHT="100.00000000000001" Z="0.5093471991051751">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1679193207918948" CI_START="-7.167919320791895" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="1.2" ORDER="361" SD_1="25.7" SD_2="20.2" SE="2.381635253306615" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" WEIGHT="30.64227160089205"/>
<CONT_DATA CI_END="17.612771943565633" CI_START="-4.412771943565636" EFFECT_SIZE="6.6" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="-2.5" ORDER="362" SD_1="36.57" SD_2="32.15" SE="5.618864443649462" STUDY_ID="STD-Jeste-2003" TOTAL_1="73" TOTAL_2="78" WEIGHT="9.508297619531318"/>
<CONT_DATA CI_END="3.995306251165945" CI_START="-5.995306251165945" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="1.2" ORDER="363" SD_1="26.6" SD_2="27.4" SE="2.54867247080471" STUDY_ID="STD-Lieberman-2005" TOTAL_1="218" TOTAL_2="231" WEIGHT="28.619542159977286"/>
<CONT_DATA CI_END="15.91766343580982" CI_START="-15.91766343580982" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="402.0" MEAN_2="402.0" ORDER="364" SD_1="25.0" SD_2="23.0" SE="8.121406087747692" STUDY_ID="STD-Sikich-2004" TOTAL_1="19" TOTAL_2="16" WEIGHT="4.963392251277221"/>
<CONT_DATA CI_END="10.121786747963075" CI_START="-8.721786747963076" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-5.1" ORDER="365" SD_1="30.4" SD_2="33.0" SE="4.807122387085133" STUDY_ID="STD-Stroup-2006" TOTAL_1="85" TOTAL_2="89" WEIGHT="12.274703340525102"/>
<CONT_DATA CI_END="17.963538202633558" CI_START="0.6364617973664455" EFFECT_SIZE="9.3" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="-4.9" ORDER="366" SD_1="35.1" SD_2="44.9" SE="4.420253775564469" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="167" WEIGHT="13.991793027797021"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.46390152016565" CI_END="1.039211619384353" CI_START="0.83998515834467" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9343031288945718" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="411" I2="4.433351358206449" I2_Q="0.0" ID="CMP-004.22" LOG_CI_END="0.016703993921684947" LOG_CI_START="-0.07572838739758941" LOG_EFFECT_SIZE="-0.029512196737952214" METHOD="MH" MODIFIED="2009-09-18 15:17:29 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.40077832734383456" P_Q="0.0" P_Z="0.21072626146036677" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0014928694951649433" TOTALS="YES" TOTAL_1="1287" TOTAL_2="1289" WEIGHT="100.00000000000001" Z="1.2515709729742788">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2322380007075744" CI_START="0.7327667815606596" EFFECT_SIZE="0.9502331681725444" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="73" LOG_CI_END="0.09069459777270614" LOG_CI_START="-0.13503422671997878" LOG_EFFECT_SIZE="-0.0221698144736363" ORDER="511" O_E="0.0" SE="0.13259422888270517" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.017581229532999204" WEIGHT="15.455371713542359"/>
<DICH_DATA CI_END="4.769822559709719" CI_START="0.679270551355097" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.6785022233226542" LOG_CI_START="-0.16795721311604198" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="512" O_E="0.0" SE="0.49721446300587663" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.24722222222222223" WEIGHT="1.1852810721923124"/>
<DICH_DATA CI_END="3.9994628191417827" CI_START="1.1610351968282528" EFFECT_SIZE="2.154882154882155" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6020016637406899" LOG_CI_START="0.06484538559265973" LOG_EFFECT_SIZE="0.3334235246666748" ORDER="513" O_E="0.0" SE="0.315528256750613" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.09955808080808079" WEIGHT="2.9173133918734173"/>
<DICH_DATA CI_END="2.15182899906305" CI_START="0.4863330140761222" EFFECT_SIZE="1.0229885057471264" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3328077559748046" LOG_CI_START="-0.31306624792221616" LOG_EFFECT_SIZE="0.009870754026294247" ORDER="514" O_E="0.0" SE="0.3793895870169919" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.14393645873692365" WEIGHT="2.0270828048571548"/>
<DICH_DATA CI_END="1.1479634075202656" CI_START="0.5043217566978262" EFFECT_SIZE="0.7608829885767212" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="41" LOG_CI_END="0.059928044712381195" LOG_CI_START="-0.29729229575124905" LOG_EFFECT_SIZE="-0.11868212551943395" ORDER="515" O_E="0.0" SE="0.20983299625754" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.0440298863184168" WEIGHT="6.475822592735939"/>
<DICH_DATA CI_END="1.1481030923901552" CI_START="0.7205509540888442" EFFECT_SIZE="0.9095420708323935" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="104" LOG_CI_END="0.059980886708269066" LOG_CI_START="-0.14233530243200018" LOG_EFFECT_SIZE="-0.041177207861865586" ORDER="516" O_E="0.0" SE="0.11884153098228208" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.01412330948621271" WEIGHT="18.877683902876672"/>
<DICH_DATA CI_END="2.3225011815478127" CI_START="0.2698539471542605" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3659559436084413" LOG_CI_START="-0.5688712251259955" LOG_EFFECT_SIZE="-0.10145764075877708" ORDER="517" O_E="0.0" SE="0.5491221063837243" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.3015350877192982" WEIGHT="0.9728385898485133"/>
<DICH_DATA CI_END="1.1741196143726293" CI_START="0.7359678285459625" EFFECT_SIZE="0.9295774647887324" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="71" LOG_CI_END="0.06971234326234903" LOG_CI_START="-0.13314116961676228" LOG_EFFECT_SIZE="-0.03171441317720662" ORDER="518" O_E="0.0" SE="0.11915715760627336" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.01419842820880627" WEIGHT="18.787311039709962"/>
<DICH_DATA CI_END="1.1336081375397735" CI_START="0.7251575012759666" EFFECT_SIZE="0.9066666666666666" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.05446295480815421" LOG_CI_START="-0.1395676561790817" LOG_EFFECT_SIZE="-0.042552350685463744" ORDER="519" O_E="0.0" SE="0.11397454136091695" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.012990196078431368" WEIGHT="20.3546196130349"/>
<DICH_DATA CI_END="1.2760921082901469" CI_START="0.4967203720073788" EFFECT_SIZE="0.7961538461538461" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.10588202287921687" LOG_CI_START="-0.30388802790701736" LOG_EFFECT_SIZE="-0.09900300251390023" ORDER="520" O_E="0.0" SE="0.24070095622629892" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="0.057936950328254674" WEIGHT="4.960427129967886"/>
<DICH_DATA CI_END="1.323908150829997" CI_START="0.6330835815805553" EFFECT_SIZE="0.9155023286759814" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="45" LOG_CI_END="0.12185785597121618" LOG_CI_START="-0.19853894934604752" LOG_EFFECT_SIZE="-0.038340546687415655" ORDER="521" O_E="0.0" SE="0.18820266943312552" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.03542024478175432" WEIGHT="7.986248149360902"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.050757991033646546" CI_END="2.3504892678076668" CI_START="0.029114976892721536" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2615997720159751" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.23" LOG_CI_END="0.3711582725663689" LOG_CI_START="-1.5358835502362758" LOG_EFFECT_SIZE="-0.5823626388349534" METHOD="MH" MODIFIED="2009-09-18 15:17:51 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.8217495244763946" P_Q="0.0" P_Z="0.2312880731102125" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="336" WEIGHT="100.0" Z="1.1970474736424674">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="522" O_E="0.0" SE="0.0" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.256100678584414" CI_START="0.014076743100520147" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9167749802965881" LOG_CI_START="-1.8514978151576003" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="523" O_E="0.0" SE="1.6260971432211297" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="2.644191919191919" WEIGHT="47.457260583438924"/>
<DICH_DATA CI_END="4.258095183677584" CI_START="0.00996135158804058" EFFECT_SIZE="0.20595238095238094" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6292153652478921" LOG_CI_START="-2.0016817311140644" LOG_EFFECT_SIZE="-0.6862331829330863" ORDER="524" O_E="0.0" SE="1.5454019775536751" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="2.38826727222681" WEIGHT="52.54273941656107"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="525" O_E="0.0" SE="0.0" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.56486190412488" CI_END="1.4481880179073183" CI_START="1.1298513680639113" CI_STUDY="95" CI_TOTAL="95" DF="45" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2791548824307195" ESTIMABLE="YES" EVENTS_1="690" EVENTS_2="537" I2="9.209875159048886" I2_Q="0.0" ID="CMP-004.24" LOG_CI_END="0.1608249498713382" LOG_CI_START="0.053021315806189954" LOG_EFFECT_SIZE="0.10692313283876409" METHOD="MH" MODIFIED="2009-09-18 15:34:59 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.29612415498802" P_Q="0.0" P_Z="1.0111051446396045E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.012752932177284567" TOTALS="SUB" TOTAL_1="4711" TOTAL_2="4722" WEIGHT="900.0" Z="3.8879114103245205">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.638203630982408" CI_END="1.6585405229049952" CI_START="1.0154748757107703" DF="7" EFFECT_SIZE="1.2977697143015112" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="98" I2="0.0" ID="CMP-004.24.01" LOG_CI_END="0.21972608704575308" LOG_CI_START="0.00666918281206722" LOG_EFFECT_SIZE="0.11319763492891015" MODIFIED="2009-09-18 15:33:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4674959969148732" P_Z="0.03728159101872453" STUDIES="8" TAU2="0.0" TOTAL_1="996" TOTAL_2="992" WEIGHT="100.00000000000001" Z="2.0826669606766854">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="19.022721047163433" CI_START="0.17032263638661366" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2792726393755882" LOG_CI_START="-0.768727629168976" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="387" O_E="0.0" SE="1.203005495507906" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="1.4472222222222224" WEIGHT="1.0822590002355814"/>
<DICH_DATA CI_END="2.3857985720614217" CI_START="0.27370063845093145" EFFECT_SIZE="0.8080808080808081" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.37763377431548095" LOG_CI_START="-0.5627241895266937" LOG_EFFECT_SIZE="-0.09254520760560633" ORDER="388" O_E="0.0" SE="0.5523709228078868" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.3051136363636364" WEIGHT="5.133396507635107"/>
<DICH_DATA CI_END="2.7442432354886557" CI_START="0.7531151642225136" EFFECT_SIZE="1.437613019891501" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.438422602351362" LOG_CI_START="-0.12313860764781792" LOG_EFFECT_SIZE="0.157641997351772" ORDER="389" O_E="0.0" SE="0.32986383452633933" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.10881014932842016" WEIGHT="14.39451452835976"/>
<DICH_DATA CI_END="2.5223547968256717" CI_START="0.684291420915388" EFFECT_SIZE="1.313782991202346" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.40180617480887676" LOG_CI_START="-0.1647589047975842" LOG_EFFECT_SIZE="0.11852363500564626" ORDER="390" O_E="0.0" SE="0.3328031323032103" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.1107579248708281" WEIGHT="14.141374327549089"/>
<DICH_DATA CI_END="1.761914981397502" CI_START="0.7006966364831878" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" LOG_CI_END="0.24598494834348386" LOG_CI_START="-0.15446996722213355" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="391" O_E="0.0" SE="0.23522919968704556" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.055332776385407956" WEIGHT="28.306356153745917"/>
<DICH_DATA CI_END="3.1503689016259644" CI_START="0.00832066108635993" EFFECT_SIZE="0.1619047619047619" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.49836141174512855" LOG_CI_START="-2.079842167128457" LOG_EFFECT_SIZE="-0.7907403776916642" ORDER="392" O_E="0.0" SE="1.5144495445438875" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="2.293557422969188" WEIGHT="0.6828995252768871"/>
<DICH_DATA CI_END="2.021999538966485" CI_START="0.1333336563735216" EFFECT_SIZE="0.5192307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.30578105223206714" LOG_CI_START="-0.8750602111836907" LOG_EFFECT_SIZE="-0.2846395794758118" ORDER="393" O_E="0.0" SE="0.6936320033889412" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="0.4811253561253561" WEIGHT="3.255428664069102"/>
<DICH_DATA CI_END="2.63082743610532" CI_START="1.1200285377628032" EFFECT_SIZE="1.7165668662674651" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="27" LOG_CI_END="0.4200923623369124" LOG_CI_START="0.04922908841573175" LOG_EFFECT_SIZE="0.23466072537632202" ORDER="394" O_E="0.0" SE="0.21784692290411484" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.04745728181879136" WEIGHT="33.00377129312858"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5252798595692956" CI_END="1.7947672788782933" CI_START="0.8160729612751916" DF="2" EFFECT_SIZE="1.2102318158410919" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="34" I2="0.0" ID="CMP-004.24.02" LOG_CI_END="0.25400814313642234" LOG_CI_START="-0.0882710112673557" LOG_EFFECT_SIZE="0.08286856593453333" MODIFIED="2009-09-18 15:34:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4664335700490094" P_Z="0.3425970101519308" STUDIES="3" TAU2="0.0" TOTAL_1="340" TOTAL_2="341" WEIGHT="100.0" Z="0.9490464294566189">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="12.539759623710928" CI_START="0.5813508566955009" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0982892115268754" LOG_CI_START="-0.23556168320890084" LOG_EFFECT_SIZE="0.43136376415898736" ORDER="395" O_E="0.0" SE="0.7835106182362105" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.6138888888888888" WEIGHT="6.584856755358597"/>
<DICH_DATA CI_END="1.697001188769349" CI_START="0.7458008918177722" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="32" LOG_CI_END="0.2296821465461895" LOG_CI_START="-0.12737710165142688" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="396" O_E="0.0" SE="0.20973836986306385" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.04399018379281537" WEIGHT="91.89255530457221"/>
<DICH_DATA CI_END="75.30141698747275" CI_START="0.12673979595998175" EFFECT_SIZE="3.0892857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8768031486316468" LOG_CI_START="-0.8970869963864565" LOG_EFFECT_SIZE="0.489858076122595" ORDER="397" O_E="0.0" SE="1.629396802161302" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="2.6549339388934765" WEIGHT="1.5225879400691837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.34226152600465976" CI_END="2.9010988108343145" CI_START="0.3568512936026766" DF="2" EFFECT_SIZE="1.017477696814732" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-004.24.03" LOG_CI_END="0.4625625210361294" LOG_CI_START="-0.4475127245663325" LOG_EFFECT_SIZE="0.007524898234898434" MODIFIED="2009-09-18 15:34:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8427114009297876" P_Z="0.9741437556065679" STUDIES="3" TAU2="0.0" TOTAL_1="287" TOTAL_2="293" WEIGHT="100.0" Z="0.03241167057118805">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="14.850735173811657" CI_START="0.06331755310657398" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1717479535876834" LOG_CI_START="-1.1984758767036463" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="398" O_E="0.0" SE="1.392281210710311" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="1.9384469696969697" WEIGHT="14.742661115320397"/>
<DICH_DATA CI_END="8.960424002286887" CI_START="0.2627819103095132" EFFECT_SIZE="1.5344827586206897" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9523285607220242" LOG_CI_START="-0.5804045345580732" LOG_EFFECT_SIZE="0.18596201308197552" ORDER="399" O_E="0.0" SE="0.9003350073187149" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.8106031254035903" WEIGHT="35.25506609665929"/>
<DICH_DATA CI_END="3.399217792813089" CI_START="0.17553652109345408" EFFECT_SIZE="0.7724550898203593" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5313789913517328" LOG_CI_START="-0.7556325130484015" LOG_EFFECT_SIZE="-0.11212676084833431" ORDER="400" O_E="0.0" SE="0.7559969284943328" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.5715313558928653" WEIGHT="50.00227278802031"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9025819083710838" CI_END="8.770464424992898" CI_START="0.36663265853849636" DF="2" EFFECT_SIZE="1.7931923178377858" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="31.09582905371338" ID="CMP-004.24.04" LOG_CI_END="0.9430225912989155" LOG_CI_START="-0.4357688519997464" LOG_EFFECT_SIZE="0.2536268696495845" MODIFIED="2009-09-18 15:34:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.23426771199133434" P_Z="0.4708691686753126" STUDIES="3" TAU2="0.693687893235615" TOTAL_1="294" TOTAL_2="297" WEIGHT="100.0" Z="0.721065586011391">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="64.42872067787793" CI_START="0.1137623975389348" EFFECT_SIZE="2.707317073170732" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8090795079092163" LOG_CI_START="-0.9440012637753723" LOG_EFFECT_SIZE="0.43253912206692197" ORDER="401" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="2.6152493957372003" WEIGHT="19.823659370467535"/>
<DICH_DATA CI_END="4.20026523045073" CI_START="0.009961000241576864" EFFECT_SIZE="0.20454545454545456" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6232767152751069" LOG_CI_START="-2.0016970493688317" LOG_EFFECT_SIZE="-0.6892101670468626" ORDER="402" O_E="0.0" SE="1.5419225831815464" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="2.3775252525252526" WEIGHT="21.35808964785631"/>
<DICH_DATA CI_END="12.255671754892106" CI_START="0.9617104195667149" EFFECT_SIZE="3.4331337325349303" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0883371206837567" LOG_CI_START="-0.016955678603150073" LOG_EFFECT_SIZE="0.5356907210403032" ORDER="403" O_E="0.0" SE="0.6492544615887252" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.42153135589286544" WEIGHT="58.81825098167616"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.962758323810487" CI_END="2.129254400878761" CI_START="0.8281287189369322" DF="3" EFFECT_SIZE="1.327891832677102" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="87" I2="62.32461318046905" ID="CMP-004.24.05" LOG_CI_END="0.3282275535460115" LOG_CI_START="-0.0819021540613935" LOG_EFFECT_SIZE="0.12316269974230894" MODIFIED="2009-09-18 15:34:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.046787788179204925" P_Z="0.23913106344197477" STUDIES="4" TAU2="0.1317365678679153" TOTAL_1="546" TOTAL_2="558" WEIGHT="100.0" Z="1.1771615235671742">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.7438335031333647" CI_START="0.8127570155280183" EFFECT_SIZE="1.1905095184770438" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.24150501722369883" LOG_CI_START="-0.09003927308750316" LOG_EFFECT_SIZE="0.07573287206809785" ORDER="404" O_E="0.0" SE="0.19475075729950558" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.03792785746873093" WEIGHT="34.207935950135514"/>
<DICH_DATA CI_END="1.3230892080050358" CI_START="0.2582713803260459" EFFECT_SIZE="0.5845648604269293" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.12158912705840806" LOG_CI_START="-0.5879237163784083" LOG_EFFECT_SIZE="-0.2331672946600002" ORDER="405" O_E="0.0" SE="0.4167713563800041" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.17369836349882842" WEIGHT="19.001984379984638"/>
<DICH_DATA CI_END="9.350540037860323" CI_START="1.0379744124379024" EFFECT_SIZE="3.1153846153846154" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9708366941548559" LOG_CI_START="0.016186647660807827" LOG_EFFECT_SIZE="0.49351167090783177" ORDER="406" O_E="0.0" SE="0.5607661629045474" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="0.31445868945868943" WEIGHT="13.00746634938848"/>
<DICH_DATA CI_END="2.5083997920032215" CI_START="1.1445747475551051" EFFECT_SIZE="1.694417616380143" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="31" LOG_CI_END="0.39939675609156894" LOG_CI_START="0.05864415995568975" LOG_EFFECT_SIZE="0.22902045802362936" ORDER="407" O_E="0.0" SE="0.20015976172276992" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.04006393021291603" WEIGHT="33.78261332049137"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1421861187144704" CI_END="2.5143306387118485" CI_START="1.0830234836176749" DF="4" EFFECT_SIZE="1.6501754837908482" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="31" I2="0.0" ID="CMP-004.24.06" LOG_CI_END="0.40042238756083065" LOG_CI_START="0.03463787370288102" LOG_EFFECT_SIZE="0.21753013063185586" MODIFIED="2009-09-18 15:34:26 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5343192739838075" P_Z="0.019744893359020424" STUDIES="5" TAU2="0.0" TOTAL_1="387" TOTAL_2="389" WEIGHT="99.99999999999999" Z="2.3311605901189236">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="64.42872067787793" CI_START="0.1137623975389348" EFFECT_SIZE="2.707317073170732" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8090795079092163" LOG_CI_START="-0.9440012637753723" LOG_EFFECT_SIZE="0.43253912206692197" ORDER="408" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="2.6152493957372003" WEIGHT="1.7652764334855164"/>
<DICH_DATA CI_END="68.94634076504033" CI_START="0.12297061175900956" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8385112215238748" LOG_CI_START="-0.910198666413285" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="409" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="2.606951871657754" WEIGHT="1.7708950349921146"/>
<DICH_DATA CI_END="2.2428004716841934" CI_START="0.029162911951572376" EFFECT_SIZE="0.2557471264367816" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.35079063876309896" LOG_CI_START="-1.5351691133664354" LOG_EFFECT_SIZE="-0.5921892373016682" ORDER="410" O_E="0.0" SE="1.107822094052225" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="1.2272697920702569" WEIGHT="3.76171413637942"/>
<DICH_DATA CI_END="5.0570250995304455" CI_START="0.6406928848940934" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7038951091715042" LOG_CI_START="-0.19335009896489197" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="411" O_E="0.0" SE="0.5270462766947299" STUDY_ID="STD-Robinson-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.2777777777777778" WEIGHT="16.61989725353562"/>
<DICH_DATA CI_END="2.8071746983922585" CI_START="1.0688397509402439" EFFECT_SIZE="1.7321720195971693" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="22" LOG_CI_END="0.448269440844944" LOG_CI_START="0.028912597164564683" LOG_EFFECT_SIZE="0.23859101900475438" ORDER="412" O_E="0.0" SE="0.24633228582770994" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.06067959504110458" WEIGHT="76.08221714160732"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.056366549433594225" CI_END="2.704181948328806" CI_START="0.06195115513295243" DF="1" EFFECT_SIZE="0.40930086170034796" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-004.24.07" LOG_CI_END="0.4320359093468053" LOG_CI_START="-1.2079505914156003" LOG_EFFECT_SIZE="-0.3879573410343976" MODIFIED="2009-09-18 15:34:30 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8123337660217069" P_Z="0.35376911202092753" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="68" WEIGHT="100.0" Z="0.9273032620839889">
<NAME>rigor</NAME>
<DICH_DATA CI_END="7.1587467419864375" CI_START="0.012640266393214982" EFFECT_SIZE="0.3008130081300813" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8548369984698914" LOG_CI_START="-1.898243773214697" LOG_EFFECT_SIZE="-0.5217033873724028" ORDER="413" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="2.6152493957372003" WEIGHT="35.48482274011919"/>
<DICH_DATA CI_END="5.087412315320494" CI_START="0.04620778476160568" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7064969369653394" LOG_CI_START="-1.335284851409265" LOG_EFFECT_SIZE="-0.31439395722196267" ORDER="414" O_E="0.0" SE="1.1993527294740984" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="1.4384469696969697" WEIGHT="64.5151772598808"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.511279016247647" CI_END="1.5659572338056504" CI_START="0.4812190644996287" DF="4" EFFECT_SIZE="0.8680832189936524" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" I2="11.333349464891093" ID="CMP-004.24.08" LOG_CI_END="0.19477989732867357" LOG_CI_START="-0.31765717550721395" LOG_EFFECT_SIZE="-0.0614386390892702" MODIFIED="2009-09-18 15:34:38 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3412122992559916" P_Z="0.638369497460065" STUDIES="5" TAU2="0.05605208834283663" TOTAL_1="485" TOTAL_2="488" WEIGHT="100.0" Z="0.46997973510276897">
<NAME>tremor</NAME>
<DICH_DATA CI_END="4.755680261790857" CI_START="0.042580659096653414" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6772126480476257" LOG_CI_START="-1.3707876204969385" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="415" O_E="0.0" SE="1.203005495507906" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="1.4472222222222224" WEIGHT="6.027233984356974"/>
<DICH_DATA CI_END="3.616879841726863" CI_START="0.11554614955887724" EFFECT_SIZE="0.6464646464646465" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5583340810751983" LOG_CI_START="-0.9372445223025239" LOG_EFFECT_SIZE="-0.18945522061366268" ORDER="416" O_E="0.0" SE="0.8785102748575585" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.771780303030303" WEIGHT="10.944952271581904"/>
<DICH_DATA CI_END="1.3871448640468282" CI_START="0.020956424595883878" EFFECT_SIZE="0.17049808429118773" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1421218182260682" LOG_CI_START="-1.678682810940767" LOG_EFFECT_SIZE="-0.7682804963573494" ORDER="417" O_E="0.0" SE="1.0695496523008754" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="1.1439364587369236" WEIGHT="7.550560407012193"/>
<DICH_DATA CI_END="1.8430568786756216" CI_START="0.3934051149691817" EFFECT_SIZE="0.8515092502434275" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.265538738210821" LOG_CI_START="-0.40515999777598677" LOG_EFFECT_SIZE="-0.06981062978258286" ORDER="418" O_E="0.0" SE="0.3939717575309385" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.15521374573201657" WEIGHT="42.88713341712548"/>
<DICH_DATA CI_END="4.075059066492435" CI_START="0.6428051295424468" EFFECT_SIZE="1.6184773310521814" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6101339080614725" LOG_CI_START="-0.19192066625360477" LOG_EFFECT_SIZE="0.20910662090393384" ORDER="419" O_E="0.0" SE="0.47113082718685034" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.22196425632576586" WEIGHT="32.590119919923445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.567512097433443" CI_END="1.550292178530737" CI_START="1.057036461600617" DF="12" EFFECT_SIZE="1.2801231811201774" ESTIMABLE="YES" EVENTS_1="312" EVENTS_2="241" I2="27.569088651162172" ID="CMP-004.24.09" LOG_CI_END="0.1904135559544604" LOG_CI_START="0.024089968195635615" LOG_EFFECT_SIZE="0.10725176207504805" MODIFIED="2009-09-18 15:34:59 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.1666029058073708" P_Z="0.011480641609376872" STUDIES="13" TAU2="0.02924097999226308" TOTAL_1="1303" TOTAL_2="1296" WEIGHT="99.99999999999999" Z="2.527718332415539">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="124.13532946180445" CI_START="0.39473049463389837" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.093895401214321" LOG_CI_START="-0.4036993211858073" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="420" O_E="0.0" SE="1.4670995032311038" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.152380952380952" WEIGHT="0.43752553260708865"/>
<DICH_DATA CI_END="1.5739921473671021" CI_START="0.8505763033352804" EFFECT_SIZE="1.157065435568045" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="53" LOG_CI_END="0.1970025613371226" LOG_CI_START="-0.070286720698038" LOG_EFFECT_SIZE="0.06335792031954228" ORDER="421" O_E="0.0" SE="0.15700704737073812" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.024651212924077202" WEIGHT="17.711569083682335"/>
<DICH_DATA CI_END="2.1011868203660073" CI_START="0.13877871171360479" EFFECT_SIZE="0.54" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3224646680399479" LOG_CI_START="-0.8576771483940109" LOG_EFFECT_SIZE="-0.2676062401770315" ORDER="422" O_E="0.0" SE="0.693221144769514" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.4805555555555555" WEIGHT="1.8723455954505284"/>
<DICH_DATA CI_END="6.378188182903751" CI_START="0.746345269534709" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8046973285775325" LOG_CI_START="-0.12706021547077062" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="423" O_E="0.0" SE="0.5473189936482021" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.2995580808080808" WEIGHT="2.903035354132309"/>
<DICH_DATA CI_END="1.8262570970392724" CI_START="0.41027802580696254" EFFECT_SIZE="0.865605658709107" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.2615619166625475" LOG_CI_START="-0.3869217429071824" LOG_EFFECT_SIZE="-0.06267991312231745" ORDER="424" O_E="0.0" SE="0.3809225116771452" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.14510195990242483" WEIGHT="5.474929460782714"/>
<DICH_DATA CI_END="1.506794324018003" CI_START="0.918811813471411" EFFECT_SIZE="1.1766309639727361" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="65" LOG_CI_END="0.1780539755793429" LOG_CI_START="-0.03677342957141363" LOG_EFFECT_SIZE="0.07064027300396464" ORDER="425" O_E="0.0" SE="0.1261906811983604" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.01592408802130623" WEIGHT="21.133928053028146"/>
<DICH_DATA CI_END="2.081509816654199" CI_START="0.7642074597026977" EFFECT_SIZE="1.2612316715542522" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="25" LOG_CI_END="0.31837846341337805" LOG_CI_START="-0.11678872732294862" LOG_EFFECT_SIZE="0.1007948680452147" ORDER="426" O_E="0.0" SE="0.2556193619508535" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.06534125820416144" WEIGHT="10.091908545519916"/>
<DICH_DATA CI_END="1.5369721093446622" CI_START="0.34989429834681685" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.1866659866489896" LOG_CI_START="-0.4560631344439021" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="427" O_E="0.0" SE="0.3775422672904256" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.14253816359079519" WEIGHT="5.556642546930452"/>
<DICH_DATA CI_END="9.552732247274859" CI_START="0.9421388318056815" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9801276051130026" LOG_CI_START="-0.02588509567367781" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="428" O_E="0.0" SE="0.5909368402852788" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.3492063492063492" WEIGHT="2.522187961876088"/>
<DICH_DATA CI_END="3.738996192131637" CI_START="0.9654997797528926" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5727550228602747" LOG_CI_START="-0.01524782095461685" LOG_EFFECT_SIZE="0.2787536009528289" ORDER="429" O_E="0.0" SE="0.3453957811178867" STUDY_ID="STD-Robinson-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1192982456140351" WEIGHT="6.426015040894522"/>
<DICH_DATA CI_END="1.644921750304905" CI_START="0.4803410597760441" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.21614524318624787" LOG_CI_START="-0.31845028808101045" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="430" O_E="0.0" SE="0.31402406135694616" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.0986111111111111" WEIGHT="7.46577775671364"/>
<DICH_DATA CI_END="2.413969367214338" CI_START="1.1498991203228262" EFFECT_SIZE="1.6660796054948925" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="34" LOG_CI_END="0.38273175468668735" LOG_CI_START="0.060659741737221294" LOG_EFFECT_SIZE="0.22169574821195434" ORDER="431" O_E="0.0" SE="0.1891866946886927" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.03579160544723263" WEIGHT="14.677492697825278"/>
<DICH_DATA CI_END="6.290835139087719" CI_START="0.9722991197414715" EFFECT_SIZE="2.473170731707317" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.798708303986048" LOG_CI_START="-0.012200107430884575" LOG_EFFECT_SIZE="0.3932540982775817" ORDER="432" O_E="0.0" SE="0.47633161492768067" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="0.22689180737961226" WEIGHT="3.726642370556997"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="44.53072282352144" CI_END="0.2979681219056195" CI_START="-0.10086682308474562" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09855064941043692" ESTIMABLE="YES" I2="57.33282822446334" I2_Q="13.306720138598129" ID="CMP-004.25" MODIFIED="2010-11-23 15:33:43 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="7.970146379170373E-4" P_Q="0.3260754936204471" P_Z="0.3327449166751575" Q="8.074443614535092" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.10854215585193826" TOTALS="SUB" TOTAL_1="1693" TOTAL_2="1711" UNITS="" WEIGHT="800.0" Z="0.9685997976037736">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7776276154591641" CI_START="-0.7176276154591641" DF="0" EFFECT_SIZE="0.03" ESTIMABLE="YES" I2="0.0" ID="CMP-004.25.01" MODIFIED="2010-11-23 15:32:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9373131362220316" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="152" WEIGHT="100.0" Z="0.07864733501061166">
<NAME>abnormal involuntary movement: AIMS (high = poor)</NAME>
<CONT_DATA CI_END="0.7776276154591641" CI_START="-0.7176276154591641" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="0.12" MEAN_2="0.09" ORDER="433" SD_1="3.67" SD_2="2.91" SE="0.38144967017575593" STUDY_ID="STD-Keefe-2006" TOTAL_1="150" TOTAL_2="152" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="16.829049071993843" CI_END="1.8117244598003106" CI_START="-0.36237608789899756" DF="1" EFFECT_SIZE="0.7246741859506566" ESTIMABLE="YES" I2="94.0578936116827" ID="CMP-004.25.02" MODIFIED="2010-11-23 15:32:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.090326396466448E-5" P_Z="0.19135002919303315" STUDIES="2" TAU2="0.5794436535947715" TOTAL_1="175" TOTAL_2="178" WEIGHT="100.0" Z="1.3065957841666578">
<NAME>akathisia: Barnes Akathisia Scale (high = poor)</NAME>
<CONT_DATA CI_END="0.42227593306382694" CI_START="-0.042275933063826904" EFFECT_SIZE="0.19" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="-0.18" ORDER="434" SD_1="1.13" SD_2="0.92" SE="0.11851030676889464" STUDY_ID="STD-Keefe-2006" TOTAL_1="150" TOTAL_2="153" WEIGHT="51.831154418859775"/>
<CONT_DATA CI_END="1.7767509155762893" CI_START="0.8232490844237108" EFFECT_SIZE="1.3" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="-0.2" ORDER="435" SD_1="0.86" SD_2="0.86" SE="0.24324473272817232" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="48.16884558114023"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2689526944750777" CI_START="-0.2689526944750777" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.25.03" MODIFIED="2010-11-23 15:33:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="179" TOTAL_2="180" WEIGHT="100.0" Z="0.0">
<NAME>akathisia: ESRS subscore for akathisia (high = poor)</NAME>
<CONT_DATA CI_END="0.2689526944750777" CI_START="-0.2689526944750777" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.1" ORDER="436" SD_1="1.3" SD_2="1.3" SE="0.13722328399732966" STUDY_ID="STD-Conley-2001" TOTAL_1="179" TOTAL_2="180" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.0618028104684942" CI_END="0.5992586954998166" CI_START="-0.7555598211089617" DF="2" EFFECT_SIZE="-0.07815056280457253" ESTIMABLE="YES" I2="34.67900698366741" ID="CMP-004.25.04" MODIFIED="2010-11-23 15:33:10 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.21634065360899613" P_Z="0.8211121002225804" STUDIES="3" TAU2="0.13460958435097692" TOTAL_1="283" TOTAL_2="289" WEIGHT="100.0" Z="0.22611484356133618">
<NAME>dyskinesia: ESRS subscore for dyskinesia (high = poor)</NAME>
<CONT_DATA CI_END="0.5585940577559307" CI_START="-0.5585940577559307" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" ORDER="437" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="179" TOTAL_2="180" WEIGHT="55.34552472700382"/>
<CONT_DATA CI_END="0.29427223848995276" CI_START="-1.8942722384899533" EFFECT_SIZE="-0.8000000000000003" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.1" ORDER="438" SD_1="3.6" SD_2="3.7" SE="0.5583124216166383" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="26.764395825598935"/>
<CONT_DATA CI_END="2.1910549544424" CI_START="-0.6710549544424003" EFFECT_SIZE="0.76" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-0.57" ORDER="439" SD_1="1.72" SD_2="2.87" SE="0.7301434953552102" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="17.89007944739724"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1040161825662489E-33" CI_END="0.7286167265207599" CI_START="-0.9086167265207599" DF="0" EFFECT_SIZE="-0.09000000000000002" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-004.25.05" MODIFIED="2010-11-23 15:33:17 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.829391935776428" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.21548149811000905">
<NAME>dystonia: ESRS subscore for dystonia (high = poor)</NAME>
<CONT_DATA CI_END="0.7286167265207599" CI_START="-0.9086167265207599" EFFECT_SIZE="-0.09000000000000001" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="-0.05" ORDER="440" SD_1="1.65" SD_2="0.97" SE="0.41766926993450093" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7403247853050652" CI_END="0.9386455796744662" CI_START="-0.34725444958915624" DF="3" EFFECT_SIZE="0.295695565042655" ESTIMABLE="YES" I2="0.0" ID="CMP-004.25.06" MODIFIED="2010-11-23 15:33:28 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6280063045527713" P_Z="0.3673777459999721" STUDIES="4" TAU2="0.0" TOTAL_1="342" TOTAL_2="340" WEIGHT="100.0" Z="0.9013961345093191">
<NAME>extrapyramidal symptoms: ESRS total score (high = poor)</NAME>
<CONT_DATA CI_END="1.1275467522310083" CI_START="-0.5275467522310086" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.2" ORDER="441" SD_1="4.0" SD_2="4.0" SE="0.4222254892225529" STUDY_ID="STD-Conley-2001" TOTAL_1="179" TOTAL_2="180" WEIGHT="60.362795420635436"/>
<CONT_DATA CI_END="2.48572864521476" CI_START="-3.0857286452147603" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.3" ORDER="442" SD_1="5.9" SD_2="6.1" SE="1.4213162421290555" STUDY_ID="STD-Dollfus-2005" TOTAL_1="39" TOTAL_2="33" WEIGHT="5.326927684597707"/>
<CONT_DATA CI_END="1.2502381800803697" CI_START="-2.05023818008037" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-1.7" ORDER="443" SD_1="5.38" SD_2="5.63" SE="0.841973726607855" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="15.17962907950905"/>
<CONT_DATA CI_END="2.4699832028993853" CI_START="-0.46998320289938555" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="3.8" ORDER="444" SD_1="3.6" SD_2="3.1" SE="0.7500052115724705" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" WEIGHT="19.13064781525781"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.118034825257736" CI_END="1.3258913592079336" CI_START="-0.078164062636633" DF="4" EFFECT_SIZE="0.6238636482856503" ESTIMABLE="YES" I2="60.46663142515811" ID="CMP-004.25.07" MODIFIED="2010-11-23 15:33:35 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.038485750662415" P_Z="0.08155381600149374" STUDIES="5" TAU2="0.3010426727347331" TOTAL_1="260" TOTAL_2="262" WEIGHT="99.99999999999999" Z="1.7417407644738976">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="1.356674589623552" CI_START="-0.01667458962355206" EFFECT_SIZE="0.6699999999999999" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="-0.73" ORDER="445" SD_1="3.16" SD_2="2.92" SE="0.35035061615415053" STUDY_ID="STD-Keefe-2006" TOTAL_1="149" TOTAL_2="153" WEIGHT="30.273556253104736"/>
<CONT_DATA CI_END="0.41483105881478655" CI_START="-0.014831058814786607" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.2" ORDER="446" SD_1="0.58" SD_2="0.58" SE="0.1096096971726759" STUDY_ID="STD-Robinson-2005" TOTAL_1="56" TOTAL_2="56" WEIGHT="40.98160536751036"/>
<CONT_DATA CI_END="5.184614276468739" CI_START="1.2153857235312613" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="-1.0" ORDER="447" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="9.6728099899993"/>
<CONT_DATA CI_END="1.73671281133168" CI_START="-1.3367128113316797" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="1.9" ORDER="448" SD_1="2.2" SD_2="2.4" SE="0.7840515557699399" STUDY_ID="STD-Sikich-2004" TOTAL_1="19" TOTAL_2="16" WEIGHT="14.00946026943215"/>
<CONT_DATA CI_END="2.9589237798512533" CI_START="-2.8989237798512537" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="-0.17" MEAN_2="-0.2" ORDER="449" SD_1="3.58" SD_2="3.58" SE="1.494376326786732" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="5.062568119953446"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.707067715961208" CI_END="1.565713586648704" CI_START="-1.090500408470457" DF="2" EFFECT_SIZE="0.23760658908912352" ESTIMABLE="YES" I2="57.51070261389708" ID="CMP-004.25.08" MODIFIED="2010-11-23 15:33:43 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.09503294236343007" P_Z="0.7258511456533683" STUDIES="3" TAU2="0.7826299031838861" TOTAL_1="283" TOTAL_2="289" WEIGHT="100.00000000000001" Z="0.35064972774017633">
<NAME>parkinsonism: ESRS subscore for parkinsonism (high = poor)</NAME>
<CONT_DATA CI_END="0.7585940577559307" CI_START="-0.3585940577559308" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.7" ORDER="450" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="179" TOTAL_2="180" WEIGHT="53.15308955941102"/>
<CONT_DATA CI_END="0.6971369594646799" CI_START="-2.4971369594646804" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="6.4" ORDER="451" SD_1="4.6" SD_2="6.0" SE="0.8148807692706054" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="31.739735469670887"/>
<CONT_DATA CI_END="5.7043603592722985" CI_START="-0.18436035927229844" EFFECT_SIZE="2.76" ESTIMABLE="YES" MEAN_1="1.33" MEAN_2="-1.43" ORDER="452" SD_1="5.36" SD_2="4.32" SE="1.5022522773362352" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="15.107174970918102"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.512931305805299" CI_END="10.590964901665533" CI_START="0.0944502333579551" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0001595404975254" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="55.68290619830042" I2_Q="0.0" ID="CMP-004.26" LOG_CI_END="1.024935528792968" LOG_CI_START="-1.0247969647305328" LOG_EFFECT_SIZE="6.928203121746797E-5" METHOD="MH" MODIFIED="2009-09-21 15:00:35 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.10472007331063815" P_Q="0.0" P_Z="0.9998942837929212" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.421929310819417" TOTALS="YES" TOTAL_1="241" TOTAL_2="243" WEIGHT="99.99999999999999" Z="1.3249561724874834E-4">
<NAME>Adverse effects: 6. Haematological: white blood cells - significant low white blood cell count (as def. by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="68.94634076504033" CI_START="0.12297061175900956" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8385112215238748" LOG_CI_START="-0.910198666413285" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="550" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="2.606951871657754" WEIGHT="28.826917227028897"/>
<DICH_DATA CI_END="1.1829760369645457" CI_START="0.018300035157717387" EFFECT_SIZE="0.14713430282292558" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.07297594740098873" LOG_CI_START="-1.737548075909571" LOG_EFFECT_SIZE="-0.8322860642542912" ORDER="551" O_E="0.0" SE="1.0635107735310794" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="1.131055165416675" WEIGHT="40.80151280182506"/>
<DICH_DATA CI_END="96.1564527598966" CI_START="0.23582127159029814" EFFECT_SIZE="4.761904761904762" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9829784337017367" LOG_CI_START="-0.6274170231695751" LOG_EFFECT_SIZE="0.6777807052660807" ORDER="552" O_E="0.0" SE="1.533359213032118" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="2.3511904761904763" WEIGHT="30.371569971146034"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="47.64027371741223" CI_END="1.4337971160861003" CI_START="1.072803255805543" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="RR" EFFECT_SIZE="1.240234741612154" ESTIMABLE="YES" EVENTS_1="505" EVENTS_2="344" I2="22.3346191932631" I2_Q="0.0" ID="CMP-004.27" LOG_CI_END="0.15648770251873498" LOG_CI_START="0.030520082867625108" LOG_EFFECT_SIZE="0.09350389269318005" METHOD="MH" MODIFIED="2009-09-18 15:36:43 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.11297550224778163" P_Q="0.0" P_Z="0.0036177086007830616" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04168678371106302" TOTALS="SUB" TOTAL_1="3544" TOTAL_2="3560" WEIGHT="900.0" Z="2.9097042970330698">
<NAME>Adverse effects: 7a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14461830389700134" CI_END="12.691355867131396" CI_START="1.485675514129861" DF="2" EFFECT_SIZE="4.342261697883427" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" I2="0.0" ID="CMP-004.27.01" LOG_CI_END="1.1035080219495432" LOG_CI_START="0.17192396567546814" LOG_EFFECT_SIZE="0.6377159938125057" MODIFIED="2009-09-18 15:36:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9302432803456964" P_Z="0.007288054966236963" STUDIES="3" TAU2="0.0" TOTAL_1="261" TOTAL_2="270" WEIGHT="100.0" Z="2.683387230212438">
<NAME>abnormal ejaculation</NAME>
<DICH_DATA CI_END="137.20439097414211" CI_START="0.37306100289901456" EFFECT_SIZE="7.154411764705882" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.137368010389138" LOG_CI_START="-0.4282201465928688" LOG_EFFECT_SIZE="0.8545739318981345" ORDER="463" O_E="0.0" SE="1.5070391832774284" STUDY_ID="STD-Conley-2001" TOTAL_1="135" TOTAL_2="138" VAR="2.2711670999334985" WEIGHT="13.184698708282253"/>
<DICH_DATA CI_END="76.5975747998518" CI_START="0.1435353516416592" EFFECT_SIZE="3.3157894736842106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8842150194013312" LOG_CI_START="-0.8430411223998253" LOG_EFFECT_SIZE="0.5205869485007527" ORDER="464" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Gureje-2003" TOTAL_1="18" TOTAL_2="20" VAR="2.5664160401002505" WEIGHT="11.667887614829837"/>
<DICH_DATA CI_END="14.294756618362783" CI_START="1.2037373925541999" EFFECT_SIZE="4.148148148148148" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.1551767654861134" LOG_CI_START="0.08053175153627523" LOG_EFFECT_SIZE="0.6178542585111942" ORDER="465" O_E="0.0" SE="0.631251800772747" STUDY_ID="STD-Tran-1997" TOTAL_1="108" TOTAL_2="112" VAR="0.39847883597883593" WEIGHT="75.14741367688791"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9323305423922172" CI_END="9.232867073180861" CI_START="0.9878732035062775" DF="2" EFFECT_SIZE="3.020083106990734" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="90" I2="49.1395756679369" ID="CMP-004.27.02" LOG_CI_END="0.9653365830100301" LOG_CI_START="-0.005298794836871624" LOG_EFFECT_SIZE="0.4800188940865793" MODIFIED="2009-09-18 15:36:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13999283346099922" P_Z="0.052554364320784835" STUDIES="3" TAU2="0.5341062914266116" TOTAL_1="241" TOTAL_2="236" WEIGHT="100.0" Z="1.9385647088104336">
<NAME>abnormally high prolactin concentration</NAME>
<DICH_DATA CI_END="30.737407135182217" CI_START="0.42163608475504466" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4876672296446556" LOG_CI_START="-0.375062228110081" LOG_EFFECT_SIZE="0.5563025007672873" ORDER="466" O_E="0.0" SE="1.094176504144657" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="1.1972222222222224" WEIGHT="18.776210929638076"/>
<DICH_DATA CI_END="76.88296301966206" CI_START="1.4907843357403556" EFFECT_SIZE="10.705882352941176" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.8858301124114256" LOG_CI_START="0.1734148208021757" LOG_EFFECT_SIZE="1.0296224666068008" ORDER="467" O_E="0.0" SE="1.0058812188836757" STUDY_ID="STD-Jeste-2003" TOTAL_1="34" TOTAL_2="28" VAR="1.0117970265029088" WEIGHT="21.028345682255242"/>
<DICH_DATA CI_END="2.1368941097198215" CI_START="1.5800648434065714" EFFECT_SIZE="1.8375068045726728" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="88" LOG_CI_END="0.3297830019470507" LOG_CI_START="0.19867491009101076" LOG_EFFECT_SIZE="0.26422895601903074" ORDER="468" O_E="0.0" SE="0.0770135421517594" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.005931085674760821" WEIGHT="60.19544338810668"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6175688698379695" CI_END="2.220840318258651" CI_START="1.016827845335353" DF="5" EFFECT_SIZE="1.5027349319320502" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="31" I2="0.0" ID="CMP-004.27.03" LOG_CI_END="0.3465173332480626" LOG_CI_START="0.007247430651683015" LOG_EFFECT_SIZE="0.17688238194987277" MODIFIED="2009-09-18 15:36:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8991166797789039" P_Z="0.040983106892078715" STUDIES="7" TAU2="0.0" TOTAL_1="286" TOTAL_2="279" WEIGHT="100.0" Z="2.0437008733654056">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="2.5982188343796957" CI_START="0.5323695876070023" EFFECT_SIZE="1.1761006289308176" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.41467572662967256" LOG_CI_START="-0.2737867621975776" LOG_EFFECT_SIZE="0.07044448221604747" ORDER="469" O_E="0.0" SE="0.40440627388140904" STUDY_ID="STD-Conley-2001" TOTAL_1="53" TOTAL_2="51" VAR="0.16354443435464522" WEIGHT="24.284552398691247"/>
<DICH_DATA CI_END="64.42872067787793" CI_START="0.1137623975389348" EFFECT_SIZE="2.707317073170732" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8090795079092163" LOG_CI_START="-0.9440012637753723" LOG_EFFECT_SIZE="0.43253912206692197" ORDER="470" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="2.6152493957372003" WEIGHT="1.5186327514589353"/>
<DICH_DATA CI_END="3.092590615401405" CI_START="0.7477259818897313" EFFECT_SIZE="1.5206611570247934" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.490322433666478" LOG_CI_START="-0.12625752828030518" LOG_EFFECT_SIZE="0.1820324526930864" ORDER="471" O_E="0.0" SE="0.362182121767576" STUDY_ID="STD-Lieberman-2005" TOTAL_1="88" TOTAL_2="92" VAR="0.13117588932806326" WEIGHT="30.276931271012415"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="472" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.814669206585643" CI_START="0.8056654244107367" EFFECT_SIZE="1.5058823529411764" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.4494273618175308" LOG_CI_START="-0.09384527395037956" LOG_EFFECT_SIZE="0.17779104393357562" ORDER="473" O_E="0.0" SE="0.31912103549298915" STUDY_ID="STD-McEvoy-2007" TOTAL_1="34" TOTAL_2="32" VAR="0.10183823529411765" WEIGHT="38.999137938018734"/>
<DICH_DATA CI_END="71.36115474761681" CI_START="0.16472690334665446" EFFECT_SIZE="3.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.853461869065101" LOG_CI_START="-0.7832354656704026" LOG_EFFECT_SIZE="0.5351132016973491" ORDER="474" O_E="0.0" SE="1.5488090662859395" STUDY_ID="STD-Sikich-2004" TOTAL_1="6" TOTAL_2="7" VAR="2.3988095238095237" WEIGHT="1.655656001937345"/>
<DICH_DATA CI_END="35.330337005529245" CI_START="0.4683501677076215" EFFECT_SIZE="4.067796610169491" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5481477800599142" LOG_CI_START="-0.32942931992099056" LOG_EFFECT_SIZE="0.6093592300694618" ORDER="475" O_E="0.0" SE="1.1028980826853225" STUDY_ID="STD-Tran-1997" TOTAL_1="59" TOTAL_2="60" VAR="1.2163841807909606" WEIGHT="3.265089638881316"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5588272135635632" CI_END="8.000530522819627" CI_START="0.7683218305064915" DF="2" EFFECT_SIZE="2.4793108430198565" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-004.27.04" LOG_CI_END="0.9031187864286677" LOG_CI_START="-0.11445682692668845" LOG_EFFECT_SIZE="0.3943309797509896" MODIFIED="2009-09-18 15:36:17 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7562270785519188" P_Z="0.12874971272098915" STUDIES="3" TAU2="0.0" TOTAL_1="388" TOTAL_2="393" WEIGHT="100.0" Z="1.519050787296002">
<NAME>decreased libido</NAME>
<DICH_DATA CI_END="28.73356923530819" CI_START="0.31656350265676103" EFFECT_SIZE="3.015957446808511" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.458389576667883" LOG_CI_START="-0.49953915740942945" LOG_EFFECT_SIZE="0.47942520962922675" ORDER="476" O_E="0.0" SE="1.150097030300556" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="1.3227231791061578" WEIGHT="27.010935178239233"/>
<DICH_DATA CI_END="14.850735173811657" CI_START="0.06331755310657398" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1717479535876834" LOG_CI_START="-1.1984758767036463" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="477" O_E="0.0" SE="1.392281210710311" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="1.9384469696969697" WEIGHT="18.431244500424057"/>
<DICH_DATA CI_END="15.092358110626527" CI_START="0.6325711186185037" EFFECT_SIZE="3.089820359281437" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1787571015663185" LOG_CI_START="-0.19889064060706244" LOG_EFFECT_SIZE="0.48993323047962806" ORDER="478" O_E="0.0" SE="0.8092371032189507" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.6548646892261987" WEIGHT="54.557820321336706"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.558505874417159" CI_END="3.2766284181854397" CI_START="0.7724589633141816" DF="6" EFFECT_SIZE="1.5909308567870921" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" I2="8.515748634086458" ID="CMP-004.27.05" LOG_CI_END="0.515427193569862" LOG_CI_START="-0.11212458307412179" LOG_EFFECT_SIZE="0.20165130524787003" MODIFIED="2009-09-18 15:36:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3636101688316272" P_Z="0.20781695623832275" STUDIES="7" TAU2="0.09041439149190322" TOTAL_1="522" TOTAL_2="522" WEIGHT="100.0" Z="1.2595910343363925">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="26.854260055169544" CI_START="0.3103258346570267" EFFECT_SIZE="2.8867924528301887" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.429013190285004" LOG_CI_START="-0.5081820678513843" LOG_EFFECT_SIZE="0.46041556121680977" ORDER="479" O_E="0.0" SE="1.137918083900496" STUDY_ID="STD-Conley-2001" TOTAL_1="53" TOTAL_2="51" VAR="1.2948575656677765" WEIGHT="9.809328716676019"/>
<DICH_DATA CI_END="4.821411005245997" CI_START="0.805481617043799" EFFECT_SIZE="1.970674486803519" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6831741548603305" LOG_CI_START="-0.09394436673767538" LOG_EFFECT_SIZE="0.2946148940613275" ORDER="480" O_E="0.0" SE="0.4564832663853909" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.20837697248987572" WEIGHT="45.47851654307219"/>
<DICH_DATA CI_END="1.547874087414388" CI_START="0.005859840188766112" EFFECT_SIZE="0.09523809523809523" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.1897356298835748" LOG_CI_START="-2.232114228023451" LOG_EFFECT_SIZE="-1.021189299069938" ORDER="481" O_E="0.0" SE="1.422606594884729" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="1" VAR="2.0238095238095237" WEIGHT="6.427222722922941"/>
<DICH_DATA CI_END="4.328128139816059" CI_START="0.20466426135585108" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6363001101371492" LOG_CI_START="-0.6889579875818475" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="482" O_E="0.0" SE="0.7784631667335227" STUDY_ID="STD-McEvoy-2007" TOTAL_1="34" TOTAL_2="32" VAR="0.6060049019607843" WEIGHT="19.512078596219425"/>
<DICH_DATA CI_END="14.916422723826622" CI_START="0.09124916451562828" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1736646825482044" LOG_CI_START="-1.0397711032869779" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="483" O_E="0.0" SE="1.300183137283433" STUDY_ID="STD-Sikich-2004" TOTAL_1="6" TOTAL_2="7" VAR="1.6904761904761905" WEIGHT="7.630220591517447"/>
<DICH_DATA CI_END="149.45791517214883" CI_START="0.37636012743259534" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1745189198742083" LOG_CI_START="-0.4243963930908084" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="484" O_E="0.0" SE="1.5266157196739314" STUDY_ID="STD-Stroup-2006" TOTAL_1="23" TOTAL_2="35" VAR="2.3305555555555557" WEIGHT="5.612869340383455"/>
<DICH_DATA CI_END="103.68369005535845" CI_START="0.24922220422499636" EFFECT_SIZE="5.083333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0157104451445966" LOG_CI_START="-0.6034132672183123" LOG_EFFECT_SIZE="0.7061485889631421" ORDER="485" O_E="0.0" SE="1.5384862335134437" STUDY_ID="STD-Tran-1997" TOTAL_1="59" TOTAL_2="60" VAR="2.3669398907103827" WEIGHT="5.5297634892085314"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8581221890536697" CI_END="2.7665441473799186" CI_START="0.7020160984441806" DF="4" EFFECT_SIZE="1.3936134788804364" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" I2="0.0" ID="CMP-004.27.06" LOG_CI_END="0.4419376048991722" LOG_CI_START="-0.15365292863185992" LOG_EFFECT_SIZE="0.14414233813365615" MODIFIED="2009-09-18 15:36:28 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9304904909673695" P_Z="0.3427810469561574" STUDIES="5" TAU2="0.0" TOTAL_1="541" TOTAL_2="542" WEIGHT="100.0" Z="0.9486846263806196">
<NAME>gynecomastia</NAME>
<DICH_DATA CI_END="15.954654377315624" CI_START="0.06334619148219932" EFFECT_SIZE="1.0053191489361701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2028874005915506" LOG_CI_START="-1.1982794907724221" LOG_EFFECT_SIZE="0.002303954909564255" ORDER="486" O_E="0.0" SE="1.4104573179550044" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="1.9893898457728245" WEIGHT="6.1524894807098365"/>
<DICH_DATA CI_END="68.94634076504033" CI_START="0.12297061175900956" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8385112215238748" LOG_CI_START="-0.910198666413285" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="487" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="2.606951871657754" WEIGHT="4.695023422647642"/>
<DICH_DATA CI_END="3.2639229850033495" CI_START="0.6392368210502609" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5137399026606614" LOG_CI_START="-0.19433821692563766" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="488" O_E="0.0" SE="0.4159285924882126" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.17299659404922563" WEIGHT="70.7511044735684"/>
<DICH_DATA CI_END="5.069711944464897" CI_START="0.12623991402484924" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7049832838928313" LOG_CI_START="-0.8988033099089441" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="489" O_E="0.0" SE="0.9420721840708386" STUDY_ID="STD-Sikich-2004" TOTAL_1="20" TOTAL_2="16" VAR="0.8875" WEIGHT="13.79121137932199"/>
<DICH_DATA CI_END="75.30141698747275" CI_START="0.12673979595998175" EFFECT_SIZE="3.0892857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8768031486316468" LOG_CI_START="-0.8970869963864565" LOG_EFFECT_SIZE="0.489858076122595" ORDER="490" O_E="0.0" SE="1.629396802161302" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="2.6549339388934765" WEIGHT="4.6101712437521245"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6698078541189594" CI_END="5.889205753882127" CI_START="0.6797623994997497" DF="2" EFFECT_SIZE="2.000814992548448" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-004.27.07" LOG_CI_END="0.7700567277302057" LOG_CI_START="-0.167642861732069" LOG_EFFECT_SIZE="0.3012069329990683" MODIFIED="2009-09-18 15:36:33 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7154068842790039" P_Z="0.2079742399860256" STUDIES="3" TAU2="0.0" TOTAL_1="261" TOTAL_2="270" WEIGHT="100.0" Z="1.2591553781323144">
<NAME>impotence</NAME>
<DICH_DATA CI_END="36.11460597282432" CI_START="0.46294323017838845" EFFECT_SIZE="4.088888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.557682880867039" LOG_CI_START="-0.3344722623986536" LOG_EFFECT_SIZE="0.6116053092341928" ORDER="491" O_E="0.0" SE="1.1114612974732851" STUDY_ID="STD-Conley-2001" TOTAL_1="135" TOTAL_2="138" VAR="1.2353462157809985" WEIGHT="24.559185903751956"/>
<DICH_DATA CI_END="22.487564609873377" CI_START="0.21960010746428618" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3519424241433209" LOG_CI_START="-0.6583674516940082" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="492" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-Gureje-2003" TOTAL_1="18" TOTAL_2="20" VAR="1.3944444444444444" WEIGHT="21.75712161910424"/>
<DICH_DATA CI_END="6.034393647335174" CI_START="0.3168344302604213" EFFECT_SIZE="1.382716049382716" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7806336375077133" LOG_CI_START="-0.4991676299246497" LOG_EFFECT_SIZE="0.14073300379153184" ORDER="493" O_E="0.0" SE="0.7517615996082153" STUDY_ID="STD-Tran-1997" TOTAL_1="108" TOTAL_2="112" VAR="0.5651455026455026" WEIGHT="53.6836924771438"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="104.00036984004572" CI_START="0.24293423352083635" DF="0" EFFECT_SIZE="5.026455026455026" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.27.08" LOG_CI_END="2.017034883714217" LOG_CI_START="-0.6145112814830099" LOG_EFFECT_SIZE="0.7012618011156035" MODIFIED="2009-09-18 15:36:38 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.2962109477801017" STUDIES="1" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.0" Z="1.0445933969144428">
<NAME>orgastic dysfunction</NAME>
<DICH_DATA CI_END="104.00036984004572" CI_START="0.24293423352083635" EFFECT_SIZE="5.026455026455026" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.017034883714217" LOG_CI_START="-0.6145112814830099" LOG_EFFECT_SIZE="0.7012618011156035" ORDER="494" O_E="0.0" SE="1.5457832438004555" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="2.389445836814258" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.786752332408984" CI_END="1.275520713252468" CI_START="0.9032409411359615" DF="6" EFFECT_SIZE="1.0733603912370588" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="186" I2="0.0" ID="CMP-004.27.09" LOG_CI_END="0.10568751553554483" LOG_CI_START="-0.04419638540277751" LOG_EFFECT_SIZE="0.030745565066383648" MODIFIED="2009-09-18 15:36:43 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4474974229102169" P_Z="0.42134402609218424" STUDIES="7" TAU2="0.0" TOTAL_1="856" TOTAL_2="859" WEIGHT="99.99999999999999" Z="0.8040916981369747">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="1.6215203425977944" CI_START="0.7224626534111479" EFFECT_SIZE="1.0823529411764705" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" LOG_CI_END="0.20992240143486407" LOG_CI_START="-0.14118459817233908" LOG_EFFECT_SIZE="0.03436890163126251" ORDER="495" O_E="0.0" SE="0.20624198957694942" STUDY_ID="STD-Conley-2001" TOTAL_1="135" TOTAL_2="138" VAR="0.04253575826465852" WEIGHT="18.22346681397616"/>
<DICH_DATA CI_END="2.813925188531191" CI_START="0.16191795071773982" EFFECT_SIZE="0.675" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.44931254702908296" LOG_CI_START="-0.790705001367033" LOG_EFFECT_SIZE="-0.17069622716897506" ORDER="496" O_E="0.0" SE="0.7283924461137385" STUDY_ID="STD-Dollfus-2005" TOTAL_1="40" TOTAL_2="36" VAR="0.5305555555555554" WEIGHT="1.461013782678503"/>
<DICH_DATA CI_END="74.30490610725971" CI_START="0.12669068790468127" EFFECT_SIZE="3.0681818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8710174897359129" LOG_CI_START="-0.8972553057182757" LOG_EFFECT_SIZE="0.4868810920088187" ORDER="497" O_E="0.0" SE="1.6260971432211297" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="2.644191919191919" WEIGHT="0.2931515573877886"/>
<DICH_DATA CI_END="1.2632438032039506" CI_START="0.7685685698771073" EFFECT_SIZE="0.9853372434017595" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="91" LOG_CI_END="0.10148717649987378" LOG_CI_START="-0.11431737970518115" LOG_EFFECT_SIZE="-0.006415101602653666" ORDER="498" O_E="0.0" SE="0.12676466456463098" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.01606928018218341" WEIGHT="48.23794036541552"/>
<DICH_DATA CI_END="11.32111883695647" CI_START="0.4982391830025525" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0538893491760335" LOG_CI_START="-0.3025621212542628" LOG_EFFECT_SIZE="0.3756636139608854" ORDER="499" O_E="0.0" SE="0.7967863082738255" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.6348684210526316" WEIGHT="1.2209600500495765"/>
<DICH_DATA CI_END="1.4382851160594075" CI_START="0.6581980134297405" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.15784498622588766" LOG_CI_START="-0.18164343282530307" LOG_EFFECT_SIZE="-0.011899223299707707" ORDER="500" O_E="0.0" SE="0.1994171778454464" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.0397672108198424" WEIGHT="19.49216359817082"/>
<DICH_DATA CI_END="2.9071593630942285" CI_START="1.0304086415782847" EFFECT_SIZE="1.7307692307692308" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.463468839343677" LOG_CI_START="0.01300949226537451" LOG_EFFECT_SIZE="0.2382391658045257" ORDER="501" O_E="0.0" SE="0.26460205028352485" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="0.07001424501424501" WEIGHT="11.071303832321634"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.163046103219386" CI_END="27.451831673958104" CI_START="19.917674638098227" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="23.684753156028165" ESTIMABLE="YES" I2="68.20734672907318" I2_Q="80.50576369191248" ID="CMP-004.28" MODIFIED="2009-09-18 15:37:00 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0014586672289433888" P_Q="0.0059182377033063505" P_Z="6.821240459034183E-35" Q="10.259442680348887" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="32.885300779393894" TOTALS="SUB" TOTAL_1="712" TOTAL_2="720" UNITS="" WEIGHT="300.0" Z="12.32288176303947">
<NAME>Adverse effects: 7b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.288768970726155" CI_END="27.981435694895694" CI_START="17.690310112510772" DF="5" EFFECT_SIZE="22.835872903703233" ESTIMABLE="YES" I2="65.00748237833746" ID="CMP-004.28.01" MODIFIED="2009-09-18 15:36:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.013875537257302173" P_Z="3.3698545363053386E-18" STUDIES="6" TAU2="24.865975102106482" TOTAL_1="642" TOTAL_2="649" WEIGHT="100.00000000000001" Z="8.69826883142944">
<NAME>change from baseline in ng/ml</NAME>
<CONT_DATA CI_END="25.26527063110632" CI_START="17.73472936889368" EFFECT_SIZE="21.5" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-6.1" ORDER="2" SD_1="27.7" SD_2="22.0" SE="1.9210917449536282" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" WEIGHT="24.135903556141457"/>
<CONT_DATA CI_END="35.11007279758952" CI_START="21.849927202410484" EFFECT_SIZE="28.48" ESTIMABLE="YES" MEAN_1="18.75" MEAN_2="-9.73" ORDER="502" SD_1="31.23" SD_2="23.15" SE="3.3827523617202577" STUDY_ID="STD-Keefe-2006" TOTAL_1="130" TOTAL_2="136" WEIGHT="18.98258836880481"/>
<CONT_DATA CI_END="31.0039595393716" CI_START="7.996040460628402" EFFECT_SIZE="19.5" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-4.1" ORDER="504" SD_1="17.91" SD_2="9.2" SE="5.869474964904132" STUDY_ID="STD-McEvoy-2006" TOTAL_1="11" TOTAL_2="16" WEIGHT="11.619635823751205"/>
<CONT_DATA CI_END="35.16595336765522" CI_START="20.83404663234478" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="-15.9" ORDER="505" SD_1="15.88" SD_2="15.57" SE="3.6561658398722354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="18.027074616182784"/>
<CONT_DATA CI_END="18.118654718458927" CI_START="-3.71865471845892" EFFECT_SIZE="7.200000000000003" ESTIMABLE="YES" MEAN_1="37.2" MEAN_2="30.0" ORDER="506" SD_1="19.8" SD_2="12.9" SE="5.57084456887161" STUDY_ID="STD-Sikich-2004" TOTAL_1="19" TOTAL_2="16" WEIGHT="12.329786761723136"/>
<CONT_DATA CI_END="36.16175456841995" CI_START="18.03824543158005" EFFECT_SIZE="27.1" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="-5.1" ORDER="507" SD_1="29.6" SD_2="37.4" SE="4.623429124156319" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" WEIGHT="14.90501087339661"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6148344521443445" CI_END="26.17760994953352" CI_START="13.644413832306093" DF="1" EFFECT_SIZE="19.911011890919806" ESTIMABLE="YES" I2="0.0" ID="CMP-004.28.02" MODIFIED="2009-09-18 15:36:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4329735300855909" P_Z="4.741168715997045E-10" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="6.227440444869478">
<NAME>change from baseline in ng/ml - of men only</NAME>
<CONT_DATA CI_END="33.53717377082296" CI_START="12.862826229177038" EFFECT_SIZE="23.2" ESTIMABLE="YES" MEAN_1="32.9" MEAN_2="9.7" ORDER="508" SD_1="24.11" SD_2="5.01" SE="5.274165164442443" STUDY_ID="STD-Jeste-2003" TOTAL_1="22" TOTAL_2="18" WEIGHT="36.750228671534664"/>
<CONT_DATA CI_END="25.879567132112577" CI_START="10.120432867887423" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="14.0" ORDER="509" SD_1="12.2" SD_2="9.8" SE="4.0202611855450385" STUDY_ID="STD-Volavka-2002" TOTAL_1="16" TOTAL_2="14" WEIGHT="63.24977132846534"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="53.15711628162574" CI_START="29.642883718374257" DF="0" EFFECT_SIZE="41.4" ESTIMABLE="YES" I2="0.0" ID="CMP-004.28.03" MODIFIED="2009-09-18 15:37:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="5.1432520371392045E-12" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="39" WEIGHT="100.0" Z="6.901565572398853">
<NAME>change from baseline in ng/ml - of women only</NAME>
<CONT_DATA CI_END="53.15711628162574" CI_START="29.642883718374257" EFFECT_SIZE="41.4" ESTIMABLE="YES" MEAN_1="60.3" MEAN_2="18.9" ORDER="510" SD_1="32.13" SD_2="12.05" SE="5.998638941513403" STUDY_ID="STD-Jeste-2003" TOTAL_1="32" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.381149742581886" CI_START="0.4434539946157101" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-004.29" LOG_CI_END="0.1402407668129005" LOG_CI_START="-0.3531514286414741" LOG_EFFECT_SIZE="-0.10645533091428679" METHOD="MH" MODIFIED="2009-09-18 15:20:07 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="0.0" P_Z="0.39768004140471436" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.00000000000001" Z="0.8457718483452983">
<NAME>Adverse effects: 8a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.381149742581886" CI_START="0.4434539946157101" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.1402407668129005" LOG_CI_START="-0.3531514286414741" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="367" O_E="0.0" SE="0.28982101794065657" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.08399622244015836" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.853495030980796" CI_END="-6.276492678498869" CI_START="-14.434490169576566" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.355491424037718" ESTIMABLE="YES" I2="23.600893916263413" I2_Q="0.0" ID="CMP-004.30" MODIFIED="2009-09-18 15:21:07 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.2490345625469642" P_Q="1.0" P_Z="6.496980696348506E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="6.892596987537467" TOTALS="YES" TOTAL_1="688" TOTAL_2="703" UNITS="" WEIGHT="99.99999999999997" Z="4.975826544571812">
<NAME>Adverse effects: 8b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1247349763022036" CI_START="-11.844734976302203" EFFECT_SIZE="-4.859999999999999" ESTIMABLE="YES" MEAN_1="95.5" MEAN_2="100.36" ORDER="368" SD_1="20.78" SD_2="21.53" SE="3.5637057779616876" STUDY_ID="STD-Jeste-2003" TOTAL_1="68" TOTAL_2="73" WEIGHT="22.106448721381"/>
<CONT_DATA CI_END="-3.863919164264808" CI_START="-18.836080835735196" EFFECT_SIZE="-11.350000000000001" ESTIMABLE="YES" MEAN_1="-2.38" MEAN_2="8.97" ORDER="369" SD_1="25.38" SD_2="31.41" SE="3.819499182017855" STUDY_ID="STD-Keefe-2006" TOTAL_1="113" TOTAL_2="111" WEIGHT="20.16290061222663"/>
<CONT_DATA CI_END="-6.247940279090313" CI_START="-17.352059720909686" EFFECT_SIZE="-11.799999999999999" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="9.7" ORDER="370" SD_1="35.1" SD_2="38.5" SE="2.8327355832574597" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" WEIGHT="29.035534478938896"/>
<CONT_DATA CI_END="18.11848966235897" CI_START="-26.51848966235897" EFFECT_SIZE="-4.2" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="0.2" ORDER="371" SD_1="27.2" SD_2="31.6" SE="11.387193763969321" STUDY_ID="STD-McEvoy-2006" TOTAL_1="11" TOTAL_2="16" WEIGHT="3.1716479612428774"/>
<CONT_DATA CI_END="8.11307549671829" CI_START="-16.71307549671829" EFFECT_SIZE="-4.299999999999999" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="15.7" ORDER="372" SD_1="28.28" SD_2="26.16" SE="6.333318160247353" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="9.21468761074968"/>
<CONT_DATA CI_END="-10.482190987926394" CI_START="-30.517809012073606" EFFECT_SIZE="-20.5" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="17.9" ORDER="373" SD_1="39.8" SD_2="34.3" SE="5.111220966861026" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" WEIGHT="13.118102702670942"/>
<CONT_DATA CI_END="11.34828504476204" CI_START="-33.14828504476205" EFFECT_SIZE="-10.900000000000002" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="20.1" ORDER="374" SD_1="36.7" SD_2="26.8" SE="11.35137442333312" STUDY_ID="STD-Volavka-2002" TOTAL_1="14" TOTAL_2="22" WEIGHT="3.1906779127899556"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.595530312134525" CI_END="1.156033183867744" CI_START="0.21736746324670764" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5012823561690021" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-004.31" LOG_CI_END="0.0629703006621969" LOG_CI_START="-0.6628054629632888" LOG_EFFECT_SIZE="-0.29991758115054595" METHOD="MH" MODIFIED="2009-09-18 15:21:45 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.7424757169368577" P_Q="0.0" P_Z="0.10526229886222252" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="333" TOTAL_2="337" WEIGHT="100.00000000000001" Z="1.619860256697052">
<NAME>Adverse effects: 8c. Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.850735173811657" CI_START="0.06331755310657398" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1717479535876834" LOG_CI_START="-1.1984758767036463" LOG_EFFECT_SIZE="-0.01336396155798149" ORDER="453" O_E="0.0" SE="1.392281210710311" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="1.9384469696969697" WEIGHT="9.376185746634853"/>
<DICH_DATA CI_END="1.0815261169071" CI_START="0.1698280480854371" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.03403701133099303" LOG_CI_START="-0.769990581920182" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="454" O_E="0.0" SE="0.47228978827651535" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.22305764411027568" WEIGHT="81.48225056521596"/>
<DICH_DATA CI_END="16.331863403056158" CI_START="0.0649513545462135" EFFECT_SIZE="1.029940119760479" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2130357389005406" LOG_CI_START="-1.1874117873806096" LOG_EFFECT_SIZE="0.012811975759965595" ORDER="455" O_E="0.0" SE="1.4100347593444398" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="1.9881980225595322" WEIGHT="9.141563688149194"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.750642548567493" CI_END="-3.9258789604303956" CI_START="-11.232323974825107" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.579101467627751" ESTIMABLE="YES" I2="11.119571850634891" I2_Q="0.0" ID="CMP-004.32" MODIFIED="2009-09-18 15:22:11 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.34452465089357964" P_Q="1.0" P_Z="4.778410427072825E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.8947219160717976" TOTALS="YES" TOTAL_1="593" TOTAL_2="608" UNITS="" WEIGHT="100.00000000000004" Z="4.066208910751839">
<NAME>Adverse effects: 8d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.814580264352577" CI_START="-19.054580264352587" EFFECT_SIZE="-6.1200000000000045" ESTIMABLE="YES" MEAN_1="114.78" MEAN_2="120.9" ORDER="456" SD_1="30.94" SD_2="46.22" SE="6.599396910544734" STUDY_ID="STD-Jeste-2003" TOTAL_1="67" TOTAL_2="73" WEIGHT="7.479983313534606"/>
<CONT_DATA CI_END="-1.5600597553911308" CI_START="-15.039940244608871" EFFECT_SIZE="-8.3" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="15.0" ORDER="457" SD_1="36.9" SD_2="51.3" SE="3.4388082116674887" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" WEIGHT="23.60177162424572"/>
<CONT_DATA CI_END="80.69764214745345" CI_START="-63.497642147453455" EFFECT_SIZE="8.600000000000001" ESTIMABLE="YES" MEAN_1="32.2" MEAN_2="23.6" ORDER="458" SD_1="111.1" SD_2="60.8" SE="36.78518723616885" STUDY_ID="STD-McEvoy-2006" TOTAL_1="11" TOTAL_2="16" WEIGHT="0.2562017279851839"/>
<CONT_DATA CI_END="0.7616570703253123" CI_START="-8.361657070325311" EFFECT_SIZE="-3.8" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="8.6" ORDER="459" SD_1="10.34" SD_2="9.67" SE="2.3274188231554667" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="41.799531819650404"/>
<CONT_DATA CI_END="-6.840037212642848" CI_START="-29.559962787357158" EFFECT_SIZE="-18.200000000000003" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="97.2" ORDER="460" SD_1="19.8" SD_2="14.4" SE="5.796005884272921" STUDY_ID="STD-Sikich-2004" TOTAL_1="19" TOTAL_2="16" WEIGHT="9.521407972019757"/>
<CONT_DATA CI_END="1.5212826638186385" CI_START="-21.52128266381864" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="14.8" ORDER="461" SD_1="43.9" SD_2="41.6" SE="5.878313456112993" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" WEIGHT="9.277104897375793"/>
<CONT_DATA CI_END="0.8250350091455179" CI_START="-24.02503500914552" EFFECT_SIZE="-11.600000000000001" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="14.3" ORDER="462" SD_1="12.2" SD_2="25.5" SE="6.339420064425984" STUDY_ID="STD-Volavka-2002" TOTAL_1="14" TOTAL_2="22" WEIGHT="8.063998645188557"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="20.97564214066918" CI_END="0.7187719698460925" CI_START="0.42616859815605923" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5534600643074246" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="357" I2="52.32565500051493" I2_Q="0.0" ID="CMP-004.33" LOG_CI_END="-0.14340886753764567" LOG_CI_START="-0.370418554035171" LOG_EFFECT_SIZE="-0.2569137107864083" METHOD="MH" MODIFIED="2009-09-18 15:37:18 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.02126407856192436" P_Q="0.0" P_Z="9.151796836465983E-6" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07708643472671753" TOTALS="YES" TOTAL_1="1293" TOTAL_2="1301" WEIGHT="100.0" Z="4.43630074156672">
<NAME>Adverse effects: 8e. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.76464289792365" CI_END="0.7603012423641864" CI_START="0.38781015064523927" DF="7" EFFECT_SIZE="0.5430032590482471" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="302" I2="64.58322047025005" ID="CMP-004.33.01" LOG_CI_END="-0.11901429985722942" LOG_CI_START="-0.41138082777015056" LOG_EFFECT_SIZE="-0.26519756381369" MODIFIED="2009-09-18 15:37:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.006101136324391132" P_Z="3.7703445404404276E-4" STUDIES="8" TAU2="0.11438414786883337" TOTAL_1="935" TOTAL_2="938" WEIGHT="76.98373892881473" Z="3.5556578762491333">
<NAME>significant weight gain (as defined by the original studies)</NAME>
<DICH_DATA CI_END="0.6847863815282489" CI_START="0.24699744008272012" EFFECT_SIZE="0.4112669245647969" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="44" LOG_CI_END="-0.16444488513864808" LOG_CI_START="-0.607307547807986" LOG_EFFECT_SIZE="-0.38587621647331705" ORDER="526" O_E="0.0" SE="0.2601397202575047" STUDY_ID="STD-Conley-2001" TOTAL_1="188" TOTAL_2="189" VAR="0.06767267405565279" WEIGHT="12.283385480018673"/>
<DICH_DATA CI_END="1.0165746299386784" CI_START="0.11438253873685002" EFFECT_SIZE="0.34099616858237547" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.00713926706733179" LOG_CI_START="-0.9416402684540681" LOG_EFFECT_SIZE="-0.46725050069336815" ORDER="527" O_E="0.0" SE="0.557317795699716" STUDY_ID="STD-Jeste-2003" TOTAL_1="87" TOTAL_2="89" VAR="0.31060312540359036" WEIGHT="4.586483923684083"/>
<DICH_DATA CI_END="0.6272283342417373" CI_START="0.3226019989381594" EFFECT_SIZE="0.4498278719877598" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="92" LOG_CI_END="-0.2025743311799784" LOG_CI_START="-0.4913329459206385" LOG_EFFECT_SIZE="-0.3469536385503085" ORDER="528" O_E="0.0" SE="0.16961823967685946" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" VAR="0.028770347231076545" WEIGHT="16.79752493918402"/>
<DICH_DATA CI_END="7.504766111784414" CI_START="0.1879014254402535" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.875337161876528" LOG_CI_START="-0.7260699252827195" LOG_EFFECT_SIZE="0.07463361829690418" ORDER="529" O_E="0.0" SE="0.9406744500902698" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" VAR="0.8848684210526316" WEIGHT="1.848456738104636"/>
<DICH_DATA CI_END="0.8596580172293055" CI_START="0.6138241937010744" EFFECT_SIZE="0.7264150943396226" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="106" LOG_CI_END="-0.06567428220772142" LOG_CI_START="-0.21195599797685538" LOG_EFFECT_SIZE="-0.1388151400922884" ORDER="530" O_E="0.0" SE="0.08592660394896058" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.0073833812662015275" WEIGHT="21.050500868462514"/>
<DICH_DATA CI_END="5.2377649569357665" CI_START="0.5846959581385349" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7191460056974361" LOG_CI_START="-0.23306990832484725" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="531" O_E="0.0" SE="0.5593363414414827" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.3128571428571429" WEIGHT="4.559972357886597"/>
<DICH_DATA CI_END="0.8938029186062382" CI_START="0.2811895258792707" EFFECT_SIZE="0.5013262599469496" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" LOG_CI_END="-0.048758231536797966" LOG_CI_START="-0.5510008605282994" LOG_EFFECT_SIZE="-0.29987954603254874" ORDER="532" O_E="0.0" SE="0.29501980641071746" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" VAR="0.0870366861746172" WEIGHT="10.83413430815006"/>
<DICH_DATA CI_END="0.8209259469283887" CI_START="0.10434960178548167" EFFECT_SIZE="0.2926829268292683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.08569601741270026" LOG_CI_START="-0.9815092039315211" LOG_EFFECT_SIZE="-0.5336026106721107" ORDER="533" O_E="0.0" SE="0.5262051001079449" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" VAR="0.2768918073796122" WEIGHT="5.023280313324136"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5450891650418497" CI_END="0.9036396278508052" CI_START="0.39467880255863724" DF="2" EFFECT_SIZE="0.5971996368591398" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="55" I2="0.0" ID="CMP-004.33.02" LOG_CI_END="-0.0440047319575564" LOG_CI_START="-0.4037561981016379" LOG_EFFECT_SIZE="-0.22388046502959705" MODIFIED="2009-09-18 15:37:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.461836526171312" P_Z="0.014709685356256942" STUDIES="3" TAU2="0.0" TOTAL_1="358" TOTAL_2="363" WEIGHT="23.01626107118527" Z="2.4394488395182785">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="1.8570797265152534" CI_START="0.0810142676903979" EFFECT_SIZE="0.3878787878787879" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.268830548889153" LOG_CI_START="-1.0914384893491913" LOG_EFFECT_SIZE="-0.41130397023001913" ORDER="534" O_E="0.0" SE="0.7990287665015382" STUDY_ID="STD-Gureje-2003" TOTAL_1="33" TOTAL_2="32" VAR="0.6384469696969697" WEIGHT="2.4850439181801356"/>
<DICH_DATA CI_END="1.4075715608018071" CI_START="0.42959782336948515" EFFECT_SIZE="0.7776179516685846" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.14847048357405454" LOG_CI_START="-0.36693792772986134" LOG_EFFECT_SIZE="-0.10923372207790343" ORDER="535" O_E="0.0" SE="0.3027534521127032" STUDY_ID="STD-Keefe-2006" TOTAL_1="158" TOTAL_2="159" VAR="0.0916596527661589" WEIGHT="10.537322443063307"/>
<DICH_DATA CI_END="0.8910310512212201" CI_START="0.2566266499172835" EFFECT_SIZE="0.47818648417450815" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="28" LOG_CI_END="-0.05010716112692317" LOG_CI_START="-0.5906982454239104" LOG_EFFECT_SIZE="-0.3204027032754168" ORDER="536" O_E="0.0" SE="0.317545878885075" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="172" VAR="0.10083538519689474" WEIGHT="9.993894709941827"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="69.45866646299366" CI_END="-1.483410983984956" CI_START="-3.7361048643105814" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.6097579241477686" ESTIMABLE="YES" I2="82.72353816871306" I2_Q="0.0" ID="CMP-004.34" MODIFIED="2009-09-18 15:23:04 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="4.043682055865361E-10" P_Q="1.0" P_Z="5.591966973425142E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="3.0439167458611527" TOTALS="YES" TOTAL_1="1050" TOTAL_2="1066" UNITS="" WEIGHT="100.0" Z="4.541257544463403">
<NAME>Adverse effects: 8f. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.634108114786509" CI_START="-10.12589188521349" EFFECT_SIZE="-8.379999999999999" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="8.92" ORDER="537" SD_1="0.72" SD_2="3.13" SE="0.8907775341714761" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="8.606190594772242"/>
<CONT_DATA CI_END="-0.8386480486621198" CI_START="-2.76135195133788" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.3" ORDER="538" SD_1="3.5" SD_2="5.1" SE="0.4904947024133614" STUDY_ID="STD-Conley-2001" TOTAL_1="155" TOTAL_2="161" WEIGHT="10.054921423398087"/>
<CONT_DATA CI_END="-0.016077454467994468" CI_START="-2.783922545532006" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="2.1" ORDER="539" SD_1="2.5" SD_2="3.2" SE="0.7060959060718514" STUDY_ID="STD-Dollfus-2005" TOTAL_1="35" TOTAL_2="32" WEIGHT="9.322658503668647"/>
<CONT_DATA CI_END="2.59799402452152" CI_START="-3.41799402452152" EFFECT_SIZE="-0.41000000000000014" ESTIMABLE="YES" MEAN_1="4.47" MEAN_2="4.88" ORDER="540" SD_1="4.54" SD_2="7.4" SE="1.5347190296598268" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="32" WEIGHT="6.116632609590499"/>
<CONT_DATA CI_END="0.21763879329021074" CI_START="-1.8176387932902105" EFFECT_SIZE="-0.7999999999999999" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.4" ORDER="541" SD_1="2.2" SD_2="4.1" SE="0.5192130066252317" STUDY_ID="STD-Jeste-2003" TOTAL_1="78" TOTAL_2="81" WEIGHT="9.966928790034888"/>
<CONT_DATA CI_END="-0.5872212249440019" CI_START="-3.7927787750559983" EFFECT_SIZE="-2.19" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="3.0" ORDER="542" SD_1="6.26" SD_2="7.87" SE="0.817759299506783" STUDY_ID="STD-Keefe-2006" TOTAL_1="150" TOTAL_2="152" WEIGHT="8.8953803971296"/>
<CONT_DATA CI_END="-2.7942100657297297" CI_START="-5.00578993427027" EFFECT_SIZE="-3.9" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="4.3" ORDER="543" SD_1="6.9" SD_2="7.0" SE="0.5641889049965203" STUDY_ID="STD-Lieberman-2005" TOTAL_1="300" TOTAL_2="307" WEIGHT="9.822483323838702"/>
<CONT_DATA CI_END="5.949831501533465" CI_START="-7.949831501533465" EFFECT_SIZE="-0.9999999999999998" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.8" ORDER="544" SD_1="5.2" SD_2="14.38" SE="3.5458975554412473" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="19" WEIGHT="2.1146673465483805"/>
<CONT_DATA CI_END="0.4448092772244019" CI_START="-9.224809277224399" EFFECT_SIZE="-4.389999999999999" ESTIMABLE="YES" MEAN_1="6.48" MEAN_2="10.87" MODIFIED="2008-12-12 13:30:13 +0000" MODIFIED_BY="[Empty name]" ORDER="545" SD_1="10.58" SD_2="10.64" SE="2.4667847549040487" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="3.6176592084618644"/>
<CONT_DATA CI_END="0.37996355658206005" CI_START="-4.779963556582059" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="7.1" ORDER="546" SD_1="3.6" SD_2="4.1" SE="1.3163321249433575" STUDY_ID="STD-Sikich-2004" TOTAL_1="19" TOTAL_2="16" WEIGHT="6.9139309312918575"/>
<CONT_DATA CI_END="-0.6510217526541819" CI_START="-2.9689782473458184" EFFECT_SIZE="-1.81" ESTIMABLE="YES" MEAN_1="2.32" MEAN_2="4.13" ORDER="547" SD_1="4.83" SD_2="5.88" SE="0.5913262980787864" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="9.731720803907635"/>
<CONT_DATA CI_END="-1.393741596679834" CI_START="-4.806258403320167" EFFECT_SIZE="-3.1000000000000005" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="5.4" ORDER="548" SD_1="2.8" SD_2="4.6" SE="0.8705559983647225" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="38" WEIGHT="8.686817354248108"/>
<CONT_DATA CI_END="1.089224988625085" CI_START="-4.8892249886250845" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.4" ORDER="549" SD_1="2.8" SD_2="4.4" SE="1.525142814971964" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="6.150008713109505"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-11-23 15:36:49 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>RISPERIDONE versus QUETIAPINE</NAME>
<DICH_OUTCOME CHI2="6.91002685165122" CI_END="1.054940487084103" CI_START="0.8215462080143521" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9309577631905533" ESTIMABLE="YES" EVENTS_1="384" EVENTS_2="416" I2="56.584828620700364" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.023227960240348393" LOG_CI_START="-0.08536800457063425" LOG_EFFECT_SIZE="-0.03107002216514293" METHOD="MH" MODIFIED="2009-09-18 15:43:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07482155790045553" P_Q="0.0" P_Z="0.2620677671158328" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.008680021775989338" TOTALS="YES" TOTAL_1="634" TOTAL_2="640" WEIGHT="100.0" Z="1.1215172598454182">
<NAME>Global state: 1a. No clinically significant response (as def. by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1598200223752566" CI_START="0.8622027389663848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.064390601853161" LOG_CI_START="-0.06439060185316105" LOG_EFFECT_SIZE="0.0" ORDER="577" O_E="0.0" SE="0.07564671653433303" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.0057224257224257336" WEIGHT="28.25311124635602"/>
<DICH_DATA CI_END="1.1466957011897139" CI_START="0.6235593451028227" EFFECT_SIZE="0.8455961331901182" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="56" LOG_CI_END="0.05944818439852902" LOG_CI_START="-0.20512220774405124" LOG_EFFECT_SIZE="-0.0728370116727611" ORDER="578" O_E="0.0" SE="0.15540995798911444" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.02415225504217832" WEIGHT="12.393717123125562"/>
<DICH_DATA CI_END="0.9554710944831887" CI_START="0.6451047391587632" EFFECT_SIZE="0.7850980392156863" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="100" LOG_CI_END="-0.01978244696201293" LOG_CI_START="-0.19036976761929764" LOG_EFFECT_SIZE="-0.10507610729065531" ORDER="579" O_E="0.0" SE="0.10020383657494494" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.010040808864338275" WEIGHT="21.73589191688783"/>
<DICH_DATA CI_END="1.1001907024032307" CI_START="0.9178386903660777" EFFECT_SIZE="1.0048868560423687" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="248" LOG_CI_END="0.04146797045192773" LOG_CI_START="-0.03723363910340984" LOG_EFFECT_SIZE="0.002117165674258923" ORDER="580" O_E="0.0" SE="0.04622971503205563" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.00213718655194507" WEIGHT="37.617279713630595"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.752928227508568" CI_END="1.0244934203390081" CI_START="0.7919690905234266" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9007591922112806" ESTIMABLE="YES" EVENTS_1="340" EVENTS_2="387" I2="55.57482770542013" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.010509173552599348" LOG_CI_START="-0.10129176800276353" LOG_EFFECT_SIZE="-0.0453912972250821" METHOD="MH" MODIFIED="2009-09-18 15:55:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0802039866319878" P_Q="0.0" P_Z="0.11149826792346429" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.009196607679049963" TOTALS="YES" TOTAL_1="634" TOTAL_2="640" WEIGHT="99.99999999999999" Z="1.591494785912137">
<NAME>Global state: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.373750900516065" CI_END="1.056748918244085" CI_START="0.7801472445997957" DF="2" EFFECT_SIZE="0.9079756366786158" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="331" I2="68.62130272712625" ID="CMP-005.02.01" LOG_CI_END="0.02397181192962037" LOG_CI_START="-0.10782342105042927" LOG_EFFECT_SIZE="-0.041925804560404435" MODIFIED="2009-09-18 15:55:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.041300766466050076" P_Z="0.21240453715568752" STUDIES="3" TAU2="0.012291461831881949" TOTAL_1="501" TOTAL_2="506" WEIGHT="87.06742224597592" Z="1.246980867262425">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1598200223752566" CI_START="0.8622027389663848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.064390601853161" LOG_CI_START="-0.06439060185316105" LOG_EFFECT_SIZE="0.0" ORDER="581" O_E="0.0" SE="0.07564671653433303" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.0057224257224257336" WEIGHT="28.90849216195864"/>
<DICH_DATA CI_END="0.9105655243601409" CI_START="0.6460053228187239" EFFECT_SIZE="0.7669616519174042" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="113" LOG_CI_END="-0.04068879688264079" LOG_CI_START="-0.18976390358188752" LOG_EFFECT_SIZE="-0.11522635023226416" ORDER="582" O_E="0.0" SE="0.08756745560881693" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.007668059281802123" WEIGHT="25.57339324587342"/>
<DICH_DATA CI_END="1.0817708277529725" CI_START="0.843224667640147" EFFECT_SIZE="0.9550789740617301" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="206" LOG_CI_END="0.03413526559122296" LOG_CI_START="-0.07405669712287478" LOG_EFFECT_SIZE="-0.01996071576582591" ORDER="583" O_E="0.0" SE="0.06355249445711386" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.004038919551721488" WEIGHT="32.58553683814386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1466957011897139" CI_START="0.6235593451028227" DF="0" EFFECT_SIZE="0.8455961331901182" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="56" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.05944818439852902" LOG_CI_START="-0.20512220774405124" LOG_EFFECT_SIZE="-0.0728370116727611" MODIFIED="2009-09-18 15:55:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.280512962483755" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="134" WEIGHT="12.932577754024065" Z="1.079167766763571">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.1466957011897139" CI_START="0.6235593451028227" EFFECT_SIZE="0.8455961331901182" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="56" LOG_CI_END="0.05944818439852902" LOG_CI_START="-0.20512220774405124" LOG_EFFECT_SIZE="-0.0728370116727611" ORDER="584" O_E="0.0" SE="0.15540995798911444" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.02415225504217832" WEIGHT="12.932577754024065"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.7030124455944" CI_END="0.9931997872929204" CI_START="0.8542781762164823" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9211237174816389" ESTIMABLE="YES" EVENTS_1="869" EVENTS_2="986" I2="31.756842100900933" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.00296338212746207" LOG_CI_START="-0.06840068818206782" LOG_EFFECT_SIZE="-0.03568203515476494" METHOD="MH" MODIFIED="2009-09-18 15:56:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06957616073659512" P_Q="0.0" P_Z="0.03255887802913353" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.011931677350142613" TOTALS="SUB" TOTAL_1="2982" TOTAL_2="2998" WEIGHT="300.0" Z="2.1374811408058885">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.731363047835874" CI_END="1.0191760080879693" CI_START="0.8671418798075862" DF="9" EFFECT_SIZE="0.9400905272941502" ESTIMABLE="YES" EVENTS_1="606" EVENTS_2="664" I2="16.133673235340098" ID="CMP-005.03.01" LOG_CI_END="0.008249191602690971" LOG_CI_START="-0.06190983842184611" LOG_EFFECT_SIZE="-0.026830323409577552" MODIFIED="2009-09-18 15:56:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29457314701361725" P_Z="0.1338568116999552" STUDIES="10" TAU2="0.0025607822871259135" TOTAL_1="1122" TOTAL_2="1156" WEIGHT="100.0" Z="1.4990648404900289">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="553" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.06697477145748852"/>
<DICH_DATA CI_END="2.12085632629423" CI_START="0.2571251230109627" EFFECT_SIZE="0.7384615384615385" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3265112489922618" LOG_CI_START="-0.5898554875267985" LOG_EFFECT_SIZE="-0.13167211926726835" ORDER="554" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.28974358974358977" WEIGHT="0.5810413564947401"/>
<DICH_DATA CI_END="1.101744519032538" CI_START="0.9254960041009379" EFFECT_SIZE="1.0097822289507394" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="277" LOG_CI_END="0.04208089865566185" LOG_CI_START="-0.03362545200633289" LOG_EFFECT_SIZE="0.0042277233246644785" ORDER="555" O_E="0.0" SE="0.04447028513133544" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="377" VAR="0.0019776062596622737" WEIGHT="37.42317941337713"/>
<DICH_DATA CI_END="1.222631111742" CI_START="0.612523700200433" EFFECT_SIZE="0.8653846153846154" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.0872954428900112" LOG_CI_START="-0.21287710260892206" LOG_EFFECT_SIZE="-0.06279082985945546" ORDER="556" O_E="0.0" SE="0.17632283910413754" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" VAR="0.031089743589743576" WEIGHT="5.047199840369048"/>
<DICH_DATA CI_END="1.1737529989147375" CI_START="0.8648277169317069" EFFECT_SIZE="1.0075187969924813" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="95" LOG_CI_END="0.06957671488904135" LOG_CI_START="-0.06307040009359763" LOG_EFFECT_SIZE="0.0032531573977218607" ORDER="557" O_E="0.0" SE="0.07791757195461102" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.006071148019301986" WEIGHT="19.675892043242694"/>
<DICH_DATA CI_END="1.1059208076575706" CI_START="0.3198717554264623" EFFECT_SIZE="0.5947712418300654" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" LOG_CI_END="0.04372402929355319" LOG_CI_START="-0.4950241062865636" LOG_EFFECT_SIZE="-0.2256500384965052" ORDER="558" O_E="0.0" SE="0.3164633216860421" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.10014903397256336" WEIGHT="1.6535997728264655"/>
<DICH_DATA CI_END="2.192150934551469" CI_START="0.5631765047634233" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.34087045299944163" LOG_CI_START="-0.24935547187809132" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="559" O_E="0.0" SE="0.346701629938511" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.12020202020202021" WEIGHT="1.3834885273907493"/>
<DICH_DATA CI_END="4.1178990744020965" CI_START="0.37944106248569703" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6146756982879912" LOG_CI_START="-0.42085567227187837" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="560" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="0.45587441542136564"/>
<DICH_DATA CI_END="0.9379402685901878" CI_START="0.6225627407713707" EFFECT_SIZE="0.7641509433962265" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="53" LOG_CI_END="-0.027824818174953674" LOG_CI_START="-0.20581687459728726" LOG_EFFECT_SIZE="-0.11682084638612045" ORDER="561" O_E="0.0" SE="0.10455341501736781" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="63" VAR="0.010931416591793953" WEIGHT="12.588083703645124"/>
<DICH_DATA CI_END="1.0587113806385444" CI_START="0.7920698845336285" EFFECT_SIZE="0.9157365347177158" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="184" LOG_CI_END="0.024777581561690076" LOG_CI_START="-0.10123649880397745" LOG_EFFECT_SIZE="-0.03822945862114369" ORDER="562" O_E="0.0" SE="0.07402129458655114" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.005479152052268985" WEIGHT="21.12466615577519"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.91598980420447" CI_END="1.274684257992486" CI_START="0.5553150893204728" DF="6" EFFECT_SIZE="0.8413390532849987" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="97" I2="32.70517203630483" ID="CMP-005.03.02" LOG_CI_END="0.10540262242233073" LOG_CI_START="-0.25546052548370474" LOG_EFFECT_SIZE="-0.07502895153068703" MODIFIED="2009-09-18 15:56:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.17835822194233275" P_Z="0.41506498931281843" STUDIES="7" TAU2="0.08961507554423054" TOTAL_1="930" TOTAL_2="921" WEIGHT="99.99999999999999" Z="0.8150128027827273">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="3.5165373509904523" CI_START="0.009807885563522621" EFFECT_SIZE="0.18571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5461152346437514" LOG_CI_START="-2.008424610058592" LOG_EFFECT_SIZE="-0.73115468770742" ORDER="563" O_E="0.0" SE="1.5005493499543263" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="2.251648351648351" WEIGHT="1.9191547245695642"/>
<DICH_DATA CI_END="1.0340595385045024" CI_START="0.45474839270962447" EFFECT_SIZE="0.6857382249087318" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="49" LOG_CI_END="0.014545545043760133" LOG_CI_START="-0.3422288272585954" LOG_EFFECT_SIZE="-0.1638416411074176" ORDER="564" O_E="0.0" SE="0.20957103235202923" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.04392001760109528" WEIGHT="33.64843399531377"/>
<DICH_DATA CI_END="2.4035299648462325" CI_START="0.007521362174569722" EFFECT_SIZE="0.13445378151260504" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.38084954085461753" LOG_CI_START="-2.123703498327829" LOG_EFFECT_SIZE="-0.871426978736606" ORDER="565" O_E="0.0" SE="1.4711868529532615" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" VAR="2.164390756302521" WEIGHT="1.9934494863649785"/>
<DICH_DATA CI_END="2.09146010100322" CI_START="0.48535189641258836" EFFECT_SIZE="1.0075187969924813" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.3204495839157324" LOG_CI_START="-0.3139432691202888" LOG_EFFECT_SIZE="0.0032531573977218607" ORDER="566" O_E="0.0" SE="0.3726455021686274" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.13886467028650848" WEIGHT="19.665842814300195"/>
<DICH_DATA CI_END="128.01989359781342" CI_START="0.3827530130116973" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1072774619013144" LOG_CI_START="-0.41708138187280086" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="567" O_E="0.0" SE="1.4828208806107213" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="2.1987577639751548" WEIGHT="1.9635116665264503"/>
<DICH_DATA CI_END="1.3868662663939997" CI_START="0.23651633677593" EFFECT_SIZE="0.5727272727272728" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.14203458467291213" LOG_CI_START="-0.6261388560821988" LOG_EFFECT_SIZE="-0.24205213570464335" ORDER="568" O_E="0.0" SE="0.4512288816194101" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="63" VAR="0.2036075036075036" WEIGHT="15.32367248373956"/>
<DICH_DATA CI_END="2.3641551851289186" CI_START="0.7454879386231534" EFFECT_SIZE="1.3275726630007856" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" LOG_CI_END="0.37367598059887425" LOG_CI_START="-0.12755937867883796" LOG_EFFECT_SIZE="0.12305830096001816" ORDER="569" O_E="0.0" SE="0.2944281311947721" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.08668792443884595" WEIGHT="25.485934829185467"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.411122161029649" CI_END="1.0077451647795757" CI_START="0.6215102130171691" DF="6" EFFECT_SIZE="0.791406287585066" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="225" I2="28.66587971104311" ID="CMP-005.03.03" LOG_CI_END="0.0033507230596838493" LOG_CI_START="-0.20655173038427216" LOG_EFFECT_SIZE="-0.10160050366229417" MODIFIED="2009-09-18 15:56:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.20950365388391634" P_Z="0.05777658509822651" STUDIES="7" TAU2="0.027697961282784237" TOTAL_1="930" TOTAL_2="921" WEIGHT="100.0" Z="1.8973892369714012">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="3.7236963680632957" CI_START="0.22882397534477933" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5709742611786153" LOG_CI_START="-0.6404984736970392" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="570" O_E="0.0" SE="0.7116250813527136" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.5064102564102563" WEIGHT="2.8463019724457337"/>
<DICH_DATA CI_END="1.2521586156910858" CI_START="0.7631305286225121" EFFECT_SIZE="0.9775277317353054" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="92" LOG_CI_END="0.09765934609180461" LOG_CI_START="-0.1174011723830461" LOG_EFFECT_SIZE="-0.009870913145620757" ORDER="571" O_E="0.0" SE="0.12632761311886287" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.015958665836309095" WEIGHT="34.82250860498334"/>
<DICH_DATA CI_END="2.2729246565475147" CI_START="0.3866851668259981" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.35658503986576195" LOG_CI_START="-0.41264248706624895" LOG_EFFECT_SIZE="-0.02802872360024354" ORDER="572" O_E="0.0" SE="0.45184805705753195" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" VAR="0.20416666666666666" WEIGHT="6.556555378729889"/>
<DICH_DATA CI_END="1.4306653477533762" CI_START="0.3535353992666904" EFFECT_SIZE="0.7111897390535161" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.15553805820354166" LOG_CI_START="-0.4515670940693962" LOG_EFFECT_SIZE="-0.14801451793292728" ORDER="573" O_E="0.0" SE="0.35661657166409505" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.12717537918545266" WEIGHT="9.815977810790248"/>
<DICH_DATA CI_END="6.137977284793343" CI_START="0.45255589079152186" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7880252768773026" LOG_CI_START="-0.34432777764458977" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="574" O_E="0.0" SE="0.6651497894641796" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.4424242424242424" WEIGHT="3.2336980928187855"/>
<DICH_DATA CI_END="1.2406934414547524" CI_START="0.43703898710296574" EFFECT_SIZE="0.7363636363636363" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.09366448646942879" LOG_CI_START="-0.3594798190285794" LOG_EFFECT_SIZE="-0.13290766627957531" ORDER="575" O_E="0.0" SE="0.26617920815001844" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="63" VAR="0.07085137085137085" WEIGHT="15.426114420031636"/>
<DICH_DATA CI_END="0.7856429502520276" CI_START="0.4077617901693626" EFFECT_SIZE="0.5659992719330178" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="82" LOG_CI_END="-0.10477478216157086" LOG_CI_START="-0.3895934727610954" LOG_EFFECT_SIZE="-0.24718412746133314" ORDER="576" O_E="0.0" SE="0.16730390873341736" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.02799059787747964" WEIGHT="27.298843720200377"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.26107227957164" CI_END="1.1535518454416374" CI_START="0.7050620758536554" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9018456956441583" ESTIMABLE="YES" EVENTS_1="324" EVENTS_2="348" I2="80.9924679445495" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.06203711830507199" LOG_CI_START="-0.15177264469103915" LOG_EFFECT_SIZE="-0.04486776319298362" METHOD="MH" MODIFIED="2009-09-18 15:56:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.021807632426423473" P_Q="0.0" P_Z="0.4107395271148757" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.025945659344537738" TOTALS="YES" TOTAL_1="488" TOTAL_2="494" WEIGHT="100.00000000000001" Z="0.8225929320797125">
<NAME>Mental state: 1a General - no clinically important change - short term (less than 30% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9554710944831887" CI_START="0.6451047391587632" EFFECT_SIZE="0.7850980392156863" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="100" LOG_CI_END="-0.01978244696201293" LOG_CI_START="-0.19036976761929764" LOG_EFFECT_SIZE="-0.10507610729065531" MODIFIED="2009-09-18 15:56:54 +0100" MODIFIED_BY="[Empty name]" ORDER="2241" O_E="0.0" SE="0.10020383657494494" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.010040808864338275" WEIGHT="43.831975242160325"/>
<DICH_DATA CI_END="1.1001907024032307" CI_START="0.9178386903660777" EFFECT_SIZE="1.0048868560423687" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="248" LOG_CI_END="0.04146797045192773" LOG_CI_START="-0.03723363910340984" LOG_EFFECT_SIZE="0.002117165674258923" MODIFIED="2009-09-18 15:56:54 +0100" MODIFIED_BY="[Empty name]" ORDER="2242" O_E="0.0" SE="0.04622971503205563" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.00213718655194507" WEIGHT="56.16802475783969"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5956944425786712" CI_START="0.6592361829486737" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.20294973249927656" LOG_CI_START="-0.1809589638963503" LOG_EFFECT_SIZE="0.010995384301463145" METHOD="MH" MODIFIED="2009-09-18 15:56:58 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.91060997826598" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="0.11226917977829039">
<NAME>Mental state: 1b. General - no clinicallly important change - short term (less than 20% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5956944425786712" CI_START="0.6592361829486737" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.20294973249927656" LOG_CI_START="-0.1809589638963503" LOG_EFFECT_SIZE="0.010995384301463145" MODIFIED="2009-09-18 15:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="2243" O_E="0.0" SE="0.22550986864148728" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.050854700854700854" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="10.496988132737153" CI_END="-1.0127054714112558" CI_START="-5.157352803078988" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.085029137245122" ESTIMABLE="YES" I2="23.787662719649546" I2_Q="4.023337304710679" ID="CMP-005.06" MODIFIED="2010-11-23 15:34:39 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.23186056126361354" P_Q="0.35277687797260826" P_Z="0.003525540077662056" Q="2.08383990840532" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.2690471019016534" TOTALS="YES" TOTAL_1="969" TOTAL_2="984" UNITS="" WEIGHT="100.0" Z="2.91776139989411">
<NAME>Mental state: 1c. General - average endpoint score (PANSS total score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.650932884988341" CI_END="0.814436205924788" CI_START="-5.690462047285832" DF="4" EFFECT_SIZE="-2.438012920680522" ESTIMABLE="YES" I2="39.85806097926048" ID="CMP-005.06.01" MODIFIED="2009-09-18 15:57:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15552545415992935" P_Z="0.14178528154504882" STUDIES="5" TAU2="5.163239925883861" TOTAL_1="524" TOTAL_2="540" WEIGHT="55.52291389749314" Z="1.4691751761124472">
<NAME>short term</NAME>
<CONT_DATA CI_END="5.075910498364263" CI_START="-3.0359104983642426" EFFECT_SIZE="1.0200000000000102" ESTIMABLE="YES" MEAN_1="78.26" MEAN_2="77.24" ORDER="587" SD_1="4.62" SD_2="6.08" SE="2.0693801163474213" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="17.064207491972077"/>
<CONT_DATA CI_END="7.138662981130059" CI_START="-9.93866298113007" EFFECT_SIZE="-1.4000000000000057" ESTIMABLE="YES" MEAN_1="71.5" MEAN_2="72.9" ORDER="588" SD_1="12.0" SD_2="15.1" SE="4.356540757116941" STUDY_ID="STD-Mori-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="5.261272875736557"/>
<CONT_DATA CI_END="-2.2164487778442563" CI_START="-12.183551222155742" EFFECT_SIZE="-7.199999999999999" ESTIMABLE="YES" MEAN_1="-27.7" MEAN_2="-20.5" ORDER="589" SD_1="22.31" SD_2="22.31" SE="2.5426748968171653" STUDY_ID="STD-Potkin-2006" TOTAL_1="152" TOTAL_2="156" WEIGHT="12.799521495669918"/>
<CONT_DATA CI_END="13.884125205312406" CI_START="-12.484125205312408" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="-29.7" MEAN_2="-30.4" ORDER="590" SD_1="22.31" SD_2="22.31" SE="6.726718097529906" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.3526797643670623"/>
<CONT_DATA CI_END="0.8835833369952106" CI_START="-6.883583336995214" EFFECT_SIZE="-3.0000000000000018" ESTIMABLE="YES" MEAN_1="-18.1" MEAN_2="-15.1" ORDER="591" SD_1="25.0" SD_2="25.36" SE="1.9814564796233105" STUDY_ID="STD-Zhong-2006" TOTAL_1="318" TOTAL_2="328" WEIGHT="18.045232269747533"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7490220222505004" CI_END="3.93532971252033" CI_START="-16.47653330198642" DF="1" EFFECT_SIZE="-6.270601794733047" ESTIMABLE="YES" I2="42.825191033713764" ID="CMP-005.06.02" MODIFIED="2009-09-18 15:57:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.18599983726260394" P_Z="0.22850583528373547" STUDIES="2" TAU2="25.909240575396815" TOTAL_1="75" TOTAL_2="71" WEIGHT="8.415566335884108" Z="1.2042167508506558">
<NAME>medium term</NAME>
<CONT_DATA CI_END="15.411717823063478" CI_START="-13.411717823063478" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-1.3" ORDER="592" SD_1="6.86" SD_2="19.23" SE="7.353052370727864" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="8" WEIGHT="1.9844021889851424"/>
<CONT_DATA CI_END="-2.380266067591653" CI_START="-17.619733932408348" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="2.0" ORDER="593" SD_1="22.31" SD_2="22.31" SE="3.88769079050015" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="63" WEIGHT="6.431164146898967"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.013193317092991451" CI_END="-0.39982423087631336" CI_START="-5.81969128852787" DF="1" EFFECT_SIZE="-3.1097577597020916" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.03" MODIFIED="2009-09-18 15:57:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.908554376003934" P_Z="0.02450374730955488" STUDIES="2" TAU2="0.0" TOTAL_1="370" TOTAL_2="373" WEIGHT="36.061519766622744" Z="2.2491375322777936">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.16904246453306282" CI_START="-6.629042464533064" EFFECT_SIZE="-3.2300000000000004" ESTIMABLE="YES" MEAN_1="-9.31" MEAN_2="-6.08" ORDER="594" SD_1="22.31" SD_2="22.31" SE="1.7342372060631095" STUDY_ID="STD-Lieberman-2005" TOTAL_1="333" TOTAL_2="329" WEIGHT="21.186669679009405"/>
<CONT_DATA CI_END="1.589387351577181" CI_START="-7.389387351577182" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-18.5" MEAN_2="-15.6" ORDER="595" SD_1="9.91" SD_2="10.68" SE="2.2905458401220105" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="14.874850087613337"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.333441935502357" CI_START="-11.693441935502356" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6799999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2010-11-23 15:34:53 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7422827235990164" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" UNITS="" WEIGHT="99.99999999999999" Z="0.328831935635736">
<NAME>Mental state: 1d. General - average endpoint score - short term (BPRS total score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.333441935502357" CI_START="-11.693441935502356" EFFECT_SIZE="-1.6799999999999997" ESTIMABLE="YES" MEAN_1="52.15" MEAN_2="53.83" MODIFIED="2009-09-18 15:57:22 +0100" MODIFIED_BY="[Empty name]" ORDER="2244" SD_1="12.34" SD_2="13.14" SE="5.108992825626955" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1152767877519791" CI_START="0.8963972920599468" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.99986553717897" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="222" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="0.047382663326477066" LOG_CI_START="-0.047499464101722934" LOG_EFFECT_SIZE="-5.8400387622915336E-5" METHOD="MH" MODIFIED="2009-09-18 15:57:32 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.9980749188445317" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="338" WEIGHT="100.0" Z="0.0024127337682370137">
<NAME>Mental state: 2a. Positive symptoms - no clinically important change - short term (less than 40% PANSS positive reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1152767877519791" CI_START="0.8963972920599468" EFFECT_SIZE="0.99986553717897" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="222" LOG_CI_END="0.047382663326477066" LOG_CI_START="-0.047499464101722934" LOG_EFFECT_SIZE="-5.8400387622915336E-5" MODIFIED="2009-09-18 15:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2245" O_E="0.0" SE="0.05573423132543029" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.0031063045414365747" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.648945929458005" CI_END="-1.161446788962372" CI_START="-2.47568497491888" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.818565881940626" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.09" MODIFIED="2010-11-23 15:35:11 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4636404805642754" P_Q="0.7118618182097163" P_Z="5.8225459994256966E-8" Q="0.6797431409588865" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="623" TOTAL_2="641" UNITS="" WEIGHT="100.00000000000001" Z="5.42416689790948">
<NAME>Mental state: 2b. Positive symptoms - average endpoint score - (PANSS positive subscore, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.668404376963501" CI_END="-1.003081214110251" CI_START="-3.1933486166856806" DF="3" EFFECT_SIZE="-2.098214915397966" ESTIMABLE="YES" I2="35.73821464987768" ID="CMP-005.09.01" MODIFIED="2009-09-18 15:57:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19775202627521982" P_Z="1.732160020693426E-4" STUDIES="4" TAU2="0.4353985044493458" TOTAL_1="511" TOTAL_2="526" WEIGHT="69.53075680623665" Z="3.7551813638546303">
<NAME>short term</NAME>
<CONT_DATA CI_END="-0.3716227381423307" CI_START="-4.628377261857669" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="13.3" ORDER="599" SD_1="2.2" SD_2="4.3" SE="1.0859267204122307" STUDY_ID="STD-Mori-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="9.532151823637353"/>
<CONT_DATA CI_END="-1.415146943201169" CI_START="-4.184853056798829" EFFECT_SIZE="-2.799999999999999" ESTIMABLE="YES" MEAN_1="-8.7" MEAN_2="-5.9" ORDER="600" SD_1="6.16" SD_2="6.24" SE="0.7065706654420051" STUDY_ID="STD-Potkin-2006" TOTAL_1="152" TOTAL_2="156" WEIGHT="22.515457924064545"/>
<CONT_DATA CI_END="0.5139450470094387" CI_START="-8.113945047009437" EFFECT_SIZE="-3.8" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-3.8" ORDER="601" SD_1="7.3" SD_2="7.3" SE="2.2010328154176744" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.320272298080585"/>
<CONT_DATA CI_END="0.008158543690458764" CI_START="-2.208158543690458" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-4.5" ORDER="602" SD_1="7.13" SD_2="7.24" SE="0.5653974013968989" STUDY_ID="STD-Zhong-2006" TOTAL_1="318" TOTAL_2="328" WEIGHT="35.16287476045417"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3007984115356175" CI_END="0.00926839772661614" CI_START="-4.313911912039684" DF="1" EFFECT_SIZE="-2.152321757156534" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.02" MODIFIED="2009-09-18 15:57:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5833824121997122" P_Z="0.05099045271788573" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="9.241478655629148" Z="1.9515601131134919">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.2375911531627435" CI_START="-5.437591153162744" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.6" ORDER="603" SD_1="1.71" SD_2="5.94" SE="2.213097376980959" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="8" WEIGHT="2.2950436144746686"/>
<CONT_DATA CI_END="-0.00676567877270573" CI_START="-4.993234321227295" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="0.2" ORDER="604" SD_1="7.3" SD_2="7.3" SE="1.2720817019565709" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="63" WEIGHT="6.946435041154479"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12623784169196628" CI_START="-2.726237841691966" DF="0" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.03" MODIFIED="2009-09-18 15:57:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07402068788955288" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="44" WEIGHT="21.22776453813421" Z="1.7864854692674523">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.12623784169196628" CI_START="-2.726237841691966" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="-5.3" ORDER="605" SD_1="3.16" SD_2="3.38" SE="0.7276857396064152" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="21.22776453813421"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.18339943608513887" CI_START="-2.0166005639148614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2010-11-23 15:35:26 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.018666430709810077" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="2.352126398205355">
<NAME>Mental state: 2c. Positive symptoms - average endpoint score - short term (BPRS positive subscore, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.18339943608513887" CI_START="-2.0166005639148614" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.77" MEAN_2="-0.67" MODIFIED="2009-09-18 15:57:55 +0100" MODIFIED_BY="[Empty name]" ORDER="2246" SD_1="1.31" SD_2="1.02" SE="0.46766194233408853" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0759101649893836" CI_START="0.959127994372216" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0158422902552087" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="293" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.03177601066294119" LOG_CI_START="-0.018123432933215118" LOG_EFFECT_SIZE="0.006826288864863063" METHOD="MH" MODIFIED="2009-09-21 15:20:34 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.5917860052132554" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="338" WEIGHT="100.0" Z="0.5362496797150256">
<NAME>Mental state: 3a. Negative symptoms - no clinicallly important change - short term (less than 40% PANSS negative reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0759101649893836" CI_START="0.959127994372216" EFFECT_SIZE="1.0158422902552087" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="293" LOG_CI_END="0.03177601066294119" LOG_CI_START="-0.018123432933215118" LOG_EFFECT_SIZE="0.006826288864863063" MODIFIED="2009-09-18 15:58:00 +0100" MODIFIED_BY="[Empty name]" ORDER="2247" O_E="0.0" SE="0.029311180174611706" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="8.591452832285504E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="28.78091124579161" CI_END="1.9422992202074179" CI_START="-1.2608507197601062" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3407242502236558" ESTIMABLE="YES" I2="79.15284909237428" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2010-11-23 15:35:39 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="6.69281691970669E-5" P_Q="0.676727281587715" P_Z="0.6767010172713" Q="0.780974419222634" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.137825518331565" TOTALS="YES" TOTAL_1="589" TOTAL_2="594" UNITS="" WEIGHT="100.0" Z="0.41696909080974814">
<NAME>Mental state: 3b. Negative symptoms - average endpoint score - (PANSS negative subscore, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="27.12837903958583" CI_END="4.107753704107715" CI_START="-1.1855873560139516" DF="3" EFFECT_SIZE="1.4610831740468817" ESTIMABLE="YES" I2="88.9414697589473" ID="CMP-005.12.01" MODIFIED="2009-09-18 15:58:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.533581894701101E-6" P_Z="0.2792570966754556" STUDIES="4" TAU2="5.879798337396278" TOTAL_1="477" TOTAL_2="479" WEIGHT="60.56569059829764" Z="1.0819897554394633">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.753394268886902" CI_START="-1.1533942688869012" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="25.6" MEAN_2="23.8" ORDER="608" SD_1="4.8" SD_2="4.6" SE="1.506861499590247" STUDY_ID="STD-Mori-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="12.345963102715615"/>
<CONT_DATA CI_END="-0.39100487221232827" CI_START="-2.6089951277876717" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-2.5" ORDER="609" SD_1="4.93" SD_2="5.0" SE="0.5658242378611463" STUDY_ID="STD-Potkin-2006" TOTAL_1="152" TOTAL_2="156" WEIGHT="19.309701566063666"/>
<CONT_DATA CI_END="12.429364918441257" CI_START="4.770635081558746" EFFECT_SIZE="8.600000000000001" ESTIMABLE="YES" MEAN_1="-4.2" MEAN_2="-12.8" ORDER="610" SD_1="6.48" SD_2="6.48" SE="1.9537935128639086" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="9.600477275725389"/>
<CONT_DATA CI_END="0.7090425542006598" CI_START="-1.5090425542006587" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-3.7" ORDER="611" SD_1="6.74" SD_2="6.71" SE="0.5658484354552662" STUDY_ID="STD-Zhong-2006" TOTAL_1="284" TOTAL_2="281" WEIGHT="19.309548653792973"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8715577869831449" CI_END="0.7472178347031433" CI_START="-3.353433626709635" DF="1" EFFECT_SIZE="-1.3031078960032458" ESTIMABLE="YES" I2="0.0" ID="CMP-005.12.02" MODIFIED="2009-09-18 15:58:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3505245037723598" P_Z="0.21288285671352458" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="21.280787115525538" Z="1.2456774579208911">
<NAME>medium term</NAME>
<CONT_DATA CI_END="6.545849663525292" CI_START="-4.345849663525293" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-1.1" ORDER="612" SD_1="4.16" SD_2="6.22" SE="2.7785457827192026" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="8" WEIGHT="6.149542953847126"/>
<CONT_DATA CI_END="0.5131723837743658" CI_START="-3.9131723837743655" EFFECT_SIZE="-1.7" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="0.2" ORDER="613" SD_1="6.48" SD_2="6.48" SE="1.129190332695696" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="63" WEIGHT="15.131244161678412"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6107967668607155" CI_START="-2.2707967668607156" DF="0" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-005.12.03" MODIFIED="2009-09-18 15:58:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2588654838407435" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="44" WEIGHT="18.15352228617682" Z="1.1290767335026286">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.6107967668607155" CI_START="-2.2707967668607156" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" MEAN_1="-3.63" MEAN_2="-2.8" ORDER="614" SD_1="3.16" SD_2="3.45" SE="0.7351138991458703" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="18.15352228617682"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.16984709667970188" CI_START="-0.970152903320298" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.57" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2010-11-23 15:35:56 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.005240255003992167" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="2.791881458107519">
<NAME>Mental state: 3c. Negative symptoms - average endpoint score - short term (BPRS negative subscore, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.16984709667970188" CI_START="-0.970152903320298" EFFECT_SIZE="-0.57" ESTIMABLE="YES" MEAN_1="-0.15" MEAN_2="0.42" MODIFIED="2009-09-18 15:58:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2248" SD_1="0.51" SD_2="0.51" SE="0.2041633961014861" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.86855860365606" CI_START="-12.86855860365606" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.14" MODIFIED="2010-11-23 15:36:13 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.9415634246598393" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.07330498532594379">
<NAME>Quality of life: General - average endpoint score - short term (QLS total score, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.86855860365606" CI_START="-12.86855860365606" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="28.4" MEAN_2="27.9" ORDER="616" SD_1="15.93" SD_2="15.93" SE="6.820818499271183" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.011164403749645233" CI_END="0.9989247073093236" CI_START="0.5594535604099546" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7475640334350449" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="-4.672449395711924E-4" LOG_CI_START="-0.2522359579198233" LOG_EFFECT_SIZE="-0.12635160142969726" METHOD="MH" MODIFIED="2009-09-21 15:23:17 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.9158507368442274" P_Q="0.0" P_Z="0.049155688874598084" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="445" TOTAL_2="432" WEIGHT="100.0" Z="1.96723878245023">
<NAME>Service use: Number of participants rehospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.407345105038898" CI_START="0.420448384843749" DF="0" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" ID="CMP-005.15.01" LOG_CI_END="0.148400606913312" LOG_CI_START="-0.37628731152698547" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2009-09-18 15:58:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3946208241045215" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="95" WEIGHT="23.02509290993068" Z="0.8512674256461668">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.407345105038898" CI_START="0.420448384843749" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.148400606913312" LOG_CI_START="-0.37628731152698547" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="617" O_E="0.0" SE="0.30820428053891485" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="0.09498987854251012" WEIGHT="23.02509290993068"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.031379997755092" CI_START="0.5326658641553558" DF="0" EFFECT_SIZE="0.7412023460410557" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="68" I2="0.0" ID="CMP-005.15.02" LOG_CI_END="0.013418704587834101" LOG_CI_START="-0.2735451340467522" LOG_EFFECT_SIZE="-0.13006321472945903" MODIFIED="2009-09-18 15:58:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0756234746597725" STUDIES="1" TAU2="0.0" TOTAL_1="341" TOTAL_2="337" WEIGHT="76.97490709006932" Z="1.7766643894657963">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.031379997755092" CI_START="0.5326658641553558" EFFECT_SIZE="0.7412023460410557" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="68" LOG_CI_END="0.013418704587834101" LOG_CI_START="-0.2735451340467522" LOG_EFFECT_SIZE="-0.13006321472945903" ORDER="618" O_E="0.0" SE="0.16856397930786662" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.028413815120102888" WEIGHT="76.97490709006932"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.205605685328907" CI_END="1.0757512214510392" CI_START="0.8535870334260842" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.958252207836162" ESTIMABLE="YES" EVENTS_1="633" EVENTS_2="641" I2="42.6493024560512" I2_Q="0.0" ID="CMP-005.16" LOG_CI_END="0.03171184787022879" LOG_CI_START="-0.06875219076525516" LOG_EFFECT_SIZE="-0.01852017144751318" METHOD="MH" MODIFIED="2009-09-18 15:49:50 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0939970095633037" P_Q="0.0" P_Z="0.46991084756115153" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.008482953868117791" TOTALS="YES" TOTAL_1="1117" TOTAL_2="1109" WEIGHT="100.00000000000003" Z="0.7226241253616518">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9860682493222113" CI_START="0.5592836573566962" EFFECT_SIZE="1.2923076923076924" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.4750997297002254" LOG_CI_START="-0.2523678708621732" LOG_EFFECT_SIZE="0.11136592941902611" ORDER="619" O_E="0.0" SE="0.42731806959305224" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.18260073260073262" WEIGHT="1.8225223304068467"/>
<DICH_DATA CI_END="1.1593619062559075" CI_START="0.9368339600930861" EFFECT_SIZE="1.0421754198880298" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="220" LOG_CI_END="0.06421902643440168" LOG_CI_START="-0.028337374539333115" LOG_EFFECT_SIZE="0.017940825947534298" ORDER="620" O_E="0.0" SE="0.05436808809354578" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.0029558890029475543" WEIGHT="30.444887607194325"/>
<DICH_DATA CI_END="1.4786937233197799" CI_START="0.48144795049356054" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.1698782294082544" LOG_CI_START="-0.3174506577300917" LOG_EFFECT_SIZE="-0.07378621416091866" ORDER="621" O_E="0.0" SE="0.28625940062196115" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" VAR="0.08194444444444444" WEIGHT="3.8512031979754617"/>
<DICH_DATA CI_END="1.081291344887831" CI_START="0.6897155361980298" EFFECT_SIZE="0.8635875402792696" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" LOG_CI_END="0.033942726727992215" LOG_CI_START="-0.16132999119377492" LOG_EFFECT_SIZE="-0.06369363223289133" ORDER="622" O_E="0.0" SE="0.11470416112278908" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.013157044578882757" WEIGHT="16.093082742998575"/>
<DICH_DATA CI_END="2.2321424504008656" CI_START="0.8092730208999938" EFFECT_SIZE="1.3440285204991087" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" LOG_CI_END="0.34872190686452925" LOG_CI_START="-0.09190493763730402" LOG_EFFECT_SIZE="0.12840848461361262" ORDER="623" O_E="0.0" SE="0.25882638959843407" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.06699109995256039" WEIGHT="4.614225259363592"/>
<DICH_DATA CI_END="0.8552699465163092" CI_START="0.25892794210676606" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="-0.06789678845427005" LOG_CI_START="-0.5868210803183906" LOG_EFFECT_SIZE="-0.32735893438633035" ORDER="624" O_E="0.0" SE="0.3048186977576569" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.0929144385026738" WEIGHT="3.434548733683789"/>
<DICH_DATA CI_END="1.1482265164998464" CI_START="0.4797331164545734" EFFECT_SIZE="0.7421875" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.06002757200084799" LOG_CI_START="-0.31900030071888924" LOG_EFFECT_SIZE="-0.1294863643590206" ORDER="625" O_E="0.0" SE="0.22264284865380285" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="0.049569838056680166" WEIGHT="5.998923979695444"/>
<DICH_DATA CI_END="1.0889059860663013" CI_START="0.9204366856166362" EFFECT_SIZE="1.0011338655559412" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="258" LOG_CI_END="0.03699038526986606" LOG_CI_START="-0.03600608009100829" LOG_EFFECT_SIZE="4.921525894288843E-4" ORDER="626" O_E="0.0" SE="0.04287848509130874" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.001838564483725586" WEIGHT="33.74060614868198"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.080793290670329" CI_END="6.993918164063216" CI_START="0.32513198594748105" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5079610413522073" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.17" LOG_CI_END="0.8447205463169923" LOG_CI_START="-0.48794030322868265" LOG_EFFECT_SIZE="0.17839012154415476" METHOD="MH" MODIFIED="2009-09-18 15:58:55 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.5558082230573578" P_Q="0.0" P_Z="0.5997764840588562" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1534" TOTAL_2="1532" WEIGHT="200.0" Z="0.5247219703999909">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-18 15:58:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="488" TOTAL_2="494" WEIGHT="0.0" Z="0.0">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="639" O_E="0.0" SE="0.0" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="640" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.043579919484128184" CI_END="15.64913474990676" CI_START="0.3390480390001969" DF="1" EFFECT_SIZE="2.3034340557102397" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-005.17.02" LOG_CI_END="1.1944903301425864" LOG_CI_START="-0.46973876316975116" LOG_EFFECT_SIZE="0.36237578348641764" MODIFIED="2009-09-18 15:58:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8346372574882591" P_Z="0.39335963476315694" STUDIES="2" TAU2="0.0" TOTAL_1="474" TOTAL_2="471" WEIGHT="100.0" Z="0.8535405219833718">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="21.69491705076486" CI_START="0.18007484147062186" EFFECT_SIZE="1.9765395894428153" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.336357993969081" LOG_CI_START="-0.7445469588834368" LOG_EFFECT_SIZE="0.29590551754282207" ORDER="641" O_E="0.0" SE="1.222333869951212" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="1.4941000896299068" WEIGHT="63.96195536641517"/>
<DICH_DATA CI_END="73.53186320457478" CI_START="0.12422954057361392" EFFECT_SIZE="3.0223880597014925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8664755705850085" LOG_CI_START="-0.9057751208852867" LOG_EFFECT_SIZE="0.4803502248498609" ORDER="642" O_E="0.0" SE="1.6284337790318937" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="2.6517965726920947" WEIGHT="36.03804463358484"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.359765633147023" CI_END="9.16231016563069" CI_START="0.05458872909982005" DF="1" EFFECT_SIZE="0.7072191085937518" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="26.45791483304268" ID="CMP-005.17.03" LOG_CI_END="0.9620049895729887" LOG_CI_START="-1.2628970165451134" LOG_EFFECT_SIZE="-0.15044601348606243" MODIFIED="2009-09-18 15:58:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24357827564887735" P_Z="0.7909615063960059" STUDIES="3" TAU2="0.9051444472313062" TOTAL_1="572" TOTAL_2="567" WEIGHT="100.0" Z="0.265062251945902">
<NAME>suicide</NAME>
<DICH_DATA CI_END="4.15760480115009" CI_START="0.00976505573155352" EFFECT_SIZE="0.20149253731343283" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6188432053329355" LOG_CI_START="-2.0103252737445763" LOG_EFFECT_SIZE="-0.6957410342058203" ORDER="643" O_E="0.0" SE="1.5443865792039984" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="2.385129906025428" WEIGHT="51.91165405582773"/>
<DICH_DATA CI_END="66.52773321435939" CI_START="0.11308464820049849" EFFECT_SIZE="2.742857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8230027260724326" LOG_CI_START="-0.9465963486938471" LOG_EFFECT_SIZE="0.43820318868929276" ORDER="644" O_E="0.0" SE="1.6268762062542406" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="2.6467261904761905" WEIGHT="48.088345944172275"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="645" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3950959234409273" CI_START="0.3915548194771275" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1529814271749756" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.18" LOG_CI_END="0.5308520491415771" LOG_CI_START="-0.4072074261226688" LOG_EFFECT_SIZE="0.061822311509454136" METHOD="MH" MODIFIED="2009-09-18 15:50:26 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.796143923509591" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="676" TOTAL_2="675" WEIGHT="100.0" Z="0.2583407709098902">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3950959234409273" CI_START="0.3915548194771275" EFFECT_SIZE="1.1529814271749756" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5308520491415771" LOG_CI_START="-0.4072074261226688" LOG_EFFECT_SIZE="0.061822311509454136" ORDER="627" O_E="0.0" SE="0.5510207792395095" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.30362389915371635" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="628" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.44466404838607" CI_END="5.051744185947557" CI_START="-9.477035354136714" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.212645584094578" ESTIMABLE="YES" I2="78.824021799465" I2_Q="0.0" ID="CMP-005.19" MODIFIED="2009-09-18 15:50:42 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.00889444410303697" P_Q="1.0" P_Z="0.5505197946454657" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="31.07341108788215" TOTALS="YES" TOTAL_1="471" TOTAL_2="469" UNITS="" WEIGHT="100.0" Z="0.5969814110555098">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5676293348867878" CI_START="-10.832370665113213" EFFECT_SIZE="-5.7" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="5.9" ORDER="629" SD_1="26.6" SD_2="27.8" SE="2.6186045792660972" STUDY_ID="STD-Lieberman-2005" TOTAL_1="218" TOTAL_2="214" WEIGHT="36.21708687576933"/>
<CONT_DATA CI_END="3.41368721440095" CI_START="-16.013687214400953" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="1.9" ORDER="630" SD_1="30.4" SD_2="33.3" SE="4.956053933144321" STUDY_ID="STD-Stroup-2006" TOTAL_1="85" TOTAL_2="81" WEIGHT="24.691479844929592"/>
<CONT_DATA CI_END="7.553158200685017" CI_START="-0.35315820068501713" EFFECT_SIZE="3.5999999999999996" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="-2.3" ORDER="631" SD_1="18.3" SD_2="19.0" SE="2.016954511341547" STUDY_ID="STD-Zhong-2006" TOTAL_1="168" TOTAL_2="174" WEIGHT="39.09143327930107"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.443567144407265" CI_END="0.972747071947306" CI_START="0.6886256725905249" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8184489029134179" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="331" I2="25.875467469455238" I2_Q="0.0" ID="CMP-005.20" LOG_CI_END="-0.01200006778614902" LOG_CI_START="-0.16201679043679482" LOG_EFFECT_SIZE="-0.08700842911147191" METHOD="MH" MODIFIED="2009-09-18 15:51:13 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.22235822275567163" P_Q="0.0" P_Z="0.022994559144089544" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.014444703163237005" TOTALS="YES" TOTAL_1="1117" TOTAL_2="1109" WEIGHT="100.00000000000001" Z="2.273525036365767">
<NAME>Adverse effects: 4. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.093317426646381" CI_START="0.4646998620079861" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7070007431985775" LOG_CI_START="-0.33282745648428863" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="704" O_E="0.0" SE="0.6108002317263175" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.3730769230769231" WEIGHT="2.003819537972644"/>
<DICH_DATA CI_END="1.1636782408819595" CI_START="0.7290984025773855" EFFECT_SIZE="0.9211058280898556" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="103" LOG_CI_END="0.06583291371024483" LOG_CI_START="-0.13721385328377064" LOG_EFFECT_SIZE="-0.03569046978676289" ORDER="705" O_E="0.0" SE="0.1192706760299913" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.014225494160651138" WEIGHT="27.084689975257408"/>
<DICH_DATA CI_END="2.2761460827526774" CI_START="0.2471282508017832" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3572001315795652" LOG_CI_START="-0.6070776047961651" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="706" O_E="0.0" SE="0.566421515598881" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" VAR="0.32083333333333336" WEIGHT="2.3160580817076823"/>
<DICH_DATA CI_END="1.081291344887831" CI_START="0.6897155361980298" EFFECT_SIZE="0.8635875402792696" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" LOG_CI_END="0.033942726727992215" LOG_CI_START="-0.16132999119377492" LOG_EFFECT_SIZE="-0.06369363223289133" ORDER="707" O_E="0.0" SE="0.11470416112278908" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.013157044578882757" WEIGHT="28.133124514503276"/>
<DICH_DATA CI_END="1.4657982879189917" CI_START="0.3152169821743984" EFFECT_SIZE="0.6797385620915033" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.1660742100929456" LOG_CI_START="-0.5013903931305824" LOG_EFFECT_SIZE="-0.16765809151881841" ORDER="708" O_E="0.0" SE="0.39207201193657265" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.15372046254399196" WEIGHT="4.617623410777422"/>
<DICH_DATA CI_END="0.6566304829677554" CI_START="0.13174105155831858" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.18267895974649911" LOG_CI_START="-0.880278874338011" LOG_EFFECT_SIZE="-0.5314789170422551" ORDER="709" O_E="0.0" SE="0.4097736430063234" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.1679144385026738" WEIGHT="4.25820937164525"/>
<DICH_DATA CI_END="1.596794620920929" CI_START="0.5711389534687111" EFFECT_SIZE="0.9549825174825175" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.20324906094962536" LOG_CI_START="-0.24325821857871735" LOG_EFFECT_SIZE="-0.020004578814545936" ORDER="710" O_E="0.0" SE="0.2622805862416286" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="0.06879110591925236" WEIGHT="9.32919874999239"/>
<DICH_DATA CI_END="0.9902211820127582" CI_START="0.5653526498796978" EFFECT_SIZE="0.7482139862485326" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="89" LOG_CI_END="-0.004267787827939562" LOG_CI_START="-0.24768056789652965" LOG_EFFECT_SIZE="-0.1259741778622346" ORDER="711" O_E="0.0" SE="0.14298187192498374" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.02044381569917245" WEIGHT="22.257276358143944"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.828115331899944" CI_END="1.9912231499096187" CI_START="1.3155242250411243" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6184876555503283" ESTIMABLE="YES" EVENTS_1="338" EVENTS_2="190" I2="51.18886038479012" I2_Q="0.0" ID="CMP-005.21" LOG_CI_END="0.29911993272647125" LOG_CI_START="0.11909884991682983" LOG_EFFECT_SIZE="0.20910939132165055" METHOD="MH" MODIFIED="2009-09-18 16:00:45 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.006552593948171093" P_Q="0.0" P_Z="5.280563919654563E-6" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1557834199719125" TOTALS="SUB" TOTAL_1="3363" TOTAL_2="3360" WEIGHT="700.0" Z="4.553320860234014">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.558210903178804" CI_END="2.937926255364" CI_START="0.886384258003706" DF="5" EFFECT_SIZE="1.6137321908948912" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="61" I2="60.185411452722356" ID="CMP-005.21.01" LOG_CI_END="0.4680408904023543" LOG_CI_START="-0.05237796552497883" LOG_EFFECT_SIZE="0.2078314624386877" MODIFIED="2009-09-18 16:00:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02788998980914914" P_Z="0.11747983471000605" STUDIES="6" TAU2="0.27647267205609005" TOTAL_1="1088" TOTAL_2="1082" WEIGHT="99.99999999999999" Z="1.5654397475982107">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.3426101606967134" CI_START="0.6514349380613949" EFFECT_SIZE="1.2353372434017595" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.3697000226367866" LOG_CI_START="-0.18612895286299203" LOG_EFFECT_SIZE="0.09178553488689732" ORDER="646" O_E="0.0" SE="0.3264966916063726" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.1066000896299068" WEIGHT="24.394952601152507"/>
<DICH_DATA CI_END="1.9411170927711245" CI_START="0.7530383135081313" EFFECT_SIZE="1.2090225563909776" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="25" LOG_CI_END="0.2880517338482085" LOG_CI_START="-0.12318292695751508" LOG_EFFECT_SIZE="0.08243440344534671" ORDER="647" O_E="0.0" SE="0.24156127540168343" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.05835184977368795" WEIGHT="27.910267184293705"/>
<DICH_DATA CI_END="85.81946106826925" CI_START="1.4657703164572484" EFFECT_SIZE="11.215686274509803" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.9335857829091712" LOG_CI_START="0.16606592248100427" LOG_EFFECT_SIZE="1.0498258526950879" ORDER="648" O_E="0.0" SE="1.0382499153799225" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="1.0779628867864162" WEIGHT="6.899583965521926"/>
<DICH_DATA CI_END="277.60717975019895" CI_START="1.0410393573395793" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4434306940795407" LOG_CI_START="0.01746714867700721" LOG_EFFECT_SIZE="1.2304489213782739" ORDER="649" O_E="0.0" SE="1.425022995282672" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="2.0306905370843986" WEIGHT="4.050446811521361"/>
<DICH_DATA CI_END="1.7754275111868902" CI_START="0.11749451568578945" EFFECT_SIZE="0.4567307692307692" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.249302945218765" LOG_CI_START="-0.9299824045665925" LOG_EFFECT_SIZE="-0.3403397296739138" ORDER="650" O_E="0.0" SE="0.6927180520205474" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="0.4798582995951417" WEIGHT="12.355757220572714"/>
<DICH_DATA CI_END="4.122143140598727" CI_START="1.1456450317256464" EFFECT_SIZE="2.1731343283582087" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.6151230684943377" LOG_CI_START="0.05905007605804614" LOG_EFFECT_SIZE="0.33708657227619193" ORDER="651" O_E="0.0" SE="0.3266400283627837" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.10669370812884016" WEIGHT="24.388992216937776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6510277242756684" CI_START="0.7316932869164398" DF="0" EFFECT_SIZE="1.0991114149008885" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" I2="0.0" ID="CMP-005.21.02" LOG_CI_END="0.21775436605434062" LOG_CI_START="-0.13567092948009743" LOG_EFFECT_SIZE="0.04104171828712159" MODIFIED="2009-09-18 16:00:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6489625431429494" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="134" WEIGHT="99.99999999999999" Z="0.4552039184674549">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="1.6510277242756684" CI_START="0.7316932869164398" EFFECT_SIZE="1.0991114149008885" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" LOG_CI_END="0.21775436605434062" LOG_CI_START="-0.13567092948009743" LOG_EFFECT_SIZE="0.04104171828712159" ORDER="652" O_E="0.0" SE="0.2076037680803571" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.0430993245211627" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="135.27116161620154" CI_START="2.438280004763281" DF="0" EFFECT_SIZE="18.161194029850748" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" I2="0.0" ID="CMP-005.21.03" LOG_CI_END="2.1312052194661706" LOG_CI_START="0.38708357722206077" LOG_EFFECT_SIZE="1.2591443983441155" MODIFIED="2009-09-18 16:00:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0046557089290703195" STUDIES="1" TAU2="0.0" TOTAL_1="335" TOTAL_2="338" WEIGHT="100.0" Z="2.829937559761574">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="135.27116161620154" CI_START="2.438280004763281" EFFECT_SIZE="18.161194029850748" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="2.1312052194661706" LOG_CI_START="0.38708357722206077" LOG_EFFECT_SIZE="1.2591443983441155" ORDER="653" O_E="0.0" SE="1.024505686195559" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="1.0496119010470333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0339632742350975" CI_END="2.3354928703020406" CI_START="1.227108243628212" DF="1" EFFECT_SIZE="1.6928976797439792" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="50" I2="0.0" ID="CMP-005.21.04" LOG_CI_END="0.36837854582923607" LOG_CI_START="0.08888287367810932" LOG_EFFECT_SIZE="0.2286307097536727" MODIFIED="2009-09-18 16:00:25 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8537850119747314" P_Z="0.0013433851716902038" STUDIES="2" TAU2="0.0" TOTAL_1="439" TOTAL_2="433" WEIGHT="100.0" Z="3.206546659046166">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="3.8120268277166978" CI_START="0.6432665901046577" EFFECT_SIZE="1.565934065934066" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.5811559483902986" LOG_CI_START="-0.1916090043434278" LOG_EFFECT_SIZE="0.1947734720234354" ORDER="654" O_E="0.0" SE="0.45392595848399975" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="0.20604877578561787" WEIGHT="13.081433577197679"/>
<DICH_DATA CI_END="2.418922050342034" CI_START="1.212915991830855" EFFECT_SIZE="1.7128774730996181" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="43" LOG_CI_END="0.3836218734665624" LOG_CI_START="0.08383072209679535" LOG_EFFECT_SIZE="0.23372629778167883" ORDER="655" O_E="0.0" SE="0.1760988063047339" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.03101078958195219" WEIGHT="86.91856642280233"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="277.60717975019895" CI_START="1.0410393573395793" DF="0" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-005.21.05" LOG_CI_END="2.4434306940795407" LOG_CI_START="0.01746714867700721" LOG_EFFECT_SIZE="1.2304489213782739" MODIFIED="2009-09-18 16:00:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.04679092297166674" STUDIES="2" TAU2="0.0" TOTAL_1="357" TOTAL_2="360" WEIGHT="100.0" Z="1.9881878070986574">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="277.60717975019895" CI_START="1.0410393573395793" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4434306940795407" LOG_CI_START="0.01746714867700721" LOG_EFFECT_SIZE="1.2304489213782739" ORDER="656" O_E="0.0" SE="1.425022995282672" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="2.0306905370843986" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="657" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.304169868506133" CI_START="0.7981486618033393" DF="0" EFFECT_SIZE="2.2431372549019604" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-005.21.06" LOG_CI_END="0.7996279068864691" LOG_CI_START="-0.09791621016833109" LOG_EFFECT_SIZE="0.35085584835906897" MODIFIED="2009-09-18 16:00:40 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.12544215484103538" STUDIES="1" TAU2="0.0" TOTAL_1="153" TOTAL_2="156" WEIGHT="100.0" Z="1.5323254054753859">
<NAME>rigor</NAME>
<DICH_DATA CI_END="6.304169868506133" CI_START="0.7981486618033395" EFFECT_SIZE="2.243137254901961" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7996279068864691" LOG_CI_START="-0.09791621016833096" LOG_EFFECT_SIZE="0.350855848359069" ORDER="658" O_E="0.0" SE="0.5272218572730234" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="0.27796288678641623" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.897473446106303" CI_END="3.3856000532357413" CI_START="1.1595234058039119" DF="5" EFFECT_SIZE="1.9813335167048005" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="40" I2="36.688612704799226" ID="CMP-005.21.07" LOG_CI_END="0.529635652847992" LOG_CI_START="0.06427951960521681" LOG_EFFECT_SIZE="0.2969575862266044" MODIFIED="2009-09-18 16:00:45 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.1619774152226241" P_Z="0.012369547790981369" STUDIES="6" TAU2="0.15063057640511873" TOTAL_1="858" TOTAL_2="857" WEIGHT="99.99999999999999" Z="2.50142259814786">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="124.13532946180445" CI_START="0.39473049463389837" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.093895401214321" LOG_CI_START="-0.4036993211858073" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="659" O_E="0.0" SE="1.4670995032311038" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.152380952380952" WEIGHT="3.2445164192187543"/>
<DICH_DATA CI_END="3.072438170677387" CI_START="0.12325658119544149" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4874831519640854" LOG_CI_START="-0.9091898825938718" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="660" O_E="0.0" SE="0.820412654142367" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" VAR="0.673076923076923" WEIGHT="9.07137390820781"/>
<DICH_DATA CI_END="5.608739986961715" CI_START="1.4736702726023083" EFFECT_SIZE="2.874966675553186" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="11" LOG_CI_END="0.7488653072148715" LOG_CI_START="0.16840032286617218" LOG_EFFECT_SIZE="0.4586328150405219" ORDER="661" O_E="0.0" SE="0.34096800515443926" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.11625918053899771" WEIGHT="27.99717308132239"/>
<DICH_DATA CI_END="6.2058588751178885" CI_START="0.7916801961059169" EFFECT_SIZE="2.216541353383459" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7928018952483986" LOG_CI_START="-0.10145021880854252" LOG_EFFECT_SIZE="0.3456758382199281" ORDER="662" O_E="0.0" SE="0.5252881184164034" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.2759276073494455" WEIGHT="17.517325896848508"/>
<DICH_DATA CI_END="18.49872928666367" CI_START="1.094669784405077" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2671418969033432" LOG_CI_START="0.03928313064734435" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="663" O_E="0.0" SE="0.7212503172976913" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.5202020202020203" WEIGHT="11.138633925346394"/>
<DICH_DATA CI_END="2.200099105813548" CI_START="0.6780317205898627" EFFECT_SIZE="1.2213668499607226" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" LOG_CI_END="0.3424422445215324" LOG_CI_START="-0.1687499879103856" LOG_EFFECT_SIZE="0.0868461283055734" ORDER="664" O_E="0.0" SE="0.30027684777286967" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.09016618530841115" WEIGHT="31.030976769056135"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="35.7617025744632" CI_END="0.770597206104891" CI_START="0.11732327011554655" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4439602381102188" ESTIMABLE="YES" I2="77.62970042228174" I2_Q="29.759062922208525" ID="CMP-005.22" MODIFIED="2010-11-23 15:36:49 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.9414527217320732E-5" P_Q="0.24082859337347318" P_Z="0.00772279679285881" Q="2.8473424233862517" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.24241256436453987" TOTALS="SUB" TOTAL_1="1353" TOTAL_2="1382" UNITS="" WEIGHT="300.0" Z="2.6639546729996852">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.12124093958426554" CI_END="0.7534861949835283" CI_START="-0.08271168451693905" DF="1" EFFECT_SIZE="0.3353872552332946" ESTIMABLE="YES" I2="0.0" ID="CMP-005.22.01" MODIFIED="2010-11-23 15:36:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7276925288631881" P_Z="0.11589763894218531" STUDIES="2" TAU2="0.0" TOTAL_1="473" TOTAL_2="485" WEIGHT="100.0" Z="1.5722281944165895">
<NAME>abnormal involuntary movement: AIMS (high = poor)</NAME>
<CONT_DATA CI_END="0.9541510609505265" CI_START="-0.15415106095052644" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.1" ORDER="665" SD_1="2.47" SD_2="2.5" SE="0.28273532846603266" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" WEIGHT="56.924836822196404"/>
<CONT_DATA CI_END="0.8870383833296409" CI_START="-0.3870383833296409" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.5" ORDER="666" SD_1="4.11" SD_2="4.17" SE="0.3250255557523089" STUDY_ID="STD-Zhong-2006" TOTAL_1="320" TOTAL_2="329" WEIGHT="43.07516317780359"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="27.082157121425592" CI_END="2.0017658466911317" CI_START="-0.5447914542988747" DF="1" EFFECT_SIZE="0.7284871961961285" ESTIMABLE="YES" I2="96.30753194615777" ID="CMP-005.22.02" MODIFIED="2010-11-23 15:36:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.9499648507004252E-7" P_Z="0.2621330294119584" STUDIES="2" TAU2="0.8137986449450336" TOTAL_1="346" TOTAL_2="354" WEIGHT="100.0" Z="1.12136386421613">
<NAME>akathisia: Barnes Akathisia Scale (high = poor)</NAME>
<CONT_DATA CI_END="1.8767509155762894" CI_START="0.9232490844237109" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="-0.3" ORDER="667" SD_1="0.86" SD_2="0.86" SE="0.24324473272817232" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="48.345168938163724"/>
<CONT_DATA CI_END="0.2114719950668943" CI_START="-0.011471995066894308" EFFECT_SIZE="0.09999999999999999" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="-0.09" ORDER="668" SD_1="0.72" SD_2="0.73" SE="0.05687451195336811" STUDY_ID="STD-Zhong-2006" TOTAL_1="321" TOTAL_2="329" WEIGHT="51.65483106183628"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.710962090067092" CI_END="1.1647385224727718" CI_START="0.016787871099452456" DF="4" EFFECT_SIZE="0.5907631967861121" ESTIMABLE="YES" I2="29.959261908653147" ID="CMP-005.22.03" MODIFIED="2010-11-23 15:36:49 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.221798720978448" P_Z="0.0436652759658673" STUDIES="5" TAU2="0.11892570413741409" TOTAL_1="534" TOTAL_2="543" WEIGHT="100.00000000000001" Z="2.01728983333445">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="2.8115326381547816" CI_START="-2.131532638154782" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-1.64" ORDER="669" SD_1="3.15" SD_2="3.15" SE="1.261009211215061" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" WEIGHT="5.017997376302252"/>
<CONT_DATA CI_END="3.4106402353010723" CI_START="-1.6106402353010725" EFFECT_SIZE="0.9" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-0.1" ORDER="670" SD_1="15.65" SD_2="2.5" SE="1.2809624335470866" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" WEIGHT="4.873369098633869"/>
<CONT_DATA CI_END="1.2445894313547694" CI_START="0.015410568645230605" EFFECT_SIZE="0.63" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.17" ORDER="671" SD_1="1.04" SD_2="1.04" SE="0.3135717983608742" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="39.475217200913754"/>
<CONT_DATA CI_END="4.584614276468739" CI_START="0.6153857235312612" EFFECT_SIZE="2.6" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="-0.4" ORDER="672" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="7.495040950205115"/>
<CONT_DATA CI_END="0.753941853551781" CI_START="-0.3539418535517811" EFFECT_SIZE="0.19999999999999998" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.41" ORDER="673" SD_1="3.58" SD_2="3.62" SE="0.28262858803590457" STUDY_ID="STD-Zhong-2006" TOTAL_1="321" TOTAL_2="328" WEIGHT="43.13837537394502"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.8530106293511986E-32" CI_END="8.226216298095627" CI_START="0.013749224638206058" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33630952380952384" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.00000000000001" I2_Q="0.0" ID="CMP-005.23" LOG_CI_END="0.9152001245549198" LOG_CI_START="-1.8617217923677687" LOG_EFFECT_SIZE="-0.47326083390642426" METHOD="MH" MODIFIED="2009-09-18 15:52:03 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.5040957751667379" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="338" WEIGHT="99.99999999999999" Z="0.6680592522946395">
<NAME>Adverse effects: 6. Haematological: Important decline in white blood cells</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.226216298095627" CI_START="0.013749224638206058" EFFECT_SIZE="0.33630952380952384" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9152001245549198" LOG_CI_START="-1.8617217923677687" LOG_EFFECT_SIZE="-0.47326083390642426" ORDER="726" O_E="0.0" SE="1.6311776799855684" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="2.6607406236831013" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.67187084839867" CI_END="1.761741041257265" CI_START="1.1948642172951383" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4508760561600649" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="134" I2="16.026220888433176" I2_Q="0.0" ID="CMP-005.24" LOG_CI_END="0.24594207171610472" LOG_CI_START="0.07731855546829997" LOG_EFFECT_SIZE="0.16163031359220237" METHOD="MH" MODIFIED="2009-09-18 16:01:36 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.2740859606634328" P_Q="0.0" P_Z="1.7171565537878186E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.038572435178381125" TOTALS="SUB" TOTAL_1="1616" TOTAL_2="1619" WEIGHT="500.0" Z="3.757359596096733">
<NAME>Adverse effects: 7a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.630723222035893" CI_END="3.635772893929514" CI_START="1.2616292602828256" DF="2" EFFECT_SIZE="2.141727682672249" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="16" I2="0.0" ID="CMP-005.24.01" LOG_CI_END="0.5605967474889808" LOG_CI_START="0.10093175279390364" LOG_EFFECT_SIZE="0.3307642501414422" MODIFIED="2009-09-18 16:01:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44247950434958516" P_Z="0.004792062226787721" STUDIES="4" TAU2="0.0" TOTAL_1="176" TOTAL_2="183" WEIGHT="100.0" Z="2.820689089368968">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="7.772526855079319" CI_START="1.143931675657202" EFFECT_SIZE="2.981818181818182" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.8905622312610784" LOG_CI_START="0.058400085845829744" LOG_EFFECT_SIZE="0.4744811585534541" ORDER="681" O_E="0.0" SE="0.4888161634859716" STUDY_ID="STD-Lieberman-2005" TOTAL_1="88" TOTAL_2="82" VAR="0.23894124168514413" WEIGHT="30.51173834102562"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="682" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.778112322926091" CI_START="1.0339650206941688" EFFECT_SIZE="1.9764705882352942" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5772748653120865" LOG_CI_START="0.014505846711053753" LOG_EFFECT_SIZE="0.29589035601157015" ORDER="683" O_E="0.0" SE="0.33057330727781675" STUDY_ID="STD-McEvoy-2007" TOTAL_1="34" TOTAL_2="42" VAR="0.10927871148459384" WEIGHT="66.7148481724613"/>
<DICH_DATA CI_END="9.303301240829402" CI_START="0.016161362001138383" EFFECT_SIZE="0.3877551020408163" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.968637083636965" LOG_CI_START="-1.7915220417883344" LOG_EFFECT_SIZE="-0.4114424790756847" ORDER="684" O_E="0.0" SE="1.621331133282846" STUDY_ID="STD-Potkin-2006" TOTAL_1="48" TOTAL_2="56" VAR="2.6287146437522377" WEIGHT="2.7734134865130797"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.857746822454768" CI_START="0.42079761541756566" DF="0" EFFECT_SIZE="2.2337662337662336" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-005.24.02" LOG_CI_END="1.074002173384164" LOG_CI_START="-0.3759267299140302" LOG_EFFECT_SIZE="0.34903772173506703" MODIFIED="2009-09-18 16:01:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34535654068299526" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="86" WEIGHT="100.0" Z="0.943634356540517">
<NAME>dysmenorrhea</NAME>
<DICH_DATA CI_END="11.857746822454768" CI_START="0.4207976154175657" EFFECT_SIZE="2.2337662337662336" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.074002173384164" LOG_CI_START="-0.3759267299140302" LOG_EFFECT_SIZE="0.34903772173506703" ORDER="685" O_E="0.0" SE="0.8516954150611842" STUDY_ID="STD-Zhong-2006" TOTAL_1="77" TOTAL_2="86" VAR="0.7253850800362428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0763127654578466" CI_END="5.908036439447178" CI_START="1.185851094834429" DF="3" EFFECT_SIZE="2.646894686238978" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="6" I2="0.0" ID="CMP-005.24.03" LOG_CI_END="0.7714431652793887" LOG_CI_START="0.0740301588834466" LOG_EFFECT_SIZE="0.4227366620814177" MODIFIED="2009-09-18 16:01:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7827951592280087" P_Z="0.017498473179614192" STUDIES="5" TAU2="0.0" TOTAL_1="242" TOTAL_2="236" WEIGHT="99.99999999999999" Z="2.3760630358931563">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="5.389744790673763" CI_START="0.8770972101602269" EFFECT_SIZE="2.1742424242424243" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7315682014342032" LOG_CI_START="-0.0569522703779183" LOG_EFFECT_SIZE="0.33730796552814246" ORDER="686" O_E="0.0" SE="0.4631808283817263" STUDY_ID="STD-Lieberman-2005" TOTAL_1="88" TOTAL_2="82" VAR="0.2145364797803822" WEIGHT="78.22654309276774"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="687" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="160.96103664184614" CI_START="0.45949008246367173" EFFECT_SIZE="8.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.2067207603836847" LOG_CI_START="-0.3377238578965494" LOG_EFFECT_SIZE="0.9344984512435677" ORDER="688" O_E="0.0" SE="1.4946193639818028" STUDY_ID="STD-McEvoy-2007" TOTAL_1="34" TOTAL_2="42" VAR="2.2338870431893687" WEIGHT="7.512665974618888"/>
<DICH_DATA CI_END="62.98872614898338" CI_START="0.1583187941503722" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7992628254944778" LOG_CI_START="-0.8004675266328485" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="689" O_E="0.0" SE="1.527094477712381" STUDY_ID="STD-Stroup-2006" TOTAL_1="37" TOTAL_2="23" VAR="2.3320175438596493" WEIGHT="7.196535559820301"/>
<DICH_DATA CI_END="114.38618015726797" CI_START="0.27190409683368527" EFFECT_SIZE="5.576923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0583735572892556" LOG_CI_START="-0.5655842487609416" LOG_EFFECT_SIZE="0.7463946542641569" ORDER="690" O_E="0.0" SE="1.5413258040745064" STUDY_ID="STD-Zhong-2006" TOTAL_1="77" TOTAL_2="86" VAR="2.375685234305924" WEIGHT="7.064255372793061"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.022162053008538" CI_START="1.3391499618098401" DF="0" EFFECT_SIZE="4.333333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" ID="CMP-005.24.04" LOG_CI_END="1.1468149819115645" LOG_CI_START="0.126829213262784" LOG_EFFECT_SIZE="0.6368220975871743" MODIFIED="2009-09-18 16:01:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.01438974756947395" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="99.99999999999999" Z="2.4473839031765894">
<NAME>gynecomastia</NAME>
<DICH_DATA CI_END="14.022162053008538" CI_START="1.3391499618098401" EFFECT_SIZE="4.333333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.1468149819115645" LOG_CI_START="0.126829213262784" LOG_EFFECT_SIZE="0.6368220975871743" ORDER="691" O_E="0.0" SE="0.599144689515278" STUDY_ID="STD-McEvoy-2007" TOTAL_1="39" TOTAL_2="39" VAR="0.3589743589743589" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.878747749441507" CI_END="1.5419199450695107" CI_START="0.9894882217074957" DF="5" EFFECT_SIZE="1.2351969982404223" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="107" I2="0.0" ID="CMP-005.24.05" LOG_CI_END="0.18806182616818745" LOG_CI_START="-0.004589371015831712" LOG_EFFECT_SIZE="0.09173622757617789" MODIFIED="2009-09-18 16:01:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5670022592135027" P_Z="0.0619598763100086" STUDIES="6" TAU2="0.0" TOTAL_1="1082" TOTAL_2="1075" WEIGHT="100.00000000000003" Z="1.8665827646545616">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="1.7146712399863526" CI_START="0.9907287897038519" EFFECT_SIZE="1.3033703089804072" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="69" LOG_CI_END="0.23418086353525996" LOG_CI_START="-0.004045216609901533" LOG_EFFECT_SIZE="0.11506782346267919" ORDER="692" O_E="0.0" SE="0.13993517871538308" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.0195818542421062" WEIGHT="65.39805238406984"/>
<DICH_DATA CI_END="8.783918833890697" CI_START="0.4002342310399982" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9436883141100868" LOG_CI_START="-0.3976857699826114" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="693" O_E="0.0" SE="0.7879297769048542" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" VAR="0.6208333333333333" WEIGHT="2.0627357790643996"/>
<DICH_DATA CI_END="1.5438815541519029" CI_START="0.6956026842323414" EFFECT_SIZE="1.0363050483351235" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" LOG_CI_END="0.18861397841459884" LOG_CI_START="-0.15763875078513195" LOG_EFFECT_SIZE="0.015487613814733453" ORDER="694" O_E="0.0" SE="0.20339056711057413" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.04136772278956096" WEIGHT="30.95686789473559"/>
<DICH_DATA CI_END="8.277658524999424" CI_START="0.013951080576461048" EFFECT_SIZE="0.3398268398268398" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9179075066543387" LOG_CI_START="-1.855392152948122" LOG_EFFECT_SIZE="-0.4687423231468918" ORDER="695" O_E="0.0" SE="1.6290499481052039" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" VAR="2.6538037334215674" WEIGHT="0.4825583419657699"/>
<DICH_DATA CI_END="94.02387434144403" CI_START="0.22226226402651034" EFFECT_SIZE="4.571428571428571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9732381427301642" LOG_CI_START="-0.653134266118866" LOG_EFFECT_SIZE="0.6600519383056491" ORDER="696" O_E="0.0" SE="1.5427441537110176" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="2.380059523809524" WEIGHT="0.5380601269386442"/>
<DICH_DATA CI_END="136.20244939945803" CI_START="0.3662115216717862" EFFECT_SIZE="7.0625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.134184917790448" LOG_CI_START="-0.43626799613545836" LOG_EFFECT_SIZE="0.8489584608274949" ORDER="697" O_E="0.0" SE="1.5098967655872106" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="2.2797882427307203" WEIGHT="0.5617254732257791"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="50.68196139072231" CI_END="44.36195149846729" CI_START="26.189643444375093" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="35.27579747142119" ESTIMABLE="YES" I2="90.13455702423687" I2_Q="0.0" ID="CMP-005.25" MODIFIED="2009-09-18 15:53:03 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0048415433061564E-9" P_Q="1.0" P_Z="2.755795365485242E-14" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="110.9876348826452" TOTALS="YES" TOTAL_1="877" TOTAL_2="854" UNITS="" WEIGHT="100.0" Z="7.609302281703866">
<NAME>Adverse effects: 7b. Prolactin - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.721523377589605" CI_START="20.6784766224104" EFFECT_SIZE="24.700000000000003" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-9.3" ORDER="698" SD_1="27.7" SD_2="25.7" SE="2.0518353445833006" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" WEIGHT="18.656077530149325"/>
<CONT_DATA CI_END="43.021290425099" CI_START="14.17870957490101" EFFECT_SIZE="28.6" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-13.2" ORDER="699" SD_1="17.91" SD_2="18.02" SE="7.357936441104168" STUDY_ID="STD-McEvoy-2006" TOTAL_1="11" TOTAL_2="13" WEIGHT="13.015063018960364"/>
<CONT_DATA CI_END="38.10400523703889" CI_START="23.495994762961104" EFFECT_SIZE="30.799999999999997" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="-18.7" ORDER="700" SD_1="15.88" SD_2="17.64" SE="3.7266017613853895" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="17.210275631264917"/>
<CONT_DATA CI_END="60.24015648063287" CI_START="40.55984351936713" EFFECT_SIZE="50.4" ESTIMABLE="YES" MEAN_1="40.3" MEAN_2="-10.1" ORDER="701" SD_1="43.29" SD_2="44.96" SE="5.0205802546632325" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" WEIGHT="15.77998097619423"/>
<CONT_DATA CI_END="37.09721810278623" CI_START="23.502781897213772" EFFECT_SIZE="30.3" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="-8.3" ORDER="702" SD_1="29.6" SD_2="18.5" SE="3.4680321456933982" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" WEIGHT="17.470540986781334"/>
<CONT_DATA CI_END="52.97402210710036" CI_START="41.02597789289964" EFFECT_SIZE="47.0" ESTIMABLE="YES" MEAN_1="35.5" MEAN_2="-11.5" ORDER="703" SD_1="30.4" SD_2="33.25" SE="3.048026471007981" STUDY_ID="STD-Zhong-2006" TOTAL_1="231" TOTAL_2="209" WEIGHT="17.86806185664983"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3917983213124365" CI_START="0.44670348906025215" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7884929715593331" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-005.26" LOG_CI_END="0.14357630834437815" LOG_CI_START="-0.3499806553775081" LOG_EFFECT_SIZE="-0.103202173516565" METHOD="MH" MODIFIED="2009-09-18 15:53:29 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.41241437367829215" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="468" TOTAL_2="472" WEIGHT="99.99999999999999" Z="0.8196522715165216">
<NAME>Adverse effects: 8a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3917983213124365" CI_START="0.44670348906025215" EFFECT_SIZE="0.7884929715593331" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.14357630834437815" LOG_CI_START="-0.3499806553775081" LOG_EFFECT_SIZE="-0.103202173516565" ORDER="632" O_E="0.0" SE="0.289917803636609" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.0840523328654754" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="633" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.2595042592908525" CI_END="-4.751579163303994" CI_START="-12.23312213539894" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.492350649351467" ESTIMABLE="YES" I2="6.092358253306602" I2_Q="0.0" ID="CMP-005.27" MODIFIED="2009-09-18 15:53:47 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.37202353834772095" P_Q="1.0" P_Z="8.605557416193591E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.2084577749628695" TOTALS="YES" TOTAL_1="726" TOTAL_2="707" UNITS="" WEIGHT="100.00000000000001" Z="4.449537075145195">
<NAME>Adverse effects: 8b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.8445551771168498" CI_START="-12.955444822883152" EFFECT_SIZE="-7.4" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="5.3" ORDER="634" SD_1="35.1" SD_2="38.6" SE="2.8344627078373836" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" WEIGHT="39.4121654685676"/>
<CONT_DATA CI_END="29.874422373662128" CI_START="-11.874422373662128" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-13.0" ORDER="635" SD_1="27.2" SD_2="24.5" SE="10.650411200571494" STUDY_ID="STD-McEvoy-2006" TOTAL_1="11" TOTAL_2="13" WEIGHT="3.1775403393186172"/>
<CONT_DATA CI_END="-1.173675436143732" CI_START="-26.426324563856266" EFFECT_SIZE="-13.799999999999999" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="25.2" ORDER="636" SD_1="28.28" SD_2="29.58" SE="6.442120703977779" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="8.52909477545541"/>
<CONT_DATA CI_END="0.2449516545141286" CI_START="-15.104951654514128" EFFECT_SIZE="-7.43" ESTIMABLE="YES" MEAN_1="-2.63" MEAN_2="4.8" ORDER="637" SD_1="9.8" SD_2="37.0" SE="3.915863615379245" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" WEIGHT="22.020463713965103"/>
<CONT_DATA CI_END="-4.461330440378063" CI_START="-18.23866955962194" EFFECT_SIZE="-11.350000000000001" ESTIMABLE="YES" MEAN_1="-6.45" MEAN_2="4.9" ORDER="638" SD_1="36.2" SD_2="38.3" SE="3.5146919096263423" STUDY_ID="STD-Zhong-2006" TOTAL_1="233" TOTAL_2="218" WEIGHT="26.860735702693276"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8339476803964369" CI_END="1.7861994975402344" CI_START="0.28961769458513037" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7192461195910068" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-005.28" LOG_CI_END="0.25192996286289876" LOG_CI_START="-0.5381749078549856" LOG_EFFECT_SIZE="-0.1431224724960434" METHOD="MH" MODIFIED="2009-09-18 15:54:08 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.36113356421612675" P_Q="0.0" P_Z="0.4776607203090071" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="468" TOTAL_2="472" WEIGHT="100.00000000000001" Z="0.7100700220103581">
<NAME>Adverse effects: 8c. Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6159845366086372" CI_START="0.2261369940039502" EFFECT_SIZE="0.6045112781954888" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.2084372006850578" LOG_CI_START="-0.6456283851223268" LOG_EFFECT_SIZE="-0.21859559221863448" ORDER="674" O_E="0.0" SE="0.5016823527960907" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.25168518310702126" WEIGHT="85.58290680585019"/>
<DICH_DATA CI_END="22.148235571610005" CI_START="0.1838504273633108" EFFECT_SIZE="2.017910447761194" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.345339134078935" LOG_CI_START="-0.7355353562693536" LOG_EFFECT_SIZE="0.3049018889047907" ORDER="675" O_E="0.0" SE="1.222315976125436" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="1.4940563454914777" WEIGHT="14.417093194149823"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.5027977229032947" CI_END="2.919273550727306" CI_START="-2.8314613348457662" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04390610794076976" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.29" MODIFIED="2009-09-18 15:54:25 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.4774531185067884" P_Q="1.0" P_Z="0.9761243659484478" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="727" TOTAL_2="709" UNITS="" WEIGHT="100.0" Z="0.029928136830345755">
<NAME>Adverse effects: 8d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.173309520309012" CI_START="-6.373309520309011" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="6.8" ORDER="676" SD_1="36.9" SD_2="45.9" SE="3.200726936715203" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" WEIGHT="21.008414152172936"/>
<CONT_DATA CI_END="125.37575562911752" CI_START="-14.37575562911752" EFFECT_SIZE="55.5" ESTIMABLE="YES" MEAN_1="32.2" MEAN_2="-23.3" ORDER="677" SD_1="111.1" SD_2="44.0" SE="35.651550834754396" STUDY_ID="STD-McEvoy-2006" TOTAL_1="11" TOTAL_2="13" WEIGHT="0.16932990601737266"/>
<CONT_DATA CI_END="3.271033055432765" CI_START="-6.071033055432766" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="6.2" ORDER="678" SD_1="10.34" SD_2="11.08" SE="2.3832239226216796" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="37.89315974227929"/>
<CONT_DATA CI_END="16.9237628145372" CI_START="-6.9237628145371986" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="-0.2" ORDER="679" SD_1="43.9" SD_2="41.9" SE="6.083664245154665" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" WEIGHT="5.815138260182465"/>
<CONT_DATA CI_END="5.452364968668128" CI_START="-4.252364968668127" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="3.9" ORDER="680" SD_1="26.0" SD_2="26.7" SE="2.4757419049242553" STUDY_ID="STD-Zhong-2006" TOTAL_1="234" TOTAL_2="220" WEIGHT="35.11395793934794"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.8162629069177703" CI_END="1.2232676602025816" CI_START="0.8753052771953593" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0347621168161014" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="176" I2="0.0" I2_Q="0.0" ID="CMP-005.30" LOG_CI_END="0.0875214943466839" LOG_CI_START="-0.057840453173186236" LOG_EFFECT_SIZE="0.014840520586748795" METHOD="MH" MODIFIED="2009-09-18 15:54:52 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.7015247598971324" P_Q="0.0" P_Z="0.6890096192585589" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="976" TOTAL_2="966" WEIGHT="100.0" Z="0.40019945189406536">
<NAME>Adverse effects: 8e. Metabolic - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2432280864509295" CI_START="0.5771738569691379" EFFECT_SIZE="0.8470883954754922" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="49" LOG_CI_END="0.09455081295367818" LOG_CI_START="-0.2386933484572228" LOG_EFFECT_SIZE="-0.07207126775177232" ORDER="712" O_E="0.0" SE="0.19574926999796635" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="337" VAR="0.03831777670473673" WEIGHT="19.027265033222147"/>
<DICH_DATA CI_END="5.838474302896339" CI_START="0.15053697325755022" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.766299373071226" LOG_CI_START="-0.8223568202717129" LOG_EFFECT_SIZE="-0.02802872360024354" ORDER="713" O_E="0.0" SE="0.9331845119446279" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" VAR="0.8708333333333333" WEIGHT="0.8372239152285375"/>
<DICH_DATA CI_END="1.4469806377962307" CI_START="0.9265640372690692" EFFECT_SIZE="1.1578947368421053" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="67" LOG_CI_END="0.16046271981667778" LOG_CI_START="-0.03312456007792324" LOG_EFFECT_SIZE="0.0636690798693773" ORDER="714" O_E="0.0" SE="0.11371412648257895" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.012930902561695962" WEIGHT="56.38295465968062"/>
<DICH_DATA CI_END="2.962530046824247" CI_START="0.037505479895543745" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47166276377893485" LOG_CI_START="-1.42590527321826" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="715" O_E="0.0" SE="1.1146408580454255" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="1.2424242424242424" WEIGHT="0.586822494240978"/>
<DICH_DATA CI_END="1.7615194931512803" CI_START="0.3434184372962746" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2458874534901221" LOG_CI_START="-0.4641763923402581" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="716" O_E="0.0" SE="0.4170950179134893" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.17396825396825394" WEIGHT="4.190893891352705"/>
<DICH_DATA CI_END="2.1875008537562324" CI_START="0.5191894752098096" EFFECT_SIZE="1.0657051282051282" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3399482311944872" LOG_CI_START="-0.28467411995312597" LOG_EFFECT_SIZE="0.027637055620680608" ORDER="717" O_E="0.0" SE="0.36690626099461215" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="95" VAR="0.13462020435704647" WEIGHT="5.415847467525321"/>
<DICH_DATA CI_END="1.542725578678395" CI_START="0.6216202474486862" EFFECT_SIZE="0.97928007023705" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" LOG_CI_END="0.18828868026603182" LOG_CI_START="-0.2064748481131482" LOG_EFFECT_SIZE="-0.009093083923558174" ORDER="718" O_E="0.0" SE="0.23188605068091134" STUDY_ID="STD-Zhong-2006" TOTAL_1="335" TOTAL_2="338" VAR="0.053771140500390176" WEIGHT="13.558992538749687"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="32.89129827091945" CI_END="1.0435236472756637" CI_START="-2.466945344774574" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7117108487494553" ESTIMABLE="YES" I2="81.7580931267014" I2_Q="0.0" ID="CMP-005.31" MODIFIED="2009-09-18 15:55:41 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="1.1003146446864065E-5" P_Q="1.0" P_Z="0.4267738595903803" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="3.5519836623593632" TOTALS="YES" TOTAL_1="710" TOTAL_2="736" UNITS="" WEIGHT="100.0" Z="0.7947243710822122">
<NAME>Adverse effects: 8f. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.6479798097092315" CI_START="-5.092020190290769" EFFECT_SIZE="-3.87" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="4.41" ORDER="719" SD_1="0.72" SD_2="2.21" SE="0.6234911457199764" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="20.35157357382552"/>
<CONT_DATA CI_END="7.034170825607917" CI_START="-5.934170825607917" EFFECT_SIZE="0.5499999999999999" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-1.2" ORDER="720" SD_1="2.43" SD_2="11.22" SE="3.3083112122234026" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" WEIGHT="5.532211360103889"/>
<CONT_DATA CI_END="1.007606390170189" CI_START="-1.2076063901701892" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.5" ORDER="721" SD_1="6.9" SD_2="7.0" SE="0.5651156852405692" STUDY_ID="STD-Lieberman-2005" TOTAL_1="300" TOTAL_2="305" WEIGHT="20.716331962031873"/>
<CONT_DATA CI_END="6.479106088298401" CI_START="-3.8791060882984016" EFFECT_SIZE="1.3" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="0.5" ORDER="722" SD_1="5.2" SD_2="8.91" SE="2.642449621090249" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="15" WEIGHT="7.613059187097879"/>
<CONT_DATA CI_END="5.5970403541450375" CI_START="-4.0170403541450375" EFFECT_SIZE="0.79" ESTIMABLE="YES" MEAN_1="6.48" MEAN_2="5.69" MODIFIED="2008-12-12 13:32:23 +0000" MODIFIED_BY="[Empty name]" ORDER="723" SD_1="10.58" SD_2="11.47" SE="2.452616676664652" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="8.382704594896463"/>
<CONT_DATA CI_END="1.0365986376359533" CI_START="-3.4565986376359534" EFFECT_SIZE="-1.2100000000000002" ESTIMABLE="YES" MEAN_1="1.72" MEAN_2="2.93" ORDER="724" SD_1="3.57" SD_2="4.02" SE="1.1462448572304578" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="16.482171031876607"/>
<CONT_DATA CI_END="1.5195370005905755" CI_START="-0.5595370005905751" EFFECT_SIZE="0.4800000000000002" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="1.64" ORDER="725" SD_1="6.68" SD_2="6.66" SE="0.5303857666724034" STUDY_ID="STD-Zhong-2006" TOTAL_1="309" TOTAL_2="324" WEIGHT="20.921948290167766"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-11-23 15:38:57 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>RISPERIDONE versus SERTINDOLE - all data short term</NAME>
<DICH_OUTCOME CHI2="3.3241766200704164E-30" CI_END="1.4021131270775895" CI_START="0.9233576698124504" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1378277153558052" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="60" I2="100.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.1467830553449724" LOG_CI_START="-0.03463003902058785" LOG_EFFECT_SIZE="0.056076508162192285" METHOD="MH" MODIFIED="2009-09-21 09:02:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.22563227199902303" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="98" WEIGHT="100.0" Z="1.2116869155562826">
<NAME>Global state - 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4021131270775895" CI_START="0.9233576698124504" EFFECT_SIZE="1.1378277153558052" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="60" LOG_CI_END="0.1467830553449724" LOG_CI_START="-0.03463003902058785" LOG_EFFECT_SIZE="0.056076508162192285" ORDER="733" O_E="0.0" SE="0.10656294963963012" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.011355662235898343" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.680962365284947" CI_START="0.9079503446003689" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.235406960811181" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.22555799021993408" LOG_CI_START="-0.04193790220109291" LOG_EFFECT_SIZE="0.09181004400942061" METHOD="MH" MODIFIED="2009-09-21 09:26:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.1784963538590428" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="98" WEIGHT="100.0" Z="1.3453991988353755">
<NAME>Global state - 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.680962365284947" CI_START="0.907950344600369" EFFECT_SIZE="1.235406960811181" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" LOG_CI_END="0.22555799021993408" LOG_CI_START="-0.04193790220109286" LOG_EFFECT_SIZE="0.09181004400942061" MODIFIED="2009-09-21 09:03:10 +0100" MODIFIED_BY="[Empty name]" ORDER="900" O_E="0.0" SE="0.15712841133413397" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.0246893376483888" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.461401772397343" CI_END="0.9852243092833641" CI_START="0.6367744132808522" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7920641586979852" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="187" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.006464880980947739" LOG_CI_START="-0.19601439563814213" LOG_EFFECT_SIZE="-0.10123963830954492" METHOD="MH" MODIFIED="2009-09-21 09:03:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9934685219439187" P_Q="0.0" P_Z="0.03629034773616665" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="582" TOTAL_2="942" WEIGHT="300.0" Z="2.0936592241180745">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0394681726448944" CI_END="1.0587914504200389" CI_START="0.626012534600472" DF="1" EFFECT_SIZE="0.8141355657940258" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="113" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.024810425781567152" LOG_CI_START="-0.20341697085775237" LOG_EFFECT_SIZE="-0.08930327253809263" MODIFIED="2009-09-21 09:03:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8425241269169623" P_Z="0.12507108376143722" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="314" WEIGHT="100.0" Z="1.5338316122742963">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="1.1694708754587975" CI_START="0.5344038473777097" EFFECT_SIZE="0.7905502736963411" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" LOG_CI_END="0.06798941059576455" LOG_CI_START="-0.27213042386916036" LOG_EFFECT_SIZE="-0.10207050663669791" ORDER="727" O_E="0.0" SE="0.1997880743850306" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.03991527466647852" WEIGHT="45.026857162015745"/>
<DICH_DATA CI_END="1.1886731387193232" CI_START="0.5851207846417513" EFFECT_SIZE="0.833976833976834" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="74" LOG_CI_END="0.0750624487599734" LOG_CI_START="-0.23275447462061524" LOG_EFFECT_SIZE="-0.07884601293032092" ORDER="728" O_E="0.0" SE="0.18081318451210268" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="0.03269340769340769" WEIGHT="54.97314283798425"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2332909267835838" CI_END="1.3549081725355019" CI_START="0.38900558859834705" DF="1" EFFECT_SIZE="0.7259936991144507" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="0.13190986235986663" LOG_CI_START="-0.4100441593941141" LOG_EFFECT_SIZE="-0.13906714851712376" MODIFIED="2009-09-21 09:03:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.629094343195289" P_Z="0.31447997517919635" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="314" WEIGHT="99.99999999999999" Z="1.0058661494719072">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.8661407117478537" CI_START="0.3654687748262162" EFFECT_SIZE="0.8258426966292135" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.27094438755176553" LOG_CI_START="-0.4371497226732013" LOG_EFFECT_SIZE="-0.08310266756071787" ORDER="729" O_E="0.0" SE="0.415937985468521" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.17300440775561157" WEIGHT="58.57913073978514"/>
<DICH_DATA CI_END="1.5952363498024527" CI_START="0.22948062971789715" EFFECT_SIZE="0.6050420168067226" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="0.20282503711775765" LOG_CI_START="-0.6392539670402823" LOG_EFFECT_SIZE="-0.2182144649612623" ORDER="730" O_E="0.0" SE="0.49464137540072967" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="0.2446700902583256" WEIGHT="41.42086926021484"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0391163870820889" CI_END="1.2537497633266166" CI_START="0.4580629133744931" DF="1" EFFECT_SIZE="0.757823376013152" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="45" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="0.09821086404565967" LOG_CI_START="-0.3390748690377492" LOG_EFFECT_SIZE="-0.1204320024960448" MODIFIED="2009-09-21 09:03:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8432183540986842" P_Z="0.28032942773197944" STUDIES="2" TAU2="0.0" TOTAL_1="194" TOTAL_2="314" WEIGHT="100.0" Z="1.079579641503019">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="2.026265911731485" CI_START="0.23374145036770513" EFFECT_SIZE="0.6882022471910112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.3066964382699205" LOG_CI_START="-0.631264265486606" LOG_EFFECT_SIZE="-0.16228391360834274" ORDER="731" O_E="0.0" SE="0.5509627603669482" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.3035599633111672" WEIGHT="21.73508429597368"/>
<DICH_DATA CI_END="1.3751045525398158" CI_START="0.4406013337734268" EFFECT_SIZE="0.7783783783783784" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="37" LOG_CI_END="0.13833571988619453" LOG_CI_START="-0.3559541925017228" LOG_EFFECT_SIZE="-0.10880923630776412" ORDER="732" O_E="0.0" SE="0.29034834131119003" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="0.08430215930215931" WEIGHT="78.26491570402632"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3241766200704164E-30" CI_END="1.4021131270775895" CI_START="0.9233576698124504" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1378277153558052" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="60" I2="100.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.1467830553449724" LOG_CI_START="-0.03463003902058785" LOG_EFFECT_SIZE="0.056076508162192285" METHOD="MH" MODIFIED="2009-09-21 09:27:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.22563227199902303" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="98" WEIGHT="100.0" Z="1.2116869155562826">
<NAME>Mental state: 1a. General - no clinically important change (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4021131270775895" CI_START="0.9233576698124504" EFFECT_SIZE="1.1378277153558052" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="60" LOG_CI_END="0.1467830553449724" LOG_CI_START="-0.03463003902058785" LOG_EFFECT_SIZE="0.056076508162192285" MODIFIED="2009-09-21 09:05:28 +0100" MODIFIED_BY="[Empty name]" ORDER="901" O_E="0.0" SE="0.10656294963963012" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.011355662235898343" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.586413110462338" CI_END="8.238716666411477" CI_START="-12.19798147122006" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.979632402404291" ESTIMABLE="YES" I2="82.09942622884115" I2_Q="0.0" ID="CMP-006.05" MODIFIED="2010-11-23 15:37:24 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.018100440392379236" P_Q="1.0" P_Z="0.7041607779975712" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="44.74156011307912" TOTALS="YES" TOTAL_1="187" TOTAL_2="306" UNITS="" WEIGHT="100.0" Z="0.3797098910216206">
<NAME>Mental state: 1b. General - average endpoint score (PANSS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.420033648427935" CI_START="-3.4200336484279354" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="-25.8" MEAN_2="-29.3" MODIFIED="2009-09-21 09:06:11 +0100" MODIFIED_BY="[Empty name]" ORDER="902" SD_1="22.4" SD_2="23.9" SE="3.530694289799342" STUDY_ID="STD-Azorin-2006" TOTAL_1="82" TOTAL_2="90" WEIGHT="47.51309959382864"/>
<CONT_DATA CI_END="-1.737900526919539" CI_START="-12.142099473080464" EFFECT_SIZE="-6.940000000000001" ESTIMABLE="YES" MEAN_1="-19.01" MEAN_2="-12.07" MODIFIED="2009-09-21 09:06:11 +0100" MODIFIED_BY="[Empty name]" ORDER="903" SD_1="22.31" SD_2="22.31" SE="2.6541811554263033" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" WEIGHT="52.486900406171365"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.9547915239311906" CI_START="-1.354791523931191" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2010-11-23 15:37:36 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.46681731820092953" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="90" UNITS="" WEIGHT="100.0" Z="0.7276672337987689">
<NAME>Mental state: 2. Positive symptoms - average endpoint score (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.9547915239311906" CI_START="-1.354791523931191" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-8.0" MODIFIED="2009-09-21 09:06:47 +0100" MODIFIED_BY="[Empty name]" ORDER="904" SD_1="6.5" SD_2="7.9" SE="1.0994036323768759" STUDY_ID="STD-Azorin-2006" TOTAL_1="82" TOTAL_2="90" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.131586052965953" CI_START="-0.5315860529659531" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.07" MODIFIED="2010-11-23 15:37:49 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.16418950620163214" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="90" UNITS="" WEIGHT="100.0" Z="1.3911184657559923">
<NAME>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.131586052965953" CI_START="-0.5315860529659531" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-7.7" MODIFIED="2009-09-21 09:27:41 +0100" MODIFIED_BY="[Empty name]" ORDER="905" SD_1="6.4" SD_2="5.8" SE="0.9344998517387411" STUDY_ID="STD-Azorin-2006" TOTAL_1="82" TOTAL_2="90" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.407392988932457" CI_START="-2.607392988932454" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.900000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.08" MODIFIED="2010-11-23 15:38:21 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.30204950742149705" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="1.0320482970052076">
<NAME>General functioning: General - average endpoint score - (GAF total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.407392988932457" CI_START="-2.607392988932454" EFFECT_SIZE="2.900000000000002" ESTIMABLE="YES" MEAN_1="-18.2" MEAN_2="-21.1" MODIFIED="2009-09-22 10:37:54 +0100" MODIFIED_BY="[Empty name]" ORDER="897" SD_1="14.3" SD_2="15.7" SE="2.8099460155258305" STUDY_ID="STD-Azorin-2006" TOTAL_1="55" TOTAL_2="59" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3298066848722251" CI_END="1.0516292571179593" CI_START="0.8997569337729756" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9727336304715732" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="269" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.021862660001970968" LOG_CI_START="-0.04587479787011746" LOG_EFFECT_SIZE="-0.012006068934073254" METHOD="MH" MODIFIED="2009-09-21 09:29:22 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5657730908385454" P_Q="0.0" P_Z="0.4871904642168948" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="314" WEIGHT="100.00000000000001" Z="0.6947843466793291">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.074120965926819" CI_START="0.8293261605038864" EFFECT_SIZE="0.9438202247191011" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="84" LOG_CI_END="0.03105319372499559" LOG_CI_START="-0.08127463489105784" LOG_EFFECT_SIZE="-0.025110720583031137" ORDER="741" O_E="0.0" SE="0.065981922560789" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.004353614104817957" WEIGHT="36.36495549568713"/>
<DICH_DATA CI_END="1.0912892295976562" CI_START="0.8974816788236852" EFFECT_SIZE="0.9896525096525096" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="185" LOG_CI_END="0.03793986898538754" LOG_CI_START="-0.04697440833960399" LOG_EFFECT_SIZE="-0.004517269677108208" ORDER="742" O_E="0.0" SE="0.049879066833151825" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="0.0024879213081460266" WEIGHT="63.63504450431289"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="79.97988349547715" CI_START="0.13615923809911312" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="1.9029807671729937" LOG_CI_START="-0.8659528874172187" LOG_EFFECT_SIZE="0.5185139398778874" METHOD="MH" MODIFIED="2009-09-21 09:30:45 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.4629179306033492" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="98" WEIGHT="100.0" Z="0.7340505583858266">
<NAME>Adverse effects: 2. Death - suicide</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.97988349547715" CI_START="0.13615923809911312" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9029807671729937" LOG_CI_START="-0.8659528874172187" LOG_EFFECT_SIZE="0.5185139398778874" MODIFIED="2009-09-21 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="906" O_E="0.0" SE="1.6264853351489357" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="2.6454545454545455" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.012885773338566994" CI_END="0.514684541091616" CI_START="0.08211262855462685" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2055774806379931" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="-0.2884588758909457" LOG_CI_START="-1.0855900451969958" LOG_EFFECT_SIZE="-0.6870244605439707" METHOD="MH" MODIFIED="2009-09-21 09:29:31 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9096218610647775" P_Q="0.0" P_Z="7.288950149527516E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="314" WEIGHT="100.0" Z="3.3784733329057697">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5585302546404056" CI_START="0.07176291246213584" EFFECT_SIZE="0.20020429009193055" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" LOG_CI_END="-0.2529532969127347" LOG_CI_START="-1.144099943980589" LOG_EFFECT_SIZE="-0.6985266204466618" ORDER="743" O_E="0.0" SE="0.5234639517347042" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.27401450876571265" WEIGHT="80.01312407220907"/>
<DICH_DATA CI_END="1.7804682690279097" CI_START="0.02934334684195639" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="0.25053423821309173" LOG_CI_START="-1.5324903529297558" LOG_EFFECT_SIZE="-0.640978057358332" ORDER="744" O_E="0.0" SE="1.0473574709513807" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="1.0969576719576721" WEIGHT="19.986875927790937"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.0164058226266906E-29" CI_END="-14.83340631759832" CI_START="-22.366593682401692" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.600000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.12" MODIFIED="2009-09-21 09:29:35 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.9999999999999964" P_Q="1.0" P_Z="3.717945530716696E-22" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="188" TOTAL_2="307" UNITS="" WEIGHT="99.99999999999999" Z="9.678593760397344">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-10.264105445812008" CI_START="-26.93589455418804" EFFECT_SIZE="-18.600000000000023" ESTIMABLE="YES" MEAN_1="411.0" MEAN_2="429.6" ORDER="745" SD_1="27.0" SD_2="29.1" SE="4.253085577051664" STUDY_ID="STD-Azorin-2006" TOTAL_1="83" TOTAL_2="91" WEIGHT="20.417056124145862"/>
<CONT_DATA CI_END="-14.377800271076019" CI_START="-22.822199728923984" EFFECT_SIZE="-18.6" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="22.7" ORDER="746" SD_1="15.6" SD_2="22.4" SE="2.1542231195206423" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" WEIGHT="79.58294387585413"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.1813356040516522" CI_END="1.917831135093436" CI_START="0.6938990969009858" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1535949430584063" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-006.13" LOG_CI_END="0.28281036491719097" LOG_CI_START="-0.1587036777369464" LOG_EFFECT_SIZE="0.06205334359012225" METHOD="MH" MODIFIED="2009-09-21 09:29:53 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6702279531307871" P_Q="0.0" P_Z="0.5816796364902739" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="314" WEIGHT="100.0" Z="0.5509329570846863">
<NAME>Adverse effects: 4. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.549083858599889" CI_START="0.3641699623275021" EFFECT_SIZE="0.9634831460674157" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40638412292636134" LOG_CI_START="-0.4386958787865707" LOG_EFFECT_SIZE="-0.016155877930104697" ORDER="762" O_E="0.0" SE="0.4964041762196507" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.24641710616831003" WEIGHT="27.295647016402462"/>
<DICH_DATA CI_END="2.240356102827138" CI_START="0.6800085140783279" EFFECT_SIZE="1.2342857142857142" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" LOG_CI_END="0.3503170545846717" LOG_CI_START="-0.16748564965539883" LOG_EFFECT_SIZE="0.09141570246463643" ORDER="763" O_E="0.0" SE="0.30415987163534164" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="0.09251322751322752" WEIGHT="72.70435298359753"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.016267484753887" CI_END="2.6718724400614775" CI_START="1.223566530199957" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8080967038913915" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="39" I2="40.194576762144315" I2_Q="0.0" ID="CMP-006.14" LOG_CI_END="0.42681572030807224" LOG_CI_START="0.08762758865566585" LOG_EFFECT_SIZE="0.25722165448186907" METHOD="MH" MODIFIED="2009-09-21 09:30:21 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.1706100060459539" P_Q="0.0" P_Z="0.002952330867095364" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1277901923789246" TOTALS="SUB" TOTAL_1="388" TOTAL_2="628" WEIGHT="400.0" Z="2.9726581314755887">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.916185905924127" CI_START="1.0244192447624973" DF="0" EFFECT_SIZE="2.244155844155844" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-006.14.01" LOG_CI_END="0.6916282974020542" LOG_CI_START="0.010477728538730875" LOG_EFFECT_SIZE="0.3510530129703926" MODIFIED="2009-09-21 09:30:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04335623136041216" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="216" WEIGHT="100.0" Z="2.0202618731844684">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="4.916185905924127" CI_START="1.0244192447624976" EFFECT_SIZE="2.244155844155844" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.6916282974020542" LOG_CI_START="0.01047772853873097" LOG_EFFECT_SIZE="0.3510530129703926" ORDER="749" O_E="0.0" SE="0.40011121590001086" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="0.16008898508898511" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.607570683627924" CI_START="0.8969558268908847" DF="0" EFFECT_SIZE="1.529338327091136" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" I2="0.0" ID="CMP-006.14.02" LOG_CI_END="0.4162360897135271" LOG_CI_START="-0.047228944480899995" LOG_EFFECT_SIZE="0.1845035726163136" MODIFIED="2009-09-21 09:30:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.11863997207318926" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="98" WEIGHT="100.0" Z="1.5605076140231227">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="2.6075706836279244" CI_START="0.8969558268908848" EFFECT_SIZE="1.529338327091136" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.41623608971352716" LOG_CI_START="-0.04722894448089994" LOG_EFFECT_SIZE="0.1845035726163136" ORDER="750" O_E="0.0" SE="0.27224165527472594" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.07411551886672273" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.732379964658843" CI_START="1.442788845039568" DF="0" EFFECT_SIZE="4.114285714285713" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-006.14.03" LOG_CI_END="1.0693861195900107" LOG_CI_START="0.15920277589993706" LOG_EFFECT_SIZE="0.6142944477449739" MODIFIED="2009-09-21 09:30:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.008154381455810223" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="216" WEIGHT="100.0" Z="2.645609814395908">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="11.732379964658843" CI_START="1.4427888450395683" EFFECT_SIZE="4.114285714285714" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="1.0693861195900107" LOG_CI_START="0.15920277589993712" LOG_EFFECT_SIZE="0.614294447744974" ORDER="751" O_E="0.0" SE="0.5346462015637639" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" VAR="0.28584656084656085" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6853079258880843" CI_START="0.16254759386082815" DF="0" EFFECT_SIZE="0.6606741573033708" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-006.14.04" LOG_CI_END="0.42899409370270947" LOG_CI_START="-0.789019454840258" LOG_EFFECT_SIZE="-0.18001268056877429" MODIFIED="2009-09-21 09:30:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5623637866320645" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="98" WEIGHT="100.0" Z="0.5793340658605401">
<NAME>tremor</NAME>
<DICH_DATA CI_END="2.6853079258880843" CI_START="0.16254759386082815" EFFECT_SIZE="0.6606741573033708" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42899409370270947" LOG_CI_START="-0.789019454840258" LOG_EFFECT_SIZE="-0.18001268056877429" ORDER="752" O_E="0.0" SE="0.7154671876784431" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.5118932966445005" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.186941722403892" CI_END="0.4109462955587809" CI_START="0.05748187478438929" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2342140851715851" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.15" MODIFIED="2010-11-23 15:38:57 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6711902615182894" P_Q="0.9163408984028725" P_Z="0.00939217454147898" Q="0.17473373351503607" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="561" TOTAL_2="916" UNITS="" WEIGHT="300.0" Z="2.5974392025233315">
<NAME>Adverse effects: 5b. Extrapyramidal symptom scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.24096467948469674" CI_END="0.8613874900791606" CI_START="-0.24866598269281381" DF="1" EFFECT_SIZE="0.3063607536931734" ESTIMABLE="YES" I2="0.0" ID="CMP-006.15.01" MODIFIED="2010-11-23 15:38:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6235102666743033" P_Z="0.2793189064559509" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="298" WEIGHT="100.0" Z="1.0818506643931938">
<NAME>abnormal involuntary movement: AIMS (high = poor)</NAME>
<CONT_DATA CI_END="1.0934489997029702" CI_START="-0.8934489997029701" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.8" ORDER="753" SD_1="3.3" SD_2="3.0" SE="0.5068710484167919" STUDY_ID="STD-Azorin-2006" TOTAL_1="74" TOTAL_2="82" WEIGHT="31.213082102275518"/>
<CONT_DATA CI_END="1.0692077762322243" CI_START="-0.26920777623222447" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-1.2" ORDER="754" SD_1="2.87" SD_2="2.87" SE="0.34143881291230344" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" WEIGHT="68.78691789772448"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.39375635106273743" CI_END="0.41052556100724585" CI_START="0.030692395481275503" DF="1" EFFECT_SIZE="0.22060897824426068" ESTIMABLE="YES" I2="0.0" ID="CMP-006.15.02" MODIFIED="2010-11-23 15:38:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5303318694735955" P_Z="0.022803338511937207" STUDIES="2" TAU2="0.0" TOTAL_1="191" TOTAL_2="309" WEIGHT="100.0" Z="2.2767135219811014">
<NAME>akathisia: Barnes Akathisia Scale (high = poor)</NAME>
<CONT_DATA CI_END="0.9916292737606246" CI_START="-0.19162927376062455" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.5" ORDER="755" SD_1="2.2" SD_2="1.8" SE="0.3018572169832307" STUDY_ID="STD-Azorin-2006" TOTAL_1="86" TOTAL_2="93" WEIGHT="10.304489122130317"/>
<CONT_DATA CI_END="0.4005291594284715" CI_START="-5.291594284713708E-4" EFFECT_SIZE="0.20000000000000007" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.1" ORDER="756" SD_1="0.86" SD_2="0.86" SE="0.10231267564619546" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" WEIGHT="89.69551087786968"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.3774869583414215" CI_END="1.3494325528038291" CI_START="-0.6072524692511948" DF="1" EFFECT_SIZE="0.3710900417763172" ESTIMABLE="YES" I2="57.9387808420359" ID="CMP-006.15.03" MODIFIED="2010-11-23 15:38:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.12309560056484281" P_Z="0.45722513936157627" STUDIES="2" TAU2="0.2896939042101794" TOTAL_1="191" TOTAL_2="309" WEIGHT="99.99999999999999" Z="0.7434238098671282">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="1.8586128628084517" CI_START="-0.05861286280845135" EFFECT_SIZE="0.9000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.1" ORDER="757" SD_1="3.5" SD_2="3.0" SE="0.48909718258593904" STUDY_ID="STD-Azorin-2006" TOTAL_1="86" TOTAL_2="93" WEIGHT="47.109004177631704"/>
<CONT_DATA CI_END="0.7347609194813115" CI_START="-0.9347609194813112" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.3" ORDER="758" SD_1="3.58" SD_2="3.58" SE="0.4259062544341625" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" WEIGHT="52.89099582236828"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.48290410589422283" CI_END="0.7562192922151588" CI_START="0.15736881036947487" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34497149214731615" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="-0.12135224737058373" LOG_CI_START="-0.8030813382200366" LOG_EFFECT_SIZE="-0.46221679279531014" METHOD="MH" MODIFIED="2009-09-21 09:32:07 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.48710985465802115" P_Q="0.0" P_Z="0.007866728902147378" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="171" TOTAL_2="266" WEIGHT="100.00000000000001" Z="2.657736860838987">
<NAME>Adverse effects: 6. Prolactin associated side effects - sexual dysfunction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0314584560562903" CI_START="0.16277927482445967" DF="0" EFFECT_SIZE="0.4097560975609756" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="25" I2="0.0" ID="CMP-006.16.01" LOG_CI_END="0.013451740628269957" LOG_CI_START="-0.7884008906160154" LOG_EFFECT_SIZE="-0.38747457499387267" MODIFIED="2009-09-21 09:31:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05819794363494315" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="168" WEIGHT="72.28272820947426" Z="1.8942039529994177">
<NAME>abnormal ejaculation</NAME>
<DICH_DATA CI_END="1.0314584560562903" CI_START="0.16277927482445967" EFFECT_SIZE="0.4097560975609756" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="25" LOG_CI_END="0.013451740628269957" LOG_CI_START="-0.7884008906160154" LOG_EFFECT_SIZE="-0.38747457499387267" ORDER="760" O_E="0.0" SE="0.47101220482743283" STUDY_ID="STD-Kane-2005" TOTAL_1="82" TOTAL_2="168" VAR="0.22185249709639954" WEIGHT="72.28272820947426"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.521814453620627E-32" CI_END="0.9779498734045974" CI_START="0.04959244662952558" DF="0" EFFECT_SIZE="0.2202247191011236" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="100.0" ID="CMP-006.16.02" LOG_CI_END="-0.00968340519368001" LOG_CI_START="-1.3045844653831935" LOG_EFFECT_SIZE="-0.6571339352884368" MODIFIED="2009-09-21 09:31:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.04667056909185185" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="98" WEIGHT="27.717271790525754" Z="1.9892776147637308">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="0.9779498734045974" CI_START="0.04959244662952558" EFFECT_SIZE="0.2202247191011236" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.00968340519368001" LOG_CI_START="-1.3045844653831935" LOG_EFFECT_SIZE="-0.6571339352884368" ORDER="761" O_E="0.0" SE="0.760631292618945" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.5785599633111671" WEIGHT="27.717271790525754"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.527093445293737" CI_START="-3.727093445293737" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.8999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.17" MODIFIED="2009-09-21 09:47:14 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.2656154382487256" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="116" UNITS="" WEIGHT="100.0" Z="1.1132165873878828">
<NAME>Adverse effects: 7a. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.527093445293737" CI_START="-3.727093445293737" EFFECT_SIZE="4.8999999999999995" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="3.2" ORDER="747" SD_1="27.3" SD_2="28.4" SE="4.40165916993534" STUDY_ID="STD-Kane-2005" TOTAL_1="60" TOTAL_2="116" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.849222125132677" CI_START="-5.849222125132677" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.18" MODIFIED="2009-09-21 09:48:47 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.6174952485100753" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="116" UNITS="" WEIGHT="100.0" Z="0.4994033684597566">
<NAME>Adverse effects: 7b. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.849222125132677" CI_START="-5.849222125132677" EFFECT_SIZE="1.9999999999999998" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="1.8" ORDER="759" SD_1="20.8" SD_2="32.0" SE="4.0047787546334215" STUDY_ID="STD-Kane-2005" TOTAL_1="60" TOTAL_2="116" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4324921157168307" CI_START="0.4147400520012771" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7707865168539326" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-006.19" LOG_CI_END="0.15609224033569485" LOG_CI_START="-0.38222402221201696" LOG_EFFECT_SIZE="-0.11306589093816106" METHOD="MH" MODIFIED="2009-09-21 09:49:01 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.4103222458729553" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="98" WEIGHT="100.0" Z="0.8233266930110185">
<NAME>Adverse effects: 7c. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4324921157168304" CI_START="0.41474005200127717" EFFECT_SIZE="0.7707865168539326" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.1560922403356948" LOG_CI_START="-0.3822240222120169" LOG_EFFECT_SIZE="-0.11306589093816106" ORDER="764" O_E="0.0" SE="0.31620963732900137" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="98" VAR="0.0999885347397386" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1100484002054074" CI_END="-0.11570760097653043" CI_START="-1.8637932709397989" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9897504359581647" ESTIMABLE="YES" I2="9.913838007878184" I2_Q="0.0" ID="CMP-006.20" MODIFIED="2009-09-21 09:49:17 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.2920714619232272" P_Q="1.0" P_Z="0.026457615298483644" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04015104393190663" TOTALS="YES" TOTAL_1="142" TOTAL_2="186" UNITS="" WEIGHT="100.0" Z="2.219428076658945">
<NAME>Adverse effects: 7d. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.492360125233654" CI_START="-1.6923601252336542" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.1" ORDER="765" SD_1="3.7" SD_2="3.9" SE="0.5573368357021106" STUDY_ID="STD-Azorin-2006" TOTAL_1="89" TOTAL_2="97" WEIGHT="56.69439600464838"/>
<CONT_DATA CI_END="-0.23119984323095366" CI_START="-2.7688001567690463" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.9" ORDER="766" SD_1="3.1" SD_2="4.6" SE="0.6473589141316779" STUDY_ID="STD-Kane-2005" TOTAL_1="53" TOTAL_2="89" WEIGHT="43.305603995351625"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-11-23 17:52:52 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>RISPERIDONE versus ZIPRASIDONE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1193056880241425" CI_START="0.9323986884933944" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0215865873908618" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="127" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.04894871073915799" LOG_CI_START="-0.03039834602713915" LOG_EFFECT_SIZE="0.009275182356009432" METHOD="MH" MODIFIED="2009-09-21 08:45:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.646797667806944" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="0.458215442605842">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1193056880241425" CI_START="0.9323986884933944" EFFECT_SIZE="1.0215865873908618" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="127" LOG_CI_END="0.04894871073915799" LOG_CI_START="-0.03039834602713915" LOG_EFFECT_SIZE="0.009275182356009432" ORDER="776" O_E="0.0" SE="0.04660885391878851" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.002172385263622967" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0430477979668955" CI_START="0.6261440248987669" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.808144879573451" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.01830421055273601" LOG_CI_START="-0.20332575940220404" LOG_EFFECT_SIZE="-0.09251077442473403" METHOD="MH" MODIFIED="2009-09-21 08:50:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.10179337966958013" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="1.636220824207591">
<NAME>Global state: 1b. No clinically important change - short term (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0430477979668955" CI_START="0.6261440248987669" EFFECT_SIZE="0.808144879573451" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="74" LOG_CI_END="0.01830421055273601" LOG_CI_START="-0.20332575940220404" LOG_EFFECT_SIZE="-0.09251077442473403" MODIFIED="2009-09-21 08:46:24 +0100" MODIFIED_BY="[Empty name]" ORDER="895" O_E="0.0" SE="0.13018654143757666" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.016948535571477866" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.559408965019706" CI_END="0.9760502863154815" CI_START="0.8309316724934114" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9005726493991454" ESTIMABLE="YES" EVENTS_1="514" EVENTS_2="470" I2="16.312817776977404" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-0.010527806814104812" LOG_CI_START="-0.08043468678038634" LOG_EFFECT_SIZE="-0.04548124679724559" METHOD="MH" MODIFIED="2009-09-21 08:46:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.29732044767577603" P_Q="0.0" P_Z="0.010763160369702518" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004397415307128541" TOTALS="SUB" TOTAL_1="1674" TOTAL_2="1413" WEIGHT="300.0" Z="2.5502956429345756">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9919105185422912" CI_END="0.9834109585282172" CI_START="0.831886277271053" DF="2" EFFECT_SIZE="0.9044811116422479" ESTIMABLE="YES" EVENTS_1="341" EVENTS_2="308" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="-0.007264956507706512" LOG_CI_START="-0.07993603973013964" LOG_EFFECT_SIZE="-0.04360049811892311" MODIFIED="2009-09-21 08:46:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3693705388230092" P_Z="0.01868077271302861" STUDIES="3" TAU2="0.0" TOTAL_1="558" TOTAL_2="471" WEIGHT="100.0" Z="2.351840711099131">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="1.0995456329599376" CI_START="0.5711315364651888" EFFECT_SIZE="0.7924551638837353" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="55" LOG_CI_END="0.04121325800917415" LOG_CI_START="-0.243263858510293" LOG_EFFECT_SIZE="-0.10102530025055939" ORDER="767" O_E="0.0" SE="0.16710326642797269" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.027923501650898023" WEIGHT="6.525722365954315"/>
<DICH_DATA CI_END="1.0281844694994169" CI_START="0.8479495851040428" EFFECT_SIZE="0.9337283300416941" ESTIMABLE="YES" EVENTS_1="253" EVENTS_2="147" LOG_CI_END="0.012071039657796236" LOG_CI_START="-0.07162996798148037" LOG_EFFECT_SIZE="-0.0297794641618421" ORDER="768" O_E="0.0" SE="0.04916638621398106" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.0024173335333423467" WEIGHT="75.38100007535081"/>
<DICH_DATA CI_END="1.0114672391606858" CI_START="0.682506089339213" EFFECT_SIZE="0.8308625336927223" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="106" LOG_CI_END="0.004951820787347339" LOG_CI_START="-0.16589346948190065" LOG_EFFECT_SIZE="-0.08047082434727663" ORDER="769" O_E="0.0" SE="0.10035536920198233" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="137" VAR="0.010071200127666184" WEIGHT="18.093277558694872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8598877228247237" CI_END="1.3198267967958235" CI_START="0.5047661879409525" DF="2" EFFECT_SIZE="0.8162131712738688" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" I2="30.067184664697564" ID="CMP-007.03.02" LOG_CI_END="0.12051694171243231" LOG_CI_START="-0.29690974426011146" LOG_EFFECT_SIZE="-0.0881964012738396" MODIFIED="2009-09-21 08:46:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23932270450431026" P_Z="0.4075426577888819" STUDIES="3" TAU2="0.05785992662330701" TOTAL_1="558" TOTAL_2="471" WEIGHT="100.0" Z="0.828225774114203">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="3.9961444743706878" CI_START="0.6348717118639968" EFFECT_SIZE="1.5928085519922255" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6016411810774029" LOG_CI_START="-0.19731402346127058" LOG_EFFECT_SIZE="0.20216357880806615" ORDER="770" O_E="0.0" SE="0.46931024203806293" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.22025210328182523" WEIGHT="21.618016748465447"/>
<DICH_DATA CI_END="1.0509491726531572" CI_START="0.4129474204789275" EFFECT_SIZE="0.658776707163804" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="28" LOG_CI_END="0.021581712631437877" LOG_CI_START="-0.3841052424103339" LOG_EFFECT_SIZE="-0.18126176488944798" ORDER="771" O_E="0.0" SE="0.23830252557435172" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.05678809369511456" WEIGHT="52.440770488147976"/>
<DICH_DATA CI_END="1.6328002222271065" CI_START="0.31842039854561577" EFFECT_SIZE="0.7210526315789474" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="0.21293305081629404" LOG_CI_START="-0.4969991184091384" LOG_EFFECT_SIZE="-0.14203303379642218" ORDER="772" O_E="0.0" SE="0.41701767042393334" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="137" VAR="0.17390373744580429" WEIGHT="25.941212763386584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9164891533394455" CI_END="1.2729948898565193" CI_START="0.6038418616190797" DF="2" EFFECT_SIZE="0.876748312871223" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="108" I2="48.93385576480727" ID="CMP-007.03.03" LOG_CI_END="0.10482666028243007" LOG_CI_START="-0.21907678260146457" LOG_EFFECT_SIZE="-0.05712506115951725" MODIFIED="2009-09-21 08:46:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14110606800679448" P_Z="0.4893543901955403" STUDIES="3" TAU2="0.05337264509412285" TOTAL_1="558" TOTAL_2="471" WEIGHT="100.0" Z="0.6913360444114551">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="1.0755419248185263" CI_START="0.2842023429106639" EFFECT_SIZE="0.5528756957328386" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="0.031627343930795256" LOG_CI_START="-0.5463723461517622" LOG_EFFECT_SIZE="-0.2573725011104835" ORDER="773" O_E="0.0" SE="0.3395198790991041" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.11527374830347026" WEIGHT="21.464920022689576"/>
<DICH_DATA CI_END="1.5332302491192051" CI_START="0.8211164478836476" EFFECT_SIZE="1.1220341242335377" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="44" LOG_CI_END="0.18560737886822773" LOG_CI_START="-0.08559524837738329" LOG_EFFECT_SIZE="0.05000606524542222" ORDER="774" O_E="0.0" SE="0.1593057657187279" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.02537832699123022" WEIGHT="45.96744967758513"/>
<DICH_DATA CI_END="1.3435481399720206" CI_START="0.5236465561500229" EFFECT_SIZE="0.8387755102040816" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="42" LOG_CI_END="0.12825323202683558" LOG_CI_START="-0.2809617483317245" LOG_EFFECT_SIZE="-0.07635425815244447" ORDER="775" O_E="0.0" SE="0.24037490510944018" STUDY_ID="STD-Stroup-2006" TOTAL_1="70" TOTAL_2="137" VAR="0.05778009500637237" WEIGHT="32.567630299725295"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1193056880241425" CI_START="0.9323986884933944" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0215865873908618" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="127" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.04894871073915799" LOG_CI_START="-0.03039834602713915" LOG_EFFECT_SIZE="0.009275182356009432" METHOD="MH" MODIFIED="2009-09-21 09:04:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.646797667806944" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="0.458215442605842">
<NAME>Mental state: 1a. General - no clinically important change - short term (less than 50% PANSS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1193056880241425" CI_START="0.9323986884933944" EFFECT_SIZE="1.0215865873908618" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="127" LOG_CI_END="0.04894871073915799" LOG_CI_START="-0.03039834602713915" LOG_EFFECT_SIZE="0.009275182356009432" MODIFIED="2009-09-21 08:47:28 +0100" MODIFIED_BY="[Empty name]" ORDER="896" O_E="0.0" SE="0.04660885391878851" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.002172385263622967" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.611510073537001" CI_END="-0.26705518909613435" CI_START="-7.547149926965239" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.9071025580306866" ESTIMABLE="YES" I2="64.3589697997392" I2_Q="64.3589697997392" ID="CMP-007.05" MODIFIED="2010-11-23 17:51:16 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.06046115452146317" P_Q="0.06046115452146317" P_Z="0.035399525645567226" Q="5.611510073537001" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="6.4801319975605765" TOTALS="YES" TOTAL_1="549" TOTAL_2="467" UNITS="" WEIGHT="100.0" Z="2.1037584189147265">
<NAME>Mental state: 1b. General - average endpoint score (PANSS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16327862004404503" CI_START="-3.163278620044045" DF="0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" MODIFIED="2009-09-21 08:48:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07713436743343303" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="149" WEIGHT="47.90350557240187" Z="1.7675607329890581">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.16327862004404503" CI_START="-3.163278620044045" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-25.8" ORDER="779" SD_1="7.3" SD_2="7.3" SE="0.8486271345615402" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" WEIGHT="47.90350557240187"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.23692355042586E-32" CI_END="0.17099874211866783" CI_START="-12.770998742118666" DF="0" EFFECT_SIZE="-6.299999999999999" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-007.05.02" MODIFIED="2009-09-21 08:48:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.056369099295503544" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="135" WEIGHT="19.845054946900223" Z="1.9081711486408912">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.17099874211866695" CI_START="-12.770998742118667" EFFECT_SIZE="-6.3" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-1.7" ORDER="780" SD_1="22.31" SD_2="22.31" SE="3.301590637971452" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="135" WEIGHT="19.845054946900223"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.9863068793990255" CI_START="-10.033693120600976" DF="0" EFFECT_SIZE="-6.010000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.03" MODIFIED="2009-09-21 08:48:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.003416930702312155" STUDIES="1" TAU2="0.0" TOTAL_1="333" TOTAL_2="183" WEIGHT="32.25143948069791" Z="2.9275054518388246">
<NAME>long term</NAME>
<CONT_DATA CI_END="-1.9863068793990255" CI_START="-10.033693120600976" EFFECT_SIZE="-6.010000000000001" ESTIMABLE="YES" MEAN_1="-9.31" MEAN_2="-3.3" ORDER="781" SD_1="22.31" SD_2="22.31" SE="2.0529423766657717" STUDY_ID="STD-Lieberman-2005" TOTAL_1="333" TOTAL_2="183" WEIGHT="32.25143948069791"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.925036006150788" CI_START="-4.32503600615079" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2010-11-23 17:51:28 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.7050799579849456" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="149" UNITS="" WEIGHT="100.0" Z="0.3784720446500775">
<NAME>Mental state: 1c. General - avergae endpoint score - short term (BPRS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.925036006150788" CI_START="-4.32503600615079" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" MEAN_1="-15.9" MEAN_2="-15.2" MODIFIED="2009-09-21 08:49:03 +0100" MODIFIED_BY="[Empty name]" ORDER="897" SD_1="15.91" SD_2="15.91" SE="1.849542152174535" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.3826404833049635" CI_START="-4.6173595166950365" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.07" MODIFIED="2010-11-23 17:51:39 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.02065891451782499" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="135" UNITS="" WEIGHT="100.0" Z="2.3141605961175413">
<NAME>Mental state: 2a. Positive symptoms - average endpoint score - medium term (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3826404833049635" CI_START="-4.6173595166950365" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="0.2" MODIFIED="2009-09-21 08:50:13 +0100" MODIFIED_BY="[Empty name]" ORDER="898" SD_1="7.3" SD_2="7.3" SE="1.080305318565289" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="135" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.153919128702248" CI_START="-1.153919128702248" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.08" MODIFIED="2010-11-23 17:52:01 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.13396997561019597" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="149" UNITS="" WEIGHT="100.0" Z="1.4986287283182487">
<NAME>Mental State: 2b. Positive symptoms - average endpoint score - short term (BPRS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.153919128702248" CI_START="-1.153919128702248" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-5.5" MODIFIED="2009-09-21 08:51:31 +0100" MODIFIED_BY="[Empty name]" ORDER="899" SD_1="2.87" SD_2="2.87" SE="0.3336383392043316" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.006724677019308771" CI_END="1.1228915085476252" CI_START="-1.1992117166121175" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.038160104032246046" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.09" MODIFIED="2010-11-23 17:52:12 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9346434309841969" P_Q="0.9346434309841969" P_Z="0.9486375303788259" Q="0.006724677019308771" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="216" TOTAL_2="284" UNITS="" WEIGHT="100.0" Z="0.06441783357357751">
<NAME>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4764445832719744" CI_START="-1.4764445832719744" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.09.01" MODIFIED="2009-09-21 08:52:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="149" WEIGHT="61.83989596775399" Z="0.0">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.4764445832719744" CI_START="-1.4764445832719744" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-6.4" ORDER="785" SD_1="6.48" SD_2="6.48" SE="0.7533018947888741" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" WEIGHT="61.83989596775399"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.779519132627923" CI_START="-1.9795191326279231" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-007.09.02" MODIFIED="2009-09-21 08:52:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9169470885657844" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="135" WEIGHT="38.16010403224601" Z="0.10428007624480289">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.7795191326279232" CI_START="-1.9795191326279233" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.4" ORDER="786" SD_1="6.48" SD_2="6.48" SE="0.9589559540141198" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="135" WEIGHT="38.16010403224601"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.13412399066435585" CI_END="1.2173873092577923" CI_START="0.6278089698214919" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8742349069322802" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-007.10" LOG_CI_END="0.08542877010629503" LOG_CI_START="-0.20217248360866089" LOG_EFFECT_SIZE="-0.058371856751182886" METHOD="MH" MODIFIED="2009-09-21 08:52:37 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7141939829696425" P_Q="0.0" P_Z="0.4262687858964187" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="445" TOTAL_2="322" WEIGHT="100.0" Z="0.7955927553531408">
<NAME>Service use: Number of patients rehospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7306769785002292" CI_START="0.5303383616763973" DF="0" EFFECT_SIZE="0.958041958041958" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" I2="0.0" ID="CMP-007.10.01" LOG_CI_END="0.23821601672234577" LOG_CI_START="-0.2754469573396558" LOG_EFFECT_SIZE="-0.01861547030865505" MODIFIED="2009-09-21 08:52:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8870320892934932" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="137" WEIGHT="31.349096293781948" Z="0.14206066312980792">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.7306769785002292" CI_START="0.5303383616763973" EFFECT_SIZE="0.958041958041958" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.23821601672234577" LOG_CI_START="-0.2754469573396558" LOG_EFFECT_SIZE="-0.01861547030865505" ORDER="787" O_E="0.0" SE="0.301728173636749" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" VAR="0.09103989076616813" WEIGHT="31.349096293781948"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2503419243482732" CI_START="0.562235647548889" DF="0" EFFECT_SIZE="0.8384430818448414" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="33" I2="0.0" ID="CMP-007.10.02" LOG_CI_END="0.09702879344937368" LOG_CI_START="-0.25008162218824376" LOG_EFFECT_SIZE="-0.07652641436943501" MODIFIED="2009-09-21 08:52:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.38746979591532693" STUDIES="1" TAU2="0.0" TOTAL_1="341" TOTAL_2="185" WEIGHT="68.65090370621805" Z="0.8642150121284136">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.2503419243482732" CI_START="0.562235647548889" EFFECT_SIZE="0.8384430818448414" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="33" LOG_CI_END="0.09702879344937368" LOG_CI_START="-0.25008162218824376" LOG_EFFECT_SIZE="-0.07652641436943501" ORDER="788" O_E="0.0" SE="0.20389437636980504" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.04157291671523171" WEIGHT="68.65090370621805"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9091905068132912" CI_END="1.165149980860559" CI_START="0.9831293772761143" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0702771487407912" ESTIMABLE="YES" EVENTS_1="380" EVENTS_2="270" I2="0.0" I2_Q="0.0" ID="CMP-007.11" LOG_CI_END="0.06638183237296569" LOG_CI_START="-0.007389326379613004" LOG_EFFECT_SIZE="0.0294962529966763" METHOD="MH" MODIFIED="2009-09-21 08:52:58 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6347048408066132" P_Q="0.0" P_Z="0.11703935997182288" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="592" TOTAL_2="471" WEIGHT="100.0" Z="1.5673223663535423">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.229529147688006" CI_START="0.9740064054127311" EFFECT_SIZE="1.094335079164409" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="113" LOG_CI_END="0.08973882874778538" LOG_CI_START="-0.011438187036932484" LOG_EFFECT_SIZE="0.03915032085542643" ORDER="789" O_E="0.0" SE="0.05943187990624877" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.0035321483491907767" WEIGHT="53.162999815977045"/>
<DICH_DATA CI_END="1.2041064561132766" CI_START="0.9290773249941477" EFFECT_SIZE="1.0576899381453462" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="119" LOG_CI_END="0.08066488497723527" LOG_CI_START="-0.03194813915946524" LOG_EFFECT_SIZE="0.02435837290888502" ORDER="790" O_E="0.0" SE="0.06614944782135768" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.004375749447070521" WEIGHT="42.91370068360465"/>
<DICH_DATA CI_END="1.3838815924428907" CI_START="0.5870228759387845" EFFECT_SIZE="0.9013157894736842" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="38" LOG_CI_END="0.14109893264345383" LOG_CI_START="-0.2313449742201854" LOG_EFFECT_SIZE="-0.04512302078836579" ORDER="791" O_E="0.0" SE="0.21877539451877434" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" VAR="0.04786267324684536" WEIGHT="3.9232995004183038"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08378416800824603" CI_END="4.57920171901523" CI_START="0.1558438827122544" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8447724993239087" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.12" LOG_CI_END="0.6607897751122401" LOG_CI_START="-0.8073102402684554" LOG_EFFECT_SIZE="-0.07326023257810763" METHOD="MH" MODIFIED="2009-09-21 08:53:21 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7722332614033067" P_Q="0.0" P_Z="0.8449155443292935" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="445" TOTAL_2="322" WEIGHT="100.0" Z="0.19560985743179776">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.886406509738897" CI_START="0.09904763525593777" DF="0" EFFECT_SIZE="1.0850439882697946" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-007.12.01" LOG_CI_END="1.0750505788514797" LOG_CI_START="-1.0041558887024853" LOG_EFFECT_SIZE="0.03544734507449725" MODIFIED="2009-09-21 08:53:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9467179319297545" STUDIES="1" TAU2="0.0" TOTAL_1="341" TOTAL_2="185" WEIGHT="49.85584157504884" Z="0.06682887993832645">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="11.886406509738897" CI_START="0.09904763525593777" EFFECT_SIZE="1.0850439882697946" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0750505788514797" LOG_CI_START="-1.0041558887024853" LOG_EFFECT_SIZE="0.03544734507449725" ORDER="799" O_E="0.0" SE="1.2213361712792046" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="1.4916620432749466" WEIGHT="49.85584157504884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.165845217878969" CI_START="0.0605406446640586" DF="0" EFFECT_SIZE="0.658653846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-007.12.02" LOG_CI_END="0.855267423178816" LOG_CI_START="-1.2179529587915259" LOG_EFFECT_SIZE="-0.18134276780635486" MODIFIED="2009-09-21 08:53:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7316942610122652" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="137" WEIGHT="50.14415842495116" Z="0.3428726601843234">
<NAME>suicide</NAME>
<DICH_DATA CI_END="7.165845217878971" CI_START="0.0605406446640586" EFFECT_SIZE="0.6586538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8552674231788161" LOG_CI_START="-1.2179529587915259" LOG_EFFECT_SIZE="-0.18134276780635478" ORDER="800" O_E="0.0" SE="1.2178199149757827" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" VAR="1.4830853453116226" WEIGHT="50.14415842495116"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.047416021042778" CI_START="0.3985164260807066" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8988269794721409" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.13" LOG_CI_END="0.9565245606371606" LOG_CI_START="-0.39955377311557705" LOG_EFFECT_SIZE="0.27848539376079173" METHOD="MH" MODIFIED="2009-09-21 08:53:48 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.42081984657334204" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="488" TOTAL_2="334" WEIGHT="100.0" Z="0.8049997236975699">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="792" O_E="0.0" SE="0.0" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.047416021042778" CI_START="0.3985164260807066" EFFECT_SIZE="1.8988269794721409" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9565245606371606" LOG_CI_START="-0.39955377311557705" LOG_EFFECT_SIZE="0.27848539376079173" ORDER="793" O_E="0.0" SE="0.7965671259423711" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.6345191861320894" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9561880374657303" CI_END="1.9196794078932147" CI_START="-6.393796042652385" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.237058317379585" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.14" MODIFIED="2009-09-21 08:53:43 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.6199639503332441" P_Q="1.0" P_Z="0.291513872900771" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="426" TOTAL_2="367" UNITS="" WEIGHT="100.0" Z="1.0548064427355734">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.05340527560146" CI_START="-10.45340527560155" EFFECT_SIZE="-0.7000000000000455" ESTIMABLE="YES" MEAN_1="408.9" MEAN_2="409.6" ORDER="794" SD_1="28.5" SD_2="45.3" SE="4.9763186224518" STUDY_ID="STD-Addington-2004" TOTAL_1="123" TOTAL_2="113" WEIGHT="18.163214216147924"/>
<CONT_DATA CI_END="4.4776942290143715" CI_START="-6.677694229014373" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="1.3" ORDER="795" SD_1="26.6" SD_2="26.8" SE="2.845814654254115" STUDY_ID="STD-Lieberman-2005" TOTAL_1="218" TOTAL_2="148" WEIGHT="55.53871677854407"/>
<CONT_DATA CI_END="2.4057031105493385" CI_START="-13.805703110549338" EFFECT_SIZE="-5.7" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="1.3" ORDER="796" SD_1="30.4" SD_2="25.7" SE="4.135638804838298" STUDY_ID="STD-Stroup-2006" TOTAL_1="85" TOTAL_2="106" WEIGHT="26.298069005308008"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.3627454847858136" CI_END="1.5911942659575173" CI_START="0.8345485864783071" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1523579849453178" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="94" I2="40.52478818130395" I2_Q="0.0" ID="CMP-007.15" LOG_CI_END="0.2017232050915575" LOG_CI_START="-0.07854837411334034" LOG_EFFECT_SIZE="0.061587415489108566" METHOD="MH" MODIFIED="2009-09-21 08:54:14 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.18611853556896163" P_Q="0.0" P_Z="0.38903292260366285" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.033660983425030676" TOTALS="YES" TOTAL_1="592" TOTAL_2="471" WEIGHT="100.00000000000003" Z="0.8613725059244086">
<NAME>Adverse effects: 4. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.358526536336522" CI_START="0.5319772371627903" EFFECT_SIZE="0.8501206934386658" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" LOG_CI_END="0.1330681259868612" LOG_CI_START="-0.2741069503855747" LOG_EFFECT_SIZE="-0.07051941219935676" ORDER="824" O_E="0.0" SE="0.2391766554103033" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.057205472493258976" WEIGHT="29.82838470611071"/>
<DICH_DATA CI_END="1.5709696776245743" CI_START="0.8526765804493973" EFFECT_SIZE="1.1573802541544478" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="45" LOG_CI_END="0.19616780250183505" LOG_CI_START="-0.06921566515235338" LOG_EFFECT_SIZE="0.06347606867474084" ORDER="825" O_E="0.0" SE="0.15588756256942177" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.02430093216383539" WEIGHT="46.76173270802382"/>
<DICH_DATA CI_END="2.9516620244499947" CI_START="0.9598834190522337" EFFECT_SIZE="1.6832264957264957" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.47006662777176034" LOG_CI_START="-0.017781510227933908" LOG_EFFECT_SIZE="0.22614255877191325" ORDER="826" O_E="0.0" SE="0.2865644111482503" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" VAR="0.08211916173674345" WEIGHT="23.409882585865486"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.851643775750523" CI_END="1.7274650496707984" CI_START="1.0389396737330834" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3396760709553202" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="107" I2="32.2159798563373" I2_Q="0.0" ID="CMP-007.16" LOG_CI_END="0.23740926942472448" LOG_CI_START="0.016590330882050357" LOG_EFFECT_SIZE="0.12699980015338744" METHOD="MH" MODIFIED="2009-09-21 08:54:38 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.1820950892723785" P_Q="0.0" P_Z="0.02416650312161526" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04911224609755862" TOTALS="SUB" TOTAL_1="1331" TOTAL_2="1091" WEIGHT="400.0" Z="2.254471794739834">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9863861456955547" CI_END="1.8918512995192587" CI_START="0.5534990522160428" DF="2" EFFECT_SIZE="1.023297562401865" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="40" I2="49.82924566503492" ID="CMP-007.16.01" LOG_CI_END="0.27688699763861835" LOG_CI_START="-0.2568831184486641" LOG_EFFECT_SIZE="0.01000193959497715" MODIFIED="2009-09-21 08:54:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1362598427089955" P_Z="0.941445842687889" STUDIES="3" TAU2="0.14387388468763634" TOTAL_1="592" TOTAL_2="471" WEIGHT="100.0" Z="0.0734527497545206">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.712387957976394" CI_START="0.9443247389440561" EFFECT_SIZE="1.6004296455424274" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.43335180759849345" LOG_CI_START="-0.024878632736630754" LOG_EFFECT_SIZE="0.2042365874309314" ORDER="801" O_E="0.0" SE="0.26916682893011395" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.07245078179629322" WEIGHT="45.44411730682745"/>
<DICH_DATA CI_END="1.498198763066393" CI_START="0.400930582172234" EFFECT_SIZE="0.7750314201927105" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.17556943417561233" LOG_CI_START="-0.3969308153830938" LOG_EFFECT_SIZE="-0.11068069060374072" ORDER="802" O_E="0.0" SE="0.3362894805127242" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.11309061470351793" WEIGHT="38.25697146239505"/>
<DICH_DATA CI_END="2.1309281481447866" CI_START="0.14957261238215175" EFFECT_SIZE="0.5645604395604396" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.32856880617111445" LOG_CI_START="-0.8251479210450505" LOG_EFFECT_SIZE="-0.24828955743696798" ORDER="803" O_E="0.0" SE="0.6776989165566807" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" VAR="0.45927582150209884" WEIGHT="16.298911230777495"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.694660403581999" CI_START="1.1495935413037106" DF="0" EFFECT_SIZE="3.161538461538462" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-007.16.02" LOG_CI_END="0.9392526239775341" LOG_CI_START="0.06054431516093066" LOG_EFFECT_SIZE="0.49989846956923245" MODIFIED="2009-09-21 08:54:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.025743932660729683" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="137" WEIGHT="100.0" Z="2.230052877505861">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="8.694660403581999" CI_START="1.1495935413037106" EFFECT_SIZE="3.1615384615384614" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.9392526239775341" LOG_CI_START="0.06054431516093066" LOG_EFFECT_SIZE="0.4998984695692324" ORDER="804" O_E="0.0" SE="0.5161576102751523" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" VAR="0.266418678644956" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8894970760818852" CI_START="0.4736583484721351" DF="0" EFFECT_SIZE="0.946031746031746" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-007.16.03" LOG_CI_END="0.27634622420091093" LOG_CI_START="-0.32453480362760145" LOG_EFFECT_SIZE="-0.02409428971334529" MODIFIED="2009-09-21 08:54:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8751011536852311" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="0.15718233022563693">
<NAME>tremor</NAME>
<DICH_DATA CI_END="1.8894970760818852" CI_START="0.4736583484721351" EFFECT_SIZE="0.946031746031746" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.27634622420091093" LOG_CI_START="-0.32453480362760145" LOG_EFFECT_SIZE="-0.02409428971334529" ORDER="805" O_E="0.0" SE="0.35296049015552655" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.12458110761082956" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2889449232049159" CI_END="1.9624391482972068" CI_START="1.0345098186649264" DF="1" EFFECT_SIZE="1.424837733724755" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="47" I2="0.0" ID="CMP-007.16.04" LOG_CI_END="0.2927961989365417" LOG_CI_START="0.01473461696575643" LOG_EFFECT_SIZE="0.15376540795114907" MODIFIED="2009-09-21 08:54:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5908975164031494" P_Z="0.030182824987268722" STUDIES="2" TAU2="0.0" TOTAL_1="488" TOTAL_2="334" WEIGHT="100.0" Z="2.1676828529589915">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="2.196435230828575" CI_START="1.031296981108008" EFFECT_SIZE="1.505050505050505" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="33" LOG_CI_END="0.3417184011781751" LOG_CI_START="0.013383746451273111" LOG_EFFECT_SIZE="0.1775510738147241" ORDER="806" O_E="0.0" SE="0.19286540146933534" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.037197063083927895" WEIGHT="71.72136249505992"/>
<DICH_DATA CI_END="2.264045457795551" CI_START="0.6791933759798391" EFFECT_SIZE="1.2400502723083369" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" LOG_CI_END="0.3548851424241729" LOG_CI_START="-0.16800655831980474" LOG_EFFECT_SIZE="0.09343929205218404" ORDER="807" O_E="0.0" SE="0.3071491733726756" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.09434061470351793" WEIGHT="28.278637504940082"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="120.65571624683723" CI_END="0.3721459071978968" CI_START="0.3158029871342331" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.34397444716606496" ESTIMABLE="YES" I2="98.34239100954952" I2_Q="98.34239100954952" ID="CMP-007.17" MODIFIED="2010-11-23 17:52:52 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="-1.1102230246251565E-15" P_Q="-1.1102230246251565E-15" P_Z="0.0" Q="120.65571624683723" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.04146788082505111" TOTALS="SUB" TOTAL_1="441" TOTAL_2="447" UNITS="" WEIGHT="300.0" Z="23.93122427044205">
<NAME>Adverse effects: 5b. Extrapyramidal symptoms - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9724887109283464E-30" CI_END="0.24873388567225857" CI_START="0.17126611432774136" DF="0" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-007.17.01" MODIFIED="2010-11-23 17:52:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="2.251967048332722E-26" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="10.626159230087156">
<NAME>abnormal involuntary movement: AIMS (high = poor)</NAME>
<CONT_DATA CI_END="0.24873388567225857" CI_START="0.17126611432774141" EFFECT_SIZE="0.21" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.25" ORDER="808" SD_1="0.17" SD_2="0.17" SE="0.01976254970896738" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6089925221116779" CI_START="0.5110074778883222" DF="0" EFFECT_SIZE="0.56" ESTIMABLE="YES" I2="0.0" ID="CMP-007.17.02" MODIFIED="2010-11-23 17:52:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="22.403007316922995">
<NAME>akathisia: Barnes Akathisia Scale (high = poor)</NAME>
<CONT_DATA CI_END="0.6089925221116779" CI_START="0.5110074778883222" EFFECT_SIZE="0.56" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="-0.28" ORDER="809" SD_1="0.21" SD_2="0.22" SE="0.0249966440700567" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4151893074814431" CI_START="0.2648106925185568" DF="0" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-007.17.03" MODIFIED="2010-11-23 17:52:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="7.802985575062357E-19" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="8.862799473290588">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="0.4151893074814431" CI_START="0.2648106925185568" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="-0.57" ORDER="810" SD_1="0.33" SD_2="0.33" SE="0.03836259649387785" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.899422709793516" CI_END="1.883538489131919" CI_START="1.1088103499370656" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4451598428043502" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-007.18" LOG_CI_END="0.274974499212404" LOG_CI_START="0.04485727110934153" LOG_EFFECT_SIZE="0.15991588516087268" METHOD="MH" MODIFIED="2009-09-21 08:55:57 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.9405098065923405" P_Q="0.0" P_Z="0.006448002657180374" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1054" TOTAL_2="878" WEIGHT="600.0" Z="2.7240843986768213">
<NAME>Adverse effects: 6a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.751243836304038" CI_START="0.6502539061217312" DF="0" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-007.18.01" LOG_CI_END="0.8293837937907695" LOG_CI_START="-0.18691703028623305" LOG_EFFECT_SIZE="0.3212333817522682" MODIFIED="2009-09-21 08:55:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2153400571401618" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="110" WEIGHT="100.0" Z="1.2390147561638665">
<NAME>abnormal ejaculation</NAME>
<DICH_DATA CI_END="6.751243836304038" CI_START="0.6502539061217312" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8293837937907695" LOG_CI_START="-0.18691703028623305" LOG_EFFECT_SIZE="0.3212333817522682" ORDER="813" O_E="0.0" SE="0.5969801348330457" STUDY_ID="STD-Addington-2004" TOTAL_1="105" TOTAL_2="110" VAR="0.35638528138528136" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12824879123761668" CI_END="2.3927957367455046" CI_START="0.5952153150888416" DF="1" EFFECT_SIZE="1.1934105196411722" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" ID="CMP-007.18.02" LOG_CI_END="0.37890562623959756" LOG_CI_START="-0.22532590277635192" LOG_EFFECT_SIZE="0.0767898617316228" MODIFIED="2009-09-21 08:55:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7202547844754177" P_Z="0.6183634039698397" STUDIES="2" TAU2="0.0" TOTAL_1="130" TOTAL_2="95" WEIGHT="100.0" Z="0.4981711683165694">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="4.330575980960513" CI_START="0.1991062855726502" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6365456628007128" LOG_CI_START="-0.7009150295435154" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="814" O_E="0.0" SE="0.7856310312202014" STUDY_ID="STD-Addington-2004" TOTAL_1="42" TOTAL_2="39" VAR="0.6172161172161171" WEIGHT="20.41008024475994"/>
<DICH_DATA CI_END="2.775748449773637" CI_START="0.5835668253281019" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.44338010593797167" LOG_CI_START="-0.23390940489794568" LOG_EFFECT_SIZE="0.10473535052001297" ORDER="815" O_E="0.0" SE="0.3978432113021671" STUDY_ID="STD-Lieberman-2005" TOTAL_1="88" TOTAL_2="56" VAR="0.1582792207792208" WEIGHT="79.58991975524006"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.856520878083109" CI_START="0.7034753935541109" DF="0" EFFECT_SIZE="1.647108843537415" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-007.18.03" LOG_CI_END="0.5861956868490004" LOG_CI_START="-0.1527510888910181" LOG_EFFECT_SIZE="0.21672229897899115" MODIFIED="2009-09-21 08:55:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.25028492999502683" STUDIES="1" TAU2="0.0" TOTAL_1="147" TOTAL_2="149" WEIGHT="100.0" Z="1.1496576332447233">
<NAME>decreased libido</NAME>
<DICH_DATA CI_END="3.856520878083109" CI_START="0.7034753935541109" EFFECT_SIZE="1.647108843537415" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5861956868490004" LOG_CI_START="-0.1527510888910181" LOG_EFFECT_SIZE="0.21672229897899115" ORDER="816" O_E="0.0" SE="0.4340609939152197" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.1884089464386684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.884819285984341" CI_START="0.3804417400654461" DF="0" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-007.18.04" LOG_CI_END="0.46011861279228256" LOG_CI_START="-0.41971184061570854" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2009-09-21 08:55:48 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9282772097809616" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="110" WEIGHT="100.0" Z="0.09001259036992641">
<NAME>erectile dysfunction</NAME>
<DICH_DATA CI_END="2.884819285984341" CI_START="0.3804417400654461" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.46011861279228256" LOG_CI_START="-0.41971184061570854" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="817" O_E="0.0" SE="0.5168167635628387" STUDY_ID="STD-Addington-2004" TOTAL_1="105" TOTAL_2="110" VAR="0.26709956709956706" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.006321906530413233" CI_END="42.44756762116327" CI_START="0.6055837339820251" DF="1" EFFECT_SIZE="5.070064743026322" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-007.18.05" LOG_CI_END="1.6278528088562323" LOG_CI_START="-0.21782579852898953" LOG_EFFECT_SIZE="0.7050135051636213" MODIFIED="2009-09-21 08:55:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9366266458361001" P_Z="0.13430569224435626" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="80" WEIGHT="100.0" Z="1.4973366145177822">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="93.95349664107178" CI_START="0.2302555634327885" EFFECT_SIZE="4.651162790697675" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9729129477538854" LOG_CI_START="-0.6377898675850959" LOG_EFFECT_SIZE="0.6675615400843947" ORDER="818" O_E="0.0" SE="1.533539756917476" STUDY_ID="STD-Addington-2004" TOTAL_1="42" TOTAL_2="39" VAR="2.3517441860465116" WEIGHT="49.98011855724259"/>
<DICH_DATA CI_END="111.49827888360629" CI_START="0.2739070639544777" EFFECT_SIZE="5.526315789473684" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.047268163553493" LOG_CI_START="-0.5623967673192748" LOG_EFFECT_SIZE="0.7424356981171091" ORDER="819" O_E="0.0" SE="1.5329300984444112" STUDY_ID="STD-Stroup-2006" TOTAL_1="37" TOTAL_2="41" VAR="2.349874686716792" WEIGHT="50.0198814427574"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2548249189450928" CI_END="2.0169272896162327" CI_START="1.0305984536884367" DF="1" EFFECT_SIZE="1.4417496821156226" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="38" I2="0.0" ID="CMP-007.18.06" LOG_CI_END="0.30469024214552204" LOG_CI_START="0.013089486509411625" LOG_EFFECT_SIZE="0.15888986432746677" MODIFIED="2009-09-21 08:55:57 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6136980459208794" P_Z="0.0326856730992374" STUDIES="2" TAU2="0.0" TOTAL_1="488" TOTAL_2="334" WEIGHT="99.99999999999999" Z="2.1359232139913282">
<NAME>orgastic dysfunction</NAME>
<DICH_DATA CI_END="7.954256102547174" CI_START="0.5166522069016959" EFFECT_SIZE="2.0272108843537415" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9005995698197486" LOG_CI_START="-0.28680171116359016" LOG_EFFECT_SIZE="0.30689892932807916" ORDER="820" O_E="0.0" SE="0.6974853901807488" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.4864858695155915" WEIGHT="6.030901895555849"/>
<DICH_DATA CI_END="1.9943300327136755" CI_START="0.9976641472648222" EFFECT_SIZE="1.4105571847507332" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="35" LOG_CI_END="0.29979702936485914" LOG_CI_START="-0.0010156346021910044" LOG_EFFECT_SIZE="0.1493906973813341" ORDER="821" O_E="0.0" SE="0.17669884786094692" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.03122248283538606" WEIGHT="93.96909810444414"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7538061671553615" CI_END="27.343246145609346" CI_START="16.59755069031768" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="21.970398417963512" ESTIMABLE="YES" I2="42.98115614327095" I2_Q="0.0" ID="CMP-007.19" MODIFIED="2009-09-21 08:56:12 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.1853990736761344" P_Q="1.0" P_Z="1.1050201328832392E-15" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="6.982288815474372" TOTALS="YES" TOTAL_1="445" TOTAL_2="322" UNITS="" WEIGHT="100.0" Z="8.014593341931906">
<NAME>Adverse effects: 6b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.202548262585033" CI_START="15.597451737414964" EFFECT_SIZE="19.9" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-4.5" ORDER="823" SD_1="27.7" SD_2="21.8" SE="2.195218022638674" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" WEIGHT="63.67722073748226"/>
<CONT_DATA CI_END="32.85621978820948" CI_START="18.343780211790524" EFFECT_SIZE="25.6" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="-3.6" ORDER="822" SD_1="29.6" SD_2="26.9" SE="3.7022209823474386" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" WEIGHT="36.322779262517734"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1348631023496153" CI_END="16.036424661943276" CI_START="1.1143605024078447" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="8.57539258217556" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.20" MODIFIED="2009-09-21 08:56:34 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.7134422499886184" P_Q="1.0" P_Z="0.024278124668238508" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="445" TOTAL_2="322" UNITS="" WEIGHT="99.99999999999999" Z="2.2526991486785435">
<NAME>Adverse effects: 7a. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.947616714196606" CI_START="-3.7476167141966066" EFFECT_SIZE="7.1" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-9.2" ORDER="797" SD_1="35.1" SD_2="70.7" SE="5.534600023143906" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" WEIGHT="47.30740777944423"/>
<CONT_DATA CI_END="20.178367108642693" CI_START="-0.3783671086426921" EFFECT_SIZE="9.9" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-12.5" ORDER="798" SD_1="39.8" SD_2="41.0" SE="5.244161214041248" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" WEIGHT="52.69259222055575"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04254478263700791" CI_END="11.796249968074633" CI_START="-1.908421003456362" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.943914482309136" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.21" MODIFIED="2009-09-21 08:56:50 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.8365849206725411" P_Q="1.0" P_Z="0.1573322553643021" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="445" TOTAL_2="322" UNITS="" WEIGHT="100.0" Z="1.414100980330125">
<NAME>Adverse effects: 7b. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.982936060750708" CI_START="-4.182936060750707" EFFECT_SIZE="4.4" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="2.3" ORDER="811" SD_1="36.9" SD_2="53.0" SE="4.37912947811889" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" WEIGHT="63.73903451272428"/>
<CONT_DATA CI_END="17.279388789884152" CI_START="-5.479388789884151" EFFECT_SIZE="5.9" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="-1.1" ORDER="812" SD_1="43.9" SD_2="45.6" SE="5.805917292176447" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" WEIGHT="36.260965487275726"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.1355283706987248" CI_END="3.0572662916946576" CI_START="1.3505136394759605" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0319645239136745" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-007.22" LOG_CI_END="0.4853332679628679" LOG_CI_START="0.1304989746909878" LOG_EFFECT_SIZE="0.3079161213269279" METHOD="MH" MODIFIED="2009-09-21 08:57:07 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.9344808231170824" P_Q="0.0" P_Z="6.698937820270341E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="592" TOTAL_2="471" WEIGHT="100.00000000000001" Z="3.401613200884329">
<NAME>Adverse effects: 7c. Metabolic - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.181833878492291" CI_START="0.9827229127341469" EFFECT_SIZE="2.0272108843537415" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.6213667766674298" LOG_CI_START="-0.007568918011271517" LOG_EFFECT_SIZE="0.30689892932807916" ORDER="827" O_E="0.0" SE="0.36943994033616817" STUDY_ID="STD-Addington-2004" TOTAL_1="147" TOTAL_2="149" VAR="0.1364858695155915" WEIGHT="31.830149987902843"/>
<DICH_DATA CI_END="3.51597416752549" CI_START="1.0254750820620626" EFFECT_SIZE="1.8988269794721409" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="12" LOG_CI_END="0.5460456755762658" LOG_CI_START="0.010925111945317666" LOG_EFFECT_SIZE="0.27848539376079173" ORDER="828" O_E="0.0" SE="0.31433246796632963" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="185" VAR="0.09880490041780364" WEIGHT="43.96913189062638"/>
<DICH_DATA CI_END="5.288975584476514" CI_START="1.0047985297002209" EFFECT_SIZE="2.3052884615384617" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.7233715621879017" LOG_CI_START="0.002078990899940176" LOG_EFFECT_SIZE="0.3627252765439209" ORDER="829" O_E="0.0" SE="0.42369082683036" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="137" VAR="0.17951391674019412" WEIGHT="24.200718121470786"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.3476548497559824" CI_START="-0.1476548497559822" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.23" MODIFIED="2009-09-21 08:57:24 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.08398638469723757" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="300" TOTAL_2="161" UNITS="" WEIGHT="100.0" Z="1.7280102613440929">
<NAME>Adverse effects: 7d. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.3476548497559824" CI_START="-0.1476548497559822" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-0.7" ORDER="830" SD_1="6.9" SD_2="6.3" SE="0.6365702939428094" STUDY_ID="STD-Lieberman-2005" TOTAL_1="300" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2009-09-21 12:40:18 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>RISPERIDONE versus CLOZAPINE - sensitivity analysis (skewed data included)</NAME>
<CONT_OUTCOME CHI2="4.7744912676026185" CI_END="7.030520273306997" CI_START="-1.356240666782841" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.837139803262078" ESTIMABLE="YES" I2="58.11072032802678" I2_Q="77.77093871911057" ID="CMP-008.01" MODIFIED="2009-09-21 12:37:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09188265767204551" P_Q="0.03392235478468908" P_Z="0.18481842395303785" Q="4.498615516705203" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="7.615336658148391" TOTALS="YES" TOTAL_1="192" TOTAL_2="176" UNITS="" WEIGHT="100.0" Z="1.326064227470197">
<NAME>Mental state: 1. General - average endpoint score (BPRS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.27587575089741506" CI_END="8.263341607779607" CI_START="2.1174549661709805" DF="1" EFFECT_SIZE="5.190398286975293" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" MODIFIED="2009-09-21 12:37:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5994172834349412" P_Z="9.312784475765927E-4" STUDIES="2" TAU2="0.0" TOTAL_1="170" TOTAL_2="146" WEIGHT="60.59320678955119" Z="3.3105048306674547">
<NAME>short term</NAME>
<CONT_DATA CI_END="8.782940477763663" CI_START="2.217059522236337" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="-17.7" MEAN_2="-23.2" ORDER="831" SD_1="13.6" SD_2="13.2" SE="1.6750004100376732" STUDY_ID="STD-Azorin-2001" TOTAL_1="130" TOTAL_2="126" WEIGHT="43.926287439857575"/>
<CONT_DATA CI_END="11.732183968593883" CI_START="-5.732183968593887" EFFECT_SIZE="2.9999999999999982" ESTIMABLE="YES" MEAN_1="-13.9" MEAN_2="-16.9" ORDER="832" SD_1="16.6" SD_2="16.1" SE="4.45527776911833" STUDY_ID="STD-Heinrich-1994" TOTAL_1="40" TOTAL_2="20" WEIGHT="16.666919349693615"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.720314003583877" CI_START="-4.120314003583875" DF="0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.02" MODIFIED="2009-09-21 12:37:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9203521430657307" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="30" WEIGHT="39.40679321044881" Z="0.0999901529698022">
<NAME>long term</NAME>
<CONT_DATA CI_END="3.720314003583877" CI_START="-4.120314003583875" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="31.3" MEAN_2="31.5" ORDER="833" SD_1="6.5" SD_2="7.9" SE="2.0001969599986595" STUDY_ID="STD-McGurk-2005" TOTAL_1="22" TOTAL_2="30" WEIGHT="39.40679321044881"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.453506628977458" CI_END="2.52677409563235" CI_START="-1.3360843401575089" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5953448777374207" ESTIMABLE="YES" I2="32.63735186830043" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2009-09-21 12:38:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21647534267291857" P_Q="0.6348230426866728" P_Z="0.5457502710382043" Q="0.22557695425976476" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.2993627189639678" TOTALS="YES" TOTAL_1="223" TOTAL_2="219" UNITS="" WEIGHT="100.0" Z="0.6041404509855686">
<NAME>Mental state: 2. Positive symptoms - average endpoint score (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.227929674717693" CI_END="3.1944232660784664" CI_START="-2.7170468370810754" DF="2" EFFECT_SIZE="0.2386882144986954" ESTIMABLE="YES" I2="52.69552348612459" ID="CMP-008.02.01" MODIFIED="2009-09-21 12:38:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12075828658216481" P_Z="0.8742397501150794" STUDIES="3" TAU2="3.637670511741871" TOTAL_1="182" TOTAL_2="179" WEIGHT="75.29882438531044" Z="0.15827545290352574">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.816446284130797" CI_START="0.38355371586920217" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-10.4" ORDER="834" SD_1="7.4" SD_2="6.6" SE="0.8757539922518509" STUDY_ID="STD-Azorin-2001" TOTAL_1="130" TOTAL_2="126" WEIGHT="46.99659594242638"/>
<CONT_DATA CI_END="2.2381698628517928" CI_START="-5.438169862851794" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-6.7" ORDER="835" SD_1="10.7" SD_2="7.1" SE="1.9582859139896382" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="18.91405733634749"/>
<CONT_DATA CI_END="3.8943923257100126" CI_START="-7.894392325710013" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="17.0" ORDER="836" SD_1="7.0" SD_2="6.0" SE="3.007398284970656" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="9.388171106536571"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.5797394609615947" CI_START="-2.779739460961595" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.02" MODIFIED="2009-09-21 12:38:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8052514342014075" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="24.701175614689557" Z="0.24655655076184577">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.5797394609615947" CI_START="-2.779739460961595" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.3" ORDER="837" SD_1="7.3" SD_2="7.3" SE="1.622345862496951" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" WEIGHT="24.701175614689557"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.274775375528241" CI_END="2.307788750592614" CI_START="-2.018794255163138" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1444972477147379" ESTIMABLE="YES" I2="63.74523943124574" I2_Q="0.0" ID="CMP-008.03" MODIFIED="2009-09-21 12:40:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04066152651131694" P_Q="0.575978256263537" P_Z="0.8958417827095088" Q="0.31278182257256937" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.0276603183020967" TOTALS="YES" TOTAL_1="223" TOTAL_2="219" UNITS="" WEIGHT="100.0" Z="0.13091596810198214">
<NAME>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.961993552955672" CI_END="2.5924739646170925" CI_START="-3.367467284875221" DF="2" EFFECT_SIZE="-0.3874966601290642" ESTIMABLE="YES" I2="74.88066290561672" ID="CMP-008.03.01" MODIFIED="2009-09-21 12:39:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.018667071185337947" P_Z="0.7988301472737536" STUDIES="3" TAU2="5.0965320885711085" TOTAL_1="182" TOTAL_2="179" WEIGHT="76.1202645849729" Z="0.2548614042285127">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.4151122384898853" CI_START="-0.015112238489882968" EFFECT_SIZE="1.700000000000001" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-8.8" ORDER="838" SD_1="7.2" SD_2="6.8" SE="0.8750733442137052" STUDY_ID="STD-Azorin-2001" TOTAL_1="130" TOTAL_2="126" WEIGHT="32.11468756474519"/>
<CONT_DATA CI_END="2.764330789454674" CI_START="-2.5643307894546745" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-6.1" ORDER="839" SD_1="6.5" SD_2="6.1" SE="1.3593774224784616" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="24.986691319824352"/>
<CONT_DATA CI_END="-0.39783478463451827" CI_START="-7.602165215365481" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="21.0" ORDER="840" SD_1="4.0" SD_2="4.0" SE="1.837873166945363" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="19.01888570040336"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.222563247538512" CI_START="-1.422563247538512" DF="0" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-008.03.02" MODIFIED="2009-09-21 12:40:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3309768741358846" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="23.8797354150271" Z="0.9721481283896852">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.222563247538512" CI_START="-1.422563247538512" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.6" ORDER="841" SD_1="6.48" SD_2="6.48" SE="1.4401097519151018" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="40" WEIGHT="23.8797354150271"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-11-23 17:53:53 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>RISPERIDONE versus OLANZAPINE - sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="11.287642120614855" CI_END="3.3691021332139472" CI_START="0.6024760919148102" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9857891125643787" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2009-09-21 12:41:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5867347492995343" P_Q="0.41806075280153765" P_Z="0.004899172936149811" Q="1.7442587918464802" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1168" TOTAL_2="1180" UNITS="" WEIGHT="100.0" Z="2.8135896094510255">
<NAME>Mental state: 1a. General - average endpoint score (PANSS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.2932982500231986" CI_END="3.1544517536549193" CI_START="-1.1120213201429938" DF="5" EFFECT_SIZE="1.0212152167559627" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.01" MODIFIED="2009-09-21 12:41:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.807250796708822" P_Z="0.3481073218759504" STUDIES="6" TAU2="0.0" TOTAL_1="339" TOTAL_2="347" WEIGHT="42.04970010416746" Z="0.9382668122755661">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.69518404569392" CI_START="-0.8951840456939086" EFFECT_SIZE="3.4000000000000057" ESTIMABLE="YES" MEAN_1="78.26" MEAN_2="74.86" ORDER="842" SD_1="4.62" SD_2="6.41" SE="2.191460700081113" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="10.372355041410616"/>
<CONT_DATA CI_END="3.4242792035423495" CI_START="-3.22427920354235" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="-12.8" MEAN_2="-12.9" ORDER="843" SD_1="15.9" SD_2="16.1" SE="1.6960919842220774" STUDY_ID="STD-Conley-2001" TOTAL_1="175" TOTAL_2="181" WEIGHT="17.31593489491165"/>
<CONT_DATA CI_END="9.097000872241495" CI_START="-7.897000872241492" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" MEAN_1="-16.9" MEAN_2="-17.5" ORDER="844" SD_1="18.8" SD_2="17.7" SE="4.3352841885181315" STUDY_ID="STD-Dollfus-2005" TOTAL_1="38" TOTAL_2="33" WEIGHT="2.6503888997075595"/>
<CONT_DATA CI_END="5.077521730134338" CI_START="-5.077521730134338" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-12.3" MEAN_2="-12.3" ORDER="845" SD_1="18.04" SD_2="15.67" SE="2.59061991454189" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="7.422280246931101"/>
<CONT_DATA CI_END="9.277576336221415" CI_START="-5.077576336221427" EFFECT_SIZE="2.0999999999999943" ESTIMABLE="YES" MEAN_1="71.5" MEAN_2="69.4" ORDER="846" SD_1="12.0" SD_2="10.8" SE="3.6620960348441236" STUDY_ID="STD-Mori-2004" TOTAL_1="19" TOTAL_2="20" WEIGHT="3.7143710819170326"/>
<CONT_DATA CI_END="12.252594840357954" CI_START="-24.252594840357954" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-15.0" MEAN_2="-9.0" ORDER="847" SD_1="22.31" SD_2="22.31" SE="9.312719511344133" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.5743699392895004"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7999604544536205" CI_END="8.928299336757078" CI_START="-0.7147127623588334" DF="2" EFFECT_SIZE="4.106793287199123" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.02" MODIFIED="2009-09-21 12:41:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40657774134073776" P_Z="0.09503218860734909" STUDIES="3" TAU2="0.0" TOTAL_1="116" TOTAL_2="115" WEIGHT="8.23143394853464" Z="1.6694300187799413">
<NAME>medium term</NAME>
<CONT_DATA CI_END="15.586754939148312" CI_START="-0.7867549391483113" EFFECT_SIZE="7.4" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-7.7" ORDER="848" SD_1="6.86" SD_2="9.8" SE="4.176992538497845" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="10" WEIGHT="2.855073865612635"/>
<CONT_DATA CI_END="7.728666030926336" CI_START="-7.328666030926337" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-8.2" ORDER="849" SD_1="22.31" SD_2="22.31" SE="3.8412267216701395" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="66" WEIGHT="3.3760188653793968"/>
<CONT_DATA CI_END="15.780665875938874" CI_START="-3.7806658759388743" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-9.1" ORDER="850" SD_1="22.31" SD_2="22.31" SE="4.990227347587771" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" WEIGHT="2.0003412175426094"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.450124624291556" CI_END="4.980614052622718" CI_START="0.20196365546916306" DF="4" EFFECT_SIZE="2.5912888540459402" ESTIMABLE="YES" I2="26.607182849145453" ID="CMP-009.01.03" MODIFIED="2009-09-21 12:41:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24414868007685175" P_Z="0.03353367836301015" STUDIES="5" TAU2="1.9590283502343953" TOTAL_1="713" TOTAL_2="718" WEIGHT="49.71886594729791" Z="2.125634815426282">
<NAME>long term</NAME>
<CONT_DATA CI_END="21.171340952533527" CI_START="2.628659047466469" EFFECT_SIZE="11.899999999999999" ESTIMABLE="YES" MEAN_1="-16.3" MEAN_2="-28.2" ORDER="851" SD_1="16.3" SD_2="20.8" SE="4.730362917719246" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" WEIGHT="2.2261571788515164"/>
<CONT_DATA CI_END="6.458570018242206" CI_START="-0.6585700182422052" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="-9.5" MEAN_2="-12.4" ORDER="852" SD_1="15.5" SD_2="16.0" SE="1.8156303107157843" STUDY_ID="STD-Keefe-2006" TOTAL_1="148" TOTAL_2="153" WEIGHT="15.110884944600214"/>
<CONT_DATA CI_END="5.356450885289281" CI_START="-1.436450885289283" EFFECT_SIZE="1.959999999999999" ESTIMABLE="YES" MEAN_1="-9.31" MEAN_2="-11.27" ORDER="853" SD_1="22.31" SD_2="22.31" SE="1.7329149474582457" STUDY_ID="STD-Lieberman-2005" TOTAL_1="333" TOTAL_2="330" WEIGHT="16.5878558258608"/>
<CONT_DATA CI_END="4.374988808061811" CI_START="-4.574988808061814" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="-18.5" MEAN_2="-18.4" ORDER="854" SD_1="9.91" SD_2="9.73" SE="2.283199509460354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="9.555579337497502"/>
<CONT_DATA CI_END="8.738399132890404" CI_START="-2.338399132890399" EFFECT_SIZE="3.200000000000003" ESTIMABLE="YES" MEAN_1="-24.9" MEAN_2="-28.1" ORDER="855" SD_1="23.2" SD_2="28.0" SE="2.8257657674205174" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="6.238388660487878"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2783476979887816" CI_END="9.907846603522582" CI_START="-1.3418164287482535" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.283015087387165" ESTIMABLE="YES" I2="69.4968291309221" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2009-09-21 12:41:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07019963163782827" P_Q="1.0" P_Z="0.1355916711670666" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="11.689366659821088" TOTALS="YES" TOTAL_1="195" TOTAL_2="198" UNITS="" WEIGHT="100.0" Z="1.4924100912960423">
<NAME>Mental state: 2. General - average endpoint score (BPRS total, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.2783476979887816" CI_END="9.907846603522582" CI_START="-1.3418164287482535" DF="1" EFFECT_SIZE="4.283015087387165" ESTIMABLE="YES" I2="69.4968291309221" ID="CMP-009.02.01" MODIFIED="2009-07-30 16:22:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07019963163782827" P_Z="0.1355916711670666" STUDIES="2" TAU2="11.689366659821088" TOTAL_1="195" TOTAL_2="198" WEIGHT="100.0" Z="1.4924100912960423">
<NAME>Long term</NAME>
<CONT_DATA CI_END="12.985140002837866" CI_START="2.2148599971621286" EFFECT_SIZE="7.599999999999998" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-16.4" ORDER="856" SD_1="9.2" SD_2="12.3" SE="2.74757089687115" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" WEIGHT="42.81060495495113"/>
<CONT_DATA CI_END="5.027770213412124" CI_START="-1.4277702134121224" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="-15.2" MEAN_2="-17.0" ORDER="857" SD_1="13.3" SD_2="16.5" SE="1.6468517987434272" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="57.18939504504887"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.0192656426304545" CI_END="1.2078345904451808" CI_START="0.027714148774739433" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6177743696099601" ESTIMABLE="YES" I2="0.0" I2_Q="35.636627054551475" ID="CMP-009.03" MODIFIED="2009-09-21 12:42:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8720757560020795" P_Q="0.21146871595562822" P_Z="0.04016769560061572" Q="3.107357350111389" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="825" TOTAL_2="838" UNITS="" WEIGHT="100.0" Z="2.052020238364091">
<NAME>Mental state: 3. Positive symptoms - average endpoint score (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.108271186130888" CI_END="1.0659605838021373" CI_START="-1.621460935161191" DF="3" EFFECT_SIZE="-0.2777501756795268" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.01" MODIFIED="2009-09-21 12:42:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7750778047865592" P_Z="0.6853804245436174" STUDIES="4" TAU2="0.0" TOTAL_1="308" TOTAL_2="314" WEIGHT="19.28328790988224" Z="0.4051320845577957">
<NAME>short term</NAME>
<CONT_DATA CI_END="9.059970711802848" CI_START="-10.059970711802848" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-4.6" MEAN_2="-4.1" ORDER="858" SD_1="5.3" SD_2="65.4" SE="4.877625704967375" STUDY_ID="STD-Conley-2001" TOTAL_1="175" TOTAL_2="181" WEIGHT="0.38096015207722705"/>
<CONT_DATA CI_END="1.2192352415235201" CI_START="-2.81923524152352" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.1" ORDER="859" SD_1="3.91" SD_2="4.7" SE="1.0302409929218035" STUDY_ID="STD-Dollfus-2005" TOTAL_1="39" TOTAL_2="33" WEIGHT="8.539232537710918"/>
<CONT_DATA CI_END="2.3258975113126548" CI_START="-1.5258975113126552" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-4.0" ORDER="860" SD_1="7.02" SD_2="5.72" SE="0.9826188269294175" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="9.386989477385836"/>
<CONT_DATA CI_END="3.8323864784676407" CI_START="-8.112386478467641" EFFECT_SIZE="-2.14" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-2.36" ORDER="861" SD_1="7.3" SD_2="7.3" SE="3.047191951269035" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.9761057427082594"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.46690689369471294" CI_END="3.201580707579363" CI_START="-0.034246268075140085" DF="2" EFFECT_SIZE="1.5836672197521116" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.02" MODIFIED="2009-09-21 12:42:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7917946395508001" P_Z="0.05505048530675875" STUDIES="3" TAU2="0.0" TOTAL_1="116" TOTAL_2="115" WEIGHT="13.300932327588876" Z="1.9184775561635172">
<NAME>medium term</NAME>
<CONT_DATA CI_END="5.291568019391902" CI_START="-0.4915680193919023" EFFECT_SIZE="2.4" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-2.9" ORDER="862" SD_1="1.71" SD_2="4.11" SE="1.4753169151067171" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="10" WEIGHT="4.164145053694794"/>
<CONT_DATA CI_END="3.5634362180978156" CI_START="-1.3634362180978155" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-3.4" ORDER="863" SD_1="7.3" SD_2="7.3" SE="1.256878308749082" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="66" WEIGHT="5.7373326432518805"/>
<CONT_DATA CI_END="4.600307525520115" CI_START="-1.800307525520116" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-3.3" ORDER="864" SD_1="7.3" SD_2="7.3" SE="1.6328399658176034" STUDY_ID="STD-Volavka-2002" TOTAL_1="41" TOTAL_2="39" WEIGHT="3.399454630642202"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3367302126934646" CI_END="1.40200505733471" CI_START="-0.03528874229455581" DF="4" EFFECT_SIZE="0.6833581575200771" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.03" MODIFIED="2009-09-21 12:42:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8551136536984457" P_Z="0.06236088332451102" STUDIES="5" TAU2="0.0" TOTAL_1="401" TOTAL_2="409" WEIGHT="67.41577976252889" Z="1.8637210814190848">
<NAME>long term</NAME>
<CONT_DATA CI_END="4.887872227877274" CI_START="-0.6878722278772726" EFFECT_SIZE="2.1000000000000005" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-6.2" ORDER="865" SD_1="5.4" SD_2="5.8" SE="1.4224099268495" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="32" WEIGHT="4.479679504791767"/>
<CONT_DATA CI_END="1.8781323726651176" CI_START="-0.4781323726651181" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-4.3" ORDER="866" SD_1="5.5" SD_2="4.9" SE="0.6010989905723144" STUDY_ID="STD-Keefe-2006" TOTAL_1="148" TOTAL_2="153" WEIGHT="25.084444942687643"/>
<CONT_DATA CI_END="1.9263513314482366" CI_START="-0.9263513314482366" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="-7.1" ORDER="867" SD_1="3.16" SD_2="3.1" SE="0.7277436436072876" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="17.11353199945844"/>
<CONT_DATA CI_END="3.2376310753164965" CI_START="-1.3376310753164962" EFFECT_SIZE="0.9500000000000002" ESTIMABLE="YES" MEAN_1="-1.19" MEAN_2="-2.14" ORDER="868" SD_1="3.14" SD_2="4.33" SE="1.1671801591054929" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="6.653048664539169"/>
<CONT_DATA CI_END="1.8722324691910581" CI_START="-1.2722324691910585" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-7.2" ORDER="869" SD_1="6.4" SD_2="8.1" SE="0.8021741631951542" STUDY_ID="STD-Tran-1997" TOTAL_1="165" TOTAL_2="166" WEIGHT="14.085074651051869"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.84393005810751" CI_END="0.6417923188007795" CI_START="-0.1093473760884967" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2662224713561414" ESTIMABLE="YES" I2="39.369156518732396" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2010-11-23 17:53:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09531317499779757" P_Q="0.9321632201454506" P_Z="0.16473566290130595" Q="0.4385760936377956" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.08482128746587632" TOTALS="SUB" TOTAL_1="903" TOTAL_2="916" UNITS="" WEIGHT="400.0" Z="1.3893193484074855">
<NAME>Adverse effects: 1. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9402024398687009" CI_END="0.620842960895722" CI_START="-0.41987157932455216" DF="1" EFFECT_SIZE="0.10048569078558495" ESTIMABLE="YES" I2="0.0" ID="CMP-009.04.01" MODIFIED="2010-11-23 17:53:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.33222594866367106" P_Z="0.7050690316557731" STUDIES="2" TAU2="0.0" TOTAL_1="200" TOTAL_2="201" WEIGHT="100.0" Z="0.37848675557024397">
<NAME>dyskinesia: ESRS subscore for dyskinesia (high = poor)</NAME>
<CONT_DATA CI_END="0.5585940577559307" CI_START="-0.5585940577559307" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" ORDER="870" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="179" TOTAL_2="180" WEIGHT="86.77819858084409"/>
<CONT_DATA CI_END="2.1910549544424" CI_START="-0.6710549544424003" EFFECT_SIZE="0.76" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-0.57" ORDER="871" SD_1="1.72" SD_2="2.87" SE="0.7301434953552102" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.221801419155913"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5523030292107468" CI_END="0.8990852658745242" CI_START="-0.5804037548154243" DF="1" EFFECT_SIZE="0.15934075552954993" ESTIMABLE="YES" I2="0.0" ID="CMP-009.04.02" MODIFIED="2010-11-23 17:53:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4573782997000886" P_Z="0.6728967922431175" STUDIES="2" TAU2="0.0" TOTAL_1="262" TOTAL_2="268" WEIGHT="100.0" Z="0.4221756805760946">
<NAME>extrapyramidal symptoms: ESRS total score (high = poor)</NAME>
<CONT_DATA CI_END="1.1275467522310083" CI_START="-0.5275467522310086" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.2" ORDER="872" SD_1="4.0" SD_2="4.0" SE="0.4222254892225529" STUDY_ID="STD-Conley-2001" TOTAL_1="179" TOTAL_2="180" WEIGHT="79.90582221850714"/>
<CONT_DATA CI_END="1.2502381800803697" CI_START="-2.05023818008037" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-1.7" ORDER="873" SD_1="5.38" SD_2="5.63" SE="0.841973726607855" STUDY_ID="STD-Jeste-2003" TOTAL_1="83" TOTAL_2="88" WEIGHT="20.094177781492856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.109754746999261" CI_END="1.5936638434144528" CI_START="-0.1024545310958015" DF="3" EFFECT_SIZE="0.7456046561593257" ESTIMABLE="YES" I2="70.32568964256578" ID="CMP-009.04.03" MODIFIED="2010-11-23 17:53:44 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.01765589975018056" P_Z="0.08485605552674162" STUDIES="4" TAU2="0.40800588619012823" TOTAL_1="241" TOTAL_2="246" WEIGHT="100.0" Z="1.7231795784296116">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="1.356674589623552" CI_START="-0.01667458962355206" EFFECT_SIZE="0.6699999999999999" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="-0.73" ORDER="874" SD_1="3.16" SD_2="2.92" SE="0.35035061615415053" STUDY_ID="STD-Keefe-2006" TOTAL_1="149" TOTAL_2="153" WEIGHT="35.27483273881471"/>
<CONT_DATA CI_END="0.41483105881478655" CI_START="-0.014831058814786607" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.2" ORDER="875" SD_1="0.58" SD_2="0.58" SE="0.1096096971726759" STUDY_ID="STD-Robinson-2005" TOTAL_1="56" TOTAL_2="56" WEIGHT="44.57445032260043"/>
<CONT_DATA CI_END="5.184614276468739" CI_START="1.2153857235312613" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="-1.0" ORDER="876" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="13.06211864613536"/>
<CONT_DATA CI_END="2.9589237798512533" CI_START="-2.8989237798512537" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="-0.17" MEAN_2="-0.2" ORDER="877" SD_1="3.58" SD_2="3.58" SE="1.494376326786732" STUDY_ID="STD-Wang-2006" TOTAL_1="11" TOTAL_2="12" WEIGHT="7.088598292449501"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.8030937483910066" CI_END="3.421581500397212" CI_START="-1.311400112810753" DF="1" EFFECT_SIZE="1.0550906937932294" ESTIMABLE="YES" I2="64.32513180930869" ID="CMP-009.04.04" MODIFIED="2010-11-23 17:53:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09408270795585383" P_Z="0.3822041522032069" STUDIES="2" TAU2="2.107805919127427" TOTAL_1="200" TOTAL_2="201" WEIGHT="100.0" Z="0.8738422961489092">
<NAME>parkinsonism: ESRS subscore for parkinsonism (high = poor)</NAME>
<CONT_DATA CI_END="0.7585940577559307" CI_START="-0.3585940577559308" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.7" ORDER="878" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="179" TOTAL_2="180" WEIGHT="66.59801977370198"/>
<CONT_DATA CI_END="5.7043603592722985" CI_START="-0.18436035927229844" EFFECT_SIZE="2.76" ESTIMABLE="YES" MEAN_1="1.33" MEAN_2="-1.43" ORDER="879" SD_1="5.36" SD_2="4.32" SE="1.5022522773362352" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="33.40198022629802"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.680218144911847" CI_END="28.328788046662694" CI_START="21.080933066530186" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="24.70486055659644" ESTIMABLE="YES" I2="29.58016931826696" I2_Q="0.0" ID="CMP-009.05" MODIFIED="2009-09-21 12:43:43 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2243365196171827" P_Q="1.0" P_Z="1.0167509215531829E-40" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.0493679076191365" TOTALS="SUB" TOTAL_1="623" TOTAL_2="633" UNITS="" WEIGHT="99.99999999999999" Z="13.36137024450451">
<NAME>Adverse effects: 2. Prolactin associated side effects - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.680218144911847" CI_END="28.328788046662694" CI_START="21.080933066530186" DF="4" EFFECT_SIZE="24.70486055659644" ESTIMABLE="YES" I2="29.58016931826696" ID="CMP-009.05.01" MODIFIED="2009-09-21 12:43:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2243365196171827" P_Z="1.0167509215531829E-40" STUDIES="5" TAU2="5.0493679076191365" TOTAL_1="623" TOTAL_2="633" WEIGHT="99.99999999999999" Z="13.36137024450451">
<NAME>change from baseline in ng/ml</NAME>
<CONT_DATA CI_END="25.26527063110632" CI_START="17.73472936889368" EFFECT_SIZE="21.5" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-6.1" ORDER="2" SD_1="27.7" SD_2="22.0" SE="1.9210917449536282" STUDY_ID="STD-Lieberman-2005" TOTAL_1="341" TOTAL_2="336" WEIGHT="39.11589775493603"/>
<CONT_DATA CI_END="35.11007279758952" CI_START="21.849927202410484" EFFECT_SIZE="28.48" ESTIMABLE="YES" MEAN_1="18.75" MEAN_2="-9.73" ORDER="880" SD_1="31.23" SD_2="23.15" SE="3.3827523617202577" STUDY_ID="STD-Keefe-2006" TOTAL_1="130" TOTAL_2="136" WEIGHT="20.729052234274313"/>
<CONT_DATA CI_END="31.0039595393716" CI_START="7.996040460628402" EFFECT_SIZE="19.5" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-4.1" ORDER="882" SD_1="17.91" SD_2="9.2" SE="5.869474964904132" STUDY_ID="STD-McEvoy-2006" TOTAL_1="11" TOTAL_2="16" WEIGHT="8.654950229057075"/>
<CONT_DATA CI_END="35.16595336765522" CI_START="20.83404663234478" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="-15.9" ORDER="883" SD_1="15.88" SD_2="15.57" SE="3.6561658398722354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="18.562903049801395"/>
<CONT_DATA CI_END="36.16175456841995" CI_START="18.03824543158005" EFFECT_SIZE="27.1" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="-5.1" ORDER="884" SD_1="29.6" SD_2="37.4" SE="4.623429124156319" STUDY_ID="STD-Stroup-2006" TOTAL_1="104" TOTAL_2="108" WEIGHT="12.937196731931179"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-11-23 17:54:45 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>RISPERIDONE versus QUETIAPINE - sensitivity analysis (skewed data included)</NAME>
<CONT_OUTCOME CHI2="5.213682230496568" CI_END="-1.0429389396189848" CI_START="-2.479016124507027" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.760977532063006" ESTIMABLE="YES" I2="4.09848972472218" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2010-11-23 17:54:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.39036304447932446" P_Q="0.7554258427159182" P_Z="1.5338168718638488E-6" Q="0.5609473734430681" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.03663426479896103" TOTALS="YES" TOTAL_1="604" TOTAL_2="621" UNITS="" WEIGHT="100.0" Z="4.806778600408999">
<NAME>Mental state: 1. Positive symptoms - average endpoint score (PANSS positive, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.351936445517882" CI_END="-0.6035643808667159" CI_START="-3.556062782612567" DF="2" EFFECT_SIZE="-2.0798135817396415" ESTIMABLE="YES" I2="54.04344652000084" ID="CMP-010.01.01" MODIFIED="2009-09-21 12:44:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11349829000728817" P_Z="0.0057572626181698686" STUDIES="3" TAU2="0.8569088578330966" TOTAL_1="492" TOTAL_2="506" WEIGHT="65.46348259120825" Z="2.761295120333711">
<NAME>short term</NAME>
<CONT_DATA CI_END="-1.415146943201169" CI_START="-4.184853056798829" EFFECT_SIZE="-2.799999999999999" ESTIMABLE="YES" MEAN_1="-8.7" MEAN_2="-5.9" ORDER="885" SD_1="6.16" SD_2="6.24" SE="0.7065706654420051" STUDY_ID="STD-Potkin-2006" TOTAL_1="152" TOTAL_2="156" WEIGHT="25.045792886482285"/>
<CONT_DATA CI_END="0.5139450470094387" CI_START="-8.113945047009437" EFFECT_SIZE="-3.8" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-3.8" ORDER="886" SD_1="7.3" SD_2="7.3" SE="2.2010328154176744" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.7496321276894893"/>
<CONT_DATA CI_END="0.008158543690458764" CI_START="-2.208158543690458" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-4.5" ORDER="887" SD_1="7.13" SD_2="7.24" SE="0.5653974013968989" STUDY_ID="STD-Zhong-2006" TOTAL_1="318" TOTAL_2="328" WEIGHT="37.668057577036464"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3007984115356175" CI_END="0.00926839772661614" CI_START="-4.313911912039684" DF="1" EFFECT_SIZE="-2.152321757156534" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.02" MODIFIED="2009-09-21 12:44:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5833824121997122" P_Z="0.05099045271788573" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="71" WEIGHT="10.830445622739255" Z="1.9515601131134919">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.2375911531627435" CI_START="-5.437591153162744" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.6" ORDER="888" SD_1="1.71" SD_2="5.94" SE="2.213097376980959" STUDY_ID="STD-McEvoy-2006" TOTAL_1="6" TOTAL_2="8" WEIGHT="2.7199569103759424"/>
<CONT_DATA CI_END="-0.00676567877270573" CI_START="-4.993234321227295" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="0.2" ORDER="889" SD_1="7.3" SD_2="7.3" SE="1.2720817019565709" STUDY_ID="STD-Stroup-2006" TOTAL_1="69" TOTAL_2="63" WEIGHT="8.110488712363312"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12623784169196628" CI_START="-2.726237841691966" DF="0" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.03" MODIFIED="2009-09-21 12:45:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07402068788955288" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="44" WEIGHT="23.706071786052505" Z="1.7864854692674523">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.12623784169196628" CI_START="-2.726237841691966" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="-5.3" ORDER="890" SD_1="3.16" SD_2="3.38" SE="0.7276857396064152" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="23.706071786052505"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.3753313535926885" CI_END="1.9512565026196935" CI_START="-0.3128565792958342" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8191999616619297" ESTIMABLE="YES" I2="44.189487072366205" I2_Q="0.0" ID="CMP-010.02" MODIFIED="2010-11-23 17:54:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14628833748488457" P_Q="1.0" P_Z="0.15610148784267416" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.5971144069148632" TOTALS="SUB" TOTAL_1="512" TOTAL_2="521" UNITS="" WEIGHT="100.0" Z="1.4183058556735806">
<NAME>Adverse effects: 1. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.3753313535926885" CI_END="1.9512565026196935" CI_START="-0.3128565792958342" DF="3" EFFECT_SIZE="0.8191999616619297" ESTIMABLE="YES" I2="44.189487072366205" ID="CMP-010.02.01" MODIFIED="2010-11-23 17:54:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14628833748488457" P_Z="0.15610148784267416" STUDIES="4" TAU2="0.5971144069148632" TOTAL_1="512" TOTAL_2="521" WEIGHT="100.0" Z="1.4183058556735806">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high = poor)</NAME>
<CONT_DATA CI_END="2.8115326381547816" CI_START="-2.131532638154782" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-1.64" ORDER="891" SD_1="3.15" SD_2="3.15" SE="1.261009211215061" STUDY_ID="STD-Conley-2005" TOTAL_1="13" TOTAL_2="12" WEIGHT="15.252460693067444"/>
<CONT_DATA CI_END="3.4106402353010723" CI_START="-1.6106402353010725" EFFECT_SIZE="0.9" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-0.1" ORDER="892" SD_1="15.65" SD_2="2.5" SE="1.2809624335470866" STUDY_ID="STD-Potkin-2006" TOTAL_1="153" TOTAL_2="156" WEIGHT="14.906785973390987"/>
<CONT_DATA CI_END="4.584614276468739" CI_START="0.6153857235312612" EFFECT_SIZE="2.6" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="-0.4" ORDER="893" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="20.562458953245766"/>
<CONT_DATA CI_END="0.753941853551781" CI_START="-0.3539418535517811" EFFECT_SIZE="0.19999999999999998" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.41" ORDER="894" SD_1="3.58" SD_2="3.62" SE="0.28262858803590457" STUDY_ID="STD-Zhong-2006" TOTAL_1="321" TOTAL_2="328" WEIGHT="49.27829438029581"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-23 21:17:11 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-11-23 21:17:09 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAV4AAAYwCAIAAAC1ELDpAABRVklEQVR42u3dva4tV1b28SOREDhw
4Ct4r8ERsggQGfeEQwct0aHvAnEJiIaw6YgICbAR7aADN2TQtOZ7miNZc31VzfoYY9Wo+j06ap1e
3ufZc89d9a/5VeP58IGI6KkaEVEnaCAiaCAiaCAiaCAiaCAiaCAiaCAiaCAiaCAiaCAqfktc/qbQ
C0Q398PTv0MDETTc3x7XxAQ0EDUjBWggGrol9AM0EBE0EBE0EK28H5Q7ggaiVzfG079DAxEutCvT
ARqIoAEaiBbdGBc+NA0NRAQNRAQNRNsnFM0OBRH9dFe8+gs0EEEDNEADETRAA9HojWHz0qVARNBA
RNBAtOrG6O8QaCAiy5DQQAQN0EAEDdBAtMONcVkuQAMRQQMRQQPRxhvjcWYBDUS48Pwv0EBH/VX5
ZUEDNNDjxdrkMkIDNNArHFy8AFHajXFlFkNDSTQUnQq52KCBYp9jpdvskoMGMtKpOg5SNhYaiF5i
yzIkNFSdt5f43ZU7PgQN0HCqIbrbDBqgARqgIXV0Zq2BoKESGtzA0EDPFxoKPYH35ULotqg7Ahro
hKOn7dezOwIaiM4zOoMGV22x6zXu+JCqCtBAzwe6V94ItMUIDQQNSc4fXgsaCBqMGhTIgAZrDZXb
HFRVoSKCoYHI6AwaiIzOoIFmn2OlT0NGtFlVBWig8wzOd3e2eQkNfluFdyhKoMHmJTTUnvoWumSL
jhpsXkKDwfkZ1hp2tz1Hz0MDwdnVJ27Q4E4zoXhDP5tQUI3brNZ2Xehyg3sYGqhqCdagG9h1Cw1U
GA1FpyrGI9BQmA4X/8WlbYvuW8+y2EtxbjlKewIf/9kedJiq1lQIGjwns9t8/LWGaDT0g77D/k6h
ARqgIWPiVjTlHBpKjsyLnmsIPbZ4/F8fNBDFrjV4CQoaiAgaaOxR2Zz5OcuU8Ji/R2godmG9+kuV
5YbQzctav8SD/x6hARry7oR92xy9wJlzuPuwA0BogAZomOnnhEoQ0EAXHULXKrgSXT/qsTeggagS
dK78Ghs0UNUJRdrcTSkXqvec3OsMb8RloDpz2m8QGnDhQ6hntH+Vxhd97wMaoCHQs9B5qogbOHqk
Aw1UFQ0J4+dCm5flehsaTFP3X2uoSLcTxH9aayCq9OS0dAoNFDs4j0NDxdOQ0EDhT7O9LtmEhbe4
3dZytSFNKCj2ebv7Kb1zlJY7fj8bNZBL9jxdfc2gXWiAhsCR/1PnuAYf+UoudzYUGqquNUQ/zco9
J8tVtTGhIPP2t32voz3boYGgoSQanlpdszo+NBSeTURvB5Zbazg+zqw1UMbj3T7FCUY6Rg0UeMn6
DUYP0K7bAy4FaKiYcKFSJjTQ1IW1Y46zWtXaDA0EDdoMDfQ+NARNVaABGqjwHDg/08FaAzSQqUr4
DdzUayCChtI4gwbD/pCnWbnTkEXRYEJBlS5Z18C7+tkyJF0UDUUvsHJvZ0ADNJQcNURn57VSJzhL
DNagwdMsfK0haBBRdIGzSq0naKCqo4ai5fCKPYTcG9BQbq3Boiw0UMZM1WJhTldErI8ETjDdckWf
7UeuPlQulCVnDLX7SCeuVh00QEPhEW/OeOT4uViP3bLRGRoMoWvjLHSBs9yowYSCAh+PO04oMjfq
qpSEjwsWhQaqPQkKutNqNbvMM8MVXPchb60hZyR1NeJAgydwOHSqHA0+wW9wR2hCgwvr/qpqhy/T
VnpbtMreBzRAQ8iFFYqG/Hu40LUBDRYaPlR5Vali/Fw5nEED1Zip5iMydLGw0Ehnx1kbNJDp1RnQ
EMJf11m5OUUrGD/XROZBA5WYTybcwNFtLvdgr1L4FxqgobxzITqk9bO1BmiAhhA0xL3pXKWfoaHq
WoP4uVZ5WxQa6OrQKT06Cxo4xIGy/xYmFERAGdYDLoWK1+vxk9Ha6+NJ+3ZIK3gqCRoob9y7l1vC
JbFjdaNyex8RZzd35y80oEPGzRD6s+9/OrhgZSqjBqqHhnK7KkUrU0GDtQYbgbFtLrrWEFLa011H
aeOaKxdcKdTP0ECpV23RjKy9TAq9SA4NtScUO15ehYrNJ2yLlhvp7I5gaPAErvowz/xZjrzcG4Rg
aDBvPxsaDjiAaunbors12NUADZmToCDza45ooIECb4aKk3Zl2qCBTj72OSAaEt6PPDjLoIEKD6rT
FmWPjzNxuO6rpMqCcVOVoOlPiWLz0ECxz1t1FpPHNSXeKLF5CQ3QkDc6U8qFoCF8RaDKK2EEDZ5m
GQNdI52n/dwiK8Q4KE1GOpXQoKI0ETRAA73p2qpyFGffBOfSaw3QQJ7A5bu61vmRpsoTNFRBw7TD
Fv845+h+rgdHd93F0RD0NHtqteMzLcIZGqCh8C+s1vVqw7Wl1GtwGpKoMM6iR5RGDUQEDURvvc0i
hv0tMpoQGogC5xFxr3sffxUDGujlFWbUEOd8/LVkaKh6A7cKxebjKFOUX4VOpkCDCysKDaEnrzOh
dvANVxMKKoyG1p3I2P2c5e73cMUjT3YooCEKDUHxc7XWAuqiwVoDOhSLbw4d8FdEQ5WaV9BAlIdg
y5CUNJC+ckicKSE0UO3khaBm10qXhQZKHTVUGY9M3BuHck57PzLiF2qtgSqh4ZVzxA5IxDGEqw9U
dUTdmcXB1xqgARooe6ZaupRLxHJDtDM0UA00eEIWml6VOwAGDVdHw08DEG9eJqAh7kC6g9LoEHWW
7gTrI9G7Kru39sj7uNBAUc/JogPpFrmFWag3oAEUsg9THR8NBA1nuI2v/Gw/wS/xsM7QcKpZwNVw
Vm4VI/9oGTSgw0FvBsyFBip8ERc9TAUN0ECxD/ZaJyaiz2KE3hHWGqjkc9I5S9MraKCXdMAF1wM0
1H6UHfmZFnpwqOhZDGigjAdaoYPSQW3OcYYGqjfQPfhbA63Umvz0qAQa6Ipo4Jw/z2phBeDajim7
7rqiyw1VxiMltusy4R5XNnYvZ2igqrdZaQRDA5GJGzRQ5Zlq2hP4yi9BNachqdZMNXMVo6KzHQq6
KBpUeUp7tkMDQUNhNFScEtq8tNZQafOyaCmXunC3DEmG0Bn3cIs5GwoNRLW5cPAbGBpcrJXeuewv
zXOUcrF5SZcb6FaEjulVXg+45S4+0KV3/QYP6wwN0FBvElR3pAMNVGaga0Ix2C1xuDyms4uAKO/Z
bq2B8n55R3a+O58X8ZDc3RkaoKH8WPfgzq82U/bNmw5Ku7/yKgM0FCbCkc/enwMNQWcxIm7muIOb
0FBv9hs3eIaGhN8gNJBRAzRAA1lrGBiWH/xcA2doOA8jajlTsSeQjiAiaCAiaCAiaCAiaCAiaLjI
b4IoV9BQAA2cOR/HGRqggTNnaIAGzpyhARo4c4YGaODMGRqggTNnaICGT/r973/87W+/+eGHr77/
/vN/+7cP33332a9//eWPP379+9//5oLOP/7ux2++++arX331+d9//uFvP3z2i8++/OWXX//r17/5
n63Ov/vxx++++eZXX331959//rcfPvzis89++eWX//r11//zm2s5Q0MNNPzXf337/fdffLy7Hv98
vOv+8z9/finnb//j2y/+4YuPRHj885EUP//39c7/8e23//DFF8+MP3y86/795xdyhoYCaPj4mH16
g/V/Pn7NRZw/Dg2eQqH/8/FrVjh/fMzOGX/4+DUXcYaGo6Ph47N39h779OfVc/hMzh/HC7Nc+PTn
1djhlfPHZ++Y8YdXz+EzOR8CDdONm/hwRbP3qXvzUExx8MPpNjz9/ONcvR+T/93fffjTP/3wx3/8
hz9/8Rcf/vEf70fp//u/P5zY+cff/fhqHvF0ZvHDf486f5yrvxqTPx2l//cPZ3Y+BBqm6xEuurWi
0fC0At/4h313j7ftt7/9pr+R/t//+8M//5u/+fDXf/2Hv/zJnwwN0U/j/M133wxyYWJa8dT5u2++
WWL8fIh+GufjouFpCdPHD+/+8urR3R4y11892F/5DI5cItDwww9fPR2H//M//8Hn43P47vNf//rL
Ezt/9auvnlzyn/Tsbvjyl6POv/rqq0W32S+/PLPzQdFwd+tu+XDkv85+5Y5oWDFE+rTnd/fnn/7p
w5/92Yc/+qMPf/VX9//pu+8+O7Hzp33KcTR89otR5097fuN/fvHZmZ3fj4aNQ/ScfzLY7CA0PH38
/vmf/+FX9pd/+Xxh78TOz6HQ6+GGGHR+BZzXxmd2PgQaHt8bPysaZscj40/gj8/ej/qXf3lyj218
th/c2ajBqOG4aJjIehqZrSzduXg1b3/1Z/uKwJGdrTVcYq3h8Zs+rjJuXDhY/U/GN0dW+GzZofj0
55PGDxGdxtkOxSV2KCbumXU7FE//Po2bpzsUE817+tjPPNcwfZttOX1Qwtm5hhznQ+xQvAtDhRrp
NGQvpyFznM+Mhh0zBd/OL+9Q9PIORY6zdyhqDG3+7y3Gz1+/xfizSzl/HDs83634v3nEz75f7/zx
Ofxq5f/j59//7ELO0FBm1vOq9sHTufrpnV/Va3i6vrDI+VXtg6dz9RM7Q8P5F0Q4c4YGaODMGRqg
gTNnaIAGzpyhARo4c4YGcslyhgaa+U0QScomTzPORg3kkuUMDeSS5QwN5MLiDA0EDZyhgaCBMzTQ
wdEgKbtXXFJ2ReeIfoaGGmiQlN0rLim7onNQP0NDATSo8tQrrspTRee4foaGo6NBbci7Z29QbciK
znH9XAwNExkQaQ3YkpQ9fTRVUvasc1xF6YrOcf1cDA0T6Zj5YNqSjtOWJIBLyu4Vl0NR0Tmun2uj
oX8CPyZcL3qMjz/YQykgKXvWOS69qqJzXD+fZ9TwCgpLQ+7GhyRpaJCU3Ssu87Kic1w/V0LDigDL
2Ttw8OYfbMwgGpauNUjKvvkwLCm7onNcPxdDw0Sm9ggapiO5J75sXzTsMmqQlG3UENrPFxo1zH44
PqFYnZS971qDpGxrDXH9XAYNI5na4xAZWWsYT7JN3qGQlG2HIqGfz4CG6R3N6dTsiR2KFpOUvf1c
g6Rs5xoS+rnYDsXp5TTkiLPTkDn9DA0F0NC8Q3Er71Dk9DM0FEBDk5T98BwOSsqu6BzUz9BQAw1N
UvbDHD4oKbuic0Q/Q0MZNHDmnOkMDdDAmTM0QANnztAADZw5QwM0cOYMDdDAmTM0XAcNRJKyydOM
s1EDuWQ5QwO5sDhDA7mwOEMDQQNnaCBo4AwN0FAADZKye9VKnf6k3/3443fffPOrr776+88//9sP
H37x2We//PLLf/366//5zRGdoaEGGiRl9yqXOv1R//Htt//wxRdPy7h8vJ///eeHc4aGAmhQ5alX
xYpJHx/gs/XfPn7NoZyh4ehoUBvybrxQrs7ix6f6YEHpV0/4fOeToGFj+8f/+fbi0YPJN/28V1J2
v75QLnX6dz/++Gq0/3T8/98/vN/5JGh4VRs+FEDrIifGQ7F+kqTsXhVTp7/75pslTX4++E92Pica
XkXgPYZHtBdRN0FJ2bMIk5Q961wxdfpXX3216Ab+5Zfvdz75qGH2Rh3MttoLDesmFJKye1VMnf60
mzj+5xefvd/5DGgYuQl3zJ6bnS/sjgZJ2TcfFkydfoWy101+v/NJ0PAqbG7HNYI3okFS9htHDbu0
2ajhQKOG1WHWCUnZe601SMqukjptreEQe5ZP1x1Cw6yj0SAp+y07FDu22Q7FUdCwaIdiERq2J2W3
zecaJGWXS512roH2J90nOQ3Zy2nIHGdoKICG5h2KW3mHIscZGgqgoUnKfhg71Eqd/vSEf7Wn8PHz
7392OGdoqIGGJin7Yd2hUOr0T6sDT6sqPF0FeLszNJRBA2fOmc7QAA2cOUMDNHDmDA3QwJkzNEAD
Z87QAA2cOUPDddBAJCmbPM04GzWQS5YzNJALizM0kAuLMzQQNHCGBoIGztAADQXQICm7V1xSdq08
6zhnaKiBBknZveKSssvlWTdJ2VdGgypPveKqPFWsxaTK03XRoDbk3XghqDZkxQqOakPGLtKkJWVP
H02VlD3rHFdRumLdZxWlh27s4ydlrwi5aJKybxWXQ1ExLUIOxTI0HDwpe+ngRVJ2r7j0qooZU9Kr
Vo4ajpaUPcsdSdmzznGZlxWTKWVeLh7kx435p79sBYxmf0mSsm8+DEvKrphnLSl7aF3w+EnZ69Ya
JGUbNRg1hCwNtsMkZa9Dg6Rsaw3WGnbYdDxyUvYuOxSSsu1Q2KFYiYYjJ2VvP9cgKdu5hgTnk+xQ
nEZOQ444Ow2Z4wwNBdDQvENxK+9Q5DhDQwE0NEnZD2OHoKTscnnWTVL2xdHQJGU/rDsEJWXXyrOO
c4aGMmjgzDnTGRqggTNnaIAGzpyhARo4c4YGaODMGRqggTNnaLgOGogkZZOnGWejBnLJcoYGcmFx
hgZyYXGGBoIGztBA0MAZGqChABokZfeKS8qOa7OkbNofDZKye8UlZce1WVI27Y8GVZ56xVV5imuz
Kk+0PxrUhrwbLwTVhoxrs9qQ+98qI8c5dxmuz1aInvCRlJ3mHFdROq7NKkqHP0U3NnJFhuWrzppg
ytIPZ1soKbtXXA5FXJvlUKSiYSL5+umDetE/n87XPUh6laTsfdOr4tosvSoPDYuSryf+66uvnO6y
ZDRIyu4Vl3kZ12aZl3lrDRvvxiA0vGLTllWMJin77sOwpOy4NkvKfv+o4S1omJ6zNEnZRZKy49ps
1HBdNAze8JKyj5yUHddmaw2HRkPdtQZJ2W/ZodixzXYo8tYa2nDy9dIdii0TCknZCc5p5xp2bLNz
DbTzKOknOQ3Zy2nIHGdoKICG5h2KW3mHIscZGgqgoUnKfhg7BCVlx7VZUjaFoKFJyn5YdwhKyo5r
s6RsCkEDZ86ZztAADZw5QwM0cOYMDdDAmTM0QANnztAADZw5Q8N10EAkKZs8zTgbNZBLljM0kAuL
MzSQC4szNBA0cIYGggbO0AANBdAgKbtXXFJ2rTzruH6GhhpokJTdKy4pu1yedVw/Q0MBNKjy1Cuu
ylPFWkxx/QwNR0eD2pB344Wg2pAVKzjG9XN5NKxO0179I0vKfqNzXEXpinWf4/r5JGjIWcjtO+vV
d5SUHe0cl0NRMS0irp/PjIbHULnp3IpXwdmP5pKy3+gcl15VMWMqrp9PjoalcVXtdYzt4DhFUna0
c1zmZcVkyrh+PvNaw3iy9uxtvAVGI/HZ078kSdk3H4YlZVfMs47r5/NPKCbw8TjXeDXQGFyGbMOB
ek1StlFD2Khhl36+EBom/uH4XbruP238UFK2tYb8fr4iGuImFE1SdryzHYqcfr7KWsPqHYpFEwpJ
2QnOzjXk9PMZ0HAmOQ054uw0ZE4/Q0MBNDTvUNzKOxQ5/QwNBdDQJGU/jB2CkrLL5VnH9TM01EBD
k5T9sO4QlJRdK886rp+hoQwaOHPOdIYGaODMGRqggTNnaIAGzpyhARo4c4YGaODMGRqugwYiSdnk
acbZqIFcspyhgVxYnKGBXFicoYGggTM0EDRwhgZoKIAGSdm9JGVHO0NDDTRIyu4lKTvBGRoKoEGV
p16qPOU4Q8PR0aA25N14QW3IBOeqaFgRjb3Los7G4tGSsiVll3CuiobBqvA531dSdqazHIoc55Jo
eBoDMfFY/ilIbjoIeyJTe7oZkrIznaVX5TifBA2zT/VXiVWDsHgvGiRl95J5meN8NjSsuHXviLAi
wCoaDZKybz6UlJ3ifEI0TGdej6Bh8D32NDRIyjZqMGrYutaw4i6dGDUMNuBdaw2Ssq01WGtY89Be
d5euuHslZWc626GwQzFPh6fN/unD1XfpxGxiIpVbUnaOs3MNOc6F0XBKOQ054uw0ZI4zNNRYYfUO
RS/vUOQ4Q0ONzRdJ2XdjB0nZ0c7QUAMNTVL2w7qDpOxQZ2gogwbOnDOdoQEaOHOGBmjgzBkaoIEz
Z2iABs6coQEaOHOGhuuggUhSNnmacTZqIJcsZ2ggFxZnaCAXFmdoIGjgDA0EDZyhARoKoEFSdq+4
pOy4NkvKpv3RICm7V1xSdlybJWXT/mhQ5alXXJWnuDar8kT7o0FtyLvxQlBtyLg2qw15iLvraR3n
aP+RD2dPp0rKnnWOqygd12YVpY/11I1I046OnJCUPescl0MR12Y5FIcbjT9GVI082J9+5cS3W4GG
RTkUkrJ7xaVXxbVZetVx1/AmwrIfPxwMudsSgbPoR5CU3Ssu8zKuzTIvD42GwZF8aFL2OjRIyr75
MCwpO67NkrLroWEwVvu9aJCU/cZRwy5tNmo4+lrDLsuHbUNS9vgkZWQOLCk7Z61he5utNdTYoXi6
6LBlZyEaDZKy37JDsWOb7VAchQ7T5xoeJxSLdha2J2UvRYOk7F5p5xp2bLNzDRS1XOI0ZC+nIXOc
oaHGSqp3KHp5hyLHGRoKoKFJyn4YOwQlZce1WVI2haChScp+WHcISsqOa7OkbApBA2fOmc7QAA2c
OUMDNHDmDA3QwJkzNEADZ87QAA2cOUPDddBAJCmbPM04GzWQS5YzNJALizM0kAuLMzQQNHCGBoIG
ztAADQXQICm7l6TsaGdoqIEGSdm9JGUnOENDATSo8tRLlaccZ2g4OhrUhrwbL6gNmeBcFQ2zZzyD
FnW2JGWP/CaeznslZffrC5KyE5yromF7Cvb2f7Uu6mb2yPrjh5Kye0nKznEuiYbZkJiR8OuJf7I0
224pL5aiQVJ2L0nZOc4nQcPsU30iJvspRILQsG5CISm7l6TsHOeroGHiw+2Pd0nZmc6SsnOcoeF5
Vt2h0CAp+42jBknZJ1lr2DhqmJhZTDQgGg2Sst+71iAp+ww7FHtNKMa5kIAGSdlv2aGQlN1Odq7h
1Q7F9K07GGm9PSm7bT7XIClbUnaCc2E0vHFFI/+bOg3Zy2nIHGdoOAoXmncohp29Q5HjDA01kCQp
+27sICk72hkayoxWJGXfrTtIyg51hobzT2Q4c4YGaODMGRqggTNnaIAGzpyhARo4c4YGcslyhgaa
+U0QScomTzPORg3kkuUMDeSS5QwN5MLiDA0EDZyhgaCBMzTQwdEgKbtXXFJ2rTzruH6GhhpokJTd
Ky4pu1yedVw/Q0MBNKjy1CuuylPFWkxx/QwNR0eD2pB344Wg2pAVKzjG9XOTlL39+6748MNwjpCk
7Lv1haCK0hXrPsf1c1U0lE7KXtoqSdm94nIoKqZFxPVzSTRUT8peigZJ2b3i0qsqZkzF9fNJ0DD7
VD9IUvbsu26Ssmed4zIvKyZTxvXzVdAw8WFmUvYsdCRlzzrHJWVXzLOO62doeENS9tIPJWUbNeT3
89nWGkokZS/9UFK2tYb8fj7bDsXBk7LX8UJSth2K/H6uioZWNil7xTKkpOxezjXk9HNhNLxxRSP/
mzoN2ctpyJx+hoajcKF5h2LY2TsUOf0MDTWQJCn7buwQlJRdLs86rp+hocxoRVL23bpDUFJ2rTzr
uH6GhvNPZDhzhgZo4MwZGqCBM2dogAbOnKEBGjhzhgZyyXKGBpr5TRBJyiZPM85GDeSS5QwN5JLl
DA3kwuIMDQQNnKGBoIEzNNDB0SApu1dcUnZcm2tlcENDDTRIyu4Vl5Qd1+ZyGdzQUAANqjz1iqvy
FNfmivWjoOHoaFAb8m68EFQbMq7NFatOtuoVpePyshfVm0+rKC0pO6iidFybK9aqro2G6PXbiXrz
r74sIYdCUnZQDkVcmysmXJwHDW3vvOyJb7ELGsZhJCm7V1x6VVybK+ZinRMNu+Rlt4Bgu6d4mv0l
ScruFZd5Gdfmimmapx01LH2M74KGV/SZ/oLZH0FS9s2HYUnZcW2umMF9/gnF9rzs8WXIp23YvtYg
KfuNo4Zd2mzUcPQJxeCoYcUOxZaRy+o5sKTsnLWG7W221nCUHYrZAfx71xo27lBIys7ZodixzXYo
stEwca5hcDC/dIdiekIhKTvBOe1cw45tdq6B9p8lfZLTkL2chsxxhoYCaGjeobiVdyhynKGhABqa
pOyHsUNQUnZcm8tlcENDDTQ0SdkP6w5BSdlxba6VwQ0NZdDAmXOmMzRAA2fO0AANnDlDAzRw5gwN
0MCZMzRAA2fO0HAdNBBJyiZPM85GDeSS5QwN5MLiDA3kwuIMDQQNnKGBoIEzNEBDATRIyu4Vl5Rd
K886zhkaaqBBUnavuKTscnnWTVL2ldGgylOvuCpPFWsxqfJ0XTSoDXk3XgiqDVmxgqPakLdtHQ7I
nigevbEBGz8cLzYvKftufSGoonTFus8qSr/8McYDZsczaQe/+7rIienvLil71jkuh6JiWoQciqkf
YzBLoo+ifRpCN/20Hx+PDH44jgZJ2b3i0qsqZkxJrxpCw2A+1caAqY1oWBFRIym7V1zmZcVkSpmX
70HD0plFiwm2k5R982FYUnbFPGtJ2XloGJxQrEPD/HUvKduowajhsGiY7bLVcbjr0CAp21qDtYZN
OxSr0TAbqL1oHXR3XkjKtkNhh2IIDbMB2YOMaM8CtacnFK++u6TsNGfnGnKc66Hh3HIacsTZacgc
Z2gogIbmHYpbeYcixxkaCqChScp+GDsEJWWXy7NukrIvjoYmKfth3SEoKbtWnnWcMzSUQQNnzpnO
0AANnDlDAzRw5gwN0MCZMzRAA2fO0AANnDlDw3XQQCQpmzzNOBs1kEuWMzSQC4szNJALizM0EDRw
hgaCBs7QAA0F0CApu1fFpOxa/QwNNdAgKbtXxaTscv0MDQXQoMpTr4pVnir2MzQcHQ1qQ96NF8rV
hqzYz+0iSdl7jeq3F4+e/k08nUNKyu7XF8pVlK7YzyXRsOjO3xcNuyRlL0WDpOxeFXMoKvZzeTS0
VUnZ08/2wUTc1UnZS9EgKbtXxfSqiv18KjTMJtMsTcTdPSl73YRCUnavipmXFfv5WmiY7ovxZ3vb
Foe7FA2Ssm8+LJiUXbGfoaE9LmpGJ2XvMmqQlF191HDwfr46GtZNKDYmZe+11iApu/paw5H7+VQ7
FFvQMLsSMb4OujsaJGWfbIeiRD+XRMPGpOw2F5Y9fVdvTMpum881SMqufq6hRD/XQ8O55TTkiLPT
kDnO0FAADc07FLfyDkWOMzQUQEOTlP0wdiiXlF2un6GhBhqapOyHdYdySdm1+hkayqCBM+dMZ2iA
Bs6coQEaOHOGBmjgzBkaoIEzZ2iABs6coeE6aCCSlE2eZpyNGsglyxkayIXFGRrIhcUZGggaOEMD
QQNnaICGAmiIy4aWlN0rLim7ljM01EBDXDa0pOxecUnZ5ZyhoQAa4uoaqfLUK67KU0VnaDg6GuKq
IaoNeffsDaoNWdG5MBrG87J3XOPZmJQ93ebkGsqSsu/m6kEVpSs6F0bDYGhtwjfdHp89/WFc8oKk
7F5xORQVnauiYV2G1UR03WyoxEQbdqRAcl6TpOxecelVFZ3Pg4bZB/teqbn5aIhLeZSU3Ssu87Ki
8xnQ8BhmO36jrkbDxjjcRWsNcdnQkrJ7xSVlV3S+1oTiDiWvci4H32NfjYaDjxokZRs1XBcNg7OD
we9+vrUGSdnWGk64QzG+vrBuQrElKfvgOxSSsu1QnAENbTKKeiL8essOxfak7COfa5CU7VzDSdCQ
s+VxhGY4DZnTG05DQsMRudC8Q3GA3vAOBTTUg1RcNrSk7LvncFBSdjlnaCgzfonLhpaUfTeHD0rK
ruUMDeef2nDmDA3QwJkzNEADZ87QAA2cOUMDNHDmDA3kkuUMDTTzmyCSlE2eZpyNGsglyxkayCXL
GRrIhcUZGggaOEMDQQNnaKCDo6FinrWk7BzniH6GhhpoqJhnLSk7xzmon6GhABoq1mJS5SnHOa6f
oeHoaKhYwVFtyBznuH4+Lhqmy7pvWacZzJ5Z1LBFxaMXVZSumGctKTvHOa6fT4WGnIXApwh4/PuO
wXYV86wlZec4x/VzYTRMZEn8FELx+F/v8ikmvmziaZ+Mhop51pKyc5zj+rkqGmYTqMY/HPmy6Yat
COBdhIaKedaSsnOc4/r56Gh49fboinC62Q9nn/azaJhF0jo0VMyzlpSd4xzXz4VHDdNp15loaM+i
9Npkvt72UcPB86wlZb9x1LBLP59hQrGCArujYeZBN0m01fPJI+dZS8p+71rD9n4+7VrD6n+yZUIx
7rNlh6JEnrWk7LfsUOzYz2feoRhfF5xeMhyfUOScayiRZy0pO8c5rp8PjYYLymnIEWenIXP6GRoK
oKF5h+JW3qHI6WdoKICGVjPPWlJ2jnNQP0NDDTS0mnnWkrJznCP6GRrKoIEz50xnaIAGzpyhARo4
c4YGaODMGRqggTNnaIAGzpyh4TpoIJKUTZ5mnI0ayCXLGRrIhcUZGsiFxRkaCBo4QwNBA2dogIYC
aJCU3SsuKVsGNzRUQoOk7F5xSdkyuKGhEhpUeeoVV+VJ/ShoqIQGtSHvnupBtSFVnSyMhrdk5D7p
rIHi0UvLTDdJ2QPOcRWl1aqGhn2++8ZEnPEi9JKye8XlUEi4OCcaZrMkXuVWvHqwz0InggKSsmed
49Kr5GJdEQ0TsHh1S8/2SRoaJGX3isu8lKZZHg3T8dmP/7vvLT39ZSM+S9caJGXffBiWlC2D+7Rr
DdNomEjWTkbDLqMGSdlGDUYNO6Bhx5XCtkcc7i5rDZKyrTVYaxjdoRhcjBy5pceTbJN3KCRl26Gw
Q7EbGp7uO8xmZ08kYj9udqSda5CU7VxDgnM9NLwXQ+/6jk5D9nIaMscZGl6OCw4FI+9Q9PIORY4z
NNQYp0jKvnvCByVly+CGhnpTGEnZd6sDQUnZMrih4SqrG5w5QwM0cOYMDdDAmTM0QANnztAADZw5
QwO5ZDlDA838JogkZZOnGWejBnLJcoYGcslyhgZyYXGGBoIGztBA0MAZGujgaJCU3SsuzzquzZKy
aX80SMruFZdnHddmSdm0PxpUeeoVV4sprs2qPNH+aFAb8m68EFTBMa7NakNWXcwb/yeSst/rHFf3
Oa7NKkqfHw2Sst/uHJcWEddmORRHRMPIo3v6/85+F0nZmc5xGVNxbZZedTg0rHieD2ZeNknZb3KO
S6aMa7PMy3poWHFLT3+ZpOxo57g867g2S8o+IhoGc+hm/8mOaNhl1CApO2fUsEubjRoOtL4wuLg4
PaEYXLOUlJ3pnL/WsL3N1hoOjYa91hokZb/XOW2HYsc226F4Px1WHy4Y3KGQlP1257RzDTu22bkG
2nPs08tpyF5OQ+Y4Q0MBNDTvUNzKOxQ5ztBQAA1NUvbD2CEozzquzZKyKQQNTVL2w7pDUJ51XJsl
ZVMIGjhzznSGBmjgzBkaoIEzZ2iABs6coQEaOHOGBmjgzBkaroMGIknZ5GnG2aiBXLKcoYFcWJyh
gVxYnKGBoIEzNBA0cIYGaCiABknZveKSsmvlWcc5Q0MNNEjK7hWXlF0uz7pJyr4yGlR56hVX5ali
LSZVnq6LBrUh78YLQbUhK1ZwVBty5a21+8+1V1L2eLF5Sdl36wtBFaUr1n1WUXolGiK48Pj3RZET
gzmavSRl94rLoaiYFiGHYtOt++oZ/unvS6MitqBh3LOXpOxecelVFTOmpFctRsNg9lxyUvbsu26S
smed4zIvKyZTyrxchobdb+nx4UlEsJ2k7JsPw5KyK+ZZS8petkb4aj3y7oktKVtStlHD1dcadlwO
aJKy3+psrcFaw547FNPrC01StqRsOxSXQsNTKIzsL0rKvmBStnMNZ0bD+dD2SU5D9nIaMscZGgqg
oXmH4lbeochxhoYCaGiSsh/GDkFJ2eXyrJuk7IujoUnKflh3CErKrpVnHecMDWXQwJlzpjM0QANn
ztAADZw5QwM0cOYMDdDAmTM0QANnztBwHTQQScomTzPORg3kkuUMDeTC4gwN5MLiDA0EDZyhgaCB
MzRAQwE0SMruJSk72hkaaqBBUnYvSdkJztBQAA2qPPVS5SnHGRqOjga1Ie/GC2pDJjifAQ27BGQP
dsJeSdnjvyRJ2XfrCypKJzifEw3ruLD0yzbG4a7OoZCULYciwfmEaFjx6J7+v7PfVFJ2prP0qhzn
s6FhdeRcWlL29MxFUvass8zLHOdToWGXyLnopOzpEYSk7FlnSdk5zudBw1M6PH0p/dWHE/91RzSs
WGuQlG3UYNSw81rDiojq0KTsdW2TlG2twVrDzjsUERMKSdnvdbZDYYdi09bj9HbD06jr6U2N6emG
pOw0Z+cacpxPgobTyGnIEWenIXOcoaEAGpp3KG7lHYocZ2gogIYmKfth7CApO9oZGmqgoUnKflh3
kJQd6gwNZdDAmXOmMzRAA2fO0AANnDlDAzRw5gwN0MCZMzRAA2fO0HAdNBBJyiZPM85GDeSS5QwN
5MLiDA3kwuIMDQQNnKGBoIEzNEBDATRIyu5VMSk7rs0R/QwNNdAgKbtXxaTsuDYH9TM0FECDKk+9
KlZ5imtzXD9Dw9HRoDbk3bO3XG3IuDbH9XM2Gj4szM8JXYBZ1/5dkrLH+0FS9t1cvVxF6bg2x/Xz
UdDwrrXZLS1ZFzmxAoKSsntVzKGIa3NcPx9x1PAqJGI8TuLuf59GTi79XhNtlpSd6VwxvSquzXH9
fDg0jKfIjnzldofd0bAiokZSdq+KmZdxbY7r5zJo2HEYv6IBgzOLFhNsJyn75sOCSdlxbY7r5yOi
YSLGet1XTv990GEXNKxbjpWUbdSQ38+HHjWM33tLcbDllm4bkrLXoUFStrWG/H4+4VrDCjQsGjVI
yn6vsx2KnH5+Dxoe5wL77lAsnVCM372Sst/u7FxDTj+/AQ20dEjVnIa8ldOQOf0MDQXQ0LxDcSvv
UOT0MzQUQEOTlP3wHC6XlB3X5qB+hoYaaGiSsh/m8OWSsuPaHNHP0FAGDZw5ZzpDAzRw5gwN0MCZ
MzRAA2fO0AANnDlDAzRw5gwN10EDkaRs8jTjbNRALlnO0EAuLM7QQC4sztBA0MAZGggaOEMDNBRA
g6TsXhWTsuOcJWVfFw2SsntVTMqOc5aUfV00qPLUq2KVpzhnVZ6uiwa1Ie/GC+VqQ8Y5qw35/GeY
/6kGToMubcMuSdnjvyRJ2XfrC+UqSsc5nyope/tt+er/JqzoBuXuTX8oKbtXxRyKOOdTJWXHoWEi
k2L23t6SbScpO9O5YnpVnPOpkrK3P7Qf/3f6L9NoGPlkXzRIyr5aUnac86mSsqPRMLvWMBJX9ciI
kdFHW5XQN/tLkpR982HBpOw451MlZWeiYdYkHw0r1hokZRs1tCskZZ8ADauTstehQVK2tYZ2haTs
XTYIFv1lxTN/nAtNUrak7MPsUNROyg5Cw6sNi1fB1k9XJeYnupKy3+3sXENOPxdDw1swdIRv6jRk
L6chc/oZGo7CheYdimFn71Dk9DM01ECSpOy7sUO5pOw4Z0nZVx+tSMq+W3col5Qd5ywp20SGM+ck
Z2iABs6coQEaOHOGBmjgzBkaoIEzZ2iABs6coeE6aCCSlE2eZpyNGsglyxkayIXFGRrIhcUZGgga
OEMDQQNnaICGAmiQlN1LUna0MzTUQIOk7F6SshOcoaEAGlR56qXKU44zNBwdDWpD3o0X1IZMcG6S
spe2YXXx6Nn2SMqedVZROse5HhpKJ2XPNk9S9qyzHIoc51Oh4fhJ2bO2krJnnaVX5TiXnFDUTcoe
9+wlKbuXzMsc5xOiYXat4Y1xuOvQICn75kNJ2SnOJ0fDrEkJNEjKNmowaqiBhtVJ2bOLo5KyrTVY
a9i0QVA0KXsdGiRl26GwQ7EeDa1OUvZSNEjK7uVcQ45zMTS8BUNH+KZOQ/ZyGjLHGRqOwoXmHYph
Z+9Q5DhDQw0kScq+GztIyo52hoYyoxVJ2XfrDpKyQ52h4fwTGc6coQEaOHOGBmjgzBkaoIEzZ2iA
Bs6coYFcspyhgWZ+E0SSssnTjLNRA7lkOUMDuWQ5QwO5sDhDA0EDZ2ggaOAMDXRwNEjK7iUpO7o3
oKEGGiRl95KUndAb0FAADao89VLlKac3oOHoaFAb8u4JqTZkQm+UQcOimOybH2zhjzZb9Hl1Una7
PQo9+K0lZd/NqFWUTuiNYmgYj8luS9IfFvXU49+TcygkZcuhSOiN86BhNiZ7PK4qLg53ZJjz+KGk
7F7Sq3J6o96EYktM9vRNu8hkNRqm5ziSsmedZV7m9MbZ0PDq/n9650/fyetmK+tmGdMfSsq++VBS
dkpvXAINK27a1QsZGykgKduowajh0GiY7rItSdkrPpSUba3BWsPQEt3gEsPIg30FGrYkZa/jhaRs
OxR2KFai4dVe5qupwU8fLt1r3CUpe+kypKTsXs415PRGJTRcQU5Djjg7DZnTG9BQAA3NOxS38g5F
Tm9AQwE0NEnZD09LSdnRvQENNdDQJGU/zLQlZYf2BjSUQQNnzpnO0AANnDlDAzRw5gwN0MCZMzRA
A2fO0AANnDlDw3XQQCQpmzzNOBs1kEuWMzSQC4szNJALizM0EDRwhgaCBs7QAA0F0CApu5ek7Ghn
aKiBBknZvSRlJzhDQwE0qPLUS5WnHGdoODoa1Ia8Gy+oDZngfHI0rMjXnv7KXYpHb6koLSlbRekE
50ugYVG+9jgsVkdOLC02Lym7lxyKHOero+FpokRbGHsZjQZJ2b2kV+U4X2VCMRuHNxtptRcapqEj
KXvWWeZljjM0LHjaz84sgtAgKfvmQ0nZKc7QkIqGpUG7E09gSdlGDUYNh0PD6qTs2foZkrKtNVhr
yN68HIzVXhFmvcJnyw6FpGw7FHYoYtEwsUMxcUtvTMpegQZJ2b2ca8hxPj8aioLsTk5D9nIaMscZ
GgqgoXmH4lbeochxhoYCaGiSsh/GDpKyo52hoQYamqTsh3UHSdmhztBQBg2cOWc6QwM0cOYMDdDA
mTM0QANnztAADZw5QwM0cOYMDddBA5GkbPI042zUQC5ZztBALizO0EAuLM7QQNDAGRoIGjhDAzQU
QIOk7F6SsqOdoaEGGiRl95KUneAMDQXQoMpTL1Wecpyh4ehoUBvybrygNmSCc3k0jFR/n60Hv+jb
bUnKXpFDISn7bn1BRekE55OgYVEW9hY0bE/KHmxbL0nZveRQ5DifHw0TSRPjkdnjiBn/cBwNkrJ7
Sa/KcT7PhGJFdN14ZPaOaJh+101S9qyzzMscZ2hY+YTfGIfbhlPzmqTsuw8lZac4Q8P9wzwUDfPX
vaRsowajhmOOGgb7a93a5Do0SMq21mCtYdPm5dKZwroJxZak7HW8kJRth8IOxc5o2L5D8bynNiRl
r1iGlJTdy7mGHOczoOFMchpyxNlpyBxnaCiAhuYdilt5hyLHGRoKoKFJyn4YO0jKjnaGhhpoaJKy
H9YdJGWHOkNDGTRw5pzpDA3QwJkzNEADZ87QAA2cOUMDNHDmDA3QwJkzNFwHDUSSssnTjLNRA7lk
OUMDubA4QwO5sDhDA0EDZ2ggaOAMDdBQAA2SsntJyo52hoYaaJCU3UtSdoIzNBRAgypPvVR5ynGG
hqOjQW3Iu/GC2pAJzu9Ew+BpzeMs2Lzyz6woLSlbRekE5/ejIeKWDv1Znt7tj3+Py6GQlC2HIsH5
uGiYDoZY8ZUTWdjjD/an8dnRaJCU3Ut6VY7zQdGw8WZbkYU9fvfmo0FSdi+ZlznOB11rWHezTTzb
NxqOE+1V1u7Eh7O/JEnZNx9Kyk5xPtaoYRoZiyYUrz5ZZzi4DPnUZ+TDFU9gSdlGDScfNYx/Pj4a
X5GFvSgsexE1mqRsSdnWGiLQMDhEb9uysI+81iAp2w7F1XcoZrcJJoboq3codpxQSMpOcHauIcf5
zWigwV+S05C9nIbMcYaGAmho3qG4lXcocpyhoQAamqTsh7GDpOxoZ2iogYYmKfth3UFSdqgzNJRB
A2fOmc7QAA2cOUMDNHDmDA3QwJkzNEADZ87QAA2cOUPDddBAJCmbPM04GzWQS5YzNJALizM0kAuL
MzQQNHCGBoIGztAADQXQICm7l6Ts6H6GhhpokJTdS1J2Qj9DQwE0qPLUS5WnnH6GhqOjQW3Iu/GC
2pAJ/VwbDYuytidiKcZ//I3FoyVlS8re0Tmun8+AhvE7fFF63ey3iwi5kJQ96yyHIqefz4yGxxi7
VzEWj3fv6jHIRgpIyp51ll6V08+nRcPSVKvZaKw3okFSdi+Zlzn9fNq1hhE0rA62a2tjuB/pM/JL
kpR986Gk7JR+PtuoYRwNr1CSgIZdRg2Sso0aQvv5umiY/UsLiMPdd61BUra1hrh+hoYP229pSdmZ
znYocvr5tGh4NWsY3KGYoMCrpQ1J2TnOzjXk9HN5NJxMTkOOODsNmdPP0FBjEOQdil7eocjpZ2go
gIYmKfth7CApO7qfoaEGGpqk7Id1B0nZof0MDWXQwJlzpjM0QANnztAADZw5QwM0cOYMDdDAmTM0
QANnztBwHTQQScomTzPORg3kkuUMDeTC4gwN5MLiDA0EDZyhgaCBMzRAQwE0VEydrthmGdzQUAkN
FVOnK7ZZBjc0VEJDxYpJFdusfhQ0VEJDxTqLFdus6uR50CAp+5ip0xXbrFb12dAwfodLyr5TXKZD
xTZLuLgKGg6YlD3u2ati6nTFNsvFugQajpmUPcud06ROV2yzNM1LrDUcMyl7ljunSZ2u2GYZ3Gce
NYyj4S1J2evWGiqmTldss1EDNLwtKXsdGiqmTldss7UGaJCUnb1DUaLNdigugYYmKXvAOe1cQ4k2
O9dwKjScTE5DvrfNTkNCQ71BkHcoctrsHQpoKIaGVjN1umKbZXBDQzE0tJqp0xXbLIMbGoqhgTPn
TGdogAbOnKEBGjhzhgZo4MwZGqCBM2dogAbOnKHhOmggkpRNnmacjRrIJcsZGsiFxRkayIXFGRoI
GjhDA0EDZ2iAhgJoqJhnXTEpOy7PulaboaEGGirmWVdMyo7Lsy7XZmgogIaKtZgqVnmKq5hUsc3Q
cHQ0VKzgWLE2ZFydxYptroSGRbnYQcs5+UnZFfOsKyZlx1VnrtjmemjYfpNv+UnfkpRdMc+6YlJ2
XKZDxTafBA3T2bP9D9km07RbYlL2OBoq5llXTMqOS4Kq2OaTo2E8CDszKXspGirmWVdMyo7Lj6zY
5pOsNSy6DzfevaHmp8mzrpiUHZc6XbHNtUcNF0FDxTzriknZRg3QsBUNyUnZFfOsKyZlW2s4MxpW
LyUcOSm7Yp51xaRsOxQnRMPTDYinBwoGdygmKJCflF0xz7piUrZzDYXRcHo5Dfne3nAaEhrqDYu8
Q5HTG96hgIZiaGg186wrJmXH5VmXazM01EBDq5lnXTEpOy7PulaboaEMGjhzznSGBmjgzBkaoIEz
Z2iABs6coQEaOHOGBmjgzBkaroMGIknZ5GnG2aiBXLKcoYFcWJyhgVxYnKGBoIEzNBA0cIYGaCiA
BknZOb0Rl5Qd5xzRz9BQAw2SsnN6Iy4pO845qJ+hoQAaVHnK6Y24iklxznH9DA1HR4PakDm9EVdn
Mc45rp9PjobxM6FLDXf8cPqXJCk7pzfiqjPHOcf18yXQsONKr6TstztXzHSIc47r56ujITkpe/b3
ISn7jb0RlwQV5xzXz5dGQ35S9jo0SMrO6Y24/Mg457h+vvRaQ34c7qyzpOw39kZc6nScc1w/X2vU
8GpFcDYI871okJRt1JDfz5ebUCwa5++elL2IOG9ca5CUXX2tYXs/Q8MOawSLfAbXL96yQyEpu/oO
xY79bIciNSl79oSFpOw39sYJzjXs2M/nR0N1kH2S05A5veE0JDQUQ0PzDkVWb3iHAhqKoaFJys7q
jbik7DjnoH6GhhpoaJKys3ojLik7zjmin6GhDBo4c850hgZo4MwZGqCBM2dogAbOnKEBGjhzhgZo
4MwZGq6DBiJJ2eRpxtmogVyynKGBXFicoYFcWJyhgaCBMzQQNHCGBmgogIaKedaSsus6Q0MNNFTM
s5aUXdoZGgqgoWItJlWeqjtDw9HRULGCo9qQ1Z2romEwlmrLAP5V0eddkrLHK0pXzLOWlF3duTYa
ti/hLkXD9lDsFTCqmGctKbu68znRMJgQ0ZZkUkw0YB0vxtFQMc9aUnZ155OjYfr+nI26jEDD9Ltu
p8mzlpRd3fnkaw07fjgys1g9y5j+sGKetaTs6s4nGTW8CrYcz8Ke/cpd0DCyxjn4BD54nrWkbKOG
o0woxh/7675yy7feiIaKedaSsq01lEHDXmsNEdsWi1b7S+RZS8q2Q3GtHYqNSdmvPpz+JVXMs5aU
Xd25MBpOKachR5ydhsxxhoYCaGjeobiVdyhynKGhABpazTxrSdmlnaGhBhpazTxrSdl1naGhDBo4
c850hgZo4MwZGqCBM2dogAbOnKEBGjhzhgZo4MwZGq6DBiJJ2eRpxtmogVyynKGBXFicoYFcWJyh
gaCBMzQQNHCGBmgogAZJ2b3ikrLj2hyXlB3RZmiogQZJ2b3ikrLj2hyXlB3UZmgogAZVnnrFVXmK
a3NcLaa4NkPD0dGgNuTdeCGoNmRcm+MqOMa1+f1oGD+2OfGTpLVfUvZ7neMqSse1Oa7uc1ybj4KG
Rff5QZoqKfstznE5FHFtjkuLiGtzATS8ioeYzrlc/WB/9c8nmi0pO9M5Lr0qrs1xGVNxbT46Giby
KV995fR/XWe+IxokZR82KTuuzXHJlHFtPvpaw7q4usHH9brsucH5gqTscknZcW2Oy7OOa/PhRg27
JFkumphkomHdYqqk7DeOGnZpc/KoYZc2H3FCETFq2DgRWNFgSdnlkrLj2py/1rC9zVXRML3WsNdK
oaTsSyVlx7U5bYdixzafdodixGd8lvFqWWSpeZOUfeCk7Lg2p51r2LHNh0ADzf6SnIbs5TRkTpuh
oQAamncobuUdipw2Q0MBNDRJ2Q9jh6Ck7Lg2xyVlB7UZGmqgoUnKflh3CErKjmtzXFJ2RJuhoQwa
OHPOdIYGaODMGRqggTNnaIAGzpyhARo4c4YGaODMGRqugwYiSdnkacbZqIFcspyhgVxYnKGBXFic
oYGggTM0EDRwhgZoKIAGSdm9JGVHO0NDDTRIyu4lKTvBGRoKoEGVp16qPOU4Q8PR0aA25N14QW3I
BOfDoWE8MnvfxZvpuvWPzVv34XSrJGXPOkvKznE+HBomMiny0TDttjpyYmmxeUnZvSRl5zhXQsPE
k3nik8Hg7KcvnOweh7sODZKye0nKznE+OhoGH9f7BmfHJWX3qBr/8SVl95KUneNccq1h4tbdJXVu
9cwiCA2Ssm8+lJSd4nz0HYqnE4pd0DDhFoeGWWdJ2UcbNRw8KftCo4ZXaw2zt9/qUcP2G3gRGqbH
RJKyD7jWcOSk7OuuNSxdO9glOHuQIOsmFCtGDZKy37JDUSIp+0I7FBNrDU83DgZ3KEb2O3r/VysC
25OyV6BBUnYvSdk5zkdfa7ianIYccXYaMscZGgqgoXmH4lbeochxhoYCaGiSsh/GDpKyo52hoQYa
mqTsh3UHSdmhztBQBg2cOWc6QwM0cOYMDdDAmTM0QANnztAADZw5QwM0cOYMDddBA5GkbPI042zU
QC5ZztBALizO0EAuLM7QQNDAGRoIGjhDAzQUQIOk7F5xSdm18qzjnKGhBhokZfeKS8oul2fdJGVf
GQ2qPPWKq/JUsRaTKk/XRYPakHfjhaDakBUrOKoNuSlB+8PC0J6RZuz44XSTJGXfrS8EVZSuWPdZ
RemtCdp7oWFjUvZ0OEWTlD3gHJdDUTEt4lo5FEvRMJKg/ZiX/Sop+/GfzDZpRwpIyp51jkuvqpgx
daH0qqWT8PEcqhUJVxFJ2Ss+lJTdKy7zsmIy5bWSshetNazIwlwRfjeIpBYTbCcp++bDsKTsinnW
103KHnliL03QfjWmmDV5FxokZRs1GDUsXmvYJbH2w3KUrlubXOo8PW+XlG2twVrDEBpW52UvmlBs
TMoeH4y8Wu2XlG2Hwg7F/FrDoh2K6bXJiX/ytA0rkrJnq25Jyp51dq4hx7nqWsNZ5TTkiLPTkDnO
0FAADc07FLfyDkWOMzQUQEOTlP0wdghKyi6XZ90kZV8cDU1S9sO6Q1BSdq086zhnaCiDBs6cM52h
ARo4c4YGaODMGRqggTNnaIAGzpyhARo4c4aG66CBSFI2eZpxNmoglyxnaCAXFmdoIBcWZ2ggaOAM
DQQNnKEBGgqgIS4bWlJ2r7g861pthoYaaIjLhpaU3Ssuz7pcm6GhABri6hqp8tQrrmJSxTZDw9HR
EFcNUW3Iu2dvUJ3Fim0+Axqmg63GE2JGZnS7hGIviqiJq6EsKfturh5Unblim8+AhtkAmEU/2orQ
qhURNYvQEJe8ICm7V1ymQ8U2nxkNE3fpYzbE4xeMDB9y0BCX1yQpu1dcElTFNp8QDSOMWJqpvSMa
Htk0+7PEpTxKyu4Vlx9Zsc0XWmvYkqk9OLMIQkNcNrSk7F5xqdMV23zCHYqJIOy3o2FFoGb+qEFS
tlHD5dYaRm7RETSsTspel3mZv9YgKdtaAzQMpWaP74AM+hxzh0JSth2KK641LNqhmLiltyRlr0ND
2rkGSdnONZx5reEcCyV3choypzechoSGYmho3qHI6g3vUEBDMTS0yGxoSdl3z+GgPOtybYaGGmho
kdnQkrLv5vBBeda12gwNZdDAmXOmMzRAA2fO0AANnDlDAzRw5gwN0MCZMzRAA2fO0HAdNBBJyiZP
M85GDeSS5QwN5MLiDA3kwuIMDQQNnKGBoIEzNEBDATRUzLOWlJ3jHNHP0FADDRXzrCVl5zgH9TM0
FEBDxVpMqjzlOMf1MzQcHQ0VKziqDZnjHNfPhdEwXUg6+pvu+OF04yvmWUvKznGO6+fCaJiNn4j+
pisyL1eEXLSaedaSsnOc4/r5bGjon8l3kRPT44vHgMyIpOxxz14V86wlZec4x/XzedDw9D5cd/fG
JWXPcuc0edaSsnOc4/r5zGsNGxNrW0wc7jR3TpNnLSk7xzmun8+zQzGeXvleNKxYa6iYZy0p+42j
hl36+czLkHFo2JKUvQINFfOsJWW/d61hez9Dw5Nx/tIxf/IORYk8a0nZb9mh2LGfz7nW8BiH3SZP
GYyvFG5Pyt5+rqFEnrWk7BznuH4+z1pD9MbHe7+705C9nIbM6WdoKICG5h2KW3mHIqefoaEGmCrm
WUvKznEO6mdoKDNmqZhnLSk7xzmin6Hh/NMZzpyhARo4c4YGaODMGRqggTNnaIAGzpyhgVyynKGB
Zn4TRJKyydOMs1EDuWQ5QwO5ZDlDA7mwOEMDQQNnaCBo4AwNdHA0SMruJSk7up+hoQYaJGX3kpSd
0M/QUAANqjz1UuUpp5+h4ehoUBvybrygNmRCP9dAw8ihzhV34Ao3SdnvdVZROqefa6BhIhImGQ2S
st/uLIcip58Lo2EiVHL6Qf2Ypj1iMsiXjRSQlD3rLL0qp59LouHVvbfi6T2eefVGNEjK7iXzMqef
a681PA2eGpkyPGZVrVieWTHL6H+W8e8oKfvmQ0nZKf1ccofi1Y09njo3OAEJQsMuowZJ2UYNTVL2
dPLt+JriXhOK1UnZ+641SMq21nD1pOyRW3H3tYaJRNx9ty2WrkJLyrZDkdDPtdca2pI47Nk07Uco
PKWApOz3OjvXkNPPJdcaTiynIUecnYbM6WdoKICG5h2KW3mHIqefoaEAGpqk7Iexg6Ts6H6Ghhpo
aJKyH9YdJGWH9jM0lEEDZ86ZztAADZw5QwM0cOYMDdDAmTM0QANnztAADZw5Q8N10EAkKZs8zTgb
NZBLljM0kAuLMzSQC4szNBA0cIYGggbO0AANBdAgKbuXpOxoZ2iogQZJ2b0kZSc4Q0MBNKjy1EuV
pxxnaDg6GtSGvBsvqA2Z4HxONCw6Dbr9Bl5UyXqiPZKyZ51VlM5xPv+oYfefa7rgfUREjaTsXnIo
cpwvh4ZXWXiPXzBx625Hw6IcCknZvaRX5ThfEQ2zAVOzSXkb0TAYpfmTJGX3knmZ43zRUcPEl23J
vHyKldnErdn/JCn75kNJ2SnOV0fD46LgCjS010l5sxOQ1U9gSdlGDUYNUWhYt3y44t4e8Vwxb5eU
ba3BWkMsGjaOGhYhZgUaJGXbobBD8Z4JxfZRw6Kk7KVokJTdy7mGHOfzo6E0yH6S05C9nIbMcYaG
Amho3qG4lXcocpyhoQAamqTsh7GDpOxoZ2iogYYmKfth3UFSdqgzNJRBA2fOmc7QAA2cOUMDNHDm
DA3QwJkzNEADZ87QAA2cOUPDddBAJCmbPM04GzWQS5YzNJALizM0kAuLMzQQNHCGBoIGztAADQXQ
ICm7l6Ts6H6GhhpokJTdS1J2Qj9DQwE0qPLUS5WnnH6GhqOjQW3Iu/GC2pAJ/TyEhvHUxhVX/2yQ
3NHu3vHi0YMfTveqpOy79QUVpRP6+T1oWFR//bBP9dnszMEPZ7tCUnYvORQ5/bxgQjGRubIxbPpp
TmR7SI4ZT3+ZeFxvbPzsYGf8w/FRg6TsXtKrcvp5KxpWhE0PomHCbRoNi5yXNn4XNCydUEjK7iXz
Mqefdxg1LB02vxojtCWpcD0FRuKndhzzL2rhUu5Iyp51lpSd08/Ldihe5T4vCpueeM7vhYbBJo1/
5Y5oWLHWICnbqCG/n7eiYcUNkICGFbOh8cFR2xCHuw4NkrKtNeT38zI0TNwV60YNr/7hSMz0or8v
WmtYevcm71BIyrZDkdDPW9HQlodNL1p9WPH3XXYopn/Yp/8q7VyDpGznGhL6eTEaTqAj/6ROQ444
Ow2Z08+XQMNIhcyDY8s7FL28Q5HTz96hqDGikZR9N3aQlB3dz9BQZrIjKftu3UFSdmg/Q8P510E4
c4YGaODMGRqggTNnaIAGzpyhARo4c4YGcslyhgaa+U0QScomTzPORg3kkuUMDeSS5QwN5MLiDA0E
DZyhgaCBMzTQwdEgKbuXpOxoZ2iogQZJ2b0kZSc4Q0MBNKjy1EuVpxxnaDg6GtSGvBsvqA2Z4FwA
DYvCeBf9ICt+aknZ73VWUTrHGRo+rG6JpOy3OMuhyHEuM6FYmtP99L+OZ+cGJWXP/j4kZc86S6/K
ca6NhtmgqlkQjKfjvBENkrJ7ybzMcT4zGiZu41f/d920ZWPw5+znkrJvPpSUneJcaYdiXRjv0znF
9Nxh8D32NDRIyjZqMGrYEw2zEdurJxSrk7LXraFKyrbWYK1h2YbCIBpGAm9n/9XgEGBRou+61X5J
2XYo7FAM3ZazOxRtYdz203/1ONdYkZQ9W3VLUvass3MNOc7F0HB6OQ054uw0ZI4zNBRAQ/MOxa28
Q5HjDA0F0NAkZT+MHSRlRztDQw00NEnZD+sOkrJDnaGhDBo4c850hgZo4MwZGqCBM2dogAbOnKEB
GjhzhgZo4MwZGq6DBiJJ2eRpxtmogVyynKGBXFicoYFcWJyhgaCBMzQQNHCGBmgogIa4bGhJ2b3i
8qxrtRkaaqAhLhtaUnavuDzrcm2GhgJoiKtrpMpTr7iKSRXbDA1HR0NcNUS1Ie+evUF1Fiu2+c1o
mM5oWBrZMJ1htcuoPj8pO66GsqTsu7l6UHXmim0+FhqmC8MfAQ1vScqOS16QlN0rLtOhYpsPjYaR
ROxXIRRP/+v0k3z6/h/EUAQa4vKaJGX3ikuCqtjmQ6w1jKfOtRfpUtPZU0uTtQeHHmloiEt5lJTd
Ky4/smKbD4SG6ZnF0ntvS7L2dHz29E0egYa4bGhJ2b3iUqcrtrkMGl5lXi9Fw7TPyEphPhqSRw2S
so0ayqBhxb03OEBok/G2uydlV1lrkJRtreEQaGhL4qfH0RC01rAlKfvgOxSSsu1QFENDe5ZePXKf
775DsTEpux37XIOkbOcaDocGmv4lOQ2Z0xtOQ0JDMTQ071Bk9YZ3KKChGBpaZDa0pOy753BQnnW5
NkNDDTS0yGxoSdl3c/igPOtabYaGMmjgzDnTGRqggTNnaIAGzpyhARo4c4YGaODMGRqggTNnaLgO
GogkZZOnGWejBnLJcoYGcmFxhgZyYXGGBoIGztBA0MAZGqChABoq5llLyq7rDA010FAxz1pSdmln
aCiAhoq1mFR5qu4MDUdHQ8UKjmpDVncuj4bVWdurv11yUnbFPGtJ2dWdz4aGRVnbu3yvFp9DUTHP
WlJ2deeTo2FF1nZ7lnkx/X235GuO/JIq5llLyq7ufJK1huis7X3RsHRCUTHPWlJ2dedToWHfrO3Z
Lls3y1iamtdq5llLyq7ufCE0LM3aDkLDirWGinnWkrKNGmqgYce7t6UnZVfMs5aUba3hoFuYbdes
7XXfKGiHokSetaRsOxQ10NCGs7andyjekpRdMc9aUnZ15/OgIQc37/qOTkP2choyxxkaXo4LDgUj
71D08g5FjjM01BinVMyzlpRd2hkaykxhKuZZS8qu6wwN51/d4MwZGqCBM2dogAbOnKEBGjhzhgZo
4MwZGsglyxkaaOY3QSQpmzzNOBs1kEuWMzSQS5YzNJALizM0EDRwhgaCBs7QQAdHg6TsXpKyo52h
oQYaJGX3kpSd4AwNBdCgylMvVZ5ynKHh6GhQG/JuvKA2ZIJzO2VF6bi87C3Fo2dPp0rKnnVWUTrH
+ZxoiMvLjo6ckJQ96yyHIsf5EmiYzrYajM+e+I4r0LAoh0JSdi/pVTnOp1prmM7Lnr7/xxNrt6Nh
MErzJ0nK7iXzMsf5hGgYHz7kx+GuQ4Ok7JsPJWWnOENDATRIyjZqMGqogYbVSdnjk5SRebukbGsN
1hpWbmEO3sYbdxai0SAp2w6FHYqjo2GXpOylaJCU3cu5hhzns6FhBTtKNM9pyF5OQ+Y4XwgNx/8Z
vUMx6Owdihxn71DUgJek7Luxg6TsaGdoKDOukZR9t+4gKTvUGRrOP+XhzBkaoIEzZ2iABs6coQEa
OHOGBmjgzBkayCXLGRpo5jdBJCmbPM04GzWQS5YzNJBLljM0kAuLMzQQNHCGBoIGztBAB0eDpOxe
krKjnaGhBhokZfeSlJ3gDA0F0KDKUy9VnnKcoeHoaFAb8m68oDZkgnNhNDw97xn9g2xJyn714fQv
SVL23fqCitIJzucZNQwGVe74VF8RdbMuPltSdi85FDnOJ0HDSNT10/CIia9sAXG44+nbvSRl95Je
leN8TjQ8zb9+eqNOfOVsn6xGw9IJhaTsXjIvc5zPgIbVCZT5cbhPYTT7S5KUffOhpOwU5/Jo2JJA
+RY0rFhrkJRt1GDUUAMN+45TVs/bJWVba7DWsGDRbi80vOqT3WG0dLVfUrYdCjsUM1yYPdcwHWY9
/ZUtLCl747kGSdnONSQ4n2SHInNU8pbv6DRkL6chc5yh4eW44FAw8g5FL+9Q5DhDQ41xiqTsu7GD
pOxoZ2goM4WRlH237iApO9QZGs6/usGZMzRAA2fO0AANnDlDAzRw5gwN0MCZMzSQS5YzNNDMb4JI
UjZ5mnE2aiCXLGdoIJcsZ2ggFxZnaCBo4AwNBA2coYEOjgZJ2b3ikrIrOkf0MzTUQIOk7F5xSdkV
nYP6GRoKoEGVp15xVZ4qOsf1MzQcHQ1qQ949e4NqQ1Z0juvns6EhOj5bUvZ7neMqSld0juvnk48a
do/PlpT9due4HIqKznH9fGY0bInPHgFKGhokZfeKS6+q6BzXzxdCw3h89tHQICm7V1zmZUXnuH4+
LRriYimnvywCDZKybz4MS8qu6BzXz+dEQ2gsZT4aJGUbNeT3MzSsQYOk7Dc6W2vI6edzbl7usrMg
KftqSdkn2KHYsZ/Phobt8dlNUvZVk7JPcK5hx34+8w7FaYY8zWnIWzkNmdPP0FAADc07FLfyDkVO
P0NDATQ0SdkPz+GgpOyKzkH9DA010NAkZT/M4YOSsis6R/QzNJRBA2fOmc7QAA2cOUMDNHDmDA3Q
wJkzNEADZ87QAA2cOUPDddBAJCmbiCo8q3QEEUEDEUEDEUEDEUEDEUEDEUEDER0CDUREd/r/KtJR
Hv0PDdIAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-11-23 21:17:11 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAEACAMAAACQ12/OAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>